id	sid	tid	token	lemma	pos
cord-016476-78r0rsio	1	1	key	key	JJ
cord-016476-78r0rsio	1	2	:	:	:
cord-016476-78r0rsio	1	3	cord-016476	cord-016476	NNP
cord-016476-78r0rsio	1	4	-	-	HYPH
cord-016476-78r0rsio	1	5	78r0rsio	78r0rsio	CD
cord-016476-78r0rsio	2	1	authors	author	NNS
cord-016476-78r0rsio	2	2	:	:	:
cord-016476-78r0rsio	2	3	Jani	Jani	NNP
cord-016476-78r0rsio	2	4	,	,	,
cord-016476-78r0rsio	2	5	Meghna	Meghna	NNP
cord-016476-78r0rsio	2	6	;	;	:
cord-016476-78r0rsio	2	7	Dixon	Dixon	NNP
cord-016476-78r0rsio	2	8	,	,	,
cord-016476-78r0rsio	2	9	William	William	NNP
cord-016476-78r0rsio	2	10	G.	G.	NNP
cord-016476-78r0rsio	2	11	;	;	:
cord-016476-78r0rsio	2	12	Matteson	Matteson	NNP
cord-016476-78r0rsio	2	13	,	,	,
cord-016476-78r0rsio	2	14	Eric	Eric	NNP
cord-016476-78r0rsio	2	15	L.	L.	NNP
cord-016476-78r0rsio	2	16	title	title	NN
cord-016476-78r0rsio	2	17	:	:	:
cord-016476-78r0rsio	2	18	Management	management	NN
cord-016476-78r0rsio	2	19	of	of	IN
cord-016476-78r0rsio	2	20	the	the	DT
cord-016476-78r0rsio	2	21	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	2	22	Arthritis	arthritis	NN
cord-016476-78r0rsio	2	23	Patient	Patient	NNP
cord-016476-78r0rsio	2	24	with	with	IN
cord-016476-78r0rsio	2	25	Interstitial	Interstitial	NNP
cord-016476-78r0rsio	2	26	Lung	Lung	NNP
cord-016476-78r0rsio	2	27	Disease	Disease	NNP
cord-016476-78r0rsio	2	28	date	date	NN
cord-016476-78r0rsio	2	29	:	:	:
cord-016476-78r0rsio	2	30	2017	2017	CD
cord-016476-78r0rsio	2	31	-	-	HYPH
cord-016476-78r0rsio	2	32	11	11	CD
cord-016476-78r0rsio	2	33	-	-	SYM
cord-016476-78r0rsio	2	34	29	29	CD
cord-016476-78r0rsio	2	35	journal	journal	NN
cord-016476-78r0rsio	2	36	:	:	:
cord-016476-78r0rsio	2	37	Lung	Lung	NNP
cord-016476-78r0rsio	2	38	Disease	Disease	NNP
cord-016476-78r0rsio	2	39	in	in	IN
cord-016476-78r0rsio	2	40	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	2	41	Arthritis	arthritis	NN
cord-016476-78r0rsio	2	42	DOI	doi	NN
cord-016476-78r0rsio	2	43	:	:	:
cord-016476-78r0rsio	3	1	10.1007/978	10.1007/978	LS
cord-016476-78r0rsio	3	2	-	-	SYM
cord-016476-78r0rsio	3	3	3	3	CD
cord-016476-78r0rsio	3	4	-	-	HYPH
cord-016476-78r0rsio	3	5	319	319	CD
cord-016476-78r0rsio	3	6	-	-	HYPH
cord-016476-78r0rsio	3	7	68888	68888	CD
cord-016476-78r0rsio	3	8	-	-	HYPH
cord-016476-78r0rsio	3	9	6_9	6_9	CD
cord-016476-78r0rsio	3	10	sha	sha	NNP
cord-016476-78r0rsio	3	11	:	:	:
cord-016476-78r0rsio	3	12	f6550d68e2993e371163dc4d6abfad0a47f16a65	f6550d68e2993e371163dc4d6abfad0a47f16a65	NNP
cord-016476-78r0rsio	3	13	doc_id	doc_id	CD
cord-016476-78r0rsio	3	14	:	:	:
cord-016476-78r0rsio	3	15	16476	16476	CD
cord-016476-78r0rsio	3	16	cord_uid	cord_uid	NNS
cord-016476-78r0rsio	3	17	:	:	:
cord-016476-78r0rsio	4	1	78r0rsio	78r0rsio	CD
cord-016476-78r0rsio	5	1	The	the	DT
cord-016476-78r0rsio	5	2	treatment	treatment	NN
cord-016476-78r0rsio	5	3	of	of	IN
cord-016476-78r0rsio	5	4	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	5	5	arthritis	arthritis	NN
cord-016476-78r0rsio	5	6	(	(	-LRB-
cord-016476-78r0rsio	5	7	RA	RA	NNP
cord-016476-78r0rsio	5	8	)	)	-RRB-
cord-016476-78r0rsio	5	9	has	have	VBZ
cord-016476-78r0rsio	5	10	undergone	undergo	VBN
cord-016476-78r0rsio	5	11	considerable	considerable	JJ
cord-016476-78r0rsio	5	12	changes	change	NNS
cord-016476-78r0rsio	5	13	over	over	IN
cord-016476-78r0rsio	5	14	the	the	DT
cord-016476-78r0rsio	5	15	last	last	JJ
cord-016476-78r0rsio	5	16	15–20	15–20	JJ
cord-016476-78r0rsio	5	17	years	year	NNS
cord-016476-78r0rsio	5	18	.	.	.
cord-016476-78r0rsio	6	1	With	with	IN
cord-016476-78r0rsio	6	2	an	an	DT
cord-016476-78r0rsio	6	3	expansion	expansion	NN
cord-016476-78r0rsio	6	4	in	in	IN
cord-016476-78r0rsio	6	5	the	the	DT
cord-016476-78r0rsio	6	6	armamentarium	armamentarium	NN
cord-016476-78r0rsio	6	7	of	of	IN
cord-016476-78r0rsio	6	8	therapies	therapy	NNS
cord-016476-78r0rsio	6	9	available	available	JJ
cord-016476-78r0rsio	6	10	for	for	IN
cord-016476-78r0rsio	6	11	RA	RA	NNP
cord-016476-78r0rsio	6	12	comes	come	VBZ
cord-016476-78r0rsio	6	13	a	a	DT
cord-016476-78r0rsio	6	14	wider	wide	JJR
cord-016476-78r0rsio	6	15	choice	choice	NN
cord-016476-78r0rsio	6	16	in	in	IN
cord-016476-78r0rsio	6	17	selecting	select	VBG
cord-016476-78r0rsio	6	18	the	the	DT
cord-016476-78r0rsio	6	19	best	good	JJS
cord-016476-78r0rsio	6	20	treatment	treatment	NN
cord-016476-78r0rsio	6	21	in	in	IN
cord-016476-78r0rsio	6	22	terms	term	NNS
cord-016476-78r0rsio	6	23	of	of	IN
cord-016476-78r0rsio	6	24	comparative	comparative	JJ
cord-016476-78r0rsio	6	25	safety	safety	NN
cord-016476-78r0rsio	6	26	in	in	IN
cord-016476-78r0rsio	6	27	the	the	DT
cord-016476-78r0rsio	6	28	presence	presence	NN
cord-016476-78r0rsio	6	29	of	of	IN
cord-016476-78r0rsio	6	30	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	6	31	.	.	.
cord-016476-78r0rsio	7	1	Clinicians	clinician	NNS
cord-016476-78r0rsio	7	2	frequently	frequently	RB
cord-016476-78r0rsio	7	3	encounter	encounter	VBP
cord-016476-78r0rsio	7	4	patients	patient	NNS
cord-016476-78r0rsio	7	5	with	with	IN
cord-016476-78r0rsio	7	6	RA	RA	NNP
cord-016476-78r0rsio	7	7	-	-	HYPH
cord-016476-78r0rsio	7	8	associated	associate	VBN
cord-016476-78r0rsio	7	9	interstitial	interstitial	JJ
cord-016476-78r0rsio	7	10	lung	lung	NN
cord-016476-78r0rsio	7	11	disease	disease	NN
cord-016476-78r0rsio	7	12	with	with	IN
cord-016476-78r0rsio	7	13	uncontrolled	uncontrolled	JJ
cord-016476-78r0rsio	7	14	joint	joint	JJ
cord-016476-78r0rsio	7	15	disease	disease	NN
cord-016476-78r0rsio	7	16	and	and	CC
cord-016476-78r0rsio	7	17	have	have	VBP
cord-016476-78r0rsio	7	18	to	to	TO
cord-016476-78r0rsio	7	19	make	make	VB
cord-016476-78r0rsio	7	20	decisions	decision	NNS
cord-016476-78r0rsio	7	21	about	about	IN
cord-016476-78r0rsio	7	22	the	the	DT
cord-016476-78r0rsio	7	23	safest	safe	JJS
cord-016476-78r0rsio	7	24	treatments	treatment	NNS
cord-016476-78r0rsio	7	25	in	in	IN
cord-016476-78r0rsio	7	26	this	this	DT
cord-016476-78r0rsio	7	27	context	context	NN
cord-016476-78r0rsio	7	28	with	with	IN
cord-016476-78r0rsio	7	29	the	the	DT
cord-016476-78r0rsio	7	30	eventual	eventual	JJ
cord-016476-78r0rsio	7	31	goal	goal	NN
cord-016476-78r0rsio	7	32	of	of	IN
cord-016476-78r0rsio	7	33	joint	joint	JJ
cord-016476-78r0rsio	7	34	remission	remission	NN
cord-016476-78r0rsio	7	35	.	.	.
cord-016476-78r0rsio	8	1	In	in	IN
cord-016476-78r0rsio	8	2	this	this	DT
cord-016476-78r0rsio	8	3	chapter	chapter	NN
cord-016476-78r0rsio	8	4	,	,	,
cord-016476-78r0rsio	8	5	available	available	JJ
cord-016476-78r0rsio	8	6	evidence	evidence	NN
cord-016476-78r0rsio	8	7	is	be	VBZ
cord-016476-78r0rsio	8	8	reviewed	review	VBN
cord-016476-78r0rsio	8	9	on	on	IN
cord-016476-78r0rsio	8	10	the	the	DT
cord-016476-78r0rsio	8	11	comparative	comparative	JJ
cord-016476-78r0rsio	8	12	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	8	13	safety	safety	NN
cord-016476-78r0rsio	8	14	of	of	IN
cord-016476-78r0rsio	8	15	non	non	JJ
cord-016476-78r0rsio	8	16	-	-	JJ
cord-016476-78r0rsio	8	17	biologic	biologic	JJ
cord-016476-78r0rsio	8	18	disease	disease	NN
cord-016476-78r0rsio	8	19	-	-	HYPH
cord-016476-78r0rsio	8	20	modifying	modify	VBG
cord-016476-78r0rsio	8	21	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	8	22	drugs	drug	NNS
cord-016476-78r0rsio	8	23	(	(	-LRB-
cord-016476-78r0rsio	8	24	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	8	25	)	)	-RRB-
cord-016476-78r0rsio	8	26	,	,	,
cord-016476-78r0rsio	8	27	biologic	biologic	JJ
cord-016476-78r0rsio	8	28	DMARDs	dmard	NNS
cord-016476-78r0rsio	8	29	,	,	,
cord-016476-78r0rsio	8	30	biosimilars	biosimilar	NNS
cord-016476-78r0rsio	8	31	and	and	CC
cord-016476-78r0rsio	8	32	targeted	target	VBN
cord-016476-78r0rsio	8	33	synthetic	synthetic	JJ
cord-016476-78r0rsio	8	34	DMARDs	dmard	NNS
cord-016476-78r0rsio	8	35	in	in	IN
cord-016476-78r0rsio	8	36	RA	RA	NNP
cord-016476-78r0rsio	8	37	-	-	HYPH
cord-016476-78r0rsio	8	38	ILD	ILD	NNP
cord-016476-78r0rsio	8	39	.	.	.
cord-016476-78r0rsio	9	1	In	in	IN
cord-016476-78r0rsio	9	2	addition	addition	NN
cord-016476-78r0rsio	9	3	,	,	,
cord-016476-78r0rsio	9	4	the	the	DT
cord-016476-78r0rsio	9	5	potential	potential	JJ
cord-016476-78r0rsio	9	6	role	role	NN
cord-016476-78r0rsio	9	7	for	for	IN
cord-016476-78r0rsio	9	8	additional	additional	JJ
cord-016476-78r0rsio	9	9	immunosuppression	immunosuppression	NN
cord-016476-78r0rsio	9	10	in	in	IN
cord-016476-78r0rsio	9	11	RA	RA	NNP
cord-016476-78r0rsio	9	12	-	-	HYPH
cord-016476-78r0rsio	9	13	ILD	ILD	NNP
cord-016476-78r0rsio	9	14	is	be	VBZ
cord-016476-78r0rsio	9	15	reviewed	review	VBN
cord-016476-78r0rsio	9	16	as	as	RB
cord-016476-78r0rsio	9	17	well	well	RB
cord-016476-78r0rsio	9	18	as	as	IN
cord-016476-78r0rsio	9	19	overarching	overarching	JJ
cord-016476-78r0rsio	9	20	recommendations	recommendation	NNS
cord-016476-78r0rsio	9	21	proposed	propose	VBN
cord-016476-78r0rsio	9	22	for	for	IN
cord-016476-78r0rsio	9	23	patient	patient	JJ
cord-016476-78r0rsio	9	24	assessment	assessment	NN
cord-016476-78r0rsio	9	25	to	to	TO
cord-016476-78r0rsio	9	26	guide	guide	VB
cord-016476-78r0rsio	9	27	treatment	treatment	NN
cord-016476-78r0rsio	9	28	decisions	decision	NNS
cord-016476-78r0rsio	9	29	and	and	CC
cord-016476-78r0rsio	9	30	management	management	NN
cord-016476-78r0rsio	9	31	.	.	.
cord-016476-78r0rsio	10	1	The	the	DT
cord-016476-78r0rsio	10	2	management	management	NN
cord-016476-78r0rsio	10	3	of	of	IN
cord-016476-78r0rsio	10	4	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	10	5	arthritis	arthritis	NN
cord-016476-78r0rsio	10	6	(	(	-LRB-
cord-016476-78r0rsio	10	7	RA	RA	NNP
cord-016476-78r0rsio	10	8	)	)	-RRB-
cord-016476-78r0rsio	10	9	has	have	VBZ
cord-016476-78r0rsio	10	10	changed	change	VBN
cord-016476-78r0rsio	10	11	dramatically	dramatically	RB
cord-016476-78r0rsio	10	12	over	over	IN
cord-016476-78r0rsio	10	13	the	the	DT
cord-016476-78r0rsio	10	14	past	past	JJ
cord-016476-78r0rsio	10	15	15	15	CD
cord-016476-78r0rsio	10	16	-	-	SYM
cord-016476-78r0rsio	10	17	20	20	CD
cord-016476-78r0rsio	10	18	years	year	NNS
cord-016476-78r0rsio	10	19	.	.	.
cord-016476-78r0rsio	11	1	New	new	JJ
cord-016476-78r0rsio	11	2	classification	classification	NN
cord-016476-78r0rsio	11	3	criteria	criterion	NNS
cord-016476-78r0rsio	11	4	for	for	IN
cord-016476-78r0rsio	11	5	RA	RA	NNP
cord-016476-78r0rsio	11	6	have	have	VBP
cord-016476-78r0rsio	11	7	been	be	VBN
cord-016476-78r0rsio	11	8	introduced	introduce	VBN
cord-016476-78r0rsio	11	9	[	[	-LRB-
cord-016476-78r0rsio	11	10	1	1	CD
cord-016476-78r0rsio	11	11	]	]	-RRB-
cord-016476-78r0rsio	11	12	that	that	WDT
cord-016476-78r0rsio	11	13	allow	allow	VBP
cord-016476-78r0rsio	11	14	the	the	DT
cord-016476-78r0rsio	11	15	study	study	NN
cord-016476-78r0rsio	11	16	of	of	IN
cord-016476-78r0rsio	11	17	patients	patient	NNS
cord-016476-78r0rsio	11	18	earlier	early	RBR
cord-016476-78r0rsio	11	19	in	in	IN
cord-016476-78r0rsio	11	20	their	-PRON-	PRP$
cord-016476-78r0rsio	11	21	disease	disease	NN
cord-016476-78r0rsio	11	22	course	course	NN
cord-016476-78r0rsio	11	23	,	,	,
cord-016476-78r0rsio	11	24	and	and	CC
cord-016476-78r0rsio	11	25	recommendations	recommendation	NNS
cord-016476-78r0rsio	11	26	have	have	VBP
cord-016476-78r0rsio	11	27	been	be	VBN
cord-016476-78r0rsio	11	28	developed	develop	VBN
cord-016476-78r0rsio	11	29	to	to	TO
cord-016476-78r0rsio	11	30	treat	treat	VB
cord-016476-78r0rsio	11	31	patients	patient	NNS
cord-016476-78r0rsio	11	32	with	with	IN
cord-016476-78r0rsio	11	33	RA	RA	NNP
cord-016476-78r0rsio	11	34	using	use	VBG
cord-016476-78r0rsio	11	35	a	a	DT
cord-016476-78r0rsio	11	36	strategic	strategic	JJ
cord-016476-78r0rsio	11	37	approach	approach	NN
cord-016476-78r0rsio	11	38	by	by	IN
cord-016476-78r0rsio	11	39	targeting	target	VBG
cord-016476-78r0rsio	11	40	an	an	DT
cord-016476-78r0rsio	11	41	optimal	optimal	JJ
cord-016476-78r0rsio	11	42	outcome	outcome	NN
cord-016476-78r0rsio	11	43	,	,	,
cord-016476-78r0rsio	11	44	with	with	IN
cord-016476-78r0rsio	11	45	the	the	DT
cord-016476-78r0rsio	11	46	primary	primary	JJ
cord-016476-78r0rsio	11	47	goal	goal	NN
cord-016476-78r0rsio	11	48	of	of	IN
cord-016476-78r0rsio	11	49	joint	joint	JJ
cord-016476-78r0rsio	11	50	disease	disease	NN
cord-016476-78r0rsio	11	51	remission	remission	NN
cord-016476-78r0rsio	11	52	[	[	-LRB-
cord-016476-78r0rsio	11	53	2	2	CD
cord-016476-78r0rsio	11	54	,	,	,
cord-016476-78r0rsio	11	55	3	3	CD
cord-016476-78r0rsio	11	56	]	]	-RRB-
cord-016476-78r0rsio	11	57	.	.	.
cord-016476-78r0rsio	12	1	The	the	DT
cord-016476-78r0rsio	12	2	armamentarium	armamentarium	NN
cord-016476-78r0rsio	12	3	of	of	IN
cord-016476-78r0rsio	12	4	treatments	treatment	NNS
cord-016476-78r0rsio	12	5	available	available	JJ
cord-016476-78r0rsio	12	6	for	for	IN
cord-016476-78r0rsio	12	7	the	the	DT
cord-016476-78r0rsio	12	8	treatment	treatment	NN
cord-016476-78r0rsio	12	9	of	of	IN
cord-016476-78r0rsio	12	10	RA	RA	NNP
cord-016476-78r0rsio	12	11	has	have	VBZ
cord-016476-78r0rsio	12	12	also	also	RB
cord-016476-78r0rsio	12	13	expanded	expand	VBN
cord-016476-78r0rsio	12	14	.	.	.
cord-016476-78r0rsio	13	1	However	however	RB
cord-016476-78r0rsio	13	2	,	,	,
cord-016476-78r0rsio	13	3	with	with	IN
cord-016476-78r0rsio	13	4	the	the	DT
cord-016476-78r0rsio	13	5	introduction	introduction	NN
cord-016476-78r0rsio	13	6	of	of	IN
cord-016476-78r0rsio	13	7	novel	novel	JJ
cord-016476-78r0rsio	13	8	therapies	therapy	NNS
cord-016476-78r0rsio	13	9	comes	come	VBZ
cord-016476-78r0rsio	13	10	a	a	DT
cord-016476-78r0rsio	13	11	wider	wide	JJR
cord-016476-78r0rsio	13	12	choice	choice	NN
cord-016476-78r0rsio	13	13	in	in	IN
cord-016476-78r0rsio	13	14	selecting	select	VBG
cord-016476-78r0rsio	13	15	the	the	DT
cord-016476-78r0rsio	13	16	best	good	JJS
cord-016476-78r0rsio	13	17	treatment	treatment	NN
cord-016476-78r0rsio	13	18	for	for	IN
cord-016476-78r0rsio	13	19	the	the	DT
cord-016476-78r0rsio	13	20	individual	individual	JJ
cord-016476-78r0rsio	13	21	patient	patient	NN
cord-016476-78r0rsio	13	22	not	not	RB
cord-016476-78r0rsio	13	23	only	only	RB
cord-016476-78r0rsio	13	24	in	in	IN
cord-016476-78r0rsio	13	25	terms	term	NNS
cord-016476-78r0rsio	13	26	of	of	IN
cord-016476-78r0rsio	13	27	comparative	comparative	JJ
cord-016476-78r0rsio	13	28	efficacy	efficacy	NN
cord-016476-78r0rsio	13	29	but	but	CC
cord-016476-78r0rsio	13	30	also	also	RB
cord-016476-78r0rsio	13	31	safety	safety	NN
cord-016476-78r0rsio	13	32	in	in	IN
cord-016476-78r0rsio	13	33	the	the	DT
cord-016476-78r0rsio	13	34	presence	presence	NN
cord-016476-78r0rsio	13	35	of	of	IN
cord-016476-78r0rsio	13	36	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	13	37	.	.	.
cord-016476-78r0rsio	14	1	Interstitial	interstitial	JJ
cord-016476-78r0rsio	14	2	lung	lung	NN
cord-016476-78r0rsio	14	3	disease	disease	NN
cord-016476-78r0rsio	14	4	(	(	-LRB-
cord-016476-78r0rsio	14	5	ILD	ILD	NNP
cord-016476-78r0rsio	14	6	)	)	-RRB-
cord-016476-78r0rsio	14	7	is	be	VBZ
cord-016476-78r0rsio	14	8	one	one	CD
cord-016476-78r0rsio	14	9	of	of	IN
cord-016476-78r0rsio	14	10	the	the	DT
cord-016476-78r0rsio	14	11	most	most	RBS
cord-016476-78r0rsio	14	12	common	common	JJ
cord-016476-78r0rsio	14	13	respiratory	respiratory	JJ
cord-016476-78r0rsio	14	14	manifestations	manifestation	NNS
cord-016476-78r0rsio	14	15	in	in	IN
cord-016476-78r0rsio	14	16	patients	patient	NNS
cord-016476-78r0rsio	14	17	with	with	IN
cord-016476-78r0rsio	14	18	RA	RA	NNP
cord-016476-78r0rsio	14	19	and	and	CC
cord-016476-78r0rsio	14	20	is	be	VBZ
cord-016476-78r0rsio	14	21	a	a	DT
cord-016476-78r0rsio	14	22	major	major	JJ
cord-016476-78r0rsio	14	23	cause	cause	NN
cord-016476-78r0rsio	14	24	of	of	IN
cord-016476-78r0rsio	14	25	morbidity	morbidity	NN
cord-016476-78r0rsio	14	26	and	and	CC
cord-016476-78r0rsio	14	27	mortality	mortality	NN
cord-016476-78r0rsio	14	28	.	.	.
cord-016476-78r0rsio	15	1	RA	RA	NNP
cord-016476-78r0rsio	15	2	-	-	HYPH
cord-016476-78r0rsio	15	3	ILD	ILD	NNP
cord-016476-78r0rsio	15	4	encompasses	encompass	VBZ
cord-016476-78r0rsio	15	5	several	several	JJ
cord-016476-78r0rsio	15	6	histopathologic	histopathologic	JJ
cord-016476-78r0rsio	15	7	patterns	pattern	NNS
cord-016476-78r0rsio	15	8	;	;	:
cord-016476-78r0rsio	15	9	the	the	DT
cord-016476-78r0rsio	15	10	most	most	RBS
cord-016476-78r0rsio	15	11	frequent	frequent	JJ
cord-016476-78r0rsio	15	12	considered	consider	VBN
cord-016476-78r0rsio	15	13	here	here	RB
cord-016476-78r0rsio	15	14	are	be	VBP
cord-016476-78r0rsio	15	15	usual	usual	JJ
cord-016476-78r0rsio	15	16	interstitial	interstitial	JJ
cord-016476-78r0rsio	15	17	pneumonia	pneumonia	NN
cord-016476-78r0rsio	15	18	(	(	-LRB-
cord-016476-78r0rsio	15	19	UIP	UIP	NNP
cord-016476-78r0rsio	15	20	)	)	-RRB-
cord-016476-78r0rsio	15	21	,	,	,
cord-016476-78r0rsio	15	22	nonspecific	nonspecific	JJ
cord-016476-78r0rsio	15	23	interstitial	interstitial	JJ
cord-016476-78r0rsio	15	24	pneumonia	pneumonia	NN
cord-016476-78r0rsio	15	25	(	(	-LRB-
cord-016476-78r0rsio	15	26	NSIP	NSIP	NNP
cord-016476-78r0rsio	15	27	)	)	-RRB-
cord-016476-78r0rsio	15	28	,	,	,
cord-016476-78r0rsio	15	29	and	and	CC
cord-016476-78r0rsio	15	30	obstructive	obstructive	JJ
cord-016476-78r0rsio	15	31	pneumonia	pneumonia	NN
cord-016476-78r0rsio	15	32	(	(	-LRB-
cord-016476-78r0rsio	15	33	OP	OP	NNP
cord-016476-78r0rsio	15	34	)	)	-RRB-
cord-016476-78r0rsio	15	35	.	.	.
cord-016476-78r0rsio	16	1	The	the	DT
cord-016476-78r0rsio	16	2	development	development	NN
cord-016476-78r0rsio	16	3	of	of	IN
cord-016476-78r0rsio	16	4	respiratory	respiratory	JJ
cord-016476-78r0rsio	16	5	complications	complication	NNS
cord-016476-78r0rsio	16	6	of	of	IN
cord-016476-78r0rsio	16	7	treatment	treatment	NN
cord-016476-78r0rsio	16	8	is	be	VBZ
cord-016476-78r0rsio	16	9	thus	thus	RB
cord-016476-78r0rsio	16	10	particularly	particularly	RB
cord-016476-78r0rsio	16	11	problematic	problematic	JJ
cord-016476-78r0rsio	16	12	in	in	IN
cord-016476-78r0rsio	16	13	patients	patient	NNS
cord-016476-78r0rsio	16	14	with	with	IN
cord-016476-78r0rsio	16	15	such	such	JJ
cord-016476-78r0rsio	16	16	coexistent	coexistent	JJ
cord-016476-78r0rsio	16	17	lung	lung	NN
cord-016476-78r0rsio	16	18	disease	disease	NN
cord-016476-78r0rsio	16	19	,	,	,
cord-016476-78r0rsio	16	20	and	and	CC
cord-016476-78r0rsio	16	21	there	there	EX
cord-016476-78r0rsio	16	22	have	have	VBP
cord-016476-78r0rsio	16	23	been	be	VBN
cord-016476-78r0rsio	16	24	many	many	JJ
cord-016476-78r0rsio	16	25	reports	report	NNS
cord-016476-78r0rsio	16	26	of	of	IN
cord-016476-78r0rsio	16	27	respiratory	respiratory	JJ
cord-016476-78r0rsio	16	28	complications	complication	NNS
cord-016476-78r0rsio	16	29	of	of	IN
cord-016476-78r0rsio	16	30	both	both	CC
cord-016476-78r0rsio	16	31	non	non	JJ
cord-016476-78r0rsio	16	32	-	-	JJ
cord-016476-78r0rsio	16	33	biologic	biologic	JJ
cord-016476-78r0rsio	16	34	disease	disease	NN
cord-016476-78r0rsio	16	35	-	-	HYPH
cord-016476-78r0rsio	16	36	modifying	modify	VBG
cord-016476-78r0rsio	16	37	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	16	38	drugs	drug	NNS
cord-016476-78r0rsio	16	39	(	(	-LRB-
cord-016476-78r0rsio	16	40	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	16	41	)	)	-RRB-
cord-016476-78r0rsio	16	42	and	and	CC
cord-016476-78r0rsio	16	43	biologic	biologic	JJ
cord-016476-78r0rsio	16	44	DMARD	DMARD	NNP
cord-016476-78r0rsio	16	45	(	(	-LRB-
cord-016476-78r0rsio	16	46	bDMARD	bDMARD	NNP
cord-016476-78r0rsio	16	47	)	)	-RRB-
cord-016476-78r0rsio	16	48	therapy	therapy	NN
cord-016476-78r0rsio	16	49	.	.	.
cord-016476-78r0rsio	17	1	Clinicians	clinician	NNS
cord-016476-78r0rsio	17	2	are	be	VBP
cord-016476-78r0rsio	17	3	frequently	frequently	RB
cord-016476-78r0rsio	17	4	encountered	encounter	VBN
cord-016476-78r0rsio	17	5	with	with	IN
cord-016476-78r0rsio	17	6	decisions	decision	NNS
cord-016476-78r0rsio	17	7	about	about	IN
cord-016476-78r0rsio	17	8	balancing	balance	VBG
cord-016476-78r0rsio	17	9	risk	risk	NN
cord-016476-78r0rsio	17	10	and	and	CC
cord-016476-78r0rsio	17	11	benefit	benefit	NN
cord-016476-78r0rsio	17	12	of	of	IN
cord-016476-78r0rsio	17	13	treatments	treatment	NNS
cord-016476-78r0rsio	17	14	in	in	IN
cord-016476-78r0rsio	17	15	patients	patient	NNS
cord-016476-78r0rsio	17	16	with	with	IN
cord-016476-78r0rsio	17	17	RA	RA	NNP
cord-016476-78r0rsio	17	18	-	-	HYPH
cord-016476-78r0rsio	17	19	ILD	ILD	NNP
cord-016476-78r0rsio	17	20	who	who	WP
cord-016476-78r0rsio	17	21	have	have	VBP
cord-016476-78r0rsio	17	22	active	active	JJ
cord-016476-78r0rsio	17	23	articular	articular	JJ
cord-016476-78r0rsio	17	24	disease	disease	NN
cord-016476-78r0rsio	17	25	.	.	.
cord-016476-78r0rsio	18	1	Serious	serious	JJ
cord-016476-78r0rsio	18	2	respiratory	respiratory	JJ
cord-016476-78r0rsio	18	3	adverse	adverse	JJ
cord-016476-78r0rsio	18	4	events	event	NNS
cord-016476-78r0rsio	18	5	(	(	-LRB-
cord-016476-78r0rsio	18	6	SRAEs	srae	NNS
cord-016476-78r0rsio	18	7	)	)	-RRB-
cord-016476-78r0rsio	18	8	in	in	IN
cord-016476-78r0rsio	18	9	the	the	DT
cord-016476-78r0rsio	18	10	patient	patient	NN
cord-016476-78r0rsio	18	11	with	with	IN
cord-016476-78r0rsio	18	12	RA	RA	NNP
cord-016476-78r0rsio	18	13	on	on	IN
cord-016476-78r0rsio	18	14	treatment	treatment	NN
cord-016476-78r0rsio	18	15	for	for	IN
cord-016476-78r0rsio	18	16	their	-PRON-	PRP$
cord-016476-78r0rsio	18	17	joint	joint	JJ
cord-016476-78r0rsio	18	18	disease	disease	NN
cord-016476-78r0rsio	18	19	may	may	MD
cord-016476-78r0rsio	18	20	be	be	VB
cord-016476-78r0rsio	18	21	due	due	JJ
cord-016476-78r0rsio	18	22	to	to	IN
cord-016476-78r0rsio	18	23	induction	induction	NN
cord-016476-78r0rsio	18	24	of	of	IN
cord-016476-78r0rsio	18	25	'	'	``
cord-016476-78r0rsio	18	26	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	18	27	'	'	''
cord-016476-78r0rsio	18	28	or	or	CC
cord-016476-78r0rsio	18	29	idiosyncratic	idiosyncratic	JJ
cord-016476-78r0rsio	18	30	adverse	adverse	JJ
cord-016476-78r0rsio	18	31	drug	drug	NN
cord-016476-78r0rsio	18	32	reactions	reaction	NNS
cord-016476-78r0rsio	18	33	(	(	-LRB-
cord-016476-78r0rsio	18	34	ADRs	adr	NNS
cord-016476-78r0rsio	18	35	)	)	-RRB-
cord-016476-78r0rsio	18	36	,	,	,
cord-016476-78r0rsio	18	37	acceleration	acceleration	NN
cord-016476-78r0rsio	18	38	of	of	IN
cord-016476-78r0rsio	18	39	pre	pre	JJ
cord-016476-78r0rsio	18	40	-	-	JJ
cord-016476-78r0rsio	18	41	existing	existing	JJ
cord-016476-78r0rsio	18	42	ILD	ILD	NNP
cord-016476-78r0rsio	18	43	or	or	CC
cord-016476-78r0rsio	18	44	increased	increase	VBN
cord-016476-78r0rsio	18	45	predisposition	predisposition	NN
cord-016476-78r0rsio	18	46	to	to	IN
cord-016476-78r0rsio	18	47	infection	infection	NN
cord-016476-78r0rsio	18	48	in	in	IN
cord-016476-78r0rsio	18	49	a	a	DT
cord-016476-78r0rsio	18	50	susceptible	susceptible	JJ
cord-016476-78r0rsio	18	51	host	host	NN
cord-016476-78r0rsio	18	52	.	.	.
cord-016476-78r0rsio	19	1	Several	several	JJ
cord-016476-78r0rsio	19	2	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	19	3	and	and	CC
cord-016476-78r0rsio	19	4	bDMARDs	bdmards	NN
cord-016476-78r0rsio	19	5	have	have	VBP
cord-016476-78r0rsio	19	6	been	be	VBN
cord-016476-78r0rsio	19	7	implicated	implicate	VBN
cord-016476-78r0rsio	19	8	in	in	IN
cord-016476-78r0rsio	19	9	the	the	DT
cord-016476-78r0rsio	19	10	development	development	NN
cord-016476-78r0rsio	19	11	of	of	IN
cord-016476-78r0rsio	19	12	ILD	ILD	NNP
cord-016476-78r0rsio	19	13	.	.	.
cord-016476-78r0rsio	20	1	Conversely	conversely	RB
cord-016476-78r0rsio	20	2	,	,	,
cord-016476-78r0rsio	20	3	treatment	treatment	NN
cord-016476-78r0rsio	20	4	of	of	IN
cord-016476-78r0rsio	20	5	the	the	DT
cord-016476-78r0rsio	20	6	underlying	underlie	VBG
cord-016476-78r0rsio	20	7	disease	disease	NN
cord-016476-78r0rsio	20	8	process	process	NN
cord-016476-78r0rsio	20	9	may	may	MD
cord-016476-78r0rsio	20	10	be	be	VB
cord-016476-78r0rsio	20	11	beneficial	beneficial	JJ
cord-016476-78r0rsio	20	12	in	in	IN
cord-016476-78r0rsio	20	13	halting	halt	VBG
cord-016476-78r0rsio	20	14	the	the	DT
cord-016476-78r0rsio	20	15	progression	progression	NN
cord-016476-78r0rsio	20	16	of	of	IN
cord-016476-78r0rsio	20	17	the	the	DT
cord-016476-78r0rsio	20	18	lung	lung	NN
cord-016476-78r0rsio	20	19	disease	disease	NN
cord-016476-78r0rsio	20	20	.	.	.
cord-016476-78r0rsio	21	1	This	this	DT
cord-016476-78r0rsio	21	2	chapter	chapter	NN
cord-016476-78r0rsio	21	3	first	first	RB
cord-016476-78r0rsio	21	4	considers	consider	VBZ
cord-016476-78r0rsio	21	5	methods	method	NNS
cord-016476-78r0rsio	21	6	for	for	IN
cord-016476-78r0rsio	21	7	assessing	assess	VBG
cord-016476-78r0rsio	21	8	drug	drug	NN
cord-016476-78r0rsio	21	9	safety	safety	NN
cord-016476-78r0rsio	21	10	and	and	CC
cord-016476-78r0rsio	21	11	then	then	RB
cord-016476-78r0rsio	21	12	reviews	review	VBZ
cord-016476-78r0rsio	21	13	the	the	DT
cord-016476-78r0rsio	21	14	available	available	JJ
cord-016476-78r0rsio	21	15	evidence	evidence	NN
cord-016476-78r0rsio	21	16	for	for	IN
cord-016476-78r0rsio	21	17	respiratory	respiratory	JJ
cord-016476-78r0rsio	21	18	outcomes	outcome	NNS
cord-016476-78r0rsio	21	19	of	of	IN
cord-016476-78r0rsio	21	20	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	21	21	and	and	CC
cord-016476-78r0rsio	21	22	bDMARDs	bdmards	NN
cord-016476-78r0rsio	21	23	in	in	IN
cord-016476-78r0rsio	21	24	RA	RA	NNP
cord-016476-78r0rsio	21	25	-	-	HYPH
cord-016476-78r0rsio	21	26	ILD	ILD	NNP
cord-016476-78r0rsio	21	27	and	and	CC
cord-016476-78r0rsio	21	28	the	the	DT
cord-016476-78r0rsio	21	29	role	role	NN
cord-016476-78r0rsio	21	30	of	of	IN
cord-016476-78r0rsio	21	31	additional	additional	JJ
cord-016476-78r0rsio	21	32	immunosuppression	immunosuppression	NN
cord-016476-78r0rsio	21	33	and	and	CC
cord-016476-78r0rsio	21	34	overarching	overarching	JJ
cord-016476-78r0rsio	21	35	recommendations	recommendation	NNS
cord-016476-78r0rsio	21	36	for	for	IN
cord-016476-78r0rsio	21	37	patient	patient	JJ
cord-016476-78r0rsio	21	38	assessment	assessment	NN
cord-016476-78r0rsio	21	39	and	and	CC
cord-016476-78r0rsio	21	40	management	management	NN
cord-016476-78r0rsio	21	41	of	of	IN
cord-016476-78r0rsio	21	42	ILD	ILD	NNP
cord-016476-78r0rsio	21	43	.	.	.
cord-016476-78r0rsio	22	1	Whilst	whilst	IN
cord-016476-78r0rsio	22	2	randomised	randomised	JJ
cord-016476-78r0rsio	22	3	controlled	control	VBN
cord-016476-78r0rsio	22	4	trials	trial	NNS
cord-016476-78r0rsio	22	5	(	(	-LRB-
cord-016476-78r0rsio	22	6	RCTs	RCTs	NNP
cord-016476-78r0rsio	22	7	)	)	-RRB-
cord-016476-78r0rsio	22	8	are	be	VBP
cord-016476-78r0rsio	22	9	considered	consider	VBN
cord-016476-78r0rsio	22	10	the	the	DT
cord-016476-78r0rsio	22	11	gold	gold	NN
cord-016476-78r0rsio	22	12	standard	standard	NN
cord-016476-78r0rsio	22	13	in	in	IN
cord-016476-78r0rsio	22	14	assessing	assess	VBG
cord-016476-78r0rsio	22	15	efficacy	efficacy	NN
cord-016476-78r0rsio	22	16	of	of	IN
cord-016476-78r0rsio	22	17	treatments	treatment	NNS
cord-016476-78r0rsio	22	18	,	,	,
cord-016476-78r0rsio	22	19	they	-PRON-	PRP
cord-016476-78r0rsio	22	20	have	have	VBP
cord-016476-78r0rsio	22	21	limited	limit	VBN
cord-016476-78r0rsio	22	22	utility	utility	NN
cord-016476-78r0rsio	22	23	in	in	IN
cord-016476-78r0rsio	22	24	terms	term	NNS
cord-016476-78r0rsio	22	25	of	of	IN
cord-016476-78r0rsio	22	26	assessing	assess	VBG
cord-016476-78r0rsio	22	27	safety	safety	NN
cord-016476-78r0rsio	22	28	.	.	.
cord-016476-78r0rsio	23	1	Although	although	IN
cord-016476-78r0rsio	23	2	safety	safety	NN
cord-016476-78r0rsio	23	3	has	have	VBZ
cord-016476-78r0rsio	23	4	been	be	VBN
cord-016476-78r0rsio	23	5	evaluated	evaluate	VBN
cord-016476-78r0rsio	23	6	as	as	IN
cord-016476-78r0rsio	23	7	part	part	NN
cord-016476-78r0rsio	23	8	of	of	IN
cord-016476-78r0rsio	23	9	a	a	DT
cord-016476-78r0rsio	23	10	number	number	NN
cord-016476-78r0rsio	23	11	of	of	IN
cord-016476-78r0rsio	23	12	RCTs	rct	NNS
cord-016476-78r0rsio	23	13	,	,	,
cord-016476-78r0rsio	23	14	uncommon	uncommon	JJ
cord-016476-78r0rsio	23	15	events	event	NNS
cord-016476-78r0rsio	23	16	such	such	JJ
cord-016476-78r0rsio	23	17	as	as	IN
cord-016476-78r0rsio	23	18	new	new	JJ
cord-016476-78r0rsio	23	19	-	-	HYPH
cord-016476-78r0rsio	23	20	onset	onset	NN
cord-016476-78r0rsio	23	21	ILD	ILD	NNP
cord-016476-78r0rsio	23	22	may	may	MD
cord-016476-78r0rsio	23	23	not	not	RB
cord-016476-78r0rsio	23	24	be	be	VB
cord-016476-78r0rsio	23	25	captured	capture	VBN
cord-016476-78r0rsio	23	26	.	.	.
cord-016476-78r0rsio	24	1	RCTs	RCTs	NNP
cord-016476-78r0rsio	24	2	often	often	RB
cord-016476-78r0rsio	24	3	have	have	VBP
cord-016476-78r0rsio	24	4	restrictive	restrictive	JJ
cord-016476-78r0rsio	24	5	eligibility	eligibility	NN
cord-016476-78r0rsio	24	6	criteria	criterion	NNS
cord-016476-78r0rsio	24	7	to	to	TO
cord-016476-78r0rsio	24	8	ensure	ensure	VB
cord-016476-78r0rsio	24	9	a	a	DT
cord-016476-78r0rsio	24	10	homogenous	homogenous	JJ
cord-016476-78r0rsio	24	11	population	population	NN
cord-016476-78r0rsio	24	12	(	(	-LRB-
cord-016476-78r0rsio	24	13	leading	lead	VBG
cord-016476-78r0rsio	24	14	to	to	IN
cord-016476-78r0rsio	24	15	exclusion	exclusion	NN
cord-016476-78r0rsio	24	16	of	of	IN
cord-016476-78r0rsio	24	17	patients	patient	NNS
cord-016476-78r0rsio	24	18	with	with	IN
cord-016476-78r0rsio	24	19	known	know	VBN
cord-016476-78r0rsio	24	20	RA	RA	NNP
cord-016476-78r0rsio	24	21	-	-	HYPH
cord-016476-78r0rsio	24	22	ILD	ILD	NNP
cord-016476-78r0rsio	24	23	)	)	-RRB-
cord-016476-78r0rsio	24	24	,	,	,
cord-016476-78r0rsio	24	25	small	small	JJ
cord-016476-78r0rsio	24	26	numbers	number	NNS
cord-016476-78r0rsio	24	27	of	of	IN
cord-016476-78r0rsio	24	28	patients	patient	NNS
cord-016476-78r0rsio	24	29	and	and	CC
cord-016476-78r0rsio	24	30	a	a	DT
cord-016476-78r0rsio	24	31	short	short	JJ
cord-016476-78r0rsio	24	32	follow	follow	NN
cord-016476-78r0rsio	24	33	-	-	HYPH
cord-016476-78r0rsio	24	34	up	up	NN
cord-016476-78r0rsio	24	35	period	period	NN
cord-016476-78r0rsio	24	36	.	.	.
cord-016476-78r0rsio	25	1	This	this	DT
cord-016476-78r0rsio	25	2	also	also	RB
cord-016476-78r0rsio	25	3	limits	limit	VBZ
cord-016476-78r0rsio	25	4	their	-PRON-	PRP$
cord-016476-78r0rsio	25	5	external	external	JJ
cord-016476-78r0rsio	25	6	validity	validity	NN
cord-016476-78r0rsio	25	7	,	,	,
cord-016476-78r0rsio	25	8	as	as	IN
cord-016476-78r0rsio	25	9	real	real	JJ
cord-016476-78r0rsio	25	10	-	-	HYPH
cord-016476-78r0rsio	25	11	life	life	NN
cord-016476-78r0rsio	25	12	patients	patient	NNS
cord-016476-78r0rsio	25	13	may	may	MD
cord-016476-78r0rsio	25	14	be	be	VB
cord-016476-78r0rsio	25	15	older	old	JJR
cord-016476-78r0rsio	25	16	and	and	CC
cord-016476-78r0rsio	25	17	have	have	VBP
cord-016476-78r0rsio	25	18	multiple	multiple	JJ
cord-016476-78r0rsio	25	19	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	25	20	compared	compare	VBN
cord-016476-78r0rsio	25	21	to	to	IN
cord-016476-78r0rsio	25	22	trial	trial	NN
cord-016476-78r0rsio	25	23	patients	patient	NNS
cord-016476-78r0rsio	25	24	.	.	.
cord-016476-78r0rsio	26	1	Open	open	JJ
cord-016476-78r0rsio	26	2	-	-	HYPH
cord-016476-78r0rsio	26	3	label	label	NN
cord-016476-78r0rsio	26	4	extension	extension	NN
cord-016476-78r0rsio	26	5	(	(	-LRB-
cord-016476-78r0rsio	26	6	OLE	OLE	NNP
cord-016476-78r0rsio	26	7	)	)	-RRB-
cord-016476-78r0rsio	26	8	studies	study	NNS
cord-016476-78r0rsio	26	9	are	be	VBP
cord-016476-78r0rsio	26	10	often	often	RB
cord-016476-78r0rsio	26	11	an	an	DT
cord-016476-78r0rsio	26	12	adjunct	adjunct	NN
cord-016476-78r0rsio	26	13	to	to	IN
cord-016476-78r0rsio	26	14	double	double	JJ
cord-016476-78r0rsio	26	15	-	-	HYPH
cord-016476-78r0rsio	26	16	blind	blind	JJ
cord-016476-78r0rsio	26	17	RCTs	rct	NNS
cord-016476-78r0rsio	26	18	,	,	,
cord-016476-78r0rsio	26	19	and	and	CC
cord-016476-78r0rsio	26	20	although	although	IN
cord-016476-78r0rsio	26	21	they	-PRON-	PRP
cord-016476-78r0rsio	26	22	do	do	VBP
cord-016476-78r0rsio	26	23	allow	allow	VB
cord-016476-78r0rsio	26	24	surveillance	surveillance	NN
cord-016476-78r0rsio	26	25	of	of	IN
cord-016476-78r0rsio	26	26	participants	participant	NNS
cord-016476-78r0rsio	26	27	for	for	IN
cord-016476-78r0rsio	26	28	a	a	DT
cord-016476-78r0rsio	26	29	longer	long	JJR
cord-016476-78r0rsio	26	30	duration	duration	NN
cord-016476-78r0rsio	26	31	,	,	,
cord-016476-78r0rsio	26	32	patients	patient	NNS
cord-016476-78r0rsio	26	33	who	who	WP
cord-016476-78r0rsio	26	34	are	be	VBP
cord-016476-78r0rsio	26	35	intolerant	intolerant	JJ
cord-016476-78r0rsio	26	36	to	to	IN
cord-016476-78r0rsio	26	37	the	the	DT
cord-016476-78r0rsio	26	38	drug	drug	NN
cord-016476-78r0rsio	26	39	during	during	IN
cord-016476-78r0rsio	26	40	the	the	DT
cord-016476-78r0rsio	26	41	previous	previous	JJ
cord-016476-78r0rsio	26	42	study	study	NN
cord-016476-78r0rsio	26	43	will	will	MD
cord-016476-78r0rsio	26	44	not	not	RB
cord-016476-78r0rsio	26	45	be	be	VB
cord-016476-78r0rsio	26	46	able	able	JJ
cord-016476-78r0rsio	26	47	to	to	TO
cord-016476-78r0rsio	26	48	participate	participate	VB
cord-016476-78r0rsio	26	49	in	in	IN
cord-016476-78r0rsio	26	50	the	the	DT
cord-016476-78r0rsio	26	51	extension	extension	NN
cord-016476-78r0rsio	26	52	period	period	NN
cord-016476-78r0rsio	26	53	,	,	,
cord-016476-78r0rsio	26	54	therefore	therefore	RB
cord-016476-78r0rsio	26	55	potentially	potentially	RB
cord-016476-78r0rsio	26	56	leading	lead	VBG
cord-016476-78r0rsio	26	57	to	to	IN
cord-016476-78r0rsio	26	58	underreporting	underreporting	NN
cord-016476-78r0rsio	26	59	of	of	IN
cord-016476-78r0rsio	26	60	adverse	adverse	JJ
cord-016476-78r0rsio	26	61	events	event	NNS
cord-016476-78r0rsio	26	62	(	(	-LRB-
cord-016476-78r0rsio	26	63	AEs	AEs	NNP
cord-016476-78r0rsio	26	64	)	)	-RRB-
cord-016476-78r0rsio	26	65	.	.	.
cord-016476-78r0rsio	27	1	OLE	OLE	NNP
cord-016476-78r0rsio	27	2	studies	study	NNS
cord-016476-78r0rsio	27	3	also	also	RB
cord-016476-78r0rsio	27	4	lack	lack	VBP
cord-016476-78r0rsio	27	5	a	a	DT
cord-016476-78r0rsio	27	6	comparator	comparator	NN
cord-016476-78r0rsio	27	7	group	group	NN
cord-016476-78r0rsio	27	8	and	and	CC
cord-016476-78r0rsio	27	9	are	be	VBP
cord-016476-78r0rsio	27	10	prone	prone	JJ
cord-016476-78r0rsio	27	11	to	to	TO
cord-016476-78r0rsio	27	12	loss	loss	NN
cord-016476-78r0rsio	27	13	to	to	TO
cord-016476-78r0rsio	27	14	follow	follow	VB
cord-016476-78r0rsio	27	15	-	-	HYPH
cord-016476-78r0rsio	27	16	up	up	NN
cord-016476-78r0rsio	27	17	,	,	,
cord-016476-78r0rsio	27	18	making	make	VBG
cord-016476-78r0rsio	27	19	it	-PRON-	PRP
cord-016476-78r0rsio	27	20	difficult	difficult	JJ
cord-016476-78r0rsio	27	21	to	to	TO
cord-016476-78r0rsio	27	22	interpret	interpret	VB
cord-016476-78r0rsio	27	23	the	the	DT
cord-016476-78r0rsio	27	24	rate	rate	NN
cord-016476-78r0rsio	27	25	of	of	IN
cord-016476-78r0rsio	27	26	AEs	ae	NNS
cord-016476-78r0rsio	27	27	.	.	.
cord-016476-78r0rsio	28	1	Post	post	JJ
cord-016476-78r0rsio	28	2	-	-	JJ
cord-016476-78r0rsio	28	3	marketing	marketing	JJ
cord-016476-78r0rsio	28	4	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	28	5	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	28	6	involves	involve	VBZ
cord-016476-78r0rsio	28	7	the	the	DT
cord-016476-78r0rsio	28	8	reporting	reporting	NN
cord-016476-78r0rsio	28	9	of	of	IN
cord-016476-78r0rsio	28	10	suspected	suspect	VBN
cord-016476-78r0rsio	28	11	adverse	adverse	JJ
cord-016476-78r0rsio	28	12	drug	drug	NN
cord-016476-78r0rsio	28	13	reactions	reaction	NNS
cord-016476-78r0rsio	28	14	by	by	IN
cord-016476-78r0rsio	28	15	healthcare	healthcare	NN
cord-016476-78r0rsio	28	16	professionals	professional	NNS
cord-016476-78r0rsio	28	17	or	or	CC
cord-016476-78r0rsio	28	18	patients	patient	NNS
cord-016476-78r0rsio	28	19	.	.	.
cord-016476-78r0rsio	29	1	This	this	DT
cord-016476-78r0rsio	29	2	is	be	VBZ
cord-016476-78r0rsio	29	3	done	do	VBN
cord-016476-78r0rsio	29	4	either	either	CC
cord-016476-78r0rsio	29	5	in	in	IN
cord-016476-78r0rsio	29	6	the	the	DT
cord-016476-78r0rsio	29	7	form	form	NN
cord-016476-78r0rsio	29	8	of	of	IN
cord-016476-78r0rsio	29	9	case	case	NN
cord-016476-78r0rsio	30	1	reports	report	NNS
cord-016476-78r0rsio	30	2	/	/	SYM
cord-016476-78r0rsio	30	3	series	series	NN
cord-016476-78r0rsio	30	4	to	to	IN
cord-016476-78r0rsio	30	5	medical	medical	JJ
cord-016476-78r0rsio	30	6	journals	journal	NNS
cord-016476-78r0rsio	30	7	or	or	CC
cord-016476-78r0rsio	30	8	to	to	IN
cord-016476-78r0rsio	30	9	national	national	JJ
cord-016476-78r0rsio	30	10	or	or	CC
cord-016476-78r0rsio	30	11	international	international	JJ
cord-016476-78r0rsio	30	12	monitoring	monitoring	NN
cord-016476-78r0rsio	30	13	centres	centre	NNS
cord-016476-78r0rsio	30	14	,	,	,
cord-016476-78r0rsio	30	15	such	such	JJ
cord-016476-78r0rsio	30	16	as	as	IN
cord-016476-78r0rsio	30	17	the	the	DT
cord-016476-78r0rsio	30	18	UK	UK	NNP
cord-016476-78r0rsio	30	19	Medicines	Medicines	NNPS
cord-016476-78r0rsio	30	20	and	and	CC
cord-016476-78r0rsio	30	21	Healthcare	Healthcare	NNP
cord-016476-78r0rsio	30	22	products	product	NNS
cord-016476-78r0rsio	30	23	Regulatory	Regulatory	NNP
cord-016476-78r0rsio	30	24	Agency	Agency	NNP
cord-016476-78r0rsio	30	25	(	(	-LRB-
cord-016476-78r0rsio	30	26	MHRA	MHRA	NNP
cord-016476-78r0rsio	30	27	)	)	-RRB-
cord-016476-78r0rsio	30	28	'	'	``
cord-016476-78r0rsio	30	29	Yellow	Yellow	NNP
cord-016476-78r0rsio	30	30	Card	Card	NNP
cord-016476-78r0rsio	30	31	Scheme	Scheme	NNP
cord-016476-78r0rsio	30	32	'	'	''
cord-016476-78r0rsio	30	33	,	,	,
cord-016476-78r0rsio	30	34	European	European	NNP
cord-016476-78r0rsio	30	35	Medicines	Medicines	NNPS
cord-016476-78r0rsio	30	36	Agency	Agency	NNP
cord-016476-78r0rsio	30	37	EudraVigilance	EudraVigilance	NNP
cord-016476-78r0rsio	30	38	database	database	NN
cord-016476-78r0rsio	30	39	and	and	CC
cord-016476-78r0rsio	30	40	the	the	DT
cord-016476-78r0rsio	30	41	US	US	NNP
cord-016476-78r0rsio	30	42	Food	Food	NNP
cord-016476-78r0rsio	30	43	and	and	CC
cord-016476-78r0rsio	30	44	Drug	Drug	NNP
cord-016476-78r0rsio	30	45	Administration	Administration	NNP
cord-016476-78r0rsio	30	46	(	(	-LRB-
cord-016476-78r0rsio	30	47	FDA	FDA	NNP
cord-016476-78r0rsio	30	48	)	)	-RRB-
cord-016476-78r0rsio	30	49	MedWatch	MedWatch	NNP
cord-016476-78r0rsio	30	50	programme	programme	NN
cord-016476-78r0rsio	30	51	.	.	.
cord-016476-78r0rsio	31	1	Whilst	whilst	IN
cord-016476-78r0rsio	31	2	these	these	DT
cord-016476-78r0rsio	31	3	are	be	VBP
cord-016476-78r0rsio	31	4	useful	useful	JJ
cord-016476-78r0rsio	31	5	for	for	IN
cord-016476-78r0rsio	31	6	drug	drug	NN
cord-016476-78r0rsio	31	7	safety	safety	NN
cord-016476-78r0rsio	31	8	signal	signal	NN
cord-016476-78r0rsio	31	9	detection	detection	NN
cord-016476-78r0rsio	31	10	,	,	,
cord-016476-78r0rsio	31	11	there	there	EX
cord-016476-78r0rsio	31	12	is	be	VBZ
cord-016476-78r0rsio	31	13	no	no	DT
cord-016476-78r0rsio	31	14	available	available	JJ
cord-016476-78r0rsio	31	15	denominator	denominator	NN
cord-016476-78r0rsio	31	16	to	to	TO
cord-016476-78r0rsio	31	17	calculate	calculate	VB
cord-016476-78r0rsio	31	18	rates	rate	NNS
cord-016476-78r0rsio	31	19	of	of	IN
cord-016476-78r0rsio	31	20	AE	AE	NNP
cord-016476-78r0rsio	31	21	or	or	CC
cord-016476-78r0rsio	31	22	to	to	TO
cord-016476-78r0rsio	31	23	determine	determine	VB
cord-016476-78r0rsio	31	24	whether	whether	IN
cord-016476-78r0rsio	31	25	these	these	DT
cord-016476-78r0rsio	31	26	reported	report	VBN
cord-016476-78r0rsio	31	27	cases	case	NNS
cord-016476-78r0rsio	31	28	represent	represent	VBP
cord-016476-78r0rsio	31	29	an	an	DT
cord-016476-78r0rsio	31	30	increased	increase	VBN
cord-016476-78r0rsio	31	31	incidence	incidence	NN
cord-016476-78r0rsio	31	32	above	above	IN
cord-016476-78r0rsio	31	33	the	the	DT
cord-016476-78r0rsio	31	34	background	background	NN
cord-016476-78r0rsio	31	35	population	population	NN
cord-016476-78r0rsio	31	36	rate	rate	NN
cord-016476-78r0rsio	31	37	.	.	.
cord-016476-78r0rsio	32	1	Observational	observational	JJ
cord-016476-78r0rsio	32	2	cohorts	cohort	NNS
cord-016476-78r0rsio	32	3	have	have	VBP
cord-016476-78r0rsio	32	4	the	the	DT
cord-016476-78r0rsio	32	5	advantage	advantage	NN
cord-016476-78r0rsio	32	6	of	of	IN
cord-016476-78r0rsio	32	7	being	be	VBG
cord-016476-78r0rsio	32	8	able	able	JJ
cord-016476-78r0rsio	32	9	to	to	TO
cord-016476-78r0rsio	32	10	examine	examine	VB
cord-016476-78r0rsio	32	11	drug	drug	NN
cord-016476-78r0rsio	32	12	safety	safety	NN
cord-016476-78r0rsio	32	13	in	in	IN
cord-016476-78r0rsio	32	14	a	a	DT
cord-016476-78r0rsio	32	15	'	'	``
cord-016476-78r0rsio	32	16	real	real	JJ
cord-016476-78r0rsio	32	17	-	-	HYPH
cord-016476-78r0rsio	32	18	world	world	NN
cord-016476-78r0rsio	32	19	'	'	''
cord-016476-78r0rsio	32	20	setting	setting	NN
cord-016476-78r0rsio	32	21	and	and	CC
cord-016476-78r0rsio	32	22	can	can	MD
cord-016476-78r0rsio	32	23	follow	follow	VB
cord-016476-78r0rsio	32	24	large	large	JJ
cord-016476-78r0rsio	32	25	numbers	number	NNS
cord-016476-78r0rsio	32	26	of	of	IN
cord-016476-78r0rsio	32	27	patients	patient	NNS
cord-016476-78r0rsio	32	28	for	for	IN
cord-016476-78r0rsio	32	29	long	long	JJ
cord-016476-78r0rsio	32	30	periods	period	NNS
cord-016476-78r0rsio	32	31	of	of	IN
cord-016476-78r0rsio	32	32	time	time	NN
cord-016476-78r0rsio	32	33	.	.	.
cord-016476-78r0rsio	33	1	They	-PRON-	PRP
cord-016476-78r0rsio	33	2	can	can	MD
cord-016476-78r0rsio	33	3	therefore	therefore	RB
cord-016476-78r0rsio	33	4	study	study	VB
cord-016476-78r0rsio	33	5	the	the	DT
cord-016476-78r0rsio	33	6	medium	medium	NN
cord-016476-78r0rsio	33	7	-	-	HYPH
cord-016476-78r0rsio	33	8	to	to	IN
cord-016476-78r0rsio	33	9	long	long	JJ
cord-016476-78r0rsio	33	10	-	-	HYPH
cord-016476-78r0rsio	33	11	term	term	NN
cord-016476-78r0rsio	33	12	side	side	NN
cord-016476-78r0rsio	33	13	effects	effect	NNS
cord-016476-78r0rsio	33	14	of	of	IN
cord-016476-78r0rsio	33	15	a	a	DT
cord-016476-78r0rsio	33	16	drug	drug	NN
cord-016476-78r0rsio	33	17	that	that	WDT
cord-016476-78r0rsio	33	18	might	may	MD
cord-016476-78r0rsio	33	19	otherwise	otherwise	RB
cord-016476-78r0rsio	33	20	be	be	VB
cord-016476-78r0rsio	33	21	missed	miss	VBN
cord-016476-78r0rsio	33	22	in	in	IN
cord-016476-78r0rsio	33	23	clinical	clinical	JJ
cord-016476-78r0rsio	33	24	trials	trial	NNS
cord-016476-78r0rsio	33	25	or	or	CC
cord-016476-78r0rsio	33	26	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	33	27	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	33	28	.	.	.
cord-016476-78r0rsio	34	1	However	however	RB
cord-016476-78r0rsio	34	2	these	these	DT
cord-016476-78r0rsio	34	3	come	come	VBP
cord-016476-78r0rsio	34	4	with	with	IN
cord-016476-78r0rsio	34	5	the	the	DT
cord-016476-78r0rsio	34	6	challenge	challenge	NN
cord-016476-78r0rsio	34	7	of	of	IN
cord-016476-78r0rsio	34	8	interpreting	interpret	VBG
cord-016476-78r0rsio	34	9	results	result	NNS
cord-016476-78r0rsio	34	10	in	in	IN
cord-016476-78r0rsio	34	11	the	the	DT
cord-016476-78r0rsio	34	12	context	context	NN
cord-016476-78r0rsio	34	13	of	of	IN
cord-016476-78r0rsio	34	14	clinical	clinical	JJ
cord-016476-78r0rsio	34	15	decisions	decision	NNS
cord-016476-78r0rsio	34	16	,	,	,
cord-016476-78r0rsio	34	17	with	with	IN
cord-016476-78r0rsio	34	18	their	-PRON-	PRP$
cord-016476-78r0rsio	34	19	consequent	consequent	JJ
cord-016476-78r0rsio	34	20	biases	bias	NNS
cord-016476-78r0rsio	34	21	and	and	CC
cord-016476-78r0rsio	34	22	confounding	confound	VBG
cord-016476-78r0rsio	34	23	.	.	.
cord-016476-78r0rsio	35	1	Each	each	DT
cord-016476-78r0rsio	35	2	of	of	IN
cord-016476-78r0rsio	35	3	these	these	DT
cord-016476-78r0rsio	35	4	methods	method	NNS
cord-016476-78r0rsio	35	5	can	can	MD
cord-016476-78r0rsio	35	6	employ	employ	VB
cord-016476-78r0rsio	35	7	a	a	DT
cord-016476-78r0rsio	35	8	wide	wide	JJ
cord-016476-78r0rsio	35	9	array	array	NN
cord-016476-78r0rsio	35	10	of	of	IN
cord-016476-78r0rsio	35	11	terminology	terminology	NN
cord-016476-78r0rsio	35	12	to	to	TO
cord-016476-78r0rsio	35	13	describe	describe	VB
cord-016476-78r0rsio	35	14	various	various	JJ
cord-016476-78r0rsio	35	15	forms	form	NNS
cord-016476-78r0rsio	35	16	of	of	IN
cord-016476-78r0rsio	35	17	respiratory	respiratory	JJ
cord-016476-78r0rsio	35	18	AEs	ae	NNS
cord-016476-78r0rsio	35	19	.	.	.
cord-016476-78r0rsio	36	1	For	for	IN
cord-016476-78r0rsio	36	2	example	example	NN
cord-016476-78r0rsio	36	3	,	,	,
cord-016476-78r0rsio	36	4	parenchymal	parenchymal	NN
cord-016476-78r0rsio	36	5	lung	lung	NN
cord-016476-78r0rsio	36	6	disorders	disorder	NNS
cord-016476-78r0rsio	36	7	are	be	VBP
cord-016476-78r0rsio	36	8	called	call	VBN
cord-016476-78r0rsio	36	9	many	many	JJ
cord-016476-78r0rsio	36	10	things	thing	NNS
cord-016476-78r0rsio	36	11	from	from	IN
cord-016476-78r0rsio	36	12	'	'	``
cord-016476-78r0rsio	36	13	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	36	14	fibrosis	fibrosis	NN
cord-016476-78r0rsio	36	15	'	'	''
cord-016476-78r0rsio	36	16	to	to	IN
cord-016476-78r0rsio	36	17	'	'	``
cord-016476-78r0rsio	36	18	allergic	allergic	JJ
cord-016476-78r0rsio	36	19	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	36	20	'	'	''
cord-016476-78r0rsio	36	21	.	.	.
cord-016476-78r0rsio	37	1	There	there	EX
cord-016476-78r0rsio	37	2	are	be	VBP
cord-016476-78r0rsio	37	3	also	also	RB
cord-016476-78r0rsio	37	4	challenges	challenge	NNS
cord-016476-78r0rsio	37	5	in	in	IN
cord-016476-78r0rsio	37	6	differentiating	differentiate	VBG
cord-016476-78r0rsio	37	7	between	between	IN
cord-016476-78r0rsio	37	8	respiratory	respiratory	JJ
cord-016476-78r0rsio	37	9	conditions	condition	NNS
cord-016476-78r0rsio	37	10	with	with	IN
cord-016476-78r0rsio	37	11	different	different	JJ
cord-016476-78r0rsio	37	12	aetiologies	aetiology	NNS
cord-016476-78r0rsio	37	13	but	but	CC
cord-016476-78r0rsio	37	14	similar	similar	JJ
cord-016476-78r0rsio	37	15	clinical	clinical	JJ
cord-016476-78r0rsio	37	16	presentations	presentation	NNS
cord-016476-78r0rsio	37	17	.	.	.
cord-016476-78r0rsio	38	1	RCTs	RCTs	NNP
cord-016476-78r0rsio	38	2	,	,	,
cord-016476-78r0rsio	38	3	for	for	IN
cord-016476-78r0rsio	38	4	example	example	NN
cord-016476-78r0rsio	38	5	,	,	,
cord-016476-78r0rsio	38	6	can	can	MD
cord-016476-78r0rsio	38	7	report	report	VB
cord-016476-78r0rsio	38	8	on	on	IN
cord-016476-78r0rsio	38	9	culturenegative	culturenegative	JJ
cord-016476-78r0rsio	38	10	pneumonias	pneumonia	NNS
cord-016476-78r0rsio	38	11	or	or	CC
cord-016476-78r0rsio	38	12	'	'	``
cord-016476-78r0rsio	38	13	community	community	NN
cord-016476-78r0rsio	38	14	-	-	HYPH
cord-016476-78r0rsio	38	15	acquired	acquire	VBN
cord-016476-78r0rsio	38	16	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	38	17	'	'	''
cord-016476-78r0rsio	38	18	,	,	,
cord-016476-78r0rsio	38	19	which	which	WDT
cord-016476-78r0rsio	38	20	may	may	MD
cord-016476-78r0rsio	38	21	indeed	indeed	RB
cord-016476-78r0rsio	38	22	be	be	VB
cord-016476-78r0rsio	38	23	idiosyncratic	idiosyncratic	JJ
cord-016476-78r0rsio	38	24	drug	drug	NN
cord-016476-78r0rsio	38	25	reactions	reaction	NNS
cord-016476-78r0rsio	38	26	or	or	CC
cord-016476-78r0rsio	38	27	pneumonias	pneumonia	NNS
cord-016476-78r0rsio	38	28	secondary	secondary	JJ
cord-016476-78r0rsio	38	29	to	to	IN
cord-016476-78r0rsio	38	30	a	a	DT
cord-016476-78r0rsio	38	31	resistant	resistant	JJ
cord-016476-78r0rsio	38	32	microorganism	microorganism	NN
cord-016476-78r0rsio	38	33	:	:	:
cord-016476-78r0rsio	38	34	often	often	RB
cord-016476-78r0rsio	38	35	patients	patient	NNS
cord-016476-78r0rsio	38	36	are	be	VBP
cord-016476-78r0rsio	38	37	administered	administer	VBN
cord-016476-78r0rsio	38	38	a	a	DT
cord-016476-78r0rsio	38	39	combination	combination	NN
cord-016476-78r0rsio	38	40	of	of	IN
cord-016476-78r0rsio	38	41	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	38	42	and	and	CC
cord-016476-78r0rsio	38	43	antibiotics	antibiotic	NNS
cord-016476-78r0rsio	38	44	due	due	JJ
cord-016476-78r0rsio	38	45	to	to	IN
cord-016476-78r0rsio	38	46	initial	initial	JJ
cord-016476-78r0rsio	38	47	uncertainty	uncertainty	NN
cord-016476-78r0rsio	38	48	of	of	IN
cord-016476-78r0rsio	38	49	the	the	DT
cord-016476-78r0rsio	38	50	diagnosis	diagnosis	NN
cord-016476-78r0rsio	38	51	.	.	.
cord-016476-78r0rsio	39	1	The	the	DT
cord-016476-78r0rsio	39	2	data	datum	NNS
cord-016476-78r0rsio	39	3	available	available	JJ
cord-016476-78r0rsio	39	4	for	for	IN
cord-016476-78r0rsio	39	5	this	this	DT
cord-016476-78r0rsio	39	6	chapter	chapter	NN
cord-016476-78r0rsio	39	7	come	come	VB
cord-016476-78r0rsio	39	8	from	from	IN
cord-016476-78r0rsio	39	9	all	all	DT
cord-016476-78r0rsio	39	10	of	of	IN
cord-016476-78r0rsio	39	11	the	the	DT
cord-016476-78r0rsio	39	12	above	above	JJ
cord-016476-78r0rsio	39	13	study	study	NN
cord-016476-78r0rsio	39	14	designs	design	NNS
cord-016476-78r0rsio	39	15	.	.	.
cord-016476-78r0rsio	40	1	Having	have	VBG
cord-016476-78r0rsio	40	2	been	be	VBN
cord-016476-78r0rsio	40	3	in	in	IN
cord-016476-78r0rsio	40	4	use	use	NN
cord-016476-78r0rsio	40	5	for	for	IN
cord-016476-78r0rsio	40	6	RA	RA	NNP
cord-016476-78r0rsio	40	7	for	for	IN
cord-016476-78r0rsio	40	8	the	the	DT
cord-016476-78r0rsio	40	9	longest	long	JJS
cord-016476-78r0rsio	40	10	duration	duration	NN
cord-016476-78r0rsio	40	11	,	,	,
cord-016476-78r0rsio	40	12	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	40	13	and	and	CC
cord-016476-78r0rsio	40	14	tumour	tumour	NN
cord-016476-78r0rsio	40	15	necrosis	necrosis	NN
cord-016476-78r0rsio	40	16	factor	factor	NN
cord-016476-78r0rsio	40	17	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	40	18	(	(	-LRB-
cord-016476-78r0rsio	40	19	TNFis	tnfis	NN
cord-016476-78r0rsio	40	20	)	)	-RRB-
cord-016476-78r0rsio	40	21	have	have	VBP
cord-016476-78r0rsio	40	22	the	the	DT
cord-016476-78r0rsio	40	23	most	most	RBS
cord-016476-78r0rsio	40	24	observational	observational	JJ
cord-016476-78r0rsio	40	25	evidence	evidence	NN
cord-016476-78r0rsio	40	26	,	,	,
cord-016476-78r0rsio	40	27	but	but	CC
cord-016476-78r0rsio	40	28	not	not	RB
cord-016476-78r0rsio	40	29	in	in	IN
cord-016476-78r0rsio	40	30	all	all	DT
cord-016476-78r0rsio	40	31	cases	case	NNS
cord-016476-78r0rsio	40	32	.	.	.
cord-016476-78r0rsio	41	1	Newer	new	JJR
cord-016476-78r0rsio	41	2	TNFis	TNFis	NNP
cord-016476-78r0rsio	41	3	,	,	,
cord-016476-78r0rsio	41	4	nbDMARD	nbdmard	JJ
cord-016476-78r0rsio	41	5	and	and	CC
cord-016476-78r0rsio	41	6	emerging	emerge	VBG
cord-016476-78r0rsio	41	7	novel	novel	JJ
cord-016476-78r0rsio	41	8	therapies	therapy	NNS
cord-016476-78r0rsio	41	9	recently	recently	RB
cord-016476-78r0rsio	41	10	licensed	license	VBN
cord-016476-78r0rsio	41	11	for	for	IN
cord-016476-78r0rsio	41	12	RA	RA	NNP
cord-016476-78r0rsio	41	13	have	have	VBP
cord-016476-78r0rsio	41	14	not	not	RB
cord-016476-78r0rsio	41	15	had	have	VBN
cord-016476-78r0rsio	41	16	the	the	DT
cord-016476-78r0rsio	41	17	opportunity	opportunity	NN
cord-016476-78r0rsio	41	18	for	for	IN
cord-016476-78r0rsio	41	19	longer	long	JJR
cord-016476-78r0rsio	41	20	follow	follow	NN
cord-016476-78r0rsio	41	21	-	-	HYPH
cord-016476-78r0rsio	41	22	up	up	NN
cord-016476-78r0rsio	41	23	;	;	:
cord-016476-78r0rsio	41	24	therefore	therefore	RB
cord-016476-78r0rsio	41	25	,	,	,
cord-016476-78r0rsio	41	26	experience	experience	VB
cord-016476-78r0rsio	41	27	about	about	IN
cord-016476-78r0rsio	41	28	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	41	29	safety	safety	NN
cord-016476-78r0rsio	41	30	may	may	MD
cord-016476-78r0rsio	41	31	be	be	VB
cord-016476-78r0rsio	41	32	restricted	restrict	VBN
cord-016476-78r0rsio	41	33	to	to	IN
cord-016476-78r0rsio	41	34	clinical	clinical	JJ
cord-016476-78r0rsio	41	35	trials	trial	NNS
cord-016476-78r0rsio	41	36	and	and	CC
cord-016476-78r0rsio	41	37	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	41	38	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	41	39	.	.	.
cord-016476-78r0rsio	42	1	Methotrexate	Methotrexate	NNP
cord-016476-78r0rsio	42	2	(	(	-LRB-
cord-016476-78r0rsio	42	3	MTX	MTX	NNP
cord-016476-78r0rsio	42	4	)	)	-RRB-
cord-016476-78r0rsio	42	5	has	have	VBZ
cord-016476-78r0rsio	42	6	been	be	VBN
cord-016476-78r0rsio	42	7	described	describe	VBN
cord-016476-78r0rsio	42	8	as	as	IN
cord-016476-78r0rsio	42	9	the	the	DT
cord-016476-78r0rsio	42	10	anchor	anchor	JJ
cord-016476-78r0rsio	42	11	drug	drug	NN
cord-016476-78r0rsio	42	12	in	in	IN
cord-016476-78r0rsio	42	13	RA	RA	NNP
cord-016476-78r0rsio	42	14	treatment	treatment	NN
cord-016476-78r0rsio	42	15	,	,	,
cord-016476-78r0rsio	42	16	as	as	IN
cord-016476-78r0rsio	42	17	it	-PRON-	PRP
cord-016476-78r0rsio	42	18	is	be	VBZ
cord-016476-78r0rsio	42	19	often	often	RB
cord-016476-78r0rsio	42	20	used	use	VBN
cord-016476-78r0rsio	42	21	first	first	JJ
cord-016476-78r0rsio	42	22	line	line	NN
cord-016476-78r0rsio	42	23	at	at	IN
cord-016476-78r0rsio	42	24	diagnosis	diagnosis	NN
cord-016476-78r0rsio	42	25	,	,	,
cord-016476-78r0rsio	42	26	in	in	IN
cord-016476-78r0rsio	42	27	combination	combination	NN
cord-016476-78r0rsio	42	28	with	with	IN
cord-016476-78r0rsio	42	29	other	other	JJ
cord-016476-78r0rsio	42	30	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	42	31	and	and	CC
cord-016476-78r0rsio	42	32	concomitantly	concomitantly	RB
cord-016476-78r0rsio	42	33	with	with	IN
cord-016476-78r0rsio	42	34	biologics	biologic	NNS
cord-016476-78r0rsio	42	35	,	,	,
cord-016476-78r0rsio	42	36	following	follow	VBG
cord-016476-78r0rsio	42	37	failure	failure	NN
cord-016476-78r0rsio	42	38	of	of	IN
cord-016476-78r0rsio	42	39	traditional	traditional	JJ
cord-016476-78r0rsio	42	40	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	42	41	for	for	IN
cord-016476-78r0rsio	42	42	controlling	control	VBG
cord-016476-78r0rsio	42	43	articular	articular	JJ
cord-016476-78r0rsio	42	44	disease	disease	NN
cord-016476-78r0rsio	42	45	.	.	.
cord-016476-78r0rsio	43	1	It	-PRON-	PRP
cord-016476-78r0rsio	43	2	inhibits	inhibit	VBZ
cord-016476-78r0rsio	43	3	folic	folic	JJ
cord-016476-78r0rsio	43	4	acid	acid	NN
cord-016476-78r0rsio	43	5	and	and	CC
cord-016476-78r0rsio	43	6	purine	purine	NN
cord-016476-78r0rsio	43	7	metabolism	metabolism	NN
cord-016476-78r0rsio	43	8	along	along	IN
cord-016476-78r0rsio	43	9	with	with	IN
cord-016476-78r0rsio	43	10	T	t	NN
cord-016476-78r0rsio	43	11	-	-	HYPH
cord-016476-78r0rsio	43	12	cell	cell	NN
cord-016476-78r0rsio	43	13	activation	activation	NN
cord-016476-78r0rsio	43	14	.	.	.
cord-016476-78r0rsio	44	1	MTX	MTX	NNP
cord-016476-78r0rsio	44	2	-	-	HYPH
cord-016476-78r0rsio	44	3	induced	induce	VBN
cord-016476-78r0rsio	44	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	44	5	injury	injury	NN
cord-016476-78r0rsio	44	6	was	be	VBD
cord-016476-78r0rsio	44	7	initially	initially	RB
cord-016476-78r0rsio	44	8	reported	report	VBN
cord-016476-78r0rsio	44	9	in	in	IN
cord-016476-78r0rsio	44	10	children	child	NNS
cord-016476-78r0rsio	44	11	with	with	IN
cord-016476-78r0rsio	44	12	leukaemia	leukaemia	NN
cord-016476-78r0rsio	44	13	in	in	IN
cord-016476-78r0rsio	44	14	the	the	DT
cord-016476-78r0rsio	44	15	1960s	1960	NNS
cord-016476-78r0rsio	44	16	[	[	-LRB-
cord-016476-78r0rsio	44	17	4	4	CD
cord-016476-78r0rsio	44	18	]	]	-RRB-
cord-016476-78r0rsio	44	19	,	,	,
cord-016476-78r0rsio	44	20	followed	follow	VBN
cord-016476-78r0rsio	44	21	by	by	IN
cord-016476-78r0rsio	44	22	a	a	DT
cord-016476-78r0rsio	44	23	case	case	NN
cord-016476-78r0rsio	44	24	series	series	NN
cord-016476-78r0rsio	44	25	in	in	IN
cord-016476-78r0rsio	44	26	treated	treat	VBN
cord-016476-78r0rsio	44	27	patients	patient	NNS
cord-016476-78r0rsio	44	28	with	with	IN
cord-016476-78r0rsio	44	29	RA	RA	NNP
cord-016476-78r0rsio	44	30	in	in	IN
cord-016476-78r0rsio	44	31	1983	1983	CD
cord-016476-78r0rsio	44	32	[	[	-LRB-
cord-016476-78r0rsio	44	33	5	5	CD
cord-016476-78r0rsio	44	34	]	]	-RRB-
cord-016476-78r0rsio	44	35	.	.	.
cord-016476-78r0rsio	45	1	Following	follow	VBG
cord-016476-78r0rsio	45	2	a	a	DT
cord-016476-78r0rsio	45	3	review	review	NN
cord-016476-78r0rsio	45	4	of	of	IN
cord-016476-78r0rsio	45	5	123	123	CD
cord-016476-78r0rsio	45	6	cases	case	NNS
cord-016476-78r0rsio	45	7	of	of	IN
cord-016476-78r0rsio	45	8	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	45	9	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	45	10	in	in	IN
cord-016476-78r0rsio	45	11	the	the	DT
cord-016476-78r0rsio	45	12	year	year	NN
cord-016476-78r0rsio	45	13	2000	2000	CD
cord-016476-78r0rsio	45	14	,	,	,
cord-016476-78r0rsio	45	15	63	63	CD
cord-016476-78r0rsio	45	16	%	%	NN
cord-016476-78r0rsio	45	17	of	of	IN
cord-016476-78r0rsio	45	18	cases	case	NNS
cord-016476-78r0rsio	45	19	arose	arise	VBD
cord-016476-78r0rsio	45	20	in	in	IN
cord-016476-78r0rsio	45	21	patients	patient	NNS
cord-016476-78r0rsio	45	22	with	with	IN
cord-016476-78r0rsio	45	23	RA	RA	NNP
cord-016476-78r0rsio	45	24	(	(	-LRB-
cord-016476-78r0rsio	45	25	dose	dose	JJ
cord-016476-78r0rsio	45	26	range	range	NN
cord-016476-78r0rsio	45	27	2.5	2.5	CD
cord-016476-78r0rsio	45	28	-	-	SYM
cord-016476-78r0rsio	45	29	15	15	CD
cord-016476-78r0rsio	45	30	mg	mg	NNP
cord-016476-78r0rsio	45	31	/	/	SYM
cord-016476-78r0rsio	45	32	week	week	NN
cord-016476-78r0rsio	45	33	)	)	-RRB-
cord-016476-78r0rsio	45	34	,	,	,
cord-016476-78r0rsio	45	35	23	23	CD
cord-016476-78r0rsio	45	36	%	%	NN
cord-016476-78r0rsio	45	37	occurred	occur	VBD
cord-016476-78r0rsio	45	38	during	during	IN
cord-016476-78r0rsio	45	39	intensification	intensification	NN
cord-016476-78r0rsio	45	40	/	/	SYM
cord-016476-78r0rsio	45	41	consolidation	consolidation	NN
cord-016476-78r0rsio	45	42	treatment	treatment	NN
cord-016476-78r0rsio	45	43	for	for	IN
cord-016476-78r0rsio	45	44	leukaemia	leukaemia	NN
cord-016476-78r0rsio	45	45	(	(	-LRB-
cord-016476-78r0rsio	45	46	dose	dose	NN
cord-016476-78r0rsio	45	47	range	range	NN
cord-016476-78r0rsio	45	48	20	20	CD
cord-016476-78r0rsio	45	49	-	-	SYM
cord-016476-78r0rsio	45	50	80	80	CD
cord-016476-78r0rsio	45	51	mg	mg	NNP
cord-016476-78r0rsio	45	52	/	/	SYM
cord-016476-78r0rsio	45	53	week	week	NN
cord-016476-78r0rsio	45	54	)	)	-RRB-
cord-016476-78r0rsio	45	55	,	,	,
cord-016476-78r0rsio	45	56	and	and	CC
cord-016476-78r0rsio	45	57	8	8	CD
cord-016476-78r0rsio	45	58	%	%	NN
cord-016476-78r0rsio	45	59	were	be	VBD
cord-016476-78r0rsio	45	60	in	in	IN
cord-016476-78r0rsio	45	61	patients	patient	NNS
cord-016476-78r0rsio	45	62	treated	treat	VBN
cord-016476-78r0rsio	45	63	for	for	IN
cord-016476-78r0rsio	45	64	other	other	JJ
cord-016476-78r0rsio	45	65	malignancies	malignancy	NNS
cord-016476-78r0rsio	45	66	(	(	-LRB-
cord-016476-78r0rsio	45	67	dose	dose	NN
cord-016476-78r0rsio	45	68	range	range	NN
cord-016476-78r0rsio	45	69	15	15	CD
cord-016476-78r0rsio	45	70	-	-	SYM
cord-016476-78r0rsio	45	71	1400	1400	CD
cord-016476-78r0rsio	45	72	mg	mg	NNP
cord-016476-78r0rsio	45	73	/	/	SYM
cord-016476-78r0rsio	45	74	week	week	NN
cord-016476-78r0rsio	45	75	)	)	-RRB-
cord-016476-78r0rsio	45	76	[	[	-LRB-
cord-016476-78r0rsio	45	77	6	6	CD
cord-016476-78r0rsio	45	78	]	]	-RRB-
cord-016476-78r0rsio	45	79	.	.	.
cord-016476-78r0rsio	46	1	Whilst	whilst	IN
cord-016476-78r0rsio	46	2	mortality	mortality	NN
cord-016476-78r0rsio	46	3	rates	rate	NNS
cord-016476-78r0rsio	46	4	have	have	VBP
cord-016476-78r0rsio	46	5	been	be	VBN
cord-016476-78r0rsio	46	6	reported	report	VBN
cord-016476-78r0rsio	46	7	up	up	IN
cord-016476-78r0rsio	46	8	to	to	TO
cord-016476-78r0rsio	46	9	17	17	CD
cord-016476-78r0rsio	46	10	%	%	NN
cord-016476-78r0rsio	46	11	,	,	,
cord-016476-78r0rsio	46	12	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	46	13	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	46	14	is	be	VBZ
cord-016476-78r0rsio	46	15	reported	report	VBN
cord-016476-78r0rsio	46	16	to	to	TO
cord-016476-78r0rsio	46	17	be	be	VB
cord-016476-78r0rsio	46	18	a	a	DT
cord-016476-78r0rsio	46	19	rare	rare	JJ
cord-016476-78r0rsio	46	20	AE	ae	NN
cord-016476-78r0rsio	46	21	in	in	IN
cord-016476-78r0rsio	46	22	RA	RA	NNP
cord-016476-78r0rsio	46	23	patients	patient	NNS
cord-016476-78r0rsio	46	24	.	.	.
cord-016476-78r0rsio	47	1	In	in	IN
cord-016476-78r0rsio	47	2	a	a	DT
cord-016476-78r0rsio	47	3	systematic	systematic	JJ
cord-016476-78r0rsio	47	4	literature	literature	NN
cord-016476-78r0rsio	47	5	review	review	NN
cord-016476-78r0rsio	47	6	of	of	IN
cord-016476-78r0rsio	47	7	3463	3463	CD
cord-016476-78r0rsio	47	8	patients	patient	NNS
cord-016476-78r0rsio	47	9	with	with	IN
cord-016476-78r0rsio	47	10	RA	RA	NNP
cord-016476-78r0rsio	47	11	on	on	IN
cord-016476-78r0rsio	47	12	MTX	MTX	NNP
cord-016476-78r0rsio	47	13	,	,	,
cord-016476-78r0rsio	47	14	84	84	CD
cord-016476-78r0rsio	47	15	patients	patient	NNS
cord-016476-78r0rsio	47	16	(	(	-LRB-
cord-016476-78r0rsio	47	17	2	2	CD
cord-016476-78r0rsio	47	18	%	%	NN
cord-016476-78r0rsio	47	19	)	)	-RRB-
cord-016476-78r0rsio	47	20	had	have	VBD
cord-016476-78r0rsio	47	21	some	some	DT
cord-016476-78r0rsio	47	22	type	type	NN
cord-016476-78r0rsio	47	23	of	of	IN
cord-016476-78r0rsio	47	24	lung	lung	NN
cord-016476-78r0rsio	47	25	toxicity	toxicity	NN
cord-016476-78r0rsio	47	26	,	,	,
cord-016476-78r0rsio	47	27	but	but	CC
cord-016476-78r0rsio	47	28	only	only	RB
cord-016476-78r0rsio	47	29	15	15	CD
cord-016476-78r0rsio	47	30	patients	patient	NNS
cord-016476-78r0rsio	47	31	were	be	VBD
cord-016476-78r0rsio	47	32	felt	feel	VBN
cord-016476-78r0rsio	47	33	to	to	TO
cord-016476-78r0rsio	47	34	be	be	VB
cord-016476-78r0rsio	47	35	definitive	definitive	JJ
cord-016476-78r0rsio	47	36	cases	case	NNS
cord-016476-78r0rsio	47	37	of	of	IN
cord-016476-78r0rsio	47	38	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	47	39	attributable	attributable	JJ
cord-016476-78r0rsio	47	40	to	to	IN
cord-016476-78r0rsio	47	41	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	47	42	(	(	-LRB-
cord-016476-78r0rsio	47	43	0.43	0.43	CD
cord-016476-78r0rsio	47	44	%	%	NN
cord-016476-78r0rsio	47	45	)	)	-RRB-
cord-016476-78r0rsio	47	46	[	[	-LRB-
cord-016476-78r0rsio	47	47	7	7	CD
cord-016476-78r0rsio	47	48	]	]	-RRB-
cord-016476-78r0rsio	47	49	.	.	.
cord-016476-78r0rsio	48	1	Estimates	estimate	NNS
cord-016476-78r0rsio	48	2	of	of	IN
cord-016476-78r0rsio	48	3	reported	report	VBN
cord-016476-78r0rsio	48	4	incidence	incidence	NN
cord-016476-78r0rsio	48	5	vary	vary	VBP
cord-016476-78r0rsio	48	6	between	between	IN
cord-016476-78r0rsio	48	7	0.43	0.43	CD
cord-016476-78r0rsio	48	8	and	and	CC
cord-016476-78r0rsio	48	9	1	1	CD
cord-016476-78r0rsio	48	10	%	%	NN
cord-016476-78r0rsio	48	11	of	of	IN
cord-016476-78r0rsio	48	12	treated	treat	VBN
cord-016476-78r0rsio	48	13	patients	patient	NNS
cord-016476-78r0rsio	48	14	(	(	-LRB-
cord-016476-78r0rsio	48	15	in	in	IN
cord-016476-78r0rsio	48	16	up	up	IN
cord-016476-78r0rsio	48	17	to	to	TO
cord-016476-78r0rsio	48	18	3-year	3-year	JJ
cord-016476-78r0rsio	48	19	follow	follow	NN
cord-016476-78r0rsio	48	20	-	-	HYPH
cord-016476-78r0rsio	48	21	up	up	NN
cord-016476-78r0rsio	48	22	)	)	-RRB-
cord-016476-78r0rsio	48	23	[	[	-LRB-
cord-016476-78r0rsio	48	24	8	8	CD
cord-016476-78r0rsio	48	25	,	,	,
cord-016476-78r0rsio	48	26	9	9	CD
cord-016476-78r0rsio	48	27	]	]	-RRB-
cord-016476-78r0rsio	48	28	.	.	.
cord-016476-78r0rsio	49	1	The	the	DT
cord-016476-78r0rsio	49	2	clinical	clinical	JJ
cord-016476-78r0rsio	49	3	presentation	presentation	NN
cord-016476-78r0rsio	49	4	of	of	IN
cord-016476-78r0rsio	49	5	acute	acute	JJ
cord-016476-78r0rsio	49	6	MTX	MTX	NNP
cord-016476-78r0rsio	49	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	49	8	is	be	VBZ
cord-016476-78r0rsio	49	9	generally	generally	RB
cord-016476-78r0rsio	49	10	nonspecific	nonspecific	JJ
cord-016476-78r0rsio	49	11	,	,	,
cord-016476-78r0rsio	49	12	with	with	IN
cord-016476-78r0rsio	49	13	symptoms	symptom	NNS
cord-016476-78r0rsio	49	14	(	(	-LRB-
cord-016476-78r0rsio	49	15	fever	fever	NN
cord-016476-78r0rsio	49	16	,	,	,
cord-016476-78r0rsio	49	17	rigors	rigor	NNS
cord-016476-78r0rsio	49	18	,	,	,
cord-016476-78r0rsio	49	19	malaise	malaise	NN
cord-016476-78r0rsio	49	20	,	,	,
cord-016476-78r0rsio	49	21	nonproductive	nonproductive	JJ
cord-016476-78r0rsio	49	22	cough	cough	NN
cord-016476-78r0rsio	49	23	,	,	,
cord-016476-78r0rsio	49	24	dyspnoea	dyspnoea	NNS
cord-016476-78r0rsio	49	25	,	,	,
cord-016476-78r0rsio	49	26	chest	chest	NN
cord-016476-78r0rsio	49	27	pain	pain	NN
cord-016476-78r0rsio	49	28	)	)	-RRB-
cord-016476-78r0rsio	49	29	that	that	WDT
cord-016476-78r0rsio	49	30	can	can	MD
cord-016476-78r0rsio	49	31	be	be	VB
cord-016476-78r0rsio	49	32	progressive	progressive	JJ
cord-016476-78r0rsio	49	33	over	over	IN
cord-016476-78r0rsio	49	34	several	several	JJ
cord-016476-78r0rsio	49	35	days	day	NNS
cord-016476-78r0rsio	49	36	.	.	.
cord-016476-78r0rsio	50	1	Criteria	criterion	NNS
cord-016476-78r0rsio	50	2	proposed	propose	VBN
cord-016476-78r0rsio	50	3	by	by	IN
cord-016476-78r0rsio	50	4	Searles	Searles	NNP
cord-016476-78r0rsio	50	5	and	and	CC
cord-016476-78r0rsio	50	6	McKendry	McKendry	NNP
cord-016476-78r0rsio	50	7	[	[	-LRB-
cord-016476-78r0rsio	50	8	10	10	CD
cord-016476-78r0rsio	50	9	]	]	-RRB-
cord-016476-78r0rsio	50	10	and	and	CC
cord-016476-78r0rsio	50	11	Carson	Carson	NNP
cord-016476-78r0rsio	50	12	et	et	NNP
cord-016476-78r0rsio	50	13	al	al	NNP
cord-016476-78r0rsio	50	14	.	.	.
cord-016476-78r0rsio	51	1	[	[	-LRB-
cord-016476-78r0rsio	51	2	11	11	CD
cord-016476-78r0rsio	51	3	]	]	-RRB-
cord-016476-78r0rsio	51	4	are	be	VBP
cord-016476-78r0rsio	51	5	generally	generally	RB
cord-016476-78r0rsio	51	6	accepted	accept	VBN
cord-016476-78r0rsio	51	7	for	for	IN
cord-016476-78r0rsio	51	8	defining	define	VBG
cord-016476-78r0rsio	51	9	MTX	MTX	NNP
cord-016476-78r0rsio	51	10	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	51	11	and	and	CC
cord-016476-78r0rsio	51	12	can	can	MD
cord-016476-78r0rsio	51	13	sometimes	sometimes	RB
cord-016476-78r0rsio	51	14	help	help	VB
cord-016476-78r0rsio	51	15	in	in	IN
cord-016476-78r0rsio	51	16	differentiating	differentiate	VBG
cord-016476-78r0rsio	51	17	the	the	DT
cord-016476-78r0rsio	51	18	disease	disease	NN
cord-016476-78r0rsio	51	19	from	from	IN
cord-016476-78r0rsio	51	20	RA	RA	NNP
cord-016476-78r0rsio	51	21	-	-	HYPH
cord-016476-78r0rsio	51	22	ILD	ILD	NNP
cord-016476-78r0rsio	51	23	and	and	CC
cord-016476-78r0rsio	51	24	respiratory	respiratory	JJ
cord-016476-78r0rsio	51	25	infections	infection	NNS
cord-016476-78r0rsio	51	26	,	,	,
cord-016476-78r0rsio	51	27	although	although	IN
cord-016476-78r0rsio	51	28	it	-PRON-	PRP
cord-016476-78r0rsio	51	29	is	be	VBZ
cord-016476-78r0rsio	51	30	possible	possible	JJ
cord-016476-78r0rsio	51	31	to	to	TO
cord-016476-78r0rsio	51	32	fulfil	fulfil	VB
cord-016476-78r0rsio	51	33	the	the	DT
cord-016476-78r0rsio	51	34	criteria	criterion	NNS
cord-016476-78r0rsio	51	35	with	with	IN
cord-016476-78r0rsio	51	36	conditions	condition	NNS
cord-016476-78r0rsio	51	37	other	other	JJ
cord-016476-78r0rsio	51	38	than	than	IN
cord-016476-78r0rsio	51	39	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	51	40	,	,	,
cord-016476-78r0rsio	51	41	for	for	IN
cord-016476-78r0rsio	51	42	example	example	NN
cord-016476-78r0rsio	51	43	,	,	,
cord-016476-78r0rsio	51	44	infection	infection	NN
cord-016476-78r0rsio	51	45	or	or	CC
cord-016476-78r0rsio	51	46	a	a	DT
cord-016476-78r0rsio	51	47	progression	progression	NN
cord-016476-78r0rsio	51	48	of	of	IN
cord-016476-78r0rsio	51	49	pre	pre	JJ
cord-016476-78r0rsio	51	50	-	-	JJ
cord-016476-78r0rsio	51	51	existing	existing	JJ
cord-016476-78r0rsio	51	52	RA	RA	NNP
cord-016476-78r0rsio	51	53	-	-	HYPH
cord-016476-78r0rsio	51	54	ILD	ILD	NNP
cord-016476-78r0rsio	51	55	(	(	-LRB-
cord-016476-78r0rsio	51	56	Table	Table	NNP
cord-016476-78r0rsio	51	57	9	9	CD
cord-016476-78r0rsio	51	58	.1	.1	CD
cord-016476-78r0rsio	51	59	)	)	-RRB-
cord-016476-78r0rsio	51	60	.	.	.
cord-016476-78r0rsio	52	1	Searles	Searles	NNP
cord-016476-78r0rsio	52	2	and	and	CC
cord-016476-78r0rsio	52	3	McKendry	McKendry	NNP
cord-016476-78r0rsio	52	4	criteria	criterion	NNS
cord-016476-78r0rsio	52	5	have	have	VBP
cord-016476-78r0rsio	52	6	since	since	IN
cord-016476-78r0rsio	52	7	been	be	VBN
cord-016476-78r0rsio	52	8	adapted	adapt	VBN
cord-016476-78r0rsio	52	9	by	by	IN
cord-016476-78r0rsio	52	10	Kremer	Kremer	NNP
cord-016476-78r0rsio	52	11	et	et	NNP
cord-016476-78r0rsio	52	12	al	al	NNP
cord-016476-78r0rsio	52	13	.	.	.
cord-016476-78r0rsio	53	1	[	[	-LRB-
cord-016476-78r0rsio	53	2	12	12	CD
cord-016476-78r0rsio	53	3	]	]	-RRB-
cord-016476-78r0rsio	53	4	categorising	categorise	VBG
cord-016476-78r0rsio	53	5	them	-PRON-	PRP
cord-016476-78r0rsio	53	6	into	into	IN
cord-016476-78r0rsio	53	7	major	major	JJ
cord-016476-78r0rsio	53	8	and	and	CC
cord-016476-78r0rsio	53	9	minor	minor	JJ
cord-016476-78r0rsio	53	10	.	.	.
cord-016476-78r0rsio	54	1	All	all	DT
cord-016476-78r0rsio	54	2	rely	rely	VBP
cord-016476-78r0rsio	54	3	on	on	IN
cord-016476-78r0rsio	54	4	a	a	DT
cord-016476-78r0rsio	54	5	combination	combination	NN
cord-016476-78r0rsio	54	6	of	of	IN
cord-016476-78r0rsio	54	7	clinical	clinical	JJ
cord-016476-78r0rsio	54	8	features	feature	NNS
cord-016476-78r0rsio	54	9	,	,	,
cord-016476-78r0rsio	54	10	radiological	radiological	JJ
cord-016476-78r0rsio	54	11	,	,	,
cord-016476-78r0rsio	54	12	histology	histology	NN
cord-016476-78r0rsio	54	13	and	and	CC
cord-016476-78r0rsio	54	14	exclusion	exclusion	NN
cord-016476-78r0rsio	54	15	of	of	IN
cord-016476-78r0rsio	54	16	infection	infection	NN
cord-016476-78r0rsio	54	17	.	.	.
cord-016476-78r0rsio	55	1	Studies	study	NNS
cord-016476-78r0rsio	55	2	have	have	VBP
cord-016476-78r0rsio	55	3	explored	explore	VBN
cord-016476-78r0rsio	55	4	other	other	JJ
cord-016476-78r0rsio	55	5	factors	factor	NNS
cord-016476-78r0rsio	55	6	that	that	WDT
cord-016476-78r0rsio	55	7	might	may	MD
cord-016476-78r0rsio	55	8	differentiate	differentiate	VB
cord-016476-78r0rsio	55	9	these	these	DT
cord-016476-78r0rsio	55	10	clinically	clinically	RB
cord-016476-78r0rsio	55	11	similar	similar	JJ
cord-016476-78r0rsio	55	12	respiratory	respiratory	JJ
cord-016476-78r0rsio	55	13	diseases	disease	NNS
cord-016476-78r0rsio	55	14	.	.	.
cord-016476-78r0rsio	56	1	Histological	Histological	NNP
cord-016476-78r0rsio	56	2	findings	finding	NNS
cord-016476-78r0rsio	56	3	in	in	IN
cord-016476-78r0rsio	56	4	MTX	MTX	NNP
cord-016476-78r0rsio	56	5	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	56	6	such	such	JJ
cord-016476-78r0rsio	56	7	as	as	IN
cord-016476-78r0rsio	56	8	cellular	cellular	JJ
cord-016476-78r0rsio	56	9	interstitial	interstitial	NN
cord-016476-78r0rsio	56	10	infiltrates	infiltrate	VBZ
cord-016476-78r0rsio	56	11	,	,	,
cord-016476-78r0rsio	56	12	diffuse	diffuse	VB
cord-016476-78r0rsio	56	13	alveolar	alveolar	JJ
cord-016476-78r0rsio	56	14	damage	damage	NN
cord-016476-78r0rsio	56	15	,	,	,
cord-016476-78r0rsio	56	16	tissue	tissue	NN
cord-016476-78r0rsio	56	17	eosinophils	eosinophil	NNS
cord-016476-78r0rsio	56	18	and	and	CC
cord-016476-78r0rsio	56	19	granuloma	granuloma	NN
cord-016476-78r0rsio	56	20	formation	formation	NN
cord-016476-78r0rsio	56	21	are	be	VBP
cord-016476-78r0rsio	56	22	nonspecific	nonspecific	JJ
cord-016476-78r0rsio	56	23	and	and	CC
cord-016476-78r0rsio	56	24	have	have	VBP
cord-016476-78r0rsio	56	25	all	all	DT
cord-016476-78r0rsio	56	26	been	be	VBN
cord-016476-78r0rsio	56	27	seen	see	VBN
cord-016476-78r0rsio	56	28	in	in	IN
cord-016476-78r0rsio	56	29	RA	RA	NNP
cord-016476-78r0rsio	56	30	lung	lung	NN
cord-016476-78r0rsio	56	31	disease	disease	NN
cord-016476-78r0rsio	56	32	[	[	-LRB-
cord-016476-78r0rsio	56	33	6	6	CD
cord-016476-78r0rsio	56	34	]	]	-RRB-
cord-016476-78r0rsio	56	35	.	.	.
cord-016476-78r0rsio	57	1	Highresolution	highresolution	NN
cord-016476-78r0rsio	57	2	computer	computer	NN
cord-016476-78r0rsio	57	3	tomography	tomography	NN
cord-016476-78r0rsio	57	4	(	(	-LRB-
cord-016476-78r0rsio	57	5	HRCT	HRCT	NNP
cord-016476-78r0rsio	57	6	)	)	-RRB-
cord-016476-78r0rsio	57	7	studies	study	NNS
cord-016476-78r0rsio	57	8	in	in	IN
cord-016476-78r0rsio	57	9	MTX	MTX	NNP
cord-016476-78r0rsio	57	10	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	57	11	typically	typically	RB
cord-016476-78r0rsio	57	12	show	show	VBP
cord-016476-78r0rsio	57	13	ground	ground	NN
cord-016476-78r0rsio	57	14	-	-	HYPH
cord-016476-78r0rsio	57	15	glass	glass	NN
cord-016476-78r0rsio	57	16	changes	change	NNS
cord-016476-78r0rsio	57	17	,	,	,
cord-016476-78r0rsio	57	18	centrilobular	centrilobular	NNP
cord-016476-78r0rsio	57	19	nodules	nodule	NNS
cord-016476-78r0rsio	57	20	+	+	SYM
cord-016476-78r0rsio	57	21	/−	/−	.
cord-016476-78r0rsio	57	22	diffuse	diffuse	JJ
cord-016476-78r0rsio	57	23	parenchymal	parenchymal	NN
cord-016476-78r0rsio	57	24	opacification	opacification	NN
cord-016476-78r0rsio	57	25	[	[	-LRB-
cord-016476-78r0rsio	57	26	13	13	CD
cord-016476-78r0rsio	57	27	]	]	-RRB-
cord-016476-78r0rsio	57	28	.	.	.
cord-016476-78r0rsio	58	1	Bronchoalveolar	Bronchoalveolar	NNP
cord-016476-78r0rsio	58	2	lavage	lavage	NN
cord-016476-78r0rsio	58	3	(	(	-LRB-
cord-016476-78r0rsio	58	4	BAL	bal	NN
cord-016476-78r0rsio	58	5	)	)	-RRB-
cord-016476-78r0rsio	58	6	cell	cell	NN
cord-016476-78r0rsio	58	7	profiles	profile	NNS
cord-016476-78r0rsio	58	8	in	in	IN
cord-016476-78r0rsio	58	9	MTX	MTX	NNP
cord-016476-78r0rsio	58	10	pneumonitis	pneumonitis	NNP
cord-016476-78r0rsio	58	11	show	show	VBP
cord-016476-78r0rsio	58	12	a	a	DT
cord-016476-78r0rsio	58	13	lymphocyte	lymphocyte	NN
cord-016476-78r0rsio	58	14	alveolitis	alveolitis	NN
cord-016476-78r0rsio	58	15	with	with	IN
cord-016476-78r0rsio	58	16	a	a	DT
cord-016476-78r0rsio	58	17	preferential	preferential	JJ
cord-016476-78r0rsio	58	18	increase	increase	NN
cord-016476-78r0rsio	58	19	in	in	IN
cord-016476-78r0rsio	58	20	CD4	CD4	NNP
cord-016476-78r0rsio	58	21	+	+	CC
cord-016476-78r0rsio	58	22	cells	cell	NNS
cord-016476-78r0rsio	58	23	compared	compare	VBN
cord-016476-78r0rsio	58	24	to	to	IN
cord-016476-78r0rsio	58	25	normal	normal	JJ
cord-016476-78r0rsio	58	26	RA	RA	NNP
cord-016476-78r0rsio	58	27	controls	control	NNS
cord-016476-78r0rsio	58	28	[	[	-LRB-
cord-016476-78r0rsio	58	29	14	14	CD
cord-016476-78r0rsio	58	30	,	,	,
cord-016476-78r0rsio	58	31	15	15	CD
cord-016476-78r0rsio	58	32	]	]	-RRB-
cord-016476-78r0rsio	58	33	,	,	,
cord-016476-78r0rsio	58	34	though	though	IN
cord-016476-78r0rsio	58	35	comparisons	comparison	NNS
cord-016476-78r0rsio	58	36	have	have	VBP
cord-016476-78r0rsio	58	37	not	not	RB
cord-016476-78r0rsio	58	38	been	be	VBN
cord-016476-78r0rsio	58	39	made	make	VBN
cord-016476-78r0rsio	58	40	between	between	IN
cord-016476-78r0rsio	58	41	BAL	BAL	NNP
cord-016476-78r0rsio	58	42	in	in	IN
cord-016476-78r0rsio	58	43	MTX	MTX	NNP
cord-016476-78r0rsio	58	44	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	58	45	and	and	CC
cord-016476-78r0rsio	58	46	RA	RA	NNP
cord-016476-78r0rsio	58	47	-	-	HYPH
cord-016476-78r0rsio	58	48	ILD	ILD	NNP
cord-016476-78r0rsio	58	49	.	.	.
cord-016476-78r0rsio	59	1	A	a	DT
cord-016476-78r0rsio	59	2	challenge	challenge	NN
cord-016476-78r0rsio	59	3	with	with	IN
cord-016476-78r0rsio	59	4	all	all	PDT
cord-016476-78r0rsio	59	5	these	these	DT
cord-016476-78r0rsio	59	6	studies	study	NNS
cord-016476-78r0rsio	59	7	is	be	VBZ
cord-016476-78r0rsio	59	8	the	the	DT
cord-016476-78r0rsio	59	9	problem	problem	NN
cord-016476-78r0rsio	59	10	of	of	IN
cord-016476-78r0rsio	59	11	measuring	measure	VBG
cord-016476-78r0rsio	59	12	the	the	DT
cord-016476-78r0rsio	59	13	accuracy	accuracy	NN
cord-016476-78r0rsio	59	14	of	of	IN
cord-016476-78r0rsio	59	15	a	a	DT
cord-016476-78r0rsio	59	16	test	test	NN
cord-016476-78r0rsio	59	17	against	against	IN
cord-016476-78r0rsio	59	18	no	no	DT
cord-016476-78r0rsio	59	19	accepted	accept	VBN
cord-016476-78r0rsio	59	20	gold	gold	NN
cord-016476-78r0rsio	59	21	standard	standard	NN
cord-016476-78r0rsio	59	22	.	.	.
cord-016476-78r0rsio	60	1	It	-PRON-	PRP
cord-016476-78r0rsio	60	2	has	have	VBZ
cord-016476-78r0rsio	60	3	been	be	VBN
cord-016476-78r0rsio	60	4	argued	argue	VBN
cord-016476-78r0rsio	60	5	on	on	IN
cord-016476-78r0rsio	60	6	several	several	JJ
cord-016476-78r0rsio	60	7	counts	count	NNS
cord-016476-78r0rsio	60	8	that	that	IN
cord-016476-78r0rsio	60	9	MTX	MTX	NNP
cord-016476-78r0rsio	60	10	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	60	11	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	60	12	is	be	VBZ
cord-016476-78r0rsio	60	13	a	a	DT
cord-016476-78r0rsio	60	14	unique	unique	JJ
cord-016476-78r0rsio	60	15	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	60	16	reaction	reaction	NN
cord-016476-78r0rsio	60	17	rather	rather	RB
cord-016476-78r0rsio	60	18	than	than	IN
cord-016476-78r0rsio	60	19	the	the	DT
cord-016476-78r0rsio	60	20	development	development	NN
cord-016476-78r0rsio	60	21	or	or	CC
cord-016476-78r0rsio	60	22	progression	progression	NN
cord-016476-78r0rsio	60	23	of	of	IN
cord-016476-78r0rsio	60	24	RA	RA	NNP
cord-016476-78r0rsio	60	25	-	-	HYPH
cord-016476-78r0rsio	60	26	ILD	ILD	NNP
cord-016476-78r0rsio	60	27	.	.	.
cord-016476-78r0rsio	61	1	Firstly	firstly	RB
cord-016476-78r0rsio	61	2	,	,	,
cord-016476-78r0rsio	61	3	MTX	MTX	NNP
cord-016476-78r0rsio	61	4	-	-	HYPH
cord-016476-78r0rsio	61	5	associated	associate	VBN
cord-016476-78r0rsio	61	6	lung	lung	NN
cord-016476-78r0rsio	61	7	injury	injury	NN
cord-016476-78r0rsio	61	8	tends	tend	VBZ
cord-016476-78r0rsio	61	9	to	to	TO
cord-016476-78r0rsio	61	10	occur	occur	VB
cord-016476-78r0rsio	61	11	early	early	RB
cord-016476-78r0rsio	61	12	in	in	IN
cord-016476-78r0rsio	61	13	the	the	DT
cord-016476-78r0rsio	61	14	[	[	-LRB-
cord-016476-78r0rsio	61	15	16	16	CD
cord-016476-78r0rsio	61	16	]	]	-RRB-
cord-016476-78r0rsio	61	17	,	,	,
cord-016476-78r0rsio	61	18	the	the	DT
cord-016476-78r0rsio	61	19	close	close	JJ
cord-016476-78r0rsio	61	20	temporal	temporal	JJ
cord-016476-78r0rsio	61	21	relationship	relationship	NN
cord-016476-78r0rsio	61	22	arguing	argue	VBG
cord-016476-78r0rsio	61	23	in	in	IN
cord-016476-78r0rsio	61	24	favour	favour	NN
cord-016476-78r0rsio	61	25	of	of	IN
cord-016476-78r0rsio	61	26	causality	causality	NN
cord-016476-78r0rsio	61	27	.	.	.
cord-016476-78r0rsio	62	1	Secondly	secondly	RB
cord-016476-78r0rsio	62	2	,	,	,
cord-016476-78r0rsio	62	3	acute	acute	JJ
cord-016476-78r0rsio	62	4	lung	lung	NN
cord-016476-78r0rsio	62	5	injury	injury	NN
cord-016476-78r0rsio	62	6	has	have	VBZ
cord-016476-78r0rsio	62	7	resolved	resolve	VBN
cord-016476-78r0rsio	62	8	after	after	IN
cord-016476-78r0rsio	62	9	discontinuation	discontinuation	NN
cord-016476-78r0rsio	62	10	of	of	IN
cord-016476-78r0rsio	62	11	the	the	DT
cord-016476-78r0rsio	62	12	drug	drug	NN
cord-016476-78r0rsio	62	13	and	and	CC
cord-016476-78r0rsio	62	14	treatment	treatment	NN
cord-016476-78r0rsio	62	15	with	with	IN
cord-016476-78r0rsio	62	16	high	high	JJ
cord-016476-78r0rsio	62	17	-	-	HYPH
cord-016476-78r0rsio	62	18	dose	dose	NN
cord-016476-78r0rsio	62	19	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	62	20	[	[	-LRB-
cord-016476-78r0rsio	62	21	5	5	CD
cord-016476-78r0rsio	62	22	]	]	-RRB-
cord-016476-78r0rsio	62	23	.	.	.
cord-016476-78r0rsio	63	1	Lastly	lastly	RB
cord-016476-78r0rsio	63	2	,	,	,
cord-016476-78r0rsio	63	3	case	case	NN
cord-016476-78r0rsio	63	4	reports	report	NNS
cord-016476-78r0rsio	63	5	of	of	IN
cord-016476-78r0rsio	63	6	ILD	ILD	NNP
cord-016476-78r0rsio	63	7	have	have	VBP
cord-016476-78r0rsio	63	8	been	be	VBN
cord-016476-78r0rsio	63	9	reported	report	VBN
cord-016476-78r0rsio	63	10	in	in	IN
cord-016476-78r0rsio	63	11	other	other	JJ
cord-016476-78r0rsio	63	12	conditions	condition	NNS
cord-016476-78r0rsio	63	13	including	include	VBG
cord-016476-78r0rsio	63	14	psoriatic	psoriatic	JJ
cord-016476-78r0rsio	63	15	patients	patient	NNS
cord-016476-78r0rsio	63	16	treated	treat	VBN
cord-016476-78r0rsio	63	17	with	with	IN
cord-016476-78r0rsio	63	18	MTX	MTX	NNP
cord-016476-78r0rsio	63	19	[	[	-LRB-
cord-016476-78r0rsio	63	20	6	6	CD
cord-016476-78r0rsio	63	21	,	,	,
cord-016476-78r0rsio	63	22	17	17	CD
cord-016476-78r0rsio	63	23	]	]	-RRB-
cord-016476-78r0rsio	63	24	as	as	RB
cord-016476-78r0rsio	63	25	well	well	RB
cord-016476-78r0rsio	63	26	as	as	IN
cord-016476-78r0rsio	63	27	in	in	IN
cord-016476-78r0rsio	63	28	other	other	JJ
cord-016476-78r0rsio	63	29	conditions	condition	NNS
cord-016476-78r0rsio	63	30	not	not	RB
cord-016476-78r0rsio	63	31	typically	typically	RB
cord-016476-78r0rsio	63	32	associated	associate	VBN
cord-016476-78r0rsio	63	33	with	with	IN
cord-016476-78r0rsio	63	34	ILD	ILD	NNP
cord-016476-78r0rsio	63	35	.	.	.
cord-016476-78r0rsio	64	1	However	however	RB
cord-016476-78r0rsio	64	2	,	,	,
cord-016476-78r0rsio	64	3	there	there	EX
cord-016476-78r0rsio	64	4	are	be	VBP
cord-016476-78r0rsio	64	5	issues	issue	NNS
cord-016476-78r0rsio	64	6	with	with	IN
cord-016476-78r0rsio	64	7	each	each	DT
cord-016476-78r0rsio	64	8	of	of	IN
cord-016476-78r0rsio	64	9	these	these	DT
cord-016476-78r0rsio	64	10	arguments	argument	NNS
cord-016476-78r0rsio	64	11	.	.	.
cord-016476-78r0rsio	65	1	Clinicians	clinician	NNS
cord-016476-78r0rsio	65	2	are	be	VBP
cord-016476-78r0rsio	65	3	more	more	RBR
cord-016476-78r0rsio	65	4	likely	likely	JJ
cord-016476-78r0rsio	65	5	to	to	TO
cord-016476-78r0rsio	65	6	diagnose	diagnose	VB
cord-016476-78r0rsio	65	7	and	and	CC
cord-016476-78r0rsio	65	8	report	report	VB
cord-016476-78r0rsio	65	9	MTX	MTX	NNP
cord-016476-78r0rsio	65	10	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	65	11	if	if	IN
cord-016476-78r0rsio	65	12	there	there	EX
cord-016476-78r0rsio	65	13	is	be	VBZ
cord-016476-78r0rsio	65	14	a	a	DT
cord-016476-78r0rsio	65	15	close	close	JJ
cord-016476-78r0rsio	65	16	temporal	temporal	JJ
cord-016476-78r0rsio	65	17	relationship	relationship	NN
cord-016476-78r0rsio	65	18	.	.	.
cord-016476-78r0rsio	66	1	If	if	IN
cord-016476-78r0rsio	66	2	cases	case	NNS
cord-016476-78r0rsio	66	3	in	in	IN
cord-016476-78r0rsio	66	4	question	question	NN
cord-016476-78r0rsio	66	5	are	be	VBP
cord-016476-78r0rsio	66	6	identified	identify	VBN
cord-016476-78r0rsio	66	7	by	by	IN
cord-016476-78r0rsio	66	8	asking	ask	VBG
cord-016476-78r0rsio	66	9	rheumatologists	rheumatologist	NNS
cord-016476-78r0rsio	66	10	to	to	TO
cord-016476-78r0rsio	66	11	identify	identify	VB
cord-016476-78r0rsio	66	12	them	-PRON-	PRP
cord-016476-78r0rsio	66	13	[	[	-LRB-
cord-016476-78r0rsio	66	14	16	16	CD
cord-016476-78r0rsio	66	15	]	]	-RRB-
cord-016476-78r0rsio	66	16	,	,	,
cord-016476-78r0rsio	66	17	it	-PRON-	PRP
cord-016476-78r0rsio	66	18	is	be	VBZ
cord-016476-78r0rsio	66	19	inevitable	inevitable	JJ
cord-016476-78r0rsio	66	20	that	that	IN
cord-016476-78r0rsio	66	21	a	a	DT
cord-016476-78r0rsio	66	22	strong	strong	JJ
cord-016476-78r0rsio	66	23	temporal	temporal	JJ
cord-016476-78r0rsio	66	24	relationship	relationship	NN
cord-016476-78r0rsio	66	25	will	will	MD
cord-016476-78r0rsio	66	26	be	be	VB
cord-016476-78r0rsio	66	27	found	find	VBN
cord-016476-78r0rsio	66	28	.	.	.
cord-016476-78r0rsio	67	1	The	the	DT
cord-016476-78r0rsio	67	2	second	second	JJ
cord-016476-78r0rsio	67	3	argument	argument	NN
cord-016476-78r0rsio	67	4	of	of	IN
cord-016476-78r0rsio	67	5	resolution	resolution	NN
cord-016476-78r0rsio	67	6	on	on	IN
cord-016476-78r0rsio	67	7	drug	drug	NN
cord-016476-78r0rsio	67	8	withdrawal	withdrawal	NN
cord-016476-78r0rsio	67	9	would	would	MD
cord-016476-78r0rsio	67	10	be	be	VB
cord-016476-78r0rsio	67	11	more	more	RBR
cord-016476-78r0rsio	67	12	convincing	convincing	JJ
cord-016476-78r0rsio	67	13	if	if	IN
cord-016476-78r0rsio	67	14	there	there	EX
cord-016476-78r0rsio	67	15	were	be	VBD
cord-016476-78r0rsio	67	16	no	no	DT
cord-016476-78r0rsio	67	17	concurrent	concurrent	JJ
cord-016476-78r0rsio	67	18	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	67	19	treatment	treatment	NN
cord-016476-78r0rsio	67	20	.	.	.
cord-016476-78r0rsio	68	1	Acute	acute	JJ
cord-016476-78r0rsio	68	2	exacerbations	exacerbation	NNS
cord-016476-78r0rsio	68	3	of	of	IN
cord-016476-78r0rsio	68	4	ILD	ILD	NNP
cord-016476-78r0rsio	68	5	,	,	,
cord-016476-78r0rsio	68	6	which	which	WDT
cord-016476-78r0rsio	68	7	may	may	MD
cord-016476-78r0rsio	68	8	resemble	resemble	VB
cord-016476-78r0rsio	68	9	drug	drug	NN
cord-016476-78r0rsio	68	10	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	68	11	,	,	,
cord-016476-78r0rsio	68	12	tend	tend	VBP
cord-016476-78r0rsio	68	13	to	to	TO
cord-016476-78r0rsio	68	14	be	be	VB
cord-016476-78r0rsio	68	15	responsive	responsive	JJ
cord-016476-78r0rsio	68	16	to	to	IN
cord-016476-78r0rsio	68	17	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	68	18	.	.	.
cord-016476-78r0rsio	69	1	That	that	DT
cord-016476-78r0rsio	69	2	said	say	VBD
cord-016476-78r0rsio	69	3	,	,	,
cord-016476-78r0rsio	69	4	there	there	EX
cord-016476-78r0rsio	69	5	are	be	VBP
cord-016476-78r0rsio	69	6	cases	case	NNS
cord-016476-78r0rsio	69	7	of	of	IN
cord-016476-78r0rsio	69	8	improvement	improvement	NN
cord-016476-78r0rsio	69	9	on	on	IN
cord-016476-78r0rsio	69	10	MTX	MTX	NNP
cord-016476-78r0rsio	69	11	withdrawal	withdrawal	NN
cord-016476-78r0rsio	69	12	with	with	IN
cord-016476-78r0rsio	69	13	no	no	DT
cord-016476-78r0rsio	69	14	increase	increase	NN
cord-016476-78r0rsio	69	15	in	in	IN
cord-016476-78r0rsio	69	16	pre	pre	JJ
cord-016476-78r0rsio	69	17	-	-	JJ
cord-016476-78r0rsio	69	18	existing	existing	JJ
cord-016476-78r0rsio	69	19	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	69	20	dose	dose	NN
cord-016476-78r0rsio	69	21	[	[	-LRB-
cord-016476-78r0rsio	69	22	14	14	CD
cord-016476-78r0rsio	69	23	]	]	-RRB-
cord-016476-78r0rsio	69	24	.	.	.
cord-016476-78r0rsio	70	1	Third	third	RB
cord-016476-78r0rsio	70	2	,	,	,
cord-016476-78r0rsio	70	3	dose	dose	NN
cord-016476-78r0rsio	70	4	and	and	CC
cord-016476-78r0rsio	70	5	duration	duration	NN
cord-016476-78r0rsio	70	6	of	of	IN
cord-016476-78r0rsio	70	7	MTX	MTX	NNP
cord-016476-78r0rsio	70	8	treatment	treatment	NN
cord-016476-78r0rsio	70	9	does	do	VBZ
cord-016476-78r0rsio	70	10	not	not	RB
cord-016476-78r0rsio	70	11	appear	appear	VB
cord-016476-78r0rsio	70	12	to	to	TO
cord-016476-78r0rsio	70	13	be	be	VB
cord-016476-78r0rsio	70	14	associated	associate	VBN
cord-016476-78r0rsio	70	15	with	with	IN
cord-016476-78r0rsio	70	16	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	70	17	toxicity	toxicity	NN
cord-016476-78r0rsio	70	18	in	in	IN
cord-016476-78r0rsio	70	19	the	the	DT
cord-016476-78r0rsio	70	20	reported	report	VBN
cord-016476-78r0rsio	70	21	literature	literature	NN
cord-016476-78r0rsio	70	22	[	[	-LRB-
cord-016476-78r0rsio	70	23	6	6	CD
cord-016476-78r0rsio	70	24	]	]	-RRB-
cord-016476-78r0rsio	70	25	.	.	.
cord-016476-78r0rsio	71	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	71	2	a	a	DT
cord-016476-78r0rsio	71	3	recent	recent	JJ
cord-016476-78r0rsio	71	4	systematic	systematic	JJ
cord-016476-78r0rsio	71	5	review	review	NN
cord-016476-78r0rsio	71	6	and	and	CC
cord-016476-78r0rsio	71	7	meta	meta	NNP
cord-016476-78r0rsio	71	8	-	-	HYPH
cord-016476-78r0rsio	71	9	analysis	analysis	NN
cord-016476-78r0rsio	71	10	evaluating	evaluate	VBG
cord-016476-78r0rsio	71	11	the	the	DT
cord-016476-78r0rsio	71	12	risk	risk	NN
cord-016476-78r0rsio	71	13	of	of	IN
cord-016476-78r0rsio	71	14	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	71	15	disease	disease	NN
cord-016476-78r0rsio	71	16	amongst	amongst	IN
cord-016476-78r0rsio	71	17	MTX	MTX	NNP
cord-016476-78r0rsio	71	18	-	-	HYPH
cord-016476-78r0rsio	71	19	treated	treat	VBN
cord-016476-78r0rsio	71	20	patients	patient	NNS
cord-016476-78r0rsio	71	21	with	with	IN
cord-016476-78r0rsio	71	22	psoriasis	psoriasis	NN
cord-016476-78r0rsio	71	23	,	,	,
cord-016476-78r0rsio	71	24	psoriatic	psoriatic	JJ
cord-016476-78r0rsio	71	25	arthritis	arthritis	NN
cord-016476-78r0rsio	71	26	and	and	CC
cord-016476-78r0rsio	71	27	inflammatory	inflammatory	JJ
cord-016476-78r0rsio	71	28	bowel	bowel	NN
cord-016476-78r0rsio	71	29	disease	disease	NN
cord-016476-78r0rsio	71	30	in	in	IN
cord-016476-78r0rsio	71	31	RCTs	RCTs	NNP
cord-016476-78r0rsio	71	32	concluded	conclude	VBD
cord-016476-78r0rsio	71	33	no	no	DT
cord-016476-78r0rsio	71	34	increased	increase	VBN
cord-016476-78r0rsio	71	35	risk	risk	NN
cord-016476-78r0rsio	71	36	[	[	-LRB-
cord-016476-78r0rsio	71	37	18	18	CD
cord-016476-78r0rsio	71	38	]	]	-RRB-
cord-016476-78r0rsio	71	39	.	.	.
cord-016476-78r0rsio	72	1	It	-PRON-	PRP
cord-016476-78r0rsio	72	2	is	be	VBZ
cord-016476-78r0rsio	72	3	not	not	RB
cord-016476-78r0rsio	72	4	clear	clear	JJ
cord-016476-78r0rsio	72	5	whether	whether	IN
cord-016476-78r0rsio	72	6	pre	pre	JJ
cord-016476-78r0rsio	72	7	-	-	JJ
cord-016476-78r0rsio	72	8	existing	existing	JJ
cord-016476-78r0rsio	72	9	RA	RA	NNP
cord-016476-78r0rsio	72	10	-	-	HYPH
cord-016476-78r0rsio	72	11	ILD	ILD	NNP
cord-016476-78r0rsio	72	12	increases	increase	VBZ
cord-016476-78r0rsio	72	13	the	the	DT
cord-016476-78r0rsio	72	14	risk	risk	NN
cord-016476-78r0rsio	72	15	of	of	IN
cord-016476-78r0rsio	72	16	MTX	MTX	NNP
cord-016476-78r0rsio	72	17	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	72	18	with	with	IN
cord-016476-78r0rsio	72	19	studies	study	NNS
cord-016476-78r0rsio	72	20	both	both	DT
cord-016476-78r0rsio	72	21	supporting	support	VBG
cord-016476-78r0rsio	72	22	and	and	CC
cord-016476-78r0rsio	72	23	opposing	oppose	VBG
cord-016476-78r0rsio	72	24	this	this	DT
cord-016476-78r0rsio	72	25	view	view	NN
cord-016476-78r0rsio	72	26	.	.	.
cord-016476-78r0rsio	73	1	The	the	DT
cord-016476-78r0rsio	73	2	largest	large	JJS
cord-016476-78r0rsio	73	3	study	study	NN
cord-016476-78r0rsio	73	4	was	be	VBD
cord-016476-78r0rsio	73	5	a	a	DT
cord-016476-78r0rsio	73	6	multicentre	multicentre	NNP
cord-016476-78r0rsio	73	7	case	case	NN
cord-016476-78r0rsio	73	8	-	-	HYPH
cord-016476-78r0rsio	73	9	control	control	NN
cord-016476-78r0rsio	73	10	study	study	NN
cord-016476-78r0rsio	73	11	from	from	IN
cord-016476-78r0rsio	73	12	the	the	DT
cord-016476-78r0rsio	73	13	USA	USA	NNP
cord-016476-78r0rsio	73	14	[	[	-LRB-
cord-016476-78r0rsio	73	15	12	12	CD
cord-016476-78r0rsio	73	16	,	,	,
cord-016476-78r0rsio	73	17	19	19	CD
cord-016476-78r0rsio	73	18	]	]	-RRB-
cord-016476-78r0rsio	73	19	,	,	,
cord-016476-78r0rsio	73	20	which	which	WDT
cord-016476-78r0rsio	73	21	identified	identify	VBD
cord-016476-78r0rsio	73	22	29	29	CD
cord-016476-78r0rsio	73	23	cases	case	NNS
cord-016476-78r0rsio	73	24	and	and	CC
cord-016476-78r0rsio	73	25	82	82	CD
cord-016476-78r0rsio	73	26	controls	control	NNS
cord-016476-78r0rsio	73	27	matched	match	VBN
cord-016476-78r0rsio	73	28	for	for	IN
cord-016476-78r0rsio	73	29	MTX	MTX	NNP
cord-016476-78r0rsio	73	30	use	use	NN
cord-016476-78r0rsio	73	31	.	.	.
cord-016476-78r0rsio	74	1	The	the	DT
cord-016476-78r0rsio	74	2	strongest	strong	JJS
cord-016476-78r0rsio	74	3	predictors	predictor	NNS
cord-016476-78r0rsio	74	4	of	of	IN
cord-016476-78r0rsio	74	5	lung	lung	NN
cord-016476-78r0rsio	74	6	injury	injury	NN
cord-016476-78r0rsio	74	7	were	be	VBD
cord-016476-78r0rsio	74	8	diabetes	diabete	NNS
cord-016476-78r0rsio	74	9	,	,	,
cord-016476-78r0rsio	74	10	hypoalbuminaemia	hypoalbuminaemia	NN
cord-016476-78r0rsio	74	11	,	,	,
cord-016476-78r0rsio	74	12	previous	previous	JJ
cord-016476-78r0rsio	74	13	use	use	NN
cord-016476-78r0rsio	74	14	of	of	IN
cord-016476-78r0rsio	74	15	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	74	16	,	,	,
cord-016476-78r0rsio	74	17	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	74	18	pleuropulmonary	pleuropulmonary	NN
cord-016476-78r0rsio	74	19	involvement	involvement	NN
cord-016476-78r0rsio	74	20	(	(	-LRB-
cord-016476-78r0rsio	74	21	OR	or	CC
cord-016476-78r0rsio	74	22	7.1	7.1	CD
cord-016476-78r0rsio	74	23	(	(	-LRB-
cord-016476-78r0rsio	74	24	95	95	CD
cord-016476-78r0rsio	74	25	%	%	NN
cord-016476-78r0rsio	74	26	CI	CI	NNP
cord-016476-78r0rsio	74	27	1.1	1.1	CD
cord-016476-78r0rsio	74	28	-	-	HYPH
cord-016476-78r0rsio	74	29	45.4	45.4	CD
cord-016476-78r0rsio	74	30	)	)	-RRB-
cord-016476-78r0rsio	74	31	)	)	-RRB-
cord-016476-78r0rsio	74	32	and	and	CC
cord-016476-78r0rsio	74	33	older	old	JJR
cord-016476-78r0rsio	74	34	age	age	NN
cord-016476-78r0rsio	74	35	(	(	-LRB-
cord-016476-78r0rsio	74	36	>	>	NFP
cord-016476-78r0rsio	74	37	60	60	CD
cord-016476-78r0rsio	74	38	)	)	-RRB-
cord-016476-78r0rsio	74	39	.	.	.
cord-016476-78r0rsio	75	1	A	a	DT
cord-016476-78r0rsio	75	2	history	history	NN
cord-016476-78r0rsio	75	3	of	of	IN
cord-016476-78r0rsio	75	4	COPD	COPD	NNP
cord-016476-78r0rsio	75	5	was	be	VBD
cord-016476-78r0rsio	75	6	modestly	modestly	RB
cord-016476-78r0rsio	75	7	associated	associate	VBN
cord-016476-78r0rsio	75	8	with	with	IN
cord-016476-78r0rsio	75	9	MTX	MTX	NNP
cord-016476-78r0rsio	75	10	-	-	HYPH
cord-016476-78r0rsio	75	11	induced	induce	VBN
cord-016476-78r0rsio	75	12	lung	lung	NN
cord-016476-78r0rsio	75	13	injury	injury	NN
cord-016476-78r0rsio	75	14	.	.	.
cord-016476-78r0rsio	76	1	Since	since	IN
cord-016476-78r0rsio	76	2	all	all	PDT
cord-016476-78r0rsio	76	3	the	the	DT
cord-016476-78r0rsio	76	4	cases	case	NNS
cord-016476-78r0rsio	76	5	were	be	VBD
cord-016476-78r0rsio	76	6	identified	identify	VBN
cord-016476-78r0rsio	76	7	following	follow	VBG
cord-016476-78r0rsio	76	8	clinical	clinical	JJ
cord-016476-78r0rsio	76	9	presentation	presentation	NN
cord-016476-78r0rsio	76	10	,	,	,
cord-016476-78r0rsio	76	11	the	the	DT
cord-016476-78r0rsio	76	12	observed	observed	JJ
cord-016476-78r0rsio	76	13	association	association	NN
cord-016476-78r0rsio	76	14	between	between	IN
cord-016476-78r0rsio	76	15	pre	pre	JJ
cord-016476-78r0rsio	76	16	-	-	JJ
cord-016476-78r0rsio	76	17	existing	existing	JJ
cord-016476-78r0rsio	76	18	lung	lung	NN
cord-016476-78r0rsio	76	19	disease	disease	NN
cord-016476-78r0rsio	76	20	and	and	CC
cord-016476-78r0rsio	76	21	MTX	MTX	NNP
cord-016476-78r0rsio	76	22	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	76	23	may	may	MD
cord-016476-78r0rsio	76	24	represent	represent	VB
cord-016476-78r0rsio	76	25	an	an	DT
cord-016476-78r0rsio	76	26	increased	increase	VBN
cord-016476-78r0rsio	76	27	likelihood	likelihood	NN
cord-016476-78r0rsio	76	28	of	of	IN
cord-016476-78r0rsio	76	29	presentation	presentation	NN
cord-016476-78r0rsio	76	30	(	(	-LRB-
cord-016476-78r0rsio	76	31	because	because	IN
cord-016476-78r0rsio	76	32	of	of	IN
cord-016476-78r0rsio	76	33	a	a	DT
cord-016476-78r0rsio	76	34	reduced	reduced	JJ
cord-016476-78r0rsio	76	35	physiological	physiological	JJ
cord-016476-78r0rsio	76	36	lung	lung	NN
cord-016476-78r0rsio	76	37	reserve	reserve	NN
cord-016476-78r0rsio	76	38	)	)	-RRB-
cord-016476-78r0rsio	76	39	or	or	CC
cord-016476-78r0rsio	76	40	a	a	DT
cord-016476-78r0rsio	76	41	surveillance	surveillance	NN
cord-016476-78r0rsio	76	42	bias	bias	NN
cord-016476-78r0rsio	76	43	rather	rather	RB
cord-016476-78r0rsio	76	44	than	than	IN
cord-016476-78r0rsio	76	45	an	an	DT
cord-016476-78r0rsio	76	46	increased	increase	VBN
cord-016476-78r0rsio	76	47	predisposition	predisposition	NN
cord-016476-78r0rsio	76	48	to	to	IN
cord-016476-78r0rsio	76	49	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	76	50	.	.	.
cord-016476-78r0rsio	77	1	Meta	Meta	NNP
cord-016476-78r0rsio	77	2	-	-	HYPH
cord-016476-78r0rsio	77	3	analysis	analysis	NN
cord-016476-78r0rsio	77	4	of	of	IN
cord-016476-78r0rsio	77	5	six	six	CD
cord-016476-78r0rsio	77	6	studies	study	NNS
cord-016476-78r0rsio	77	7	that	that	WDT
cord-016476-78r0rsio	77	8	suggested	suggest	VBD
cord-016476-78r0rsio	77	9	an	an	DT
cord-016476-78r0rsio	77	10	association	association	NN
cord-016476-78r0rsio	77	11	between	between	IN
cord-016476-78r0rsio	77	12	pre	pre	JJ
cord-016476-78r0rsio	77	13	-	-	JJ
cord-016476-78r0rsio	77	14	existing	existing	JJ
cord-016476-78r0rsio	77	15	lung	lung	NN
cord-016476-78r0rsio	77	16	disease	disease	NN
cord-016476-78r0rsio	77	17	(	(	-LRB-
cord-016476-78r0rsio	77	18	of	of	IN
cord-016476-78r0rsio	77	19	varying	vary	VBG
cord-016476-78r0rsio	77	20	definitions	definition	NNS
cord-016476-78r0rsio	77	21	)	)	-RRB-
cord-016476-78r0rsio	77	22	and	and	CC
cord-016476-78r0rsio	77	23	an	an	DT
cord-016476-78r0rsio	77	24	increased	increase	VBN
cord-016476-78r0rsio	77	25	risk	risk	NN
cord-016476-78r0rsio	77	26	of	of	IN
cord-016476-78r0rsio	77	27	MTX	MTX	NNP
cord-016476-78r0rsio	77	28	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	77	29	found	find	VBD
cord-016476-78r0rsio	77	30	a	a	DT
cord-016476-78r0rsio	77	31	pooled	pool	VBN
cord-016476-78r0rsio	77	32	odds	odd	NNS
cord-016476-78r0rsio	77	33	ratio	ratio	NN
cord-016476-78r0rsio	77	34	of	of	IN
cord-016476-78r0rsio	77	35	7.5	7.5	CD
cord-016476-78r0rsio	77	36	(	(	-LRB-
cord-016476-78r0rsio	77	37	95	95	CD
cord-016476-78r0rsio	77	38	%	%	NN
cord-016476-78r0rsio	77	39	CI	CI	NNP
cord-016476-78r0rsio	77	40	3.6	3.6	CD
cord-016476-78r0rsio	77	41	,	,	,
cord-016476-78r0rsio	77	42	15.8	15.8	CD
cord-016476-78r0rsio	77	43	)	)	-RRB-
cord-016476-78r0rsio	78	1	[	[	-LRB-
cord-016476-78r0rsio	78	2	20	20	CD
cord-016476-78r0rsio	78	3	]	]	-RRB-
cord-016476-78r0rsio	78	4	.	.	.
cord-016476-78r0rsio	79	1	However	however	RB
cord-016476-78r0rsio	79	2	,	,	,
cord-016476-78r0rsio	79	3	two	two	CD
cord-016476-78r0rsio	79	4	studies	study	NNS
cord-016476-78r0rsio	79	5	that	that	WDT
cord-016476-78r0rsio	79	6	suggested	suggest	VBD
cord-016476-78r0rsio	79	7	no	no	DT
cord-016476-78r0rsio	79	8	such	such	JJ
cord-016476-78r0rsio	79	9	association	association	NN
cord-016476-78r0rsio	79	10	[	[	-LRB-
cord-016476-78r0rsio	79	11	11	11	CD
cord-016476-78r0rsio	79	12	,	,	,
cord-016476-78r0rsio	79	13	21	21	CD
cord-016476-78r0rsio	79	14	]	]	-RRB-
cord-016476-78r0rsio	79	15	were	be	VBD
cord-016476-78r0rsio	79	16	not	not	RB
cord-016476-78r0rsio	79	17	included	include	VBN
cord-016476-78r0rsio	79	18	in	in	IN
cord-016476-78r0rsio	79	19	the	the	DT
cord-016476-78r0rsio	79	20	meta	meta	JJ
cord-016476-78r0rsio	79	21	-	-	HYPH
cord-016476-78r0rsio	79	22	analysis	analysis	NN
cord-016476-78r0rsio	79	23	for	for	IN
cord-016476-78r0rsio	79	24	reasons	reason	NNS
cord-016476-78r0rsio	79	25	that	that	WDT
cord-016476-78r0rsio	79	26	are	be	VBP
cord-016476-78r0rsio	79	27	not	not	RB
cord-016476-78r0rsio	79	28	clear	clear	JJ
cord-016476-78r0rsio	79	29	.	.	.
cord-016476-78r0rsio	80	1	Howes	Howes	NNP
cord-016476-78r0rsio	80	2	et	et	NNP
cord-016476-78r0rsio	80	3	al	al	NNP
cord-016476-78r0rsio	80	4	.	.	.
cord-016476-78r0rsio	81	1	[	[	-LRB-
cord-016476-78r0rsio	81	2	22	22	CD
cord-016476-78r0rsio	81	3	]	]	-RRB-
cord-016476-78r0rsio	81	4	followed	follow	VBD
cord-016476-78r0rsio	81	5	120	120	CD
cord-016476-78r0rsio	81	6	patients	patient	NNS
cord-016476-78r0rsio	81	7	who	who	WP
cord-016476-78r0rsio	81	8	received	receive	VBD
cord-016476-78r0rsio	81	9	MTX	MTX	NNP
cord-016476-78r0rsio	81	10	for	for	IN
cord-016476-78r0rsio	81	11	RA	RA	NNP
cord-016476-78r0rsio	81	12	for	for	IN
cord-016476-78r0rsio	81	13	a	a	DT
cord-016476-78r0rsio	81	14	median	median	JJ
cord-016476-78r0rsio	81	15	treatment	treatment	NN
cord-016476-78r0rsio	81	16	duration	duration	NN
cord-016476-78r0rsio	81	17	of	of	IN
cord-016476-78r0rsio	81	18	15	15	CD
cord-016476-78r0rsio	81	19	months	month	NNS
cord-016476-78r0rsio	81	20	,	,	,
cord-016476-78r0rsio	81	21	all	all	DT
cord-016476-78r0rsio	81	22	of	of	IN
cord-016476-78r0rsio	81	23	whom	whom	WP
cord-016476-78r0rsio	81	24	had	have	VBD
cord-016476-78r0rsio	81	25	baseline	baseline	JJ
cord-016476-78r0rsio	81	26	PFTs	pft	NNS
cord-016476-78r0rsio	81	27	.	.	.
cord-016476-78r0rsio	82	1	Three	three	CD
cord-016476-78r0rsio	82	2	patients	patient	NNS
cord-016476-78r0rsio	82	3	developed	develop	VBD
cord-016476-78r0rsio	82	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	82	5	toxicity	toxicity	NN
cord-016476-78r0rsio	82	6	according	accord	VBG
cord-016476-78r0rsio	82	7	the	the	DT
cord-016476-78r0rsio	82	8	established	establish	VBN
cord-016476-78r0rsio	82	9	criteria	criterion	NNS
cord-016476-78r0rsio	82	10	[	[	-LRB-
cord-016476-78r0rsio	82	11	5	5	CD
cord-016476-78r0rsio	82	12	]	]	-RRB-
cord-016476-78r0rsio	82	13	,	,	,
cord-016476-78r0rsio	82	14	all	all	DT
cord-016476-78r0rsio	82	15	of	of	IN
cord-016476-78r0rsio	82	16	whom	whom	WP
cord-016476-78r0rsio	82	17	had	have	VBD
cord-016476-78r0rsio	82	18	abnormal	abnormal	JJ
cord-016476-78r0rsio	82	19	baseline	baseline	JJ
cord-016476-78r0rsio	82	20	PFTs	pft	NNS
cord-016476-78r0rsio	82	21	.	.	.
cord-016476-78r0rsio	83	1	Of	of	IN
cord-016476-78r0rsio	83	2	the	the	DT
cord-016476-78r0rsio	83	3	patients	patient	NNS
cord-016476-78r0rsio	83	4	studied	study	VBD
cord-016476-78r0rsio	83	5	,	,	,
cord-016476-78r0rsio	83	6	3/120	3/120	CD
cord-016476-78r0rsio	83	7	patients	patient	NNS
cord-016476-78r0rsio	83	8	had	have	VBD
cord-016476-78r0rsio	83	9	a	a	DT
cord-016476-78r0rsio	83	10	transfer	transfer	NN
cord-016476-78r0rsio	83	11	factor	factor	NN
cord-016476-78r0rsio	83	12	of	of	IN
cord-016476-78r0rsio	83	13	<	<	$
cord-016476-78r0rsio	83	14	70	70	CD
cord-016476-78r0rsio	83	15	%	%	NN
cord-016476-78r0rsio	83	16	at	at	IN
cord-016476-78r0rsio	83	17	baseline	baseline	NN
cord-016476-78r0rsio	83	18	,	,	,
cord-016476-78r0rsio	83	19	one	one	CD
cord-016476-78r0rsio	83	20	of	of	IN
cord-016476-78r0rsio	83	21	whom	whom	WP
cord-016476-78r0rsio	83	22	developed	develop	VBD
cord-016476-78r0rsio	83	23	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	83	24	toxicity	toxicity	NN
cord-016476-78r0rsio	83	25	.	.	.
cord-016476-78r0rsio	84	1	The	the	DT
cord-016476-78r0rsio	84	2	authors	author	NNS
cord-016476-78r0rsio	84	3	report	report	VBP
cord-016476-78r0rsio	84	4	a	a	DT
cord-016476-78r0rsio	84	5	relative	relative	JJ
cord-016476-78r0rsio	84	6	risk	risk	NN
cord-016476-78r0rsio	84	7	for	for	IN
cord-016476-78r0rsio	84	8	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	84	9	of	of	IN
cord-016476-78r0rsio	84	10	10	10	CD
cord-016476-78r0rsio	84	11	,	,	,
cord-016476-78r0rsio	84	12	though	though	IN
cord-016476-78r0rsio	84	13	this	this	DT
cord-016476-78r0rsio	84	14	estimate	estimate	NN
cord-016476-78r0rsio	84	15	is	be	VBZ
cord-016476-78r0rsio	84	16	not	not	RB
cord-016476-78r0rsio	84	17	robust	robust	JJ
cord-016476-78r0rsio	84	18	given	give	VBN
cord-016476-78r0rsio	84	19	the	the	DT
cord-016476-78r0rsio	84	20	small	small	JJ
cord-016476-78r0rsio	84	21	numbers	number	NNS
cord-016476-78r0rsio	84	22	.	.	.
cord-016476-78r0rsio	85	1	There	there	EX
cord-016476-78r0rsio	85	2	is	be	VBZ
cord-016476-78r0rsio	85	3	currently	currently	RB
cord-016476-78r0rsio	85	4	no	no	DT
cord-016476-78r0rsio	85	5	conclusive	conclusive	JJ
cord-016476-78r0rsio	85	6	evidence	evidence	NN
cord-016476-78r0rsio	85	7	that	that	IN
cord-016476-78r0rsio	85	8	lung	lung	NN
cord-016476-78r0rsio	85	9	function	function	NN
cord-016476-78r0rsio	85	10	is	be	VBZ
cord-016476-78r0rsio	85	11	likely	likely	JJ
cord-016476-78r0rsio	85	12	to	to	TO
cord-016476-78r0rsio	85	13	decline	decline	VB
cord-016476-78r0rsio	85	14	faster	fast	RBR
cord-016476-78r0rsio	85	15	in	in	IN
cord-016476-78r0rsio	85	16	patients	patient	NNS
cord-016476-78r0rsio	85	17	with	with	IN
cord-016476-78r0rsio	85	18	RA	RA	NNP
cord-016476-78r0rsio	85	19	-	-	HYPH
cord-016476-78r0rsio	85	20	ILD	ILD	NNP
cord-016476-78r0rsio	85	21	on	on	IN
cord-016476-78r0rsio	85	22	MTX	MTX	NNP
cord-016476-78r0rsio	85	23	who	who	WP
cord-016476-78r0rsio	85	24	do	do	VBP
cord-016476-78r0rsio	85	25	not	not	RB
cord-016476-78r0rsio	85	26	develop	develop	VB
cord-016476-78r0rsio	85	27	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	85	28	.	.	.
cord-016476-78r0rsio	86	1	In	in	IN
cord-016476-78r0rsio	86	2	a	a	DT
cord-016476-78r0rsio	86	3	retrospective	retrospective	JJ
cord-016476-78r0rsio	86	4	cohort	cohort	NN
cord-016476-78r0rsio	86	5	analysis	analysis	NN
cord-016476-78r0rsio	86	6	,	,	,
cord-016476-78r0rsio	86	7	following	follow	VBG
cord-016476-78r0rsio	86	8	6	6	CD
cord-016476-78r0rsio	86	9	weeks	week	NNS
cord-016476-78r0rsio	86	10	of	of	IN
cord-016476-78r0rsio	86	11	high	high	JJ
cord-016476-78r0rsio	86	12	-	-	HYPH
cord-016476-78r0rsio	86	13	dose	dose	NN
cord-016476-78r0rsio	86	14	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	86	15	treatment	treatment	NN
cord-016476-78r0rsio	86	16	,	,	,
cord-016476-78r0rsio	86	17	one	one	CD
cord-016476-78r0rsio	86	18	study	study	NN
cord-016476-78r0rsio	86	19	reported	report	VBD
cord-016476-78r0rsio	86	20	treatment	treatment	NN
cord-016476-78r0rsio	86	21	with	with	IN
cord-016476-78r0rsio	86	22	MTX	MTX	NNP
cord-016476-78r0rsio	86	23	vs.	vs.	IN
cord-016476-78r0rsio	86	24	leflunomide	leflunomide	NN
cord-016476-78r0rsio	86	25	or	or	CC
cord-016476-78r0rsio	86	26	azathioprine	azathioprine	NN
cord-016476-78r0rsio	86	27	was	be	VBD
cord-016476-78r0rsio	86	28	associated	associate	VBN
cord-016476-78r0rsio	86	29	with	with	IN
cord-016476-78r0rsio	86	30	an	an	DT
cord-016476-78r0rsio	86	31	improvement	improvement	NN
cord-016476-78r0rsio	86	32	in	in	IN
cord-016476-78r0rsio	86	33	FVC	FVC	NNP
cord-016476-78r0rsio	86	34	at	at	IN
cord-016476-78r0rsio	86	35	6	6	CD
cord-016476-78r0rsio	86	36	months	month	NNS
cord-016476-78r0rsio	86	37	in	in	IN
cord-016476-78r0rsio	86	38	patients	patient	NNS
cord-016476-78r0rsio	86	39	with	with	IN
cord-016476-78r0rsio	86	40	less	less	JJR
cord-016476-78r0rsio	86	41	fibrosis	fibrosis	NN
cord-016476-78r0rsio	86	42	at	at	IN
cord-016476-78r0rsio	86	43	baseline	baseline	NN
cord-016476-78r0rsio	86	44	,	,	,
cord-016476-78r0rsio	86	45	although	although	IN
cord-016476-78r0rsio	86	46	there	there	EX
cord-016476-78r0rsio	86	47	were	be	VBD
cord-016476-78r0rsio	86	48	no	no	DT
cord-016476-78r0rsio	86	49	another	another	DT
cord-016476-78r0rsio	86	50	differences	difference	NNS
cord-016476-78r0rsio	86	51	in	in	IN
cord-016476-78r0rsio	86	52	other	other	JJ
cord-016476-78r0rsio	86	53	major	major	JJ
cord-016476-78r0rsio	86	54	outcomes	outcome	NNS
cord-016476-78r0rsio	86	55	such	such	JJ
cord-016476-78r0rsio	86	56	as	as	IN
cord-016476-78r0rsio	86	57	mortality	mortality	NN
cord-016476-78r0rsio	86	58	[	[	-LRB-
cord-016476-78r0rsio	86	59	23	23	CD
cord-016476-78r0rsio	86	60	]	]	-RRB-
cord-016476-78r0rsio	86	61	.	.	.
cord-016476-78r0rsio	87	1	Another	another	DT
cord-016476-78r0rsio	87	2	study	study	NN
cord-016476-78r0rsio	87	3	by	by	IN
cord-016476-78r0rsio	87	4	Dawson	Dawson	NNP
cord-016476-78r0rsio	87	5	et	et	NNP
cord-016476-78r0rsio	87	6	al	al	NNP
cord-016476-78r0rsio	87	7	.	.	.
cord-016476-78r0rsio	88	1	[	[	-LRB-
cord-016476-78r0rsio	88	2	7	7	CD
cord-016476-78r0rsio	88	3	]	]	-RRB-
cord-016476-78r0rsio	88	4	followed	follow	VBD
cord-016476-78r0rsio	88	5	128	128	CD
cord-016476-78r0rsio	88	6	patients	patient	NNS
cord-016476-78r0rsio	88	7	with	with	IN
cord-016476-78r0rsio	88	8	RA	RA	NNP
cord-016476-78r0rsio	88	9	for	for	IN
cord-016476-78r0rsio	88	10	2	2	CD
cord-016476-78r0rsio	88	11	years	year	NNS
cord-016476-78r0rsio	88	12	,	,	,
cord-016476-78r0rsio	88	13	43	43	CD
cord-016476-78r0rsio	88	14	%	%	NN
cord-016476-78r0rsio	88	15	of	of	IN
cord-016476-78r0rsio	88	16	whom	whom	WP
cord-016476-78r0rsio	88	17	were	be	VBD
cord-016476-78r0rsio	88	18	on	on	IN
cord-016476-78r0rsio	88	19	low	low	JJ
cord-016476-78r0rsio	88	20	-	-	HYPH
cord-016476-78r0rsio	88	21	dose	dose	NN
cord-016476-78r0rsio	88	22	MTX	MTX	NNP
cord-016476-78r0rsio	88	23	(	(	-LRB-
cord-016476-78r0rsio	88	24	mean	mean	VB
cord-016476-78r0rsio	88	25	10.7	10.7	CD
cord-016476-78r0rsio	88	26	mg	mg	NNP
cord-016476-78r0rsio	88	27	/	/	SYM
cord-016476-78r0rsio	88	28	week	week	NN
cord-016476-78r0rsio	88	29	)	)	-RRB-
cord-016476-78r0rsio	88	30	,	,	,
cord-016476-78r0rsio	88	31	with	with	IN
cord-016476-78r0rsio	88	32	HRCT	HRCT	NNP
cord-016476-78r0rsio	88	33	in	in	IN
cord-016476-78r0rsio	88	34	all	all	DT
cord-016476-78r0rsio	88	35	patients	patient	NNS
cord-016476-78r0rsio	88	36	at	at	IN
cord-016476-78r0rsio	88	37	baseline	baseline	NN
cord-016476-78r0rsio	88	38	and	and	CC
cord-016476-78r0rsio	88	39	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	88	40	function	function	NN
cord-016476-78r0rsio	88	41	tests	test	NNS
cord-016476-78r0rsio	88	42	(	(	-LRB-
cord-016476-78r0rsio	88	43	PFTs	pft	NNS
cord-016476-78r0rsio	88	44	)	)	-RRB-
cord-016476-78r0rsio	88	45	at	at	IN
cord-016476-78r0rsio	88	46	baseline	baseline	NN
cord-016476-78r0rsio	88	47	and	and	CC
cord-016476-78r0rsio	88	48	at	at	IN
cord-016476-78r0rsio	88	49	4-month	4-month	JJ
cord-016476-78r0rsio	88	50	follow	follow	NN
cord-016476-78r0rsio	88	51	-	-	HYPH
cord-016476-78r0rsio	88	52	up	up	RP
cord-016476-78r0rsio	88	53	intervals	interval	NNS
cord-016476-78r0rsio	88	54	.	.	.
cord-016476-78r0rsio	89	1	There	there	EX
cord-016476-78r0rsio	89	2	was	be	VBD
cord-016476-78r0rsio	89	3	no	no	DT
cord-016476-78r0rsio	89	4	significant	significant	JJ
cord-016476-78r0rsio	89	5	difference	difference	NN
cord-016476-78r0rsio	89	6	in	in	IN
cord-016476-78r0rsio	89	7	the	the	DT
cord-016476-78r0rsio	89	8	change	change	NN
cord-016476-78r0rsio	89	9	in	in	IN
cord-016476-78r0rsio	89	10	PFTs	pft	NNS
cord-016476-78r0rsio	89	11	over	over	IN
cord-016476-78r0rsio	89	12	the	the	DT
cord-016476-78r0rsio	89	13	follow	follow	VB
cord-016476-78r0rsio	89	14	-	-	HYPH
cord-016476-78r0rsio	89	15	up	up	NN
cord-016476-78r0rsio	89	16	period	period	NN
cord-016476-78r0rsio	89	17	either	either	CC
cord-016476-78r0rsio	89	18	between	between	IN
cord-016476-78r0rsio	89	19	the	the	DT
cord-016476-78r0rsio	89	20	MTX	MTX	NNP
cord-016476-78r0rsio	89	21	and	and	CC
cord-016476-78r0rsio	89	22	non	non	JJ
cord-016476-78r0rsio	89	23	-	-	JJ
cord-016476-78r0rsio	89	24	MTX	mtx	JJ
cord-016476-78r0rsio	89	25	patients	patient	NNS
cord-016476-78r0rsio	89	26	or	or	CC
cord-016476-78r0rsio	89	27	between	between	IN
cord-016476-78r0rsio	89	28	MTX	MTX	NNP
cord-016476-78r0rsio	89	29	and	and	CC
cord-016476-78r0rsio	89	30	non	non	JJ
cord-016476-78r0rsio	89	31	-	-	JJ
cord-016476-78r0rsio	89	32	MTX	mtx	JJ
cord-016476-78r0rsio	89	33	patients	patient	NNS
cord-016476-78r0rsio	89	34	with	with	IN
cord-016476-78r0rsio	89	35	proven	prove	VBN
cord-016476-78r0rsio	89	36	ILD	ILD	NNP
cord-016476-78r0rsio	89	37	on	on	IN
cord-016476-78r0rsio	89	38	HRCT	HRCT	NNP
cord-016476-78r0rsio	89	39	at	at	IN
cord-016476-78r0rsio	89	40	baseline	baseline	NN
cord-016476-78r0rsio	89	41	.	.	.
cord-016476-78r0rsio	90	1	The	the	DT
cord-016476-78r0rsio	90	2	authors	author	NNS
cord-016476-78r0rsio	90	3	concluded	conclude	VBD
cord-016476-78r0rsio	90	4	that	that	IN
cord-016476-78r0rsio	90	5	they	-PRON-	PRP
cord-016476-78r0rsio	90	6	found	find	VBD
cord-016476-78r0rsio	90	7	no	no	DT
cord-016476-78r0rsio	90	8	association	association	NN
cord-016476-78r0rsio	90	9	between	between	IN
cord-016476-78r0rsio	90	10	MTX	MTX	NNP
cord-016476-78r0rsio	90	11	therapy	therapy	NN
cord-016476-78r0rsio	90	12	and	and	CC
cord-016476-78r0rsio	90	13	progression	progression	NN
cord-016476-78r0rsio	90	14	of	of	IN
cord-016476-78r0rsio	90	15	chronic	chronic	JJ
cord-016476-78r0rsio	90	16	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	90	17	fibrosis	fibrosis	NN
cord-016476-78r0rsio	90	18	.	.	.
cord-016476-78r0rsio	91	1	Current	current	JJ
cord-016476-78r0rsio	91	2	guidelines	guideline	NNS
cord-016476-78r0rsio	91	3	on	on	IN
cord-016476-78r0rsio	91	4	the	the	DT
cord-016476-78r0rsio	91	5	use	use	NN
cord-016476-78r0rsio	91	6	of	of	IN
cord-016476-78r0rsio	91	7	MTX	MTX	NNP
cord-016476-78r0rsio	91	8	recommend	recommend	VBP
cord-016476-78r0rsio	91	9	that	that	IN
cord-016476-78r0rsio	91	10	all	all	DT
cord-016476-78r0rsio	91	11	patients	patient	NNS
cord-016476-78r0rsio	91	12	should	should	MD
cord-016476-78r0rsio	91	13	have	have	VB
cord-016476-78r0rsio	91	14	a	a	DT
cord-016476-78r0rsio	91	15	baseline	baseline	JJ
cord-016476-78r0rsio	91	16	chest	chest	NN
cord-016476-78r0rsio	91	17	radiograph	radiograph	NN
cord-016476-78r0rsio	91	18	with	with	IN
cord-016476-78r0rsio	91	19	or	or	CC
cord-016476-78r0rsio	91	20	without	without	IN
cord-016476-78r0rsio	91	21	PFTs	pft	NNS
cord-016476-78r0rsio	91	22	.	.	.
cord-016476-78r0rsio	92	1	There	there	EX
cord-016476-78r0rsio	92	2	appears	appear	VBZ
cord-016476-78r0rsio	92	3	to	to	TO
cord-016476-78r0rsio	92	4	be	be	VB
cord-016476-78r0rsio	92	5	little	little	JJ
cord-016476-78r0rsio	92	6	evidence	evidence	NN
cord-016476-78r0rsio	92	7	to	to	TO
cord-016476-78r0rsio	92	8	support	support	VB
cord-016476-78r0rsio	92	9	this	this	DT
cord-016476-78r0rsio	92	10	;	;	:
cord-016476-78r0rsio	92	11	however	however	RB
cord-016476-78r0rsio	92	12	,	,	,
cord-016476-78r0rsio	92	13	PFTs	pft	NNS
cord-016476-78r0rsio	92	14	may	may	MD
cord-016476-78r0rsio	92	15	be	be	VB
cord-016476-78r0rsio	92	16	useful	useful	JJ
cord-016476-78r0rsio	92	17	in	in	IN
cord-016476-78r0rsio	92	18	patients	patient	NNS
cord-016476-78r0rsio	92	19	with	with	IN
cord-016476-78r0rsio	92	20	RA	RA	NNP
cord-016476-78r0rsio	92	21	deemed	deem	VBN
cord-016476-78r0rsio	92	22	to	to	TO
cord-016476-78r0rsio	92	23	be	be	VB
cord-016476-78r0rsio	92	24	at	at	IN
cord-016476-78r0rsio	92	25	high	high	JJ
cord-016476-78r0rsio	92	26	risk	risk	NN
cord-016476-78r0rsio	92	27	of	of	IN
cord-016476-78r0rsio	92	28	ILD	ILD	NNP
cord-016476-78r0rsio	92	29	or	or	CC
cord-016476-78r0rsio	92	30	known	know	VBN
cord-016476-78r0rsio	92	31	to	to	TO
cord-016476-78r0rsio	92	32	have	have	VB
cord-016476-78r0rsio	92	33	RA	RA	NNP
cord-016476-78r0rsio	92	34	-	-	HYPH
cord-016476-78r0rsio	92	35	ILD	ILD	NNP
cord-016476-78r0rsio	92	36	to	to	TO
cord-016476-78r0rsio	92	37	assess	assess	VB
cord-016476-78r0rsio	92	38	for	for	IN
cord-016476-78r0rsio	92	39	progression	progression	NN
cord-016476-78r0rsio	92	40	(	(	-LRB-
cord-016476-78r0rsio	92	41	discussed	discuss	VBN
cord-016476-78r0rsio	92	42	further	further	RB
cord-016476-78r0rsio	92	43	in	in	IN
cord-016476-78r0rsio	92	44	section	section	NN
cord-016476-78r0rsio	92	45	"	"	``
cord-016476-78r0rsio	92	46	Patient	Patient	NNP
cord-016476-78r0rsio	92	47	Management	Management	NNP
cord-016476-78r0rsio	92	48	and	and	CC
cord-016476-78r0rsio	92	49	Treatment	Treatment	NNP
cord-016476-78r0rsio	92	50	"	"	''
cord-016476-78r0rsio	92	51	)	)	-RRB-
cord-016476-78r0rsio	92	52	.	.	.
cord-016476-78r0rsio	93	1	In	in	IN
cord-016476-78r0rsio	93	2	summary	summary	NN
cord-016476-78r0rsio	93	3	,	,	,
cord-016476-78r0rsio	93	4	diagnostic	diagnostic	JJ
cord-016476-78r0rsio	93	5	uncertainty	uncertainty	NN
cord-016476-78r0rsio	93	6	and	and	CC
cord-016476-78r0rsio	93	7	the	the	DT
cord-016476-78r0rsio	93	8	lack	lack	NN
cord-016476-78r0rsio	93	9	of	of	IN
cord-016476-78r0rsio	93	10	any	any	DT
cord-016476-78r0rsio	93	11	gold	gold	JJ
cord-016476-78r0rsio	93	12	standard	standard	JJ
cord-016476-78r0rsio	93	13	test	test	NN
cord-016476-78r0rsio	93	14	for	for	IN
cord-016476-78r0rsio	93	15	MTX	MTX	NNP
cord-016476-78r0rsio	93	16	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	93	17	leaves	leave	VBZ
cord-016476-78r0rsio	93	18	ambiguity	ambiguity	NN
cord-016476-78r0rsio	93	19	about	about	IN
cord-016476-78r0rsio	93	20	the	the	DT
cord-016476-78r0rsio	93	21	true	true	JJ
cord-016476-78r0rsio	93	22	pattern	pattern	NN
cord-016476-78r0rsio	93	23	of	of	IN
cord-016476-78r0rsio	93	24	disease	disease	NN
cord-016476-78r0rsio	93	25	.	.	.
cord-016476-78r0rsio	94	1	However	however	RB
cord-016476-78r0rsio	94	2	MTX	MTX	NNP
cord-016476-78r0rsio	94	3	has	have	VBZ
cord-016476-78r0rsio	94	4	not	not	RB
cord-016476-78r0rsio	94	5	been	be	VBN
cord-016476-78r0rsio	94	6	shown	show	VBN
cord-016476-78r0rsio	94	7	to	to	TO
cord-016476-78r0rsio	94	8	consistently	consistently	RB
cord-016476-78r0rsio	94	9	accelerate	accelerate	VB
cord-016476-78r0rsio	94	10	the	the	DT
cord-016476-78r0rsio	94	11	progression	progression	NN
cord-016476-78r0rsio	94	12	of	of	IN
cord-016476-78r0rsio	94	13	underlying	underlie	VBG
cord-016476-78r0rsio	94	14	RA	RA	NNP
cord-016476-78r0rsio	94	15	-	-	HYPH
cord-016476-78r0rsio	94	16	ILD	ILD	NNP
cord-016476-78r0rsio	94	17	.	.	.
cord-016476-78r0rsio	95	1	Whilst	whilst	IN
cord-016476-78r0rsio	95	2	few	few	JJ
cord-016476-78r0rsio	95	3	studies	study	NNS
cord-016476-78r0rsio	95	4	have	have	VBP
cord-016476-78r0rsio	95	5	been	be	VBN
cord-016476-78r0rsio	95	6	conducted	conduct	VBN
cord-016476-78r0rsio	95	7	in	in	IN
cord-016476-78r0rsio	95	8	pre	pre	JJ
cord-016476-78r0rsio	95	9	-	-	JJ
cord-016476-78r0rsio	95	10	existing	existing	JJ
cord-016476-78r0rsio	95	11	RA	RA	NNP
cord-016476-78r0rsio	95	12	-	-	HYPH
cord-016476-78r0rsio	95	13	ILD	ILD	NNP
cord-016476-78r0rsio	95	14	stratified	stratify	VBN
cord-016476-78r0rsio	95	15	by	by	IN
cord-016476-78r0rsio	95	16	severity	severity	NN
cord-016476-78r0rsio	95	17	of	of	IN
cord-016476-78r0rsio	95	18	lung	lung	NN
cord-016476-78r0rsio	95	19	disease	disease	NN
cord-016476-78r0rsio	95	20	,	,	,
cord-016476-78r0rsio	95	21	the	the	DT
cord-016476-78r0rsio	95	22	risk	risk	NN
cord-016476-78r0rsio	95	23	of	of	IN
cord-016476-78r0rsio	95	24	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	95	25	means	mean	VBZ
cord-016476-78r0rsio	95	26	that	that	IN
cord-016476-78r0rsio	95	27	it	-PRON-	PRP
cord-016476-78r0rsio	95	28	may	may	MD
cord-016476-78r0rsio	95	29	not	not	RB
cord-016476-78r0rsio	95	30	always	always	RB
cord-016476-78r0rsio	95	31	be	be	VB
cord-016476-78r0rsio	95	32	the	the	DT
cord-016476-78r0rsio	95	33	safest	safe	JJS
cord-016476-78r0rsio	95	34	first	first	JJ
cord-016476-78r0rsio	95	35	-	-	HYPH
cord-016476-78r0rsio	95	36	line	line	NN
cord-016476-78r0rsio	95	37	nbDMARD	nbdmard	JJ
cord-016476-78r0rsio	95	38	in	in	IN
cord-016476-78r0rsio	95	39	patients	patient	NNS
cord-016476-78r0rsio	95	40	with	with	IN
cord-016476-78r0rsio	95	41	RA	RA	NNP
cord-016476-78r0rsio	95	42	who	who	WP
cord-016476-78r0rsio	95	43	have	have	VBP
cord-016476-78r0rsio	95	44	severe	severe	JJ
cord-016476-78r0rsio	95	45	pre	pre	JJ
cord-016476-78r0rsio	95	46	-	-	JJ
cord-016476-78r0rsio	95	47	existing	existing	JJ
cord-016476-78r0rsio	95	48	lung	lung	NN
cord-016476-78r0rsio	95	49	disease	disease	NN
cord-016476-78r0rsio	95	50	.	.	.
cord-016476-78r0rsio	96	1	Leflunomide	Leflunomide	NNP
cord-016476-78r0rsio	96	2	is	be	VBZ
cord-016476-78r0rsio	96	3	an	an	DT
cord-016476-78r0rsio	96	4	isoxazole	isoxazole	NN
cord-016476-78r0rsio	96	5	derivative	derivative	NN
cord-016476-78r0rsio	96	6	,	,	,
cord-016476-78r0rsio	96	7	which	which	WDT
cord-016476-78r0rsio	96	8	inhibits	inhibit	VBZ
cord-016476-78r0rsio	96	9	de	de	FW
cord-016476-78r0rsio	96	10	novo	novo	NNP
cord-016476-78r0rsio	96	11	pyrimidine	pyrimidine	NNP
cord-016476-78r0rsio	96	12	synthesis	synthesis	NN
cord-016476-78r0rsio	96	13	,	,	,
cord-016476-78r0rsio	96	14	resulting	result	VBG
cord-016476-78r0rsio	96	15	in	in	IN
cord-016476-78r0rsio	96	16	several	several	JJ
cord-016476-78r0rsio	96	17	downstream	downstream	JJ
cord-016476-78r0rsio	96	18	anti	anti	JJ
cord-016476-78r0rsio	96	19	-	-	JJ
cord-016476-78r0rsio	96	20	inflammatory	inflammatory	JJ
cord-016476-78r0rsio	96	21	effects	effect	NNS
cord-016476-78r0rsio	96	22	such	such	JJ
cord-016476-78r0rsio	96	23	as	as	IN
cord-016476-78r0rsio	96	24	suppression	suppression	NN
cord-016476-78r0rsio	96	25	of	of	IN
cord-016476-78r0rsio	96	26	TNF	TNF	NNP
cord-016476-78r0rsio	96	27	-	-	HYPH
cord-016476-78r0rsio	96	28	induced	induce	VBN
cord-016476-78r0rsio	96	29	cellular	cellular	JJ
cord-016476-78r0rsio	96	30	responses	response	NNS
cord-016476-78r0rsio	96	31	and	and	CC
cord-016476-78r0rsio	96	32	inhibition	inhibition	NN
cord-016476-78r0rsio	96	33	of	of	IN
cord-016476-78r0rsio	96	34	matrix	matrix	NN
cord-016476-78r0rsio	96	35	metalloproteinases	metalloproteinase	NNS
cord-016476-78r0rsio	96	36	and	and	CC
cord-016476-78r0rsio	96	37	osteoclasts	osteoclast	NNS
cord-016476-78r0rsio	96	38	.	.	.
cord-016476-78r0rsio	97	1	Leflunomide	leflunomide	NN
cord-016476-78r0rsio	97	2	-	-	HYPH
cord-016476-78r0rsio	97	3	induced	induce	VBN
cord-016476-78r0rsio	97	4	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	97	5	is	be	VBZ
cord-016476-78r0rsio	97	6	rare	rare	JJ
cord-016476-78r0rsio	97	7	but	but	CC
cord-016476-78r0rsio	97	8	well	well	RB
cord-016476-78r0rsio	97	9	reported	report	VBN
cord-016476-78r0rsio	97	10	.	.	.
cord-016476-78r0rsio	98	1	A	a	DT
cord-016476-78r0rsio	98	2	signal	signal	NN
cord-016476-78r0rsio	98	3	of	of	IN
cord-016476-78r0rsio	98	4	concern	concern	NN
cord-016476-78r0rsio	98	5	was	be	VBD
cord-016476-78r0rsio	98	6	raised	raise	VBN
cord-016476-78r0rsio	98	7	in	in	IN
cord-016476-78r0rsio	98	8	2004	2004	CD
cord-016476-78r0rsio	98	9	after	after	IN
cord-016476-78r0rsio	98	10	an	an	DT
cord-016476-78r0rsio	98	11	investigation	investigation	NN
cord-016476-78r0rsio	98	12	by	by	IN
cord-016476-78r0rsio	98	13	the	the	DT
cord-016476-78r0rsio	98	14	Japanese	Japanese	NNP
cord-016476-78r0rsio	98	15	Ministry	Ministry	NNP
cord-016476-78r0rsio	98	16	of	of	IN
cord-016476-78r0rsio	98	17	Health	Health	NNP
cord-016476-78r0rsio	98	18	following	follow	VBG
cord-016476-78r0rsio	98	19	post	post	JJ
cord-016476-78r0rsio	98	20	-	-	JJ
cord-016476-78r0rsio	98	21	marketing	marketing	JJ
cord-016476-78r0rsio	98	22	surveillance	surveillance	NN
cord-016476-78r0rsio	98	23	in	in	IN
cord-016476-78r0rsio	98	24	16	16	CD
cord-016476-78r0rsio	98	25	(	(	-LRB-
cord-016476-78r0rsio	98	26	0.5	0.5	CD
cord-016476-78r0rsio	98	27	%	%	NN
cord-016476-78r0rsio	98	28	)	)	-RRB-
cord-016476-78r0rsio	98	29	of	of	IN
cord-016476-78r0rsio	98	30	the	the	DT
cord-016476-78r0rsio	98	31	first	first	JJ
cord-016476-78r0rsio	98	32	3000	3000	CD
cord-016476-78r0rsio	98	33	Japanese	japanese	JJ
cord-016476-78r0rsio	98	34	patients	patient	NNS
cord-016476-78r0rsio	98	35	treated	treat	VBN
cord-016476-78r0rsio	98	36	with	with	IN
cord-016476-78r0rsio	98	37	leflunomide	leflunomide	NN
cord-016476-78r0rsio	98	38	,	,	,
cord-016476-78r0rsio	98	39	resulting	result	VBG
cord-016476-78r0rsio	98	40	in	in	IN
cord-016476-78r0rsio	98	41	five	five	CD
cord-016476-78r0rsio	98	42	fatalities	fatality	NNS
cord-016476-78r0rsio	98	43	[	[	-LRB-
cord-016476-78r0rsio	98	44	24	24	CD
cord-016476-78r0rsio	98	45	,	,	,
cord-016476-78r0rsio	98	46	25	25	CD
cord-016476-78r0rsio	98	47	]	]	-RRB-
cord-016476-78r0rsio	98	48	and	and	CC
cord-016476-78r0rsio	99	1	the	the	DT
cord-016476-78r0rsio	99	2	Committee	Committee	NNP
cord-016476-78r0rsio	99	3	on	on	IN
cord-016476-78r0rsio	99	4	the	the	DT
cord-016476-78r0rsio	99	5	Safety	Safety	NNP
cord-016476-78r0rsio	99	6	of	of	IN
cord-016476-78r0rsio	99	7	Medicines	Medicines	NNP
cord-016476-78r0rsio	99	8	also	also	RB
cord-016476-78r0rsio	99	9	reporting	report	VBG
cord-016476-78r0rsio	99	10	17	17	CD
cord-016476-78r0rsio	99	11	cases	case	NNS
cord-016476-78r0rsio	99	12	in	in	IN
cord-016476-78r0rsio	99	13	the	the	DT
cord-016476-78r0rsio	99	14	UK	UK	NNP
cord-016476-78r0rsio	99	15	of	of	IN
cord-016476-78r0rsio	99	16	which	which	WDT
cord-016476-78r0rsio	99	17	five	five	CD
cord-016476-78r0rsio	99	18	were	be	VBD
cord-016476-78r0rsio	99	19	fatal	fatal	JJ
cord-016476-78r0rsio	99	20	.	.	.
cord-016476-78r0rsio	100	1	Further	further	JJ
cord-016476-78r0rsio	100	2	case	case	NN
cord-016476-78r0rsio	100	3	reports	report	NNS
cord-016476-78r0rsio	100	4	have	have	VBP
cord-016476-78r0rsio	100	5	subsequently	subsequently	RB
cord-016476-78r0rsio	100	6	been	be	VBN
cord-016476-78r0rsio	100	7	reported	report	VBN
cord-016476-78r0rsio	100	8	especially	especially	RB
cord-016476-78r0rsio	100	9	in	in	IN
cord-016476-78r0rsio	100	10	the	the	DT
cord-016476-78r0rsio	100	11	Japanese	japanese	JJ
cord-016476-78r0rsio	100	12	and	and	CC
cord-016476-78r0rsio	100	13	Korean	korean	JJ
cord-016476-78r0rsio	100	14	populations	population	NNS
cord-016476-78r0rsio	100	15	[	[	-LRB-
cord-016476-78r0rsio	100	16	26	26	CD
cord-016476-78r0rsio	100	17	]	]	-RRB-
cord-016476-78r0rsio	100	18	[	[	-LRB-
cord-016476-78r0rsio	100	19	27	27	CD
cord-016476-78r0rsio	100	20	]	]	-RRB-
cord-016476-78r0rsio	100	21	[	[	-LRB-
cord-016476-78r0rsio	100	22	28	28	CD
cord-016476-78r0rsio	100	23	]	]	-RRB-
cord-016476-78r0rsio	100	24	.	.	.
cord-016476-78r0rsio	101	1	However	however	RB
cord-016476-78r0rsio	101	2	leflunomide	leflunomide	NN
cord-016476-78r0rsio	101	3	is	be	VBZ
cord-016476-78r0rsio	101	4	often	often	RB
cord-016476-78r0rsio	101	5	used	use	VBN
cord-016476-78r0rsio	101	6	second	second	JJ
cord-016476-78r0rsio	101	7	line	line	NN
cord-016476-78r0rsio	101	8	after	after	IN
cord-016476-78r0rsio	101	9	MTX	MTX	NNP
cord-016476-78r0rsio	101	10	exposure	exposure	NN
cord-016476-78r0rsio	101	11	or	or	CC
cord-016476-78r0rsio	101	12	in	in	IN
cord-016476-78r0rsio	101	13	combination	combination	NN
cord-016476-78r0rsio	101	14	with	with	IN
cord-016476-78r0rsio	101	15	MTX	MTX	NNP
cord-016476-78r0rsio	101	16	in	in	IN
cord-016476-78r0rsio	101	17	patients	patient	NNS
cord-016476-78r0rsio	101	18	with	with	IN
cord-016476-78r0rsio	101	19	active	active	JJ
cord-016476-78r0rsio	101	20	articular	articular	JJ
cord-016476-78r0rsio	101	21	disease	disease	NN
cord-016476-78r0rsio	101	22	,	,	,
cord-016476-78r0rsio	101	23	which	which	WDT
cord-016476-78r0rsio	101	24	make	make	VBP
cord-016476-78r0rsio	101	25	studies	study	NNS
cord-016476-78r0rsio	101	26	evaluating	evaluate	VBG
cord-016476-78r0rsio	101	27	leflunomide	leflunomide	NN
cord-016476-78r0rsio	101	28	-	-	HYPH
cord-016476-78r0rsio	101	29	induced	induce	VBN
cord-016476-78r0rsio	101	30	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	101	31	difficult	difficult	JJ
cord-016476-78r0rsio	101	32	to	to	TO
cord-016476-78r0rsio	101	33	interpret	interpret	VB
cord-016476-78r0rsio	101	34	.	.	.
cord-016476-78r0rsio	102	1	In	in	IN
cord-016476-78r0rsio	102	2	a	a	DT
cord-016476-78r0rsio	102	3	report	report	NN
cord-016476-78r0rsio	102	4	of	of	IN
cord-016476-78r0rsio	102	5	14	14	CD
cord-016476-78r0rsio	102	6	such	such	JJ
cord-016476-78r0rsio	102	7	cases	case	NNS
cord-016476-78r0rsio	102	8	from	from	IN
cord-016476-78r0rsio	102	9	Australia	Australia	NNP
cord-016476-78r0rsio	102	10	and	and	CC
cord-016476-78r0rsio	102	11	New	New	NNP
cord-016476-78r0rsio	102	12	Zealand	Zealand	NNP
cord-016476-78r0rsio	102	13	,	,	,
cord-016476-78r0rsio	102	14	12	12	CD
cord-016476-78r0rsio	102	15	were	be	VBD
cord-016476-78r0rsio	102	16	co	co	JJ
cord-016476-78r0rsio	102	17	-	-	JJ
cord-016476-78r0rsio	102	18	prescribed	prescribed	JJ
cord-016476-78r0rsio	102	19	MTX	MTX	NNP
cord-016476-78r0rsio	102	20	[	[	-LRB-
cord-016476-78r0rsio	102	21	29	29	CD
cord-016476-78r0rsio	102	22	]	]	-RRB-
cord-016476-78r0rsio	102	23	.	.	.
cord-016476-78r0rsio	103	1	Chikura	Chikura	NNP
cord-016476-78r0rsio	103	2	et	et	NNP
cord-016476-78r0rsio	103	3	al	al	NNP
cord-016476-78r0rsio	103	4	.	.	.
cord-016476-78r0rsio	104	1	[	[	-LRB-
cord-016476-78r0rsio	104	2	30	30	CD
cord-016476-78r0rsio	104	3	]	]	-RRB-
cord-016476-78r0rsio	104	4	reported	report	VBN
cord-016476-78r0rsio	104	5	on	on	IN
cord-016476-78r0rsio	104	6	32	32	CD
cord-016476-78r0rsio	104	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	104	8	cases	case	NNS
cord-016476-78r0rsio	104	9	following	follow	VBG
cord-016476-78r0rsio	104	10	leflunomide	leflunomide	NN
cord-016476-78r0rsio	104	11	exposure	exposure	NN
cord-016476-78r0rsio	104	12	,	,	,
cord-016476-78r0rsio	104	13	classified	classify	VBN
cord-016476-78r0rsio	104	14	using	use	VBG
cord-016476-78r0rsio	104	15	Searles	Searles	NNP
cord-016476-78r0rsio	104	16	and	and	CC
cord-016476-78r0rsio	104	17	McKendry	McKendry	NNP
cord-016476-78r0rsio	104	18	criteria	criterion	NNS
cord-016476-78r0rsio	104	19	(	(	-LRB-
cord-016476-78r0rsio	104	20	Table	table	NN
cord-016476-78r0rsio	104	21	9	9	CD
cord-016476-78r0rsio	104	22	.1	.1	CD
cord-016476-78r0rsio	104	23	)	)	-RRB-
cord-016476-78r0rsio	104	24	,	,	,
cord-016476-78r0rsio	104	25	and	and	CC
cord-016476-78r0rsio	104	26	found	find	VBD
cord-016476-78r0rsio	104	27	97	97	CD
cord-016476-78r0rsio	104	28	%	%	NN
cord-016476-78r0rsio	104	29	had	have	VBD
cord-016476-78r0rsio	104	30	a	a	DT
cord-016476-78r0rsio	104	31	history	history	NN
cord-016476-78r0rsio	104	32	of	of	IN
cord-016476-78r0rsio	104	33	MTX	MTX	NNP
cord-016476-78r0rsio	104	34	exposure	exposure	NN
cord-016476-78r0rsio	104	35	,	,	,
cord-016476-78r0rsio	104	36	whilst	whilst	IN
cord-016476-78r0rsio	104	37	41	41	CD
cord-016476-78r0rsio	104	38	%	%	NN
cord-016476-78r0rsio	104	39	were	be	VBD
cord-016476-78r0rsio	104	40	on	on	IN
cord-016476-78r0rsio	104	41	concomitant	concomitant	JJ
cord-016476-78r0rsio	104	42	MTX	mtx	NN
cord-016476-78r0rsio	104	43	at	at	IN
cord-016476-78r0rsio	104	44	the	the	DT
cord-016476-78r0rsio	104	45	onset	onset	NN
cord-016476-78r0rsio	104	46	of	of	IN
cord-016476-78r0rsio	104	47	ILD	ILD	NNP
cord-016476-78r0rsio	104	48	.	.	.
cord-016476-78r0rsio	105	1	The	the	DT
cord-016476-78r0rsio	105	2	majority	majority	NN
cord-016476-78r0rsio	105	3	presented	present	VBD
cord-016476-78r0rsio	105	4	within	within	IN
cord-016476-78r0rsio	105	5	20	20	CD
cord-016476-78r0rsio	105	6	weeks	week	NNS
cord-016476-78r0rsio	105	7	of	of	IN
cord-016476-78r0rsio	105	8	initiation	initiation	NN
cord-016476-78r0rsio	105	9	.	.	.
cord-016476-78r0rsio	106	1	Clinical	clinical	JJ
cord-016476-78r0rsio	106	2	features	feature	NNS
cord-016476-78r0rsio	106	3	of	of	IN
cord-016476-78r0rsio	106	4	those	those	DT
cord-016476-78r0rsio	106	5	who	who	WP
cord-016476-78r0rsio	106	6	died	die	VBD
cord-016476-78r0rsio	106	7	were	be	VBD
cord-016476-78r0rsio	106	8	pre	pre	JJ
cord-016476-78r0rsio	106	9	-	-	JJ
cord-016476-78r0rsio	106	10	existing	existing	JJ
cord-016476-78r0rsio	106	11	ILD	ILD	NNP
cord-016476-78r0rsio	106	12	and	and	CC
cord-016476-78r0rsio	106	13	diffuse	diffuse	VB
cord-016476-78r0rsio	106	14	alveolar	alveolar	JJ
cord-016476-78r0rsio	106	15	damage	damage	NN
cord-016476-78r0rsio	106	16	on	on	IN
cord-016476-78r0rsio	106	17	histology	histology	NN
cord-016476-78r0rsio	106	18	(	(	-LRB-
cord-016476-78r0rsio	106	19	n	n	NN
cord-016476-78r0rsio	106	20	=	=	SYM
cord-016476-78r0rsio	106	21	6/32	6/32	CD
cord-016476-78r0rsio	106	22	)	)	-RRB-
cord-016476-78r0rsio	106	23	.	.	.
cord-016476-78r0rsio	107	1	Pre	pre	JJ
cord-016476-78r0rsio	107	2	-	-	JJ
cord-016476-78r0rsio	107	3	existing	existing	JJ
cord-016476-78r0rsio	107	4	ILD	ILD	NNP
cord-016476-78r0rsio	107	5	was	be	VBD
cord-016476-78r0rsio	107	6	also	also	RB
cord-016476-78r0rsio	107	7	shown	show	VBN
cord-016476-78r0rsio	107	8	to	to	TO
cord-016476-78r0rsio	107	9	be	be	VB
cord-016476-78r0rsio	107	10	a	a	DT
cord-016476-78r0rsio	107	11	risk	risk	NN
cord-016476-78r0rsio	107	12	factor	factor	NN
cord-016476-78r0rsio	107	13	for	for	IN
cord-016476-78r0rsio	107	14	leflunomide	leflunomide	NN
cord-016476-78r0rsio	107	15	-	-	HYPH
cord-016476-78r0rsio	107	16	induced	induce	VBN
cord-016476-78r0rsio	107	17	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	107	18	in	in	IN
cord-016476-78r0rsio	107	19	a	a	DT
cord-016476-78r0rsio	107	20	large	large	JJ
cord-016476-78r0rsio	107	21	case	case	NN
cord-016476-78r0rsio	107	22	-	-	HYPH
cord-016476-78r0rsio	107	23	control	control	NN
cord-016476-78r0rsio	107	24	study	study	NN
cord-016476-78r0rsio	107	25	using	use	VBG
cord-016476-78r0rsio	107	26	a	a	DT
cord-016476-78r0rsio	107	27	Canadian	canadian	JJ
cord-016476-78r0rsio	107	28	claims	claim	NNS
cord-016476-78r0rsio	107	29	database	database	NN
cord-016476-78r0rsio	107	30	[	[	-LRB-
cord-016476-78r0rsio	107	31	31	31	CD
cord-016476-78r0rsio	107	32	]	]	-RRB-
cord-016476-78r0rsio	107	33	.	.	.
cord-016476-78r0rsio	108	1	The	the	DT
cord-016476-78r0rsio	108	2	risk	risk	NN
cord-016476-78r0rsio	108	3	of	of	IN
cord-016476-78r0rsio	108	4	ILD	ILD	NNP
cord-016476-78r0rsio	108	5	was	be	VBD
cord-016476-78r0rsio	108	6	increased	increase	VBN
cord-016476-78r0rsio	108	7	with	with	IN
cord-016476-78r0rsio	108	8	the	the	DT
cord-016476-78r0rsio	108	9	use	use	NN
cord-016476-78r0rsio	108	10	of	of	IN
cord-016476-78r0rsio	108	11	leflunomide	leflunomide	NN
cord-016476-78r0rsio	108	12	(	(	-LRB-
cord-016476-78r0rsio	108	13	adjusted	adjust	VBN
cord-016476-78r0rsio	108	14	RR	RR	NNP
cord-016476-78r0rsio	108	15	1.9	1.9	CD
cord-016476-78r0rsio	108	16	[	[	-LRB-
cord-016476-78r0rsio	108	17	95	95	CD
cord-016476-78r0rsio	108	18	%	%	NN
cord-016476-78r0rsio	108	19	CI	CI	NNP
cord-016476-78r0rsio	108	20	1.1	1.1	CD
cord-016476-78r0rsio	108	21	-	-	SYM
cord-016476-78r0rsio	108	22	3.6	3.6	CD
cord-016476-78r0rsio	108	23	]	]	-RRB-
cord-016476-78r0rsio	108	24	)	)	-RRB-
cord-016476-78r0rsio	108	25	;	;	:
cord-016476-78r0rsio	108	26	however	however	RB
cord-016476-78r0rsio	108	27	,	,	,
cord-016476-78r0rsio	108	28	in	in	IN
cord-016476-78r0rsio	108	29	patients	patient	NNS
cord-016476-78r0rsio	108	30	without	without	IN
cord-016476-78r0rsio	108	31	previous	previous	JJ
cord-016476-78r0rsio	108	32	MTX	MTX	NNP
cord-016476-78r0rsio	108	33	exposure	exposure	NN
cord-016476-78r0rsio	108	34	or	or	CC
cord-016476-78r0rsio	108	35	ILD	ILD	NNP
cord-016476-78r0rsio	108	36	history	history	NN
cord-016476-78r0rsio	108	37	,	,	,
cord-016476-78r0rsio	108	38	the	the	DT
cord-016476-78r0rsio	108	39	risk	risk	NN
cord-016476-78r0rsio	108	40	associated	associate	VBN
cord-016476-78r0rsio	108	41	with	with	IN
cord-016476-78r0rsio	108	42	leflunomide	leflunomide	NN
cord-016476-78r0rsio	108	43	treatment	treatment	NN
cord-016476-78r0rsio	108	44	was	be	VBD
cord-016476-78r0rsio	108	45	not	not	RB
cord-016476-78r0rsio	108	46	elevated	elevate	VBN
cord-016476-78r0rsio	108	47	(	(	-LRB-
cord-016476-78r0rsio	108	48	RR	RR	NNP
cord-016476-78r0rsio	108	49	1.2	1.2	CD
cord-016476-78r0rsio	108	50	[	[	-LRB-
cord-016476-78r0rsio	108	51	95	95	CD
cord-016476-78r0rsio	108	52	%	%	NN
cord-016476-78r0rsio	108	53	CI	CI	NNP
cord-016476-78r0rsio	108	54	0.4	0.4	CD
cord-016476-78r0rsio	108	55	-	-	SYM
cord-016476-78r0rsio	108	56	3.1	3.1	CD
cord-016476-78r0rsio	108	57	]	]	-RRB-
cord-016476-78r0rsio	108	58	)	)	-RRB-
cord-016476-78r0rsio	108	59	.	.	.
cord-016476-78r0rsio	109	1	However	however	RB
cord-016476-78r0rsio	109	2	,	,	,
cord-016476-78r0rsio	109	3	it	-PRON-	PRP
cord-016476-78r0rsio	109	4	was	be	VBD
cord-016476-78r0rsio	109	5	acknowledged	acknowledge	VBN
cord-016476-78r0rsio	109	6	given	give	VBN
cord-016476-78r0rsio	109	7	the	the	DT
cord-016476-78r0rsio	109	8	probable	probable	JJ
cord-016476-78r0rsio	109	9	association	association	NN
cord-016476-78r0rsio	109	10	between	between	IN
cord-016476-78r0rsio	109	11	prior	prior	JJ
cord-016476-78r0rsio	109	12	ILD	ILD	NNP
cord-016476-78r0rsio	109	13	and	and	CC
cord-016476-78r0rsio	109	14	MTX	MTX	NNP
cord-016476-78r0rsio	109	15	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	109	16	;	;	:
cord-016476-78r0rsio	109	17	clinicians	clinician	NNS
cord-016476-78r0rsio	109	18	may	may	MD
cord-016476-78r0rsio	109	19	be	be	VB
cord-016476-78r0rsio	109	20	more	more	RBR
cord-016476-78r0rsio	109	21	likely	likely	JJ
cord-016476-78r0rsio	109	22	to	to	TO
cord-016476-78r0rsio	109	23	prescribe	prescribe	VB
cord-016476-78r0rsio	109	24	leflunomide	leflunomide	NN
cord-016476-78r0rsio	109	25	than	than	IN
cord-016476-78r0rsio	109	26	MTX	MTX	NNP
cord-016476-78r0rsio	109	27	to	to	IN
cord-016476-78r0rsio	109	28	patients	patient	NNS
cord-016476-78r0rsio	109	29	with	with	IN
cord-016476-78r0rsio	109	30	prevalent	prevalent	JJ
cord-016476-78r0rsio	109	31	ILD	ILD	NNP
cord-016476-78r0rsio	109	32	,	,	,
cord-016476-78r0rsio	109	33	leading	lead	VBG
cord-016476-78r0rsio	109	34	to	to	IN
cord-016476-78r0rsio	109	35	channelling	channel	VBG
cord-016476-78r0rsio	109	36	bias	bias	NN
cord-016476-78r0rsio	109	37	explaining	explain	VBG
cord-016476-78r0rsio	109	38	the	the	DT
cord-016476-78r0rsio	109	39	increased	increase	VBN
cord-016476-78r0rsio	109	40	risk	risk	NN
cord-016476-78r0rsio	109	41	observed	observe	VBD
cord-016476-78r0rsio	109	42	.	.	.
cord-016476-78r0rsio	110	1	Leflunomide	leflunomide	NN
cord-016476-78r0rsio	110	2	-	-	HYPH
cord-016476-78r0rsio	110	3	induced	induce	VBN
cord-016476-78r0rsio	110	4	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	110	5	appears	appear	VBZ
cord-016476-78r0rsio	110	6	to	to	TO
cord-016476-78r0rsio	110	7	occur	occur	VB
cord-016476-78r0rsio	110	8	more	more	RBR
cord-016476-78r0rsio	110	9	frequently	frequently	RB
cord-016476-78r0rsio	110	10	in	in	IN
cord-016476-78r0rsio	110	11	Japanese	japanese	JJ
cord-016476-78r0rsio	110	12	and	and	CC
cord-016476-78r0rsio	110	13	Korean	korean	JJ
cord-016476-78r0rsio	110	14	population	population	NN
cord-016476-78r0rsio	110	15	(	(	-LRB-
cord-016476-78r0rsio	110	16	reported	report	VBN
cord-016476-78r0rsio	110	17	rate	rate	NN
cord-016476-78r0rsio	110	18	~1	~1	NNP
cord-016476-78r0rsio	110	19	%	%	NN
cord-016476-78r0rsio	110	20	)	)	-RRB-
cord-016476-78r0rsio	110	21	[	[	-LRB-
cord-016476-78r0rsio	110	22	26	26	CD
cord-016476-78r0rsio	110	23	,	,	,
cord-016476-78r0rsio	110	24	32	32	CD
cord-016476-78r0rsio	110	25	]	]	-RRB-
cord-016476-78r0rsio	110	26	,	,	,
cord-016476-78r0rsio	110	27	whilst	whilst	IN
cord-016476-78r0rsio	110	28	in	in	IN
cord-016476-78r0rsio	110	29	the	the	DT
cord-016476-78r0rsio	110	30	Western	western	JJ
cord-016476-78r0rsio	110	31	Caucasian	caucasian	JJ
cord-016476-78r0rsio	110	32	population	population	NN
cord-016476-78r0rsio	110	33	,	,	,
cord-016476-78r0rsio	111	1	a	a	DT
cord-016476-78r0rsio	111	2	rate	rate	NN
cord-016476-78r0rsio	111	3	of	of	IN
cord-016476-78r0rsio	111	4	<	<	$
cord-016476-78r0rsio	111	5	0.1	0.1	CD
cord-016476-78r0rsio	111	6	%	%	NN
cord-016476-78r0rsio	111	7	is	be	VBZ
cord-016476-78r0rsio	111	8	reported	report	VBN
cord-016476-78r0rsio	111	9	[	[	-LRB-
cord-016476-78r0rsio	111	10	33	33	CD
cord-016476-78r0rsio	111	11	]	]	-RRB-
cord-016476-78r0rsio	111	12	.	.	.
cord-016476-78r0rsio	112	1	Genetic	genetic	JJ
cord-016476-78r0rsio	112	2	susceptibility	susceptibility	NN
cord-016476-78r0rsio	112	3	in	in	IN
cord-016476-78r0rsio	112	4	Japanese	japanese	JJ
cord-016476-78r0rsio	112	5	patients	patient	NNS
cord-016476-78r0rsio	112	6	has	have	VBZ
cord-016476-78r0rsio	112	7	been	be	VBN
cord-016476-78r0rsio	112	8	described	describe	VBN
cord-016476-78r0rsio	112	9	in	in	IN
cord-016476-78r0rsio	112	10	a	a	DT
cord-016476-78r0rsio	112	11	study	study	NN
cord-016476-78r0rsio	112	12	which	which	WDT
cord-016476-78r0rsio	112	13	investigated	investigate	VBD
cord-016476-78r0rsio	112	14	human	human	JJ
cord-016476-78r0rsio	112	15	leukocyte	leukocyte	NN
cord-016476-78r0rsio	112	16	antigen	antigen	NN
cord-016476-78r0rsio	112	17	(	(	-LRB-
cord-016476-78r0rsio	112	18	HLA	HLA	NNP
cord-016476-78r0rsio	112	19	)	)	-RRB-
cord-016476-78r0rsio	112	20	class	class	NN
cord-016476-78r0rsio	112	21	I	I	NNP
cord-016476-78r0rsio	112	22	associations	association	NNS
cord-016476-78r0rsio	112	23	with	with	IN
cord-016476-78r0rsio	112	24	MTX	MTX	NNP
cord-016476-78r0rsio	112	25	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	112	26	in	in	IN
cord-016476-78r0rsio	112	27	Japanese	japanese	JJ
cord-016476-78r0rsio	112	28	patients	patient	NNS
cord-016476-78r0rsio	112	29	with	with	IN
cord-016476-78r0rsio	112	30	RA	RA	NNP
cord-016476-78r0rsio	112	31	and	and	CC
cord-016476-78r0rsio	112	32	found	find	VBD
cord-016476-78r0rsio	112	33	HLA	HLA	NNP
cord-016476-78r0rsio	112	34	-	-	HYPH
cord-016476-78r0rsio	112	35	A	A	NNP
cord-016476-78r0rsio	112	36	×	×	NN
cord-016476-78r0rsio	112	37	31:01	31:01	CD
cord-016476-78r0rsio	112	38	as	as	IN
cord-016476-78r0rsio	112	39	a	a	DT
cord-016476-78r0rsio	112	40	possible	possible	JJ
cord-016476-78r0rsio	112	41	predictor	predictor	NN
cord-016476-78r0rsio	112	42	.	.	.
cord-016476-78r0rsio	113	1	The	the	DT
cord-016476-78r0rsio	113	2	prevalence	prevalence	NN
cord-016476-78r0rsio	113	3	of	of	IN
cord-016476-78r0rsio	113	4	this	this	DT
cord-016476-78r0rsio	113	5	allele	allele	NN
cord-016476-78r0rsio	113	6	is	be	VBZ
cord-016476-78r0rsio	113	7	proportionally	proportionally	RB
cord-016476-78r0rsio	113	8	higher	high	JJR
cord-016476-78r0rsio	113	9	in	in	IN
cord-016476-78r0rsio	113	10	the	the	DT
cord-016476-78r0rsio	113	11	Japanese	japanese	JJ
cord-016476-78r0rsio	113	12	population	population	NN
cord-016476-78r0rsio	113	13	(	(	-LRB-
cord-016476-78r0rsio	113	14	8.7	8.7	CD
cord-016476-78r0rsio	113	15	%	%	NN
cord-016476-78r0rsio	113	16	)	)	-RRB-
cord-016476-78r0rsio	113	17	than	than	IN
cord-016476-78r0rsio	113	18	in	in	IN
cord-016476-78r0rsio	113	19	the	the	DT
cord-016476-78r0rsio	113	20	Caucasian	caucasian	JJ
cord-016476-78r0rsio	113	21	population	population	NN
cord-016476-78r0rsio	113	22	(	(	-LRB-
cord-016476-78r0rsio	113	23	3.9	3.9	CD
cord-016476-78r0rsio	113	24	%	%	NN
cord-016476-78r0rsio	113	25	)	)	-RRB-
cord-016476-78r0rsio	113	26	[	[	-LRB-
cord-016476-78r0rsio	113	27	34	34	CD
cord-016476-78r0rsio	113	28	]	]	-RRB-
cord-016476-78r0rsio	113	29	.	.	.
cord-016476-78r0rsio	114	1	Therefore	therefore	RB
cord-016476-78r0rsio	114	2	such	such	JJ
cord-016476-78r0rsio	114	3	genetic	genetic	JJ
cord-016476-78r0rsio	114	4	differences	difference	NNS
cord-016476-78r0rsio	114	5	and	and	CC
cord-016476-78r0rsio	114	6	undiscovered	undiscovered	JJ
cord-016476-78r0rsio	114	7	genetic	genetic	JJ
cord-016476-78r0rsio	114	8	predictors	predictor	NNS
cord-016476-78r0rsio	114	9	may	may	MD
cord-016476-78r0rsio	114	10	explain	explain	VB
cord-016476-78r0rsio	114	11	some	some	DT
cord-016476-78r0rsio	114	12	of	of	IN
cord-016476-78r0rsio	114	13	the	the	DT
cord-016476-78r0rsio	114	14	differences	difference	NNS
cord-016476-78r0rsio	114	15	in	in	IN
cord-016476-78r0rsio	114	16	frequency	frequency	NN
cord-016476-78r0rsio	114	17	observed	observe	VBN
cord-016476-78r0rsio	114	18	in	in	IN
cord-016476-78r0rsio	114	19	such	such	JJ
cord-016476-78r0rsio	114	20	populations	population	NNS
cord-016476-78r0rsio	114	21	.	.	.
cord-016476-78r0rsio	115	1	Several	several	JJ
cord-016476-78r0rsio	115	2	risk	risk	NN
cord-016476-78r0rsio	115	3	factors	factor	NNS
cord-016476-78r0rsio	115	4	of	of	IN
cord-016476-78r0rsio	115	5	leflunomide	leflunomide	NN
cord-016476-78r0rsio	115	6	-	-	HYPH
cord-016476-78r0rsio	115	7	induced	induce	VBN
cord-016476-78r0rsio	115	8	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	115	9	have	have	VBP
cord-016476-78r0rsio	115	10	been	be	VBN
cord-016476-78r0rsio	115	11	reported	report	VBN
cord-016476-78r0rsio	115	12	in	in	IN
cord-016476-78r0rsio	115	13	small	small	JJ
cord-016476-78r0rsio	115	14	numbers	number	NNS
cord-016476-78r0rsio	115	15	of	of	IN
cord-016476-78r0rsio	115	16	patients	patient	NNS
cord-016476-78r0rsio	115	17	in	in	IN
cord-016476-78r0rsio	115	18	case	case	NN
cord-016476-78r0rsio	115	19	series	series	NN
cord-016476-78r0rsio	115	20	and	and	CC
cord-016476-78r0rsio	115	21	retrospective	retrospective	JJ
cord-016476-78r0rsio	115	22	studies	study	NNS
cord-016476-78r0rsio	115	23	including	include	VBG
cord-016476-78r0rsio	115	24	preexisting	preexist	VBG
cord-016476-78r0rsio	115	25	lung	lung	NN
cord-016476-78r0rsio	115	26	disease	disease	NN
cord-016476-78r0rsio	115	27	[	[	-LRB-
cord-016476-78r0rsio	115	28	32	32	CD
cord-016476-78r0rsio	115	29	,	,	,
cord-016476-78r0rsio	115	30	35	35	CD
cord-016476-78r0rsio	115	31	,	,	,
cord-016476-78r0rsio	115	32	36	36	CD
cord-016476-78r0rsio	115	33	]	]	-RRB-
cord-016476-78r0rsio	115	34	,	,	,
cord-016476-78r0rsio	115	35	a	a	DT
cord-016476-78r0rsio	115	36	prescribed	prescribed	JJ
cord-016476-78r0rsio	115	37	loading	loading	NN
cord-016476-78r0rsio	115	38	dose	dose	NN
cord-016476-78r0rsio	115	39	,	,	,
cord-016476-78r0rsio	115	40	smoking	smoking	NN
cord-016476-78r0rsio	115	41	,	,	,
cord-016476-78r0rsio	115	42	low	low	JJ
cord-016476-78r0rsio	115	43	body	body	NN
cord-016476-78r0rsio	115	44	weight	weight	NN
cord-016476-78r0rsio	115	45	[	[	-LRB-
cord-016476-78r0rsio	115	46	32	32	CD
cord-016476-78r0rsio	115	47	]	]	-RRB-
cord-016476-78r0rsio	115	48	and	and	CC
cord-016476-78r0rsio	115	49	increased	increase	VBN
cord-016476-78r0rsio	115	50	C	c	NN
cord-016476-78r0rsio	115	51	-	-	HYPH
cord-016476-78r0rsio	115	52	reactive	reactive	JJ
cord-016476-78r0rsio	115	53	protein	protein	NN
cord-016476-78r0rsio	115	54	,	,	,
cord-016476-78r0rsio	115	55	hypoalbuminaemia	hypoalbuminaemia	NN
cord-016476-78r0rsio	115	56	,	,	,
cord-016476-78r0rsio	115	57	hypoxia	hypoxia	NN
cord-016476-78r0rsio	115	58	and	and	CC
cord-016476-78r0rsio	115	59	lymphopaenia	lymphopaenia	NNP
cord-016476-78r0rsio	115	60	[	[	-LRB-
cord-016476-78r0rsio	115	61	36	36	CD
cord-016476-78r0rsio	115	62	]	]	-RRB-
cord-016476-78r0rsio	115	63	.	.	.
cord-016476-78r0rsio	116	1	Treatment	treatment	NN
cord-016476-78r0rsio	116	2	includes	include	VBZ
cord-016476-78r0rsio	116	3	cessation	cessation	NN
cord-016476-78r0rsio	116	4	of	of	IN
cord-016476-78r0rsio	116	5	the	the	DT
cord-016476-78r0rsio	116	6	drug	drug	NN
cord-016476-78r0rsio	116	7	,	,	,
cord-016476-78r0rsio	116	8	treatment	treatment	NN
cord-016476-78r0rsio	116	9	with	with	IN
cord-016476-78r0rsio	116	10	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	116	11	with	with	IN
cord-016476-78r0rsio	116	12	some	some	DT
cord-016476-78r0rsio	116	13	benefit	benefit	NN
cord-016476-78r0rsio	116	14	reported	report	VBN
cord-016476-78r0rsio	116	15	with	with	IN
cord-016476-78r0rsio	116	16	activated	activate	VBN
cord-016476-78r0rsio	116	17	charcoal	charcoal	NN
cord-016476-78r0rsio	116	18	and	and	CC
cord-016476-78r0rsio	116	19	cholestyramine	cholestyramine	NN
cord-016476-78r0rsio	116	20	as	as	IN
cord-016476-78r0rsio	116	21	washout	washout	NN
cord-016476-78r0rsio	116	22	treatments	treatment	NNS
cord-016476-78r0rsio	116	23	.	.	.
cord-016476-78r0rsio	117	1	Whilst	whilst	IN
cord-016476-78r0rsio	117	2	conclusions	conclusion	NNS
cord-016476-78r0rsio	117	3	of	of	IN
cord-016476-78r0rsio	117	4	use	use	NN
cord-016476-78r0rsio	117	5	in	in	IN
cord-016476-78r0rsio	117	6	RA	RA	NNP
cord-016476-78r0rsio	117	7	-	-	HYPH
cord-016476-78r0rsio	117	8	ILD	ILD	NNP
cord-016476-78r0rsio	117	9	are	be	VBP
cord-016476-78r0rsio	117	10	limited	limit	VBN
cord-016476-78r0rsio	117	11	from	from	IN
cord-016476-78r0rsio	117	12	studies	study	NNS
cord-016476-78r0rsio	117	13	due	due	JJ
cord-016476-78r0rsio	117	14	to	to	IN
cord-016476-78r0rsio	117	15	channelling	channel	VBG
cord-016476-78r0rsio	117	16	bias	bias	NN
cord-016476-78r0rsio	117	17	,	,	,
cord-016476-78r0rsio	117	18	leflunomide	leflunomide	NNP
cord-016476-78r0rsio	117	19	should	should	MD
cord-016476-78r0rsio	117	20	be	be	VB
cord-016476-78r0rsio	117	21	avoided	avoid	VBN
cord-016476-78r0rsio	117	22	in	in	IN
cord-016476-78r0rsio	117	23	patients	patient	NNS
cord-016476-78r0rsio	117	24	with	with	IN
cord-016476-78r0rsio	117	25	previous	previous	JJ
cord-016476-78r0rsio	117	26	MTX	MTX	NNP
cord-016476-78r0rsio	117	27	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	117	28	and	and	CC
cord-016476-78r0rsio	117	29	should	should	MD
cord-016476-78r0rsio	117	30	be	be	VB
cord-016476-78r0rsio	117	31	used	use	VBN
cord-016476-78r0rsio	117	32	with	with	IN
cord-016476-78r0rsio	117	33	caution	caution	NN
cord-016476-78r0rsio	117	34	in	in	IN
cord-016476-78r0rsio	117	35	patients	patient	NNS
cord-016476-78r0rsio	117	36	with	with	IN
cord-016476-78r0rsio	117	37	pre	pre	JJ
cord-016476-78r0rsio	117	38	-	-	JJ
cord-016476-78r0rsio	117	39	existing	existing	JJ
cord-016476-78r0rsio	117	40	ILD	ILD	NNP
cord-016476-78r0rsio	117	41	.	.	.
cord-016476-78r0rsio	118	1	Sulphasalazine	Sulphasalazine	NNP
cord-016476-78r0rsio	118	2	is	be	VBZ
cord-016476-78r0rsio	118	3	a	a	DT
cord-016476-78r0rsio	118	4	5-aminosalicyclic	5-aminosalicyclic	CD
cord-016476-78r0rsio	118	5	acid	acid	NN
cord-016476-78r0rsio	118	6	(	(	-LRB-
cord-016476-78r0rsio	118	7	5-ASA	5-asa	CD
cord-016476-78r0rsio	118	8	)	)	-RRB-
cord-016476-78r0rsio	118	9	derivative	derivative	NN
cord-016476-78r0rsio	118	10	metabolised	metabolise	VBN
cord-016476-78r0rsio	118	11	to	to	TO
cord-016476-78r0rsio	118	12	sulphapyridine	sulphapyridine	VB
cord-016476-78r0rsio	118	13	,	,	,
cord-016476-78r0rsio	118	14	which	which	WDT
cord-016476-78r0rsio	118	15	is	be	VBZ
cord-016476-78r0rsio	118	16	the	the	DT
cord-016476-78r0rsio	118	17	active	active	JJ
cord-016476-78r0rsio	118	18	moiety	moiety	NN
cord-016476-78r0rsio	118	19	in	in	IN
cord-016476-78r0rsio	118	20	RA	RA	NNP
cord-016476-78r0rsio	118	21	.	.	.
cord-016476-78r0rsio	119	1	Pulmonary	pulmonary	JJ
cord-016476-78r0rsio	119	2	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	119	3	reactions	reaction	NNS
cord-016476-78r0rsio	119	4	such	such	JJ
cord-016476-78r0rsio	119	5	as	as	IN
cord-016476-78r0rsio	119	6	eosinophilic	eosinophilic	JJ
cord-016476-78r0rsio	119	7	pneumonias	pneumonia	NNS
cord-016476-78r0rsio	119	8	[	[	-LRB-
cord-016476-78r0rsio	119	9	37	37	CD
cord-016476-78r0rsio	119	10	,	,	,
cord-016476-78r0rsio	119	11	38	38	CD
cord-016476-78r0rsio	119	12	]	]	-RRB-
cord-016476-78r0rsio	119	13	,	,	,
cord-016476-78r0rsio	119	14	fibrosing	fibrose	VBG
cord-016476-78r0rsio	119	15	alveolitis	alveolitis	NNP
cord-016476-78r0rsio	119	16	and	and	CC
cord-016476-78r0rsio	119	17	bronchiolitis	bronchiolitis	NNP
cord-016476-78r0rsio	119	18	obliterans	obliteran	NNS
cord-016476-78r0rsio	119	19	have	have	VBP
cord-016476-78r0rsio	119	20	been	be	VBN
cord-016476-78r0rsio	119	21	well	well	RB
cord-016476-78r0rsio	119	22	described	describe	VBN
cord-016476-78r0rsio	119	23	,	,	,
cord-016476-78r0rsio	119	24	with	with	IN
cord-016476-78r0rsio	119	25	over	over	IN
cord-016476-78r0rsio	119	26	50	50	CD
cord-016476-78r0rsio	119	27	case	case	NN
cord-016476-78r0rsio	119	28	reports	report	NNS
cord-016476-78r0rsio	119	29	in	in	IN
cord-016476-78r0rsio	119	30	the	the	DT
cord-016476-78r0rsio	119	31	literature	literature	NN
cord-016476-78r0rsio	119	32	[	[	-LRB-
cord-016476-78r0rsio	119	33	39	39	CD
cord-016476-78r0rsio	119	34	,	,	,
cord-016476-78r0rsio	119	35	40	40	CD
cord-016476-78r0rsio	119	36	]	]	-RRB-
cord-016476-78r0rsio	119	37	.	.	.
cord-016476-78r0rsio	120	1	Drug	drug	NN
cord-016476-78r0rsio	120	2	reaction	reaction	NN
cord-016476-78r0rsio	120	3	with	with	IN
cord-016476-78r0rsio	120	4	eosinophilia	eosinophilia	JJ
cord-016476-78r0rsio	120	5	and	and	CC
cord-016476-78r0rsio	120	6	systemic	systemic	JJ
cord-016476-78r0rsio	120	7	symptoms	symptom	NNS
cord-016476-78r0rsio	120	8	(	(	-LRB-
cord-016476-78r0rsio	120	9	DRESS	dress	NN
cord-016476-78r0rsio	120	10	)	)	-RRB-
cord-016476-78r0rsio	120	11	is	be	VBZ
cord-016476-78r0rsio	120	12	also	also	RB
cord-016476-78r0rsio	120	13	reported	report	VBN
cord-016476-78r0rsio	120	14	[	[	-LRB-
cord-016476-78r0rsio	120	15	41	41	CD
cord-016476-78r0rsio	120	16	,	,	,
cord-016476-78r0rsio	120	17	42	42	CD
cord-016476-78r0rsio	120	18	]	]	-RRB-
cord-016476-78r0rsio	120	19	.	.	.
cord-016476-78r0rsio	121	1	Typical	typical	JJ
cord-016476-78r0rsio	121	2	presentation	presentation	NN
cord-016476-78r0rsio	121	3	of	of	IN
cord-016476-78r0rsio	121	4	sulphasalazineinduced	sulphasalazineinduced	NNP
cord-016476-78r0rsio	121	5	lung	lung	NNP
cord-016476-78r0rsio	121	6	disease	disease	NNP
cord-016476-78r0rsio	121	7	reported	report	VBD
cord-016476-78r0rsio	121	8	is	be	VBZ
cord-016476-78r0rsio	121	9	with	with	IN
cord-016476-78r0rsio	121	10	new	new	JJ
cord-016476-78r0rsio	121	11	-	-	HYPH
cord-016476-78r0rsio	121	12	onset	onset	NN
cord-016476-78r0rsio	121	13	dyspnoea	dyspnoea	NNS
cord-016476-78r0rsio	121	14	and	and	CC
cord-016476-78r0rsio	121	15	infiltrates	infiltrate	VBZ
cord-016476-78r0rsio	121	16	on	on	IN
cord-016476-78r0rsio	121	17	chest	chest	NN
cord-016476-78r0rsio	121	18	radiograph	radiograph	NN
cord-016476-78r0rsio	121	19	(	(	-LRB-
cord-016476-78r0rsio	121	20	with	with	IN
cord-016476-78r0rsio	121	21	or	or	CC
cord-016476-78r0rsio	121	22	without	without	IN
cord-016476-78r0rsio	121	23	peripheral	peripheral	JJ
cord-016476-78r0rsio	121	24	eosinophilia	eosinophilia	NN
cord-016476-78r0rsio	121	25	with	with	IN
cord-016476-78r0rsio	121	26	eosinophilic	eosinophilic	JJ
cord-016476-78r0rsio	121	27	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	121	28	)	)	-RRB-
cord-016476-78r0rsio	121	29	.	.	.
cord-016476-78r0rsio	122	1	Cough	cough	NN
cord-016476-78r0rsio	122	2	and	and	CC
cord-016476-78r0rsio	122	3	fever	fever	NN
cord-016476-78r0rsio	122	4	are	be	VBP
cord-016476-78r0rsio	122	5	the	the	DT
cord-016476-78r0rsio	122	6	most	most	RBS
cord-016476-78r0rsio	122	7	common	common	JJ
cord-016476-78r0rsio	122	8	symptoms	symptom	NNS
cord-016476-78r0rsio	122	9	with	with	IN
cord-016476-78r0rsio	122	10	sputum	sputum	NN
cord-016476-78r0rsio	122	11	production	production	NN
cord-016476-78r0rsio	122	12	,	,	,
cord-016476-78r0rsio	122	13	whilst	whilst	IN
cord-016476-78r0rsio	122	14	allergy	allergy	NN
cord-016476-78r0rsio	122	15	history	history	NN
cord-016476-78r0rsio	122	16	,	,	,
cord-016476-78r0rsio	122	17	rash	rash	JJ
cord-016476-78r0rsio	122	18	,	,	,
cord-016476-78r0rsio	122	19	chest	chest	NN
cord-016476-78r0rsio	122	20	pain	pain	NN
cord-016476-78r0rsio	122	21	and	and	CC
cord-016476-78r0rsio	122	22	weight	weight	NN
cord-016476-78r0rsio	122	23	loss	loss	NN
cord-016476-78r0rsio	122	24	were	be	VBD
cord-016476-78r0rsio	122	25	inconsistent	inconsistent	JJ
cord-016476-78r0rsio	122	26	findings	finding	NNS
cord-016476-78r0rsio	122	27	[	[	-LRB-
cord-016476-78r0rsio	122	28	40	40	CD
cord-016476-78r0rsio	122	29	]	]	-RRB-
cord-016476-78r0rsio	122	30	.	.	.
cord-016476-78r0rsio	123	1	Histology	histology	NN
cord-016476-78r0rsio	123	2	is	be	VBZ
cord-016476-78r0rsio	123	3	often	often	RB
cord-016476-78r0rsio	123	4	variable	variable	JJ
cord-016476-78r0rsio	123	5	;	;	:
cord-016476-78r0rsio	123	6	the	the	DT
cord-016476-78r0rsio	123	7	most	most	RBS
cord-016476-78r0rsio	123	8	frequent	frequent	JJ
cord-016476-78r0rsio	123	9	appears	appear	VBZ
cord-016476-78r0rsio	123	10	to	to	IN
cord-016476-78r0rsio	123	11	eosinophilic	eosinophilic	JJ
cord-016476-78r0rsio	123	12	pneumonia	pneumonia	NN
cord-016476-78r0rsio	123	13	with	with	IN
cord-016476-78r0rsio	123	14	interstitial	interstitial	JJ
cord-016476-78r0rsio	123	15	inflammation	inflammation	NN
cord-016476-78r0rsio	123	16	with	with	IN
cord-016476-78r0rsio	123	17	or	or	CC
cord-016476-78r0rsio	123	18	without	without	IN
cord-016476-78r0rsio	123	19	fibrosis	fibrosis	NN
cord-016476-78r0rsio	123	20	.	.	.
cord-016476-78r0rsio	124	1	Drug	drug	NN
cord-016476-78r0rsio	124	2	cessation	cessation	NN
cord-016476-78r0rsio	124	3	often	often	RB
cord-016476-78r0rsio	124	4	results	result	VBZ
cord-016476-78r0rsio	124	5	in	in	IN
cord-016476-78r0rsio	124	6	resolution	resolution	NN
cord-016476-78r0rsio	124	7	of	of	IN
cord-016476-78r0rsio	124	8	symptoms	symptom	NNS
cord-016476-78r0rsio	124	9	in	in	IN
cord-016476-78r0rsio	124	10	patients	patient	NNS
cord-016476-78r0rsio	124	11	who	who	WP
cord-016476-78r0rsio	124	12	develop	develop	VBP
cord-016476-78r0rsio	124	13	eosinophilic	eosinophilic	JJ
cord-016476-78r0rsio	124	14	pneumonia	pneumonia	NN
cord-016476-78r0rsio	124	15	[	[	-LRB-
cord-016476-78r0rsio	124	16	43	43	CD
cord-016476-78r0rsio	124	17	]	]	-RRB-
cord-016476-78r0rsio	124	18	.	.	.
cord-016476-78r0rsio	125	1	The	the	DT
cord-016476-78r0rsio	125	2	role	role	NN
cord-016476-78r0rsio	125	3	of	of	IN
cord-016476-78r0rsio	125	4	systemic	systemic	JJ
cord-016476-78r0rsio	125	5	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	125	6	is	be	VBZ
cord-016476-78r0rsio	125	7	not	not	RB
cord-016476-78r0rsio	125	8	wellstudied	wellstudie	VBN
cord-016476-78r0rsio	125	9	,	,	,
cord-016476-78r0rsio	125	10	as	as	IN
cord-016476-78r0rsio	125	11	most	most	JJS
cord-016476-78r0rsio	125	12	patients	patient	NNS
cord-016476-78r0rsio	125	13	improve	improve	VBP
cord-016476-78r0rsio	125	14	with	with	IN
cord-016476-78r0rsio	125	15	withdrawal	withdrawal	NN
cord-016476-78r0rsio	125	16	of	of	IN
cord-016476-78r0rsio	125	17	sulphasalazine	sulphasalazine	NN
cord-016476-78r0rsio	125	18	.	.	.
cord-016476-78r0rsio	126	1	There	there	EX
cord-016476-78r0rsio	126	2	are	be	VBP
cord-016476-78r0rsio	126	3	no	no	DT
cord-016476-78r0rsio	126	4	studies	study	NNS
cord-016476-78r0rsio	126	5	that	that	WDT
cord-016476-78r0rsio	126	6	have	have	VBP
cord-016476-78r0rsio	126	7	systematically	systematically	RB
cord-016476-78r0rsio	126	8	evaluated	evaluate	VBN
cord-016476-78r0rsio	126	9	the	the	DT
cord-016476-78r0rsio	126	10	safety	safety	NN
cord-016476-78r0rsio	126	11	of	of	IN
cord-016476-78r0rsio	126	12	sulphasalazine	sulphasalazine	NN
cord-016476-78r0rsio	126	13	in	in	IN
cord-016476-78r0rsio	126	14	preexisting	preexist	VBG
cord-016476-78r0rsio	126	15	RA	RA	NNP
cord-016476-78r0rsio	126	16	-	-	HYPH
cord-016476-78r0rsio	126	17	ILD	ILD	NNP
cord-016476-78r0rsio	126	18	;	;	:
cord-016476-78r0rsio	126	19	however	however	RB
cord-016476-78r0rsio	126	20	,	,	,
cord-016476-78r0rsio	126	21	it	-PRON-	PRP
cord-016476-78r0rsio	126	22	is	be	VBZ
cord-016476-78r0rsio	126	23	worth	worth	JJ
cord-016476-78r0rsio	126	24	observing	observe	VBG
cord-016476-78r0rsio	126	25	that	that	IN
cord-016476-78r0rsio	126	26	the	the	DT
cord-016476-78r0rsio	126	27	rates	rate	NNS
cord-016476-78r0rsio	126	28	of	of	IN
cord-016476-78r0rsio	126	29	SRAEs	srae	NNS
cord-016476-78r0rsio	126	30	with	with	IN
cord-016476-78r0rsio	126	31	sulphasalazine	sulphasalazine	NN
cord-016476-78r0rsio	126	32	appear	appear	VBP
cord-016476-78r0rsio	126	33	much	much	RB
cord-016476-78r0rsio	126	34	lower	low	JJR
cord-016476-78r0rsio	126	35	than	than	IN
cord-016476-78r0rsio	126	36	those	those	DT
cord-016476-78r0rsio	126	37	seen	see	VBN
cord-016476-78r0rsio	126	38	with	with	IN
cord-016476-78r0rsio	126	39	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	126	40	and	and	CC
cord-016476-78r0rsio	126	41	leflunomide	leflunomide	VB
cord-016476-78r0rsio	126	42	in	in	IN
cord-016476-78r0rsio	126	43	the	the	DT
cord-016476-78r0rsio	126	44	literature	literature	NN
cord-016476-78r0rsio	126	45	.	.	.
cord-016476-78r0rsio	127	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-016476-78r0rsio	127	2	is	be	VBZ
cord-016476-78r0rsio	127	3	an	an	DT
cord-016476-78r0rsio	127	4	antimalarial	antimalarial	JJ
cord-016476-78r0rsio	127	5	drug	drug	NN
cord-016476-78r0rsio	127	6	and	and	CC
cord-016476-78r0rsio	127	7	is	be	VBZ
cord-016476-78r0rsio	127	8	a	a	DT
cord-016476-78r0rsio	127	9	4-aminoquinoline	4-aminoquinoline	CD
cord-016476-78r0rsio	127	10	derivative	derivative	NN
cord-016476-78r0rsio	127	11	,	,	,
cord-016476-78r0rsio	127	12	often	often	RB
cord-016476-78r0rsio	127	13	used	use	VBN
cord-016476-78r0rsio	127	14	in	in	IN
cord-016476-78r0rsio	127	15	combination	combination	NN
cord-016476-78r0rsio	127	16	with	with	IN
cord-016476-78r0rsio	127	17	other	other	JJ
cord-016476-78r0rsio	127	18	nbDMARDS	nbDMARDS	NNP
cord-016476-78r0rsio	127	19	.	.	.
cord-016476-78r0rsio	128	1	It	-PRON-	PRP
cord-016476-78r0rsio	128	2	is	be	VBZ
cord-016476-78r0rsio	128	3	usually	usually	RB
cord-016476-78r0rsio	128	4	well	well	RB
cord-016476-78r0rsio	128	5	tolerated	tolerate	VBN
cord-016476-78r0rsio	128	6	and	and	CC
cord-016476-78r0rsio	128	7	serious	serious	JJ
cord-016476-78r0rsio	128	8	AEs	AEs	NNP
cord-016476-78r0rsio	128	9	are	be	VBP
cord-016476-78r0rsio	128	10	rare	rare	JJ
cord-016476-78r0rsio	128	11	.	.	.
cord-016476-78r0rsio	129	1	Few	few	JJ
cord-016476-78r0rsio	129	2	cases	case	NNS
cord-016476-78r0rsio	129	3	of	of	IN
cord-016476-78r0rsio	129	4	drug	drug	NN
cord-016476-78r0rsio	129	5	-	-	HYPH
cord-016476-78r0rsio	129	6	induced	induce	VBN
cord-016476-78r0rsio	129	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	129	8	exist	exist	VBP
cord-016476-78r0rsio	129	9	[	[	-LRB-
cord-016476-78r0rsio	129	10	44	44	CD
cord-016476-78r0rsio	129	11	]	]	-RRB-
cord-016476-78r0rsio	129	12	,	,	,
cord-016476-78r0rsio	129	13	with	with	IN
cord-016476-78r0rsio	129	14	some	some	DT
cord-016476-78r0rsio	129	15	reports	report	NNS
cord-016476-78r0rsio	129	16	in	in	IN
cord-016476-78r0rsio	129	17	association	association	NN
cord-016476-78r0rsio	129	18	with	with	IN
cord-016476-78r0rsio	129	19	drug	drug	NN
cord-016476-78r0rsio	129	20	reaction	reaction	NN
cord-016476-78r0rsio	129	21	with	with	IN
cord-016476-78r0rsio	129	22	eosinophilia	eosinophilia	JJ
cord-016476-78r0rsio	129	23	and	and	CC
cord-016476-78r0rsio	129	24	systemic	systemic	JJ
cord-016476-78r0rsio	129	25	symptoms	symptom	NNS
cord-016476-78r0rsio	129	26	(	(	-LRB-
cord-016476-78r0rsio	129	27	DRESS	dress	NN
cord-016476-78r0rsio	129	28	)	)	-RRB-
cord-016476-78r0rsio	129	29	syndrome	syndrome	NN
cord-016476-78r0rsio	129	30	[	[	-LRB-
cord-016476-78r0rsio	129	31	45	45	CD
cord-016476-78r0rsio	129	32	,	,	,
cord-016476-78r0rsio	129	33	46	46	CD
cord-016476-78r0rsio	129	34	]	]	-RRB-
cord-016476-78r0rsio	129	35	.	.	.
cord-016476-78r0rsio	130	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-016476-78r0rsio	130	2	has	have	VBZ
cord-016476-78r0rsio	130	3	been	be	VBN
cord-016476-78r0rsio	130	4	tried	try	VBN
cord-016476-78r0rsio	130	5	in	in	IN
cord-016476-78r0rsio	130	6	childhood	childhood	NN
cord-016476-78r0rsio	130	7	ILD	ILD	NNP
cord-016476-78r0rsio	130	8	(	(	-LRB-
cord-016476-78r0rsio	130	9	diffuse	diffuse	JJ
cord-016476-78r0rsio	130	10	parenchymal	parenchymal	NN
cord-016476-78r0rsio	130	11	lung	lung	NN
cord-016476-78r0rsio	130	12	diseases	disease	NNS
cord-016476-78r0rsio	130	13	)	)	-RRB-
cord-016476-78r0rsio	130	14	in	in	IN
cord-016476-78r0rsio	130	15	case	case	NN
cord-016476-78r0rsio	130	16	reports	report	NNS
cord-016476-78r0rsio	130	17	given	give	VBN
cord-016476-78r0rsio	130	18	the	the	DT
cord-016476-78r0rsio	130	19	lack	lack	NN
cord-016476-78r0rsio	130	20	of	of	IN
cord-016476-78r0rsio	130	21	therapeutic	therapeutic	JJ
cord-016476-78r0rsio	130	22	options	option	NNS
cord-016476-78r0rsio	130	23	.	.	.
cord-016476-78r0rsio	131	1	In	in	IN
cord-016476-78r0rsio	131	2	a	a	DT
cord-016476-78r0rsio	131	3	systematic	systematic	JJ
cord-016476-78r0rsio	131	4	review	review	NN
cord-016476-78r0rsio	131	5	from	from	IN
cord-016476-78r0rsio	131	6	1984	1984	CD
cord-016476-78r0rsio	131	7	to	to	IN
cord-016476-78r0rsio	131	8	2013	2013	CD
cord-016476-78r0rsio	131	9	[	[	-LRB-
cord-016476-78r0rsio	131	10	47	47	CD
cord-016476-78r0rsio	131	11	]	]	-RRB-
cord-016476-78r0rsio	131	12	,	,	,
cord-016476-78r0rsio	131	13	85	85	CD
cord-016476-78r0rsio	131	14	case	case	NN
cord-016476-78r0rsio	131	15	reports	report	NNS
cord-016476-78r0rsio	131	16	were	be	VBD
cord-016476-78r0rsio	131	17	identified	identify	VBN
cord-016476-78r0rsio	131	18	:	:	:
cord-016476-78r0rsio	131	19	a	a	DT
cord-016476-78r0rsio	131	20	favourable	favourable	JJ
cord-016476-78r0rsio	131	21	response	response	NN
cord-016476-78r0rsio	131	22	to	to	IN
cord-016476-78r0rsio	131	23	hydroxychloroquine	hydroxychloroquine	NNP
cord-016476-78r0rsio	131	24	was	be	VBD
cord-016476-78r0rsio	131	25	reported	report	VBN
cord-016476-78r0rsio	131	26	in	in	IN
cord-016476-78r0rsio	131	27	35	35	CD
cord-016476-78r0rsio	131	28	cases	case	NNS
cord-016476-78r0rsio	131	29	(	(	-LRB-
cord-016476-78r0rsio	131	30	41	41	CD
cord-016476-78r0rsio	131	31	%	%	NN
cord-016476-78r0rsio	131	32	)	)	-RRB-
cord-016476-78r0rsio	131	33	,	,	,
cord-016476-78r0rsio	131	34	with	with	IN
cord-016476-78r0rsio	131	35	an	an	DT
cord-016476-78r0rsio	131	36	unclear	unclear	JJ
cord-016476-78r0rsio	131	37	effect	effect	NN
cord-016476-78r0rsio	131	38	in	in	IN
cord-016476-78r0rsio	131	39	the	the	DT
cord-016476-78r0rsio	131	40	rest	rest	NN
cord-016476-78r0rsio	131	41	.	.	.
cord-016476-78r0rsio	132	1	Whilst	whilst	IN
cord-016476-78r0rsio	132	2	idiosyncratic	idiosyncratic	JJ
cord-016476-78r0rsio	132	3	reactions	reaction	NNS
cord-016476-78r0rsio	132	4	leading	lead	VBG
cord-016476-78r0rsio	132	5	to	to	IN
cord-016476-78r0rsio	132	6	lung	lung	NN
cord-016476-78r0rsio	132	7	toxicity	toxicity	NN
cord-016476-78r0rsio	132	8	have	have	VBP
cord-016476-78r0rsio	132	9	been	be	VBN
cord-016476-78r0rsio	132	10	reported	report	VBN
cord-016476-78r0rsio	132	11	,	,	,
cord-016476-78r0rsio	132	12	no	no	DT
cord-016476-78r0rsio	132	13	studies	study	NNS
cord-016476-78r0rsio	132	14	have	have	VBP
cord-016476-78r0rsio	132	15	demonstrated	demonstrate	VBN
cord-016476-78r0rsio	132	16	a	a	DT
cord-016476-78r0rsio	132	17	benefit	benefit	NN
cord-016476-78r0rsio	132	18	or	or	CC
cord-016476-78r0rsio	132	19	harm	harm	NN
cord-016476-78r0rsio	132	20	of	of	IN
cord-016476-78r0rsio	132	21	this	this	DT
cord-016476-78r0rsio	132	22	drug	drug	NN
cord-016476-78r0rsio	132	23	in	in	IN
cord-016476-78r0rsio	132	24	RA	RA	NNP
cord-016476-78r0rsio	132	25	-	-	HYPH
cord-016476-78r0rsio	132	26	ILD	ILD	NNP
cord-016476-78r0rsio	132	27	.	.	.
cord-016476-78r0rsio	133	1	In	in	IN
cord-016476-78r0rsio	133	2	summary	summary	NN
cord-016476-78r0rsio	133	3	,	,	,
cord-016476-78r0rsio	133	4	case	case	NN
cord-016476-78r0rsio	133	5	report	report	VB
cord-016476-78r0rsio	133	6	evidence	evidence	NN
cord-016476-78r0rsio	133	7	for	for	IN
cord-016476-78r0rsio	133	8	drug	drug	NN
cord-016476-78r0rsio	133	9	-	-	HYPH
cord-016476-78r0rsio	133	10	induced	induce	VBN
cord-016476-78r0rsio	133	11	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	133	12	exists	exist	VBZ
cord-016476-78r0rsio	133	13	for	for	IN
cord-016476-78r0rsio	133	14	all	all	DT
cord-016476-78r0rsio	133	15	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	133	16	commonly	commonly	RB
cord-016476-78r0rsio	133	17	used	use	VBN
cord-016476-78r0rsio	133	18	to	to	TO
cord-016476-78r0rsio	133	19	treat	treat	VB
cord-016476-78r0rsio	133	20	joint	joint	JJ
cord-016476-78r0rsio	133	21	disease	disease	NN
cord-016476-78r0rsio	133	22	;	;	:
cord-016476-78r0rsio	133	23	therefore	therefore	RB
cord-016476-78r0rsio	133	24	,	,	,
cord-016476-78r0rsio	133	25	incident	incident	NN
cord-016476-78r0rsio	133	26	ILD	ILD	NNP
cord-016476-78r0rsio	133	27	may	may	MD
cord-016476-78r0rsio	133	28	be	be	VB
cord-016476-78r0rsio	133	29	a	a	DT
cord-016476-78r0rsio	133	30	theoretical	theoretical	JJ
cord-016476-78r0rsio	133	31	risk	risk	NN
cord-016476-78r0rsio	133	32	in	in	IN
cord-016476-78r0rsio	133	33	most	most	RBS
cord-016476-78r0rsio	133	34	treated	treat	VBN
cord-016476-78r0rsio	133	35	patients	patient	NNS
cord-016476-78r0rsio	133	36	.	.	.
cord-016476-78r0rsio	134	1	With	with	IN
cord-016476-78r0rsio	134	2	treat	treat	NN
cord-016476-78r0rsio	134	3	-	-	HYPH
cord-016476-78r0rsio	134	4	to	to	IN
cord-016476-78r0rsio	134	5	-	-	HYPH
cord-016476-78r0rsio	134	6	target	target	NN
cord-016476-78r0rsio	134	7	guidelines	guideline	NNS
cord-016476-78r0rsio	134	8	[	[	-LRB-
cord-016476-78r0rsio	134	9	2	2	CD
cord-016476-78r0rsio	134	10	]	]	-RRB-
cord-016476-78r0rsio	134	11	and	and	CC
cord-016476-78r0rsio	134	12	the	the	DT
cord-016476-78r0rsio	134	13	eventual	eventual	JJ
cord-016476-78r0rsio	134	14	aim	aim	NN
cord-016476-78r0rsio	134	15	of	of	IN
cord-016476-78r0rsio	134	16	abrogation	abrogation	NN
cord-016476-78r0rsio	134	17	of	of	IN
cord-016476-78r0rsio	134	18	joint	joint	JJ
cord-016476-78r0rsio	134	19	inflammation	inflammation	NN
cord-016476-78r0rsio	134	20	as	as	RB
cord-016476-78r0rsio	134	21	soon	soon	RB
cord-016476-78r0rsio	134	22	as	as	IN
cord-016476-78r0rsio	134	23	possible	possible	JJ
cord-016476-78r0rsio	134	24	,	,	,
cord-016476-78r0rsio	134	25	most	most	JJS
cord-016476-78r0rsio	134	26	patients	patient	NNS
cord-016476-78r0rsio	134	27	with	with	IN
cord-016476-78r0rsio	134	28	RA	RA	NNP
cord-016476-78r0rsio	134	29	are	be	VBP
cord-016476-78r0rsio	134	30	likely	likely	JJ
cord-016476-78r0rsio	134	31	to	to	TO
cord-016476-78r0rsio	134	32	be	be	VB
cord-016476-78r0rsio	134	33	treated	treat	VBN
cord-016476-78r0rsio	134	34	with	with	IN
cord-016476-78r0rsio	134	35	a	a	DT
cord-016476-78r0rsio	134	36	nbDMARD	nbdmard	RB
cord-016476-78r0rsio	134	37	early	early	JJ
cord-016476-78r0rsio	134	38	in	in	IN
cord-016476-78r0rsio	134	39	the	the	DT
cord-016476-78r0rsio	134	40	course	course	NN
cord-016476-78r0rsio	134	41	of	of	IN
cord-016476-78r0rsio	134	42	their	-PRON-	PRP$
cord-016476-78r0rsio	134	43	disease	disease	NN
cord-016476-78r0rsio	134	44	.	.	.
cord-016476-78r0rsio	135	1	Whether	whether	IN
cord-016476-78r0rsio	135	2	the	the	DT
cord-016476-78r0rsio	135	3	risk	risk	NN
cord-016476-78r0rsio	135	4	of	of	IN
cord-016476-78r0rsio	135	5	progression	progression	NN
cord-016476-78r0rsio	135	6	of	of	IN
cord-016476-78r0rsio	135	7	RA	RA	NNP
cord-016476-78r0rsio	135	8	-	-	HYPH
cord-016476-78r0rsio	135	9	ILD	ILD	NNP
cord-016476-78r0rsio	135	10	or	or	CC
cord-016476-78r0rsio	135	11	SRAEs	srae	NNS
cord-016476-78r0rsio	135	12	increases	increase	VBZ
cord-016476-78r0rsio	135	13	with	with	IN
cord-016476-78r0rsio	135	14	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	135	15	is	be	VBZ
cord-016476-78r0rsio	135	16	not	not	RB
cord-016476-78r0rsio	135	17	clear	clear	JJ
cord-016476-78r0rsio	135	18	and	and	CC
cord-016476-78r0rsio	135	19	may	may	MD
cord-016476-78r0rsio	135	20	vary	vary	VB
cord-016476-78r0rsio	135	21	according	accord	VBG
cord-016476-78r0rsio	135	22	to	to	IN
cord-016476-78r0rsio	135	23	the	the	DT
cord-016476-78r0rsio	135	24	individual	individual	JJ
cord-016476-78r0rsio	135	25	patient	patient	NN
cord-016476-78r0rsio	135	26	profile	profile	NN
cord-016476-78r0rsio	135	27	including	include	VBG
cord-016476-78r0rsio	135	28	their	-PRON-	PRP$
cord-016476-78r0rsio	135	29	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	135	30	,	,	,
cord-016476-78r0rsio	135	31	concomitant	concomitant	JJ
cord-016476-78r0rsio	135	32	treatments	treatment	NNS
cord-016476-78r0rsio	135	33	,	,	,
cord-016476-78r0rsio	135	34	severity	severity	NN
cord-016476-78r0rsio	135	35	of	of	IN
cord-016476-78r0rsio	135	36	ILD	ILD	NNP
cord-016476-78r0rsio	135	37	at	at	IN
cord-016476-78r0rsio	135	38	the	the	DT
cord-016476-78r0rsio	135	39	outset	outset	NN
cord-016476-78r0rsio	135	40	of	of	IN
cord-016476-78r0rsio	135	41	treatment	treatment	NN
cord-016476-78r0rsio	135	42	and	and	CC
cord-016476-78r0rsio	135	43	their	-PRON-	PRP$
cord-016476-78r0rsio	135	44	genotype	genotype	NN
cord-016476-78r0rsio	135	45	.	.	.
cord-016476-78r0rsio	136	1	Evidence	evidence	NN
cord-016476-78r0rsio	136	2	to	to	IN
cord-016476-78r0rsio	136	3	date	date	NN
cord-016476-78r0rsio	136	4	suggests	suggest	VBZ
cord-016476-78r0rsio	136	5	caution	caution	NN
cord-016476-78r0rsio	136	6	should	should	MD
cord-016476-78r0rsio	136	7	be	be	VB
cord-016476-78r0rsio	136	8	exercised	exercise	VBN
cord-016476-78r0rsio	136	9	whilst	whilst	IN
cord-016476-78r0rsio	136	10	treating	treat	VBG
cord-016476-78r0rsio	136	11	patients	patient	NNS
cord-016476-78r0rsio	136	12	with	with	IN
cord-016476-78r0rsio	136	13	pre	pre	JJ
cord-016476-78r0rsio	136	14	-	-	JJ
cord-016476-78r0rsio	136	15	existing	existing	JJ
cord-016476-78r0rsio	136	16	RA	RA	NNP
cord-016476-78r0rsio	136	17	-	-	HYPH
cord-016476-78r0rsio	136	18	ILD	ILD	NNP
cord-016476-78r0rsio	136	19	with	with	IN
cord-016476-78r0rsio	136	20	all	all	DT
cord-016476-78r0rsio	136	21	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	136	22	,	,	,
cord-016476-78r0rsio	136	23	particularly	particularly	RB
cord-016476-78r0rsio	136	24	MTX	MTX	NNP
cord-016476-78r0rsio	136	25	and	and	CC
cord-016476-78r0rsio	136	26	leflunomide	leflunomide	NNP
cord-016476-78r0rsio	136	27	,	,	,
cord-016476-78r0rsio	136	28	with	with	IN
cord-016476-78r0rsio	136	29	careful	careful	JJ
cord-016476-78r0rsio	136	30	monitoring	monitoring	NN
cord-016476-78r0rsio	136	31	of	of	IN
cord-016476-78r0rsio	136	32	disease	disease	NN
cord-016476-78r0rsio	136	33	progression	progression	NN
cord-016476-78r0rsio	136	34	and	and	CC
cord-016476-78r0rsio	136	35	vigilance	vigilance	NN
cord-016476-78r0rsio	136	36	for	for	IN
cord-016476-78r0rsio	136	37	(	(	-LRB-
cord-016476-78r0rsio	136	38	sometimes	sometimes	RB
cord-016476-78r0rsio	136	39	rare	rare	JJ
cord-016476-78r0rsio	136	40	)	)	-RRB-
cord-016476-78r0rsio	136	41	SRAEs	srae	NNS
cord-016476-78r0rsio	136	42	associated	associate	VBN
cord-016476-78r0rsio	136	43	with	with	IN
cord-016476-78r0rsio	136	44	such	such	JJ
cord-016476-78r0rsio	136	45	treatments	treatment	NNS
cord-016476-78r0rsio	136	46	(	(	-LRB-
cord-016476-78r0rsio	136	47	summarised	summarise	VBN
cord-016476-78r0rsio	136	48	in	in	IN
cord-016476-78r0rsio	136	49	Table	Table	NNP
cord-016476-78r0rsio	136	50	9	9	CD
cord-016476-78r0rsio	136	51	.4	.4	CD
cord-016476-78r0rsio	136	52	)	)	-RRB-
cord-016476-78r0rsio	136	53	.	.	.
cord-016476-78r0rsio	137	1	Five	five	CD
cord-016476-78r0rsio	137	2	TNFi	TNFi	NNS
cord-016476-78r0rsio	137	3	agents	agent	NNS
cord-016476-78r0rsio	137	4	have	have	VBP
cord-016476-78r0rsio	137	5	been	be	VBN
cord-016476-78r0rsio	137	6	approved	approve	VBN
cord-016476-78r0rsio	137	7	for	for	IN
cord-016476-78r0rsio	137	8	treating	treat	VBG
cord-016476-78r0rsio	137	9	patients	patient	NNS
cord-016476-78r0rsio	137	10	with	with	IN
cord-016476-78r0rsio	137	11	RA	RA	NNP
cord-016476-78r0rsio	137	12	:	:	:
cord-016476-78r0rsio	137	13	three	three	CD
cord-016476-78r0rsio	137	14	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	137	15	antibodies	antibody	NNS
cord-016476-78r0rsio	137	16	(	(	-LRB-
cord-016476-78r0rsio	137	17	infliximab	infliximab	VBN
cord-016476-78r0rsio	137	18	,	,	,
cord-016476-78r0rsio	137	19	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	137	20	and	and	CC
cord-016476-78r0rsio	137	21	golimumab	golimumab	NNP
cord-016476-78r0rsio	137	22	)	)	-RRB-
cord-016476-78r0rsio	137	23	,	,	,
cord-016476-78r0rsio	137	24	the	the	DT
cord-016476-78r0rsio	137	25	recombinant	recombinant	JJ
cord-016476-78r0rsio	137	26	soluble	soluble	JJ
cord-016476-78r0rsio	137	27	TNF	TNF	NNP
cord-016476-78r0rsio	137	28	receptor	receptor	NN
cord-016476-78r0rsio	137	29	etanercept	etanercept	NNP
cord-016476-78r0rsio	137	30	and	and	CC
cord-016476-78r0rsio	137	31	pegylated	pegylated	JJ
cord-016476-78r0rsio	137	32	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	137	33	.	.	.
cord-016476-78r0rsio	138	1	As	as	IN
cord-016476-78r0rsio	138	2	biologic	biologic	JJ
cord-016476-78r0rsio	138	3	therapies	therapy	NNS
cord-016476-78r0rsio	138	4	such	such	JJ
cord-016476-78r0rsio	138	5	as	as	IN
cord-016476-78r0rsio	138	6	TNFis	TNFis	NNP
cord-016476-78r0rsio	138	7	target	target	NN
cord-016476-78r0rsio	138	8	key	key	JJ
cord-016476-78r0rsio	138	9	cytokines	cytokine	NNS
cord-016476-78r0rsio	138	10	and	and	CC
cord-016476-78r0rsio	138	11	cells	cell	NNS
cord-016476-78r0rsio	138	12	in	in	IN
cord-016476-78r0rsio	138	13	the	the	DT
cord-016476-78r0rsio	138	14	inflammatory	inflammatory	JJ
cord-016476-78r0rsio	138	15	cascade	cascade	NN
cord-016476-78r0rsio	138	16	with	with	IN
cord-016476-78r0rsio	138	17	pleiotropic	pleiotropic	JJ
cord-016476-78r0rsio	138	18	effects	effect	NNS
cord-016476-78r0rsio	138	19	on	on	IN
cord-016476-78r0rsio	138	20	the	the	DT
cord-016476-78r0rsio	138	21	immune	immune	JJ
cord-016476-78r0rsio	138	22	system	system	NN
cord-016476-78r0rsio	138	23	,	,	,
cord-016476-78r0rsio	138	24	there	there	EX
cord-016476-78r0rsio	138	25	have	have	VBP
cord-016476-78r0rsio	138	26	been	be	VBN
cord-016476-78r0rsio	138	27	particular	particular	JJ
cord-016476-78r0rsio	138	28	concerns	concern	NNS
cord-016476-78r0rsio	138	29	regarding	regard	VBG
cord-016476-78r0rsio	138	30	their	-PRON-	PRP$
cord-016476-78r0rsio	138	31	long	long	JJ
cord-016476-78r0rsio	138	32	-	-	HYPH
cord-016476-78r0rsio	138	33	term	term	NN
cord-016476-78r0rsio	138	34	safety	safety	NN
cord-016476-78r0rsio	138	35	profile	profile	NN
cord-016476-78r0rsio	138	36	.	.	.
cord-016476-78r0rsio	139	1	Although	although	IN
cord-016476-78r0rsio	139	2	these	these	DT
cord-016476-78r0rsio	139	3	drugs	drug	NNS
cord-016476-78r0rsio	139	4	are	be	VBP
cord-016476-78r0rsio	139	5	highly	highly	RB
cord-016476-78r0rsio	139	6	effective	effective	JJ
cord-016476-78r0rsio	139	7	in	in	IN
cord-016476-78r0rsio	139	8	controlling	control	VBG
cord-016476-78r0rsio	139	9	joint	joint	JJ
cord-016476-78r0rsio	139	10	disease	disease	NN
cord-016476-78r0rsio	139	11	,	,	,
cord-016476-78r0rsio	139	12	and	and	CC
cord-016476-78r0rsio	139	13	often	often	RB
cord-016476-78r0rsio	139	14	are	be	VBP
cord-016476-78r0rsio	139	15	used	use	VBN
cord-016476-78r0rsio	139	16	as	as	IN
cord-016476-78r0rsio	139	17	first	first	JJ
cord-016476-78r0rsio	139	18	-	-	HYPH
cord-016476-78r0rsio	139	19	line	line	NN
cord-016476-78r0rsio	139	20	biologics	biologic	NNS
cord-016476-78r0rsio	139	21	in	in	IN
cord-016476-78r0rsio	139	22	combination	combination	NN
cord-016476-78r0rsio	139	23	with	with	IN
cord-016476-78r0rsio	139	24	MTX	MTX	NNP
cord-016476-78r0rsio	139	25	,	,	,
cord-016476-78r0rsio	139	26	they	-PRON-	PRP
cord-016476-78r0rsio	139	27	are	be	VBP
cord-016476-78r0rsio	139	28	reported	report	VBN
cord-016476-78r0rsio	139	29	to	to	TO
cord-016476-78r0rsio	139	30	be	be	VB
cord-016476-78r0rsio	139	31	associated	associate	VBN
cord-016476-78r0rsio	139	32	with	with	IN
cord-016476-78r0rsio	139	33	various	various	JJ
cord-016476-78r0rsio	139	34	autoimmune	autoimmune	JJ
cord-016476-78r0rsio	139	35	AEs	ae	NNS
cord-016476-78r0rsio	139	36	[	[	-LRB-
cord-016476-78r0rsio	139	37	48	48	CD
cord-016476-78r0rsio	139	38	]	]	-RRB-
cord-016476-78r0rsio	139	39	.	.	.
cord-016476-78r0rsio	140	1	Whilst	whilst	IN
cord-016476-78r0rsio	140	2	the	the	DT
cord-016476-78r0rsio	140	3	most	most	RBS
cord-016476-78r0rsio	140	4	common	common	JJ
cord-016476-78r0rsio	140	5	of	of	IN
cord-016476-78r0rsio	140	6	these	these	DT
cord-016476-78r0rsio	140	7	appear	appear	VBP
cord-016476-78r0rsio	140	8	to	to	TO
cord-016476-78r0rsio	140	9	be	be	VB
cord-016476-78r0rsio	140	10	lupus	lupus	NN
cord-016476-78r0rsio	140	11	-	-	:
cord-016476-78r0rsio	140	12	and	and	CC
cord-016476-78r0rsio	140	13	vasculitis	vasculitis	NN
cord-016476-78r0rsio	140	14	-	-	HYPH
cord-016476-78r0rsio	140	15	like	like	JJ
cord-016476-78r0rsio	140	16	events	event	NNS
cord-016476-78r0rsio	140	17	,	,	,
cord-016476-78r0rsio	140	18	TNFiassociated	tnfiassociated	JJ
cord-016476-78r0rsio	140	19	lung	lung	NN
cord-016476-78r0rsio	140	20	injury	injury	NN
cord-016476-78r0rsio	140	21	has	have	VBZ
cord-016476-78r0rsio	140	22	been	be	VBN
cord-016476-78r0rsio	140	23	reported	report	VBN
cord-016476-78r0rsio	140	24	[	[	-LRB-
cord-016476-78r0rsio	140	25	49	49	CD
cord-016476-78r0rsio	140	26	]	]	-RRB-
cord-016476-78r0rsio	140	27	.	.	.
cord-016476-78r0rsio	141	1	The	the	DT
cord-016476-78r0rsio	141	2	safety	safety	NN
cord-016476-78r0rsio	141	3	of	of	IN
cord-016476-78r0rsio	141	4	these	these	DT
cord-016476-78r0rsio	141	5	drugs	drug	NNS
cord-016476-78r0rsio	141	6	in	in	IN
cord-016476-78r0rsio	141	7	patients	patient	NNS
cord-016476-78r0rsio	141	8	with	with	IN
cord-016476-78r0rsio	141	9	established	establish	VBN
cord-016476-78r0rsio	141	10	RA	RA	NNP
cord-016476-78r0rsio	141	11	-	-	HYPH
cord-016476-78r0rsio	141	12	ILD	ILD	NNP
cord-016476-78r0rsio	141	13	continues	continue	VBZ
cord-016476-78r0rsio	141	14	to	to	TO
cord-016476-78r0rsio	141	15	be	be	VB
cord-016476-78r0rsio	141	16	scrutinised	scrutinise	VBN
cord-016476-78r0rsio	141	17	.	.	.
cord-016476-78r0rsio	142	1	Conversely	conversely	RB
cord-016476-78r0rsio	142	2	elevated	elevated	JJ
cord-016476-78r0rsio	142	3	levels	level	NNS
cord-016476-78r0rsio	142	4	of	of	IN
cord-016476-78r0rsio	142	5	TNF	TNF	NNP
cord-016476-78r0rsio	142	6	-	-	HYPH
cord-016476-78r0rsio	142	7	α	α	NNP
cord-016476-78r0rsio	142	8	have	have	VBP
cord-016476-78r0rsio	142	9	been	be	VBN
cord-016476-78r0rsio	142	10	detected	detect	VBN
cord-016476-78r0rsio	142	11	in	in	IN
cord-016476-78r0rsio	142	12	the	the	DT
cord-016476-78r0rsio	142	13	lungs	lung	NNS
cord-016476-78r0rsio	142	14	of	of	IN
cord-016476-78r0rsio	142	15	both	both	DT
cord-016476-78r0rsio	142	16	experimental	experimental	JJ
cord-016476-78r0rsio	142	17	animal	animal	NN
cord-016476-78r0rsio	142	18	models	model	NNS
cord-016476-78r0rsio	142	19	[	[	-LRB-
cord-016476-78r0rsio	142	20	50	50	CD
cord-016476-78r0rsio	142	21	]	]	-RRB-
cord-016476-78r0rsio	142	22	and	and	CC
cord-016476-78r0rsio	142	23	patients	patient	NNS
cord-016476-78r0rsio	142	24	with	with	IN
cord-016476-78r0rsio	142	25	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	142	26	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	142	27	fibrosis	fibrosis	NN
cord-016476-78r0rsio	142	28	(	(	-LRB-
cord-016476-78r0rsio	142	29	IPF	IPF	NNP
cord-016476-78r0rsio	142	30	)	)	-RRB-
cord-016476-78r0rsio	142	31	[	[	-LRB-
cord-016476-78r0rsio	142	32	51	51	CD
cord-016476-78r0rsio	142	33	]	]	-RRB-
cord-016476-78r0rsio	142	34	.	.	.
cord-016476-78r0rsio	143	1	Interestingly	interestingly	RB
cord-016476-78r0rsio	143	2	serum	serum	NN
cord-016476-78r0rsio	143	3	levels	level	NNS
cord-016476-78r0rsio	143	4	of	of	IN
cord-016476-78r0rsio	143	5	TNF	TNF	NNP
cord-016476-78r0rsio	143	6	-	-	HYPH
cord-016476-78r0rsio	143	7	α	α	NNP
cord-016476-78r0rsio	143	8	have	have	VBP
cord-016476-78r0rsio	143	9	also	also	RB
cord-016476-78r0rsio	143	10	been	be	VBN
cord-016476-78r0rsio	143	11	found	find	VBN
cord-016476-78r0rsio	143	12	to	to	TO
cord-016476-78r0rsio	143	13	be	be	VB
cord-016476-78r0rsio	143	14	elevated	elevate	VBN
cord-016476-78r0rsio	143	15	in	in	IN
cord-016476-78r0rsio	143	16	patients	patient	NNS
cord-016476-78r0rsio	143	17	with	with	IN
cord-016476-78r0rsio	143	18	rituximab	rituximab	NN
cord-016476-78r0rsio	143	19	-	-	HYPH
cord-016476-78r0rsio	143	20	induced	induce	VBN
cord-016476-78r0rsio	143	21	ILD	ILD	NNP
cord-016476-78r0rsio	143	22	[	[	-LRB-
cord-016476-78r0rsio	143	23	52	52	CD
cord-016476-78r0rsio	143	24	]	]	-RRB-
cord-016476-78r0rsio	143	25	.	.	.
cord-016476-78r0rsio	144	1	Etanercept	Etanercept	NNP
cord-016476-78r0rsio	144	2	has	have	VBZ
cord-016476-78r0rsio	144	3	been	be	VBN
cord-016476-78r0rsio	144	4	used	use	VBN
cord-016476-78r0rsio	144	5	in	in	IN
cord-016476-78r0rsio	144	6	a	a	DT
cord-016476-78r0rsio	144	7	randomised	randomised	JJ
cord-016476-78r0rsio	144	8	double	double	JJ
cord-016476-78r0rsio	144	9	-	-	HYPH
cord-016476-78r0rsio	144	10	blind	blind	JJ
cord-016476-78r0rsio	144	11	placebo	placebo	NN
cord-016476-78r0rsio	144	12	-	-	HYPH
cord-016476-78r0rsio	144	13	controlled	control	VBN
cord-016476-78r0rsio	144	14	exploratory	exploratory	JJ
cord-016476-78r0rsio	144	15	trial	trial	NN
cord-016476-78r0rsio	144	16	in	in	IN
cord-016476-78r0rsio	144	17	clinically	clinically	RB
cord-016476-78r0rsio	144	18	progressive	progressive	JJ
cord-016476-78r0rsio	144	19	IPF	IPF	NNP
cord-016476-78r0rsio	144	20	subjects	subject	NNS
cord-016476-78r0rsio	144	21	,	,	,
cord-016476-78r0rsio	144	22	however	however	RB
cord-016476-78r0rsio	144	23	failed	fail	VBD
cord-016476-78r0rsio	144	24	to	to	TO
cord-016476-78r0rsio	144	25	show	show	VB
cord-016476-78r0rsio	144	26	a	a	DT
cord-016476-78r0rsio	144	27	difference	difference	NN
cord-016476-78r0rsio	144	28	in	in	IN
cord-016476-78r0rsio	144	29	primary	primary	JJ
cord-016476-78r0rsio	144	30	endpoint	endpoint	NN
cord-016476-78r0rsio	144	31	of	of	IN
cord-016476-78r0rsio	144	32	improvement	improvement	NN
cord-016476-78r0rsio	144	33	in	in	IN
cord-016476-78r0rsio	144	34	FVC	FVC	NNP
cord-016476-78r0rsio	144	35	over	over	IN
cord-016476-78r0rsio	144	36	48	48	CD
cord-016476-78r0rsio	144	37	weeks	week	NNS
cord-016476-78r0rsio	144	38	.	.	.
cord-016476-78r0rsio	145	1	The	the	DT
cord-016476-78r0rsio	145	2	study	study	NN
cord-016476-78r0rsio	145	3	was	be	VBD
cord-016476-78r0rsio	145	4	underpowered	underpowere	VBN
cord-016476-78r0rsio	145	5	;	;	:
cord-016476-78r0rsio	145	6	however	however	RB
cord-016476-78r0rsio	145	7	,	,	,
cord-016476-78r0rsio	145	8	a	a	DT
cord-016476-78r0rsio	145	9	nonsignificant	nonsignificant	JJ
cord-016476-78r0rsio	145	10	reduction	reduction	NN
cord-016476-78r0rsio	145	11	in	in	IN
cord-016476-78r0rsio	145	12	disease	disease	NN
cord-016476-78r0rsio	145	13	progression	progression	NN
cord-016476-78r0rsio	145	14	was	be	VBD
cord-016476-78r0rsio	145	15	seen	see	VBN
cord-016476-78r0rsio	145	16	in	in	IN
cord-016476-78r0rsio	145	17	several	several	JJ
cord-016476-78r0rsio	145	18	physiologic	physiologic	JJ
cord-016476-78r0rsio	145	19	(	(	-LRB-
cord-016476-78r0rsio	145	20	including	include	VBG
cord-016476-78r0rsio	145	21	transfer	transfer	NN
cord-016476-78r0rsio	145	22	factor	factor	NN
cord-016476-78r0rsio	145	23	)	)	-RRB-
cord-016476-78r0rsio	145	24	,	,	,
cord-016476-78r0rsio	145	25	functional	functional	JJ
cord-016476-78r0rsio	145	26	and	and	CC
cord-016476-78r0rsio	145	27	quality	quality	NN
cord-016476-78r0rsio	145	28	-	-	HYPH
cord-016476-78r0rsio	145	29	of	of	IN
cord-016476-78r0rsio	145	30	-	-	HYPH
cord-016476-78r0rsio	145	31	life	life	NN
cord-016476-78r0rsio	145	32	endpoints	endpoint	NNS
cord-016476-78r0rsio	145	33	amongst	amongst	IN
cord-016476-78r0rsio	145	34	participants	participant	NNS
cord-016476-78r0rsio	145	35	receiving	receive	VBG
cord-016476-78r0rsio	145	36	TNFi	TNFi	NNS
cord-016476-78r0rsio	145	37	.	.	.
cord-016476-78r0rsio	146	1	Importantly	importantly	RB
cord-016476-78r0rsio	146	2	there	there	EX
cord-016476-78r0rsio	146	3	was	be	VBD
cord-016476-78r0rsio	146	4	no	no	DT
cord-016476-78r0rsio	146	5	decline	decline	NN
cord-016476-78r0rsio	146	6	in	in	IN
cord-016476-78r0rsio	146	7	lung	lung	NN
cord-016476-78r0rsio	146	8	function	function	NN
cord-016476-78r0rsio	146	9	or	or	CC
cord-016476-78r0rsio	146	10	higher	high	JJR
cord-016476-78r0rsio	146	11	incidence	incidence	NN
cord-016476-78r0rsio	146	12	of	of	IN
cord-016476-78r0rsio	146	13	SRAEs	srae	NNS
cord-016476-78r0rsio	146	14	in	in	IN
cord-016476-78r0rsio	146	15	the	the	DT
cord-016476-78r0rsio	146	16	etanercept	etanercept	NNP
cord-016476-78r0rsio	146	17	group	group	NN
cord-016476-78r0rsio	146	18	compared	compare	VBN
cord-016476-78r0rsio	146	19	to	to	IN
cord-016476-78r0rsio	146	20	placebo	placebo	NN
cord-016476-78r0rsio	146	21	.	.	.
cord-016476-78r0rsio	147	1	Therefore	therefore	RB
cord-016476-78r0rsio	147	2	whilst	whilst	IN
cord-016476-78r0rsio	147	3	legitimate	legitimate	JJ
cord-016476-78r0rsio	147	4	concerns	concern	NNS
cord-016476-78r0rsio	147	5	about	about	IN
cord-016476-78r0rsio	147	6	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	147	7	toxicity	toxicity	NN
cord-016476-78r0rsio	147	8	have	have	VBP
cord-016476-78r0rsio	147	9	been	be	VBN
cord-016476-78r0rsio	147	10	highlighted	highlight	VBN
cord-016476-78r0rsio	147	11	,	,	,
cord-016476-78r0rsio	147	12	TNFi	tnfi	JJ
cord-016476-78r0rsio	147	13	treatments	treatment	NNS
cord-016476-78r0rsio	147	14	may	may	MD
cord-016476-78r0rsio	147	15	have	have	VB
cord-016476-78r0rsio	147	16	plausible	plausible	JJ
cord-016476-78r0rsio	147	17	bidirectional	bidirectional	JJ
cord-016476-78r0rsio	147	18	effects	effect	NNS
cord-016476-78r0rsio	147	19	.	.	.
cord-016476-78r0rsio	148	1	The	the	DT
cord-016476-78r0rsio	148	2	next	next	JJ
cord-016476-78r0rsio	148	3	section	section	NN
cord-016476-78r0rsio	148	4	will	will	MD
cord-016476-78r0rsio	148	5	review	review	VB
cord-016476-78r0rsio	148	6	the	the	DT
cord-016476-78r0rsio	148	7	levels	level	NNS
cord-016476-78r0rsio	148	8	of	of	IN
cord-016476-78r0rsio	148	9	evidence	evidence	NN
cord-016476-78r0rsio	148	10	for	for	IN
cord-016476-78r0rsio	148	11	both	both	DT
cord-016476-78r0rsio	148	12	incident	incident	NN
cord-016476-78r0rsio	148	13	ILD	ILD	NNP
cord-016476-78r0rsio	148	14	and	and	CC
cord-016476-78r0rsio	148	15	safety	safety	NN
cord-016476-78r0rsio	148	16	in	in	IN
cord-016476-78r0rsio	148	17	pre	pre	JJ
cord-016476-78r0rsio	148	18	-	-	JJ
cord-016476-78r0rsio	148	19	existing	existing	JJ
cord-016476-78r0rsio	148	20	RA	RA	NNP
cord-016476-78r0rsio	148	21	-	-	HYPH
cord-016476-78r0rsio	148	22	ILD	ILD	NNP
cord-016476-78r0rsio	148	23	.	.	.
cord-016476-78r0rsio	149	1	Clinical	clinical	JJ
cord-016476-78r0rsio	149	2	trials	trial	NNS
cord-016476-78r0rsio	149	3	of	of	IN
cord-016476-78r0rsio	149	4	TNFi	TNFi	NNS
cord-016476-78r0rsio	149	5	therapy	therapy	NN
cord-016476-78r0rsio	149	6	have	have	VBP
cord-016476-78r0rsio	149	7	been	be	VBN
cord-016476-78r0rsio	149	8	significantly	significantly	RB
cord-016476-78r0rsio	149	9	underpowered	underpowere	VBN
cord-016476-78r0rsio	149	10	to	to	TO
cord-016476-78r0rsio	149	11	detect	detect	VB
cord-016476-78r0rsio	149	12	even	even	RB
cord-016476-78r0rsio	149	13	a	a	DT
cord-016476-78r0rsio	149	14	large	large	JJ
cord-016476-78r0rsio	149	15	increase	increase	NN
cord-016476-78r0rsio	149	16	in	in	IN
cord-016476-78r0rsio	149	17	the	the	DT
cord-016476-78r0rsio	149	18	incidence	incidence	NN
cord-016476-78r0rsio	149	19	of	of	IN
cord-016476-78r0rsio	149	20	serious	serious	JJ
cord-016476-78r0rsio	149	21	RA	RA	NNP
cord-016476-78r0rsio	149	22	-	-	HYPH
cord-016476-78r0rsio	149	23	ILD	ILD	NNP
cord-016476-78r0rsio	149	24	.	.	.
cord-016476-78r0rsio	150	1	The	the	DT
cord-016476-78r0rsio	150	2	original	original	JJ
cord-016476-78r0rsio	150	3	RCTs	rct	NNS
cord-016476-78r0rsio	150	4	leading	lead	VBG
cord-016476-78r0rsio	150	5	to	to	IN
cord-016476-78r0rsio	150	6	eventual	eventual	JJ
cord-016476-78r0rsio	150	7	approval	approval	NN
cord-016476-78r0rsio	150	8	of	of	IN
cord-016476-78r0rsio	150	9	TNFi	TNFi	NNS
cord-016476-78r0rsio	150	10	provided	provide	VBD
cord-016476-78r0rsio	150	11	no	no	DT
cord-016476-78r0rsio	150	12	RA	RA	NNP
cord-016476-78r0rsio	150	13	-	-	HYPH
cord-016476-78r0rsio	150	14	ILD	ILD	NNP
cord-016476-78r0rsio	150	15	safety	safety	NN
cord-016476-78r0rsio	150	16	signals	signal	NNS
cord-016476-78r0rsio	150	17	.	.	.
cord-016476-78r0rsio	151	1	In	in	IN
cord-016476-78r0rsio	151	2	the	the	DT
cord-016476-78r0rsio	151	3	first	first	JJ
cord-016476-78r0rsio	151	4	reported	report	VBN
cord-016476-78r0rsio	151	5	phase	phase	NN
cord-016476-78r0rsio	151	6	III	iii	CD
cord-016476-78r0rsio	151	7	trial	trial	NN
cord-016476-78r0rsio	151	8	of	of	IN
cord-016476-78r0rsio	151	9	infliximab	infliximab	NNP
cord-016476-78r0rsio	151	10	and	and	CC
cord-016476-78r0rsio	151	11	MTX	MTX	NNP
cord-016476-78r0rsio	151	12	versus	versus	IN
cord-016476-78r0rsio	151	13	placebo	placebo	NN
cord-016476-78r0rsio	151	14	and	and	CC
cord-016476-78r0rsio	151	15	MTX	MTX	NNP
cord-016476-78r0rsio	151	16	over	over	IN
cord-016476-78r0rsio	151	17	30	30	CD
cord-016476-78r0rsio	151	18	weeks	week	NNS
cord-016476-78r0rsio	151	19	,	,	,
cord-016476-78r0rsio	151	20	there	there	EX
cord-016476-78r0rsio	151	21	was	be	VBD
cord-016476-78r0rsio	151	22	a	a	DT
cord-016476-78r0rsio	151	23	death	death	NN
cord-016476-78r0rsio	151	24	in	in	IN
cord-016476-78r0rsio	151	25	both	both	CC
cord-016476-78r0rsio	151	26	the	the	DT
cord-016476-78r0rsio	151	27	placebo	placebo	NN
cord-016476-78r0rsio	151	28	arm	arm	NN
cord-016476-78r0rsio	151	29	due	due	JJ
cord-016476-78r0rsio	151	30	to	to	IN
cord-016476-78r0rsio	151	31	ILD	ILD	NNP
cord-016476-78r0rsio	151	32	and	and	CC
cord-016476-78r0rsio	151	33	the	the	DT
cord-016476-78r0rsio	151	34	infliximab	infliximab	NNP
cord-016476-78r0rsio	151	35	arm	arm	NN
cord-016476-78r0rsio	151	36	due	due	JJ
cord-016476-78r0rsio	151	37	to	to	IN
cord-016476-78r0rsio	151	38	cardiopulmonary	cardiopulmonary	JJ
cord-016476-78r0rsio	151	39	failure	failure	NN
cord-016476-78r0rsio	151	40	as	as	IN
cord-016476-78r0rsio	151	41	a	a	DT
cord-016476-78r0rsio	151	42	result	result	NN
cord-016476-78r0rsio	151	43	of	of	IN
cord-016476-78r0rsio	151	44	suspected	suspect	VBN
cord-016476-78r0rsio	151	45	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	151	46	embolism	embolism	NN
cord-016476-78r0rsio	151	47	or	or	CC
cord-016476-78r0rsio	151	48	ILD	ILD	NNP
cord-016476-78r0rsio	151	49	[	[	-LRB-
cord-016476-78r0rsio	151	50	53	53	CD
cord-016476-78r0rsio	151	51	]	]	-RRB-
cord-016476-78r0rsio	151	52	.	.	.
cord-016476-78r0rsio	152	1	In	in	IN
cord-016476-78r0rsio	152	2	a	a	DT
cord-016476-78r0rsio	152	3	two	two	CD
cord-016476-78r0rsio	152	4	-	-	HYPH
cord-016476-78r0rsio	152	5	year	year	NN
cord-016476-78r0rsio	152	6	extension	extension	NN
cord-016476-78r0rsio	152	7	of	of	IN
cord-016476-78r0rsio	152	8	this	this	DT
cord-016476-78r0rsio	152	9	trial	trial	NN
cord-016476-78r0rsio	152	10	,	,	,
cord-016476-78r0rsio	152	11	there	there	EX
cord-016476-78r0rsio	152	12	was	be	VBD
cord-016476-78r0rsio	152	13	a	a	DT
cord-016476-78r0rsio	152	14	single	single	JJ
cord-016476-78r0rsio	152	15	death	death	NN
cord-016476-78r0rsio	152	16	attributed	attribute	VBN
cord-016476-78r0rsio	152	17	to	to	IN
cord-016476-78r0rsio	152	18	ILD	ILD	NNP
cord-016476-78r0rsio	152	19	in	in	IN
cord-016476-78r0rsio	152	20	the	the	DT
cord-016476-78r0rsio	152	21	infliximab	infliximab	JJ
cord-016476-78r0rsio	152	22	arm	arm	NN
cord-016476-78r0rsio	152	23	;	;	:
cord-016476-78r0rsio	152	24	however	however	RB
cord-016476-78r0rsio	152	25	,	,	,
cord-016476-78r0rsio	152	26	it	-PRON-	PRP
cord-016476-78r0rsio	152	27	was	be	VBD
cord-016476-78r0rsio	152	28	not	not	RB
cord-016476-78r0rsio	152	29	clear	clear	JJ
cord-016476-78r0rsio	152	30	whether	whether	IN
cord-016476-78r0rsio	152	31	this	this	DT
cord-016476-78r0rsio	152	32	is	be	VBZ
cord-016476-78r0rsio	152	33	the	the	DT
cord-016476-78r0rsio	152	34	same	same	JJ
cord-016476-78r0rsio	152	35	patient	patient	NN
cord-016476-78r0rsio	152	36	reported	report	VBN
cord-016476-78r0rsio	152	37	in	in	IN
cord-016476-78r0rsio	152	38	the	the	DT
cord-016476-78r0rsio	152	39	previous	previous	JJ
cord-016476-78r0rsio	152	40	paper	paper	NN
cord-016476-78r0rsio	152	41	.	.	.
cord-016476-78r0rsio	153	1	A	a	DT
cord-016476-78r0rsio	153	2	clinical	clinical	JJ
cord-016476-78r0rsio	153	3	trial	trial	NN
cord-016476-78r0rsio	153	4	of	of	IN
cord-016476-78r0rsio	153	5	etanercept	etanercept	NNP
cord-016476-78r0rsio	153	6	versus	versus	IN
cord-016476-78r0rsio	153	7	MTX	MTX	NNP
cord-016476-78r0rsio	153	8	in	in	IN
cord-016476-78r0rsio	153	9	early	early	JJ
cord-016476-78r0rsio	153	10	RA	RA	NNP
cord-016476-78r0rsio	153	11	reported	report	VBD
cord-016476-78r0rsio	153	12	three	three	CD
cord-016476-78r0rsio	153	13	cases	case	NNS
cord-016476-78r0rsio	153	14	of	of	IN
cord-016476-78r0rsio	153	15	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	153	16	in	in	IN
cord-016476-78r0rsio	153	17	the	the	DT
cord-016476-78r0rsio	153	18	MTX	MTX	NNP
cord-016476-78r0rsio	153	19	group	group	NN
cord-016476-78r0rsio	153	20	at	at	IN
cord-016476-78r0rsio	153	21	1	1	CD
cord-016476-78r0rsio	153	22	year	year	NN
cord-016476-78r0rsio	153	23	follow	follow	NN
cord-016476-78r0rsio	153	24	-	-	HYPH
cord-016476-78r0rsio	153	25	up	up	NN
cord-016476-78r0rsio	153	26	[	[	-LRB-
cord-016476-78r0rsio	153	27	54	54	CD
cord-016476-78r0rsio	153	28	]	]	-RRB-
cord-016476-78r0rsio	153	29	and	and	CC
cord-016476-78r0rsio	153	30	four	four	CD
cord-016476-78r0rsio	153	31	cases	case	NNS
cord-016476-78r0rsio	153	32	at	at	IN
cord-016476-78r0rsio	153	33	2	2	CD
cord-016476-78r0rsio	153	34	year	year	NN
cord-016476-78r0rsio	153	35	follow	follow	NN
cord-016476-78r0rsio	153	36	-	-	HYPH
cord-016476-78r0rsio	153	37	up	up	NN
cord-016476-78r0rsio	153	38	[	[	-LRB-
cord-016476-78r0rsio	153	39	55	55	CD
cord-016476-78r0rsio	153	40	]	]	-RRB-
cord-016476-78r0rsio	153	41	with	with	IN
cord-016476-78r0rsio	153	42	no	no	DT
cord-016476-78r0rsio	153	43	reported	report	VBN
cord-016476-78r0rsio	153	44	cases	case	NNS
cord-016476-78r0rsio	153	45	in	in	IN
cord-016476-78r0rsio	153	46	the	the	DT
cord-016476-78r0rsio	153	47	etanercept	etanercept	NNP
cord-016476-78r0rsio	153	48	arm	arm	NN
cord-016476-78r0rsio	153	49	despite	despite	IN
cord-016476-78r0rsio	153	50	a	a	DT
cord-016476-78r0rsio	153	51	ratio	ratio	NN
cord-016476-78r0rsio	153	52	of	of	IN
cord-016476-78r0rsio	153	53	etanercept	etanercept	NNP
cord-016476-78r0rsio	153	54	/	/	SYM
cord-016476-78r0rsio	153	55	MTX	MTX	NNP
cord-016476-78r0rsio	153	56	of	of	IN
cord-016476-78r0rsio	153	57	2:1	2:1	CD
cord-016476-78r0rsio	153	58	.	.	.
cord-016476-78r0rsio	154	1	There	there	EX
cord-016476-78r0rsio	154	2	was	be	VBD
cord-016476-78r0rsio	154	3	one	one	CD
cord-016476-78r0rsio	154	4	case	case	NN
cord-016476-78r0rsio	154	5	of	of	IN
cord-016476-78r0rsio	154	6	death	death	NN
cord-016476-78r0rsio	154	7	from	from	IN
cord-016476-78r0rsio	154	8	respiratory	respiratory	JJ
cord-016476-78r0rsio	154	9	failure	failure	NN
cord-016476-78r0rsio	154	10	in	in	IN
cord-016476-78r0rsio	154	11	the	the	DT
cord-016476-78r0rsio	154	12	5-year	5-year	CD
cord-016476-78r0rsio	154	13	OLE	ole	NN
cord-016476-78r0rsio	154	14	of	of	IN
cord-016476-78r0rsio	154	15	this	this	DT
cord-016476-78r0rsio	154	16	study	study	NN
cord-016476-78r0rsio	154	17	in	in	IN
cord-016476-78r0rsio	154	18	the	the	DT
cord-016476-78r0rsio	154	19	etanercept	etanercept	NNP
cord-016476-78r0rsio	154	20	arm	arm	NN
cord-016476-78r0rsio	154	21	[	[	-LRB-
cord-016476-78r0rsio	154	22	56	56	CD
cord-016476-78r0rsio	154	23	]	]	-RRB-
cord-016476-78r0rsio	154	24	.	.	.
cord-016476-78r0rsio	155	1	No	no	DT
cord-016476-78r0rsio	155	2	cases	case	NNS
cord-016476-78r0rsio	155	3	of	of	IN
cord-016476-78r0rsio	155	4	ILD	ILD	NNP
cord-016476-78r0rsio	155	5	were	be	VBD
cord-016476-78r0rsio	155	6	reported	report	VBN
cord-016476-78r0rsio	155	7	in	in	IN
cord-016476-78r0rsio	155	8	the	the	DT
cord-016476-78r0rsio	155	9	7-year	7-year	JJ
cord-016476-78r0rsio	155	10	OLE	ole	NN
cord-016476-78r0rsio	155	11	of	of	IN
cord-016476-78r0rsio	155	12	etanercept	etanercept	NN
cord-016476-78r0rsio	155	13	[	[	-LRB-
cord-016476-78r0rsio	155	14	57	57	CD
cord-016476-78r0rsio	155	15	]	]	-RRB-
cord-016476-78r0rsio	155	16	.	.	.
cord-016476-78r0rsio	156	1	ILD	ILD	NNP
cord-016476-78r0rsio	156	2	was	be	VBD
cord-016476-78r0rsio	156	3	not	not	RB
cord-016476-78r0rsio	156	4	reported	report	VBN
cord-016476-78r0rsio	156	5	in	in	IN
cord-016476-78r0rsio	156	6	any	any	DT
cord-016476-78r0rsio	156	7	of	of	IN
cord-016476-78r0rsio	156	8	the	the	DT
cord-016476-78r0rsio	156	9	initial	initial	JJ
cord-016476-78r0rsio	156	10	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	156	11	clinical	clinical	JJ
cord-016476-78r0rsio	156	12	trials	trial	NNS
cord-016476-78r0rsio	156	13	,	,	,
cord-016476-78r0rsio	156	14	in	in	IN
cord-016476-78r0rsio	156	15	either	either	CC
cord-016476-78r0rsio	156	16	the	the	DT
cord-016476-78r0rsio	156	17	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	156	18	or	or	CC
cord-016476-78r0rsio	156	19	placebo	placebo	NN
cord-016476-78r0rsio	156	20	arms	arm	NNS
cord-016476-78r0rsio	156	21	[	[	-LRB-
cord-016476-78r0rsio	156	22	58	58	CD
cord-016476-78r0rsio	156	23	]	]	-RRB-
cord-016476-78r0rsio	156	24	.	.	.
cord-016476-78r0rsio	157	1	However	however	RB
cord-016476-78r0rsio	157	2	,	,	,
cord-016476-78r0rsio	157	3	within	within	IN
cord-016476-78r0rsio	157	4	an	an	DT
cord-016476-78r0rsio	157	5	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	157	6	OLE	OLE	NNP
cord-016476-78r0rsio	157	7	study	study	NN
cord-016476-78r0rsio	157	8	[	[	-LRB-
cord-016476-78r0rsio	157	9	59	59	CD
cord-016476-78r0rsio	157	10	]	]	-RRB-
cord-016476-78r0rsio	157	11	,	,	,
cord-016476-78r0rsio	157	12	SAEs	SAEs	NNP
cord-016476-78r0rsio	157	13	coded	code	VBN
cord-016476-78r0rsio	157	14	as	as	IN
cord-016476-78r0rsio	157	15	'	'	``
cord-016476-78r0rsio	157	16	parenchymal	parenchymal	JJ
cord-016476-78r0rsio	157	17	lung	lung	NN
cord-016476-78r0rsio	157	18	disorders	disorder	NNS
cord-016476-78r0rsio	157	19	'	'	POS
cord-016476-78r0rsio	157	20	occurred	occur	VBD
cord-016476-78r0rsio	157	21	at	at	IN
cord-016476-78r0rsio	157	22	a	a	DT
cord-016476-78r0rsio	157	23	rate	rate	NN
cord-016476-78r0rsio	157	24	of	of	IN
cord-016476-78r0rsio	157	25	0.2	0.2	CD
cord-016476-78r0rsio	157	26	-	-	HYPH
cord-016476-78r0rsio	157	27	0.3/100	0.3/100	NN
cord-016476-78r0rsio	157	28	patient	patient	NN
cord-016476-78r0rsio	157	29	-	-	HYPH
cord-016476-78r0rsio	157	30	years	year	NNS
cord-016476-78r0rsio	157	31	,	,	,
cord-016476-78r0rsio	157	32	accounting	account	VBG
cord-016476-78r0rsio	157	33	for	for	IN
cord-016476-78r0rsio	157	34	20	20	CD
cord-016476-78r0rsio	157	35	%	%	NN
cord-016476-78r0rsio	157	36	of	of	IN
cord-016476-78r0rsio	157	37	all	all	DT
cord-016476-78r0rsio	157	38	SAE	SAE	NNP
cord-016476-78r0rsio	157	39	's	's	POS
cord-016476-78r0rsio	157	40	.	.	.
cord-016476-78r0rsio	158	1	In	in	IN
cord-016476-78r0rsio	158	2	this	this	DT
cord-016476-78r0rsio	158	3	trial	trial	NN
cord-016476-78r0rsio	158	4	,	,	,
cord-016476-78r0rsio	158	5	however	however	RB
cord-016476-78r0rsio	158	6	,	,	,
cord-016476-78r0rsio	158	7	there	there	EX
cord-016476-78r0rsio	158	8	was	be	VBD
cord-016476-78r0rsio	158	9	no	no	DT
cord-016476-78r0rsio	158	10	placebo	placebo	NN
cord-016476-78r0rsio	158	11	-	-	HYPH
cord-016476-78r0rsio	158	12	controlled	control	VBN
cord-016476-78r0rsio	158	13	or	or	CC
cord-016476-78r0rsio	158	14	nbDMARDexposed	nbdmardexposed	JJ
cord-016476-78r0rsio	158	15	arm	arm	NN
cord-016476-78r0rsio	158	16	,	,	,
cord-016476-78r0rsio	158	17	making	make	VBG
cord-016476-78r0rsio	158	18	the	the	DT
cord-016476-78r0rsio	158	19	interpretation	interpretation	NN
cord-016476-78r0rsio	158	20	of	of	IN
cord-016476-78r0rsio	158	21	these	these	DT
cord-016476-78r0rsio	158	22	figures	figure	NNS
cord-016476-78r0rsio	158	23	challenging	challenge	VBG
cord-016476-78r0rsio	158	24	.	.	.
cord-016476-78r0rsio	159	1	Similarly	similarly	RB
cord-016476-78r0rsio	159	2	no	no	DT
cord-016476-78r0rsio	159	3	signal	signal	NN
cord-016476-78r0rsio	159	4	of	of	IN
cord-016476-78r0rsio	159	5	concern	concern	NN
cord-016476-78r0rsio	159	6	for	for	IN
cord-016476-78r0rsio	159	7	incident	incident	NN
cord-016476-78r0rsio	159	8	ILD	ILD	NNP
cord-016476-78r0rsio	159	9	was	be	VBD
cord-016476-78r0rsio	159	10	observed	observe	VBN
cord-016476-78r0rsio	159	11	in	in	IN
cord-016476-78r0rsio	159	12	the	the	DT
cord-016476-78r0rsio	159	13	initial	initial	JJ
cord-016476-78r0rsio	159	14	golimumab	golimumab	NNP
cord-016476-78r0rsio	159	15	-	-	HYPH
cord-016476-78r0rsio	159	16	RA	RA	NNP
cord-016476-78r0rsio	159	17	trials	trial	NNS
cord-016476-78r0rsio	159	18	[	[	-LRB-
cord-016476-78r0rsio	159	19	60	60	CD
cord-016476-78r0rsio	159	20	,	,	,
cord-016476-78r0rsio	159	21	61	61	CD
cord-016476-78r0rsio	159	22	]	]	-RRB-
cord-016476-78r0rsio	159	23	in	in	IN
cord-016476-78r0rsio	159	24	the	the	DT
cord-016476-78r0rsio	159	25	two	two	CD
cord-016476-78r0rsio	159	26	-	-	HYPH
cord-016476-78r0rsio	159	27	year	year	NN
cord-016476-78r0rsio	159	28	[	[	-LRB-
cord-016476-78r0rsio	159	29	62	62	CD
cord-016476-78r0rsio	159	30	]	]	-RRB-
cord-016476-78r0rsio	159	31	or	or	CC
cord-016476-78r0rsio	159	32	five	five	CD
cord-016476-78r0rsio	159	33	-	-	HYPH
cord-016476-78r0rsio	159	34	year	year	NN
cord-016476-78r0rsio	159	35	[	[	-LRB-
cord-016476-78r0rsio	159	36	63	63	CD
cord-016476-78r0rsio	159	37	]	]	-RRB-
cord-016476-78r0rsio	159	38	extension	extension	NN
cord-016476-78r0rsio	159	39	studies	study	NNS
cord-016476-78r0rsio	159	40	.	.	.
cord-016476-78r0rsio	160	1	In	in	IN
cord-016476-78r0rsio	160	2	the	the	DT
cord-016476-78r0rsio	160	3	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	160	4	RAPID	RAPID	NNP
cord-016476-78r0rsio	160	5	1	1	CD
cord-016476-78r0rsio	160	6	and	and	CC
cord-016476-78r0rsio	160	7	RAPID	rapid	JJ
cord-016476-78r0rsio	160	8	2	2	CD
cord-016476-78r0rsio	160	9	trials	trial	NNS
cord-016476-78r0rsio	160	10	[	[	-LRB-
cord-016476-78r0rsio	160	11	64	64	CD
cord-016476-78r0rsio	160	12	,	,	,
cord-016476-78r0rsio	160	13	65	65	CD
cord-016476-78r0rsio	160	14	]	]	-RRB-
cord-016476-78r0rsio	160	15	,	,	,
cord-016476-78r0rsio	160	16	and	and	CC
cord-016476-78r0rsio	160	17	subsequent	subsequent	JJ
cord-016476-78r0rsio	160	18	OLEs	ole	NNS
cord-016476-78r0rsio	160	19	[	[	-LRB-
cord-016476-78r0rsio	160	20	66	66	CD
cord-016476-78r0rsio	160	21	]	]	-RRB-
cord-016476-78r0rsio	160	22	,	,	,
cord-016476-78r0rsio	160	23	no	no	DT
cord-016476-78r0rsio	160	24	cases	case	NNS
cord-016476-78r0rsio	160	25	of	of	IN
cord-016476-78r0rsio	160	26	druginduced	druginduced	JJ
cord-016476-78r0rsio	160	27	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	160	28	were	be	VBD
cord-016476-78r0rsio	160	29	reported	report	VBN
cord-016476-78r0rsio	160	30	in	in	IN
cord-016476-78r0rsio	160	31	any	any	DT
cord-016476-78r0rsio	160	32	arms	arm	NNS
cord-016476-78r0rsio	160	33	.	.	.
cord-016476-78r0rsio	161	1	Therefore	therefore	RB
cord-016476-78r0rsio	161	2	original	original	JJ
cord-016476-78r0rsio	161	3	RCTs	rct	NNS
cord-016476-78r0rsio	161	4	of	of	IN
cord-016476-78r0rsio	161	5	TNFi	TNFi	NNP
cord-016476-78r0rsio	161	6	agents	agent	NNS
cord-016476-78r0rsio	161	7	did	do	VBD
cord-016476-78r0rsio	161	8	not	not	RB
cord-016476-78r0rsio	161	9	raise	raise	VB
cord-016476-78r0rsio	161	10	concern	concern	NN
cord-016476-78r0rsio	161	11	over	over	IN
cord-016476-78r0rsio	161	12	the	the	DT
cord-016476-78r0rsio	161	13	potential	potential	JJ
cord-016476-78r0rsio	161	14	development	development	NN
cord-016476-78r0rsio	161	15	of	of	IN
cord-016476-78r0rsio	161	16	ILD	ILD	NNP
cord-016476-78r0rsio	161	17	.	.	.
cord-016476-78r0rsio	162	1	These	these	DT
cord-016476-78r0rsio	162	2	trials	trial	NNS
cord-016476-78r0rsio	162	3	typically	typically	RB
cord-016476-78r0rsio	162	4	had	have	VBD
cord-016476-78r0rsio	162	5	short	short	JJ
cord-016476-78r0rsio	162	6	duration	duration	NN
cord-016476-78r0rsio	162	7	,	,	,
cord-016476-78r0rsio	162	8	included	include	VBN
cord-016476-78r0rsio	162	9	between	between	IN
cord-016476-78r0rsio	162	10	210	210	CD
cord-016476-78r0rsio	162	11	and	and	CC
cord-016476-78r0rsio	162	12	340	340	CD
cord-016476-78r0rsio	162	13	patients	patient	NNS
cord-016476-78r0rsio	162	14	in	in	IN
cord-016476-78r0rsio	162	15	the	the	DT
cord-016476-78r0rsio	162	16	TNFi	TNFi	NNP
cord-016476-78r0rsio	162	17	arm	arm	NN
cord-016476-78r0rsio	162	18	each	each	DT
cord-016476-78r0rsio	162	19	and	and	CC
cord-016476-78r0rsio	162	20	excluded	exclude	VBD
cord-016476-78r0rsio	162	21	patients	patient	NNS
cord-016476-78r0rsio	162	22	with	with	IN
cord-016476-78r0rsio	162	23	RA	RA	NNP
cord-016476-78r0rsio	162	24	-	-	HYPH
cord-016476-78r0rsio	162	25	ILD	ILD	NNP
cord-016476-78r0rsio	162	26	at	at	IN
cord-016476-78r0rsio	162	27	baseline	baseline	NN
cord-016476-78r0rsio	162	28	.	.	.
cord-016476-78r0rsio	163	1	Concerns	concern	NNS
cord-016476-78r0rsio	163	2	regarding	regard	VBG
cord-016476-78r0rsio	163	3	the	the	DT
cord-016476-78r0rsio	163	4	respiratory	respiratory	JJ
cord-016476-78r0rsio	163	5	safety	safety	NN
cord-016476-78r0rsio	163	6	of	of	IN
cord-016476-78r0rsio	163	7	TNFi	TNFi	NNP
cord-016476-78r0rsio	163	8	agents	agent	NNS
cord-016476-78r0rsio	163	9	arose	arise	VBD
cord-016476-78r0rsio	163	10	initially	initially	RB
cord-016476-78r0rsio	163	11	following	follow	VBG
cord-016476-78r0rsio	163	12	three	three	CD
cord-016476-78r0rsio	163	13	case	case	NN
cord-016476-78r0rsio	163	14	reports	report	NNS
cord-016476-78r0rsio	163	15	of	of	IN
cord-016476-78r0rsio	163	16	rapid	rapid	JJ
cord-016476-78r0rsio	163	17	fatal	fatal	JJ
cord-016476-78r0rsio	163	18	exacerbations	exacerbation	NNS
cord-016476-78r0rsio	163	19	of	of	IN
cord-016476-78r0rsio	163	20	RA	RA	NNP
cord-016476-78r0rsio	163	21	-	-	HYPH
cord-016476-78r0rsio	163	22	associated	associate	VBN
cord-016476-78r0rsio	163	23	fibrosing	fibrose	VBG
cord-016476-78r0rsio	163	24	alveolitis	alveolitis	NN
cord-016476-78r0rsio	163	25	following	follow	VBG
cord-016476-78r0rsio	163	26	commencement	commencement	NN
cord-016476-78r0rsio	163	27	of	of	IN
cord-016476-78r0rsio	163	28	infliximab	infliximab	NNP
cord-016476-78r0rsio	163	29	in	in	IN
cord-016476-78r0rsio	163	30	2004	2004	CD
cord-016476-78r0rsio	163	31	[	[	-LRB-
cord-016476-78r0rsio	163	32	67	67	CD
cord-016476-78r0rsio	163	33	]	]	-RRB-
cord-016476-78r0rsio	163	34	,	,	,
cord-016476-78r0rsio	163	35	which	which	WDT
cord-016476-78r0rsio	163	36	was	be	VBD
cord-016476-78r0rsio	163	37	extended	extend	VBN
cord-016476-78r0rsio	163	38	in	in	IN
cord-016476-78r0rsio	163	39	a	a	DT
cord-016476-78r0rsio	163	40	later	later	JJ
cord-016476-78r0rsio	163	41	publication	publication	NN
cord-016476-78r0rsio	163	42	to	to	IN
cord-016476-78r0rsio	163	43	five	five	CD
cord-016476-78r0rsio	163	44	cases	case	NNS
cord-016476-78r0rsio	163	45	[	[	-LRB-
cord-016476-78r0rsio	163	46	68	68	CD
cord-016476-78r0rsio	163	47	]	]	-RRB-
cord-016476-78r0rsio	163	48	.	.	.
cord-016476-78r0rsio	164	1	Of	of	IN
cord-016476-78r0rsio	164	2	these	these	DT
cord-016476-78r0rsio	164	3	cases	case	NNS
cord-016476-78r0rsio	164	4	,	,	,
cord-016476-78r0rsio	164	5	three	three	CD
cord-016476-78r0rsio	164	6	patients	patient	NNS
cord-016476-78r0rsio	164	7	were	be	VBD
cord-016476-78r0rsio	164	8	taking	take	VBG
cord-016476-78r0rsio	164	9	concomitant	concomitant	JJ
cord-016476-78r0rsio	164	10	azathioprine	azathioprine	NN
cord-016476-78r0rsio	164	11	,	,	,
cord-016476-78r0rsio	164	12	and	and	CC
cord-016476-78r0rsio	164	13	one	one	CD
cord-016476-78r0rsio	164	14	taking	take	VBG
cord-016476-78r0rsio	164	15	leflunomide	leflunomide	NN
cord-016476-78r0rsio	164	16	developed	develop	VBD
cord-016476-78r0rsio	164	17	rapid	rapid	JJ
cord-016476-78r0rsio	164	18	progression	progression	NN
cord-016476-78r0rsio	164	19	of	of	IN
cord-016476-78r0rsio	164	20	RA	RA	NNP
cord-016476-78r0rsio	164	21	-	-	HYPH
cord-016476-78r0rsio	164	22	ILD	ILD	NNP
cord-016476-78r0rsio	164	23	(	(	-LRB-
cord-016476-78r0rsio	164	24	known	know	VBN
cord-016476-78r0rsio	164	25	UIP	UIP	NNP
cord-016476-78r0rsio	164	26	preceding	precede	VBG
cord-016476-78r0rsio	164	27	treatment	treatment	NN
cord-016476-78r0rsio	164	28	)	)	-RRB-
cord-016476-78r0rsio	164	29	.	.	.
cord-016476-78r0rsio	165	1	The	the	DT
cord-016476-78r0rsio	165	2	fifth	fifth	JJ
cord-016476-78r0rsio	165	3	patient	patient	NN
cord-016476-78r0rsio	165	4	did	do	VBD
cord-016476-78r0rsio	165	5	not	not	RB
cord-016476-78r0rsio	165	6	have	have	VB
cord-016476-78r0rsio	165	7	a	a	DT
cord-016476-78r0rsio	165	8	history	history	NN
cord-016476-78r0rsio	165	9	of	of	IN
cord-016476-78r0rsio	165	10	lung	lung	NN
cord-016476-78r0rsio	165	11	disease	disease	NN
cord-016476-78r0rsio	165	12	pretreatment	pretreatment	NN
cord-016476-78r0rsio	165	13	and	and	CC
cord-016476-78r0rsio	165	14	,	,	,
cord-016476-78r0rsio	165	15	following	follow	VBG
cord-016476-78r0rsio	165	16	infliximab	infliximab	VBN
cord-016476-78r0rsio	165	17	,	,	,
cord-016476-78r0rsio	165	18	developed	develop	VBD
cord-016476-78r0rsio	165	19	nonfatal	nonfatal	JJ
cord-016476-78r0rsio	165	20	cryptogenic	cryptogenic	JJ
cord-016476-78r0rsio	165	21	organising	organise	VBG
cord-016476-78r0rsio	165	22	pneumonia	pneumonia	NN
cord-016476-78r0rsio	165	23	(	(	-LRB-
cord-016476-78r0rsio	165	24	COP	cop	NN
cord-016476-78r0rsio	165	25	or	or	CC
cord-016476-78r0rsio	165	26	bronchiolitis	bronchiolitis	NN
cord-016476-78r0rsio	165	27	obliterans	obliteran	NNS
cord-016476-78r0rsio	165	28	organising	organise	VBG
cord-016476-78r0rsio	165	29	pneumonia	pneumonia	NN
cord-016476-78r0rsio	165	30	[	[	-LRB-
cord-016476-78r0rsio	165	31	BOOP	BOOP	NNP
cord-016476-78r0rsio	165	32	]	]	-RRB-
cord-016476-78r0rsio	165	33	)	)	-RRB-
cord-016476-78r0rsio	166	1	[	[	-LRB-
cord-016476-78r0rsio	166	2	68	68	CD
cord-016476-78r0rsio	166	3	]	]	-RRB-
cord-016476-78r0rsio	166	4	.	.	.
cord-016476-78r0rsio	167	1	In	in	IN
cord-016476-78r0rsio	167	2	a	a	DT
cord-016476-78r0rsio	167	3	case	case	NN
cord-016476-78r0rsio	167	4	series	series	NN
cord-016476-78r0rsio	167	5	of	of	IN
cord-016476-78r0rsio	167	6	autoimmune	autoimmune	JJ
cord-016476-78r0rsio	167	7	diseases	disease	NNS
cord-016476-78r0rsio	167	8	associated	associate	VBN
cord-016476-78r0rsio	167	9	with	with	IN
cord-016476-78r0rsio	167	10	TNFi	TNFi	NNS
cord-016476-78r0rsio	167	11	,	,	,
cord-016476-78r0rsio	167	12	24/226	24/226	CD
cord-016476-78r0rsio	167	13	(	(	-LRB-
cord-016476-78r0rsio	167	14	~10	~10	CD
cord-016476-78r0rsio	167	15	%	%	NN
cord-016476-78r0rsio	167	16	)	)	-RRB-
cord-016476-78r0rsio	167	17	were	be	VBD
cord-016476-78r0rsio	167	18	reported	report	VBN
cord-016476-78r0rsio	167	19	to	to	TO
cord-016476-78r0rsio	167	20	develop	develop	VB
cord-016476-78r0rsio	167	21	ILD	ILD	NNP
cord-016476-78r0rsio	167	22	(	(	-LRB-
cord-016476-78r0rsio	167	23	interstitial	interstitial	JJ
cord-016476-78r0rsio	167	24	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	167	25	in	in	IN
cord-016476-78r0rsio	167	26	18	18	CD
cord-016476-78r0rsio	167	27	patients	patient	NNS
cord-016476-78r0rsio	167	28	,	,	,
cord-016476-78r0rsio	167	29	sarcoidosis	sarcoidosis	NN
cord-016476-78r0rsio	167	30	in	in	IN
cord-016476-78r0rsio	167	31	three	three	CD
cord-016476-78r0rsio	167	32	,	,	,
cord-016476-78r0rsio	167	33	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	167	34	haemorrhage	haemorrhage	NN
cord-016476-78r0rsio	167	35	in	in	IN
cord-016476-78r0rsio	167	36	two	two	CD
cord-016476-78r0rsio	167	37	and	and	CC
cord-016476-78r0rsio	167	38	BOOP	boop	NN
cord-016476-78r0rsio	167	39	in	in	IN
cord-016476-78r0rsio	167	40	one	one	CD
cord-016476-78r0rsio	167	41	patient	patient	NN
cord-016476-78r0rsio	167	42	)	)	-RRB-
cord-016476-78r0rsio	167	43	[	[	-LRB-
cord-016476-78r0rsio	167	44	49	49	CD
cord-016476-78r0rsio	167	45	]	]	-RRB-
cord-016476-78r0rsio	167	46	.	.	.
cord-016476-78r0rsio	168	1	Exacerbation	exacerbation	NN
cord-016476-78r0rsio	168	2	of	of	IN
cord-016476-78r0rsio	168	3	previous	previous	JJ
cord-016476-78r0rsio	168	4	ILD	ILD	NNP
cord-016476-78r0rsio	168	5	was	be	VBD
cord-016476-78r0rsio	168	6	reported	report	VBN
cord-016476-78r0rsio	168	7	in	in	IN
cord-016476-78r0rsio	168	8	four	four	CD
cord-016476-78r0rsio	168	9	patients	patient	NNS
cord-016476-78r0rsio	168	10	.	.	.
cord-016476-78r0rsio	169	1	Perez	Perez	NNP
cord-016476-78r0rsio	169	2	-	-	HYPH
cord-016476-78r0rsio	169	3	Alvarez	Alvarez	NNP
cord-016476-78r0rsio	169	4	et	et	NNP
cord-016476-78r0rsio	169	5	al	al	NNP
cord-016476-78r0rsio	169	6	.	.	.
cord-016476-78r0rsio	170	1	described	describe	VBD
cord-016476-78r0rsio	170	2	a	a	DT
cord-016476-78r0rsio	170	3	further	further	JJ
cord-016476-78r0rsio	170	4	series	series	NN
cord-016476-78r0rsio	170	5	of	of	IN
cord-016476-78r0rsio	170	6	122	122	CD
cord-016476-78r0rsio	170	7	patient	patient	NN
cord-016476-78r0rsio	170	8	case	case	NN
cord-016476-78r0rsio	170	9	reports	report	VBZ
cord-016476-78r0rsio	170	10	from	from	IN
cord-016476-78r0rsio	170	11	the	the	DT
cord-016476-78r0rsio	170	12	literature	literature	NN
cord-016476-78r0rsio	170	13	(	(	-LRB-
cord-016476-78r0rsio	170	14	89	89	CD
cord-016476-78r0rsio	170	15	%	%	NN
cord-016476-78r0rsio	170	16	with	with	IN
cord-016476-78r0rsio	170	17	RA	RA	NNP
cord-016476-78r0rsio	170	18	)	)	-RRB-
cord-016476-78r0rsio	170	19	,	,	,
cord-016476-78r0rsio	170	20	with	with	IN
cord-016476-78r0rsio	170	21	incident	incident	NN
cord-016476-78r0rsio	170	22	ILD	ILD	NNP
cord-016476-78r0rsio	170	23	or	or	CC
cord-016476-78r0rsio	170	24	exacerbation	exacerbation	NN
cord-016476-78r0rsio	170	25	of	of	IN
cord-016476-78r0rsio	170	26	pre	pre	JJ
cord-016476-78r0rsio	170	27	-	-	JJ
cord-016476-78r0rsio	170	28	existing	existing	JJ
cord-016476-78r0rsio	170	29	ILD	ILD	NNP
cord-016476-78r0rsio	170	30	(	(	-LRB-
cord-016476-78r0rsio	170	31	20	20	CD
cord-016476-78r0rsio	170	32	patients	patient	NNS
cord-016476-78r0rsio	170	33	,	,	,
cord-016476-78r0rsio	170	34	38	38	CD
cord-016476-78r0rsio	170	35	%	%	NN
cord-016476-78r0rsio	170	36	)	)	-RRB-
cord-016476-78r0rsio	170	37	[	[	-LRB-
cord-016476-78r0rsio	170	38	69	69	CD
cord-016476-78r0rsio	170	39	]	]	-RRB-
cord-016476-78r0rsio	170	40	.	.	.
cord-016476-78r0rsio	171	1	The	the	DT
cord-016476-78r0rsio	171	2	outcome	outcome	NN
cord-016476-78r0rsio	171	3	was	be	VBD
cord-016476-78r0rsio	171	4	available	available	JJ
cord-016476-78r0rsio	171	5	in	in	IN
cord-016476-78r0rsio	171	6	52	52	CD
cord-016476-78r0rsio	171	7	of	of	IN
cord-016476-78r0rsio	171	8	the	the	DT
cord-016476-78r0rsio	171	9	described	describe	VBN
cord-016476-78r0rsio	171	10	cases	case	NNS
cord-016476-78r0rsio	171	11	:	:	:
cord-016476-78r0rsio	171	12	21	21	CD
cord-016476-78r0rsio	171	13	(	(	-LRB-
cord-016476-78r0rsio	171	14	40	40	CD
cord-016476-78r0rsio	171	15	%	%	NN
cord-016476-78r0rsio	171	16	)	)	-RRB-
cord-016476-78r0rsio	171	17	had	have	VBD
cord-016476-78r0rsio	171	18	complete	complete	JJ
cord-016476-78r0rsio	171	19	resolution	resolution	NN
cord-016476-78r0rsio	171	20	,	,	,
cord-016476-78r0rsio	171	21	improvement	improvement	NN
cord-016476-78r0rsio	171	22	or	or	CC
cord-016476-78r0rsio	171	23	partial	partial	JJ
cord-016476-78r0rsio	171	24	resolution	resolution	NN
cord-016476-78r0rsio	171	25	in	in	IN
cord-016476-78r0rsio	171	26	13	13	CD
cord-016476-78r0rsio	171	27	(	(	-LRB-
cord-016476-78r0rsio	171	28	25	25	CD
cord-016476-78r0rsio	171	29	%	%	NN
cord-016476-78r0rsio	171	30	)	)	-RRB-
cord-016476-78r0rsio	171	31	and	and	CC
cord-016476-78r0rsio	171	32	no	no	DT
cord-016476-78r0rsio	171	33	resolution	resolution	NN
cord-016476-78r0rsio	171	34	reported	report	VBN
cord-016476-78r0rsio	171	35	in	in	IN
cord-016476-78r0rsio	171	36	18	18	CD
cord-016476-78r0rsio	171	37	(	(	-LRB-
cord-016476-78r0rsio	171	38	35	35	CD
cord-016476-78r0rsio	171	39	%	%	NN
cord-016476-78r0rsio	171	40	)	)	-RRB-
cord-016476-78r0rsio	171	41	.	.	.
cord-016476-78r0rsio	172	1	Case	case	NN
cord-016476-78r0rsio	172	2	reports	report	NNS
cord-016476-78r0rsio	172	3	of	of	IN
cord-016476-78r0rsio	172	4	incident	incident	NN
cord-016476-78r0rsio	172	5	ILD	ILD	NNP
cord-016476-78r0rsio	172	6	have	have	VBP
cord-016476-78r0rsio	172	7	been	be	VBN
cord-016476-78r0rsio	172	8	reported	report	VBN
cord-016476-78r0rsio	172	9	with	with	IN
cord-016476-78r0rsio	172	10	newer	new	JJR
cord-016476-78r0rsio	172	11	TNFis	tnfis	NN
cord-016476-78r0rsio	172	12	such	such	JJ
cord-016476-78r0rsio	172	13	as	as	IN
cord-016476-78r0rsio	172	14	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	172	15	[	[	-LRB-
cord-016476-78r0rsio	172	16	70	70	CD
cord-016476-78r0rsio	172	17	]	]	-RRB-
cord-016476-78r0rsio	172	18	[	[	-LRB-
cord-016476-78r0rsio	172	19	71	71	CD
cord-016476-78r0rsio	172	20	]	]	-RRB-
cord-016476-78r0rsio	172	21	[	[	-LRB-
cord-016476-78r0rsio	172	22	72	72	CD
cord-016476-78r0rsio	172	23	]	]	-RRB-
cord-016476-78r0rsio	172	24	[	[	-LRB-
cord-016476-78r0rsio	172	25	73	73	CD
cord-016476-78r0rsio	172	26	]	]	-RRB-
cord-016476-78r0rsio	172	27	and	and	CC
cord-016476-78r0rsio	172	28	golimumab	golimumab	NNS
cord-016476-78r0rsio	172	29	[	[	-LRB-
cord-016476-78r0rsio	172	30	74	74	CD
cord-016476-78r0rsio	172	31	]	]	-RRB-
cord-016476-78r0rsio	172	32	,	,	,
cord-016476-78r0rsio	172	33	including	include	VBG
cord-016476-78r0rsio	172	34	possible	possible	JJ
cord-016476-78r0rsio	172	35	deterioration	deterioration	NN
cord-016476-78r0rsio	172	36	of	of	IN
cord-016476-78r0rsio	172	37	pre	pre	JJ
cord-016476-78r0rsio	172	38	-	-	JJ
cord-016476-78r0rsio	172	39	existing	existing	JJ
cord-016476-78r0rsio	172	40	ILD	ILD	NNP
cord-016476-78r0rsio	172	41	in	in	IN
cord-016476-78r0rsio	172	42	a	a	DT
cord-016476-78r0rsio	172	43	patient	patient	NN
cord-016476-78r0rsio	172	44	with	with	IN
cord-016476-78r0rsio	172	45	RA	RA	NNP
cord-016476-78r0rsio	172	46	treated	treat	VBN
cord-016476-78r0rsio	172	47	with	with	IN
cord-016476-78r0rsio	172	48	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	172	49	and	and	CC
cord-016476-78r0rsio	172	50	leflunomide	leflunomide	NN
cord-016476-78r0rsio	172	51	after	after	IN
cord-016476-78r0rsio	172	52	3	3	CD
cord-016476-78r0rsio	172	53	months	month	NNS
cord-016476-78r0rsio	172	54	of	of	IN
cord-016476-78r0rsio	172	55	therapy	therapy	NN
cord-016476-78r0rsio	172	56	[	[	-LRB-
cord-016476-78r0rsio	172	57	75	75	CD
cord-016476-78r0rsio	172	58	]	]	-RRB-
cord-016476-78r0rsio	172	59	.	.	.
cord-016476-78r0rsio	173	1	Whilst	whilst	IN
cord-016476-78r0rsio	173	2	the	the	DT
cord-016476-78r0rsio	173	3	temporal	temporal	NNP
cord-016476-78r0rsio	173	4	association	association	NN
cord-016476-78r0rsio	173	5	with	with	IN
cord-016476-78r0rsio	173	6	onset	onset	NN
cord-016476-78r0rsio	173	7	of	of	IN
cord-016476-78r0rsio	173	8	ILD	ILD	NNP
cord-016476-78r0rsio	173	9	and	and	CC
cord-016476-78r0rsio	173	10	repeated	repeat	VBD
cord-016476-78r0rsio	173	11	reporting	reporting	NN
cord-016476-78r0rsio	173	12	of	of	IN
cord-016476-78r0rsio	173	13	such	such	JJ
cord-016476-78r0rsio	173	14	events	event	NNS
cord-016476-78r0rsio	173	15	provides	provide	VBZ
cord-016476-78r0rsio	173	16	a	a	DT
cord-016476-78r0rsio	173	17	signal	signal	NN
cord-016476-78r0rsio	173	18	of	of	IN
cord-016476-78r0rsio	173	19	concern	concern	NN
cord-016476-78r0rsio	173	20	,	,	,
cord-016476-78r0rsio	173	21	the	the	DT
cord-016476-78r0rsio	173	22	interpretation	interpretation	NN
cord-016476-78r0rsio	173	23	of	of	IN
cord-016476-78r0rsio	173	24	such	such	JJ
cord-016476-78r0rsio	173	25	data	datum	NNS
cord-016476-78r0rsio	173	26	for	for	IN
cord-016476-78r0rsio	173	27	extrapolation	extrapolation	NN
cord-016476-78r0rsio	173	28	into	into	IN
cord-016476-78r0rsio	173	29	clinical	clinical	JJ
cord-016476-78r0rsio	173	30	practice	practice	NN
cord-016476-78r0rsio	173	31	is	be	VBZ
cord-016476-78r0rsio	173	32	limited	limit	VBN
cord-016476-78r0rsio	173	33	by	by	IN
cord-016476-78r0rsio	173	34	a	a	DT
cord-016476-78r0rsio	173	35	likely	likely	JJ
cord-016476-78r0rsio	173	36	reporting	reporting	NN
cord-016476-78r0rsio	173	37	bias	bias	NN
cord-016476-78r0rsio	173	38	,	,	,
cord-016476-78r0rsio	173	39	a	a	DT
cord-016476-78r0rsio	173	40	possible	possible	JJ
cord-016476-78r0rsio	173	41	'	'	``
cord-016476-78r0rsio	173	42	bandwagon	bandwagon	NN
cord-016476-78r0rsio	173	43	'	'	''
cord-016476-78r0rsio	173	44	effect	effect	NN
cord-016476-78r0rsio	173	45	(	(	-LRB-
cord-016476-78r0rsio	173	46	a	a	DT
cord-016476-78r0rsio	173	47	phenomenon	phenomenon	NN
cord-016476-78r0rsio	173	48	where	where	WRB
cord-016476-78r0rsio	173	49	following	follow	VBG
cord-016476-78r0rsio	173	50	the	the	DT
cord-016476-78r0rsio	173	51	publication	publication	NN
cord-016476-78r0rsio	173	52	of	of	IN
cord-016476-78r0rsio	173	53	an	an	DT
cord-016476-78r0rsio	173	54	index	index	NN
cord-016476-78r0rsio	173	55	case	case	NN
cord-016476-78r0rsio	173	56	,	,	,
cord-016476-78r0rsio	173	57	further	further	JJ
cord-016476-78r0rsio	173	58	cases	case	NNS
cord-016476-78r0rsio	173	59	are	be	VBP
cord-016476-78r0rsio	173	60	consequently	consequently	RB
cord-016476-78r0rsio	173	61	more	more	RBR
cord-016476-78r0rsio	173	62	likely	likely	JJ
cord-016476-78r0rsio	173	63	to	to	TO
cord-016476-78r0rsio	173	64	be	be	VB
cord-016476-78r0rsio	173	65	reported	report	VBN
cord-016476-78r0rsio	173	66	)	)	-RRB-
cord-016476-78r0rsio	173	67	,	,	,
cord-016476-78r0rsio	173	68	and	and	CC
cord-016476-78r0rsio	173	69	lack	lack	NN
cord-016476-78r0rsio	173	70	of	of	IN
cord-016476-78r0rsio	173	71	an	an	DT
cord-016476-78r0rsio	173	72	adequate	adequate	JJ
cord-016476-78r0rsio	173	73	denominator	denominator	NN
cord-016476-78r0rsio	173	74	.	.	.
cord-016476-78r0rsio	174	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	174	2	,	,	,
cord-016476-78r0rsio	174	3	reports	report	NNS
cord-016476-78r0rsio	174	4	of	of	IN
cord-016476-78r0rsio	174	5	stabilisation	stabilisation	NN
cord-016476-78r0rsio	174	6	of	of	IN
cord-016476-78r0rsio	174	7	RA	RA	NNP
cord-016476-78r0rsio	174	8	-	-	HYPH
cord-016476-78r0rsio	174	9	ILD	ILD	NNP
cord-016476-78r0rsio	174	10	in	in	IN
cord-016476-78r0rsio	174	11	patients	patient	NNS
cord-016476-78r0rsio	174	12	exposed	expose	VBN
cord-016476-78r0rsio	174	13	to	to	IN
cord-016476-78r0rsio	174	14	TNFi	TNFi	NNS
cord-016476-78r0rsio	174	15	therapy	therapy	NN
cord-016476-78r0rsio	174	16	have	have	VBP
cord-016476-78r0rsio	174	17	also	also	RB
cord-016476-78r0rsio	174	18	been	be	VBN
cord-016476-78r0rsio	174	19	published	publish	VBN
cord-016476-78r0rsio	174	20	[	[	-LRB-
cord-016476-78r0rsio	174	21	76	76	CD
cord-016476-78r0rsio	174	22	]	]	-RRB-
cord-016476-78r0rsio	174	23	[	[	-LRB-
cord-016476-78r0rsio	174	24	77	77	CD
cord-016476-78r0rsio	174	25	]	]	-RRB-
cord-016476-78r0rsio	174	26	[	[	-LRB-
cord-016476-78r0rsio	174	27	78	78	CD
cord-016476-78r0rsio	174	28	]	]	-RRB-
cord-016476-78r0rsio	174	29	,	,	,
cord-016476-78r0rsio	174	30	suggesting	suggest	VBG
cord-016476-78r0rsio	174	31	a	a	DT
cord-016476-78r0rsio	174	32	further	further	JJ
cord-016476-78r0rsio	174	33	bidirectional	bidirectional	JJ
cord-016476-78r0rsio	174	34	influence	influence	NN
cord-016476-78r0rsio	174	35	of	of	IN
cord-016476-78r0rsio	174	36	TNFi	TNFi	NNS
cord-016476-78r0rsio	174	37	on	on	IN
cord-016476-78r0rsio	174	38	ILD	ILD	NNP
cord-016476-78r0rsio	174	39	.	.	.
cord-016476-78r0rsio	175	1	To	to	TO
cord-016476-78r0rsio	175	2	accurately	accurately	RB
cord-016476-78r0rsio	175	3	evaluate	evaluate	VB
cord-016476-78r0rsio	175	4	the	the	DT
cord-016476-78r0rsio	175	5	risk	risk	NN
cord-016476-78r0rsio	175	6	of	of	IN
cord-016476-78r0rsio	175	7	incident	incident	NN
cord-016476-78r0rsio	175	8	ILD	ILD	NNP
cord-016476-78r0rsio	175	9	or	or	CC
cord-016476-78r0rsio	175	10	exacerbation	exacerbation	NN
cord-016476-78r0rsio	175	11	in	in	IN
cord-016476-78r0rsio	175	12	patients	patient	NNS
cord-016476-78r0rsio	175	13	with	with	IN
cord-016476-78r0rsio	175	14	RA	RA	NNP
cord-016476-78r0rsio	175	15	-	-	HYPH
cord-016476-78r0rsio	175	16	ILD	ILD	NNP
cord-016476-78r0rsio	175	17	on	on	IN
cord-016476-78r0rsio	175	18	TNFi	TNFi	NNS
cord-016476-78r0rsio	175	19	in	in	IN
cord-016476-78r0rsio	175	20	patients	patient	NNS
cord-016476-78r0rsio	175	21	who	who	WP
cord-016476-78r0rsio	175	22	are	be	VBP
cord-016476-78r0rsio	175	23	most	most	RBS
cord-016476-78r0rsio	175	24	likely	likely	JJ
cord-016476-78r0rsio	175	25	to	to	TO
cord-016476-78r0rsio	175	26	receive	receive	VB
cord-016476-78r0rsio	175	27	them	-PRON-	PRP
cord-016476-78r0rsio	175	28	in	in	IN
cord-016476-78r0rsio	175	29	the	the	DT
cord-016476-78r0rsio	175	30	real	real	JJ
cord-016476-78r0rsio	175	31	world	world	NN
cord-016476-78r0rsio	175	32	,	,	,
cord-016476-78r0rsio	175	33	observational	observational	JJ
cord-016476-78r0rsio	175	34	studies	study	NNS
cord-016476-78r0rsio	175	35	offer	offer	VBP
cord-016476-78r0rsio	175	36	the	the	DT
cord-016476-78r0rsio	175	37	best	good	JJS
cord-016476-78r0rsio	175	38	design	design	NN
cord-016476-78r0rsio	175	39	to	to	TO
cord-016476-78r0rsio	175	40	examine	examine	VB
cord-016476-78r0rsio	175	41	rare	rare	JJ
cord-016476-78r0rsio	175	42	outcomes	outcome	NNS
cord-016476-78r0rsio	175	43	.	.	.
cord-016476-78r0rsio	176	1	However	however	RB
cord-016476-78r0rsio	176	2	all	all	DT
cord-016476-78r0rsio	176	3	studies	study	NNS
cord-016476-78r0rsio	176	4	evaluating	evaluate	VBG
cord-016476-78r0rsio	176	5	such	such	JJ
cord-016476-78r0rsio	176	6	events	event	NNS
cord-016476-78r0rsio	176	7	have	have	VBP
cord-016476-78r0rsio	176	8	faced	face	VBN
cord-016476-78r0rsio	176	9	methodological	methodological	JJ
cord-016476-78r0rsio	176	10	issues	issue	NNS
cord-016476-78r0rsio	176	11	,	,	,
cord-016476-78r0rsio	176	12	namely	namely	RB
cord-016476-78r0rsio	176	13	,	,	,
cord-016476-78r0rsio	176	14	with	with	IN
cord-016476-78r0rsio	176	15	channelling	channel	VBG
cord-016476-78r0rsio	176	16	bias	bias	NN
cord-016476-78r0rsio	176	17	and	and	CC
cord-016476-78r0rsio	176	18	challenges	challenge	NNS
cord-016476-78r0rsio	176	19	with	with	IN
cord-016476-78r0rsio	176	20	classification	classification	NN
cord-016476-78r0rsio	176	21	.	.	.
cord-016476-78r0rsio	177	1	Using	use	VBG
cord-016476-78r0rsio	177	2	the	the	DT
cord-016476-78r0rsio	177	3	National	National	NNP
cord-016476-78r0rsio	177	4	Databank	Databank	NNP
cord-016476-78r0rsio	177	5	for	for	IN
cord-016476-78r0rsio	177	6	Rheumatic	rheumatic	JJ
cord-016476-78r0rsio	177	7	Diseases	Diseases	NNPS
cord-016476-78r0rsio	177	8	,	,	,
cord-016476-78r0rsio	177	9	Wolfe	Wolfe	NNP
cord-016476-78r0rsio	177	10	et	et	NNP
cord-016476-78r0rsio	177	11	al	al	NNP
cord-016476-78r0rsio	177	12	.	.	NNP
cord-016476-78r0rsio	177	13	used	use	VBD
cord-016476-78r0rsio	177	14	a	a	DT
cord-016476-78r0rsio	177	15	combination	combination	NN
cord-016476-78r0rsio	177	16	of	of	IN
cord-016476-78r0rsio	177	17	hospital	hospital	NN
cord-016476-78r0rsio	177	18	records	record	NNS
cord-016476-78r0rsio	177	19	,	,	,
cord-016476-78r0rsio	177	20	patient	patient	JJ
cord-016476-78r0rsio	177	21	descriptive	descriptive	JJ
cord-016476-78r0rsio	177	22	reports	report	NNS
cord-016476-78r0rsio	177	23	and	and	CC
cord-016476-78r0rsio	177	24	physician	physician	NN
cord-016476-78r0rsio	177	25	and	and	CC
cord-016476-78r0rsio	177	26	mortality	mortality	NN
cord-016476-78r0rsio	177	27	records	record	NNS
cord-016476-78r0rsio	177	28	to	to	TO
cord-016476-78r0rsio	177	29	classify	classify	VB
cord-016476-78r0rsio	177	30	patients	patient	NNS
cord-016476-78r0rsio	177	31	who	who	WP
cord-016476-78r0rsio	177	32	had	have	VBD
cord-016476-78r0rsio	177	33	severe	severe	JJ
cord-016476-78r0rsio	177	34	RA	RA	NNP
cord-016476-78r0rsio	177	35	-	-	HYPH
cord-016476-78r0rsio	177	36	ILD	ILD	NNP
cord-016476-78r0rsio	177	37	(	(	-LRB-
cord-016476-78r0rsio	177	38	requiring	require	VBG
cord-016476-78r0rsio	177	39	hospitalisation	hospitalisation	NN
cord-016476-78r0rsio	177	40	or	or	CC
cord-016476-78r0rsio	177	41	who	who	WP
cord-016476-78r0rsio	177	42	died	die	VBD
cord-016476-78r0rsio	177	43	)	)	-RRB-
cord-016476-78r0rsio	177	44	[	[	-LRB-
cord-016476-78r0rsio	177	45	79	79	CD
cord-016476-78r0rsio	177	46	]	]	-RRB-
cord-016476-78r0rsio	177	47	.	.	.
cord-016476-78r0rsio	178	1	They	-PRON-	PRP
cord-016476-78r0rsio	178	2	reported	report	VBD
cord-016476-78r0rsio	178	3	a	a	DT
cord-016476-78r0rsio	178	4	significant	significant	JJ
cord-016476-78r0rsio	178	5	association	association	NN
cord-016476-78r0rsio	178	6	with	with	IN
cord-016476-78r0rsio	178	7	previous	previous	JJ
cord-016476-78r0rsio	178	8	use	use	NN
cord-016476-78r0rsio	178	9	of	of	IN
cord-016476-78r0rsio	178	10	infliximab	infliximab	FW
cord-016476-78r0rsio	178	11	(	(	-LRB-
cord-016476-78r0rsio	178	12	HR	HR	NNP
cord-016476-78r0rsio	178	13	2.1	2.1	CD
cord-016476-78r0rsio	178	14	,	,	,
cord-016476-78r0rsio	178	15	95	95	CD
cord-016476-78r0rsio	178	16	%	%	NN
cord-016476-78r0rsio	178	17	CI	CI	NNP
cord-016476-78r0rsio	178	18	1.1	1.1	CD
cord-016476-78r0rsio	178	19	-	-	HYPH
cord-016476-78r0rsio	178	20	3.8	3.8	CD
cord-016476-78r0rsio	178	21	)	)	-RRB-
cord-016476-78r0rsio	178	22	and	and	CC
cord-016476-78r0rsio	178	23	etanercept	etanercept	NNP
cord-016476-78r0rsio	178	24	(	(	-LRB-
cord-016476-78r0rsio	178	25	HR	HR	NNP
cord-016476-78r0rsio	178	26	1.7	1.7	CD
cord-016476-78r0rsio	178	27	,	,	,
cord-016476-78r0rsio	178	28	95	95	CD
cord-016476-78r0rsio	178	29	%	%	NN
cord-016476-78r0rsio	178	30	CI	CI	NNP
cord-016476-78r0rsio	178	31	1.0	1.0	CD
cord-016476-78r0rsio	178	32	-	-	HYPH
cord-016476-78r0rsio	178	33	3.0	3.0	CD
cord-016476-78r0rsio	178	34	)	)	-RRB-
cord-016476-78r0rsio	178	35	.	.	.
cord-016476-78r0rsio	179	1	However	however	RB
cord-016476-78r0rsio	179	2	the	the	DT
cord-016476-78r0rsio	179	3	study	study	NN
cord-016476-78r0rsio	179	4	was	be	VBD
cord-016476-78r0rsio	179	5	confounded	confound	VBN
cord-016476-78r0rsio	179	6	by	by	IN
cord-016476-78r0rsio	179	7	the	the	DT
cord-016476-78r0rsio	179	8	fact	fact	NN
cord-016476-78r0rsio	179	9	that	that	IN
cord-016476-78r0rsio	179	10	physicians	physician	NNS
cord-016476-78r0rsio	179	11	were	be	VBD
cord-016476-78r0rsio	179	12	,	,	,
cord-016476-78r0rsio	179	13	at	at	IN
cord-016476-78r0rsio	179	14	the	the	DT
cord-016476-78r0rsio	179	15	time	time	NN
cord-016476-78r0rsio	179	16	,	,	,
cord-016476-78r0rsio	179	17	prescribing	prescribe	VBG
cord-016476-78r0rsio	179	18	TNFis	tnfis	NN
cord-016476-78r0rsio	179	19	for	for	IN
cord-016476-78r0rsio	179	20	treatment	treatment	NN
cord-016476-78r0rsio	179	21	of	of	IN
cord-016476-78r0rsio	179	22	RA	RA	NNP
cord-016476-78r0rsio	179	23	-	-	HYPH
cord-016476-78r0rsio	179	24	ILD	ILD	NNP
cord-016476-78r0rsio	179	25	,	,	,
cord-016476-78r0rsio	179	26	possibly	possibly	RB
cord-016476-78r0rsio	179	27	accounting	account	VBG
cord-016476-78r0rsio	179	28	for	for	IN
cord-016476-78r0rsio	179	29	such	such	PDT
cord-016476-78r0rsio	179	30	an	an	DT
cord-016476-78r0rsio	179	31	association	association	NN
cord-016476-78r0rsio	179	32	.	.	.
cord-016476-78r0rsio	180	1	The	the	DT
cord-016476-78r0rsio	180	2	incidence	incidence	NN
cord-016476-78r0rsio	180	3	of	of	IN
cord-016476-78r0rsio	180	4	hospitalisation	hospitalisation	NN
cord-016476-78r0rsio	180	5	for	for	IN
cord-016476-78r0rsio	180	6	ILD	ILD	NNP
cord-016476-78r0rsio	180	7	requiring	require	VBG
cord-016476-78r0rsio	180	8	hospitalisation	hospitalisation	NN
cord-016476-78r0rsio	180	9	was	be	VBD
cord-016476-78r0rsio	180	10	reported	report	VBN
cord-016476-78r0rsio	180	11	260	260	CD
cord-016476-78r0rsio	180	12	per	per	IN
cord-016476-78r0rsio	180	13	100,000	100,000	CD
cord-016476-78r0rsio	180	14	patient	patient	NN
cord-016476-78r0rsio	180	15	-	-	HYPH
cord-016476-78r0rsio	180	16	years	year	NNS
cord-016476-78r0rsio	180	17	with	with	IN
cord-016476-78r0rsio	180	18	a	a	DT
cord-016476-78r0rsio	180	19	27	27	CD
cord-016476-78r0rsio	180	20	%	%	NN
cord-016476-78r0rsio	180	21	mortality	mortality	NN
cord-016476-78r0rsio	180	22	,	,	,
cord-016476-78r0rsio	180	23	likely	likely	RB
cord-016476-78r0rsio	180	24	reflecting	reflect	VBG
cord-016476-78r0rsio	180	25	the	the	DT
cord-016476-78r0rsio	180	26	types	type	NNS
cord-016476-78r0rsio	180	27	of	of	IN
cord-016476-78r0rsio	180	28	patients	patient	NNS
cord-016476-78r0rsio	180	29	included	include	VBN
cord-016476-78r0rsio	180	30	in	in	IN
cord-016476-78r0rsio	180	31	this	this	DT
cord-016476-78r0rsio	180	32	analysis	analysis	NN
cord-016476-78r0rsio	180	33	.	.	.
cord-016476-78r0rsio	181	1	Whilst	whilst	IN
cord-016476-78r0rsio	181	2	the	the	DT
cord-016476-78r0rsio	181	3	authors	author	NNS
cord-016476-78r0rsio	181	4	concluded	conclude	VBD
cord-016476-78r0rsio	181	5	that	that	IN
cord-016476-78r0rsio	181	6	there	there	EX
cord-016476-78r0rsio	181	7	was	be	VBD
cord-016476-78r0rsio	181	8	no	no	DT
cord-016476-78r0rsio	181	9	evidence	evidence	NN
cord-016476-78r0rsio	181	10	of	of	IN
cord-016476-78r0rsio	181	11	an	an	DT
cord-016476-78r0rsio	181	12	association	association	NN
cord-016476-78r0rsio	181	13	between	between	IN
cord-016476-78r0rsio	181	14	TNFi	TNFi	NNP
cord-016476-78r0rsio	181	15	and	and	CC
cord-016476-78r0rsio	181	16	hospitalisation	hospitalisation	NN
cord-016476-78r0rsio	181	17	for	for	IN
cord-016476-78r0rsio	181	18	ILD	ILD	NNP
cord-016476-78r0rsio	181	19	as	as	IN
cord-016476-78r0rsio	181	20	the	the	DT
cord-016476-78r0rsio	181	21	observed	observed	JJ
cord-016476-78r0rsio	181	22	effect	effect	NN
cord-016476-78r0rsio	181	23	with	with	IN
cord-016476-78r0rsio	181	24	TNFi	TNFi	NNS
cord-016476-78r0rsio	181	25	was	be	VBD
cord-016476-78r0rsio	181	26	likely	likely	JJ
cord-016476-78r0rsio	181	27	to	to	TO
cord-016476-78r0rsio	181	28	be	be	VB
cord-016476-78r0rsio	181	29	due	due	JJ
cord-016476-78r0rsio	181	30	to	to	IN
cord-016476-78r0rsio	181	31	confounding	confound	VBG
cord-016476-78r0rsio	181	32	by	by	IN
cord-016476-78r0rsio	181	33	indication	indication	NN
cord-016476-78r0rsio	181	34	,	,	,
cord-016476-78r0rsio	181	35	the	the	DT
cord-016476-78r0rsio	181	36	specific	specific	JJ
cord-016476-78r0rsio	181	37	effect	effect	NN
cord-016476-78r0rsio	181	38	of	of	IN
cord-016476-78r0rsio	181	39	TNFi	TNFi	NNS
cord-016476-78r0rsio	181	40	on	on	IN
cord-016476-78r0rsio	181	41	patients	patient	NNS
cord-016476-78r0rsio	181	42	with	with	IN
cord-016476-78r0rsio	181	43	RA	RA	NNP
cord-016476-78r0rsio	181	44	-	-	HYPH
cord-016476-78r0rsio	181	45	ILD	ILD	NNP
cord-016476-78r0rsio	181	46	at	at	IN
cord-016476-78r0rsio	181	47	baseline	baseline	NN
cord-016476-78r0rsio	181	48	was	be	VBD
cord-016476-78r0rsio	181	49	not	not	RB
cord-016476-78r0rsio	181	50	assessed	assess	VBN
cord-016476-78r0rsio	181	51	[	[	-LRB-
cord-016476-78r0rsio	181	52	79	79	CD
cord-016476-78r0rsio	181	53	]	]	-RRB-
cord-016476-78r0rsio	181	54	.	.	.
cord-016476-78r0rsio	182	1	Two	two	CD
cord-016476-78r0rsio	182	2	claims	claim	NNS
cord-016476-78r0rsio	182	3	database	database	NN
cord-016476-78r0rsio	182	4	studies	study	NNS
cord-016476-78r0rsio	182	5	have	have	VBP
cord-016476-78r0rsio	182	6	evaluated	evaluate	VBN
cord-016476-78r0rsio	182	7	ILD	ILD	NNP
cord-016476-78r0rsio	182	8	incidence	incidence	NN
cord-016476-78r0rsio	182	9	in	in	IN
cord-016476-78r0rsio	182	10	patients	patient	NNS
cord-016476-78r0rsio	182	11	treated	treat	VBN
cord-016476-78r0rsio	182	12	with	with	IN
cord-016476-78r0rsio	182	13	biologics	biologic	NNS
cord-016476-78r0rsio	182	14	including	include	VBG
cord-016476-78r0rsio	182	15	TNFis	tnfis	VBP
cord-016476-78r0rsio	182	16	.	.	.
cord-016476-78r0rsio	183	1	To	to	TO
cord-016476-78r0rsio	183	2	assess	assess	VB
cord-016476-78r0rsio	183	3	the	the	DT
cord-016476-78r0rsio	183	4	risk	risk	NN
cord-016476-78r0rsio	183	5	of	of	IN
cord-016476-78r0rsio	183	6	incident	incident	NN
cord-016476-78r0rsio	183	7	ILD	ILD	NNP
cord-016476-78r0rsio	183	8	in	in	IN
cord-016476-78r0rsio	183	9	8417	8417	CD
cord-016476-78r0rsio	183	10	patients	patient	NNS
cord-016476-78r0rsio	183	11	with	with	IN
cord-016476-78r0rsio	183	12	autoimmune	autoimmune	JJ
cord-016476-78r0rsio	183	13	diseases	disease	NNS
cord-016476-78r0rsio	183	14	who	who	WP
cord-016476-78r0rsio	183	15	were	be	VBD
cord-016476-78r0rsio	183	16	members	member	NNS
cord-016476-78r0rsio	183	17	of	of	IN
cord-016476-78r0rsio	183	18	Kaiser	Kaiser	NNP
cord-016476-78r0rsio	183	19	Permanente	Permanente	NNP
cord-016476-78r0rsio	183	20	,	,	,
cord-016476-78r0rsio	183	21	Northern	Northern	NNP
cord-016476-78r0rsio	183	22	California	California	NNP
cord-016476-78r0rsio	183	23	,	,	,
cord-016476-78r0rsio	183	24	Herrington	Herrington	NNP
cord-016476-78r0rsio	183	25	and	and	CC
cord-016476-78r0rsio	183	26	colleagues	colleague	NNS
cord-016476-78r0rsio	183	27	compared	compare	VBD
cord-016476-78r0rsio	183	28	new	new	JJ
cord-016476-78r0rsio	183	29	users	user	NNS
cord-016476-78r0rsio	183	30	of	of	IN
cord-016476-78r0rsio	183	31	TNFi	TNFi	NNS
cord-016476-78r0rsio	183	32	and	and	CC
cord-016476-78r0rsio	183	33	nbD	nbd	NN
cord-016476-78r0rsio	183	34	-	-	HYPH
cord-016476-78r0rsio	183	35	MARDs	mard	NNS
cord-016476-78r0rsio	183	36	[	[	-LRB-
cord-016476-78r0rsio	183	37	80	80	CD
cord-016476-78r0rsio	183	38	]	]	-RRB-
cord-016476-78r0rsio	183	39	.	.	.
cord-016476-78r0rsio	184	1	ILD	ILD	NNP
cord-016476-78r0rsio	184	2	cases	case	NNS
cord-016476-78r0rsio	184	3	were	be	VBD
cord-016476-78r0rsio	184	4	identified	identify	VBN
cord-016476-78r0rsio	184	5	using	use	VBG
cord-016476-78r0rsio	184	6	ICD	ICD	NNP
cord-016476-78r0rsio	184	7	codes	code	NNS
cord-016476-78r0rsio	184	8	,	,	,
cord-016476-78r0rsio	184	9	with	with	IN
cord-016476-78r0rsio	184	10	a	a	DT
cord-016476-78r0rsio	184	11	pilot	pilot	NN
cord-016476-78r0rsio	184	12	of	of	IN
cord-016476-78r0rsio	184	13	the	the	DT
cord-016476-78r0rsio	184	14	first	first	JJ
cord-016476-78r0rsio	184	15	100	100	CD
cord-016476-78r0rsio	184	16	cases	case	NNS
cord-016476-78r0rsio	184	17	verified	verify	VBN
cord-016476-78r0rsio	184	18	using	use	VBG
cord-016476-78r0rsio	184	19	CT	CT	NNP
cord-016476-78r0rsio	184	20	reports	report	NNS
cord-016476-78r0rsio	184	21	.	.	.
cord-016476-78r0rsio	185	1	The	the	DT
cord-016476-78r0rsio	185	2	study	study	NN
cord-016476-78r0rsio	185	3	demonstrated	demonstrate	VBD
cord-016476-78r0rsio	185	4	no	no	DT
cord-016476-78r0rsio	185	5	increased	increase	VBN
cord-016476-78r0rsio	185	6	risk	risk	NN
cord-016476-78r0rsio	185	7	in	in	IN
cord-016476-78r0rsio	185	8	the	the	DT
cord-016476-78r0rsio	185	9	TNFi	TNFi	NNS
cord-016476-78r0rsio	185	10	-	-	HYPH
cord-016476-78r0rsio	185	11	exposed	expose	VBN
cord-016476-78r0rsio	185	12	group	group	NN
cord-016476-78r0rsio	185	13	of	of	IN
cord-016476-78r0rsio	185	14	new	new	JJ
cord-016476-78r0rsio	185	15	ILD	ILD	NNP
cord-016476-78r0rsio	185	16	;	;	:
cord-016476-78r0rsio	185	17	however	however	RB
cord-016476-78r0rsio	185	18	,	,	,
cord-016476-78r0rsio	185	19	patients	patient	NNS
cord-016476-78r0rsio	185	20	with	with	IN
cord-016476-78r0rsio	185	21	known	know	VBN
cord-016476-78r0rsio	185	22	ILD	ILD	NNP
cord-016476-78r0rsio	185	23	at	at	IN
cord-016476-78r0rsio	185	24	baseline	baseline	NN
cord-016476-78r0rsio	185	25	were	be	VBD
cord-016476-78r0rsio	185	26	systematically	systematically	RB
cord-016476-78r0rsio	185	27	excluded	exclude	VBN
cord-016476-78r0rsio	185	28	.	.	.
cord-016476-78r0rsio	186	1	Using	use	VBG
cord-016476-78r0rsio	186	2	data	datum	NNS
cord-016476-78r0rsio	186	3	from	from	IN
cord-016476-78r0rsio	186	4	the	the	DT
cord-016476-78r0rsio	186	5	commercial	commercial	JJ
cord-016476-78r0rsio	186	6	claims	claim	NNS
cord-016476-78r0rsio	186	7	and	and	CC
cord-016476-78r0rsio	186	8	benefit	benefit	NN
cord-016476-78r0rsio	186	9	(	(	-LRB-
cord-016476-78r0rsio	186	10	Medicare	Medicare	NNP
cord-016476-78r0rsio	186	11	)	)	-RRB-
cord-016476-78r0rsio	186	12	databases	database	NNS
cord-016476-78r0rsio	186	13	,	,	,
cord-016476-78r0rsio	186	14	Curtis	Curtis	NNP
cord-016476-78r0rsio	186	15	et	et	NNP
cord-016476-78r0rsio	186	16	al	al	NNP
cord-016476-78r0rsio	186	17	.	.	NNP
cord-016476-78r0rsio	186	18	assessed	assess	VBD
cord-016476-78r0rsio	186	19	the	the	DT
cord-016476-78r0rsio	186	20	ILD	ILD	NNP
cord-016476-78r0rsio	186	21	incidence	incidence	NN
cord-016476-78r0rsio	186	22	and	and	CC
cord-016476-78r0rsio	186	23	exacerbation	exacerbation	NN
cord-016476-78r0rsio	186	24	amongst	amongst	IN
cord-016476-78r0rsio	186	25	users	user	NNS
cord-016476-78r0rsio	186	26	of	of	IN
cord-016476-78r0rsio	186	27	rituximab	rituximab	NN
cord-016476-78r0rsio	186	28	,	,	,
cord-016476-78r0rsio	186	29	abatacept	abatacept	NNP
cord-016476-78r0rsio	186	30	and	and	CC
cord-016476-78r0rsio	186	31	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	186	32	to	to	IN
cord-016476-78r0rsio	186	33	TNFi	tnfi	JJ
cord-016476-78r0rsio	186	34	agents	agent	NNS
cord-016476-78r0rsio	186	35	[	[	-LRB-
cord-016476-78r0rsio	186	36	81	81	CD
cord-016476-78r0rsio	186	37	]	]	-RRB-
cord-016476-78r0rsio	186	38	.	.	.
cord-016476-78r0rsio	187	1	Two	two	CD
cord-016476-78r0rsio	187	2	definitions	definition	NNS
cord-016476-78r0rsio	187	3	of	of	IN
cord-016476-78r0rsio	187	4	ILD	ILD	NNP
cord-016476-78r0rsio	187	5	were	be	VBD
cord-016476-78r0rsio	187	6	used	use	VBN
cord-016476-78r0rsio	187	7	(	(	-LRB-
cord-016476-78r0rsio	187	8	one	one	NN
cord-016476-78r0rsio	187	9	more	more	RBR
cord-016476-78r0rsio	187	10	sensitive	sensitive	JJ
cord-016476-78r0rsio	187	11	,	,	,
cord-016476-78r0rsio	187	12	the	the	DT
cord-016476-78r0rsio	187	13	other	other	JJ
cord-016476-78r0rsio	187	14	more	more	RBR
cord-016476-78r0rsio	187	15	specific	specific	JJ
cord-016476-78r0rsio	187	16	in	in	IN
cord-016476-78r0rsio	187	17	the	the	DT
cord-016476-78r0rsio	187	18	absence	absence	NN
cord-016476-78r0rsio	187	19	of	of	IN
cord-016476-78r0rsio	187	20	CT	CT	NNP
cord-016476-78r0rsio	187	21	results	result	NNS
cord-016476-78r0rsio	187	22	and	and	CC
cord-016476-78r0rsio	187	23	lung	lung	NN
cord-016476-78r0rsio	187	24	histology	histology	NN
cord-016476-78r0rsio	187	25	)	)	-RRB-
cord-016476-78r0rsio	187	26	.	.	.
cord-016476-78r0rsio	188	1	There	there	EX
cord-016476-78r0rsio	188	2	were	be	VBD
cord-016476-78r0rsio	188	3	no	no	DT
cord-016476-78r0rsio	188	4	significant	significant	JJ
cord-016476-78r0rsio	188	5	differences	difference	NNS
cord-016476-78r0rsio	188	6	in	in	IN
cord-016476-78r0rsio	188	7	the	the	DT
cord-016476-78r0rsio	188	8	risk	risk	NN
cord-016476-78r0rsio	188	9	of	of	IN
cord-016476-78r0rsio	188	10	ILD	ILD	NNP
cord-016476-78r0rsio	188	11	and	and	CC
cord-016476-78r0rsio	188	12	its	-PRON-	PRP$
cord-016476-78r0rsio	188	13	related	related	JJ
cord-016476-78r0rsio	188	14	complications	complication	NNS
cord-016476-78r0rsio	188	15	between	between	IN
cord-016476-78r0rsio	188	16	patients	patient	NNS
cord-016476-78r0rsio	188	17	with	with	IN
cord-016476-78r0rsio	188	18	RA	RA	NNP
cord-016476-78r0rsio	188	19	receiving	receive	VBG
cord-016476-78r0rsio	188	20	TNFis	tnfis	NN
cord-016476-78r0rsio	188	21	and	and	CC
cord-016476-78r0rsio	188	22	those	those	DT
cord-016476-78r0rsio	188	23	on	on	IN
cord-016476-78r0rsio	188	24	non	non	AFX
cord-016476-78r0rsio	188	25	-	-	JJ
cord-016476-78r0rsio	188	26	TNFis	tnfis	JJ
cord-016476-78r0rsio	188	27	.	.	.
cord-016476-78r0rsio	189	1	Of	of	IN
cord-016476-78r0rsio	189	2	the	the	DT
cord-016476-78r0rsio	189	3	patients	patient	NNS
cord-016476-78r0rsio	189	4	'	'	POS
cord-016476-78r0rsio	189	5	studies	study	NNS
cord-016476-78r0rsio	189	6	,	,	,
cord-016476-78r0rsio	189	7	419	419	CD
cord-016476-78r0rsio	189	8	patients	patient	NNS
cord-016476-78r0rsio	189	9	had	have	VBD
cord-016476-78r0rsio	189	10	a	a	DT
cord-016476-78r0rsio	189	11	history	history	NN
cord-016476-78r0rsio	189	12	of	of	IN
cord-016476-78r0rsio	189	13	ILD	ILD	NNP
cord-016476-78r0rsio	189	14	,	,	,
cord-016476-78r0rsio	189	15	of	of	IN
cord-016476-78r0rsio	189	16	which	which	WDT
cord-016476-78r0rsio	189	17	232	232	CD
cord-016476-78r0rsio	189	18	were	be	VBD
cord-016476-78r0rsio	189	19	put	put	VBN
cord-016476-78r0rsio	189	20	on	on	IN
cord-016476-78r0rsio	189	21	TNFi	tnfi	JJ
cord-016476-78r0rsio	189	22	agents	agent	NNS
cord-016476-78r0rsio	189	23	[	[	-LRB-
cord-016476-78r0rsio	189	24	81	81	CD
cord-016476-78r0rsio	189	25	]	]	-RRB-
cord-016476-78r0rsio	189	26	.	.	.
cord-016476-78r0rsio	190	1	However	however	RB
cord-016476-78r0rsio	190	2	there	there	EX
cord-016476-78r0rsio	190	3	were	be	VBD
cord-016476-78r0rsio	190	4	clear	clear	JJ
cord-016476-78r0rsio	190	5	baseline	baseline	JJ
cord-016476-78r0rsio	190	6	differences	difference	NNS
cord-016476-78r0rsio	190	7	between	between	IN
cord-016476-78r0rsio	190	8	the	the	DT
cord-016476-78r0rsio	190	9	groups	group	NNS
cord-016476-78r0rsio	190	10	receiving	receive	VBG
cord-016476-78r0rsio	190	11	the	the	DT
cord-016476-78r0rsio	190	12	different	different	JJ
cord-016476-78r0rsio	190	13	drugs	drug	NNS
cord-016476-78r0rsio	190	14	,	,	,
cord-016476-78r0rsio	190	15	which	which	WDT
cord-016476-78r0rsio	190	16	were	be	VBD
cord-016476-78r0rsio	190	17	not	not	RB
cord-016476-78r0rsio	190	18	adjusted	adjust	VBN
cord-016476-78r0rsio	190	19	in	in	IN
cord-016476-78r0rsio	190	20	the	the	DT
cord-016476-78r0rsio	190	21	analysis	analysis	NN
cord-016476-78r0rsio	190	22	.	.	.
cord-016476-78r0rsio	191	1	Therefore	therefore	RB
cord-016476-78r0rsio	191	2	the	the	DT
cord-016476-78r0rsio	191	3	true	true	JJ
cord-016476-78r0rsio	191	4	risk	risk	NN
cord-016476-78r0rsio	191	5	in	in	IN
cord-016476-78r0rsio	191	6	the	the	DT
cord-016476-78r0rsio	191	7	TNFi	TNFi	NNP
cord-016476-78r0rsio	191	8	group	group	NN
cord-016476-78r0rsio	191	9	may	may	MD
cord-016476-78r0rsio	191	10	be	be	VB
cord-016476-78r0rsio	191	11	confounded	confound	VBN
cord-016476-78r0rsio	191	12	if	if	IN
cord-016476-78r0rsio	191	13	patients	patient	NNS
cord-016476-78r0rsio	191	14	with	with	IN
cord-016476-78r0rsio	191	15	higher	high	JJR
cord-016476-78r0rsio	191	16	levels	level	NNS
cord-016476-78r0rsio	191	17	of	of	IN
cord-016476-78r0rsio	191	18	RA	RA	NNP
cord-016476-78r0rsio	191	19	joint	joint	JJ
cord-016476-78r0rsio	191	20	disease	disease	NN
cord-016476-78r0rsio	191	21	or	or	CC
cord-016476-78r0rsio	191	22	ILD	ILD	NNP
cord-016476-78r0rsio	191	23	disease	disease	NN
cord-016476-78r0rsio	191	24	severity	severity	NN
cord-016476-78r0rsio	191	25	were	be	VBD
cord-016476-78r0rsio	191	26	channelled	channel	VBN
cord-016476-78r0rsio	191	27	to	to	IN
cord-016476-78r0rsio	191	28	specific	specific	JJ
cord-016476-78r0rsio	191	29	therapies	therapy	NNS
cord-016476-78r0rsio	191	30	,	,	,
cord-016476-78r0rsio	191	31	which	which	WDT
cord-016476-78r0rsio	191	32	may	may	MD
cord-016476-78r0rsio	191	33	have	have	VB
cord-016476-78r0rsio	191	34	led	lead	VBN
cord-016476-78r0rsio	191	35	to	to	IN
cord-016476-78r0rsio	191	36	an	an	DT
cord-016476-78r0rsio	191	37	overall	overall	JJ
cord-016476-78r0rsio	191	38	underrepresentation	underrepresentation	NN
cord-016476-78r0rsio	191	39	of	of	IN
cord-016476-78r0rsio	191	40	risk	risk	NN
cord-016476-78r0rsio	191	41	in	in	IN
cord-016476-78r0rsio	191	42	this	this	DT
cord-016476-78r0rsio	191	43	group	group	NN
cord-016476-78r0rsio	191	44	.	.	.
cord-016476-78r0rsio	192	1	In	in	IN
cord-016476-78r0rsio	192	2	a	a	DT
cord-016476-78r0rsio	192	3	recent	recent	JJ
cord-016476-78r0rsio	192	4	single	single	JJ
cord-016476-78r0rsio	192	5	-	-	HYPH
cord-016476-78r0rsio	192	6	centre	centre	NN
cord-016476-78r0rsio	192	7	retrospective	retrospective	JJ
cord-016476-78r0rsio	192	8	evaluation	evaluation	NN
cord-016476-78r0rsio	192	9	from	from	IN
cord-016476-78r0rsio	192	10	Japan	Japan	NNP
cord-016476-78r0rsio	192	11	,	,	,
cord-016476-78r0rsio	192	12	Nakashita	Nakashita	NNP
cord-016476-78r0rsio	192	13	et	et	NNP
cord-016476-78r0rsio	192	14	al	al	NNP
cord-016476-78r0rsio	192	15	.	.	.
cord-016476-78r0rsio	193	1	described	describe	VBN
cord-016476-78r0rsio	193	2	up	up	RP
cord-016476-78r0rsio	193	3	to	to	IN
cord-016476-78r0rsio	193	4	one	one	CD
cord-016476-78r0rsio	193	5	-	-	HYPH
cord-016476-78r0rsio	193	6	year	year	NN
cord-016476-78r0rsio	193	7	outcomes	outcome	NNS
cord-016476-78r0rsio	193	8	of	of	IN
cord-016476-78r0rsio	193	9	163	163	CD
cord-016476-78r0rsio	193	10	RA	RA	NNP
cord-016476-78r0rsio	193	11	patients	patient	NNS
cord-016476-78r0rsio	193	12	with	with	IN
cord-016476-78r0rsio	193	13	(	(	-LRB-
cord-016476-78r0rsio	193	14	n	n	NN
cord-016476-78r0rsio	193	15	=	=	SYM
cord-016476-78r0rsio	193	16	58	58	CD
cord-016476-78r0rsio	193	17	)	)	-RRB-
cord-016476-78r0rsio	193	18	or	or	CC
cord-016476-78r0rsio	193	19	without	without	IN
cord-016476-78r0rsio	193	20	(	(	-LRB-
cord-016476-78r0rsio	193	21	n	n	NN
cord-016476-78r0rsio	193	22	=	=	SYM
cord-016476-78r0rsio	193	23	105	105	CD
cord-016476-78r0rsio	193	24	)	)	-RRB-
cord-016476-78r0rsio	194	1	established	establish	VBD
cord-016476-78r0rsio	194	2	ILD	ILD	NNP
cord-016476-78r0rsio	194	3	on	on	IN
cord-016476-78r0rsio	194	4	a	a	DT
cord-016476-78r0rsio	194	5	biologic	biologic	JJ
cord-016476-78r0rsio	194	6	drug	drug	NN
cord-016476-78r0rsio	194	7	[	[	-LRB-
cord-016476-78r0rsio	194	8	82	82	CD
cord-016476-78r0rsio	194	9	]	]	-RRB-
cord-016476-78r0rsio	194	10	.	.	.
cord-016476-78r0rsio	195	1	In	in	IN
cord-016476-78r0rsio	195	2	patients	patient	NNS
cord-016476-78r0rsio	195	3	with	with	IN
cord-016476-78r0rsio	195	4	established	establish	VBN
cord-016476-78r0rsio	195	5	RA	RA	NNP
cord-016476-78r0rsio	195	6	-	-	HYPH
cord-016476-78r0rsio	195	7	ILD	ILD	NNP
cord-016476-78r0rsio	195	8	,	,	,
cord-016476-78r0rsio	195	9	14	14	CD
cord-016476-78r0rsio	195	10	(	(	-LRB-
cord-016476-78r0rsio	195	11	24	24	CD
cord-016476-78r0rsio	195	12	%	%	NN
cord-016476-78r0rsio	195	13	)	)	-RRB-
cord-016476-78r0rsio	195	14	had	have	VBD
cord-016476-78r0rsio	195	15	an	an	DT
cord-016476-78r0rsio	195	16	exacerbation	exacerbation	NN
cord-016476-78r0rsio	195	17	of	of	IN
cord-016476-78r0rsio	195	18	ILD	ILD	NNP
cord-016476-78r0rsio	195	19	,	,	,
cord-016476-78r0rsio	195	20	which	which	WDT
cord-016476-78r0rsio	195	21	the	the	DT
cord-016476-78r0rsio	195	22	authors	author	NNS
cord-016476-78r0rsio	195	23	concluded	conclude	VBD
cord-016476-78r0rsio	195	24	was	be	VBD
cord-016476-78r0rsio	195	25	greater	great	JJR
cord-016476-78r0rsio	195	26	in	in	IN
cord-016476-78r0rsio	195	27	patients	patient	NNS
cord-016476-78r0rsio	195	28	exposed	expose	VBN
cord-016476-78r0rsio	195	29	to	to	IN
cord-016476-78r0rsio	195	30	TNFi	tnfi	JJ
cord-016476-78r0rsio	195	31	agents	agent	NNS
cord-016476-78r0rsio	195	32	using	use	VBG
cord-016476-78r0rsio	195	33	descriptive	descriptive	JJ
cord-016476-78r0rsio	195	34	statistics	statistic	NNS
cord-016476-78r0rsio	195	35	.	.	.
cord-016476-78r0rsio	196	1	None	none	NN
cord-016476-78r0rsio	196	2	of	of	IN
cord-016476-78r0rsio	196	3	the	the	DT
cord-016476-78r0rsio	196	4	patients	patient	NNS
cord-016476-78r0rsio	196	5	on	on	IN
cord-016476-78r0rsio	196	6	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	196	7	(	(	-LRB-
cord-016476-78r0rsio	196	8	n	n	NN
cord-016476-78r0rsio	196	9	=	=	SYM
cord-016476-78r0rsio	196	10	9	9	CD
cord-016476-78r0rsio	196	11	)	)	-RRB-
cord-016476-78r0rsio	196	12	or	or	CC
cord-016476-78r0rsio	196	13	abatacept	abatacept	NNP
cord-016476-78r0rsio	196	14	(	(	-LRB-
cord-016476-78r0rsio	196	15	n	n	NN
cord-016476-78r0rsio	196	16	=	=	SYM
cord-016476-78r0rsio	196	17	3	3	CD
cord-016476-78r0rsio	196	18	)	)	-RRB-
cord-016476-78r0rsio	196	19	were	be	VBD
cord-016476-78r0rsio	196	20	reported	report	VBN
cord-016476-78r0rsio	196	21	to	to	TO
cord-016476-78r0rsio	196	22	have	have	VB
cord-016476-78r0rsio	196	23	an	an	DT
cord-016476-78r0rsio	196	24	exacerbation	exacerbation	NN
cord-016476-78r0rsio	196	25	;	;	:
cord-016476-78r0rsio	196	26	however	however	RB
cord-016476-78r0rsio	196	27	,	,	,
cord-016476-78r0rsio	196	28	conclusions	conclusion	NNS
cord-016476-78r0rsio	196	29	were	be	VBD
cord-016476-78r0rsio	196	30	limited	limit	VBN
cord-016476-78r0rsio	196	31	due	due	IN
cord-016476-78r0rsio	196	32	to	to	IN
cord-016476-78r0rsio	196	33	low	low	JJ
cord-016476-78r0rsio	196	34	numbers	number	NNS
cord-016476-78r0rsio	196	35	.	.	.
cord-016476-78r0rsio	197	1	Similar	similar	JJ
cord-016476-78r0rsio	197	2	to	to	IN
cord-016476-78r0rsio	197	3	Curtis	Curtis	NNP
cord-016476-78r0rsio	197	4	et	et	NNP
cord-016476-78r0rsio	197	5	al	al	NNP
cord-016476-78r0rsio	197	6	.	.	NNP
cord-016476-78r0rsio	197	7	's	's	POS
cord-016476-78r0rsio	197	8	study	study	NN
cord-016476-78r0rsio	197	9	[	[	-LRB-
cord-016476-78r0rsio	197	10	81	81	CD
cord-016476-78r0rsio	197	11	]	]	-RRB-
cord-016476-78r0rsio	197	12	,	,	.
cord-016476-78r0rsio	198	1	it	-PRON-	PRP
cord-016476-78r0rsio	198	2	did	do	VBD
cord-016476-78r0rsio	198	3	not	not	RB
cord-016476-78r0rsio	198	4	adjust	adjust	VB
cord-016476-78r0rsio	198	5	for	for	IN
cord-016476-78r0rsio	198	6	severity	severity	NN
cord-016476-78r0rsio	198	7	of	of	IN
cord-016476-78r0rsio	198	8	RA	RA	NNP
cord-016476-78r0rsio	198	9	or	or	CC
cord-016476-78r0rsio	198	10	any	any	DT
cord-016476-78r0rsio	198	11	confounders	confounder	NNS
cord-016476-78r0rsio	198	12	potentially	potentially	RB
cord-016476-78r0rsio	198	13	introducing	introduce	VBG
cord-016476-78r0rsio	198	14	channelling	channel	VBG
cord-016476-78r0rsio	198	15	bias	bias	NN
cord-016476-78r0rsio	198	16	.	.	.
cord-016476-78r0rsio	199	1	In	in	IN
cord-016476-78r0rsio	199	2	this	this	DT
cord-016476-78r0rsio	199	3	case	case	NN
cord-016476-78r0rsio	199	4	,	,	,
cord-016476-78r0rsio	199	5	it	-PRON-	PRP
cord-016476-78r0rsio	199	6	is	be	VBZ
cord-016476-78r0rsio	199	7	likely	likely	JJ
cord-016476-78r0rsio	199	8	that	that	IN
cord-016476-78r0rsio	199	9	patients	patient	NNS
cord-016476-78r0rsio	199	10	on	on	IN
cord-016476-78r0rsio	199	11	TNFi	TNFi	NNS
cord-016476-78r0rsio	199	12	(	(	-LRB-
cord-016476-78r0rsio	199	13	approved	approve	VBN
cord-016476-78r0rsio	199	14	earlier	early	RBR
cord-016476-78r0rsio	199	15	than	than	IN
cord-016476-78r0rsio	199	16	the	the	DT
cord-016476-78r0rsio	199	17	non	non	JJ
cord-016476-78r0rsio	199	18	-	-	JJ
cord-016476-78r0rsio	199	19	TNFi	tnfi	JJ
cord-016476-78r0rsio	199	20	drugs	drug	NNS
cord-016476-78r0rsio	199	21	in	in	IN
cord-016476-78r0rsio	199	22	this	this	DT
cord-016476-78r0rsio	199	23	study	study	NN
cord-016476-78r0rsio	199	24	)	)	-RRB-
cord-016476-78r0rsio	199	25	had	have	VBD
cord-016476-78r0rsio	199	26	more	more	RBR
cord-016476-78r0rsio	199	27	severe	severe	JJ
cord-016476-78r0rsio	199	28	disease	disease	NN
cord-016476-78r0rsio	199	29	at	at	IN
cord-016476-78r0rsio	199	30	the	the	DT
cord-016476-78r0rsio	199	31	outset	outset	NN
cord-016476-78r0rsio	199	32	,	,	,
cord-016476-78r0rsio	199	33	in	in	IN
cord-016476-78r0rsio	199	34	turn	turn	NN
cord-016476-78r0rsio	199	35	is	be	VBZ
cord-016476-78r0rsio	199	36	known	know	VBN
cord-016476-78r0rsio	199	37	to	to	TO
cord-016476-78r0rsio	199	38	be	be	VB
cord-016476-78r0rsio	199	39	associated	associate	VBN
cord-016476-78r0rsio	199	40	with	with	IN
cord-016476-78r0rsio	199	41	the	the	DT
cord-016476-78r0rsio	199	42	outcome	outcome	NN
cord-016476-78r0rsio	199	43	.	.	.
cord-016476-78r0rsio	200	1	Data	datum	NNS
cord-016476-78r0rsio	200	2	from	from	IN
cord-016476-78r0rsio	200	3	the	the	DT
cord-016476-78r0rsio	200	4	British	British	NNP
cord-016476-78r0rsio	200	5	Society	Society	NNP
cord-016476-78r0rsio	200	6	for	for	IN
cord-016476-78r0rsio	200	7	Rheumatology	Rheumatology	NNP
cord-016476-78r0rsio	200	8	Biologics	Biologics	NNPS
cord-016476-78r0rsio	200	9	Register	Register	NNP
cord-016476-78r0rsio	200	10	for	for	IN
cord-016476-78r0rsio	200	11	RA	RA	NNP
cord-016476-78r0rsio	200	12	(	(	-LRB-
cord-016476-78r0rsio	200	13	BSRBR	BSRBR	NNP
cord-016476-78r0rsio	200	14	-	-	HYPH
cord-016476-78r0rsio	200	15	RA	RA	NNP
cord-016476-78r0rsio	200	16	)	)	-RRB-
cord-016476-78r0rsio	200	17	evaluated	evaluate	VBD
cord-016476-78r0rsio	200	18	the	the	DT
cord-016476-78r0rsio	200	19	effect	effect	NN
cord-016476-78r0rsio	200	20	of	of	IN
cord-016476-78r0rsio	200	21	TNFi	TNFi	NNS
cord-016476-78r0rsio	200	22	in	in	IN
cord-016476-78r0rsio	200	23	patients	patient	NNS
cord-016476-78r0rsio	200	24	with	with	IN
cord-016476-78r0rsio	200	25	RA	RA	NNP
cord-016476-78r0rsio	200	26	who	who	WP
cord-016476-78r0rsio	200	27	have	have	VBP
cord-016476-78r0rsio	200	28	established	establish	VBN
cord-016476-78r0rsio	200	29	ILD	ILD	NNP
cord-016476-78r0rsio	200	30	[	[	-LRB-
cord-016476-78r0rsio	200	31	83	83	CD
cord-016476-78r0rsio	200	32	]	]	-RRB-
cord-016476-78r0rsio	200	33	and	and	CC
cord-016476-78r0rsio	200	34	reported	report	VBD
cord-016476-78r0rsio	200	35	no	no	DT
cord-016476-78r0rsio	200	36	difference	difference	NN
cord-016476-78r0rsio	200	37	in	in	IN
cord-016476-78r0rsio	200	38	all	all	DT
cord-016476-78r0rsio	200	39	-	-	HYPH
cord-016476-78r0rsio	200	40	cause	cause	NN
cord-016476-78r0rsio	200	41	mortality	mortality	NN
cord-016476-78r0rsio	200	42	between	between	IN
cord-016476-78r0rsio	200	43	patients	patient	NNS
cord-016476-78r0rsio	200	44	on	on	IN
cord-016476-78r0rsio	200	45	TNFis	TNFis	NNP
cord-016476-78r0rsio	200	46	and	and	CC
cord-016476-78r0rsio	200	47	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	200	48	.	.	.
cord-016476-78r0rsio	201	1	However	however	RB
cord-016476-78r0rsio	201	2	RA	RA	NNP
cord-016476-78r0rsio	201	3	-	-	HYPH
cord-016476-78r0rsio	201	4	ILD	ILD	NNP
cord-016476-78r0rsio	201	5	as	as	IN
cord-016476-78r0rsio	201	6	an	an	DT
cord-016476-78r0rsio	201	7	underlying	underlying	JJ
cord-016476-78r0rsio	201	8	cause	cause	NN
cord-016476-78r0rsio	201	9	of	of	IN
cord-016476-78r0rsio	201	10	death	death	NN
cord-016476-78r0rsio	201	11	was	be	VBD
cord-016476-78r0rsio	201	12	reported	report	VBN
cord-016476-78r0rsio	201	13	in	in	IN
cord-016476-78r0rsio	201	14	a	a	DT
cord-016476-78r0rsio	201	15	higher	high	JJR
cord-016476-78r0rsio	201	16	proportion	proportion	NN
cord-016476-78r0rsio	201	17	of	of	IN
cord-016476-78r0rsio	201	18	TNFi	TNFi	NNS
cord-016476-78r0rsio	201	19	-	-	HYPH
cord-016476-78r0rsio	201	20	treated	treat	VBN
cord-016476-78r0rsio	201	21	patients	patient	NNS
cord-016476-78r0rsio	201	22	than	than	IN
cord-016476-78r0rsio	201	23	nbDMARD	nbdmard	RB
cord-016476-78r0rsio	201	24	-	-	HYPH
cord-016476-78r0rsio	201	25	treated	treat	VBN
cord-016476-78r0rsio	201	26	patients	patient	NNS
cord-016476-78r0rsio	201	27	(	(	-LRB-
cord-016476-78r0rsio	201	28	21	21	CD
cord-016476-78r0rsio	201	29	vs.	vs.	CC
cord-016476-78r0rsio	201	30	7	7	CD
cord-016476-78r0rsio	201	31	%	%	NN
cord-016476-78r0rsio	201	32	)	)	-RRB-
cord-016476-78r0rsio	201	33	,	,	,
cord-016476-78r0rsio	201	34	suggesting	suggest	VBG
cord-016476-78r0rsio	201	35	a	a	DT
cord-016476-78r0rsio	201	36	signal	signal	NN
cord-016476-78r0rsio	201	37	for	for	IN
cord-016476-78r0rsio	201	38	concern	concern	NN
cord-016476-78r0rsio	201	39	.	.	.
cord-016476-78r0rsio	202	1	Methodological	methodological	JJ
cord-016476-78r0rsio	202	2	challenges	challenge	NNS
cord-016476-78r0rsio	202	3	included	include	VBD
cord-016476-78r0rsio	202	4	potential	potential	NN
cord-016476-78r0rsio	202	5	for	for	IN
cord-016476-78r0rsio	202	6	misclassification	misclassification	NN
cord-016476-78r0rsio	202	7	,	,	,
cord-016476-78r0rsio	202	8	as	as	IN
cord-016476-78r0rsio	202	9	prevalent	prevalent	JJ
cord-016476-78r0rsio	202	10	ILD	ILD	NNP
cord-016476-78r0rsio	202	11	was	be	VBD
cord-016476-78r0rsio	202	12	identified	identify	VBN
cord-016476-78r0rsio	202	13	from	from	IN
cord-016476-78r0rsio	202	14	clinician	clinician	NN
cord-016476-78r0rsio	202	15	questionnaires	questionnaire	NNS
cord-016476-78r0rsio	202	16	since	since	IN
cord-016476-78r0rsio	202	17	attempts	attempt	NNS
cord-016476-78r0rsio	202	18	to	to	TO
cord-016476-78r0rsio	202	19	retrospectively	retrospectively	RB
cord-016476-78r0rsio	202	20	verify	verify	VB
cord-016476-78r0rsio	202	21	such	such	JJ
cord-016476-78r0rsio	202	22	cases	case	NNS
cord-016476-78r0rsio	202	23	were	be	VBD
cord-016476-78r0rsio	202	24	unsuccessful	unsuccessful	JJ
cord-016476-78r0rsio	202	25	.	.	.
cord-016476-78r0rsio	203	1	Whilst	whilst	IN
cord-016476-78r0rsio	203	2	it	-PRON-	PRP
cord-016476-78r0rsio	203	3	could	could	MD
cord-016476-78r0rsio	203	4	be	be	VB
cord-016476-78r0rsio	203	5	that	that	IN
cord-016476-78r0rsio	203	6	TNFi	TNFi	NNS
cord-016476-78r0rsio	203	7	truly	truly	RB
cord-016476-78r0rsio	203	8	increased	increase	VBD
cord-016476-78r0rsio	203	9	the	the	DT
cord-016476-78r0rsio	203	10	proportion	proportion	NN
cord-016476-78r0rsio	203	11	of	of	IN
cord-016476-78r0rsio	203	12	deaths	death	NNS
cord-016476-78r0rsio	203	13	attributable	attributable	JJ
cord-016476-78r0rsio	203	14	to	to	IN
cord-016476-78r0rsio	203	15	RA	RA	NNP
cord-016476-78r0rsio	203	16	-	-	HYPH
cord-016476-78r0rsio	203	17	ILD	ILD	NNP
cord-016476-78r0rsio	203	18	,	,	,
cord-016476-78r0rsio	203	19	given	give	VBN
cord-016476-78r0rsio	203	20	the	the	DT
cord-016476-78r0rsio	203	21	well	well	RB
cord-016476-78r0rsio	203	22	-	-	HYPH
cord-016476-78r0rsio	203	23	publicised	publicise	VBN
cord-016476-78r0rsio	203	24	respiratory	respiratory	JJ
cord-016476-78r0rsio	203	25	concerns	concern	NNS
cord-016476-78r0rsio	203	26	with	with	IN
cord-016476-78r0rsio	203	27	TNFi	TNFi	NNS
cord-016476-78r0rsio	203	28	,	,	,
cord-016476-78r0rsio	203	29	it	-PRON-	PRP
cord-016476-78r0rsio	203	30	may	may	MD
cord-016476-78r0rsio	203	31	be	be	VB
cord-016476-78r0rsio	203	32	that	that	IN
cord-016476-78r0rsio	203	33	physicians	physician	NNS
cord-016476-78r0rsio	203	34	at	at	IN
cord-016476-78r0rsio	203	35	that	that	DT
cord-016476-78r0rsio	203	36	time	time	NN
cord-016476-78r0rsio	203	37	were	be	VBD
cord-016476-78r0rsio	203	38	more	more	RBR
cord-016476-78r0rsio	203	39	inclined	inclined	JJ
cord-016476-78r0rsio	203	40	to	to	TO
cord-016476-78r0rsio	203	41	report	report	VB
cord-016476-78r0rsio	203	42	RA	RA	NNP
cord-016476-78r0rsio	203	43	-	-	HYPH
cord-016476-78r0rsio	203	44	ILD	ILD	NNP
cord-016476-78r0rsio	203	45	on	on	IN
cord-016476-78r0rsio	203	46	death	death	NN
cord-016476-78r0rsio	203	47	certificates	certificate	NNS
cord-016476-78r0rsio	203	48	of	of	IN
cord-016476-78r0rsio	203	49	patients	patient	NNS
cord-016476-78r0rsio	203	50	exposed	expose	VBN
cord-016476-78r0rsio	203	51	to	to	IN
cord-016476-78r0rsio	203	52	TNFis	tnfis	NN
cord-016476-78r0rsio	203	53	leading	lead	VBG
cord-016476-78r0rsio	203	54	to	to	IN
cord-016476-78r0rsio	203	55	the	the	DT
cord-016476-78r0rsio	203	56	observed	observed	JJ
cord-016476-78r0rsio	203	57	relationship	relationship	NN
cord-016476-78r0rsio	203	58	.	.	.
cord-016476-78r0rsio	204	1	PFTs	pft	NNS
cord-016476-78r0rsio	204	2	,	,	,
cord-016476-78r0rsio	204	3	imaging	imaging	NN
cord-016476-78r0rsio	204	4	or	or	CC
cord-016476-78r0rsio	204	5	nonfatal	nonfatal	JJ
cord-016476-78r0rsio	204	6	exacerbation	exacerbation	NN
cord-016476-78r0rsio	204	7	of	of	IN
cord-016476-78r0rsio	204	8	ILD	ILD	NNP
cord-016476-78r0rsio	204	9	details	detail	NNS
cord-016476-78r0rsio	204	10	were	be	VBD
cord-016476-78r0rsio	204	11	not	not	RB
cord-016476-78r0rsio	204	12	available	available	JJ
cord-016476-78r0rsio	204	13	to	to	TO
cord-016476-78r0rsio	204	14	examine	examine	VB
cord-016476-78r0rsio	204	15	the	the	DT
cord-016476-78r0rsio	204	16	effect	effect	NN
cord-016476-78r0rsio	204	17	of	of	IN
cord-016476-78r0rsio	204	18	treatment	treatment	NN
cord-016476-78r0rsio	204	19	on	on	IN
cord-016476-78r0rsio	204	20	such	such	JJ
cord-016476-78r0rsio	204	21	outcomes	outcome	NNS
cord-016476-78r0rsio	204	22	.	.	.
cord-016476-78r0rsio	205	1	Challenges	challenge	NNS
cord-016476-78r0rsio	205	2	in	in	IN
cord-016476-78r0rsio	205	3	interpreting	interpret	VBG
cord-016476-78r0rsio	205	4	the	the	DT
cord-016476-78r0rsio	205	5	data	datum	NNS
cord-016476-78r0rsio	205	6	common	common	JJ
cord-016476-78r0rsio	205	7	to	to	IN
cord-016476-78r0rsio	205	8	all	all	DT
cord-016476-78r0rsio	205	9	studies	study	NNS
cord-016476-78r0rsio	205	10	is	be	VBZ
cord-016476-78r0rsio	205	11	delineating	delineate	VBG
cord-016476-78r0rsio	205	12	the	the	DT
cord-016476-78r0rsio	205	13	effect	effect	NN
cord-016476-78r0rsio	205	14	of	of	IN
cord-016476-78r0rsio	205	15	TNFi	TNFi	NNS
cord-016476-78r0rsio	205	16	on	on	IN
cord-016476-78r0rsio	205	17	RA	RA	NNP
cord-016476-78r0rsio	205	18	-	-	HYPH
cord-016476-78r0rsio	205	19	ILD	ILD	NNP
cord-016476-78r0rsio	205	20	in	in	IN
cord-016476-78r0rsio	205	21	the	the	DT
cord-016476-78r0rsio	205	22	presence	presence	NN
cord-016476-78r0rsio	205	23	of	of	IN
cord-016476-78r0rsio	205	24	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	205	25	,	,	,
cord-016476-78r0rsio	205	26	the	the	DT
cord-016476-78r0rsio	205	27	majority	majority	NN
cord-016476-78r0rsio	205	28	of	of	IN
cord-016476-78r0rsio	205	29	which	which	WDT
cord-016476-78r0rsio	205	30	are	be	VBP
cord-016476-78r0rsio	205	31	linked	link	VBN
cord-016476-78r0rsio	205	32	to	to	IN
cord-016476-78r0rsio	205	33	reports	report	NNS
cord-016476-78r0rsio	205	34	of	of	IN
cord-016476-78r0rsio	205	35	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	205	36	or	or	CC
cord-016476-78r0rsio	205	37	exacerbation	exacerbation	NN
cord-016476-78r0rsio	205	38	of	of	IN
cord-016476-78r0rsio	205	39	RA	RA	NNP
cord-016476-78r0rsio	205	40	-	-	HYPH
cord-016476-78r0rsio	205	41	ILD	ILD	NNP
cord-016476-78r0rsio	205	42	.	.	.
cord-016476-78r0rsio	206	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	206	2	,	,	,
cord-016476-78r0rsio	206	3	it	-PRON-	PRP
cord-016476-78r0rsio	206	4	can	can	MD
cord-016476-78r0rsio	206	5	be	be	VB
cord-016476-78r0rsio	206	6	difficult	difficult	JJ
cord-016476-78r0rsio	206	7	to	to	TO
cord-016476-78r0rsio	206	8	ascertain	ascertain	VB
cord-016476-78r0rsio	206	9	if	if	IN
cord-016476-78r0rsio	206	10	severity	severity	NN
cord-016476-78r0rsio	206	11	of	of	IN
cord-016476-78r0rsio	206	12	RA	RA	NNP
cord-016476-78r0rsio	206	13	associated	associate	VBN
cord-016476-78r0rsio	206	14	with	with	IN
cord-016476-78r0rsio	206	15	both	both	DT
cord-016476-78r0rsio	206	16	development	development	NN
cord-016476-78r0rsio	206	17	of	of	IN
cord-016476-78r0rsio	206	18	ILD	ILD	NNP
cord-016476-78r0rsio	206	19	and	and	CC
cord-016476-78r0rsio	206	20	also	also	RB
cord-016476-78r0rsio	206	21	being	be	VBG
cord-016476-78r0rsio	206	22	the	the	DT
cord-016476-78r0rsio	206	23	indication	indication	NN
cord-016476-78r0rsio	206	24	for	for	IN
cord-016476-78r0rsio	206	25	TNFi	TNFi	NNS
cord-016476-78r0rsio	206	26	could	could	MD
cord-016476-78r0rsio	206	27	explain	explain	VB
cord-016476-78r0rsio	206	28	the	the	DT
cord-016476-78r0rsio	206	29	association	association	NN
cord-016476-78r0rsio	206	30	between	between	IN
cord-016476-78r0rsio	206	31	TNFi	TNFi	NNP
cord-016476-78r0rsio	206	32	and	and	CC
cord-016476-78r0rsio	206	33	RA	RA	NNP
cord-016476-78r0rsio	206	34	-	-	HYPH
cord-016476-78r0rsio	206	35	ILD	ILD	NNP
cord-016476-78r0rsio	206	36	exacerbation	exacerbation	NN
cord-016476-78r0rsio	206	37	.	.	.
cord-016476-78r0rsio	207	1	However	however	RB
cord-016476-78r0rsio	207	2	,	,	,
cord-016476-78r0rsio	207	3	no	no	DT
cord-016476-78r0rsio	207	4	studies	study	NNS
cord-016476-78r0rsio	207	5	have	have	VBP
cord-016476-78r0rsio	207	6	completely	completely	RB
cord-016476-78r0rsio	207	7	excluded	exclude	VBN
cord-016476-78r0rsio	207	8	a	a	DT
cord-016476-78r0rsio	207	9	clinically	clinically	RB
cord-016476-78r0rsio	207	10	meaningful	meaningful	JJ
cord-016476-78r0rsio	207	11	risk	risk	NN
cord-016476-78r0rsio	207	12	,	,	,
cord-016476-78r0rsio	207	13	and	and	CC
cord-016476-78r0rsio	207	14	the	the	DT
cord-016476-78r0rsio	207	15	multiple	multiple	JJ
cord-016476-78r0rsio	207	16	case	case	NN
cord-016476-78r0rsio	207	17	reports	report	NNS
cord-016476-78r0rsio	207	18	,	,	,
cord-016476-78r0rsio	207	19	observational	observational	JJ
cord-016476-78r0rsio	207	20	evidence	evidence	NN
cord-016476-78r0rsio	207	21	and	and	CC
cord-016476-78r0rsio	207	22	possible	possible	JJ
cord-016476-78r0rsio	207	23	increase	increase	NN
cord-016476-78r0rsio	207	24	in	in	IN
cord-016476-78r0rsio	207	25	ILD	ILD	NNP
cord-016476-78r0rsio	207	26	-	-	HYPH
cord-016476-78r0rsio	207	27	specific	specific	JJ
cord-016476-78r0rsio	207	28	mortality	mortality	NN
cord-016476-78r0rsio	207	29	in	in	IN
cord-016476-78r0rsio	207	30	patients	patient	NNS
cord-016476-78r0rsio	207	31	with	with	IN
cord-016476-78r0rsio	207	32	known	know	VBN
cord-016476-78r0rsio	207	33	RA	RA	NNP
cord-016476-78r0rsio	207	34	-	-	HYPH
cord-016476-78r0rsio	207	35	ILD	ILD	NNP
cord-016476-78r0rsio	207	36	indicate	indicate	VBP
cord-016476-78r0rsio	207	37	that	that	IN
cord-016476-78r0rsio	207	38	careful	careful	JJ
cord-016476-78r0rsio	207	39	monitoring	monitoring	NN
cord-016476-78r0rsio	207	40	and	and	CC
cord-016476-78r0rsio	207	41	caution	caution	NN
cord-016476-78r0rsio	207	42	is	be	VBZ
cord-016476-78r0rsio	207	43	required	require	VBN
cord-016476-78r0rsio	207	44	when	when	WRB
cord-016476-78r0rsio	207	45	considering	consider	VBG
cord-016476-78r0rsio	207	46	use	use	NN
cord-016476-78r0rsio	207	47	in	in	IN
cord-016476-78r0rsio	207	48	this	this	DT
cord-016476-78r0rsio	207	49	setting	setting	NN
cord-016476-78r0rsio	207	50	.	.	.
cord-016476-78r0rsio	208	1	With	with	IN
cord-016476-78r0rsio	208	2	several	several	JJ
cord-016476-78r0rsio	208	3	biologics	biologic	NNS
cord-016476-78r0rsio	208	4	approaching	approach	VBG
cord-016476-78r0rsio	208	5	patent	patent	NN
cord-016476-78r0rsio	208	6	expiration	expiration	NN
cord-016476-78r0rsio	208	7	,	,	,
cord-016476-78r0rsio	208	8	substantial	substantial	JJ
cord-016476-78r0rsio	208	9	interest	interest	NN
cord-016476-78r0rsio	208	10	has	have	VBZ
cord-016476-78r0rsio	208	11	been	be	VBN
cord-016476-78r0rsio	208	12	in	in	IN
cord-016476-78r0rsio	208	13	the	the	DT
cord-016476-78r0rsio	208	14	development	development	NN
cord-016476-78r0rsio	208	15	of	of	IN
cord-016476-78r0rsio	208	16	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	208	17	products	product	NNS
cord-016476-78r0rsio	208	18	that	that	WDT
cord-016476-78r0rsio	208	19	are	be	VBP
cord-016476-78r0rsio	208	20	not	not	RB
cord-016476-78r0rsio	208	21	bioidentical	bioidentical	JJ
cord-016476-78r0rsio	208	22	but	but	CC
cord-016476-78r0rsio	208	23	highly	highly	RB
cord-016476-78r0rsio	208	24	similar	similar	JJ
cord-016476-78r0rsio	208	25	to	to	IN
cord-016476-78r0rsio	208	26	already	already	RB
cord-016476-78r0rsio	208	27	approved	approve	VBN
cord-016476-78r0rsio	208	28	reference	reference	NN
cord-016476-78r0rsio	208	29	products	product	NNS
cord-016476-78r0rsio	208	30	listed	list	VBN
cord-016476-78r0rsio	208	31	above	above	IN
cord-016476-78r0rsio	208	32	[	[	-LRB-
cord-016476-78r0rsio	208	33	84	84	CD
cord-016476-78r0rsio	208	34	]	]	-RRB-
cord-016476-78r0rsio	208	35	.	.	.
cord-016476-78r0rsio	209	1	To	to	IN
cord-016476-78r0rsio	209	2	date	date	NN
cord-016476-78r0rsio	209	3	,	,	,
cord-016476-78r0rsio	209	4	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	209	5	infliximab	infliximab	VBD
cord-016476-78r0rsio	209	6	CT	CT	NNP
cord-016476-78r0rsio	209	7	-	-	HYPH
cord-016476-78r0rsio	209	8	P13	P13	NNP
cord-016476-78r0rsio	209	9	(	(	-LRB-
cord-016476-78r0rsio	209	10	marketed	market	VBN
cord-016476-78r0rsio	209	11	as	as	IN
cord-016476-78r0rsio	209	12	Remsima	Remsima	NNP
cord-016476-78r0rsio	209	13	and	and	CC
cord-016476-78r0rsio	209	14	Inflectra	Inflectra	NNP
cord-016476-78r0rsio	209	15	)	)	-RRB-
cord-016476-78r0rsio	209	16	and	and	CC
cord-016476-78r0rsio	210	1	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	210	2	etanercept	etanercept	NNP
cord-016476-78r0rsio	210	3	SB4	SB4	NNP
cord-016476-78r0rsio	210	4	(	(	-LRB-
cord-016476-78r0rsio	210	5	marketed	market	VBN
cord-016476-78r0rsio	210	6	as	as	IN
cord-016476-78r0rsio	210	7	Benepali	Benepali	NNP
cord-016476-78r0rsio	210	8	)	)	-RRB-
cord-016476-78r0rsio	210	9	have	have	VBP
cord-016476-78r0rsio	210	10	been	be	VBN
cord-016476-78r0rsio	210	11	approved	approve	VBN
cord-016476-78r0rsio	210	12	for	for	IN
cord-016476-78r0rsio	210	13	use	use	NN
cord-016476-78r0rsio	210	14	by	by	IN
cord-016476-78r0rsio	210	15	the	the	DT
cord-016476-78r0rsio	210	16	FDA	FDA	NNP
cord-016476-78r0rsio	210	17	and	and	CC
cord-016476-78r0rsio	210	18	EMA	EMA	NNP
cord-016476-78r0rsio	210	19	.	.	.
cord-016476-78r0rsio	211	1	There	there	EX
cord-016476-78r0rsio	211	2	were	be	VBD
cord-016476-78r0rsio	211	3	no	no	DT
cord-016476-78r0rsio	211	4	cases	case	NNS
cord-016476-78r0rsio	211	5	of	of	IN
cord-016476-78r0rsio	211	6	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	211	7	or	or	CC
cord-016476-78r0rsio	211	8	ILD	ILD	NNP
cord-016476-78r0rsio	211	9	in	in	IN
cord-016476-78r0rsio	211	10	the	the	DT
cord-016476-78r0rsio	211	11	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	211	12	infliximab	infliximab	VBD
cord-016476-78r0rsio	211	13	CT	CT	NNP
cord-016476-78r0rsio	211	14	-	-	HYPH
cord-016476-78r0rsio	211	15	P13	P13	NNP
cord-016476-78r0rsio	211	16	trials	trial	NNS
cord-016476-78r0rsio	211	17	in	in	IN
cord-016476-78r0rsio	211	18	RA	RA	NNP
cord-016476-78r0rsio	211	19	[	[	-LRB-
cord-016476-78r0rsio	211	20	85	85	CD
cord-016476-78r0rsio	211	21	,	,	,
cord-016476-78r0rsio	211	22	86	86	CD
cord-016476-78r0rsio	211	23	]	]	-RRB-
cord-016476-78r0rsio	211	24	or	or	CC
cord-016476-78r0rsio	211	25	ankylosing	ankylose	VBG
cord-016476-78r0rsio	211	26	spondylitis	spondylitis	NN
cord-016476-78r0rsio	211	27	[	[	-LRB-
cord-016476-78r0rsio	211	28	87	87	CD
cord-016476-78r0rsio	211	29	]	]	-RRB-
cord-016476-78r0rsio	211	30	,	,	,
cord-016476-78r0rsio	211	31	although	although	IN
cord-016476-78r0rsio	211	32	there	there	EX
cord-016476-78r0rsio	211	33	was	be	VBD
cord-016476-78r0rsio	211	34	a	a	DT
cord-016476-78r0rsio	211	35	case	case	NN
cord-016476-78r0rsio	211	36	of	of	IN
cord-016476-78r0rsio	211	37	noninfective	noninfective	NNP
cord-016476-78r0rsio	211	38	dyspnoea	dyspnoea	NNS
cord-016476-78r0rsio	211	39	reported	report	VBD
cord-016476-78r0rsio	211	40	within	within	IN
cord-016476-78r0rsio	211	41	the	the	DT
cord-016476-78r0rsio	211	42	CT	CT	NNP
cord-016476-78r0rsio	211	43	-	-	HYPH
cord-016476-78r0rsio	211	44	P13	P13	NNP
cord-016476-78r0rsio	211	45	arm	arm	NN
cord-016476-78r0rsio	211	46	of	of	IN
cord-016476-78r0rsio	211	47	the	the	DT
cord-016476-78r0rsio	211	48	latter	latter	JJ
cord-016476-78r0rsio	211	49	trial	trial	NN
cord-016476-78r0rsio	211	50	felt	feel	VBD
cord-016476-78r0rsio	211	51	to	to	TO
cord-016476-78r0rsio	211	52	be	be	VB
cord-016476-78r0rsio	211	53	related	relate	VBN
cord-016476-78r0rsio	211	54	to	to	IN
cord-016476-78r0rsio	211	55	the	the	DT
cord-016476-78r0rsio	211	56	drug	drug	NN
cord-016476-78r0rsio	211	57	by	by	IN
cord-016476-78r0rsio	211	58	the	the	DT
cord-016476-78r0rsio	211	59	investigators	investigator	NNS
cord-016476-78r0rsio	211	60	.	.	.
cord-016476-78r0rsio	212	1	Open	open	JJ
cord-016476-78r0rsio	212	2	-	-	HYPH
cord-016476-78r0rsio	212	3	label	label	NN
cord-016476-78r0rsio	212	4	extensions	extension	NNS
cord-016476-78r0rsio	212	5	of	of	IN
cord-016476-78r0rsio	212	6	these	these	DT
cord-016476-78r0rsio	212	7	trials	trial	NNS
cord-016476-78r0rsio	212	8	have	have	VBP
cord-016476-78r0rsio	212	9	not	not	RB
cord-016476-78r0rsio	212	10	suggested	suggest	VBN
cord-016476-78r0rsio	212	11	a	a	DT
cord-016476-78r0rsio	212	12	signal	signal	NN
cord-016476-78r0rsio	212	13	for	for	IN
cord-016476-78r0rsio	212	14	concern	concern	NN
cord-016476-78r0rsio	212	15	[	[	-LRB-
cord-016476-78r0rsio	212	16	88	88	CD
cord-016476-78r0rsio	212	17	,	,	,
cord-016476-78r0rsio	212	18	89	89	CD
cord-016476-78r0rsio	212	19	]	]	-RRB-
cord-016476-78r0rsio	212	20	.	.	.
cord-016476-78r0rsio	213	1	Similarly	similarly	RB
cord-016476-78r0rsio	213	2	no	no	DT
cord-016476-78r0rsio	213	3	cases	case	NNS
cord-016476-78r0rsio	213	4	of	of	IN
cord-016476-78r0rsio	213	5	new	new	JJ
cord-016476-78r0rsio	213	6	ILD	ILD	NNP
cord-016476-78r0rsio	213	7	were	be	VBD
cord-016476-78r0rsio	213	8	reported	report	VBN
cord-016476-78r0rsio	213	9	with	with	IN
cord-016476-78r0rsio	213	10	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	213	11	etanercept	etanercept	NNP
cord-016476-78r0rsio	213	12	SB4	SB4	NNP
cord-016476-78r0rsio	213	13	,	,	,
cord-016476-78r0rsio	213	14	albeit	albeit	IN
cord-016476-78r0rsio	213	15	treatment	treatment	NN
cord-016476-78r0rsio	213	16	-	-	HYPH
cord-016476-78r0rsio	213	17	emergent	emergent	JJ
cord-016476-78r0rsio	213	18	AEs	ae	NNS
cord-016476-78r0rsio	213	19	in	in	IN
cord-016476-78r0rsio	213	20	≥2	≥2	NNP
cord-016476-78r0rsio	213	21	%	%	NN
cord-016476-78r0rsio	213	22	of	of	IN
cord-016476-78r0rsio	213	23	patients	patient	NNS
cord-016476-78r0rsio	213	24	were	be	VBD
cord-016476-78r0rsio	213	25	reported	report	VBN
cord-016476-78r0rsio	213	26	only	only	RB
cord-016476-78r0rsio	213	27	[	[	-LRB-
cord-016476-78r0rsio	213	28	90	90	CD
cord-016476-78r0rsio	213	29	]	]	-RRB-
cord-016476-78r0rsio	213	30	.	.	.
cord-016476-78r0rsio	214	1	One	one	CD
cord-016476-78r0rsio	214	2	patient	patient	NN
cord-016476-78r0rsio	214	3	in	in	IN
cord-016476-78r0rsio	214	4	the	the	DT
cord-016476-78r0rsio	214	5	SB4	SB4	NNP
cord-016476-78r0rsio	214	6	arm	arm	NN
cord-016476-78r0rsio	214	7	died	die	VBD
cord-016476-78r0rsio	214	8	due	due	JJ
cord-016476-78r0rsio	214	9	to	to	IN
cord-016476-78r0rsio	214	10	cardiorespiratory	cardiorespiratory	JJ
cord-016476-78r0rsio	214	11	failure	failure	NN
cord-016476-78r0rsio	214	12	(	(	-LRB-
cord-016476-78r0rsio	214	13	felt	feel	VBN
cord-016476-78r0rsio	214	14	to	to	TO
cord-016476-78r0rsio	214	15	be	be	VB
cord-016476-78r0rsio	214	16	unrelated	unrelated	JJ
cord-016476-78r0rsio	214	17	to	to	IN
cord-016476-78r0rsio	214	18	the	the	DT
cord-016476-78r0rsio	214	19	drug	drug	NN
cord-016476-78r0rsio	214	20	by	by	IN
cord-016476-78r0rsio	214	21	the	the	DT
cord-016476-78r0rsio	214	22	investigators	investigator	NNS
cord-016476-78r0rsio	214	23	)	)	-RRB-
cord-016476-78r0rsio	214	24	,	,	,
cord-016476-78r0rsio	214	25	and	and	CC
cord-016476-78r0rsio	214	26	further	further	JJ
cord-016476-78r0rsio	214	27	details	detail	NNS
cord-016476-78r0rsio	214	28	of	of	IN
cord-016476-78r0rsio	214	29	the	the	DT
cord-016476-78r0rsio	214	30	event	event	NN
cord-016476-78r0rsio	214	31	were	be	VBD
cord-016476-78r0rsio	214	32	not	not	RB
cord-016476-78r0rsio	214	33	provided	provide	VBN
cord-016476-78r0rsio	214	34	[	[	-LRB-
cord-016476-78r0rsio	214	35	90	90	CD
cord-016476-78r0rsio	214	36	]	]	-RRB-
cord-016476-78r0rsio	214	37	.	.	.
cord-016476-78r0rsio	215	1	Whilst	whilst	IN
cord-016476-78r0rsio	215	2	this	this	DT
cord-016476-78r0rsio	215	3	provides	provide	VBZ
cord-016476-78r0rsio	215	4	some	some	DT
cord-016476-78r0rsio	215	5	initial	initial	JJ
cord-016476-78r0rsio	215	6	reassurance	reassurance	NN
cord-016476-78r0rsio	215	7	,	,	,
cord-016476-78r0rsio	215	8	biosimilars	biosimilar	NNS
cord-016476-78r0rsio	215	9	should	should	MD
cord-016476-78r0rsio	215	10	be	be	VB
cord-016476-78r0rsio	215	11	considered	consider	VBN
cord-016476-78r0rsio	215	12	as	as	IN
cord-016476-78r0rsio	215	13	having	have	VBG
cord-016476-78r0rsio	215	14	similar	similar	JJ
cord-016476-78r0rsio	215	15	risks	risk	NNS
cord-016476-78r0rsio	215	16	to	to	IN
cord-016476-78r0rsio	215	17	the	the	DT
cord-016476-78r0rsio	215	18	originator	originator	NN
cord-016476-78r0rsio	215	19	reference	reference	NN
cord-016476-78r0rsio	215	20	products	product	NNS
cord-016476-78r0rsio	215	21	and	and	CC
cord-016476-78r0rsio	215	22	therefore	therefore	RB
cord-016476-78r0rsio	215	23	be	be	VB
cord-016476-78r0rsio	215	24	used	use	VBN
cord-016476-78r0rsio	215	25	with	with	IN
cord-016476-78r0rsio	215	26	vigilance	vigilance	NN
cord-016476-78r0rsio	215	27	in	in	IN
cord-016476-78r0rsio	215	28	the	the	DT
cord-016476-78r0rsio	215	29	context	context	NN
cord-016476-78r0rsio	215	30	of	of	IN
cord-016476-78r0rsio	215	31	established	establish	VBN
cord-016476-78r0rsio	215	32	RA	RA	NNP
cord-016476-78r0rsio	215	33	-	-	HYPH
cord-016476-78r0rsio	215	34	ILD	ILD	NNP
cord-016476-78r0rsio	215	35	.	.	.
cord-016476-78r0rsio	216	1	Rituximab	Rituximab	NNP
cord-016476-78r0rsio	216	2	is	be	VBZ
cord-016476-78r0rsio	216	3	a	a	DT
cord-016476-78r0rsio	216	4	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	216	5	chimeric	chimeric	JJ
cord-016476-78r0rsio	216	6	anti	anti	JJ
cord-016476-78r0rsio	216	7	-	-	JJ
cord-016476-78r0rsio	216	8	CD20	cd20	JJ
cord-016476-78r0rsio	216	9	antibody	antibody	NN
cord-016476-78r0rsio	216	10	licensed	license	VBN
cord-016476-78r0rsio	216	11	for	for	IN
cord-016476-78r0rsio	216	12	the	the	DT
cord-016476-78r0rsio	216	13	treatment	treatment	NN
cord-016476-78r0rsio	216	14	of	of	IN
cord-016476-78r0rsio	216	15	non	non	JJ
cord-016476-78r0rsio	216	16	-	-	JJ
cord-016476-78r0rsio	216	17	Hodgkin	Hodgkin	NNP
cord-016476-78r0rsio	216	18	lymphoma	lymphoma	NN
cord-016476-78r0rsio	216	19	and	and	CC
cord-016476-78r0rsio	216	20	RA	RA	NNP
cord-016476-78r0rsio	216	21	in	in	IN
cord-016476-78r0rsio	216	22	TNFi	TNFi	NNP
cord-016476-78r0rsio	216	23	nonresponders	nonresponder	NNS
cord-016476-78r0rsio	216	24	.	.	.
cord-016476-78r0rsio	217	1	Rituximab	Rituximab	NNP
cord-016476-78r0rsio	217	2	-	-	HYPH
cord-016476-78r0rsio	217	3	induced	induce	VBN
cord-016476-78r0rsio	217	4	ILD	ILD	NNP
cord-016476-78r0rsio	217	5	has	have	VBZ
cord-016476-78r0rsio	217	6	been	be	VBN
cord-016476-78r0rsio	217	7	a	a	DT
cord-016476-78r0rsio	217	8	well	well	RB
cord-016476-78r0rsio	217	9	-	-	HYPH
cord-016476-78r0rsio	217	10	described	describe	VBN
cord-016476-78r0rsio	217	11	AE	AE	NNP
cord-016476-78r0rsio	217	12	in	in	IN
cord-016476-78r0rsio	217	13	haematology	haematology	NN
cord-016476-78r0rsio	217	14	patients	patient	NNS
cord-016476-78r0rsio	217	15	often	often	RB
cord-016476-78r0rsio	217	16	presenting	present	VBG
cord-016476-78r0rsio	217	17	as	as	IN
cord-016476-78r0rsio	217	18	acute	acute	JJ
cord-016476-78r0rsio	217	19	/	/	SYM
cord-016476-78r0rsio	217	20	subacute	subacute	JJ
cord-016476-78r0rsio	217	21	hypoxaemic	hypoxaemic	JJ
cord-016476-78r0rsio	217	22	organising	organise	VBG
cord-016476-78r0rsio	217	23	pneumonia	pneumonia	NN
cord-016476-78r0rsio	217	24	,	,	,
cord-016476-78r0rsio	217	25	NSIP	NSIP	NNP
cord-016476-78r0rsio	217	26	or	or	CC
cord-016476-78r0rsio	217	27	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	217	28	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	217	29	[	[	-LRB-
cord-016476-78r0rsio	217	30	91	91	CD
cord-016476-78r0rsio	217	31	]	]	-RRB-
cord-016476-78r0rsio	217	32	[	[	-LRB-
cord-016476-78r0rsio	217	33	92	92	CD
cord-016476-78r0rsio	217	34	]	]	-RRB-
cord-016476-78r0rsio	217	35	[	[	-LRB-
cord-016476-78r0rsio	217	36	93	93	CD
cord-016476-78r0rsio	217	37	]	]	-RRB-
cord-016476-78r0rsio	217	38	.	.	.
cord-016476-78r0rsio	218	1	Whilst	whilst	IN
cord-016476-78r0rsio	218	2	its	-PRON-	PRP$
cord-016476-78r0rsio	218	3	pathogenesis	pathogenesis	NN
cord-016476-78r0rsio	218	4	is	be	VBZ
cord-016476-78r0rsio	218	5	unknown	unknown	JJ
cord-016476-78r0rsio	218	6	,	,	,
cord-016476-78r0rsio	218	7	it	-PRON-	PRP
cord-016476-78r0rsio	218	8	may	may	MD
cord-016476-78r0rsio	218	9	involve	involve	VB
cord-016476-78r0rsio	218	10	induction	induction	NN
cord-016476-78r0rsio	218	11	and	and	CC
cord-016476-78r0rsio	218	12	release	release	NN
cord-016476-78r0rsio	218	13	of	of	IN
cord-016476-78r0rsio	218	14	cytokines	cytokine	NNS
cord-016476-78r0rsio	218	15	,	,	,
cord-016476-78r0rsio	218	16	and	and	CC
cord-016476-78r0rsio	218	17	it	-PRON-	PRP
cord-016476-78r0rsio	218	18	has	have	VBZ
cord-016476-78r0rsio	218	19	been	be	VBN
cord-016476-78r0rsio	218	20	reported	report	VBN
cord-016476-78r0rsio	218	21	to	to	TO
cord-016476-78r0rsio	218	22	occur	occur	VB
cord-016476-78r0rsio	218	23	in	in	IN
cord-016476-78r0rsio	218	24	patients	patient	NNS
cord-016476-78r0rsio	218	25	receiving	receive	VBG
cord-016476-78r0rsio	218	26	rituximab	rituximab	NN
cord-016476-78r0rsio	218	27	for	for	IN
cord-016476-78r0rsio	218	28	several	several	JJ
cord-016476-78r0rsio	218	29	months	month	NNS
cord-016476-78r0rsio	218	30	[	[	-LRB-
cord-016476-78r0rsio	218	31	94	94	CD
cord-016476-78r0rsio	218	32	]	]	-RRB-
cord-016476-78r0rsio	218	33	.	.	.
cord-016476-78r0rsio	219	1	In	in	IN
cord-016476-78r0rsio	219	2	RA	RA	NNP
cord-016476-78r0rsio	219	3	,	,	,
cord-016476-78r0rsio	219	4	a	a	DT
cord-016476-78r0rsio	219	5	number	number	NN
cord-016476-78r0rsio	219	6	of	of	IN
cord-016476-78r0rsio	219	7	rituximab	rituximab	NN
cord-016476-78r0rsio	219	8	trials	trial	NNS
cord-016476-78r0rsio	219	9	have	have	VBP
cord-016476-78r0rsio	219	10	reported	report	VBN
cord-016476-78r0rsio	219	11	incident	incident	NN
cord-016476-78r0rsio	219	12	ILD	ILD	NNP
cord-016476-78r0rsio	219	13	[	[	-LRB-
cord-016476-78r0rsio	219	14	95	95	CD
cord-016476-78r0rsio	219	15	]	]	-RRB-
cord-016476-78r0rsio	219	16	[	[	-LRB-
cord-016476-78r0rsio	219	17	96	96	CD
cord-016476-78r0rsio	219	18	]	]	-RRB-
cord-016476-78r0rsio	219	19	[	[	-LRB-
cord-016476-78r0rsio	219	20	97	97	CD
cord-016476-78r0rsio	219	21	]	]	-RRB-
cord-016476-78r0rsio	219	22	,	,	,
cord-016476-78r0rsio	219	23	including	include	VBG
cord-016476-78r0rsio	219	24	subsequent	subsequent	JJ
cord-016476-78r0rsio	219	25	deaths	death	NNS
cord-016476-78r0rsio	219	26	from	from	IN
cord-016476-78r0rsio	219	27	acute	acute	JJ
cord-016476-78r0rsio	219	28	respiratory	respiratory	JJ
cord-016476-78r0rsio	219	29	distress	distress	NN
cord-016476-78r0rsio	219	30	syndrome	syndrome	NN
cord-016476-78r0rsio	219	31	(	(	-LRB-
cord-016476-78r0rsio	219	32	ARDS	ARDS	NNP
cord-016476-78r0rsio	219	33	)	)	-RRB-
cord-016476-78r0rsio	220	1	[	[	-LRB-
cord-016476-78r0rsio	220	2	98	98	CD
cord-016476-78r0rsio	220	3	]	]	-RRB-
cord-016476-78r0rsio	220	4	and	and	CC
cord-016476-78r0rsio	220	5	culture	culture	NN
cord-016476-78r0rsio	220	6	-	-	HYPH
cord-016476-78r0rsio	220	7	negative	negative	JJ
cord-016476-78r0rsio	220	8	(	(	-LRB-
cord-016476-78r0rsio	220	9	non	non	JJ
cord-016476-78r0rsio	220	10	-	-	JJ
cord-016476-78r0rsio	220	11	infective	infective	JJ
cord-016476-78r0rsio	220	12	)	)	-RRB-
cord-016476-78r0rsio	220	13	bronchopneumonia	bronchopneumonia	NN
cord-016476-78r0rsio	220	14	[	[	-LRB-
cord-016476-78r0rsio	220	15	99	99	CD
cord-016476-78r0rsio	220	16	]	]	-RRB-
cord-016476-78r0rsio	220	17	.	.	.
cord-016476-78r0rsio	221	1	Hadjinicolaou	Hadjinicolaou	NNP
cord-016476-78r0rsio	221	2	et	et	NNP
cord-016476-78r0rsio	221	3	al	al	NNP
cord-016476-78r0rsio	221	4	.	.	.
cord-016476-78r0rsio	222	1	identified	identify	VBN
cord-016476-78r0rsio	222	2	>	>	XX
cord-016476-78r0rsio	222	3	120	120	CD
cord-016476-78r0rsio	222	4	cases	case	NNS
cord-016476-78r0rsio	222	5	of	of	IN
cord-016476-78r0rsio	222	6	rituximab	rituximab	NN
cord-016476-78r0rsio	222	7	-	-	HYPH
cord-016476-78r0rsio	222	8	associated	associate	VBN
cord-016476-78r0rsio	222	9	ILD	ILD	NNP
cord-016476-78r0rsio	222	10	up	up	RP
cord-016476-78r0rsio	222	11	to	to	IN
cord-016476-78r0rsio	222	12	June	June	NNP
cord-016476-78r0rsio	222	13	2010	2010	CD
cord-016476-78r0rsio	222	14	in	in	IN
cord-016476-78r0rsio	222	15	a	a	DT
cord-016476-78r0rsio	222	16	systematic	systematic	JJ
cord-016476-78r0rsio	222	17	review	review	NN
cord-016476-78r0rsio	222	18	of	of	IN
cord-016476-78r0rsio	222	19	published	publish	VBN
cord-016476-78r0rsio	222	20	studies	study	NNS
cord-016476-78r0rsio	222	21	and	and	CC
cord-016476-78r0rsio	222	22	reports	report	VBZ
cord-016476-78r0rsio	222	23	to	to	IN
cord-016476-78r0rsio	222	24	the	the	DT
cord-016476-78r0rsio	222	25	FDA	FDA	NNP
cord-016476-78r0rsio	222	26	and	and	CC
cord-016476-78r0rsio	222	27	EMA	EMA	NNP
cord-016476-78r0rsio	222	28	[	[	-LRB-
cord-016476-78r0rsio	222	29	100	100	CD
cord-016476-78r0rsio	222	30	]	]	-RRB-
cord-016476-78r0rsio	222	31	.	.	.
cord-016476-78r0rsio	223	1	In	in	IN
cord-016476-78r0rsio	223	2	addition	addition	NN
cord-016476-78r0rsio	223	3	,	,	,
cord-016476-78r0rsio	223	4	UK	UK	NNP
cord-016476-78r0rsio	223	5	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	223	6	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	223	7	reporting	reporting	NN
cord-016476-78r0rsio	223	8	systems	system	NNS
cord-016476-78r0rsio	223	9	(	(	-LRB-
cord-016476-78r0rsio	223	10	via	via	IN
cord-016476-78r0rsio	223	11	its	-PRON-	PRP$
cord-016476-78r0rsio	223	12	Yellow	Yellow	NNP
cord-016476-78r0rsio	223	13	Card	Card	NNP
cord-016476-78r0rsio	223	14	system	system	NN
cord-016476-78r0rsio	223	15	)	)	-RRB-
cord-016476-78r0rsio	223	16	have	have	VBP
cord-016476-78r0rsio	223	17	recorded	record	VBN
cord-016476-78r0rsio	223	18	hundreds	hundred	NNS
cord-016476-78r0rsio	223	19	of	of	IN
cord-016476-78r0rsio	223	20	rituximab	rituximab	NN
cord-016476-78r0rsio	223	21	-	-	HYPH
cord-016476-78r0rsio	223	22	associated	associate	VBN
cord-016476-78r0rsio	223	23	cases	case	NNS
cord-016476-78r0rsio	223	24	of	of	IN
cord-016476-78r0rsio	223	25	non	non	JJ
cord-016476-78r0rsio	223	26	-	-	JJ
cord-016476-78r0rsio	223	27	infectious	infectious	JJ
cord-016476-78r0rsio	223	28	respiratory	respiratory	JJ
cord-016476-78r0rsio	223	29	disorders	disorder	NNS
cord-016476-78r0rsio	223	30	till	till	IN
cord-016476-78r0rsio	223	31	March	March	NNP
cord-016476-78r0rsio	223	32	2016	2016	CD
cord-016476-78r0rsio	223	33	(	(	-LRB-
cord-016476-78r0rsio	223	34	Table	table	NN
cord-016476-78r0rsio	223	35	9	9	CD
cord-016476-78r0rsio	223	36	.2	.2	CD
cord-016476-78r0rsio	223	37	)	)	-RRB-
cord-016476-78r0rsio	223	38	.	.	.
cord-016476-78r0rsio	224	1	Of	of	IN
cord-016476-78r0rsio	224	2	the	the	DT
cord-016476-78r0rsio	224	3	patients	patient	NNS
cord-016476-78r0rsio	224	4	with	with	IN
cord-016476-78r0rsio	224	5	possible	possible	JJ
cord-016476-78r0rsio	224	6	rituximab	rituximab	NN
cord-016476-78r0rsio	224	7	-	-	HYPH
cord-016476-78r0rsio	224	8	associated	associate	VBN
cord-016476-78r0rsio	224	9	ILD	ILD	NNP
cord-016476-78r0rsio	224	10	/	/	SYM
cord-016476-78r0rsio	224	11	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	224	12	,	,	,
cord-016476-78r0rsio	224	13	15	15	CD
cord-016476-78r0rsio	224	14	deaths	death	NNS
cord-016476-78r0rsio	224	15	have	have	VBP
cord-016476-78r0rsio	224	16	been	be	VBN
cord-016476-78r0rsio	224	17	reported	report	VBN
cord-016476-78r0rsio	224	18	(	(	-LRB-
cord-016476-78r0rsio	224	19	Table	table	NN
cord-016476-78r0rsio	224	20	9	9	CD
cord-016476-78r0rsio	224	21	.2	.2	CD
cord-016476-78r0rsio	224	22	)	)	-RRB-
cord-016476-78r0rsio	224	23	.	.	.
cord-016476-78r0rsio	225	1	Further	further	JJ
cord-016476-78r0rsio	225	2	observational	observational	JJ
cord-016476-78r0rsio	225	3	evidence	evidence	NN
cord-016476-78r0rsio	225	4	has	have	VBZ
cord-016476-78r0rsio	225	5	been	be	VBN
cord-016476-78r0rsio	225	6	discussed	discuss	VBN
cord-016476-78r0rsio	225	7	in	in	IN
cord-016476-78r0rsio	225	8	section	section	NN
cord-016476-78r0rsio	225	9	"	"	``
cord-016476-78r0rsio	225	10	Other	other	JJ
cord-016476-78r0rsio	225	11	Agents	Agents	NNPS
cord-016476-78r0rsio	225	12	with	with	IN
cord-016476-78r0rsio	225	13	Limited	Limited	NNP
cord-016476-78r0rsio	225	14	Agents	Agents	NNPS
cord-016476-78r0rsio	225	15	in	in	IN
cord-016476-78r0rsio	225	16	RA	RA	NNP
cord-016476-78r0rsio	225	17	-	-	HYPH
cord-016476-78r0rsio	225	18	ILD	ILD	NNP
cord-016476-78r0rsio	225	19	"	"	''
cord-016476-78r0rsio	225	20	)	)	-RRB-
cord-016476-78r0rsio	225	21	.	.	.
cord-016476-78r0rsio	226	1	Abatacept	Abatacept	NNP
cord-016476-78r0rsio	226	2	is	be	VBZ
cord-016476-78r0rsio	226	3	a	a	DT
cord-016476-78r0rsio	226	4	selective	selective	JJ
cord-016476-78r0rsio	226	5	T	t	NN
cord-016476-78r0rsio	226	6	-	-	HYPH
cord-016476-78r0rsio	226	7	cell	cell	NN
cord-016476-78r0rsio	226	8	costimulation	costimulation	NN
cord-016476-78r0rsio	226	9	modulator	modulator	NN
cord-016476-78r0rsio	226	10	.	.	.
cord-016476-78r0rsio	227	1	It	-PRON-	PRP
cord-016476-78r0rsio	227	2	is	be	VBZ
cord-016476-78r0rsio	227	3	a	a	DT
cord-016476-78r0rsio	227	4	fully	fully	RB
cord-016476-78r0rsio	227	5	human	human	JJ
cord-016476-78r0rsio	227	6	recombinant	recombinant	JJ
cord-016476-78r0rsio	227	7	protein	protein	NN
cord-016476-78r0rsio	227	8	that	that	WDT
cord-016476-78r0rsio	227	9	comprises	comprise	VBZ
cord-016476-78r0rsio	227	10	of	of	IN
cord-016476-78r0rsio	227	11	the	the	DT
cord-016476-78r0rsio	227	12	extracellular	extracellular	JJ
cord-016476-78r0rsio	227	13	domain	domain	NN
cord-016476-78r0rsio	227	14	of	of	IN
cord-016476-78r0rsio	227	15	CTLA4	CTLA4	NNS
cord-016476-78r0rsio	227	16	and	and	CC
cord-016476-78r0rsio	227	17	the	the	DT
cord-016476-78r0rsio	227	18	Fc	Fc	NNP
cord-016476-78r0rsio	227	19	portion	portion	NN
cord-016476-78r0rsio	227	20	of	of	IN
cord-016476-78r0rsio	227	21	an	an	DT
cord-016476-78r0rsio	227	22	IgG1	igg1	NN
cord-016476-78r0rsio	227	23	molecule	molecule	NN
cord-016476-78r0rsio	227	24	that	that	WDT
cord-016476-78r0rsio	227	25	has	have	VBZ
cord-016476-78r0rsio	227	26	been	be	VBN
cord-016476-78r0rsio	227	27	modified	modify	VBN
cord-016476-78r0rsio	227	28	to	to	TO
cord-016476-78r0rsio	227	29	prevent	prevent	VB
cord-016476-78r0rsio	227	30	complement	complement	NN
cord-016476-78r0rsio	227	31	activation	activation	NN
cord-016476-78r0rsio	227	32	.	.	.
cord-016476-78r0rsio	228	1	Pooled	pool	VBN
cord-016476-78r0rsio	228	2	safety	safety	NN
cord-016476-78r0rsio	228	3	data	datum	NNS
cord-016476-78r0rsio	228	4	from	from	IN
cord-016476-78r0rsio	228	5	eight	eight	CD
cord-016476-78r0rsio	228	6	trials	trial	NNS
cord-016476-78r0rsio	228	7	of	of	IN
cord-016476-78r0rsio	228	8	abatacept	abatacept	NNP
cord-016476-78r0rsio	228	9	involving	involve	VBG
cord-016476-78r0rsio	228	10	3173	3173	CD
cord-016476-78r0rsio	228	11	patients	patient	NNS
cord-016476-78r0rsio	228	12	with	with	IN
cord-016476-78r0rsio	228	13	RA	RA	NNP
cord-016476-78r0rsio	228	14	reported	report	VBD
cord-016476-78r0rsio	228	15	incident	incident	NN
cord-016476-78r0rsio	228	16	ILD	ILD	NNP
cord-016476-78r0rsio	228	17	in	in	IN
cord-016476-78r0rsio	228	18	11	11	CD
cord-016476-78r0rsio	228	19	patients	patient	NNS
cord-016476-78r0rsio	228	20	(	(	-LRB-
cord-016476-78r0rsio	228	21	0.11	0.11	CD
cord-016476-78r0rsio	228	22	cases	case	NNS
cord-016476-78r0rsio	228	23	per	per	IN
cord-016476-78r0rsio	228	24	100	100	CD
cord-016476-78r0rsio	228	25	person	person	NN
cord-016476-78r0rsio	228	26	-	-	HYPH
cord-016476-78r0rsio	228	27	years	year	NNS
cord-016476-78r0rsio	228	28	)	)	-RRB-
cord-016476-78r0rsio	228	29	,	,	,
cord-016476-78r0rsio	228	30	with	with	IN
cord-016476-78r0rsio	228	31	no	no	DT
cord-016476-78r0rsio	228	32	events	event	NNS
cord-016476-78r0rsio	228	33	reported	report	VBN
cord-016476-78r0rsio	228	34	in	in	IN
cord-016476-78r0rsio	228	35	the	the	DT
cord-016476-78r0rsio	228	36	placebo	placebo	NN
cord-016476-78r0rsio	228	37	control	control	NN
cord-016476-78r0rsio	228	38	groups	group	NNS
cord-016476-78r0rsio	228	39	[	[	-LRB-
cord-016476-78r0rsio	228	40	101	101	CD
cord-016476-78r0rsio	228	41	]	]	-RRB-
cord-016476-78r0rsio	228	42	.	.	.
cord-016476-78r0rsio	229	1	Patients	patient	NNS
cord-016476-78r0rsio	229	2	with	with	IN
cord-016476-78r0rsio	229	3	pre	pre	JJ
cord-016476-78r0rsio	229	4	-	-	JJ
cord-016476-78r0rsio	229	5	existing	existing	JJ
cord-016476-78r0rsio	229	6	RA	RA	NNP
cord-016476-78r0rsio	229	7	-	-	HYPH
cord-016476-78r0rsio	229	8	ILD	ILD	NNP
cord-016476-78r0rsio	229	9	were	be	VBD
cord-016476-78r0rsio	229	10	excluded	exclude	VBN
cord-016476-78r0rsio	229	11	from	from	IN
cord-016476-78r0rsio	229	12	all	all	DT
cord-016476-78r0rsio	229	13	of	of	IN
cord-016476-78r0rsio	229	14	the	the	DT
cord-016476-78r0rsio	229	15	initial	initial	JJ
cord-016476-78r0rsio	229	16	abatacept	abatacept	NNP
cord-016476-78r0rsio	229	17	trials	trial	NNS
cord-016476-78r0rsio	229	18	[	[	-LRB-
cord-016476-78r0rsio	229	19	101	101	CD
cord-016476-78r0rsio	229	20	]	]	-RRB-
cord-016476-78r0rsio	229	21	.	.	.
cord-016476-78r0rsio	230	1	Therefore	therefore	RB
cord-016476-78r0rsio	230	2	limited	limited	JJ
cord-016476-78r0rsio	230	3	conclusions	conclusion	NNS
cord-016476-78r0rsio	230	4	can	can	MD
cord-016476-78r0rsio	230	5	be	be	VB
cord-016476-78r0rsio	230	6	drawn	draw	VBN
cord-016476-78r0rsio	230	7	from	from	IN
cord-016476-78r0rsio	230	8	existing	exist	VBG
cord-016476-78r0rsio	230	9	trial	trial	NN
cord-016476-78r0rsio	230	10	data	datum	NNS
cord-016476-78r0rsio	230	11	,	,	,
cord-016476-78r0rsio	230	12	which	which	WDT
cord-016476-78r0rsio	230	13	may	may	MD
cord-016476-78r0rsio	230	14	suggest	suggest	VB
cord-016476-78r0rsio	230	15	a	a	DT
cord-016476-78r0rsio	230	16	small	small	JJ
cord-016476-78r0rsio	230	17	increase	increase	NN
cord-016476-78r0rsio	230	18	in	in	IN
cord-016476-78r0rsio	230	19	incident	incident	NN
cord-016476-78r0rsio	230	20	ILD	ILD	NNP
cord-016476-78r0rsio	230	21	in	in	IN
cord-016476-78r0rsio	230	22	patients	patient	NNS
cord-016476-78r0rsio	230	23	with	with	IN
cord-016476-78r0rsio	230	24	RA	RA	NNP
cord-016476-78r0rsio	230	25	.	.	.
cord-016476-78r0rsio	231	1	Despite	despite	IN
cord-016476-78r0rsio	231	2	its	-PRON-	PRP$
cord-016476-78r0rsio	231	3	FDA	FDA	NNP
cord-016476-78r0rsio	231	4	licence	licence	NN
cord-016476-78r0rsio	231	5	back	back	RB
cord-016476-78r0rsio	231	6	in	in	IN
cord-016476-78r0rsio	231	7	2005	2005	CD
cord-016476-78r0rsio	231	8	,	,	,
cord-016476-78r0rsio	231	9	few	few	JJ
cord-016476-78r0rsio	231	10	case	case	NN
cord-016476-78r0rsio	231	11	reports	report	NNS
cord-016476-78r0rsio	231	12	exist	exist	VBP
cord-016476-78r0rsio	231	13	describing	describe	VBG
cord-016476-78r0rsio	231	14	abataceptinduced	abataceptinduce	VBN
cord-016476-78r0rsio	231	15	lung	lung	NN
cord-016476-78r0rsio	231	16	injury	injury	NN
cord-016476-78r0rsio	231	17	.	.	.
cord-016476-78r0rsio	232	1	One	one	CD
cord-016476-78r0rsio	232	2	case	case	NN
cord-016476-78r0rsio	232	3	reported	report	VBD
cord-016476-78r0rsio	232	4	drug	drug	NN
cord-016476-78r0rsio	232	5	-	-	HYPH
cord-016476-78r0rsio	232	6	induced	induce	VBN
cord-016476-78r0rsio	232	7	respiratory	respiratory	JJ
cord-016476-78r0rsio	232	8	failure	failure	NN
cord-016476-78r0rsio	232	9	,	,	,
cord-016476-78r0rsio	232	10	2	2	CD
cord-016476-78r0rsio	232	11	weeks	week	NNS
cord-016476-78r0rsio	232	12	after	after	IN
cord-016476-78r0rsio	232	13	the	the	DT
cord-016476-78r0rsio	232	14	second	second	JJ
cord-016476-78r0rsio	232	15	abatacept	abatacept	NN
cord-016476-78r0rsio	232	16	dose	dose	NN
cord-016476-78r0rsio	232	17	[	[	-LRB-
cord-016476-78r0rsio	232	18	102	102	CD
cord-016476-78r0rsio	232	19	]	]	-RRB-
cord-016476-78r0rsio	232	20	,	,	,
cord-016476-78r0rsio	232	21	however	however	RB
cord-016476-78r0rsio	232	22	was	be	VBD
cord-016476-78r0rsio	232	23	unable	unable	JJ
cord-016476-78r0rsio	232	24	to	to	TO
cord-016476-78r0rsio	232	25	distinguish	distinguish	VB
cord-016476-78r0rsio	232	26	if	if	IN
cord-016476-78r0rsio	232	27	infection	infection	NN
cord-016476-78r0rsio	232	28	was	be	VBD
cord-016476-78r0rsio	232	29	the	the	DT
cord-016476-78r0rsio	232	30	reason	reason	NN
cord-016476-78r0rsio	232	31	for	for	IN
cord-016476-78r0rsio	232	32	deterioration	deterioration	NN
cord-016476-78r0rsio	232	33	by	by	IN
cord-016476-78r0rsio	232	34	the	the	DT
cord-016476-78r0rsio	232	35	time	time	NN
cord-016476-78r0rsio	232	36	of	of	IN
cord-016476-78r0rsio	232	37	death	death	NN
cord-016476-78r0rsio	232	38	.	.	.
cord-016476-78r0rsio	233	1	Relatively	relatively	RB
cord-016476-78r0rsio	233	2	few	few	JJ
cord-016476-78r0rsio	233	3	respiratory	respiratory	JJ
cord-016476-78r0rsio	233	4	ADRs	adr	NNS
cord-016476-78r0rsio	233	5	have	have	VBP
cord-016476-78r0rsio	233	6	been	be	VBN
cord-016476-78r0rsio	233	7	reported	report	VBN
cord-016476-78r0rsio	233	8	to	to	IN
cord-016476-78r0rsio	233	9	the	the	DT
cord-016476-78r0rsio	233	10	regulatory	regulatory	JJ
cord-016476-78r0rsio	233	11	agencies	agency	NNS
cord-016476-78r0rsio	233	12	after	after	IN
cord-016476-78r0rsio	233	13	treatment	treatment	NN
cord-016476-78r0rsio	233	14	with	with	IN
cord-016476-78r0rsio	233	15	abatacept	abatacept	NN
cord-016476-78r0rsio	233	16	compared	compare	VBN
cord-016476-78r0rsio	233	17	with	with	IN
cord-016476-78r0rsio	233	18	other	other	JJ
cord-016476-78r0rsio	233	19	biologic	biologic	JJ
cord-016476-78r0rsio	233	20	agents	agent	NNS
cord-016476-78r0rsio	233	21	(	(	-LRB-
cord-016476-78r0rsio	233	22	Table	table	NN
cord-016476-78r0rsio	233	23	9	9	CD
cord-016476-78r0rsio	233	24	.	.	CD
cord-016476-78r0rsio	233	25	2	2	CD
cord-016476-78r0rsio	233	26	)	)	-RRB-
cord-016476-78r0rsio	233	27	.	.	.
cord-016476-78r0rsio	234	1	Indeed	indeed	RB
cord-016476-78r0rsio	234	2	,	,	,
cord-016476-78r0rsio	234	3	only	only	RB
cord-016476-78r0rsio	234	4	one	one	CD
cord-016476-78r0rsio	234	5	case	case	NN
cord-016476-78r0rsio	234	6	of	of	IN
cord-016476-78r0rsio	234	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	234	8	and	and	CC
cord-016476-78r0rsio	234	9	23	23	CD
cord-016476-78r0rsio	234	10	cases	case	NNS
cord-016476-78r0rsio	234	11	of	of	IN
cord-016476-78r0rsio	234	12	non	non	JJ
cord-016476-78r0rsio	234	13	-	-	JJ
cord-016476-78r0rsio	234	14	infectious	infectious	JJ
cord-016476-78r0rsio	234	15	respiratory	respiratory	JJ
cord-016476-78r0rsio	234	16	events	event	NNS
cord-016476-78r0rsio	234	17	had	have	VBD
cord-016476-78r0rsio	234	18	been	be	VBN
cord-016476-78r0rsio	234	19	reported	report	VBN
cord-016476-78r0rsio	234	20	through	through	IN
cord-016476-78r0rsio	234	21	the	the	DT
cord-016476-78r0rsio	234	22	UK	UK	NNP
cord-016476-78r0rsio	234	23	Medicines	Medicines	NNPS
cord-016476-78r0rsio	234	24	and	and	CC
cord-016476-78r0rsio	234	25	Healthcare	Healthcare	NNP
cord-016476-78r0rsio	234	26	Products	Products	NNPS
cord-016476-78r0rsio	234	27	Regulatory	Regulatory	NNP
cord-016476-78r0rsio	234	28	Agency	Agency	NNP
cord-016476-78r0rsio	234	29	(	(	-LRB-
cord-016476-78r0rsio	234	30	MHRA	MHRA	NNP
cord-016476-78r0rsio	234	31	)	)	-RRB-
cord-016476-78r0rsio	234	32	'	'	``
cord-016476-78r0rsio	234	33	Yellow	Yellow	NNP
cord-016476-78r0rsio	234	34	Card	Card	NNP
cord-016476-78r0rsio	234	35	'	'	''
cord-016476-78r0rsio	234	36	system	system	NN
cord-016476-78r0rsio	234	37	by	by	IN
cord-016476-78r0rsio	234	38	March	March	NNP
cord-016476-78r0rsio	234	39	2016	2016	CD
cord-016476-78r0rsio	234	40	.	.	.
cord-016476-78r0rsio	235	1	However	however	RB
cord-016476-78r0rsio	235	2	it	-PRON-	PRP
cord-016476-78r0rsio	235	3	is	be	VBZ
cord-016476-78r0rsio	235	4	worth	worth	JJ
cord-016476-78r0rsio	235	5	noting	note	VBG
cord-016476-78r0rsio	235	6	at	at	IN
cord-016476-78r0rsio	235	7	exposure	exposure	NN
cord-016476-78r0rsio	235	8	to	to	IN
cord-016476-78r0rsio	235	9	abatacept	abatacept	NNP
cord-016476-78r0rsio	235	10	may	may	MD
cord-016476-78r0rsio	235	11	be	be	VB
cord-016476-78r0rsio	235	12	limited	limit	VBN
cord-016476-78r0rsio	235	13	in	in	IN
cord-016476-78r0rsio	235	14	the	the	DT
cord-016476-78r0rsio	235	15	UK	UK	NNP
cord-016476-78r0rsio	235	16	due	due	IN
cord-016476-78r0rsio	235	17	to	to	IN
cord-016476-78r0rsio	235	18	lack	lack	NN
cord-016476-78r0rsio	235	19	of	of	IN
cord-016476-78r0rsio	235	20	its	-PRON-	PRP$
cord-016476-78r0rsio	235	21	initial	initial	JJ
cord-016476-78r0rsio	235	22	approval	approval	NN
cord-016476-78r0rsio	235	23	by	by	IN
cord-016476-78r0rsio	235	24	the	the	DT
cord-016476-78r0rsio	235	25	National	National	NNP
cord-016476-78r0rsio	235	26	Institute	Institute	NNP
cord-016476-78r0rsio	235	27	of	of	IN
cord-016476-78r0rsio	235	28	Health	Health	NNP
cord-016476-78r0rsio	235	29	and	and	CC
cord-016476-78r0rsio	235	30	Care	Care	NNP
cord-016476-78r0rsio	235	31	Excellence	Excellence	NNP
cord-016476-78r0rsio	235	32	(	(	-LRB-
cord-016476-78r0rsio	235	33	NICE	NICE	NNP
cord-016476-78r0rsio	235	34	)	)	-RRB-
cord-016476-78r0rsio	235	35	until	until	IN
cord-016476-78r0rsio	235	36	2010	2010	CD
cord-016476-78r0rsio	235	37	as	as	IN
cord-016476-78r0rsio	235	38	a	a	DT
cord-016476-78r0rsio	235	39	second	second	JJ
cord-016476-78r0rsio	235	40	-	-	HYPH
cord-016476-78r0rsio	235	41	line	line	NN
cord-016476-78r0rsio	235	42	biologic	biologic	JJ
cord-016476-78r0rsio	235	43	(	(	-LRB-
cord-016476-78r0rsio	235	44	following	follow	VBG
cord-016476-78r0rsio	235	45	TNFi	TNFi	NNS
cord-016476-78r0rsio	235	46	failure	failure	NN
cord-016476-78r0rsio	235	47	and	and	CC
cord-016476-78r0rsio	235	48	if	if	IN
cord-016476-78r0rsio	235	49	rituximab	rituximab	NN
cord-016476-78r0rsio	235	50	was	be	VBD
cord-016476-78r0rsio	235	51	contraindicated	contraindicate	VBN
cord-016476-78r0rsio	235	52	)	)	-RRB-
cord-016476-78r0rsio	235	53	and	and	CC
cord-016476-78r0rsio	235	54	first	first	JJ
cord-016476-78r0rsio	235	55	-	-	HYPH
cord-016476-78r0rsio	235	56	line	line	NN
cord-016476-78r0rsio	235	57	biologic	biologic	NN
cord-016476-78r0rsio	235	58	approved	approve	VBN
cord-016476-78r0rsio	235	59	in	in	IN
cord-016476-78r0rsio	235	60	2013	2013	CD
cord-016476-78r0rsio	235	61	.	.	.
cord-016476-78r0rsio	236	1	Whilst	whilst	IN
cord-016476-78r0rsio	236	2	experience	experience	NN
cord-016476-78r0rsio	236	3	of	of	IN
cord-016476-78r0rsio	236	4	using	use	VBG
cord-016476-78r0rsio	236	5	abatacept	abatacept	NN
cord-016476-78r0rsio	236	6	in	in	IN
cord-016476-78r0rsio	236	7	the	the	DT
cord-016476-78r0rsio	236	8	context	context	NN
cord-016476-78r0rsio	236	9	of	of	IN
cord-016476-78r0rsio	236	10	pre	pre	JJ
cord-016476-78r0rsio	236	11	-	-	JJ
cord-016476-78r0rsio	236	12	existing	existing	JJ
cord-016476-78r0rsio	236	13	ILD	ILD	NNP
cord-016476-78r0rsio	236	14	is	be	VBZ
cord-016476-78r0rsio	236	15	limited	limit	VBN
cord-016476-78r0rsio	236	16	,	,	,
cord-016476-78r0rsio	236	17	a	a	DT
cord-016476-78r0rsio	236	18	case	case	NN
cord-016476-78r0rsio	236	19	report	report	NN
cord-016476-78r0rsio	236	20	of	of	IN
cord-016476-78r0rsio	236	21	rapid	rapid	JJ
cord-016476-78r0rsio	236	22	-	-	HYPH
cord-016476-78r0rsio	236	23	onset	onset	NN
cord-016476-78r0rsio	236	24	interstitial	interstitial	JJ
cord-016476-78r0rsio	236	25	pneumonia	pneumonia	NN
cord-016476-78r0rsio	236	26	2	2	CD
cord-016476-78r0rsio	236	27	days	day	NNS
cord-016476-78r0rsio	236	28	post	post	NN
cord-016476-78r0rsio	236	29	initiation	initiation	NN
cord-016476-78r0rsio	236	30	of	of	IN
cord-016476-78r0rsio	236	31	Administration	Administration	NNP
cord-016476-78r0rsio	236	32	,	,	,
cord-016476-78r0rsio	237	1	MHRA	MHRA	NNP
cord-016476-78r0rsio	237	2	medicines	medicine	NNS
cord-016476-78r0rsio	237	3	and	and	CC
cord-016476-78r0rsio	237	4	healthcare	healthcare	NN
cord-016476-78r0rsio	237	5	products	product	NNS
cord-016476-78r0rsio	237	6	regulatory	regulatory	JJ
cord-016476-78r0rsio	237	7	agency	agency	NN
cord-016476-78r0rsio	237	8	,	,	,
cord-016476-78r0rsio	237	9	NA	NA	NNP
cord-016476-78r0rsio	237	10	data	datum	NNS
cord-016476-78r0rsio	237	11	not	not	RB
cord-016476-78r0rsio	237	12	available	available	JJ
cord-016476-78r0rsio	237	13	,	,	,
cord-016476-78r0rsio	237	14	RA	RA	NNP
cord-016476-78r0rsio	237	15	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	237	16	arthritis	arthritis	NN
cord-016476-78r0rsio	237	17	a	a	NNP
cord-016476-78r0rsio	237	18	Includes	include	VBZ
cord-016476-78r0rsio	237	19	cases	case	NNS
cord-016476-78r0rsio	237	20	reported	report	VBN
cord-016476-78r0rsio	237	21	as	as	IN
cord-016476-78r0rsio	237	22	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	237	23	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	237	24	fibrosis	fibrosis	NN
cord-016476-78r0rsio	237	25	,	,	,
cord-016476-78r0rsio	237	26	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	237	27	fibrosis	fibrosis	NN
cord-016476-78r0rsio	237	28	and	and	CC
cord-016476-78r0rsio	237	29	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	237	30	toxicity	toxicity	NN
cord-016476-78r0rsio	237	31	treatment	treatment	NN
cord-016476-78r0rsio	237	32	has	have	VBZ
cord-016476-78r0rsio	237	33	been	be	VBN
cord-016476-78r0rsio	237	34	described	describe	VBN
cord-016476-78r0rsio	237	35	in	in	IN
cord-016476-78r0rsio	237	36	a	a	DT
cord-016476-78r0rsio	237	37	Japanese	japanese	JJ
cord-016476-78r0rsio	237	38	patient	patient	NN
cord-016476-78r0rsio	237	39	[	[	-LRB-
cord-016476-78r0rsio	237	40	103	103	CD
cord-016476-78r0rsio	237	41	]	]	-RRB-
cord-016476-78r0rsio	237	42	.	.	.
cord-016476-78r0rsio	238	1	Conversely	conversely	RB
cord-016476-78r0rsio	238	2	,	,	,
cord-016476-78r0rsio	238	3	there	there	EX
cord-016476-78r0rsio	238	4	are	be	VBP
cord-016476-78r0rsio	238	5	reports	report	NNS
cord-016476-78r0rsio	238	6	of	of	IN
cord-016476-78r0rsio	238	7	stabilisation	stabilisation	NN
cord-016476-78r0rsio	238	8	of	of	IN
cord-016476-78r0rsio	238	9	RA	RA	NNP
cord-016476-78r0rsio	238	10	-	-	HYPH
cord-016476-78r0rsio	238	11	ILD	ILD	NNP
cord-016476-78r0rsio	238	12	on	on	IN
cord-016476-78r0rsio	238	13	abatacept	abatacept	NNP
cord-016476-78r0rsio	238	14	[	[	-LRB-
cord-016476-78r0rsio	238	15	104	104	CD
cord-016476-78r0rsio	238	16	]	]	-RRB-
cord-016476-78r0rsio	238	17	and	and	CC
cord-016476-78r0rsio	238	18	improvement	improvement	NN
cord-016476-78r0rsio	238	19	in	in	IN
cord-016476-78r0rsio	238	20	some	some	DT
cord-016476-78r0rsio	238	21	patients	patient	NNS
cord-016476-78r0rsio	238	22	[	[	-LRB-
cord-016476-78r0rsio	238	23	105	105	CD
cord-016476-78r0rsio	238	24	]	]	-RRB-
cord-016476-78r0rsio	238	25	.	.	.
cord-016476-78r0rsio	239	1	In	in	IN
cord-016476-78r0rsio	239	2	a	a	DT
cord-016476-78r0rsio	239	3	case	case	NN
cord-016476-78r0rsio	239	4	series	series	NN
cord-016476-78r0rsio	239	5	of	of	IN
cord-016476-78r0rsio	239	6	16	16	CD
cord-016476-78r0rsio	239	7	patients	patient	NNS
cord-016476-78r0rsio	239	8	with	with	IN
cord-016476-78r0rsio	239	9	RA	RA	NNP
cord-016476-78r0rsio	239	10	-	-	HYPH
cord-016476-78r0rsio	239	11	ILD	ILD	NNP
cord-016476-78r0rsio	239	12	(	(	-LRB-
cord-016476-78r0rsio	239	13	with	with	IN
cord-016476-78r0rsio	239	14	varying	vary	VBG
cord-016476-78r0rsio	239	15	grades	grade	NNS
cord-016476-78r0rsio	239	16	of	of	IN
cord-016476-78r0rsio	239	17	severity	severity	NN
cord-016476-78r0rsio	239	18	at	at	IN
cord-016476-78r0rsio	239	19	baseline	baseline	NN
cord-016476-78r0rsio	239	20	)	)	-RRB-
cord-016476-78r0rsio	239	21	,	,	,
cord-016476-78r0rsio	239	22	all	all	DT
cord-016476-78r0rsio	239	23	patients	patient	NNS
cord-016476-78r0rsio	239	24	completed	complete	VBD
cord-016476-78r0rsio	239	25	52	52	CD
cord-016476-78r0rsio	239	26	weeks	week	NNS
cord-016476-78r0rsio	239	27	of	of	IN
cord-016476-78r0rsio	239	28	abatacept	abatacept	NNP
cord-016476-78r0rsio	239	29	treatment	treatment	NN
cord-016476-78r0rsio	239	30	,	,	,
cord-016476-78r0rsio	239	31	and	and	CC
cord-016476-78r0rsio	239	32	no	no	DT
cord-016476-78r0rsio	239	33	one	one	NN
cord-016476-78r0rsio	239	34	was	be	VBD
cord-016476-78r0rsio	239	35	reported	report	VBN
cord-016476-78r0rsio	239	36	to	to	TO
cord-016476-78r0rsio	239	37	have	have	VB
cord-016476-78r0rsio	239	38	an	an	DT
cord-016476-78r0rsio	239	39	exacerbation	exacerbation	NN
cord-016476-78r0rsio	239	40	of	of	IN
cord-016476-78r0rsio	239	41	their	-PRON-	PRP$
cord-016476-78r0rsio	239	42	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	239	43	disease	disease	NN
cord-016476-78r0rsio	239	44	[	[	-LRB-
cord-016476-78r0rsio	239	45	105	105	CD
cord-016476-78r0rsio	239	46	]	]	-RRB-
cord-016476-78r0rsio	239	47	.	.	.
cord-016476-78r0rsio	240	1	In	in	IN
cord-016476-78r0rsio	240	2	the	the	DT
cord-016476-78r0rsio	240	3	three	three	CD
cord-016476-78r0rsio	240	4	patients	patient	NNS
cord-016476-78r0rsio	240	5	with	with	IN
cord-016476-78r0rsio	240	6	RA	RA	NNP
cord-016476-78r0rsio	240	7	-	-	HYPH
cord-016476-78r0rsio	240	8	ILD	ILD	NNP
cord-016476-78r0rsio	240	9	on	on	IN
cord-016476-78r0rsio	240	10	abatacept	abatacept	NNP
cord-016476-78r0rsio	240	11	,	,	,
cord-016476-78r0rsio	240	12	as	as	IN
cord-016476-78r0rsio	240	13	part	part	NN
cord-016476-78r0rsio	240	14	of	of	IN
cord-016476-78r0rsio	240	15	Nakashita	Nakashita	NNP
cord-016476-78r0rsio	240	16	and	and	CC
cord-016476-78r0rsio	240	17	colleagues	colleague	NNS
cord-016476-78r0rsio	240	18	'	'	POS
cord-016476-78r0rsio	240	19	retrospective	retrospective	JJ
cord-016476-78r0rsio	240	20	study	study	NN
cord-016476-78r0rsio	240	21	[	[	-LRB-
cord-016476-78r0rsio	240	22	82	82	CD
cord-016476-78r0rsio	240	23	]	]	-RRB-
cord-016476-78r0rsio	240	24	,	,	,
cord-016476-78r0rsio	240	25	none	none	NN
cord-016476-78r0rsio	240	26	had	have	VBD
cord-016476-78r0rsio	240	27	ILD	ILD	NNP
cord-016476-78r0rsio	240	28	-	-	HYPH
cord-016476-78r0rsio	240	29	related	relate	VBN
cord-016476-78r0rsio	240	30	complications	complication	NNS
cord-016476-78r0rsio	240	31	reported	report	VBN
cord-016476-78r0rsio	240	32	by	by	IN
cord-016476-78r0rsio	240	33	one	one	CD
cord-016476-78r0rsio	240	34	-	-	HYPH
cord-016476-78r0rsio	240	35	year	year	NN
cord-016476-78r0rsio	240	36	follow	follow	NN
cord-016476-78r0rsio	240	37	-	-	HYPH
cord-016476-78r0rsio	240	38	up	up	NN
cord-016476-78r0rsio	240	39	.	.	.
cord-016476-78r0rsio	241	1	However	however	RB
cord-016476-78r0rsio	241	2	using	use	VBG
cord-016476-78r0rsio	241	3	claims	claim	NNS
cord-016476-78r0rsio	241	4	data	datum	NNS
cord-016476-78r0rsio	241	5	,	,	,
cord-016476-78r0rsio	241	6	in	in	IN
cord-016476-78r0rsio	241	7	the	the	DT
cord-016476-78r0rsio	241	8	Curtis	Curtis	NNP
cord-016476-78r0rsio	241	9	et	et	NNP
cord-016476-78r0rsio	241	10	al	al	NNP
cord-016476-78r0rsio	241	11	.	.	.
cord-016476-78r0rsio	242	1	study	study	VB
cord-016476-78r0rsio	242	2	[	[	-LRB-
cord-016476-78r0rsio	242	3	81	81	CD
cord-016476-78r0rsio	242	4	]	]	-RRB-
cord-016476-78r0rsio	242	5	,	,	,
cord-016476-78r0rsio	242	6	of	of	IN
cord-016476-78r0rsio	242	7	the	the	DT
cord-016476-78r0rsio	242	8	102	102	CD
cord-016476-78r0rsio	242	9	patients	patient	NNS
cord-016476-78r0rsio	242	10	with	with	IN
cord-016476-78r0rsio	242	11	RA	RA	NNP
cord-016476-78r0rsio	242	12	-	-	HYPH
cord-016476-78r0rsio	242	13	ILD	ILD	NNP
cord-016476-78r0rsio	242	14	on	on	IN
cord-016476-78r0rsio	242	15	abatacept	abatacept	NNP
cord-016476-78r0rsio	242	16	,	,	,
cord-016476-78r0rsio	243	1	there	there	EX
cord-016476-78r0rsio	243	2	was	be	VBD
cord-016476-78r0rsio	243	3	no	no	DT
cord-016476-78r0rsio	243	4	significant	significant	JJ
cord-016476-78r0rsio	243	5	decreased	decrease	VBN
cord-016476-78r0rsio	243	6	risk	risk	NN
cord-016476-78r0rsio	243	7	of	of	IN
cord-016476-78r0rsio	243	8	ILD	ILD	NNP
cord-016476-78r0rsio	243	9	events	event	NNS
cord-016476-78r0rsio	243	10	compared	compare	VBN
cord-016476-78r0rsio	243	11	to	to	IN
cord-016476-78r0rsio	243	12	TNFis	tnfis	NN
cord-016476-78r0rsio	243	13	.	.	.
cord-016476-78r0rsio	244	1	In	in	IN
cord-016476-78r0rsio	244	2	comparison	comparison	NN
cord-016476-78r0rsio	244	3	with	with	IN
cord-016476-78r0rsio	244	4	other	other	JJ
cord-016476-78r0rsio	244	5	biologic	biologic	JJ
cord-016476-78r0rsio	244	6	agents	agent	NNS
cord-016476-78r0rsio	244	7	introduced	introduce	VBN
cord-016476-78r0rsio	244	8	to	to	IN
cord-016476-78r0rsio	244	9	the	the	DT
cord-016476-78r0rsio	244	10	market	market	NN
cord-016476-78r0rsio	244	11	at	at	IN
cord-016476-78r0rsio	244	12	around	around	IN
cord-016476-78r0rsio	244	13	the	the	DT
cord-016476-78r0rsio	244	14	same	same	JJ
cord-016476-78r0rsio	244	15	time	time	NN
cord-016476-78r0rsio	244	16	,	,	,
cord-016476-78r0rsio	244	17	the	the	DT
cord-016476-78r0rsio	244	18	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	244	19	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	244	20	and	and	CC
cord-016476-78r0rsio	244	21	case	case	NN
cord-016476-78r0rsio	244	22	report	report	NN
cord-016476-78r0rsio	244	23	figures	figure	NNS
cord-016476-78r0rsio	244	24	are	be	VBP
cord-016476-78r0rsio	244	25	cautiously	cautiously	RB
cord-016476-78r0rsio	244	26	encouraging	encouraging	JJ
cord-016476-78r0rsio	244	27	.	.	.
cord-016476-78r0rsio	245	1	The	the	DT
cord-016476-78r0rsio	245	2	lack	lack	NN
cord-016476-78r0rsio	245	3	of	of	IN
cord-016476-78r0rsio	245	4	a	a	DT
cord-016476-78r0rsio	245	5	clear	clear	JJ
cord-016476-78r0rsio	245	6	denominator	denominator	NN
cord-016476-78r0rsio	245	7	or	or	CC
cord-016476-78r0rsio	245	8	the	the	DT
cord-016476-78r0rsio	245	9	number	number	NN
cord-016476-78r0rsio	245	10	of	of	IN
cord-016476-78r0rsio	245	11	patients	patient	NNS
cord-016476-78r0rsio	245	12	treated	treat	VBN
cord-016476-78r0rsio	245	13	with	with	IN
cord-016476-78r0rsio	245	14	each	each	DT
cord-016476-78r0rsio	245	15	drug	drug	NN
cord-016476-78r0rsio	245	16	in	in	IN
cord-016476-78r0rsio	245	17	these	these	DT
cord-016476-78r0rsio	245	18	settings	setting	NNS
cord-016476-78r0rsio	245	19	makes	make	VBZ
cord-016476-78r0rsio	245	20	accurate	accurate	JJ
cord-016476-78r0rsio	245	21	interpretation	interpretation	NN
cord-016476-78r0rsio	245	22	challenging	challenging	JJ
cord-016476-78r0rsio	245	23	.	.	.
cord-016476-78r0rsio	246	1	Whilst	whilst	IN
cord-016476-78r0rsio	246	2	experience	experience	NN
cord-016476-78r0rsio	246	3	in	in	IN
cord-016476-78r0rsio	246	4	baseline	baseline	JJ
cord-016476-78r0rsio	246	5	RA	RA	NNP
cord-016476-78r0rsio	246	6	-	-	HYPH
cord-016476-78r0rsio	246	7	ILD	ILD	NNP
cord-016476-78r0rsio	246	8	is	be	VBZ
cord-016476-78r0rsio	246	9	limited	limit	VBN
cord-016476-78r0rsio	246	10	,	,	,
cord-016476-78r0rsio	246	11	emerging	emerge	VBG
cord-016476-78r0rsio	246	12	observational	observational	JJ
cord-016476-78r0rsio	246	13	data	datum	NNS
cord-016476-78r0rsio	246	14	thus	thus	RB
cord-016476-78r0rsio	246	15	far	far	RB
cord-016476-78r0rsio	246	16	appears	appear	VBZ
cord-016476-78r0rsio	246	17	tentatively	tentatively	RB
cord-016476-78r0rsio	246	18	reassuring	reassure	VBG
cord-016476-78r0rsio	246	19	.	.	.
cord-016476-78r0rsio	247	1	Additionally	additionally	RB
cord-016476-78r0rsio	247	2	patients	patient	NNS
cord-016476-78r0rsio	247	3	on	on	IN
cord-016476-78r0rsio	247	4	abatacept	abatacept	NNP
cord-016476-78r0rsio	247	5	may	may	MD
cord-016476-78r0rsio	247	6	have	have	VB
cord-016476-78r0rsio	247	7	a	a	DT
cord-016476-78r0rsio	247	8	more	more	RBR
cord-016476-78r0rsio	247	9	favourable	favourable	JJ
cord-016476-78r0rsio	247	10	infection	infection	NN
cord-016476-78r0rsio	247	11	profile	profile	NN
cord-016476-78r0rsio	247	12	in	in	IN
cord-016476-78r0rsio	247	13	comparison	comparison	NN
cord-016476-78r0rsio	247	14	to	to	IN
cord-016476-78r0rsio	247	15	other	other	JJ
cord-016476-78r0rsio	247	16	biologics	biologic	NNS
cord-016476-78r0rsio	247	17	in	in	IN
cord-016476-78r0rsio	247	18	those	those	DT
cord-016476-78r0rsio	247	19	who	who	WP
cord-016476-78r0rsio	247	20	have	have	VBP
cord-016476-78r0rsio	247	21	experienced	experience	VBN
cord-016476-78r0rsio	247	22	a	a	DT
cord-016476-78r0rsio	247	23	hospitalised	hospitalise	VBN
cord-016476-78r0rsio	247	24	infection	infection	NN
cord-016476-78r0rsio	247	25	previously	previously	RB
cord-016476-78r0rsio	247	26	[	[	-LRB-
cord-016476-78r0rsio	247	27	106	106	CD
cord-016476-78r0rsio	247	28	]	]	-RRB-
cord-016476-78r0rsio	247	29	.	.	.
cord-016476-78r0rsio	248	1	This	this	DT
cord-016476-78r0rsio	248	2	study	study	NN
cord-016476-78r0rsio	248	3	also	also	RB
cord-016476-78r0rsio	248	4	forms	form	VBZ
cord-016476-78r0rsio	248	5	the	the	DT
cord-016476-78r0rsio	248	6	basis	basis	NN
cord-016476-78r0rsio	248	7	of	of	IN
cord-016476-78r0rsio	248	8	its	-PRON-	PRP$
cord-016476-78r0rsio	248	9	use	use	NN
cord-016476-78r0rsio	248	10	as	as	IN
cord-016476-78r0rsio	248	11	a	a	DT
cord-016476-78r0rsio	248	12	conditional	conditional	JJ
cord-016476-78r0rsio	248	13	recommendation	recommendation	NN
cord-016476-78r0rsio	248	14	in	in	IN
cord-016476-78r0rsio	248	15	the	the	DT
cord-016476-78r0rsio	248	16	context	context	NN
cord-016476-78r0rsio	248	17	of	of	IN
cord-016476-78r0rsio	248	18	prior	prior	JJ
cord-016476-78r0rsio	248	19	serious	serious	JJ
cord-016476-78r0rsio	248	20	infection	infection	NN
cord-016476-78r0rsio	248	21	in	in	IN
cord-016476-78r0rsio	248	22	the	the	DT
cord-016476-78r0rsio	248	23	ACR	ACR	NNP
cord-016476-78r0rsio	248	24	2015	2015	CD
cord-016476-78r0rsio	248	25	guidelines	guideline	NNS
cord-016476-78r0rsio	248	26	for	for	IN
cord-016476-78r0rsio	248	27	RA	RA	NNP
cord-016476-78r0rsio	248	28	[	[	-LRB-
cord-016476-78r0rsio	248	29	107	107	CD
cord-016476-78r0rsio	248	30	]	]	-RRB-
cord-016476-78r0rsio	248	31	.	.	.
cord-016476-78r0rsio	249	1	Therefore	therefore	RB
cord-016476-78r0rsio	249	2	given	give	VBN
cord-016476-78r0rsio	249	3	the	the	DT
cord-016476-78r0rsio	249	4	limitations	limitation	NNS
cord-016476-78r0rsio	249	5	of	of	IN
cord-016476-78r0rsio	249	6	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	249	7	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	249	8	and	and	CC
cord-016476-78r0rsio	249	9	inconsistent	inconsistent	JJ
cord-016476-78r0rsio	249	10	findings	finding	NNS
cord-016476-78r0rsio	249	11	from	from	IN
cord-016476-78r0rsio	249	12	observational	observational	JJ
cord-016476-78r0rsio	249	13	data	datum	NNS
cord-016476-78r0rsio	249	14	,	,	,
cord-016476-78r0rsio	249	15	more	more	JJR
cord-016476-78r0rsio	249	16	observational	observational	JJ
cord-016476-78r0rsio	249	17	data	data	NN
cord-016476-78r0rsio	249	18	is	be	VBZ
cord-016476-78r0rsio	249	19	required	require	VBN
cord-016476-78r0rsio	249	20	before	before	IN
cord-016476-78r0rsio	249	21	robust	robust	JJ
cord-016476-78r0rsio	249	22	conclusions	conclusion	NNS
cord-016476-78r0rsio	249	23	can	can	MD
cord-016476-78r0rsio	249	24	be	be	VB
cord-016476-78r0rsio	249	25	formed	form	VBN
cord-016476-78r0rsio	249	26	regarding	regard	VBG
cord-016476-78r0rsio	249	27	safety	safety	NN
cord-016476-78r0rsio	249	28	of	of	IN
cord-016476-78r0rsio	249	29	abatacept	abatacept	NN
cord-016476-78r0rsio	249	30	in	in	IN
cord-016476-78r0rsio	249	31	RA	RA	NNP
cord-016476-78r0rsio	249	32	-	-	HYPH
cord-016476-78r0rsio	249	33	ILD	ILD	NNP
cord-016476-78r0rsio	249	34	.	.	.
cord-016476-78r0rsio	250	1	However	however	RB
cord-016476-78r0rsio	250	2	,	,	,
cord-016476-78r0rsio	250	3	there	there	EX
cord-016476-78r0rsio	250	4	may	may	MD
cord-016476-78r0rsio	250	5	be	be	VB
cord-016476-78r0rsio	250	6	a	a	DT
cord-016476-78r0rsio	250	7	role	role	NN
cord-016476-78r0rsio	250	8	for	for	IN
cord-016476-78r0rsio	250	9	abatacept	abatacept	NNP
cord-016476-78r0rsio	250	10	particularly	particularly	RB
cord-016476-78r0rsio	250	11	in	in	IN
cord-016476-78r0rsio	250	12	patients	patient	NNS
cord-016476-78r0rsio	250	13	in	in	IN
cord-016476-78r0rsio	250	14	whom	whom	WP
cord-016476-78r0rsio	250	15	serious	serious	JJ
cord-016476-78r0rsio	250	16	infection	infection	NN
cord-016476-78r0rsio	250	17	is	be	VBZ
cord-016476-78r0rsio	250	18	a	a	DT
cord-016476-78r0rsio	250	19	concern	concern	NN
cord-016476-78r0rsio	250	20	.	.	.
cord-016476-78r0rsio	251	1	Tocilizumab	Tocilizumab	NNP
cord-016476-78r0rsio	251	2	Tocilizumab	Tocilizumab	NNP
cord-016476-78r0rsio	251	3	is	be	VBZ
cord-016476-78r0rsio	251	4	a	a	DT
cord-016476-78r0rsio	251	5	humanised	humanised	JJ
cord-016476-78r0rsio	251	6	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	251	7	antibody	antibody	NN
cord-016476-78r0rsio	251	8	that	that	WDT
cord-016476-78r0rsio	251	9	inhibits	inhibit	VBZ
cord-016476-78r0rsio	251	10	IL-6	IL-6	NNP
cord-016476-78r0rsio	251	11	receptor	receptor	NN
cord-016476-78r0rsio	251	12	signalling	signal	VBG
cord-016476-78r0rsio	251	13	through	through	IN
cord-016476-78r0rsio	251	14	its	-PRON-	PRP$
cord-016476-78r0rsio	251	15	membrane	membrane	NN
cord-016476-78r0rsio	251	16	-	-	HYPH
cord-016476-78r0rsio	251	17	bound	bind	VBN
cord-016476-78r0rsio	251	18	and	and	CC
cord-016476-78r0rsio	251	19	soluble	soluble	JJ
cord-016476-78r0rsio	251	20	forms	form	NNS
cord-016476-78r0rsio	251	21	.	.	.
cord-016476-78r0rsio	252	1	In	in	IN
cord-016476-78r0rsio	252	2	the	the	DT
cord-016476-78r0rsio	252	3	treatment	treatment	NN
cord-016476-78r0rsio	252	4	of	of	IN
cord-016476-78r0rsio	252	5	active	active	JJ
cord-016476-78r0rsio	252	6	joint	joint	JJ
cord-016476-78r0rsio	252	7	disease	disease	NN
cord-016476-78r0rsio	252	8	,	,	,
cord-016476-78r0rsio	252	9	where	where	WRB
cord-016476-78r0rsio	252	10	MTX	MTX	NNP
cord-016476-78r0rsio	252	11	is	be	VBZ
cord-016476-78r0rsio	252	12	contradicted	contradict	VBN
cord-016476-78r0rsio	252	13	or	or	CC
cord-016476-78r0rsio	252	14	not	not	RB
cord-016476-78r0rsio	252	15	tolerated	tolerate	VBN
cord-016476-78r0rsio	252	16	,	,	,
cord-016476-78r0rsio	252	17	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	252	18	monotherapy	monotherapy	NN
cord-016476-78r0rsio	252	19	has	have	VBZ
cord-016476-78r0rsio	252	20	been	be	VBN
cord-016476-78r0rsio	252	21	shown	show	VBN
cord-016476-78r0rsio	252	22	to	to	TO
cord-016476-78r0rsio	252	23	be	be	VB
cord-016476-78r0rsio	252	24	as	as	RB
cord-016476-78r0rsio	252	25	effective	effective	JJ
cord-016476-78r0rsio	252	26	as	as	IN
cord-016476-78r0rsio	252	27	combination	combination	NN
cord-016476-78r0rsio	252	28	treatment	treatment	NN
cord-016476-78r0rsio	252	29	with	with	IN
cord-016476-78r0rsio	252	30	MTX	MTX	NNP
cord-016476-78r0rsio	252	31	[	[	-LRB-
cord-016476-78r0rsio	252	32	108	108	CD
cord-016476-78r0rsio	252	33	,	,	,
cord-016476-78r0rsio	252	34	109	109	CD
cord-016476-78r0rsio	252	35	]	]	-RRB-
cord-016476-78r0rsio	252	36	.	.	.
cord-016476-78r0rsio	253	1	Given	give	VBN
cord-016476-78r0rsio	253	2	the	the	DT
cord-016476-78r0rsio	253	3	potential	potential	JJ
cord-016476-78r0rsio	253	4	concerns	concern	NNS
cord-016476-78r0rsio	253	5	regarding	regard	VBG
cord-016476-78r0rsio	253	6	the	the	DT
cord-016476-78r0rsio	253	7	respiratory	respiratory	JJ
cord-016476-78r0rsio	253	8	safety	safety	NN
cord-016476-78r0rsio	253	9	profile	profile	NN
cord-016476-78r0rsio	253	10	of	of	IN
cord-016476-78r0rsio	253	11	MTX	MTX	NNP
cord-016476-78r0rsio	253	12	,	,	,
cord-016476-78r0rsio	253	13	there	there	EX
cord-016476-78r0rsio	253	14	may	may	MD
cord-016476-78r0rsio	253	15	be	be	VB
cord-016476-78r0rsio	253	16	a	a	DT
cord-016476-78r0rsio	253	17	preference	preference	NN
cord-016476-78r0rsio	253	18	for	for	IN
cord-016476-78r0rsio	253	19	using	use	VBG
cord-016476-78r0rsio	253	20	this	this	DT
cord-016476-78r0rsio	253	21	drug	drug	NN
cord-016476-78r0rsio	253	22	over	over	IN
cord-016476-78r0rsio	253	23	other	other	JJ
cord-016476-78r0rsio	253	24	biologics	biologic	NNS
cord-016476-78r0rsio	253	25	in	in	IN
cord-016476-78r0rsio	253	26	RA	RA	NNP
cord-016476-78r0rsio	253	27	-	-	HYPH
cord-016476-78r0rsio	253	28	ILD	ILD	NNP
cord-016476-78r0rsio	253	29	by	by	IN
cord-016476-78r0rsio	253	30	some	some	DT
cord-016476-78r0rsio	253	31	physicians	physician	NNS
cord-016476-78r0rsio	253	32	.	.	.
cord-016476-78r0rsio	254	1	Experimental	experimental	JJ
cord-016476-78r0rsio	254	2	work	work	NN
cord-016476-78r0rsio	254	3	has	have	VBZ
cord-016476-78r0rsio	254	4	demonstrated	demonstrate	VBN
cord-016476-78r0rsio	254	5	profibrotic	profibrotic	JJ
cord-016476-78r0rsio	254	6	effects	effect	NNS
cord-016476-78r0rsio	254	7	of	of	IN
cord-016476-78r0rsio	254	8	IL-6	IL-6	NNP
cord-016476-78r0rsio	254	9	on	on	IN
cord-016476-78r0rsio	254	10	lung	lung	NN
cord-016476-78r0rsio	254	11	fibroblasts	fibroblast	NNS
cord-016476-78r0rsio	254	12	,	,	,
cord-016476-78r0rsio	254	13	which	which	WDT
cord-016476-78r0rsio	254	14	may	may	MD
cord-016476-78r0rsio	254	15	have	have	VB
cord-016476-78r0rsio	254	16	the	the	DT
cord-016476-78r0rsio	254	17	potential	potential	NN
cord-016476-78r0rsio	254	18	to	to	TO
cord-016476-78r0rsio	254	19	be	be	VB
cord-016476-78r0rsio	254	20	antagonised	antagonise	VBN
cord-016476-78r0rsio	254	21	by	by	IN
cord-016476-78r0rsio	254	22	blocking	block	VBG
cord-016476-78r0rsio	254	23	the	the	DT
cord-016476-78r0rsio	254	24	IL-6/	IL-6/	NNP
cord-016476-78r0rsio	254	25	IL-6	IL-6	NNP
cord-016476-78r0rsio	254	26	receptor	receptor	NN
cord-016476-78r0rsio	254	27	pathway	pathway	NN
cord-016476-78r0rsio	254	28	,	,	,
cord-016476-78r0rsio	254	29	suggesting	suggest	VBG
cord-016476-78r0rsio	254	30	a	a	DT
cord-016476-78r0rsio	254	31	potential	potential	JJ
cord-016476-78r0rsio	254	32	benefit	benefit	NN
cord-016476-78r0rsio	254	33	of	of	IN
cord-016476-78r0rsio	254	34	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	254	35	in	in	IN
cord-016476-78r0rsio	254	36	RA	RA	NNP
cord-016476-78r0rsio	254	37	-	-	HYPH
cord-016476-78r0rsio	254	38	ILD	ILD	NNP
cord-016476-78r0rsio	254	39	[	[	-LRB-
cord-016476-78r0rsio	254	40	110	110	CD
cord-016476-78r0rsio	254	41	]	]	-RRB-
cord-016476-78r0rsio	254	42	.	.	.
cord-016476-78r0rsio	255	1	However	however	RB
cord-016476-78r0rsio	255	2	,	,	,
cord-016476-78r0rsio	255	3	clinical	clinical	JJ
cord-016476-78r0rsio	255	4	data	datum	NNS
cord-016476-78r0rsio	255	5	on	on	IN
cord-016476-78r0rsio	255	6	the	the	DT
cord-016476-78r0rsio	255	7	use	use	NN
cord-016476-78r0rsio	255	8	of	of	IN
cord-016476-78r0rsio	255	9	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	255	10	in	in	IN
cord-016476-78r0rsio	255	11	pre	pre	JJ
cord-016476-78r0rsio	255	12	-	-	JJ
cord-016476-78r0rsio	255	13	existing	existing	JJ
cord-016476-78r0rsio	255	14	RA	RA	NNP
cord-016476-78r0rsio	255	15	-	-	HYPH
cord-016476-78r0rsio	255	16	ILD	ILD	NNP
cord-016476-78r0rsio	255	17	is	be	VBZ
cord-016476-78r0rsio	255	18	sparse	sparse	JJ
cord-016476-78r0rsio	255	19	and	and	CC
cord-016476-78r0rsio	255	20	inconclusive	inconclusive	JJ
cord-016476-78r0rsio	255	21	.	.	.
cord-016476-78r0rsio	256	1	Unlike	unlike	IN
cord-016476-78r0rsio	256	2	other	other	JJ
cord-016476-78r0rsio	256	3	biologics	biologic	NNS
cord-016476-78r0rsio	256	4	,	,	,
cord-016476-78r0rsio	256	5	early	early	JJ
cord-016476-78r0rsio	256	6	RCTs	rct	NNS
cord-016476-78r0rsio	256	7	of	of	IN
cord-016476-78r0rsio	256	8	this	this	DT
cord-016476-78r0rsio	256	9	biologic	biologic	JJ
cord-016476-78r0rsio	256	10	agent	agent	NN
cord-016476-78r0rsio	256	11	have	have	VBP
cord-016476-78r0rsio	256	12	raised	raise	VBN
cord-016476-78r0rsio	256	13	some	some	DT
cord-016476-78r0rsio	256	14	concerns	concern	NNS
cord-016476-78r0rsio	256	15	regarding	regard	VBG
cord-016476-78r0rsio	256	16	an	an	DT
cord-016476-78r0rsio	256	17	association	association	NN
cord-016476-78r0rsio	256	18	with	with	IN
cord-016476-78r0rsio	256	19	development	development	NN
cord-016476-78r0rsio	256	20	of	of	IN
cord-016476-78r0rsio	256	21	ILD	ILD	NNP
cord-016476-78r0rsio	256	22	.	.	.
cord-016476-78r0rsio	257	1	A	a	DT
cord-016476-78r0rsio	257	2	single	single	JJ
cord-016476-78r0rsio	257	3	case	case	NN
cord-016476-78r0rsio	257	4	of	of	IN
cord-016476-78r0rsio	257	5	'	'	``
cord-016476-78r0rsio	257	6	allergic	allergic	JJ
cord-016476-78r0rsio	257	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	257	8	'	'	''
cord-016476-78r0rsio	257	9	after	after	IN
cord-016476-78r0rsio	257	10	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	257	11	monotherapy	monotherapy	VBD
cord-016476-78r0rsio	257	12	exposure	exposure	NN
cord-016476-78r0rsio	257	13	in	in	IN
cord-016476-78r0rsio	257	14	109	109	CD
cord-016476-78r0rsio	257	15	patients	patient	NNS
cord-016476-78r0rsio	257	16	with	with	IN
cord-016476-78r0rsio	257	17	RA	RA	NNP
cord-016476-78r0rsio	257	18	was	be	VBD
cord-016476-78r0rsio	257	19	reported	report	VBN
cord-016476-78r0rsio	257	20	in	in	IN
cord-016476-78r0rsio	257	21	2004	2004	CD
cord-016476-78r0rsio	257	22	by	by	IN
cord-016476-78r0rsio	257	23	Nishimoto	Nishimoto	NNP
cord-016476-78r0rsio	257	24	et	et	NNP
cord-016476-78r0rsio	257	25	al	al	NNP
cord-016476-78r0rsio	257	26	.	.	.
cord-016476-78r0rsio	258	1	[	[	-LRB-
cord-016476-78r0rsio	258	2	111	111	CD
cord-016476-78r0rsio	258	3	]	]	-RRB-
cord-016476-78r0rsio	258	4	.	.	.
cord-016476-78r0rsio	259	1	In	in	IN
cord-016476-78r0rsio	259	2	2008	2008	CD
cord-016476-78r0rsio	259	3	,	,	,
cord-016476-78r0rsio	259	4	two	two	CD
cord-016476-78r0rsio	259	5	of	of	IN
cord-016476-78r0rsio	259	6	419	419	CD
cord-016476-78r0rsio	259	7	patients	patient	NNS
cord-016476-78r0rsio	259	8	treated	treat	VBN
cord-016476-78r0rsio	259	9	with	with	IN
cord-016476-78r0rsio	259	10	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	259	11	and	and	CC
cord-016476-78r0rsio	259	12	MTX	MTX	NNP
cord-016476-78r0rsio	259	13	in	in	IN
cord-016476-78r0rsio	259	14	the	the	DT
cord-016476-78r0rsio	259	15	OPTION	option	NN
cord-016476-78r0rsio	259	16	study	study	NN
cord-016476-78r0rsio	259	17	[	[	-LRB-
cord-016476-78r0rsio	259	18	112	112	CD
cord-016476-78r0rsio	259	19	]	]	-RRB-
cord-016476-78r0rsio	259	20	developed	develop	VBD
cord-016476-78r0rsio	259	21	ILD	ILD	NNP
cord-016476-78r0rsio	259	22	at	at	IN
cord-016476-78r0rsio	259	23	weeks	week	NNS
cord-016476-78r0rsio	259	24	9	9	CD
cord-016476-78r0rsio	259	25	and	and	CC
cord-016476-78r0rsio	259	26	13	13	CD
cord-016476-78r0rsio	259	27	,	,	,
cord-016476-78r0rsio	259	28	with	with	IN
cord-016476-78r0rsio	259	29	a	a	DT
cord-016476-78r0rsio	259	30	further	further	JJ
cord-016476-78r0rsio	259	31	two	two	CD
cord-016476-78r0rsio	259	32	cases	case	NNS
cord-016476-78r0rsio	259	33	of	of	IN
cord-016476-78r0rsio	259	34	'	'	``
cord-016476-78r0rsio	259	35	culture	culture	NN
cord-016476-78r0rsio	259	36	-	-	HYPH
cord-016476-78r0rsio	259	37	negative	negative	JJ
cord-016476-78r0rsio	259	38	pneumonia	pneumonia	NN
cord-016476-78r0rsio	259	39	'	'	''
cord-016476-78r0rsio	259	40	.	.	.
cord-016476-78r0rsio	260	1	A	a	DT
cord-016476-78r0rsio	260	2	similar	similar	JJ
cord-016476-78r0rsio	260	3	case	case	NN
cord-016476-78r0rsio	260	4	was	be	VBD
cord-016476-78r0rsio	260	5	also	also	RB
cord-016476-78r0rsio	260	6	reported	report	VBN
cord-016476-78r0rsio	260	7	in	in	IN
cord-016476-78r0rsio	260	8	the	the	DT
cord-016476-78r0rsio	260	9	SATORI	SATORI	NNP
cord-016476-78r0rsio	260	10	[	[	-LRB-
cord-016476-78r0rsio	260	11	113	113	CD
cord-016476-78r0rsio	260	12	]	]	-RRB-
cord-016476-78r0rsio	260	13	trial	trial	NN
cord-016476-78r0rsio	260	14	,	,	,
cord-016476-78r0rsio	260	15	which	which	WDT
cord-016476-78r0rsio	260	16	included	include	VBD
cord-016476-78r0rsio	260	17	patients	patient	NNS
cord-016476-78r0rsio	260	18	on	on	IN
cord-016476-78r0rsio	260	19	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	260	20	monotherapy	monotherapy	RB
cord-016476-78r0rsio	260	21	.	.	.
cord-016476-78r0rsio	261	1	In	in	IN
cord-016476-78r0rsio	261	2	one	one	CD
cord-016476-78r0rsio	261	3	of	of	IN
cord-016476-78r0rsio	261	4	the	the	DT
cord-016476-78r0rsio	261	5	few	few	JJ
cord-016476-78r0rsio	261	6	head	head	NN
cord-016476-78r0rsio	261	7	-	-	HYPH
cord-016476-78r0rsio	261	8	to	to	IN
cord-016476-78r0rsio	261	9	-	-	HYPH
cord-016476-78r0rsio	261	10	head	head	NN
cord-016476-78r0rsio	261	11	biologics	biologic	NNS
cord-016476-78r0rsio	261	12	studies	study	NNS
cord-016476-78r0rsio	261	13	,	,	,
cord-016476-78r0rsio	261	14	the	the	DT
cord-016476-78r0rsio	261	15	2013	2013	CD
cord-016476-78r0rsio	261	16	ADACTA	ADACTA	NNP
cord-016476-78r0rsio	261	17	trial	trial	NN
cord-016476-78r0rsio	261	18	compared	compare	VBD
cord-016476-78r0rsio	261	19	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	261	20	monotherapy	monotherapy	VBD
cord-016476-78r0rsio	261	21	with	with	IN
cord-016476-78r0rsio	261	22	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	261	23	monotherapy	monotherapy	IN
cord-016476-78r0rsio	261	24	and	and	CC
cord-016476-78r0rsio	261	25	reported	report	VBD
cord-016476-78r0rsio	261	26	two	two	CD
cord-016476-78r0rsio	261	27	deaths	death	NNS
cord-016476-78r0rsio	261	28	in	in	IN
cord-016476-78r0rsio	261	29	the	the	DT
cord-016476-78r0rsio	261	30	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	261	31	arm	arm	NN
cord-016476-78r0rsio	261	32	,	,	,
cord-016476-78r0rsio	261	33	one	one	CD
cord-016476-78r0rsio	261	34	of	of	IN
cord-016476-78r0rsio	261	35	which	which	WDT
cord-016476-78r0rsio	261	36	occurred	occur	VBD
cord-016476-78r0rsio	261	37	suddenly	suddenly	RB
cord-016476-78r0rsio	261	38	in	in	IN
cord-016476-78r0rsio	261	39	a	a	DT
cord-016476-78r0rsio	261	40	56-year	56-year	JJ
cord-016476-78r0rsio	261	41	-	-	HYPH
cord-016476-78r0rsio	261	42	old	old	JJ
cord-016476-78r0rsio	261	43	man	man	NN
cord-016476-78r0rsio	261	44	with	with	IN
cord-016476-78r0rsio	261	45	multiple	multiple	JJ
cord-016476-78r0rsio	261	46	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	261	47	,	,	,
cord-016476-78r0rsio	261	48	including	include	VBG
cord-016476-78r0rsio	261	49	pre	pre	JJ
cord-016476-78r0rsio	261	50	-	-	JJ
cord-016476-78r0rsio	261	51	existing	existing	JJ
cord-016476-78r0rsio	261	52	ILD	ILD	NNP
cord-016476-78r0rsio	261	53	[	[	-LRB-
cord-016476-78r0rsio	261	54	114	114	CD
cord-016476-78r0rsio	261	55	]	]	-RRB-
cord-016476-78r0rsio	261	56	.	.	.
cord-016476-78r0rsio	262	1	Further	further	JJ
cord-016476-78r0rsio	262	2	deaths	death	NNS
cord-016476-78r0rsio	262	3	due	due	JJ
cord-016476-78r0rsio	262	4	to	to	IN
cord-016476-78r0rsio	262	5	interstitial	interstitial	JJ
cord-016476-78r0rsio	262	6	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	262	7	have	have	VBP
cord-016476-78r0rsio	262	8	been	be	VBN
cord-016476-78r0rsio	262	9	reported	report	VBN
cord-016476-78r0rsio	262	10	in	in	IN
cord-016476-78r0rsio	262	11	tocilizumabexposed	tocilizumabexposed	JJ
cord-016476-78r0rsio	262	12	arms	arm	NNS
cord-016476-78r0rsio	262	13	in	in	IN
cord-016476-78r0rsio	262	14	recent	recent	JJ
cord-016476-78r0rsio	262	15	trials	trial	NNS
cord-016476-78r0rsio	262	16	such	such	JJ
cord-016476-78r0rsio	262	17	as	as	IN
cord-016476-78r0rsio	262	18	the	the	DT
cord-016476-78r0rsio	262	19	SURPRISE	SURPRISE	NNP
cord-016476-78r0rsio	262	20	(	(	-LRB-
cord-016476-78r0rsio	262	21	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	262	22	+	+	CC
cord-016476-78r0rsio	262	23	MTX	MTX	NNP
cord-016476-78r0rsio	262	24	arm	arm	NN
cord-016476-78r0rsio	262	25	)	)	-RRB-
cord-016476-78r0rsio	262	26	[	[	-LRB-
cord-016476-78r0rsio	262	27	109	109	CD
cord-016476-78r0rsio	262	28	]	]	-RRB-
cord-016476-78r0rsio	262	29	,	,	,
cord-016476-78r0rsio	262	30	as	as	RB
cord-016476-78r0rsio	262	31	well	well	RB
cord-016476-78r0rsio	262	32	as	as	IN
cord-016476-78r0rsio	262	33	the	the	DT
cord-016476-78r0rsio	262	34	SUMMACTA	SUMMACTA	NNP
cord-016476-78r0rsio	262	35	trial	trial	NN
cord-016476-78r0rsio	262	36	,	,	,
cord-016476-78r0rsio	262	37	the	the	DT
cord-016476-78r0rsio	262	38	latter	latter	JJ
cord-016476-78r0rsio	262	39	reporting	report	VBG
cord-016476-78r0rsio	262	40	one	one	CD
cord-016476-78r0rsio	262	41	death	death	NN
cord-016476-78r0rsio	262	42	due	due	IN
cord-016476-78r0rsio	262	43	to	to	IN
cord-016476-78r0rsio	262	44	ILD	ILD	NNP
cord-016476-78r0rsio	262	45	and	and	CC
cord-016476-78r0rsio	262	46	ARDS	ARDS	NNP
cord-016476-78r0rsio	262	47	each	each	DT
cord-016476-78r0rsio	262	48	[	[	-LRB-
cord-016476-78r0rsio	262	49	115	115	CD
cord-016476-78r0rsio	262	50	]	]	-RRB-
cord-016476-78r0rsio	262	51	.	.	.
cord-016476-78r0rsio	263	1	Of	of	IN
cord-016476-78r0rsio	263	2	note	note	VB
cord-016476-78r0rsio	263	3	other	other	JJ
cord-016476-78r0rsio	263	4	anti	anti	JJ
cord-016476-78r0rsio	263	5	-	-	JJ
cord-016476-78r0rsio	263	6	IL-6	il-6	JJ
cord-016476-78r0rsio	263	7	drugs	drug	NNS
cord-016476-78r0rsio	263	8	being	be	VBG
cord-016476-78r0rsio	263	9	evaluated	evaluate	VBN
cord-016476-78r0rsio	263	10	for	for	IN
cord-016476-78r0rsio	263	11	RA	RA	NNP
cord-016476-78r0rsio	263	12	,	,	,
cord-016476-78r0rsio	263	13	such	such	JJ
cord-016476-78r0rsio	263	14	as	as	IN
cord-016476-78r0rsio	263	15	sarilumab	sarilumab	NNP
cord-016476-78r0rsio	263	16	(	(	-LRB-
cord-016476-78r0rsio	263	17	a	a	DT
cord-016476-78r0rsio	263	18	fully	fully	RB
cord-016476-78r0rsio	263	19	human	human	JJ
cord-016476-78r0rsio	263	20	anti	anti	JJ
cord-016476-78r0rsio	263	21	-	-	JJ
cord-016476-78r0rsio	263	22	IL-6Rα	il-6rα	JJ
cord-016476-78r0rsio	263	23	mAb	mAb	NNS
cord-016476-78r0rsio	263	24	that	that	WDT
cord-016476-78r0rsio	263	25	binds	bind	VBZ
cord-016476-78r0rsio	263	26	membrane	membrane	NN
cord-016476-78r0rsio	263	27	-	-	HYPH
cord-016476-78r0rsio	263	28	bound	bind	VBN
cord-016476-78r0rsio	263	29	and	and	CC
cord-016476-78r0rsio	263	30	soluble	soluble	JJ
cord-016476-78r0rsio	263	31	human	human	JJ
cord-016476-78r0rsio	263	32	IL-6Rα	il-6rα	CD
cord-016476-78r0rsio	263	33	)	)	-RRB-
cord-016476-78r0rsio	263	34	,	,	,
cord-016476-78r0rsio	263	35	have	have	VBP
cord-016476-78r0rsio	263	36	also	also	RB
cord-016476-78r0rsio	263	37	reported	report	VBN
cord-016476-78r0rsio	263	38	SRAEs	srae	NNS
cord-016476-78r0rsio	263	39	within	within	IN
cord-016476-78r0rsio	263	40	trials	trial	NNS
cord-016476-78r0rsio	263	41	.	.	.
cord-016476-78r0rsio	264	1	Of	of	IN
cord-016476-78r0rsio	264	2	the	the	DT
cord-016476-78r0rsio	264	3	two	two	CD
cord-016476-78r0rsio	264	4	deaths	death	NNS
cord-016476-78r0rsio	264	5	reported	report	VBN
cord-016476-78r0rsio	264	6	in	in	IN
cord-016476-78r0rsio	264	7	the	the	DT
cord-016476-78r0rsio	264	8	SARIL	SARIL	NNP
cord-016476-78r0rsio	264	9	-	-	HYPH
cord-016476-78r0rsio	264	10	RA	RA	NNP
cord-016476-78r0rsio	264	11	-	-	HYPH
cord-016476-78r0rsio	264	12	MOBILITY	MOBILITY	NNP
cord-016476-78r0rsio	264	13	trial	trial	NN
cord-016476-78r0rsio	264	14	(	(	-LRB-
cord-016476-78r0rsio	264	15	sarilumab	sarilumab	NNP
cord-016476-78r0rsio	264	16	+	+	CC
cord-016476-78r0rsio	264	17	MTX	MTX	NNP
cord-016476-78r0rsio	264	18	)	)	-RRB-
cord-016476-78r0rsio	264	19	,	,	,
cord-016476-78r0rsio	264	20	one	one	CD
cord-016476-78r0rsio	264	21	was	be	VBD
cord-016476-78r0rsio	264	22	due	due	JJ
cord-016476-78r0rsio	264	23	to	to	IN
cord-016476-78r0rsio	264	24	ARDS	ARDS	NNP
cord-016476-78r0rsio	264	25	(	(	-LRB-
cord-016476-78r0rsio	264	26	investigator	investigator	NN
cord-016476-78r0rsio	264	27	felt	feel	VBD
cord-016476-78r0rsio	264	28	was	be	VBD
cord-016476-78r0rsio	264	29	drug	drug	NN
cord-016476-78r0rsio	264	30	-	-	HYPH
cord-016476-78r0rsio	264	31	related	relate	VBN
cord-016476-78r0rsio	264	32	)	)	-RRB-
cord-016476-78r0rsio	264	33	[	[	-LRB-
cord-016476-78r0rsio	264	34	116	116	CD
cord-016476-78r0rsio	264	35	]	]	-RRB-
cord-016476-78r0rsio	264	36	.	.	.
cord-016476-78r0rsio	265	1	Within	within	IN
cord-016476-78r0rsio	265	2	the	the	DT
cord-016476-78r0rsio	265	3	phase	phase	NN
cord-016476-78r0rsio	265	4	III	iii	CD
cord-016476-78r0rsio	265	5	study	study	NN
cord-016476-78r0rsio	265	6	published	publish	VBN
cord-016476-78r0rsio	265	7	to	to	IN
cord-016476-78r0rsio	265	8	date	date	NN
cord-016476-78r0rsio	265	9	,	,	,
cord-016476-78r0rsio	265	10	four	four	CD
cord-016476-78r0rsio	265	11	deaths	death	NNS
cord-016476-78r0rsio	265	12	in	in	IN
cord-016476-78r0rsio	265	13	the	the	DT
cord-016476-78r0rsio	265	14	sarilumab	sarilumab	JJ
cord-016476-78r0rsio	265	15	arms	arm	NNS
cord-016476-78r0rsio	265	16	were	be	VBD
cord-016476-78r0rsio	265	17	described	describe	VBN
cord-016476-78r0rsio	265	18	[	[	-LRB-
cord-016476-78r0rsio	265	19	117	117	CD
cord-016476-78r0rsio	265	20	]	]	-RRB-
cord-016476-78r0rsio	265	21	,	,	,
cord-016476-78r0rsio	265	22	one	one	CD
cord-016476-78r0rsio	265	23	due	due	IN
cord-016476-78r0rsio	265	24	to	to	IN
cord-016476-78r0rsio	265	25	unspecified	unspecified	JJ
cord-016476-78r0rsio	265	26	respiratory	respiratory	JJ
cord-016476-78r0rsio	265	27	complications	complication	NNS
cord-016476-78r0rsio	265	28	post	post	VBP
cord-016476-78r0rsio	265	29	surgery	surgery	NN
cord-016476-78r0rsio	265	30	.	.	.
cord-016476-78r0rsio	266	1	Whilst	whilst	IN
cord-016476-78r0rsio	266	2	the	the	DT
cord-016476-78r0rsio	266	3	consequences	consequence	NNS
cord-016476-78r0rsio	266	4	of	of	IN
cord-016476-78r0rsio	266	5	such	such	JJ
cord-016476-78r0rsio	266	6	reports	report	NNS
cord-016476-78r0rsio	266	7	are	be	VBP
cord-016476-78r0rsio	266	8	not	not	RB
cord-016476-78r0rsio	266	9	clear	clear	JJ
cord-016476-78r0rsio	266	10	at	at	IN
cord-016476-78r0rsio	266	11	present	present	NN
cord-016476-78r0rsio	266	12	for	for	IN
cord-016476-78r0rsio	266	13	the	the	DT
cord-016476-78r0rsio	266	14	patient	patient	NN
cord-016476-78r0rsio	266	15	with	with	IN
cord-016476-78r0rsio	266	16	pre	pre	JJ
cord-016476-78r0rsio	266	17	-	-	JJ
cord-016476-78r0rsio	266	18	existing	existing	JJ
cord-016476-78r0rsio	266	19	ILD	ILD	NNP
cord-016476-78r0rsio	266	20	,	,	,
cord-016476-78r0rsio	266	21	such	such	JJ
cord-016476-78r0rsio	266	22	observations	observation	NNS
cord-016476-78r0rsio	266	23	suggest	suggest	VBP
cord-016476-78r0rsio	266	24	the	the	DT
cord-016476-78r0rsio	266	25	need	need	NN
cord-016476-78r0rsio	266	26	for	for	IN
cord-016476-78r0rsio	266	27	alertness	alertness	NN
cord-016476-78r0rsio	266	28	especially	especially	RB
cord-016476-78r0rsio	266	29	since	since	IN
cord-016476-78r0rsio	266	30	most	most	JJS
cord-016476-78r0rsio	266	31	trials	trial	NNS
cord-016476-78r0rsio	266	32	exclude	exclude	VBP
cord-016476-78r0rsio	266	33	patients	patient	NNS
cord-016476-78r0rsio	266	34	with	with	IN
cord-016476-78r0rsio	266	35	multimorbidity	multimorbidity	NN
cord-016476-78r0rsio	266	36	.	.	.
cord-016476-78r0rsio	267	1	Case	case	NN
cord-016476-78r0rsio	267	2	reports	report	NNS
cord-016476-78r0rsio	267	3	have	have	VBP
cord-016476-78r0rsio	267	4	suggested	suggest	VBN
cord-016476-78r0rsio	267	5	an	an	DT
cord-016476-78r0rsio	267	6	association	association	NN
cord-016476-78r0rsio	267	7	between	between	IN
cord-016476-78r0rsio	267	8	incident	incident	NN
cord-016476-78r0rsio	267	9	ILD	ILD	NNP
cord-016476-78r0rsio	267	10	and	and	CC
cord-016476-78r0rsio	267	11	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	267	12	exposure	exposure	NN
cord-016476-78r0rsio	267	13	in	in	IN
cord-016476-78r0rsio	267	14	patients	patient	NNS
cord-016476-78r0rsio	267	15	on	on	IN
cord-016476-78r0rsio	267	16	a	a	DT
cord-016476-78r0rsio	267	17	concurrent	concurrent	JJ
cord-016476-78r0rsio	267	18	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	267	19	both	both	DT
cord-016476-78r0rsio	267	20	in	in	IN
cord-016476-78r0rsio	267	21	RA	RA	NNP
cord-016476-78r0rsio	267	22	[	[	-LRB-
cord-016476-78r0rsio	267	23	118	118	CD
cord-016476-78r0rsio	267	24	]	]	-RRB-
cord-016476-78r0rsio	267	25	[	[	-LRB-
cord-016476-78r0rsio	267	26	119	119	CD
cord-016476-78r0rsio	267	27	]	]	-RRB-
cord-016476-78r0rsio	267	28	[	[	-LRB-
cord-016476-78r0rsio	267	29	120	120	CD
cord-016476-78r0rsio	267	30	]	]	-RRB-
cord-016476-78r0rsio	267	31	and	and	CC
cord-016476-78r0rsio	267	32	adult	adult	NN
cord-016476-78r0rsio	267	33	-	-	HYPH
cord-016476-78r0rsio	267	34	onset	onset	NN
cord-016476-78r0rsio	268	1	Still	still	RB
cord-016476-78r0rsio	268	2	's	's	POS
cord-016476-78r0rsio	268	3	disease	disease	NN
cord-016476-78r0rsio	268	4	[	[	-LRB-
cord-016476-78r0rsio	268	5	121	121	CD
cord-016476-78r0rsio	268	6	]	]	-RRB-
cord-016476-78r0rsio	268	7	.	.	.
cord-016476-78r0rsio	269	1	Spontaneous	spontaneous	JJ
cord-016476-78r0rsio	269	2	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	269	3	figures	figure	NNS
cord-016476-78r0rsio	269	4	from	from	IN
cord-016476-78r0rsio	269	5	the	the	DT
cord-016476-78r0rsio	269	6	UK	UK	NNP
cord-016476-78r0rsio	269	7	have	have	VBP
cord-016476-78r0rsio	269	8	reported	report	VBN
cord-016476-78r0rsio	269	9	five	five	CD
cord-016476-78r0rsio	269	10	deaths	death	NNS
cord-016476-78r0rsio	269	11	due	due	JJ
cord-016476-78r0rsio	269	12	to	to	IN
cord-016476-78r0rsio	269	13	SRAEs	srae	NNS
cord-016476-78r0rsio	269	14	in	in	IN
cord-016476-78r0rsio	269	15	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	269	16	-	-	HYPH
cord-016476-78r0rsio	269	17	exposed	expose	VBN
cord-016476-78r0rsio	269	18	patients	patient	NNS
cord-016476-78r0rsio	269	19	to	to	IN
cord-016476-78r0rsio	269	20	date	date	NN
cord-016476-78r0rsio	269	21	,	,	,
cord-016476-78r0rsio	269	22	four	four	CD
cord-016476-78r0rsio	269	23	due	due	JJ
cord-016476-78r0rsio	269	24	to	to	IN
cord-016476-78r0rsio	269	25	ILD	ILD	NNP
cord-016476-78r0rsio	269	26	and	and	CC
cord-016476-78r0rsio	269	27	one	one	CD
cord-016476-78r0rsio	269	28	secondary	secondary	JJ
cord-016476-78r0rsio	269	29	to	to	IN
cord-016476-78r0rsio	269	30	ARDS	ARDS	NNP
cord-016476-78r0rsio	269	31	(	(	-LRB-
cord-016476-78r0rsio	269	32	Table	table	NN
cord-016476-78r0rsio	269	33	9	9	CD
cord-016476-78r0rsio	269	34	.2	.2	CD
cord-016476-78r0rsio	269	35	)	)	-RRB-
cord-016476-78r0rsio	269	36	.	.	.
cord-016476-78r0rsio	270	1	Whilst	whilst	IN
cord-016476-78r0rsio	270	2	the	the	DT
cord-016476-78r0rsio	270	3	total	total	JJ
cord-016476-78r0rsio	270	4	number	number	NN
cord-016476-78r0rsio	270	5	of	of	IN
cord-016476-78r0rsio	270	6	patients	patient	NNS
cord-016476-78r0rsio	270	7	exposed	expose	VBN
cord-016476-78r0rsio	270	8	to	to	IN
cord-016476-78r0rsio	270	9	treatment	treatment	NN
cord-016476-78r0rsio	270	10	(	(	-LRB-
cord-016476-78r0rsio	270	11	denominator	denominator	NN
cord-016476-78r0rsio	270	12	)	)	-RRB-
cord-016476-78r0rsio	270	13	is	be	VBZ
cord-016476-78r0rsio	270	14	not	not	RB
cord-016476-78r0rsio	270	15	available	available	JJ
cord-016476-78r0rsio	270	16	,	,	,
cord-016476-78r0rsio	270	17	cautious	cautious	JJ
cord-016476-78r0rsio	270	18	comparison	comparison	NN
cord-016476-78r0rsio	270	19	of	of	IN
cord-016476-78r0rsio	270	20	these	these	DT
cord-016476-78r0rsio	270	21	figures	figure	NNS
cord-016476-78r0rsio	270	22	with	with	IN
cord-016476-78r0rsio	270	23	abatacept	abatacept	NNP
cord-016476-78r0rsio	270	24	,	,	,
cord-016476-78r0rsio	270	25	which	which	WDT
cord-016476-78r0rsio	270	26	was	be	VBD
cord-016476-78r0rsio	270	27	approved	approve	VBN
cord-016476-78r0rsio	270	28	earlier	early	RBR
cord-016476-78r0rsio	270	29	than	than	IN
cord-016476-78r0rsio	270	30	tocilizumab	tocilizumab	NNS
cord-016476-78r0rsio	270	31	by	by	IN
cord-016476-78r0rsio	270	32	FDA	FDA	NNP
cord-016476-78r0rsio	270	33	and	and	CC
cord-016476-78r0rsio	270	34	EMA	EMA	NNP
cord-016476-78r0rsio	270	35	,	,	,
cord-016476-78r0rsio	270	36	is	be	VBZ
cord-016476-78r0rsio	270	37	of	of	IN
cord-016476-78r0rsio	270	38	interest	interest	NN
cord-016476-78r0rsio	270	39	.	.	.
cord-016476-78r0rsio	271	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	271	2	,	,	,
cord-016476-78r0rsio	271	3	the	the	DT
cord-016476-78r0rsio	271	4	REACTION	reaction	NN
cord-016476-78r0rsio	271	5	study	study	NN
cord-016476-78r0rsio	271	6	,	,	,
cord-016476-78r0rsio	271	7	a	a	DT
cord-016476-78r0rsio	271	8	retrospective	retrospective	JJ
cord-016476-78r0rsio	271	9	study	study	NN
cord-016476-78r0rsio	271	10	of	of	IN
cord-016476-78r0rsio	271	11	229	229	CD
cord-016476-78r0rsio	271	12	tocilizumabexposed	tocilizumabexpose	VBN
cord-016476-78r0rsio	271	13	patients	patient	NNS
cord-016476-78r0rsio	271	14	with	with	IN
cord-016476-78r0rsio	271	15	RA	RA	NNP
cord-016476-78r0rsio	271	16	in	in	IN
cord-016476-78r0rsio	271	17	Japan	Japan	NNP
cord-016476-78r0rsio	271	18	,	,	,
cord-016476-78r0rsio	271	19	reported	report	VBD
cord-016476-78r0rsio	271	20	interstitial	interstitial	JJ
cord-016476-78r0rsio	271	21	pneumonia	pneumonia	NN
cord-016476-78r0rsio	271	22	in	in	IN
cord-016476-78r0rsio	271	23	two	two	CD
cord-016476-78r0rsio	271	24	of	of	IN
cord-016476-78r0rsio	271	25	the	the	DT
cord-016476-78r0rsio	271	26	229	229	CD
cord-016476-78r0rsio	271	27	patients	patient	NNS
cord-016476-78r0rsio	271	28	followed	follow	VBD
cord-016476-78r0rsio	271	29	up	up	RP
cord-016476-78r0rsio	271	30	over	over	IN
cord-016476-78r0rsio	271	31	6	6	CD
cord-016476-78r0rsio	271	32	months	month	NNS
cord-016476-78r0rsio	271	33	and	and	CC
cord-016476-78r0rsio	271	34	an	an	DT
cord-016476-78r0rsio	271	35	additional	additional	JJ
cord-016476-78r0rsio	271	36	six	six	CD
cord-016476-78r0rsio	271	37	discontinuations	discontinuation	NNS
cord-016476-78r0rsio	271	38	for	for	IN
cord-016476-78r0rsio	271	39	pneumonia	pneumonia	NN
cord-016476-78r0rsio	271	40	(	(	-LRB-
cord-016476-78r0rsio	271	41	presumed	presume	VBN
cord-016476-78r0rsio	271	42	infective	infective	NN
cord-016476-78r0rsio	271	43	)	)	-RRB-
cord-016476-78r0rsio	271	44	,	,	,
cord-016476-78r0rsio	271	45	raising	raise	VBG
cord-016476-78r0rsio	271	46	further	further	JJ
cord-016476-78r0rsio	271	47	concerns	concern	NNS
cord-016476-78r0rsio	271	48	of	of	IN
cord-016476-78r0rsio	271	49	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	271	50	toxicity	toxicity	NN
cord-016476-78r0rsio	271	51	in	in	IN
cord-016476-78r0rsio	271	52	this	this	DT
cord-016476-78r0rsio	271	53	population	population	NN
cord-016476-78r0rsio	271	54	.	.	.
cord-016476-78r0rsio	272	1	RA	RA	NNP
cord-016476-78r0rsio	272	2	-	-	HYPH
cord-016476-78r0rsio	272	3	ILD	ILD	NNP
cord-016476-78r0rsio	272	4	was	be	VBD
cord-016476-78r0rsio	272	5	found	find	VBN
cord-016476-78r0rsio	272	6	to	to	TO
cord-016476-78r0rsio	272	7	have	have	VB
cord-016476-78r0rsio	272	8	improved	improve	VBN
cord-016476-78r0rsio	272	9	in	in	IN
cord-016476-78r0rsio	272	10	one	one	CD
cord-016476-78r0rsio	272	11	patient	patient	NN
cord-016476-78r0rsio	272	12	with	with	IN
cord-016476-78r0rsio	272	13	pre	pre	JJ
cord-016476-78r0rsio	272	14	-	-	JJ
cord-016476-78r0rsio	272	15	existing	existing	JJ
cord-016476-78r0rsio	272	16	RA	RA	NNP
cord-016476-78r0rsio	272	17	-	-	HYPH
cord-016476-78r0rsio	272	18	ILD	ILD	NNP
cord-016476-78r0rsio	272	19	within	within	IN
cord-016476-78r0rsio	272	20	16	16	CD
cord-016476-78r0rsio	272	21	weeks	week	NNS
cord-016476-78r0rsio	272	22	after	after	IN
cord-016476-78r0rsio	272	23	administration	administration	NN
cord-016476-78r0rsio	272	24	of	of	IN
cord-016476-78r0rsio	272	25	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	272	26	[	[	-LRB-
cord-016476-78r0rsio	272	27	122	122	CD
cord-016476-78r0rsio	272	28	]	]	-RRB-
cord-016476-78r0rsio	272	29	,	,	,
cord-016476-78r0rsio	272	30	whereas	whereas	IN
cord-016476-78r0rsio	272	31	another	another	DT
cord-016476-78r0rsio	272	32	patient	patient	NN
cord-016476-78r0rsio	272	33	with	with	IN
cord-016476-78r0rsio	272	34	biopsy	biopsy	NN
cord-016476-78r0rsio	272	35	-	-	HYPH
cord-016476-78r0rsio	272	36	proven	prove	VBN
cord-016476-78r0rsio	272	37	UIP	UIP	NNP
cord-016476-78r0rsio	272	38	and	and	CC
cord-016476-78r0rsio	272	39	emphysema	emphysema	NN
cord-016476-78r0rsio	272	40	developed	develop	VBD
cord-016476-78r0rsio	272	41	a	a	DT
cord-016476-78r0rsio	272	42	fatal	fatal	JJ
cord-016476-78r0rsio	272	43	exacerbation	exacerbation	NN
cord-016476-78r0rsio	272	44	of	of	IN
cord-016476-78r0rsio	272	45	ILD	ILD	NNP
cord-016476-78r0rsio	272	46	after	after	IN
cord-016476-78r0rsio	272	47	treatment	treatment	NN
cord-016476-78r0rsio	272	48	with	with	IN
cord-016476-78r0rsio	272	49	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	272	50	[	[	-LRB-
cord-016476-78r0rsio	272	51	119	119	CD
cord-016476-78r0rsio	272	52	]	]	-RRB-
cord-016476-78r0rsio	272	53	.	.	.
cord-016476-78r0rsio	273	1	Of	of	IN
cord-016476-78r0rsio	273	2	the	the	DT
cord-016476-78r0rsio	273	3	23	23	CD
cord-016476-78r0rsio	273	4	ILD	ILD	NNP
cord-016476-78r0rsio	273	5	events	event	NNS
cord-016476-78r0rsio	273	6	reported	report	VBN
cord-016476-78r0rsio	273	7	in	in	IN
cord-016476-78r0rsio	273	8	3881	3881	CD
cord-016476-78r0rsio	273	9	patients	patient	NNS
cord-016476-78r0rsio	273	10	who	who	WP
cord-016476-78r0rsio	273	11	received	receive	VBD
cord-016476-78r0rsio	273	12	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	273	13	every	every	DT
cord-016476-78r0rsio	273	14	4	4	CD
cord-016476-78r0rsio	273	15	weeks	week	NNS
cord-016476-78r0rsio	273	16	over	over	IN
cord-016476-78r0rsio	273	17	28	28	CD
cord-016476-78r0rsio	273	18	weeks	week	NNS
cord-016476-78r0rsio	273	19	(	(	-LRB-
cord-016476-78r0rsio	273	20	1.28	1.28	CD
cord-016476-78r0rsio	273	21	per	per	IN
cord-016476-78r0rsio	273	22	100	100	CD
cord-016476-78r0rsio	273	23	patient	patient	NN
cord-016476-78r0rsio	273	24	-	-	HYPH
cord-016476-78r0rsio	273	25	years	year	NNS
cord-016476-78r0rsio	273	26	)	)	-RRB-
cord-016476-78r0rsio	273	27	in	in	IN
cord-016476-78r0rsio	273	28	a	a	DT
cord-016476-78r0rsio	273	29	post	post	JJ
cord-016476-78r0rsio	273	30	-	-	JJ
cord-016476-78r0rsio	273	31	marketing	marketing	JJ
cord-016476-78r0rsio	273	32	surveillance	surveillance	NN
cord-016476-78r0rsio	273	33	programme	programme	NN
cord-016476-78r0rsio	273	34	in	in	IN
cord-016476-78r0rsio	273	35	Japan	Japan	NNP
cord-016476-78r0rsio	273	36	,	,	,
cord-016476-78r0rsio	273	37	the	the	DT
cord-016476-78r0rsio	273	38	presence	presence	NN
cord-016476-78r0rsio	273	39	of	of	IN
cord-016476-78r0rsio	273	40	a	a	DT
cord-016476-78r0rsio	273	41	known	know	VBN
cord-016476-78r0rsio	273	42	ILD	ILD	NNP
cord-016476-78r0rsio	273	43	was	be	VBD
cord-016476-78r0rsio	273	44	a	a	DT
cord-016476-78r0rsio	273	45	risk	risk	NN
cord-016476-78r0rsio	273	46	factor	factor	NN
cord-016476-78r0rsio	273	47	for	for	IN
cord-016476-78r0rsio	273	48	acute	acute	JJ
cord-016476-78r0rsio	273	49	presentation	presentation	NN
cord-016476-78r0rsio	273	50	with	with	IN
cord-016476-78r0rsio	273	51	ILD	ILD	NNP
cord-016476-78r0rsio	273	52	exacerbation	exacerbation	NN
cord-016476-78r0rsio	273	53	and	and	CC
cord-016476-78r0rsio	273	54	serious	serious	JJ
cord-016476-78r0rsio	273	55	infections	infection	NNS
cord-016476-78r0rsio	273	56	[	[	-LRB-
cord-016476-78r0rsio	273	57	123	123	CD
cord-016476-78r0rsio	273	58	]	]	-RRB-
cord-016476-78r0rsio	273	59	.	.	.
cord-016476-78r0rsio	274	1	Recent	recent	JJ
cord-016476-78r0rsio	274	2	small	small	JJ
cord-016476-78r0rsio	274	3	retrospective	retrospective	JJ
cord-016476-78r0rsio	274	4	observational	observational	JJ
cord-016476-78r0rsio	274	5	studies	study	NNS
cord-016476-78r0rsio	274	6	demonstrate	demonstrate	VBP
cord-016476-78r0rsio	274	7	limited	limited	JJ
cord-016476-78r0rsio	274	8	reassurance	reassurance	NN
cord-016476-78r0rsio	274	9	.	.	.
cord-016476-78r0rsio	275	1	In	in	IN
cord-016476-78r0rsio	275	2	the	the	DT
cord-016476-78r0rsio	275	3	nine	nine	CD
cord-016476-78r0rsio	275	4	patients	patient	NNS
cord-016476-78r0rsio	275	5	with	with	IN
cord-016476-78r0rsio	275	6	RA	RA	NNP
cord-016476-78r0rsio	275	7	-	-	HYPH
cord-016476-78r0rsio	275	8	ILD	ILD	NNP
cord-016476-78r0rsio	275	9	selected	select	VBN
cord-016476-78r0rsio	275	10	to	to	TO
cord-016476-78r0rsio	275	11	receive	receive	VB
cord-016476-78r0rsio	275	12	tocilizumab	tocilizumab	JJ
cord-016476-78r0rsio	275	13	treatment	treatment	NN
cord-016476-78r0rsio	275	14	over	over	IN
cord-016476-78r0rsio	275	15	1	1	CD
cord-016476-78r0rsio	275	16	year	year	NN
cord-016476-78r0rsio	275	17	in	in	IN
cord-016476-78r0rsio	275	18	the	the	DT
cord-016476-78r0rsio	275	19	Nakashita	Nakashita	NNP
cord-016476-78r0rsio	275	20	et	et	NNP
cord-016476-78r0rsio	275	21	al	al	NNP
cord-016476-78r0rsio	275	22	.	.	.
cord-016476-78r0rsio	276	1	study	study	VB
cord-016476-78r0rsio	276	2	[	[	-LRB-
cord-016476-78r0rsio	276	3	82	82	CD
cord-016476-78r0rsio	276	4	]	]	-RRB-
cord-016476-78r0rsio	276	5	,	,	.
cord-016476-78r0rsio	277	1	no	no	DT
cord-016476-78r0rsio	277	2	patients	patient	NNS
cord-016476-78r0rsio	277	3	were	be	VBD
cord-016476-78r0rsio	277	4	reported	report	VBN
cord-016476-78r0rsio	277	5	to	to	TO
cord-016476-78r0rsio	277	6	have	have	VB
cord-016476-78r0rsio	277	7	an	an	DT
cord-016476-78r0rsio	277	8	ILD	ILD	NNP
cord-016476-78r0rsio	277	9	exacerbation	exacerbation	NN
cord-016476-78r0rsio	277	10	.	.	.
cord-016476-78r0rsio	278	1	However	however	RB
cord-016476-78r0rsio	278	2	patients	patient	NNS
cord-016476-78r0rsio	278	3	who	who	WP
cord-016476-78r0rsio	278	4	did	do	VBD
cord-016476-78r0rsio	278	5	not	not	RB
cord-016476-78r0rsio	278	6	complete	complete	VB
cord-016476-78r0rsio	278	7	at	at	RB
cord-016476-78r0rsio	278	8	least	least	RBS
cord-016476-78r0rsio	278	9	1	1	CD
cord-016476-78r0rsio	278	10	year	year	NN
cord-016476-78r0rsio	278	11	of	of	IN
cord-016476-78r0rsio	278	12	follow	follow	NN
cord-016476-78r0rsio	278	13	-	-	HYPH
cord-016476-78r0rsio	278	14	up	up	NN
cord-016476-78r0rsio	278	15	lacked	lack	VBD
cord-016476-78r0rsio	278	16	imaging	imaging	NN
cord-016476-78r0rsio	278	17	data	datum	NNS
cord-016476-78r0rsio	278	18	or	or	CC
cord-016476-78r0rsio	278	19	discontinued	discontinue	VBN
cord-016476-78r0rsio	278	20	treatment	treatment	NN
cord-016476-78r0rsio	278	21	because	because	IN
cord-016476-78r0rsio	278	22	infections	infection	NNS
cord-016476-78r0rsio	278	23	were	be	VBD
cord-016476-78r0rsio	278	24	excluded	exclude	VBN
cord-016476-78r0rsio	278	25	from	from	IN
cord-016476-78r0rsio	278	26	the	the	DT
cord-016476-78r0rsio	278	27	study	study	NN
cord-016476-78r0rsio	278	28	leading	lead	VBG
cord-016476-78r0rsio	278	29	to	to	IN
cord-016476-78r0rsio	278	30	a	a	DT
cord-016476-78r0rsio	278	31	likely	likely	JJ
cord-016476-78r0rsio	278	32	selection	selection	NN
cord-016476-78r0rsio	278	33	bias	bias	NN
cord-016476-78r0rsio	278	34	of	of	IN
cord-016476-78r0rsio	278	35	reported	report	VBN
cord-016476-78r0rsio	278	36	outcomes	outcome	NNS
cord-016476-78r0rsio	278	37	.	.	.
cord-016476-78r0rsio	279	1	In	in	IN
cord-016476-78r0rsio	279	2	a	a	DT
cord-016476-78r0rsio	279	3	retrospective	retrospective	JJ
cord-016476-78r0rsio	279	4	case	case	NN
cord-016476-78r0rsio	279	5	-	-	HYPH
cord-016476-78r0rsio	279	6	control	control	NN
cord-016476-78r0rsio	279	7	study	study	NN
cord-016476-78r0rsio	279	8	in	in	IN
cord-016476-78r0rsio	279	9	RA	RA	NNP
cord-016476-78r0rsio	279	10	,	,	,
cord-016476-78r0rsio	279	11	patients	patient	NNS
cord-016476-78r0rsio	279	12	were	be	VBD
cord-016476-78r0rsio	279	13	stratified	stratify	VBN
cord-016476-78r0rsio	279	14	according	accord	VBG
cord-016476-78r0rsio	279	15	to	to	IN
cord-016476-78r0rsio	279	16	the	the	DT
cord-016476-78r0rsio	279	17	presence	presence	NN
cord-016476-78r0rsio	279	18	of	of	IN
cord-016476-78r0rsio	279	19	baseline	baseline	JJ
cord-016476-78r0rsio	279	20	RA	RA	NNP
cord-016476-78r0rsio	279	21	-	-	HYPH
cord-016476-78r0rsio	279	22	ILD	ILD	NNP
cord-016476-78r0rsio	279	23	(	(	-LRB-
cord-016476-78r0rsio	279	24	n	n	NN
cord-016476-78r0rsio	279	25	=	=	SYM
cord-016476-78r0rsio	279	26	78	78	CD
cord-016476-78r0rsio	279	27	)	)	-RRB-
cord-016476-78r0rsio	279	28	or	or	CC
cord-016476-78r0rsio	279	29	without	without	IN
cord-016476-78r0rsio	279	30	(	(	-LRB-
cord-016476-78r0rsio	279	31	n	n	NN
cord-016476-78r0rsio	279	32	=	=	SYM
cord-016476-78r0rsio	279	33	317	317	CD
cord-016476-78r0rsio	279	34	)	)	-RRB-
cord-016476-78r0rsio	279	35	[	[	-LRB-
cord-016476-78r0rsio	279	36	124	124	CD
cord-016476-78r0rsio	279	37	]	]	-RRB-
cord-016476-78r0rsio	279	38	.	.	.
cord-016476-78r0rsio	280	1	During	during	IN
cord-016476-78r0rsio	280	2	observation	observation	NN
cord-016476-78r0rsio	280	3	period	period	NN
cord-016476-78r0rsio	280	4	of	of	IN
cord-016476-78r0rsio	280	5	148.8	148.8	CD
cord-016476-78r0rsio	280	6	patient	patient	NN
cord-016476-78r0rsio	280	7	-	-	HYPH
cord-016476-78r0rsio	280	8	years	year	NNS
cord-016476-78r0rsio	280	9	and	and	CC
cord-016476-78r0rsio	280	10	629.7	629.7	CD
cord-016476-78r0rsio	280	11	patient	patient	NN
cord-016476-78r0rsio	280	12	-	-	HYPH
cord-016476-78r0rsio	280	13	years	year	NNS
cord-016476-78r0rsio	280	14	for	for	IN
cord-016476-78r0rsio	280	15	the	the	DT
cord-016476-78r0rsio	280	16	RA	RA	NNP
cord-016476-78r0rsio	280	17	-	-	HYPH
cord-016476-78r0rsio	280	18	ILD	ILD	NNP
cord-016476-78r0rsio	280	19	and	and	CC
cord-016476-78r0rsio	280	20	non	non	JJ
cord-016476-78r0rsio	280	21	-	-	JJ
cord-016476-78r0rsio	280	22	ILD	ILD	NNP
cord-016476-78r0rsio	280	23	groups	group	NNS
cord-016476-78r0rsio	280	24	,	,	,
cord-016476-78r0rsio	280	25	respectively	respectively	RB
cord-016476-78r0rsio	280	26	,	,	,
cord-016476-78r0rsio	280	27	six	six	CD
cord-016476-78r0rsio	280	28	patients	patient	NNS
cord-016476-78r0rsio	280	29	developed	develop	VBD
cord-016476-78r0rsio	280	30	an	an	DT
cord-016476-78r0rsio	280	31	acute	acute	JJ
cord-016476-78r0rsio	280	32	exacerbation	exacerbation	NN
cord-016476-78r0rsio	280	33	in	in	IN
cord-016476-78r0rsio	280	34	the	the	DT
cord-016476-78r0rsio	280	35	RA	RA	NNP
cord-016476-78r0rsio	280	36	-	-	HYPH
cord-016476-78r0rsio	280	37	ILD	ILD	NNP
cord-016476-78r0rsio	280	38	group	group	NN
cord-016476-78r0rsio	280	39	(	(	-LRB-
cord-016476-78r0rsio	280	40	none	none	NN
cord-016476-78r0rsio	280	41	in	in	IN
cord-016476-78r0rsio	280	42	the	the	DT
cord-016476-78r0rsio	280	43	non	non	JJ
cord-016476-78r0rsio	280	44	-	-	JJ
cord-016476-78r0rsio	280	45	ILD	ILD	NNP
cord-016476-78r0rsio	280	46	group	group	NN
cord-016476-78r0rsio	280	47	)	)	-RRB-
cord-016476-78r0rsio	280	48	.	.	.
cord-016476-78r0rsio	281	1	Interesting	interest	VBG
cord-016476-78r0rsio	281	2	all	all	PDT
cord-016476-78r0rsio	281	3	the	the	DT
cord-016476-78r0rsio	281	4	patients	patient	NNS
cord-016476-78r0rsio	281	5	who	who	WP
cord-016476-78r0rsio	281	6	developed	develop	VBD
cord-016476-78r0rsio	281	7	an	an	DT
cord-016476-78r0rsio	281	8	exacerbation	exacerbation	NN
cord-016476-78r0rsio	281	9	of	of	IN
cord-016476-78r0rsio	281	10	ILD	ILD	NNP
cord-016476-78r0rsio	281	11	were	be	VBD
cord-016476-78r0rsio	281	12	on	on	IN
cord-016476-78r0rsio	281	13	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	281	14	monotherapy	monotherapy	NN
cord-016476-78r0rsio	281	15	,	,	,
cord-016476-78r0rsio	281	16	and	and	CC
cord-016476-78r0rsio	281	17	there	there	EX
cord-016476-78r0rsio	281	18	was	be	VBD
cord-016476-78r0rsio	281	19	a	a	DT
cord-016476-78r0rsio	281	20	suggestion	suggestion	NN
cord-016476-78r0rsio	281	21	that	that	IN
cord-016476-78r0rsio	281	22	all	all	DT
cord-016476-78r0rsio	281	23	patients	patient	NNS
cord-016476-78r0rsio	281	24	who	who	WP
cord-016476-78r0rsio	281	25	developed	develop	VBD
cord-016476-78r0rsio	281	26	an	an	DT
cord-016476-78r0rsio	281	27	exacerbation	exacerbation	NN
cord-016476-78r0rsio	281	28	had	have	VBD
cord-016476-78r0rsio	281	29	more	more	RBR
cord-016476-78r0rsio	281	30	uncontrolled	uncontrolled	JJ
cord-016476-78r0rsio	281	31	articular	articular	JJ
cord-016476-78r0rsio	281	32	disease	disease	NN
cord-016476-78r0rsio	281	33	that	that	WDT
cord-016476-78r0rsio	281	34	may	may	MD
cord-016476-78r0rsio	281	35	in	in	IN
cord-016476-78r0rsio	281	36	turn	turn	NN
cord-016476-78r0rsio	281	37	be	be	VB
cord-016476-78r0rsio	281	38	associated	associate	VBN
cord-016476-78r0rsio	281	39	with	with	IN
cord-016476-78r0rsio	281	40	the	the	DT
cord-016476-78r0rsio	281	41	outcome	outcome	NN
cord-016476-78r0rsio	281	42	[	[	-LRB-
cord-016476-78r0rsio	281	43	124	124	CD
cord-016476-78r0rsio	281	44	]	]	-RRB-
cord-016476-78r0rsio	281	45	.	.	.
cord-016476-78r0rsio	282	1	The	the	DT
cord-016476-78r0rsio	282	2	administrative	administrative	JJ
cord-016476-78r0rsio	282	3	data	data	NN
cord-016476-78r0rsio	282	4	study	study	NN
cord-016476-78r0rsio	282	5	by	by	IN
cord-016476-78r0rsio	282	6	Curtis	Curtis	NNP
cord-016476-78r0rsio	282	7	et	et	NNP
cord-016476-78r0rsio	282	8	al	al	NNP
cord-016476-78r0rsio	282	9	.	.	NNP
cord-016476-78r0rsio	282	10	concluded	conclude	VBD
cord-016476-78r0rsio	282	11	no	no	DT
cord-016476-78r0rsio	282	12	significant	significant	JJ
cord-016476-78r0rsio	282	13	differences	difference	NNS
cord-016476-78r0rsio	282	14	between	between	IN
cord-016476-78r0rsio	282	15	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	282	16	and	and	CC
cord-016476-78r0rsio	282	17	other	other	JJ
cord-016476-78r0rsio	282	18	biologic	biologic	JJ
cord-016476-78r0rsio	282	19	drugs	drug	NNS
cord-016476-78r0rsio	282	20	in	in	IN
cord-016476-78r0rsio	282	21	the	the	DT
cord-016476-78r0rsio	282	22	risk	risk	NN
cord-016476-78r0rsio	282	23	of	of	IN
cord-016476-78r0rsio	282	24	ILD	ILD	NNP
cord-016476-78r0rsio	282	25	or	or	CC
cord-016476-78r0rsio	282	26	its	-PRON-	PRP$
cord-016476-78r0rsio	282	27	exacerbation	exacerbation	NN
cord-016476-78r0rsio	282	28	[	[	-LRB-
cord-016476-78r0rsio	282	29	81	81	CD
cord-016476-78r0rsio	282	30	]	]	-RRB-
cord-016476-78r0rsio	282	31	.	.	.
cord-016476-78r0rsio	283	1	However	however	RB
cord-016476-78r0rsio	283	2	exacerbation	exacerbation	NN
cord-016476-78r0rsio	283	3	of	of	IN
cord-016476-78r0rsio	283	4	ILD	ILD	NNP
cord-016476-78r0rsio	283	5	can	can	MD
cord-016476-78r0rsio	283	6	be	be	VB
cord-016476-78r0rsio	283	7	difficult	difficult	JJ
cord-016476-78r0rsio	283	8	to	to	TO
cord-016476-78r0rsio	283	9	define	define	VB
cord-016476-78r0rsio	283	10	in	in	IN
cord-016476-78r0rsio	283	11	such	such	JJ
cord-016476-78r0rsio	283	12	databases	database	NNS
cord-016476-78r0rsio	283	13	as	as	IN
cord-016476-78r0rsio	283	14	recognised	recognise	VBN
cord-016476-78r0rsio	283	15	by	by	IN
cord-016476-78r0rsio	283	16	the	the	DT
cord-016476-78r0rsio	283	17	authors	author	NNS
cord-016476-78r0rsio	283	18	.	.	.
cord-016476-78r0rsio	284	1	Hence	hence	RB
cord-016476-78r0rsio	284	2	surrogate	surrogate	JJ
cord-016476-78r0rsio	284	3	measures	measure	NNS
cord-016476-78r0rsio	284	4	such	such	JJ
cord-016476-78r0rsio	284	5	as	as	IN
cord-016476-78r0rsio	284	6	hospitalisations	hospitalisation	NNS
cord-016476-78r0rsio	284	7	for	for	IN
cord-016476-78r0rsio	284	8	ILD	ILD	NNP
cord-016476-78r0rsio	284	9	,	,	,
cord-016476-78r0rsio	284	10	pneumonia	pneumonia	NN
cord-016476-78r0rsio	284	11	or	or	CC
cord-016476-78r0rsio	284	12	lung	lung	NN
cord-016476-78r0rsio	284	13	transplant	transplant	NN
cord-016476-78r0rsio	284	14	were	be	VBD
cord-016476-78r0rsio	284	15	used	use	VBN
cord-016476-78r0rsio	284	16	,	,	,
cord-016476-78r0rsio	284	17	which	which	WDT
cord-016476-78r0rsio	284	18	as	as	IN
cord-016476-78r0rsio	284	19	expected	expect	VBN
cord-016476-78r0rsio	284	20	were	be	VBD
cord-016476-78r0rsio	284	21	observed	observe	VBN
cord-016476-78r0rsio	284	22	infrequently	infrequently	RB
cord-016476-78r0rsio	284	23	and	and	CC
cord-016476-78r0rsio	284	24	capture	capture	VB
cord-016476-78r0rsio	284	25	a	a	DT
cord-016476-78r0rsio	284	26	heterogeneous	heterogeneous	JJ
cord-016476-78r0rsio	284	27	overall	overall	JJ
cord-016476-78r0rsio	284	28	outcome	outcome	NN
cord-016476-78r0rsio	284	29	that	that	WDT
cord-016476-78r0rsio	284	30	includes	include	VBZ
cord-016476-78r0rsio	284	31	infection	infection	NN
cord-016476-78r0rsio	284	32	.	.	.
cord-016476-78r0rsio	285	1	Therefore	therefore	RB
cord-016476-78r0rsio	285	2	,	,	,
cord-016476-78r0rsio	285	3	whilst	whilst	IN
cord-016476-78r0rsio	285	4	current	current	JJ
cord-016476-78r0rsio	285	5	evidence	evidence	NN
cord-016476-78r0rsio	285	6	does	do	VBZ
cord-016476-78r0rsio	285	7	not	not	RB
cord-016476-78r0rsio	285	8	allow	allow	VB
cord-016476-78r0rsio	285	9	robust	robust	JJ
cord-016476-78r0rsio	285	10	conclusions	conclusion	NNS
cord-016476-78r0rsio	285	11	about	about	IN
cord-016476-78r0rsio	285	12	the	the	DT
cord-016476-78r0rsio	285	13	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	285	14	safety	safety	NN
cord-016476-78r0rsio	285	15	of	of	IN
cord-016476-78r0rsio	285	16	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	285	17	in	in	IN
cord-016476-78r0rsio	285	18	RA	RA	NNP
cord-016476-78r0rsio	285	19	-	-	HYPH
cord-016476-78r0rsio	285	20	ILD	ILD	NNP
cord-016476-78r0rsio	285	21	,	,	,
cord-016476-78r0rsio	285	22	ongoing	ongoing	JJ
cord-016476-78r0rsio	285	23	vigilance	vigilance	NN
cord-016476-78r0rsio	285	24	is	be	VBZ
cord-016476-78r0rsio	285	25	recommended	recommend	VBN
cord-016476-78r0rsio	285	26	if	if	IN
cord-016476-78r0rsio	285	27	used	use	VBN
cord-016476-78r0rsio	285	28	in	in	IN
cord-016476-78r0rsio	285	29	this	this	DT
cord-016476-78r0rsio	285	30	context	context	NN
cord-016476-78r0rsio	285	31	in	in	IN
cord-016476-78r0rsio	285	32	the	the	DT
cord-016476-78r0rsio	285	33	absence	absence	NN
cord-016476-78r0rsio	285	34	of	of	IN
cord-016476-78r0rsio	285	35	clear	clear	JJ
cord-016476-78r0rsio	285	36	predictors	predictor	NNS
cord-016476-78r0rsio	285	37	of	of	IN
cord-016476-78r0rsio	285	38	ILD	ILD	NNP
cord-016476-78r0rsio	285	39	exacerbation	exacerbation	NN
cord-016476-78r0rsio	285	40	.	.	.
cord-016476-78r0rsio	286	1	Anakinra	Anakinra	NNP
cord-016476-78r0rsio	286	2	is	be	VBZ
cord-016476-78r0rsio	286	3	a	a	DT
cord-016476-78r0rsio	286	4	recombinant	recombinant	JJ
cord-016476-78r0rsio	286	5	IL-1	IL-1	NNP
cord-016476-78r0rsio	286	6	antagonist	antagonist	NN
cord-016476-78r0rsio	286	7	,	,	,
cord-016476-78r0rsio	286	8	which	which	WDT
cord-016476-78r0rsio	286	9	binds	bind	VBZ
cord-016476-78r0rsio	286	10	competitively	competitively	RB
cord-016476-78r0rsio	286	11	to	to	IN
cord-016476-78r0rsio	286	12	the	the	DT
cord-016476-78r0rsio	286	13	type	type	NN
cord-016476-78r0rsio	287	1	I	-PRON-	PRP
cord-016476-78r0rsio	287	2	IL-1	IL-1	NNP
cord-016476-78r0rsio	287	3	receptor	receptor	NN
cord-016476-78r0rsio	287	4	and	and	CC
cord-016476-78r0rsio	287	5	therefore	therefore	RB
cord-016476-78r0rsio	287	6	acts	act	VBZ
cord-016476-78r0rsio	287	7	as	as	IN
cord-016476-78r0rsio	287	8	a	a	DT
cord-016476-78r0rsio	287	9	competitive	competitive	JJ
cord-016476-78r0rsio	287	10	antagonist	antagonist	NN
cord-016476-78r0rsio	287	11	to	to	IN
cord-016476-78r0rsio	287	12	IL-1	IL-1	NNP
cord-016476-78r0rsio	287	13	.	.	.
cord-016476-78r0rsio	288	1	Initial	initial	JJ
cord-016476-78r0rsio	288	2	trials	trial	NNS
cord-016476-78r0rsio	288	3	that	that	WDT
cord-016476-78r0rsio	288	4	supported	support	VBD
cord-016476-78r0rsio	288	5	the	the	DT
cord-016476-78r0rsio	288	6	licensing	licensing	NN
cord-016476-78r0rsio	288	7	in	in	IN
cord-016476-78r0rsio	288	8	RA	RA	NNP
cord-016476-78r0rsio	288	9	did	do	VBD
cord-016476-78r0rsio	288	10	not	not	RB
cord-016476-78r0rsio	288	11	demonstrate	demonstrate	VB
cord-016476-78r0rsio	288	12	a	a	DT
cord-016476-78r0rsio	288	13	signal	signal	NN
cord-016476-78r0rsio	288	14	of	of	IN
cord-016476-78r0rsio	288	15	concern	concern	NN
cord-016476-78r0rsio	288	16	in	in	IN
cord-016476-78r0rsio	288	17	relation	relation	NN
cord-016476-78r0rsio	288	18	to	to	IN
cord-016476-78r0rsio	288	19	incident	incident	NN
cord-016476-78r0rsio	288	20	ILD	ILD	NNP
cord-016476-78r0rsio	288	21	either	either	CC
cord-016476-78r0rsio	288	22	as	as	IN
cord-016476-78r0rsio	288	23	monotherapy	monotherapy	NN
cord-016476-78r0rsio	288	24	[	[	-LRB-
cord-016476-78r0rsio	288	25	125	125	CD
cord-016476-78r0rsio	288	26	]	]	-RRB-
cord-016476-78r0rsio	288	27	[	[	-LRB-
cord-016476-78r0rsio	288	28	126	126	CD
cord-016476-78r0rsio	288	29	]	]	-RRB-
cord-016476-78r0rsio	288	30	[	[	-LRB-
cord-016476-78r0rsio	288	31	127	127	CD
cord-016476-78r0rsio	288	32	]	]	-RRB-
cord-016476-78r0rsio	288	33	or	or	CC
cord-016476-78r0rsio	288	34	in	in	IN
cord-016476-78r0rsio	288	35	combination	combination	NN
cord-016476-78r0rsio	288	36	with	with	IN
cord-016476-78r0rsio	288	37	MTX	MTX	NNP
cord-016476-78r0rsio	288	38	[	[	-LRB-
cord-016476-78r0rsio	288	39	128	128	CD
cord-016476-78r0rsio	288	40	]	]	-RRB-
cord-016476-78r0rsio	288	41	.	.	.
cord-016476-78r0rsio	289	1	Whilst	whilst	IN
cord-016476-78r0rsio	289	2	such	such	JJ
cord-016476-78r0rsio	289	3	data	datum	NNS
cord-016476-78r0rsio	289	4	supported	support	VBD
cord-016476-78r0rsio	289	5	the	the	DT
cord-016476-78r0rsio	289	6	initial	initial	JJ
cord-016476-78r0rsio	289	7	licensing	licensing	NN
cord-016476-78r0rsio	289	8	of	of	IN
cord-016476-78r0rsio	289	9	anakinra	anakinra	NNP
cord-016476-78r0rsio	289	10	in	in	IN
cord-016476-78r0rsio	289	11	RA	RA	NNP
cord-016476-78r0rsio	289	12	,	,	,
cord-016476-78r0rsio	289	13	in	in	IN
cord-016476-78r0rsio	289	14	clinical	clinical	JJ
cord-016476-78r0rsio	289	15	practice	practice	NN
cord-016476-78r0rsio	289	16	,	,	,
cord-016476-78r0rsio	289	17	it	-PRON-	PRP
cord-016476-78r0rsio	289	18	is	be	VBZ
cord-016476-78r0rsio	289	19	not	not	RB
cord-016476-78r0rsio	289	20	widely	widely	RB
cord-016476-78r0rsio	289	21	used	use	VBN
cord-016476-78r0rsio	289	22	in	in	IN
cord-016476-78r0rsio	289	23	RA	RA	NNP
cord-016476-78r0rsio	289	24	for	for	IN
cord-016476-78r0rsio	289	25	active	active	JJ
cord-016476-78r0rsio	289	26	joint	joint	JJ
cord-016476-78r0rsio	289	27	disease	disease	NN
cord-016476-78r0rsio	289	28	as	as	IN
cord-016476-78r0rsio	289	29	it	-PRON-	PRP
cord-016476-78r0rsio	289	30	appears	appear	VBZ
cord-016476-78r0rsio	289	31	less	less	RBR
cord-016476-78r0rsio	289	32	efficacious	efficacious	JJ
cord-016476-78r0rsio	289	33	than	than	IN
cord-016476-78r0rsio	289	34	TNFi	tnfi	JJ
cord-016476-78r0rsio	289	35	agents	agent	NNS
cord-016476-78r0rsio	289	36	and	and	CC
cord-016476-78r0rsio	289	37	of	of	IN
cord-016476-78r0rsio	289	38	no	no	DT
cord-016476-78r0rsio	289	39	additional	additional	JJ
cord-016476-78r0rsio	289	40	value	value	NN
cord-016476-78r0rsio	289	41	in	in	IN
cord-016476-78r0rsio	289	42	early	early	JJ
cord-016476-78r0rsio	289	43	RA	RA	NNP
cord-016476-78r0rsio	289	44	[	[	-LRB-
cord-016476-78r0rsio	289	45	129	129	CD
cord-016476-78r0rsio	289	46	]	]	-RRB-
cord-016476-78r0rsio	289	47	.	.	.
cord-016476-78r0rsio	290	1	Moreover	moreover	RB
cord-016476-78r0rsio	290	2	,	,	,
cord-016476-78r0rsio	290	3	combination	combination	NN
cord-016476-78r0rsio	290	4	of	of	IN
cord-016476-78r0rsio	290	5	anakinra	anakinra	NNP
cord-016476-78r0rsio	290	6	and	and	CC
cord-016476-78r0rsio	290	7	etanercept	etanercept	NNP
cord-016476-78r0rsio	290	8	provided	provide	VBD
cord-016476-78r0rsio	290	9	no	no	DT
cord-016476-78r0rsio	290	10	added	add	VBN
cord-016476-78r0rsio	290	11	benefit	benefit	NN
cord-016476-78r0rsio	290	12	compared	compare	VBN
cord-016476-78r0rsio	290	13	to	to	IN
cord-016476-78r0rsio	290	14	etanercept	etanercept	NNP
cord-016476-78r0rsio	290	15	monotherapy	monotherapy	NN
cord-016476-78r0rsio	290	16	,	,	,
cord-016476-78r0rsio	290	17	and	and	CC
cord-016476-78r0rsio	290	18	indeed	indeed	RB
cord-016476-78r0rsio	290	19	increased	increase	VBD
cord-016476-78r0rsio	290	20	serious	serious	JJ
cord-016476-78r0rsio	290	21	safety	safety	NN
cord-016476-78r0rsio	290	22	concerns	concern	NNS
cord-016476-78r0rsio	290	23	were	be	VBD
cord-016476-78r0rsio	290	24	reported	report	VBN
cord-016476-78r0rsio	290	25	including	include	VBG
cord-016476-78r0rsio	290	26	two	two	CD
cord-016476-78r0rsio	290	27	patients	patient	NNS
cord-016476-78r0rsio	290	28	with	with	IN
cord-016476-78r0rsio	290	29	new	new	JJ
cord-016476-78r0rsio	290	30	ILD	ILD	NNP
cord-016476-78r0rsio	290	31	and	and	CC
cord-016476-78r0rsio	290	32	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	290	33	in	in	IN
cord-016476-78r0rsio	290	34	the	the	DT
cord-016476-78r0rsio	290	35	combination	combination	NN
cord-016476-78r0rsio	290	36	biologic	biologic	JJ
cord-016476-78r0rsio	290	37	arms	arm	NNS
cord-016476-78r0rsio	290	38	[	[	-LRB-
cord-016476-78r0rsio	290	39	130	130	CD
cord-016476-78r0rsio	290	40	]	]	-RRB-
cord-016476-78r0rsio	290	41	.	.	.
cord-016476-78r0rsio	291	1	There	there	EX
cord-016476-78r0rsio	291	2	are	be	VBP
cord-016476-78r0rsio	291	3	sparse	sparse	JJ
cord-016476-78r0rsio	291	4	reports	report	NNS
cord-016476-78r0rsio	291	5	of	of	IN
cord-016476-78r0rsio	291	6	non	non	JJ
cord-016476-78r0rsio	291	7	-	-	JJ
cord-016476-78r0rsio	291	8	infective	infective	JJ
cord-016476-78r0rsio	291	9	SRAEs	srae	NNS
cord-016476-78r0rsio	291	10	on	on	IN
cord-016476-78r0rsio	291	11	anakinra	anakinra	NNP
cord-016476-78r0rsio	291	12	from	from	IN
cord-016476-78r0rsio	291	13	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	291	14	pharmacovigilance	pharmacovigilance	NN
cord-016476-78r0rsio	291	15	(	(	-LRB-
cord-016476-78r0rsio	291	16	Table	table	NN
cord-016476-78r0rsio	291	17	9	9	CD
cord-016476-78r0rsio	291	18	.2	.2	CD
cord-016476-78r0rsio	291	19	)	)	-RRB-
cord-016476-78r0rsio	291	20	,	,	,
cord-016476-78r0rsio	291	21	possibly	possibly	RB
cord-016476-78r0rsio	291	22	reflecting	reflect	VBG
cord-016476-78r0rsio	291	23	fewer	few	JJR
cord-016476-78r0rsio	291	24	exposed	expose	VBN
cord-016476-78r0rsio	291	25	patients	patient	NNS
cord-016476-78r0rsio	291	26	with	with	IN
cord-016476-78r0rsio	291	27	RA	RA	NNP
cord-016476-78r0rsio	291	28	.	.	.
cord-016476-78r0rsio	292	1	Therefore	therefore	RB
cord-016476-78r0rsio	292	2	apart	apart	RB
cord-016476-78r0rsio	292	3	from	from	IN
cord-016476-78r0rsio	292	4	one	one	CD
cord-016476-78r0rsio	292	5	case	case	NN
cord-016476-78r0rsio	292	6	of	of	IN
cord-016476-78r0rsio	292	7	improvement	improvement	NN
cord-016476-78r0rsio	292	8	in	in	IN
cord-016476-78r0rsio	292	9	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	292	10	-	-	HYPH
cord-016476-78r0rsio	292	11	induced	induce	VBN
cord-016476-78r0rsio	292	12	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	292	13	following	follow	VBG
cord-016476-78r0rsio	292	14	anakinra	anakinra	NNP
cord-016476-78r0rsio	292	15	in	in	IN
cord-016476-78r0rsio	292	16	a	a	DT
cord-016476-78r0rsio	292	17	patient	patient	NN
cord-016476-78r0rsio	292	18	with	with	IN
cord-016476-78r0rsio	292	19	adult	adult	NN
cord-016476-78r0rsio	292	20	-	-	HYPH
cord-016476-78r0rsio	292	21	onset	onset	NN
cord-016476-78r0rsio	292	22	Still	still	RB
cord-016476-78r0rsio	292	23	's	's	POS
cord-016476-78r0rsio	292	24	disease	disease	NN
cord-016476-78r0rsio	292	25	[	[	-LRB-
cord-016476-78r0rsio	292	26	121	121	CD
cord-016476-78r0rsio	292	27	]	]	-RRB-
cord-016476-78r0rsio	292	28	,	,	,
cord-016476-78r0rsio	292	29	there	there	EX
cord-016476-78r0rsio	292	30	is	be	VBZ
cord-016476-78r0rsio	292	31	no	no	DT
cord-016476-78r0rsio	292	32	further	further	JJ
cord-016476-78r0rsio	292	33	literature	literature	NN
cord-016476-78r0rsio	292	34	indicative	indicative	NN
cord-016476-78r0rsio	292	35	of	of	IN
cord-016476-78r0rsio	292	36	non	non	JJ
cord-016476-78r0rsio	292	37	-	-	JJ
cord-016476-78r0rsio	292	38	infective	infective	JJ
cord-016476-78r0rsio	292	39	SRAEs	srae	NNS
cord-016476-78r0rsio	292	40	with	with	IN
cord-016476-78r0rsio	292	41	its	-PRON-	PRP$
cord-016476-78r0rsio	292	42	use	use	NN
cord-016476-78r0rsio	292	43	[	[	-LRB-
cord-016476-78r0rsio	292	44	33	33	CD
cord-016476-78r0rsio	292	45	]	]	-RRB-
cord-016476-78r0rsio	292	46	but	but	CC
cord-016476-78r0rsio	292	47	also	also	RB
cord-016476-78r0rsio	292	48	minimal	minimal	JJ
cord-016476-78r0rsio	292	49	evidence	evidence	NN
cord-016476-78r0rsio	292	50	to	to	TO
cord-016476-78r0rsio	292	51	suggest	suggest	VB
cord-016476-78r0rsio	292	52	a	a	DT
cord-016476-78r0rsio	292	53	potential	potential	JJ
cord-016476-78r0rsio	292	54	beneficial	beneficial	JJ
cord-016476-78r0rsio	292	55	role	role	NN
cord-016476-78r0rsio	292	56	in	in	IN
cord-016476-78r0rsio	292	57	RA	RA	NNP
cord-016476-78r0rsio	292	58	-	-	HYPH
cord-016476-78r0rsio	292	59	ILD	ILD	NNP
cord-016476-78r0rsio	292	60	.	.	.
cord-016476-78r0rsio	293	1	Janus	Janus	NNP
cord-016476-78r0rsio	293	2	kinase	kinase	NN
cord-016476-78r0rsio	293	3	(	(	-LRB-
cord-016476-78r0rsio	293	4	JAK	JAK	NNP
cord-016476-78r0rsio	293	5	)	)	-RRB-
cord-016476-78r0rsio	293	6	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	293	7	,	,	,
cord-016476-78r0rsio	293	8	such	such	JJ
cord-016476-78r0rsio	293	9	as	as	IN
cord-016476-78r0rsio	293	10	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	293	11	and	and	CC
cord-016476-78r0rsio	293	12	baricitinib	baricitinib	NNP
cord-016476-78r0rsio	293	13	,	,	,
cord-016476-78r0rsio	293	14	are	be	VBP
cord-016476-78r0rsio	293	15	synthetic	synthetic	JJ
cord-016476-78r0rsio	293	16	orally	orally	RB
cord-016476-78r0rsio	293	17	administered	administer	VBN
cord-016476-78r0rsio	293	18	compounds	compound	NNS
cord-016476-78r0rsio	293	19	that	that	WDT
cord-016476-78r0rsio	293	20	block	block	VBP
cord-016476-78r0rsio	293	21	JAK	JAK	NNP
cord-016476-78r0rsio	293	22	,	,	,
cord-016476-78r0rsio	293	23	a	a	DT
cord-016476-78r0rsio	293	24	protein	protein	NN
cord-016476-78r0rsio	293	25	that	that	WDT
cord-016476-78r0rsio	293	26	mediates	mediate	VBZ
cord-016476-78r0rsio	293	27	signal	signal	JJ
cord-016476-78r0rsio	293	28	transduction	transduction	NN
cord-016476-78r0rsio	293	29	of	of	IN
cord-016476-78r0rsio	293	30	multiple	multiple	JJ
cord-016476-78r0rsio	293	31	cytokines	cytokine	NNS
cord-016476-78r0rsio	293	32	.	.	.
cord-016476-78r0rsio	294	1	Although	although	IN
cord-016476-78r0rsio	294	2	these	these	DT
cord-016476-78r0rsio	294	3	are	be	VBP
cord-016476-78r0rsio	294	4	not	not	RB
cord-016476-78r0rsio	294	5	biologic	biologic	JJ
cord-016476-78r0rsio	294	6	drugs	drug	NNS
cord-016476-78r0rsio	294	7	,	,	,
cord-016476-78r0rsio	294	8	though	though	IN
cord-016476-78r0rsio	294	9	they	-PRON-	PRP
cord-016476-78r0rsio	294	10	interact	interact	VBP
cord-016476-78r0rsio	294	11	with	with	IN
cord-016476-78r0rsio	294	12	biological	biological	JJ
cord-016476-78r0rsio	294	13	pathways	pathway	NNS
cord-016476-78r0rsio	294	14	,	,	,
cord-016476-78r0rsio	294	15	they	-PRON-	PRP
cord-016476-78r0rsio	294	16	have	have	VBP
cord-016476-78r0rsio	294	17	been	be	VBN
cord-016476-78r0rsio	294	18	classed	class	VBN
cord-016476-78r0rsio	294	19	as	as	IN
cord-016476-78r0rsio	294	20	targeted	target	VBN
cord-016476-78r0rsio	294	21	synthetic	synthetic	JJ
cord-016476-78r0rsio	294	22	DMARDs	dmard	NNS
cord-016476-78r0rsio	294	23	(	(	-LRB-
cord-016476-78r0rsio	294	24	tsDMARDs	tsdmards	NN
cord-016476-78r0rsio	294	25	)	)	-RRB-
cord-016476-78r0rsio	294	26	for	for	IN
cord-016476-78r0rsio	294	27	use	use	NN
cord-016476-78r0rsio	294	28	in	in	IN
cord-016476-78r0rsio	294	29	moderate	moderate	JJ
cord-016476-78r0rsio	294	30	to	to	IN
cord-016476-78r0rsio	294	31	severe	severe	JJ
cord-016476-78r0rsio	294	32	RA	RA	NNP
cord-016476-78r0rsio	294	33	,	,	,
cord-016476-78r0rsio	294	34	who	who	WP
cord-016476-78r0rsio	294	35	are	be	VBP
cord-016476-78r0rsio	294	36	nonresponders	nonresponder	NNS
cord-016476-78r0rsio	294	37	or	or	CC
cord-016476-78r0rsio	294	38	intolerant	intolerant	JJ
cord-016476-78r0rsio	294	39	to	to	IN
cord-016476-78r0rsio	294	40	MTX	MTX	NNP
cord-016476-78r0rsio	294	41	[	[	-LRB-
cord-016476-78r0rsio	294	42	3	3	CD
cord-016476-78r0rsio	294	43	,	,	,
cord-016476-78r0rsio	294	44	131	131	CD
cord-016476-78r0rsio	294	45	]	]	-RRB-
cord-016476-78r0rsio	294	46	.	.	.
cord-016476-78r0rsio	295	1	Tofacitinib	Tofacitinib	NNP
cord-016476-78r0rsio	295	2	has	have	VBZ
cord-016476-78r0rsio	295	3	been	be	VBN
cord-016476-78r0rsio	295	4	approved	approve	VBN
cord-016476-78r0rsio	295	5	in	in	IN
cord-016476-78r0rsio	295	6	several	several	JJ
cord-016476-78r0rsio	295	7	countries	country	NNS
cord-016476-78r0rsio	295	8	,	,	,
cord-016476-78r0rsio	295	9	such	such	JJ
cord-016476-78r0rsio	295	10	as	as	IN
cord-016476-78r0rsio	295	11	in	in	IN
cord-016476-78r0rsio	295	12	the	the	DT
cord-016476-78r0rsio	295	13	USA	USA	NNP
cord-016476-78r0rsio	295	14	,	,	,
cord-016476-78r0rsio	295	15	Latin	Latin	NNP
cord-016476-78r0rsio	295	16	America	America	NNP
cord-016476-78r0rsio	295	17	and	and	CC
cord-016476-78r0rsio	295	18	Asia	Asia	NNP
cord-016476-78r0rsio	295	19	although	although	IN
cord-016476-78r0rsio	295	20	not	not	RB
cord-016476-78r0rsio	295	21	in	in	IN
cord-016476-78r0rsio	295	22	the	the	DT
cord-016476-78r0rsio	295	23	European	European	NNP
cord-016476-78r0rsio	295	24	Union	Union	NNP
cord-016476-78r0rsio	295	25	or	or	CC
cord-016476-78r0rsio	295	26	UK	UK	NNP
cord-016476-78r0rsio	295	27	.	.	.
cord-016476-78r0rsio	296	1	Baricitinib	Baricitinib	NNP
cord-016476-78r0rsio	296	2	has	have	VBZ
cord-016476-78r0rsio	296	3	completed	complete	VBN
cord-016476-78r0rsio	296	4	phase	phase	NN
cord-016476-78r0rsio	296	5	III	iii	CD
cord-016476-78r0rsio	296	6	trials	trial	NNS
cord-016476-78r0rsio	296	7	,	,	,
cord-016476-78r0rsio	296	8	and	and	CC
cord-016476-78r0rsio	296	9	early	early	JJ
cord-016476-78r0rsio	296	10	results	result	NNS
cord-016476-78r0rsio	296	11	from	from	IN
cord-016476-78r0rsio	296	12	head	head	NN
cord-016476-78r0rsio	296	13	-	-	HYPH
cord-016476-78r0rsio	296	14	to	to	IN
cord-016476-78r0rsio	296	15	-	-	HYPH
cord-016476-78r0rsio	296	16	head	head	NN
cord-016476-78r0rsio	296	17	trials	trial	NNS
cord-016476-78r0rsio	296	18	even	even	RB
cord-016476-78r0rsio	296	19	suggest	suggest	VBP
cord-016476-78r0rsio	296	20	that	that	IN
cord-016476-78r0rsio	296	21	it	-PRON-	PRP
cord-016476-78r0rsio	296	22	may	may	MD
cord-016476-78r0rsio	296	23	be	be	VB
cord-016476-78r0rsio	296	24	more	more	RBR
cord-016476-78r0rsio	296	25	efficacious	efficacious	JJ
cord-016476-78r0rsio	296	26	than	than	IN
cord-016476-78r0rsio	296	27	a	a	DT
cord-016476-78r0rsio	296	28	TNF	TNF	NNP
cord-016476-78r0rsio	296	29	inhibitor	inhibitor	NN
cord-016476-78r0rsio	296	30	[	[	-LRB-
cord-016476-78r0rsio	296	31	132	132	CD
cord-016476-78r0rsio	296	32	]	]	-RRB-
cord-016476-78r0rsio	296	33	.	.	.
cord-016476-78r0rsio	297	1	RCT	RCT	NNP
cord-016476-78r0rsio	297	2	data	datum	NNS
cord-016476-78r0rsio	297	3	thus	thus	RB
cord-016476-78r0rsio	297	4	far	far	RB
cord-016476-78r0rsio	297	5	with	with	IN
cord-016476-78r0rsio	297	6	regard	regard	NN
cord-016476-78r0rsio	297	7	to	to	IN
cord-016476-78r0rsio	297	8	respiratory	respiratory	JJ
cord-016476-78r0rsio	297	9	safety	safety	NN
cord-016476-78r0rsio	297	10	of	of	IN
cord-016476-78r0rsio	297	11	JAK	JAK	NNP
cord-016476-78r0rsio	297	12	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	297	13	are	be	VBP
cord-016476-78r0rsio	297	14	inconclusive	inconclusive	JJ
cord-016476-78r0rsio	297	15	.	.	.
cord-016476-78r0rsio	298	1	Phase	phase	NN
cord-016476-78r0rsio	298	2	III	iii	CD
cord-016476-78r0rsio	298	3	trials	trial	NNS
cord-016476-78r0rsio	298	4	of	of	IN
cord-016476-78r0rsio	298	5	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	298	6	with	with	IN
cord-016476-78r0rsio	298	7	concomitant	concomitant	JJ
cord-016476-78r0rsio	298	8	MTX	MTX	NNP
cord-016476-78r0rsio	298	9	in	in	IN
cord-016476-78r0rsio	298	10	patients	patient	NNS
cord-016476-78r0rsio	298	11	with	with	IN
cord-016476-78r0rsio	298	12	RA	RA	NNP
cord-016476-78r0rsio	298	13	have	have	VBP
cord-016476-78r0rsio	298	14	reported	report	VBN
cord-016476-78r0rsio	298	15	cases	case	NNS
cord-016476-78r0rsio	298	16	of	of	IN
cord-016476-78r0rsio	298	17	new	new	JJ
cord-016476-78r0rsio	298	18	-	-	HYPH
cord-016476-78r0rsio	298	19	onset	onset	NN
cord-016476-78r0rsio	298	20	ILD	ILD	NNP
cord-016476-78r0rsio	298	21	and	and	CC
cord-016476-78r0rsio	298	22	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	298	23	sarcoidosis	sarcoidosi	NNS
cord-016476-78r0rsio	298	24	[	[	-LRB-
cord-016476-78r0rsio	298	25	133	133	CD
cord-016476-78r0rsio	298	26	]	]	-RRB-
cord-016476-78r0rsio	298	27	.	.	.
cord-016476-78r0rsio	299	1	Other	other	JJ
cord-016476-78r0rsio	299	2	SRAEs	srae	NNS
cord-016476-78r0rsio	299	3	reported	report	VBN
cord-016476-78r0rsio	299	4	in	in	IN
cord-016476-78r0rsio	299	5	tofacitinib	tofacitinib	RB
cord-016476-78r0rsio	299	6	-	-	HYPH
cord-016476-78r0rsio	299	7	treated	treat	VBN
cord-016476-78r0rsio	299	8	arms	arm	NNS
cord-016476-78r0rsio	299	9	in	in	IN
cord-016476-78r0rsio	299	10	RCTs	rct	NNS
cord-016476-78r0rsio	299	11	include	include	VBP
cord-016476-78r0rsio	299	12	bronchopneumonia	bronchopneumonia	NN
cord-016476-78r0rsio	299	13	[	[	-LRB-
cord-016476-78r0rsio	299	14	134	134	CD
cord-016476-78r0rsio	299	15	]	]	-RRB-
cord-016476-78r0rsio	299	16	and	and	CC
cord-016476-78r0rsio	299	17	a	a	DT
cord-016476-78r0rsio	299	18	death	death	NN
cord-016476-78r0rsio	299	19	due	due	IN
cord-016476-78r0rsio	299	20	to	to	IN
cord-016476-78r0rsio	299	21	ARDS	ARDS	NNP
cord-016476-78r0rsio	299	22	[	[	-LRB-
cord-016476-78r0rsio	299	23	135	135	CD
cord-016476-78r0rsio	299	24	]	]	-RRB-
cord-016476-78r0rsio	299	25	.	.	.
cord-016476-78r0rsio	300	1	A	a	DT
cord-016476-78r0rsio	300	2	combination	combination	NN
cord-016476-78r0rsio	300	3	of	of	IN
cord-016476-78r0rsio	300	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	300	5	fibrosis	fibrosis	NN
cord-016476-78r0rsio	300	6	and	and	CC
cord-016476-78r0rsio	300	7	chronic	chronic	JJ
cord-016476-78r0rsio	300	8	obstructive	obstructive	JJ
cord-016476-78r0rsio	300	9	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	300	10	disease	disease	NN
cord-016476-78r0rsio	300	11	has	have	VBZ
cord-016476-78r0rsio	300	12	been	be	VBN
cord-016476-78r0rsio	300	13	observed	observe	VBN
cord-016476-78r0rsio	300	14	in	in	IN
cord-016476-78r0rsio	300	15	such	such	JJ
cord-016476-78r0rsio	300	16	trials	trial	NNS
cord-016476-78r0rsio	300	17	using	use	VBG
cord-016476-78r0rsio	300	18	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	300	19	monotherapy	monotherapy	NN
cord-016476-78r0rsio	300	20	[	[	-LRB-
cord-016476-78r0rsio	300	21	136	136	CD
cord-016476-78r0rsio	300	22	]	]	-RRB-
cord-016476-78r0rsio	300	23	.	.	.
cord-016476-78r0rsio	301	1	However	however	RB
cord-016476-78r0rsio	301	2	data	datum	NNS
cord-016476-78r0rsio	301	3	from	from	IN
cord-016476-78r0rsio	301	4	two	two	CD
cord-016476-78r0rsio	301	5	long	long	JJ
cord-016476-78r0rsio	301	6	-	-	HYPH
cord-016476-78r0rsio	301	7	term	term	NN
cord-016476-78r0rsio	301	8	extension	extension	NN
cord-016476-78r0rsio	301	9	studies	study	NNS
cord-016476-78r0rsio	301	10	from	from	IN
cord-016476-78r0rsio	301	11	Japan	Japan	NNP
cord-016476-78r0rsio	301	12	following	follow	VBG
cord-016476-78r0rsio	301	13	up	up	IN
cord-016476-78r0rsio	301	14	4102	4102	CD
cord-016476-78r0rsio	301	15	tofacitinib	tofacitinib	RB
cord-016476-78r0rsio	301	16	-	-	HYPH
cord-016476-78r0rsio	301	17	treated	treat	VBN
cord-016476-78r0rsio	301	18	patients	patient	NNS
cord-016476-78r0rsio	301	19	over	over	IN
cord-016476-78r0rsio	301	20	5963	5963	CD
cord-016476-78r0rsio	301	21	patient	patient	NN
cord-016476-78r0rsio	301	22	-	-	HYPH
cord-016476-78r0rsio	301	23	years	year	NNS
cord-016476-78r0rsio	301	24	reported	report	VBD
cord-016476-78r0rsio	301	25	no	no	DT
cord-016476-78r0rsio	301	26	additional	additional	JJ
cord-016476-78r0rsio	301	27	ILD	ILD	NNP
cord-016476-78r0rsio	301	28	events	event	NNS
cord-016476-78r0rsio	301	29	[	[	-LRB-
cord-016476-78r0rsio	301	30	137	137	CD
cord-016476-78r0rsio	301	31	]	]	-RRB-
cord-016476-78r0rsio	301	32	,	,	,
cord-016476-78r0rsio	301	33	nor	nor	CC
cord-016476-78r0rsio	301	34	did	do	VBD
cord-016476-78r0rsio	301	35	subsequent	subsequent	JJ
cord-016476-78r0rsio	301	36	meta	meta	JJ
cord-016476-78r0rsio	301	37	-	-	HYPH
cord-016476-78r0rsio	301	38	analysis	analysis	NN
cord-016476-78r0rsio	301	39	of	of	IN
cord-016476-78r0rsio	301	40	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	301	41	trials	trial	NNS
cord-016476-78r0rsio	301	42	[	[	-LRB-
cord-016476-78r0rsio	301	43	138	138	CD
cord-016476-78r0rsio	301	44	]	]	-RRB-
cord-016476-78r0rsio	301	45	.	.	.
cord-016476-78r0rsio	302	1	In	in	IN
cord-016476-78r0rsio	302	2	addition	addition	NN
cord-016476-78r0rsio	302	3	phase	phase	NN
cord-016476-78r0rsio	302	4	IIb	iib	JJ
cord-016476-78r0rsio	302	5	studies	study	NNS
cord-016476-78r0rsio	302	6	and	and	CC
cord-016476-78r0rsio	302	7	phase	phase	NN
cord-016476-78r0rsio	302	8	III	iii	CD
cord-016476-78r0rsio	302	9	studies	study	NNS
cord-016476-78r0rsio	302	10	of	of	IN
cord-016476-78r0rsio	302	11	baricitinib	baricitinib	NNP
cord-016476-78r0rsio	302	12	also	also	RB
cord-016476-78r0rsio	302	13	have	have	VBP
cord-016476-78r0rsio	302	14	not	not	RB
cord-016476-78r0rsio	302	15	reported	report	VBN
cord-016476-78r0rsio	302	16	incident	incident	NN
cord-016476-78r0rsio	302	17	ILD	ILD	NNP
cord-016476-78r0rsio	302	18	cases	case	NNS
cord-016476-78r0rsio	302	19	[	[	-LRB-
cord-016476-78r0rsio	302	20	139	139	CD
cord-016476-78r0rsio	302	21	,	,	,
cord-016476-78r0rsio	302	22	140	140	CD
cord-016476-78r0rsio	302	23	]	]	-RRB-
cord-016476-78r0rsio	302	24	and	and	CC
cord-016476-78r0rsio	302	25	is	be	VBZ
cord-016476-78r0rsio	302	26	currently	currently	RB
cord-016476-78r0rsio	302	27	under	under	IN
cord-016476-78r0rsio	302	28	regulatory	regulatory	JJ
cord-016476-78r0rsio	302	29	review	review	NN
cord-016476-78r0rsio	302	30	.	.	.
cord-016476-78r0rsio	303	1	In	in	IN
cord-016476-78r0rsio	303	2	2015	2015	CD
cord-016476-78r0rsio	303	3	,	,	,
cord-016476-78r0rsio	303	4	the	the	DT
cord-016476-78r0rsio	303	5	FDA	FDA	NNP
cord-016476-78r0rsio	303	6	released	release	VBD
cord-016476-78r0rsio	303	7	a	a	DT
cord-016476-78r0rsio	303	8	Risk	Risk	NNP
cord-016476-78r0rsio	303	9	Evaluation	Evaluation	NNP
cord-016476-78r0rsio	303	10	and	and	CC
cord-016476-78r0rsio	303	11	Mitigation	Mitigation	NNP
cord-016476-78r0rsio	303	12	Strategy	Strategy	NNP
cord-016476-78r0rsio	303	13	(	(	-LRB-
cord-016476-78r0rsio	303	14	REMS	REMS	NNP
cord-016476-78r0rsio	303	15	)	)	-RRB-
cord-016476-78r0rsio	303	16	document	document	NN
cord-016476-78r0rsio	303	17	highlighting	highlight	VBG
cord-016476-78r0rsio	303	18	the	the	DT
cord-016476-78r0rsio	303	19	known	know	VBN
cord-016476-78r0rsio	303	20	concerns	concern	NNS
cord-016476-78r0rsio	303	21	with	with	IN
cord-016476-78r0rsio	303	22	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	303	23	,	,	,
cord-016476-78r0rsio	303	24	instructing	instruct	VBG
cord-016476-78r0rsio	303	25	the	the	DT
cord-016476-78r0rsio	303	26	pharmaceutical	pharmaceutical	JJ
cord-016476-78r0rsio	303	27	company	company	NN
cord-016476-78r0rsio	303	28	to	to	TO
cord-016476-78r0rsio	303	29	send	send	VB
cord-016476-78r0rsio	303	30	information	information	NN
cord-016476-78r0rsio	303	31	out	out	RP
cord-016476-78r0rsio	303	32	to	to	IN
cord-016476-78r0rsio	303	33	healthcare	healthcare	NN
cord-016476-78r0rsio	303	34	professionals	professional	NNS
cord-016476-78r0rsio	303	35	regarding	regard	VBG
cord-016476-78r0rsio	303	36	the	the	DT
cord-016476-78r0rsio	303	37	risk	risk	NN
cord-016476-78r0rsio	303	38	of	of	IN
cord-016476-78r0rsio	303	39	serious	serious	JJ
cord-016476-78r0rsio	303	40	infections	infection	NNS
cord-016476-78r0rsio	303	41	,	,	,
cord-016476-78r0rsio	303	42	malignancies	malignancy	NNS
cord-016476-78r0rsio	303	43	,	,	,
cord-016476-78r0rsio	303	44	decreases	decrease	VBZ
cord-016476-78r0rsio	303	45	in	in	IN
cord-016476-78r0rsio	303	46	peripheral	peripheral	JJ
cord-016476-78r0rsio	303	47	lymphocyte	lymphocyte	NN
cord-016476-78r0rsio	303	48	counts	count	NNS
cord-016476-78r0rsio	303	49	,	,	,
cord-016476-78r0rsio	303	50	neutrophil	neutrophil	NN
cord-016476-78r0rsio	303	51	counts	count	NNS
cord-016476-78r0rsio	303	52	and	and	CC
cord-016476-78r0rsio	303	53	haemoglobin	haemoglobin	NN
cord-016476-78r0rsio	303	54	and	and	CC
cord-016476-78r0rsio	303	55	derangement	derangement	NN
cord-016476-78r0rsio	303	56	in	in	IN
cord-016476-78r0rsio	303	57	lipid	lipid	NN
cord-016476-78r0rsio	303	58	profiles	profile	NNS
cord-016476-78r0rsio	303	59	[	[	-LRB-
cord-016476-78r0rsio	303	60	141	141	CD
cord-016476-78r0rsio	303	61	]	]	-RRB-
cord-016476-78r0rsio	303	62	;	;	:
cord-016476-78r0rsio	303	63	lung	lung	NN
cord-016476-78r0rsio	303	64	toxicity	toxicity	NN
cord-016476-78r0rsio	303	65	was	be	VBD
cord-016476-78r0rsio	303	66	not	not	RB
cord-016476-78r0rsio	303	67	mentioned	mention	VBN
cord-016476-78r0rsio	303	68	.	.	.
cord-016476-78r0rsio	304	1	No	no	DT
cord-016476-78r0rsio	304	2	case	case	NN
cord-016476-78r0rsio	304	3	reports	report	NNS
cord-016476-78r0rsio	304	4	or	or	CC
cord-016476-78r0rsio	304	5	regulatory	regulatory	JJ
cord-016476-78r0rsio	304	6	reports	report	NNS
cord-016476-78r0rsio	304	7	of	of	IN
cord-016476-78r0rsio	304	8	ILD	ILD	NNP
cord-016476-78r0rsio	304	9	have	have	VBP
cord-016476-78r0rsio	304	10	been	be	VBN
cord-016476-78r0rsio	304	11	published	publish	VBN
cord-016476-78r0rsio	304	12	to	to	IN
cord-016476-78r0rsio	304	13	date	date	NN
cord-016476-78r0rsio	304	14	,	,	,
cord-016476-78r0rsio	304	15	although	although	IN
cord-016476-78r0rsio	304	16	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	304	17	was	be	VBD
cord-016476-78r0rsio	304	18	licensed	license	VBN
cord-016476-78r0rsio	304	19	for	for	IN
cord-016476-78r0rsio	304	20	the	the	DT
cord-016476-78r0rsio	304	21	treatment	treatment	NN
cord-016476-78r0rsio	304	22	of	of	IN
cord-016476-78r0rsio	304	23	RA	RA	NNP
cord-016476-78r0rsio	304	24	a	a	DT
cord-016476-78r0rsio	304	25	few	few	JJ
cord-016476-78r0rsio	304	26	years	year	NNS
cord-016476-78r0rsio	304	27	ago	ago	RB
cord-016476-78r0rsio	304	28	in	in	IN
cord-016476-78r0rsio	304	29	November	November	NNP
cord-016476-78r0rsio	304	30	2012	2012	CD
cord-016476-78r0rsio	304	31	in	in	IN
cord-016476-78r0rsio	304	32	the	the	DT
cord-016476-78r0rsio	304	33	USA	USA	NNP
cord-016476-78r0rsio	304	34	and	and	CC
cord-016476-78r0rsio	304	35	remains	remain	VBZ
cord-016476-78r0rsio	304	36	unlicensed	unlicensed	JJ
cord-016476-78r0rsio	304	37	in	in	IN
cord-016476-78r0rsio	304	38	most	most	JJS
cord-016476-78r0rsio	304	39	of	of	IN
cord-016476-78r0rsio	304	40	Europe	Europe	NNP
cord-016476-78r0rsio	304	41	,	,	,
cord-016476-78r0rsio	304	42	limiting	limit	VBG
cord-016476-78r0rsio	304	43	the	the	DT
cord-016476-78r0rsio	304	44	numbers	number	NNS
cord-016476-78r0rsio	304	45	of	of	IN
cord-016476-78r0rsio	304	46	exposed	expose	VBN
cord-016476-78r0rsio	304	47	patients	patient	NNS
cord-016476-78r0rsio	304	48	.	.	.
cord-016476-78r0rsio	305	1	Conclusions	conclusion	NNS
cord-016476-78r0rsio	305	2	drawn	draw	VBN
cord-016476-78r0rsio	305	3	regarding	regard	VBG
cord-016476-78r0rsio	305	4	the	the	DT
cord-016476-78r0rsio	305	5	association	association	NN
cord-016476-78r0rsio	305	6	between	between	IN
cord-016476-78r0rsio	305	7	JAK	JAK	NNP
cord-016476-78r0rsio	305	8	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	305	9	and	and	CC
cord-016476-78r0rsio	305	10	ILD	ILD	NNP
cord-016476-78r0rsio	305	11	in	in	IN
cord-016476-78r0rsio	305	12	patients	patient	NNS
cord-016476-78r0rsio	305	13	with	with	IN
cord-016476-78r0rsio	305	14	RA	RA	NNP
cord-016476-78r0rsio	305	15	are	be	VBP
cord-016476-78r0rsio	305	16	therefore	therefore	RB
cord-016476-78r0rsio	305	17	restricted	restrict	VBN
cord-016476-78r0rsio	305	18	,	,	,
cord-016476-78r0rsio	305	19	given	give	VBN
cord-016476-78r0rsio	305	20	limited	limited	JJ
cord-016476-78r0rsio	305	21	data	datum	NNS
cord-016476-78r0rsio	305	22	and	and	CC
cord-016476-78r0rsio	305	23	further	further	JJ
cord-016476-78r0rsio	305	24	observational	observational	JJ
cord-016476-78r0rsio	305	25	evidence	evidence	NN
cord-016476-78r0rsio	305	26	are	be	VBP
cord-016476-78r0rsio	305	27	required	require	VBN
cord-016476-78r0rsio	305	28	to	to	TO
cord-016476-78r0rsio	305	29	assess	assess	VB
cord-016476-78r0rsio	305	30	its	-PRON-	PRP$
cord-016476-78r0rsio	305	31	effect	effect	NN
cord-016476-78r0rsio	305	32	on	on	IN
cord-016476-78r0rsio	305	33	pre	pre	JJ
cord-016476-78r0rsio	305	34	-	-	JJ
cord-016476-78r0rsio	305	35	existing	existing	JJ
cord-016476-78r0rsio	305	36	RA	RA	NNP
cord-016476-78r0rsio	305	37	-	-	HYPH
cord-016476-78r0rsio	305	38	ILD	ILD	NNP
cord-016476-78r0rsio	305	39	.	.	.
cord-016476-78r0rsio	306	1	Although	although	IN
cord-016476-78r0rsio	306	2	RA	RA	NNP
cord-016476-78r0rsio	306	3	-	-	HYPH
cord-016476-78r0rsio	306	4	ILD	ILD	NNP
cord-016476-78r0rsio	306	5	is	be	VBZ
cord-016476-78r0rsio	306	6	a	a	DT
cord-016476-78r0rsio	306	7	fairly	fairly	RB
cord-016476-78r0rsio	306	8	heterogeneous	heterogeneous	JJ
cord-016476-78r0rsio	306	9	extra	extra	JJ
cord-016476-78r0rsio	306	10	-	-	JJ
cord-016476-78r0rsio	306	11	articular	articular	JJ
cord-016476-78r0rsio	306	12	manifestation	manifestation	NN
cord-016476-78r0rsio	306	13	of	of	IN
cord-016476-78r0rsio	306	14	RA	RA	NNP
cord-016476-78r0rsio	306	15	,	,	,
cord-016476-78r0rsio	306	16	the	the	DT
cord-016476-78r0rsio	306	17	majority	majority	NN
cord-016476-78r0rsio	306	18	of	of	IN
cord-016476-78r0rsio	306	19	cases	case	NNS
cord-016476-78r0rsio	306	20	mimic	mimic	VBP
cord-016476-78r0rsio	306	21	the	the	DT
cord-016476-78r0rsio	306	22	two	two	CD
cord-016476-78r0rsio	306	23	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	306	24	interstitial	interstitial	JJ
cord-016476-78r0rsio	306	25	pneumonia	pneumonia	NN
cord-016476-78r0rsio	306	26	patterns	pattern	NNS
cord-016476-78r0rsio	306	27	of	of	IN
cord-016476-78r0rsio	306	28	NSIP	NSIP	NNP
cord-016476-78r0rsio	306	29	and	and	CC
cord-016476-78r0rsio	306	30	UIP	UIP	NNP
cord-016476-78r0rsio	306	31	.	.	.
cord-016476-78r0rsio	307	1	Whilst	whilst	IN
cord-016476-78r0rsio	307	2	NSIP	NSIP	NNP
cord-016476-78r0rsio	307	3	and	and	CC
cord-016476-78r0rsio	307	4	organising	organise	VBG
cord-016476-78r0rsio	307	5	pneumonia	pneumonia	NN
cord-016476-78r0rsio	307	6	appear	appear	VB
cord-016476-78r0rsio	307	7	to	to	TO
cord-016476-78r0rsio	307	8	be	be	VB
cord-016476-78r0rsio	307	9	more	more	RBR
cord-016476-78r0rsio	307	10	responsive	responsive	JJ
cord-016476-78r0rsio	307	11	to	to	IN
cord-016476-78r0rsio	307	12	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	307	13	treatment	treatment	NN
cord-016476-78r0rsio	307	14	,	,	,
cord-016476-78r0rsio	307	15	the	the	DT
cord-016476-78r0rsio	307	16	presence	presence	NN
cord-016476-78r0rsio	307	17	of	of	IN
cord-016476-78r0rsio	307	18	the	the	DT
cord-016476-78r0rsio	307	19	UIP	UIP	NNP
cord-016476-78r0rsio	307	20	pattern	pattern	NN
cord-016476-78r0rsio	307	21	on	on	IN
cord-016476-78r0rsio	307	22	HRCT	HRCT	NNP
cord-016476-78r0rsio	307	23	in	in	IN
cord-016476-78r0rsio	307	24	patients	patient	NNS
cord-016476-78r0rsio	307	25	with	with	IN
cord-016476-78r0rsio	307	26	RA	RA	NNP
cord-016476-78r0rsio	307	27	may	may	MD
cord-016476-78r0rsio	307	28	be	be	VB
cord-016476-78r0rsio	307	29	associated	associate	VBN
cord-016476-78r0rsio	307	30	with	with	IN
cord-016476-78r0rsio	307	31	a	a	DT
cord-016476-78r0rsio	307	32	significantly	significantly	RB
cord-016476-78r0rsio	307	33	shorter	short	JJR
cord-016476-78r0rsio	307	34	survival	survival	NN
cord-016476-78r0rsio	307	35	compared	compare	VBN
cord-016476-78r0rsio	307	36	to	to	IN
cord-016476-78r0rsio	307	37	other	other	JJ
cord-016476-78r0rsio	307	38	forms	form	NNS
cord-016476-78r0rsio	307	39	of	of	IN
cord-016476-78r0rsio	307	40	interstitial	interstitial	JJ
cord-016476-78r0rsio	307	41	disease	disease	NN
cord-016476-78r0rsio	307	42	[	[	-LRB-
cord-016476-78r0rsio	307	43	142	142	CD
cord-016476-78r0rsio	307	44	]	]	-RRB-
cord-016476-78r0rsio	307	45	.	.	.
cord-016476-78r0rsio	308	1	As	as	IN
cord-016476-78r0rsio	308	2	a	a	DT
cord-016476-78r0rsio	308	3	general	general	JJ
cord-016476-78r0rsio	308	4	clinical	clinical	JJ
cord-016476-78r0rsio	308	5	guidance	guidance	NN
cord-016476-78r0rsio	308	6	,	,	,
cord-016476-78r0rsio	308	7	lung	lung	NN
cord-016476-78r0rsio	308	8	disease	disease	NN
cord-016476-78r0rsio	308	9	features	feature	VBZ
cord-016476-78r0rsio	308	10	that	that	WDT
cord-016476-78r0rsio	308	11	may	may	MD
cord-016476-78r0rsio	308	12	be	be	VB
cord-016476-78r0rsio	308	13	predictive	predictive	JJ
cord-016476-78r0rsio	308	14	of	of	IN
cord-016476-78r0rsio	308	15	treatment	treatment	NN
cord-016476-78r0rsio	308	16	benefit	benefit	NN
cord-016476-78r0rsio	308	17	include	include	VBP
cord-016476-78r0rsio	308	18	histopathologic	histopathologic	JJ
cord-016476-78r0rsio	308	19	patterns	pattern	NNS
cord-016476-78r0rsio	308	20	other	other	JJ
cord-016476-78r0rsio	308	21	than	than	IN
cord-016476-78r0rsio	308	22	UIP	UIP	NNP
cord-016476-78r0rsio	308	23	(	(	-LRB-
cord-016476-78r0rsio	308	24	especially	especially	RB
cord-016476-78r0rsio	308	25	NSIP	NSIP	NNP
cord-016476-78r0rsio	308	26	and	and	CC
cord-016476-78r0rsio	308	27	OP	OP	NNP
cord-016476-78r0rsio	308	28	,	,	,
cord-016476-78r0rsio	308	29	younger	young	JJR
cord-016476-78r0rsio	308	30	age	age	NN
cord-016476-78r0rsio	308	31	of	of	IN
cord-016476-78r0rsio	308	32	the	the	DT
cord-016476-78r0rsio	308	33	patient	patient	NN
cord-016476-78r0rsio	308	34	and	and	CC
cord-016476-78r0rsio	308	35	worsening	worsening	NN
cord-016476-78r0rsio	308	36	of	of	IN
cord-016476-78r0rsio	308	37	symptoms	symptom	NNS
cord-016476-78r0rsio	308	38	,	,	,
cord-016476-78r0rsio	308	39	PFTs	pft	NNS
cord-016476-78r0rsio	308	40	or	or	CC
cord-016476-78r0rsio	308	41	finding	find	VBG
cord-016476-78r0rsio	308	42	on	on	IN
cord-016476-78r0rsio	308	43	HRCT	HRCT	NNP
cord-016476-78r0rsio	308	44	over	over	IN
cord-016476-78r0rsio	308	45	the	the	DT
cord-016476-78r0rsio	308	46	preceding	precede	VBG
cord-016476-78r0rsio	308	47	3	3	CD
cord-016476-78r0rsio	308	48	-	-	SYM
cord-016476-78r0rsio	308	49	6	6	CD
cord-016476-78r0rsio	308	50	months	month	NNS
cord-016476-78r0rsio	308	51	[	[	-LRB-
cord-016476-78r0rsio	308	52	143	143	CD
cord-016476-78r0rsio	308	53	]	]	-RRB-
cord-016476-78r0rsio	309	1	[	[	-LRB-
cord-016476-78r0rsio	309	2	144	144	CD
cord-016476-78r0rsio	309	3	]	]	-RRB-
cord-016476-78r0rsio	309	4	[	[	-LRB-
cord-016476-78r0rsio	309	5	145	145	CD
cord-016476-78r0rsio	309	6	]	]	-RRB-
cord-016476-78r0rsio	309	7	.	.	.
cord-016476-78r0rsio	310	1	A	a	DT
cord-016476-78r0rsio	310	2	DLCO	dlco	NN
cord-016476-78r0rsio	310	3	of	of	IN
cord-016476-78r0rsio	310	4	less	less	JJR
cord-016476-78r0rsio	310	5	than	than	IN
cord-016476-78r0rsio	310	6	54	54	CD
cord-016476-78r0rsio	310	7	%	%	NN
cord-016476-78r0rsio	310	8	is	be	VBZ
cord-016476-78r0rsio	310	9	associated	associate	VBN
cord-016476-78r0rsio	310	10	with	with	IN
cord-016476-78r0rsio	310	11	progression	progression	NN
cord-016476-78r0rsio	310	12	and	and	CC
cord-016476-78r0rsio	310	13	poor	poor	JJ
cord-016476-78r0rsio	310	14	prognosis	prognosis	NN
cord-016476-78r0rsio	310	15	and	and	CC
cord-016476-78r0rsio	310	16	may	may	MD
cord-016476-78r0rsio	310	17	identify	identify	VB
cord-016476-78r0rsio	310	18	patients	patient	NNS
cord-016476-78r0rsio	310	19	who	who	WP
cord-016476-78r0rsio	310	20	could	could	MD
cord-016476-78r0rsio	310	21	be	be	VB
cord-016476-78r0rsio	310	22	considered	consider	VBN
cord-016476-78r0rsio	310	23	for	for	IN
cord-016476-78r0rsio	310	24	treatment	treatment	NN
cord-016476-78r0rsio	310	25	[	[	-LRB-
cord-016476-78r0rsio	310	26	7	7	CD
cord-016476-78r0rsio	310	27	]	]	-RRB-
cord-016476-78r0rsio	310	28	.	.	.
cord-016476-78r0rsio	311	1	Numerous	numerous	JJ
cord-016476-78r0rsio	311	2	medications	medication	NNS
cord-016476-78r0rsio	311	3	have	have	VBP
cord-016476-78r0rsio	311	4	been	be	VBN
cord-016476-78r0rsio	311	5	described	describe	VBN
cord-016476-78r0rsio	311	6	for	for	IN
cord-016476-78r0rsio	311	7	potential	potential	JJ
cord-016476-78r0rsio	311	8	therapies	therapy	NNS
cord-016476-78r0rsio	311	9	for	for	IN
cord-016476-78r0rsio	311	10	RA	RA	NNP
cord-016476-78r0rsio	311	11	-	-	HYPH
cord-016476-78r0rsio	311	12	ILD	ILD	NNP
cord-016476-78r0rsio	311	13	,	,	,
cord-016476-78r0rsio	311	14	but	but	CC
cord-016476-78r0rsio	311	15	currently	currently	RB
cord-016476-78r0rsio	311	16	there	there	EX
cord-016476-78r0rsio	311	17	are	be	VBP
cord-016476-78r0rsio	311	18	no	no	DT
cord-016476-78r0rsio	311	19	large	large	JJ
cord-016476-78r0rsio	311	20	RCTs	rct	NNS
cord-016476-78r0rsio	311	21	to	to	TO
cord-016476-78r0rsio	311	22	help	help	VB
cord-016476-78r0rsio	311	23	guide	guide	VB
cord-016476-78r0rsio	311	24	physicians	physician	NNS
cord-016476-78r0rsio	311	25	specifically	specifically	RB
cord-016476-78r0rsio	311	26	in	in	IN
cord-016476-78r0rsio	311	27	the	the	DT
cord-016476-78r0rsio	311	28	management	management	NN
cord-016476-78r0rsio	311	29	of	of	IN
cord-016476-78r0rsio	311	30	the	the	DT
cord-016476-78r0rsio	311	31	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	311	32	manifestations	manifestation	NNS
cord-016476-78r0rsio	311	33	of	of	IN
cord-016476-78r0rsio	311	34	RA	RA	NNP
cord-016476-78r0rsio	311	35	-	-	HYPH
cord-016476-78r0rsio	311	36	ILD	ILD	NNP
cord-016476-78r0rsio	311	37	.	.	.
cord-016476-78r0rsio	312	1	In	in	IN
cord-016476-78r0rsio	312	2	addition	addition	NN
cord-016476-78r0rsio	312	3	to	to	IN
cord-016476-78r0rsio	312	4	immunosuppressive	immunosuppressive	JJ
cord-016476-78r0rsio	312	5	treatments	treatment	NNS
cord-016476-78r0rsio	312	6	,	,	,
cord-016476-78r0rsio	312	7	general	general	JJ
cord-016476-78r0rsio	312	8	considerations	consideration	NNS
cord-016476-78r0rsio	312	9	for	for	IN
cord-016476-78r0rsio	312	10	management	management	NN
cord-016476-78r0rsio	312	11	of	of	IN
cord-016476-78r0rsio	312	12	RA	RA	NNP
cord-016476-78r0rsio	312	13	-	-	HYPH
cord-016476-78r0rsio	312	14	ILD	ILD	NNP
cord-016476-78r0rsio	312	15	include	include	VBP
cord-016476-78r0rsio	312	16	smoking	smoke	VBG
cord-016476-78r0rsio	312	17	cessation	cessation	NN
cord-016476-78r0rsio	312	18	and	and	CC
cord-016476-78r0rsio	312	19	age	age	NN
cord-016476-78r0rsio	312	20	-	-	HYPH
cord-016476-78r0rsio	312	21	appropriate	appropriate	JJ
cord-016476-78r0rsio	312	22	vaccinations	vaccination	NNS
cord-016476-78r0rsio	312	23	for	for	IN
cord-016476-78r0rsio	312	24	pneumonia	pneumonia	NN
cord-016476-78r0rsio	312	25	and	and	CC
cord-016476-78r0rsio	312	26	influenza	influenza	NN
cord-016476-78r0rsio	312	27	,	,	,
cord-016476-78r0rsio	312	28	as	as	RB
cord-016476-78r0rsio	312	29	well	well	RB
cord-016476-78r0rsio	312	30	as	as	IN
cord-016476-78r0rsio	312	31	prophylaxis	prophylaxis	NN
cord-016476-78r0rsio	312	32	for	for	IN
cord-016476-78r0rsio	312	33	Pneumocystis	Pneumocystis	NNP
cord-016476-78r0rsio	312	34	jirovecii	jirovecii	NNP
cord-016476-78r0rsio	312	35	pneumonia	pneumonia	NN
cord-016476-78r0rsio	312	36	in	in	IN
cord-016476-78r0rsio	312	37	patients	patient	NNS
cord-016476-78r0rsio	312	38	who	who	WP
cord-016476-78r0rsio	312	39	are	be	VBP
cord-016476-78r0rsio	312	40	profoundly	profoundly	RB
cord-016476-78r0rsio	312	41	immunosuppressed	immunosuppressed	JJ
cord-016476-78r0rsio	312	42	[	[	-LRB-
cord-016476-78r0rsio	312	43	145	145	CD
cord-016476-78r0rsio	312	44	]	]	-RRB-
cord-016476-78r0rsio	312	45	.	.	.
cord-016476-78r0rsio	313	1	Typically	typically	RB
cord-016476-78r0rsio	313	2	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	313	3	were	be	VBD
cord-016476-78r0rsio	313	4	used	use	VBN
cord-016476-78r0rsio	313	5	as	as	IN
cord-016476-78r0rsio	313	6	first	first	JJ
cord-016476-78r0rsio	313	7	-	-	HYPH
cord-016476-78r0rsio	313	8	line	line	NN
cord-016476-78r0rsio	313	9	therapies	therapy	NNS
cord-016476-78r0rsio	313	10	in	in	IN
cord-016476-78r0rsio	313	11	an	an	DT
cord-016476-78r0rsio	313	12	attempt	attempt	NN
cord-016476-78r0rsio	313	13	to	to	TO
cord-016476-78r0rsio	313	14	stabilise	stabilise	VB
cord-016476-78r0rsio	313	15	and	and	CC
cord-016476-78r0rsio	313	16	improve	improve	VB
cord-016476-78r0rsio	313	17	the	the	DT
cord-016476-78r0rsio	313	18	disease	disease	NN
cord-016476-78r0rsio	313	19	course	course	NN
cord-016476-78r0rsio	313	20	of	of	IN
cord-016476-78r0rsio	313	21	RA	RA	NNP
cord-016476-78r0rsio	313	22	-	-	HYPH
cord-016476-78r0rsio	313	23	ILD	ILD	NNP
cord-016476-78r0rsio	313	24	based	base	VBN
cord-016476-78r0rsio	313	25	on	on	IN
cord-016476-78r0rsio	313	26	limited	limited	JJ
cord-016476-78r0rsio	313	27	evidence	evidence	NN
cord-016476-78r0rsio	313	28	from	from	IN
cord-016476-78r0rsio	313	29	IPF	IPF	NNP
cord-016476-78r0rsio	313	30	.	.	.
cord-016476-78r0rsio	314	1	Because	because	IN
cord-016476-78r0rsio	314	2	RA	RA	NNP
cord-016476-78r0rsio	314	3	-	-	HYPH
cord-016476-78r0rsio	314	4	ILD	ILD	NNP
cord-016476-78r0rsio	314	5	is	be	VBZ
cord-016476-78r0rsio	314	6	a	a	DT
cord-016476-78r0rsio	314	7	heterogeneous	heterogeneous	JJ
cord-016476-78r0rsio	314	8	spectrum	spectrum	NN
cord-016476-78r0rsio	314	9	of	of	IN
cord-016476-78r0rsio	314	10	histopathologic	histopathologic	JJ
cord-016476-78r0rsio	314	11	patterns	pattern	NNS
cord-016476-78r0rsio	314	12	beyond	beyond	IN
cord-016476-78r0rsio	314	13	UIP	UIP	NNP
cord-016476-78r0rsio	314	14	(	(	-LRB-
cord-016476-78r0rsio	314	15	IPF	IPF	NNP
cord-016476-78r0rsio	314	16	)	)	-RRB-
cord-016476-78r0rsio	314	17	,	,	,
cord-016476-78r0rsio	314	18	experience	experience	NN
cord-016476-78r0rsio	314	19	extrapolated	extrapolate	VBN
cord-016476-78r0rsio	314	20	from	from	IN
cord-016476-78r0rsio	314	21	management	management	NN
cord-016476-78r0rsio	314	22	of	of	IN
cord-016476-78r0rsio	314	23	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	314	24	ILD	ILD	NNP
cord-016476-78r0rsio	314	25	suggests	suggest	VBZ
cord-016476-78r0rsio	314	26	that	that	IN
cord-016476-78r0rsio	314	27	some	some	DT
cord-016476-78r0rsio	314	28	forms	form	NNS
cord-016476-78r0rsio	314	29	,	,	,
cord-016476-78r0rsio	314	30	including	include	VBG
cord-016476-78r0rsio	314	31	NSIP	NSIP	NNP
cord-016476-78r0rsio	314	32	and	and	CC
cord-016476-78r0rsio	314	33	OP	OP	NNP
cord-016476-78r0rsio	314	34	,	,	,
cord-016476-78r0rsio	314	35	may	may	MD
cord-016476-78r0rsio	314	36	respond	respond	VB
cord-016476-78r0rsio	314	37	to	to	IN
cord-016476-78r0rsio	314	38	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	314	39	therapy	therapy	NN
cord-016476-78r0rsio	314	40	[	[	-LRB-
cord-016476-78r0rsio	314	41	145	145	CD
cord-016476-78r0rsio	314	42	]	]	-RRB-
cord-016476-78r0rsio	314	43	.	.	.
cord-016476-78r0rsio	315	1	Given	give	VBN
cord-016476-78r0rsio	315	2	the	the	DT
cord-016476-78r0rsio	315	3	paucity	paucity	NN
cord-016476-78r0rsio	315	4	of	of	IN
cord-016476-78r0rsio	315	5	evidence	evidence	NN
cord-016476-78r0rsio	315	6	in	in	IN
cord-016476-78r0rsio	315	7	RA	RA	NNP
cord-016476-78r0rsio	315	8	-	-	HYPH
cord-016476-78r0rsio	315	9	ILD	ILD	NNP
cord-016476-78r0rsio	315	10	,	,	,
cord-016476-78r0rsio	315	11	it	-PRON-	PRP
cord-016476-78r0rsio	315	12	was	be	VBD
cord-016476-78r0rsio	315	13	felt	feel	VBN
cord-016476-78r0rsio	315	14	that	that	IN
cord-016476-78r0rsio	315	15	the	the	DT
cord-016476-78r0rsio	315	16	addition	addition	NN
cord-016476-78r0rsio	315	17	of	of	IN
cord-016476-78r0rsio	315	18	azathioprine	azathioprine	JJ
cord-016476-78r0rsio	315	19	maybe	maybe	RB
cord-016476-78r0rsio	315	20	beneficial	beneficial	JJ
cord-016476-78r0rsio	315	21	in	in	IN
cord-016476-78r0rsio	315	22	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	315	23	-	-	HYPH
cord-016476-78r0rsio	315	24	responsive	responsive	JJ
cord-016476-78r0rsio	315	25	patients	patient	NNS
cord-016476-78r0rsio	315	26	and	and	CC
cord-016476-78r0rsio	315	27	could	could	MD
cord-016476-78r0rsio	315	28	result	result	VB
cord-016476-78r0rsio	315	29	in	in	IN
cord-016476-78r0rsio	315	30	improved	improved	JJ
cord-016476-78r0rsio	315	31	survival	survival	NN
cord-016476-78r0rsio	315	32	compared	compare	VBN
cord-016476-78r0rsio	315	33	to	to	IN
cord-016476-78r0rsio	315	34	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	315	35	alone	alone	RB
cord-016476-78r0rsio	315	36	,	,	,
cord-016476-78r0rsio	315	37	again	again	RB
cord-016476-78r0rsio	315	38	based	base	VBN
cord-016476-78r0rsio	315	39	on	on	IN
cord-016476-78r0rsio	315	40	historic	historic	JJ
cord-016476-78r0rsio	315	41	data	datum	NNS
cord-016476-78r0rsio	315	42	from	from	IN
cord-016476-78r0rsio	315	43	IPF	IPF	NNP
cord-016476-78r0rsio	315	44	studies	study	NNS
cord-016476-78r0rsio	315	45	[	[	-LRB-
cord-016476-78r0rsio	315	46	146	146	CD
cord-016476-78r0rsio	315	47	]	]	-RRB-
cord-016476-78r0rsio	315	48	.	.	.
cord-016476-78r0rsio	316	1	However	however	RB
cord-016476-78r0rsio	316	2	,	,	,
cord-016476-78r0rsio	316	3	the	the	DT
cord-016476-78r0rsio	316	4	2012	2012	CD
cord-016476-78r0rsio	316	5	multicentre	multicentre	NNP
cord-016476-78r0rsio	316	6	Prednisone	Prednisone	NNP
cord-016476-78r0rsio	316	7	,	,	,
cord-016476-78r0rsio	316	8	Azathioprine	Azathioprine	NNP
cord-016476-78r0rsio	316	9	,	,	,
cord-016476-78r0rsio	316	10	and	and	CC
cord-016476-78r0rsio	316	11	(	(	-LRB-
cord-016476-78r0rsio	316	12	N	n	NN
cord-016476-78r0rsio	316	13	)	)	-RRB-
cord-016476-78r0rsio	316	14	acetylcysteine	acetylcysteine	NN
cord-016476-78r0rsio	316	15	[	[	-LRB-
cord-016476-78r0rsio	316	16	NAC	NAC	NNP
cord-016476-78r0rsio	316	17	]	]	-RRB-
cord-016476-78r0rsio	316	18	:	:	:
cord-016476-78r0rsio	317	1	A	a	DT
cord-016476-78r0rsio	317	2	Study	study	NN
cord-016476-78r0rsio	317	3	That	that	WDT
cord-016476-78r0rsio	317	4	Evaluates	evaluate	VBZ
cord-016476-78r0rsio	317	5	Response	response	NN
cord-016476-78r0rsio	317	6	in	in	IN
cord-016476-78r0rsio	317	7	IPF	IPF	NNP
cord-016476-78r0rsio	317	8	(	(	-LRB-
cord-016476-78r0rsio	317	9	PANTHER	PANTHER	NNP
cord-016476-78r0rsio	317	10	-	-	HYPH
cord-016476-78r0rsio	317	11	IPF	IPF	NNP
cord-016476-78r0rsio	317	12	)	)	-RRB-
cord-016476-78r0rsio	317	13	trial	trial	NN
cord-016476-78r0rsio	317	14	had	have	VBD
cord-016476-78r0rsio	317	15	to	to	TO
cord-016476-78r0rsio	317	16	be	be	VB
cord-016476-78r0rsio	317	17	prematurely	prematurely	RB
cord-016476-78r0rsio	317	18	stopped	stop	VBN
cord-016476-78r0rsio	317	19	as	as	IN
cord-016476-78r0rsio	317	20	it	-PRON-	PRP
cord-016476-78r0rsio	317	21	is	be	VBZ
cord-016476-78r0rsio	317	22	found	find	VBN
cord-016476-78r0rsio	317	23	that	that	IN
cord-016476-78r0rsio	317	24	combination	combination	NN
cord-016476-78r0rsio	317	25	of	of	IN
cord-016476-78r0rsio	317	26	prednisone	prednisone	NN
cord-016476-78r0rsio	317	27	,	,	,
cord-016476-78r0rsio	317	28	azathioprine	azathioprine	NN
cord-016476-78r0rsio	317	29	and	and	CC
cord-016476-78r0rsio	317	30	NAC	NAC	NNP
cord-016476-78r0rsio	317	31	was	be	VBD
cord-016476-78r0rsio	317	32	associated	associate	VBN
cord-016476-78r0rsio	317	33	with	with	IN
cord-016476-78r0rsio	317	34	greater	great	JJR
cord-016476-78r0rsio	317	35	mortality	mortality	NN
cord-016476-78r0rsio	317	36	(	(	-LRB-
cord-016476-78r0rsio	317	37	eight	eight	CD
cord-016476-78r0rsio	317	38	vs.	vs.	IN
cord-016476-78r0rsio	317	39	one	one	CD
cord-016476-78r0rsio	317	40	death	death	NN
cord-016476-78r0rsio	317	41	)	)	-RRB-
cord-016476-78r0rsio	317	42	,	,	,
cord-016476-78r0rsio	317	43	more	more	JJR
cord-016476-78r0rsio	317	44	hospitalisations	hospitalisation	NNS
cord-016476-78r0rsio	317	45	(	(	-LRB-
cord-016476-78r0rsio	317	46	23	23	CD
cord-016476-78r0rsio	317	47	vs.	vs.	CC
cord-016476-78r0rsio	317	48	7	7	CD
cord-016476-78r0rsio	317	49	)	)	-RRB-
cord-016476-78r0rsio	317	50	and	and	CC
cord-016476-78r0rsio	317	51	more	more	RBR
cord-016476-78r0rsio	317	52	serious	serious	JJ
cord-016476-78r0rsio	317	53	AEs	ae	NNS
cord-016476-78r0rsio	317	54	(	(	-LRB-
cord-016476-78r0rsio	317	55	24	24	CD
cord-016476-78r0rsio	317	56	vs.	vs.	NN
cord-016476-78r0rsio	317	57	8)	8)	NN
cord-016476-78r0rsio	317	58	compared	compare	VBN
cord-016476-78r0rsio	317	59	to	to	IN
cord-016476-78r0rsio	317	60	placebo	placebo	NN
cord-016476-78r0rsio	317	61	in	in	IN
cord-016476-78r0rsio	317	62	IPF	IPF	NNP
cord-016476-78r0rsio	317	63	patients	patient	NNS
cord-016476-78r0rsio	317	64	with	with	IN
cord-016476-78r0rsio	317	65	mild	mild	JJ
cord-016476-78r0rsio	317	66	to	to	IN
cord-016476-78r0rsio	317	67	moderate	moderate	JJ
cord-016476-78r0rsio	317	68	disease	disease	NN
cord-016476-78r0rsio	317	69	[	[	-LRB-
cord-016476-78r0rsio	317	70	147	147	CD
cord-016476-78r0rsio	317	71	]	]	-RRB-
cord-016476-78r0rsio	317	72	.	.	.
cord-016476-78r0rsio	318	1	A	a	DT
cord-016476-78r0rsio	318	2	large	large	JJ
cord-016476-78r0rsio	318	3	proportion	proportion	NN
cord-016476-78r0rsio	318	4	of	of	IN
cord-016476-78r0rsio	318	5	deaths	death	NNS
cord-016476-78r0rsio	318	6	were	be	VBD
cord-016476-78r0rsio	318	7	due	due	JJ
cord-016476-78r0rsio	318	8	to	to	IN
cord-016476-78r0rsio	318	9	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	318	10	infection	infection	NN
cord-016476-78r0rsio	318	11	,	,	,
cord-016476-78r0rsio	318	12	highlighting	highlight	VBG
cord-016476-78r0rsio	318	13	the	the	DT
cord-016476-78r0rsio	318	14	need	need	NN
cord-016476-78r0rsio	318	15	for	for	IN
cord-016476-78r0rsio	318	16	adequate	adequate	JJ
cord-016476-78r0rsio	318	17	precautions	precaution	NNS
cord-016476-78r0rsio	318	18	to	to	TO
cord-016476-78r0rsio	318	19	be	be	VB
cord-016476-78r0rsio	318	20	taken	take	VBN
cord-016476-78r0rsio	318	21	against	against	IN
cord-016476-78r0rsio	318	22	respiratory	respiratory	JJ
cord-016476-78r0rsio	318	23	infections	infection	NNS
cord-016476-78r0rsio	318	24	in	in	IN
cord-016476-78r0rsio	318	25	patients	patient	NNS
cord-016476-78r0rsio	318	26	with	with	IN
cord-016476-78r0rsio	318	27	RA	RA	NNP
cord-016476-78r0rsio	318	28	-	-	HYPH
cord-016476-78r0rsio	318	29	ILD	ILD	NNP
cord-016476-78r0rsio	318	30	who	who	WP
cord-016476-78r0rsio	318	31	are	be	VBP
cord-016476-78r0rsio	318	32	susceptible	susceptible	JJ
cord-016476-78r0rsio	318	33	to	to	IN
cord-016476-78r0rsio	318	34	serious	serious	JJ
cord-016476-78r0rsio	318	35	infections	infection	NNS
cord-016476-78r0rsio	318	36	[	[	-LRB-
cord-016476-78r0rsio	318	37	148	148	CD
cord-016476-78r0rsio	318	38	]	]	-RRB-
cord-016476-78r0rsio	318	39	.	.	.
cord-016476-78r0rsio	319	1	Indeed	indeed	RB
cord-016476-78r0rsio	319	2	in	in	IN
cord-016476-78r0rsio	319	3	elderly	elderly	JJ
cord-016476-78r0rsio	319	4	patients	patient	NNS
cord-016476-78r0rsio	319	5	with	with	IN
cord-016476-78r0rsio	319	6	RA	RA	NNP
cord-016476-78r0rsio	319	7	,	,	,
cord-016476-78r0rsio	319	8	prednisolone	prednisolone	NN
cord-016476-78r0rsio	319	9	has	have	VBZ
cord-016476-78r0rsio	319	10	been	be	VBN
cord-016476-78r0rsio	319	11	shown	show	VBN
cord-016476-78r0rsio	319	12	to	to	TO
cord-016476-78r0rsio	319	13	have	have	VB
cord-016476-78r0rsio	319	14	a	a	DT
cord-016476-78r0rsio	319	15	dose	dose	NN
cord-016476-78r0rsio	319	16	-	-	HYPH
cord-016476-78r0rsio	319	17	dependent	dependent	JJ
cord-016476-78r0rsio	319	18	risk	risk	NN
cord-016476-78r0rsio	319	19	of	of	IN
cord-016476-78r0rsio	319	20	infection	infection	NN
cord-016476-78r0rsio	319	21	,	,	,
cord-016476-78r0rsio	319	22	with	with	IN
cord-016476-78r0rsio	319	23	current	current	JJ
cord-016476-78r0rsio	319	24	/	/	SYM
cord-016476-78r0rsio	319	25	recent	recent	JJ
cord-016476-78r0rsio	319	26	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	319	27	therapy	therapy	NN
cord-016476-78r0rsio	319	28	demonstrating	demonstrate	VBG
cord-016476-78r0rsio	319	29	the	the	DT
cord-016476-78r0rsio	319	30	greatest	great	JJS
cord-016476-78r0rsio	319	31	impact	impact	NN
cord-016476-78r0rsio	319	32	on	on	IN
cord-016476-78r0rsio	319	33	infection	infection	NN
cord-016476-78r0rsio	319	34	risk	risk	NN
cord-016476-78r0rsio	319	35	[	[	-LRB-
cord-016476-78r0rsio	319	36	149	149	CD
cord-016476-78r0rsio	319	37	]	]	-RRB-
cord-016476-78r0rsio	319	38	.	.	.
cord-016476-78r0rsio	320	1	Therefore	therefore	RB
cord-016476-78r0rsio	320	2	use	use	NN
cord-016476-78r0rsio	320	3	of	of	IN
cord-016476-78r0rsio	320	4	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	320	5	specifically	specifically	RB
cord-016476-78r0rsio	320	6	for	for	IN
cord-016476-78r0rsio	320	7	ILD	ILD	NNP
cord-016476-78r0rsio	320	8	in	in	IN
cord-016476-78r0rsio	320	9	RA	RA	NNP
cord-016476-78r0rsio	320	10	is	be	VBZ
cord-016476-78r0rsio	320	11	best	well	RBS
cord-016476-78r0rsio	320	12	performed	perform	VBN
cord-016476-78r0rsio	320	13	after	after	IN
cord-016476-78r0rsio	320	14	liaison	liaison	NN
cord-016476-78r0rsio	320	15	with	with	IN
cord-016476-78r0rsio	320	16	respiratory	respiratory	JJ
cord-016476-78r0rsio	320	17	colleagues	colleague	NNS
cord-016476-78r0rsio	320	18	,	,	,
cord-016476-78r0rsio	320	19	with	with	IN
cord-016476-78r0rsio	320	20	use	use	NN
cord-016476-78r0rsio	320	21	of	of	IN
cord-016476-78r0rsio	320	22	the	the	DT
cord-016476-78r0rsio	320	23	lowest	low	JJS
cord-016476-78r0rsio	320	24	possible	possible	JJ
cord-016476-78r0rsio	320	25	dose	dose	NN
cord-016476-78r0rsio	320	26	prescribed	prescribe	VBN
cord-016476-78r0rsio	320	27	for	for	IN
cord-016476-78r0rsio	320	28	the	the	DT
cord-016476-78r0rsio	320	29	shortest	short	JJS
cord-016476-78r0rsio	320	30	duration	duration	NN
cord-016476-78r0rsio	320	31	.	.	.
cord-016476-78r0rsio	321	1	Pirfenidone	Pirfenidone	NNP
cord-016476-78r0rsio	321	2	is	be	VBZ
cord-016476-78r0rsio	321	3	an	an	DT
cord-016476-78r0rsio	321	4	anti	anti	JJ
cord-016476-78r0rsio	321	5	-	-	JJ
cord-016476-78r0rsio	321	6	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	321	7	drug	drug	NN
cord-016476-78r0rsio	321	8	that	that	WDT
cord-016476-78r0rsio	321	9	inhibits	inhibit	VBZ
cord-016476-78r0rsio	321	10	transforming	transform	VBG
cord-016476-78r0rsio	321	11	growth	growth	NN
cord-016476-78r0rsio	321	12	factor	factor	NN
cord-016476-78r0rsio	321	13	beta	beta	NN
cord-016476-78r0rsio	321	14	(	(	-LRB-
cord-016476-78r0rsio	321	15	TGF	TGF	NNP
cord-016476-78r0rsio	321	16	-	-	HYPH
cord-016476-78r0rsio	321	17	β)-stimulated	β)-stimulate	VBN
cord-016476-78r0rsio	321	18	collagen	collagen	NN
cord-016476-78r0rsio	321	19	synthesis	synthesis	NN
cord-016476-78r0rsio	321	20	,	,	,
cord-016476-78r0rsio	321	21	decreases	decrease	VBZ
cord-016476-78r0rsio	321	22	the	the	DT
cord-016476-78r0rsio	321	23	extracellular	extracellular	JJ
cord-016476-78r0rsio	321	24	matrix	matrix	NN
cord-016476-78r0rsio	321	25	and	and	CC
cord-016476-78r0rsio	321	26	blocks	block	VBZ
cord-016476-78r0rsio	321	27	fibroblast	fibroblast	NN
cord-016476-78r0rsio	321	28	proliferation	proliferation	NN
cord-016476-78r0rsio	321	29	.	.	.
cord-016476-78r0rsio	322	1	It	-PRON-	PRP
cord-016476-78r0rsio	322	2	has	have	VBZ
cord-016476-78r0rsio	322	3	demonstrated	demonstrate	VBN
cord-016476-78r0rsio	322	4	efficacy	efficacy	NN
cord-016476-78r0rsio	322	5	in	in	IN
cord-016476-78r0rsio	322	6	IPF	IPF	NNP
cord-016476-78r0rsio	322	7	[	[	-LRB-
cord-016476-78r0rsio	322	8	150	150	CD
cord-016476-78r0rsio	322	9	]	]	-RRB-
cord-016476-78r0rsio	322	10	[	[	-LRB-
cord-016476-78r0rsio	322	11	151	151	CD
cord-016476-78r0rsio	322	12	]	]	-RRB-
cord-016476-78r0rsio	322	13	[	[	-LRB-
cord-016476-78r0rsio	322	14	152	152	CD
cord-016476-78r0rsio	322	15	]	]	-RRB-
cord-016476-78r0rsio	322	16	and	and	CC
cord-016476-78r0rsio	322	17	has	have	VBZ
cord-016476-78r0rsio	322	18	been	be	VBN
cord-016476-78r0rsio	322	19	approved	approve	VBN
cord-016476-78r0rsio	322	20	by	by	IN
cord-016476-78r0rsio	322	21	the	the	DT
cord-016476-78r0rsio	322	22	National	National	NNP
cord-016476-78r0rsio	322	23	Institute	Institute	NNP
cord-016476-78r0rsio	322	24	of	of	IN
cord-016476-78r0rsio	322	25	Health	Health	NNP
cord-016476-78r0rsio	322	26	and	and	CC
cord-016476-78r0rsio	322	27	Care	Care	NNP
cord-016476-78r0rsio	322	28	Excellence	Excellence	NNP
cord-016476-78r0rsio	322	29	in	in	IN
cord-016476-78r0rsio	322	30	the	the	DT
cord-016476-78r0rsio	322	31	UK	UK	NNP
cord-016476-78r0rsio	322	32	and	and	CC
cord-016476-78r0rsio	322	33	the	the	DT
cord-016476-78r0rsio	322	34	FDA	FDA	NNP
cord-016476-78r0rsio	322	35	in	in	IN
cord-016476-78r0rsio	322	36	the	the	DT
cord-016476-78r0rsio	322	37	USA	USA	NNP
cord-016476-78r0rsio	322	38	for	for	IN
cord-016476-78r0rsio	322	39	use	use	NN
cord-016476-78r0rsio	322	40	in	in	IN
cord-016476-78r0rsio	322	41	patients	patient	NNS
cord-016476-78r0rsio	322	42	with	with	IN
cord-016476-78r0rsio	322	43	mild	mild	JJ
cord-016476-78r0rsio	322	44	or	or	CC
cord-016476-78r0rsio	322	45	moderate	moderate	JJ
cord-016476-78r0rsio	322	46	IPF	IPF	NNP
cord-016476-78r0rsio	322	47	.	.	.
cord-016476-78r0rsio	323	1	In	in	IN
cord-016476-78r0rsio	323	2	CTD	CTD	NNP
cord-016476-78r0rsio	323	3	-	-	HYPH
cord-016476-78r0rsio	323	4	ILD	ILD	NNP
cord-016476-78r0rsio	323	5	,	,	,
cord-016476-78r0rsio	323	6	specifically	specifically	RB
cord-016476-78r0rsio	323	7	secondary	secondary	JJ
cord-016476-78r0rsio	323	8	to	to	IN
cord-016476-78r0rsio	323	9	systemic	systemic	JJ
cord-016476-78r0rsio	323	10	sclerosis	sclerosis	NN
cord-016476-78r0rsio	323	11	,	,	,
cord-016476-78r0rsio	323	12	case	case	NN
cord-016476-78r0rsio	323	13	reports	report	NNS
cord-016476-78r0rsio	323	14	and	and	CC
cord-016476-78r0rsio	323	15	small	small	JJ
cord-016476-78r0rsio	323	16	retrospective	retrospective	JJ
cord-016476-78r0rsio	323	17	studies	study	NNS
cord-016476-78r0rsio	323	18	have	have	VBP
cord-016476-78r0rsio	323	19	suggested	suggest	VBN
cord-016476-78r0rsio	323	20	modest	modest	JJ
cord-016476-78r0rsio	323	21	benefit	benefit	NN
cord-016476-78r0rsio	323	22	[	[	-LRB-
cord-016476-78r0rsio	323	23	153	153	CD
cord-016476-78r0rsio	323	24	]	]	-RRB-
cord-016476-78r0rsio	323	25	[	[	-LRB-
cord-016476-78r0rsio	323	26	154	154	CD
cord-016476-78r0rsio	323	27	]	]	-RRB-
cord-016476-78r0rsio	323	28	[	[	-LRB-
cord-016476-78r0rsio	323	29	155	155	CD
cord-016476-78r0rsio	323	30	]	]	-RRB-
cord-016476-78r0rsio	323	31	[	[	-LRB-
cord-016476-78r0rsio	323	32	156	156	CD
cord-016476-78r0rsio	323	33	]	]	-RRB-
cord-016476-78r0rsio	323	34	,	,	,
cord-016476-78r0rsio	323	35	whilst	whilst	IN
cord-016476-78r0rsio	323	36	a	a	DT
cord-016476-78r0rsio	323	37	recent	recent	JJ
cord-016476-78r0rsio	323	38	open	open	JJ
cord-016476-78r0rsio	323	39	-	-	HYPH
cord-016476-78r0rsio	323	40	label	label	NN
cord-016476-78r0rsio	323	41	study	study	NN
cord-016476-78r0rsio	323	42	in	in	IN
cord-016476-78r0rsio	323	43	systemic	systemic	JJ
cord-016476-78r0rsio	323	44	sclerosis	sclerosis	NN
cord-016476-78r0rsio	323	45	demonstrated	demonstrate	VBD
cord-016476-78r0rsio	323	46	acceptable	acceptable	JJ
cord-016476-78r0rsio	323	47	tolerability	tolerability	NN
cord-016476-78r0rsio	323	48	of	of	IN
cord-016476-78r0rsio	323	49	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	323	50	,	,	,
cord-016476-78r0rsio	323	51	especially	especially	RB
cord-016476-78r0rsio	323	52	important	important	JJ
cord-016476-78r0rsio	323	53	since	since	IN
cord-016476-78r0rsio	323	54	63.5	63.5	CD
cord-016476-78r0rsio	323	55	%	%	NN
cord-016476-78r0rsio	323	56	of	of	IN
cord-016476-78r0rsio	323	57	patients	patient	NNS
cord-016476-78r0rsio	323	58	were	be	VBD
cord-016476-78r0rsio	323	59	on	on	IN
cord-016476-78r0rsio	323	60	concomitant	concomitant	JJ
cord-016476-78r0rsio	323	61	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	323	62	mofetil	mofetil	NNP
cord-016476-78r0rsio	323	63	[	[	-LRB-
cord-016476-78r0rsio	323	64	157	157	CD
cord-016476-78r0rsio	323	65	]	]	-RRB-
cord-016476-78r0rsio	323	66	.	.	.
cord-016476-78r0rsio	324	1	Currently	currently	RB
cord-016476-78r0rsio	324	2	there	there	EX
cord-016476-78r0rsio	324	3	is	be	VBZ
cord-016476-78r0rsio	324	4	no	no	DT
cord-016476-78r0rsio	324	5	evidence	evidence	NN
cord-016476-78r0rsio	324	6	for	for	IN
cord-016476-78r0rsio	324	7	its	-PRON-	PRP$
cord-016476-78r0rsio	324	8	use	use	NN
cord-016476-78r0rsio	324	9	in	in	IN
cord-016476-78r0rsio	324	10	RA	RA	NNP
cord-016476-78r0rsio	324	11	-	-	HYPH
cord-016476-78r0rsio	324	12	ILD	ILD	NNP
cord-016476-78r0rsio	324	13	.	.	.
cord-016476-78r0rsio	325	1	Theoretically	theoretically	RB
cord-016476-78r0rsio	325	2	,	,	,
cord-016476-78r0rsio	325	3	however	however	RB
cord-016476-78r0rsio	325	4	,	,	,
cord-016476-78r0rsio	325	5	given	give	VBN
cord-016476-78r0rsio	325	6	its	-PRON-	PRP$
cord-016476-78r0rsio	325	7	action	action	NN
cord-016476-78r0rsio	325	8	on	on	IN
cord-016476-78r0rsio	325	9	TGF	TGF	NNP
cord-016476-78r0rsio	325	10	-	-	HYPH
cord-016476-78r0rsio	325	11	β	β	NN
cord-016476-78r0rsio	325	12	and	and	CC
cord-016476-78r0rsio	325	13	fibroblast	fibroblast	NN
cord-016476-78r0rsio	325	14	proliferation	proliferation	NN
cord-016476-78r0rsio	325	15	,	,	,
cord-016476-78r0rsio	325	16	there	there	EX
cord-016476-78r0rsio	325	17	may	may	MD
cord-016476-78r0rsio	325	18	be	be	VB
cord-016476-78r0rsio	325	19	justification	justification	NN
cord-016476-78r0rsio	325	20	of	of	IN
cord-016476-78r0rsio	325	21	its	-PRON-	PRP$
cord-016476-78r0rsio	325	22	use	use	NN
cord-016476-78r0rsio	325	23	in	in	IN
cord-016476-78r0rsio	325	24	the	the	DT
cord-016476-78r0rsio	325	25	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	325	26	NSIP	NSIP	NNP
cord-016476-78r0rsio	325	27	pattern	pattern	NN
cord-016476-78r0rsio	325	28	and	and	CC
cord-016476-78r0rsio	325	29	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	325	30	stages	stage	NNS
cord-016476-78r0rsio	325	31	of	of	IN
cord-016476-78r0rsio	325	32	other	other	JJ
cord-016476-78r0rsio	325	33	RA	RA	NNP
cord-016476-78r0rsio	325	34	-	-	HYPH
cord-016476-78r0rsio	325	35	ILD	ILD	NNP
cord-016476-78r0rsio	325	36	subtypes	subtype	NNS
cord-016476-78r0rsio	325	37	[	[	-LRB-
cord-016476-78r0rsio	325	38	158	158	CD
cord-016476-78r0rsio	325	39	,	,	,
cord-016476-78r0rsio	325	40	159	159	CD
cord-016476-78r0rsio	325	41	]	]	-RRB-
cord-016476-78r0rsio	325	42	.	.	.
cord-016476-78r0rsio	326	1	Currently	currently	RB
cord-016476-78r0rsio	326	2	there	there	EX
cord-016476-78r0rsio	326	3	is	be	VBZ
cord-016476-78r0rsio	326	4	a	a	DT
cord-016476-78r0rsio	326	5	phase	phase	NN
cord-016476-78r0rsio	326	6	II	II	NNP
cord-016476-78r0rsio	326	7	trial	trial	NN
cord-016476-78r0rsio	326	8	underway	underway	JJ
cord-016476-78r0rsio	326	9	to	to	TO
cord-016476-78r0rsio	326	10	assess	assess	VB
cord-016476-78r0rsio	326	11	the	the	DT
cord-016476-78r0rsio	326	12	safety	safety	NN
cord-016476-78r0rsio	326	13	and	and	CC
cord-016476-78r0rsio	326	14	tolerability	tolerability	NN
cord-016476-78r0rsio	326	15	of	of	IN
cord-016476-78r0rsio	326	16	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	326	17	2403	2403	CD
cord-016476-78r0rsio	326	18	mg	mg	NNP
cord-016476-78r0rsio	326	19	/	/	SYM
cord-016476-78r0rsio	326	20	day	day	NN
cord-016476-78r0rsio	326	21	for	for	IN
cord-016476-78r0rsio	326	22	the	the	DT
cord-016476-78r0rsio	326	23	treatment	treatment	NN
cord-016476-78r0rsio	326	24	of	of	IN
cord-016476-78r0rsio	326	25	RA	RA	NNP
cord-016476-78r0rsio	326	26	-	-	HYPH
cord-016476-78r0rsio	326	27	ILD	ILD	NNP
cord-016476-78r0rsio	326	28	[	[	-LRB-
cord-016476-78r0rsio	326	29	160	160	CD
cord-016476-78r0rsio	326	30	]	]	-RRB-
cord-016476-78r0rsio	326	31	,	,	,
cord-016476-78r0rsio	326	32	with	with	IN
cord-016476-78r0rsio	326	33	a	a	DT
cord-016476-78r0rsio	326	34	need	need	NN
cord-016476-78r0rsio	326	35	for	for	IN
cord-016476-78r0rsio	326	36	more	more	JJR
cord-016476-78r0rsio	326	37	RCTs	rct	NNS
cord-016476-78r0rsio	326	38	the	the	DT
cord-016476-78r0rsio	326	39	effect	effect	NN
cord-016476-78r0rsio	326	40	on	on	IN
cord-016476-78r0rsio	326	41	respiratory	respiratory	JJ
cord-016476-78r0rsio	326	42	function	function	NN
cord-016476-78r0rsio	326	43	in	in	IN
cord-016476-78r0rsio	326	44	this	this	DT
cord-016476-78r0rsio	326	45	setting	setting	NN
cord-016476-78r0rsio	326	46	.	.	.
cord-016476-78r0rsio	327	1	Other	other	JJ
cord-016476-78r0rsio	327	2	anti	anti	JJ
cord-016476-78r0rsio	327	3	-	-	JJ
cord-016476-78r0rsio	327	4	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	327	5	agents	agent	NNS
cord-016476-78r0rsio	327	6	such	such	JJ
cord-016476-78r0rsio	327	7	as	as	IN
cord-016476-78r0rsio	327	8	nintedanib	nintedanib	NNP
cord-016476-78r0rsio	327	9	,	,	,
cord-016476-78r0rsio	327	10	a	a	DT
cord-016476-78r0rsio	327	11	tyrosine	tyrosine	NN
cord-016476-78r0rsio	327	12	kinase	kinase	NN
cord-016476-78r0rsio	327	13	inhibitor	inhibitor	NN
cord-016476-78r0rsio	327	14	that	that	WDT
cord-016476-78r0rsio	327	15	targets	target	VBZ
cord-016476-78r0rsio	327	16	multiple	multiple	JJ
cord-016476-78r0rsio	327	17	tyrosine	tyrosine	NN
cord-016476-78r0rsio	327	18	kinases	kinase	NNS
cord-016476-78r0rsio	327	19	,	,	,
cord-016476-78r0rsio	327	20	including	include	VBG
cord-016476-78r0rsio	327	21	vascular	vascular	JJ
cord-016476-78r0rsio	327	22	endothelial	endothelial	JJ
cord-016476-78r0rsio	327	23	growth	growth	NN
cord-016476-78r0rsio	327	24	factor	factor	NN
cord-016476-78r0rsio	327	25	,	,	,
cord-016476-78r0rsio	327	26	fibroblast	fibroblast	NN
cord-016476-78r0rsio	327	27	growth	growth	NN
cord-016476-78r0rsio	327	28	factor	factor	NN
cord-016476-78r0rsio	327	29	and	and	CC
cord-016476-78r0rsio	327	30	platelet	platelet	NN
cord-016476-78r0rsio	327	31	-	-	HYPH
cord-016476-78r0rsio	327	32	derived	derive	VBN
cord-016476-78r0rsio	327	33	growth	growth	NN
cord-016476-78r0rsio	327	34	factor	factor	NN
cord-016476-78r0rsio	327	35	receptors	receptor	NNS
cord-016476-78r0rsio	327	36	,	,	,
cord-016476-78r0rsio	327	37	have	have	VBP
cord-016476-78r0rsio	327	38	been	be	VBN
cord-016476-78r0rsio	327	39	recommended	recommend	VBN
cord-016476-78r0rsio	327	40	by	by	IN
cord-016476-78r0rsio	327	41	the	the	DT
cord-016476-78r0rsio	327	42	international	international	JJ
cord-016476-78r0rsio	327	43	thoracic	thoracic	JJ
cord-016476-78r0rsio	327	44	guidelines	guideline	NNS
cord-016476-78r0rsio	327	45	for	for	IN
cord-016476-78r0rsio	327	46	its	-PRON-	PRP$
cord-016476-78r0rsio	327	47	use	use	NN
cord-016476-78r0rsio	327	48	in	in	IN
cord-016476-78r0rsio	327	49	IPF	IPF	NNP
cord-016476-78r0rsio	327	50	[	[	-LRB-
cord-016476-78r0rsio	327	51	144	144	CD
cord-016476-78r0rsio	327	52	]	]	-RRB-
cord-016476-78r0rsio	327	53	.	.	.
cord-016476-78r0rsio	328	1	It	-PRON-	PRP
cord-016476-78r0rsio	328	2	was	be	VBD
cord-016476-78r0rsio	328	3	recently	recently	RB
cord-016476-78r0rsio	328	4	found	find	VBN
cord-016476-78r0rsio	328	5	in	in	IN
cord-016476-78r0rsio	328	6	various	various	JJ
cord-016476-78r0rsio	328	7	murine	murine	JJ
cord-016476-78r0rsio	328	8	systemic	systemic	JJ
cord-016476-78r0rsio	328	9	sclerosis	sclerosis	NN
cord-016476-78r0rsio	328	10	models	model	NNS
cord-016476-78r0rsio	328	11	to	to	TO
cord-016476-78r0rsio	328	12	effectively	effectively	RB
cord-016476-78r0rsio	328	13	inhibit	inhibit	VB
cord-016476-78r0rsio	328	14	the	the	DT
cord-016476-78r0rsio	328	15	endogenous	endogenous	JJ
cord-016476-78r0rsio	328	16	as	as	RB
cord-016476-78r0rsio	328	17	well	well	RB
cord-016476-78r0rsio	328	18	as	as	IN
cord-016476-78r0rsio	328	19	cytokine	cytokine	NN
cord-016476-78r0rsio	328	20	-	-	HYPH
cord-016476-78r0rsio	328	21	induced	induce	VBN
cord-016476-78r0rsio	328	22	activation	activation	NN
cord-016476-78r0rsio	328	23	of	of	IN
cord-016476-78r0rsio	328	24	fibroblasts	fibroblast	NNS
cord-016476-78r0rsio	328	25	and	and	CC
cord-016476-78r0rsio	328	26	exert	exert	VB
cord-016476-78r0rsio	328	27	potent	potent	JJ
cord-016476-78r0rsio	328	28	anti	anti	JJ
cord-016476-78r0rsio	328	29	-	-	JJ
cord-016476-78r0rsio	328	30	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	328	31	effects	effect	NNS
cord-016476-78r0rsio	328	32	[	[	-LRB-
cord-016476-78r0rsio	328	33	161	161	CD
cord-016476-78r0rsio	328	34	]	]	-RRB-
cord-016476-78r0rsio	328	35	.	.	.
cord-016476-78r0rsio	329	1	Whilst	whilst	IN
cord-016476-78r0rsio	329	2	there	there	EX
cord-016476-78r0rsio	329	3	is	be	VBZ
cord-016476-78r0rsio	329	4	currently	currently	RB
cord-016476-78r0rsio	329	5	no	no	DT
cord-016476-78r0rsio	329	6	clinical	clinical	JJ
cord-016476-78r0rsio	329	7	evidence	evidence	NN
cord-016476-78r0rsio	329	8	to	to	IN
cord-016476-78r0rsio	329	9	date	date	NN
cord-016476-78r0rsio	329	10	in	in	IN
cord-016476-78r0rsio	329	11	CTD	CTD	NNP
cord-016476-78r0rsio	329	12	/	/	SYM
cord-016476-78r0rsio	329	13	RA	RA	NNP
cord-016476-78r0rsio	329	14	-	-	HYPH
cord-016476-78r0rsio	329	15	ILD	ILD	NNP
cord-016476-78r0rsio	329	16	,	,	,
cord-016476-78r0rsio	329	17	there	there	EX
cord-016476-78r0rsio	329	18	may	may	MD
cord-016476-78r0rsio	329	19	be	be	VB
cord-016476-78r0rsio	329	20	potential	potential	JJ
cord-016476-78r0rsio	329	21	for	for	IN
cord-016476-78r0rsio	329	22	future	future	JJ
cord-016476-78r0rsio	329	23	clinical	clinical	JJ
cord-016476-78r0rsio	329	24	trials	trial	NNS
cord-016476-78r0rsio	329	25	with	with	IN
cord-016476-78r0rsio	329	26	this	this	DT
cord-016476-78r0rsio	329	27	drug	drug	NN
cord-016476-78r0rsio	329	28	.	.	.
cord-016476-78r0rsio	330	1	Cyclophosphamide	Cyclophosphamide	NNP
cord-016476-78r0rsio	330	2	has	have	VBZ
cord-016476-78r0rsio	330	3	been	be	VBN
cord-016476-78r0rsio	330	4	commonly	commonly	RB
cord-016476-78r0rsio	330	5	used	use	VBN
cord-016476-78r0rsio	330	6	to	to	TO
cord-016476-78r0rsio	330	7	treat	treat	VB
cord-016476-78r0rsio	330	8	ILD	ILD	NNP
cord-016476-78r0rsio	330	9	unresponsive	unresponsive	JJ
cord-016476-78r0rsio	330	10	to	to	IN
cord-016476-78r0rsio	330	11	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	330	12	.	.	.
cord-016476-78r0rsio	331	1	However	however	RB
cord-016476-78r0rsio	331	2	evidence	evidence	NN
cord-016476-78r0rsio	331	3	of	of	IN
cord-016476-78r0rsio	331	4	its	-PRON-	PRP$
cord-016476-78r0rsio	331	5	use	use	NN
cord-016476-78r0rsio	331	6	in	in	IN
cord-016476-78r0rsio	331	7	IPF	IPF	NNP
cord-016476-78r0rsio	331	8	is	be	VBZ
cord-016476-78r0rsio	331	9	lacking	lack	VBG
cord-016476-78r0rsio	331	10	[	[	-LRB-
cord-016476-78r0rsio	331	11	162	162	CD
cord-016476-78r0rsio	331	12	]	]	-RRB-
cord-016476-78r0rsio	331	13	.	.	.
cord-016476-78r0rsio	332	1	Conflicting	conflicting	JJ
cord-016476-78r0rsio	332	2	data	datum	NNS
cord-016476-78r0rsio	332	3	exist	exist	VBP
cord-016476-78r0rsio	332	4	regarding	regard	VBG
cord-016476-78r0rsio	332	5	its	-PRON-	PRP$
cord-016476-78r0rsio	332	6	use	use	NN
cord-016476-78r0rsio	332	7	in	in	IN
cord-016476-78r0rsio	332	8	scleroderma	scleroderma	NN
cord-016476-78r0rsio	332	9	-	-	HYPH
cord-016476-78r0rsio	332	10	related	relate	VBN
cord-016476-78r0rsio	332	11	ILD	ILD	NNP
cord-016476-78r0rsio	332	12	[	[	-LRB-
cord-016476-78r0rsio	332	13	163	163	CD
cord-016476-78r0rsio	332	14	]	]	-RRB-
cord-016476-78r0rsio	332	15	,	,	,
cord-016476-78r0rsio	332	16	with	with	IN
cord-016476-78r0rsio	332	17	additional	additional	JJ
cord-016476-78r0rsio	332	18	concerns	concern	NNS
cord-016476-78r0rsio	332	19	regarding	regard	VBG
cord-016476-78r0rsio	332	20	its	-PRON-	PRP$
cord-016476-78r0rsio	332	21	toxicity	toxicity	NN
cord-016476-78r0rsio	332	22	profile	profile	NN
cord-016476-78r0rsio	332	23	.	.	.
cord-016476-78r0rsio	333	1	RCTs	RCTs	NNP
cord-016476-78r0rsio	333	2	using	use	VBG
cord-016476-78r0rsio	333	3	cyclophosphamide	cyclophosphamide	RB
cord-016476-78r0rsio	333	4	suggest	suggest	VBP
cord-016476-78r0rsio	333	5	moderate	moderate	JJ
cord-016476-78r0rsio	333	6	benefit	benefit	NN
cord-016476-78r0rsio	333	7	in	in	IN
cord-016476-78r0rsio	333	8	scleroderma	scleroderma	NN
cord-016476-78r0rsio	333	9	-	-	HYPH
cord-016476-78r0rsio	333	10	ILD	ILD	NNP
cord-016476-78r0rsio	333	11	patients	patient	NNS
cord-016476-78r0rsio	333	12	with	with	IN
cord-016476-78r0rsio	333	13	early	early	JJ
cord-016476-78r0rsio	333	14	disease	disease	NN
cord-016476-78r0rsio	333	15	[	[	-LRB-
cord-016476-78r0rsio	333	16	164	164	CD
cord-016476-78r0rsio	333	17	]	]	-RRB-
cord-016476-78r0rsio	333	18	[	[	-LRB-
cord-016476-78r0rsio	333	19	165	165	CD
cord-016476-78r0rsio	333	20	]	]	-RRB-
cord-016476-78r0rsio	333	21	[	[	-LRB-
cord-016476-78r0rsio	333	22	166	166	CD
cord-016476-78r0rsio	333	23	]	]	-RRB-
cord-016476-78r0rsio	333	24	,	,	,
cord-016476-78r0rsio	333	25	although	although	IN
cord-016476-78r0rsio	333	26	a	a	DT
cord-016476-78r0rsio	333	27	previous	previous	JJ
cord-016476-78r0rsio	333	28	metaanalysis	metaanalysis	NN
cord-016476-78r0rsio	333	29	concluded	conclude	VBD
cord-016476-78r0rsio	333	30	no	no	DT
cord-016476-78r0rsio	333	31	improvement	improvement	NN
cord-016476-78r0rsio	333	32	in	in	IN
cord-016476-78r0rsio	333	33	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	333	34	function	function	NN
cord-016476-78r0rsio	333	35	following	follow	VBG
cord-016476-78r0rsio	333	36	12	12	CD
cord-016476-78r0rsio	333	37	months	month	NNS
cord-016476-78r0rsio	333	38	of	of	IN
cord-016476-78r0rsio	333	39	treatment	treatment	NN
cord-016476-78r0rsio	333	40	[	[	-LRB-
cord-016476-78r0rsio	333	41	167	167	CD
cord-016476-78r0rsio	333	42	]	]	-RRB-
cord-016476-78r0rsio	333	43	.	.	.
cord-016476-78r0rsio	334	1	No	no	DT
cord-016476-78r0rsio	334	2	RCTs	rct	NNS
cord-016476-78r0rsio	334	3	have	have	VBP
cord-016476-78r0rsio	334	4	been	be	VBN
cord-016476-78r0rsio	334	5	performed	perform	VBN
cord-016476-78r0rsio	334	6	assessing	assess	VBG
cord-016476-78r0rsio	334	7	the	the	DT
cord-016476-78r0rsio	334	8	use	use	NN
cord-016476-78r0rsio	334	9	of	of	IN
cord-016476-78r0rsio	334	10	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	334	11	in	in	IN
cord-016476-78r0rsio	334	12	RA	RA	NNP
cord-016476-78r0rsio	334	13	-	-	HYPH
cord-016476-78r0rsio	334	14	ILD	ILD	NNP
cord-016476-78r0rsio	334	15	.	.	.
cord-016476-78r0rsio	335	1	Limited	limited	JJ
cord-016476-78r0rsio	335	2	evidence	evidence	NN
cord-016476-78r0rsio	335	3	suggests	suggest	VBZ
cord-016476-78r0rsio	335	4	that	that	IN
cord-016476-78r0rsio	335	5	there	there	EX
cord-016476-78r0rsio	335	6	may	may	MD
cord-016476-78r0rsio	335	7	be	be	VB
cord-016476-78r0rsio	335	8	some	some	DT
cord-016476-78r0rsio	335	9	role	role	NN
cord-016476-78r0rsio	335	10	in	in	IN
cord-016476-78r0rsio	335	11	rapidly	rapidly	RB
cord-016476-78r0rsio	335	12	progressing	progress	VBG
cord-016476-78r0rsio	335	13	patients	patient	NNS
cord-016476-78r0rsio	335	14	with	with	IN
cord-016476-78r0rsio	335	15	restricted	restricted	JJ
cord-016476-78r0rsio	335	16	therapeutic	therapeutic	JJ
cord-016476-78r0rsio	335	17	options	option	NNS
cord-016476-78r0rsio	335	18	in	in	IN
cord-016476-78r0rsio	335	19	the	the	DT
cord-016476-78r0rsio	335	20	acute	acute	JJ
cord-016476-78r0rsio	335	21	or	or	CC
cord-016476-78r0rsio	335	22	subacute	subacute	JJ
cord-016476-78r0rsio	335	23	setting	set	VBG
cord-016476-78r0rsio	335	24	[	[	-LRB-
cord-016476-78r0rsio	335	25	168	168	CD
cord-016476-78r0rsio	335	26	]	]	-RRB-
cord-016476-78r0rsio	335	27	or	or	CC
cord-016476-78r0rsio	335	28	in	in	IN
cord-016476-78r0rsio	335	29	refractory	refractory	JJ
cord-016476-78r0rsio	335	30	drug	drug	NN
cord-016476-78r0rsio	335	31	-	-	HYPH
cord-016476-78r0rsio	335	32	induced	induce	VBN
cord-016476-78r0rsio	335	33	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	335	34	unresponsive	unresponsive	JJ
cord-016476-78r0rsio	335	35	to	to	IN
cord-016476-78r0rsio	335	36	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	335	37	[	[	-LRB-
cord-016476-78r0rsio	335	38	169	169	CD
cord-016476-78r0rsio	335	39	]	]	-RRB-
cord-016476-78r0rsio	335	40	.	.	.
cord-016476-78r0rsio	336	1	The	the	DT
cord-016476-78r0rsio	336	2	use	use	NN
cord-016476-78r0rsio	336	3	of	of	IN
cord-016476-78r0rsio	336	4	this	this	DT
cord-016476-78r0rsio	336	5	agent	agent	NN
cord-016476-78r0rsio	336	6	is	be	VBZ
cord-016476-78r0rsio	336	7	not	not	RB
cord-016476-78r0rsio	336	8	recommended	recommend	VBN
cord-016476-78r0rsio	336	9	for	for	IN
cord-016476-78r0rsio	336	10	mild	mild	JJ
cord-016476-78r0rsio	336	11	/	/	SYM
cord-016476-78r0rsio	336	12	moderate	moderate	JJ
cord-016476-78r0rsio	336	13	stable	stable	JJ
cord-016476-78r0rsio	336	14	RA	RA	NNP
cord-016476-78r0rsio	336	15	-	-	HYPH
cord-016476-78r0rsio	336	16	ILD	ILD	NNP
cord-016476-78r0rsio	336	17	disease	disease	NN
cord-016476-78r0rsio	336	18	.	.	.
cord-016476-78r0rsio	337	1	Experience	experience	NN
cord-016476-78r0rsio	337	2	of	of	IN
cord-016476-78r0rsio	337	3	using	use	VBG
cord-016476-78r0rsio	337	4	cyclosporine	cyclosporine	NN
cord-016476-78r0rsio	337	5	in	in	IN
cord-016476-78r0rsio	337	6	the	the	DT
cord-016476-78r0rsio	337	7	treatment	treatment	NN
cord-016476-78r0rsio	337	8	of	of	IN
cord-016476-78r0rsio	337	9	RA	RA	NNP
cord-016476-78r0rsio	337	10	-	-	HYPH
cord-016476-78r0rsio	337	11	ILD	ILD	NNP
cord-016476-78r0rsio	337	12	is	be	VBZ
cord-016476-78r0rsio	337	13	limited	limit	VBN
cord-016476-78r0rsio	337	14	and	and	CC
cord-016476-78r0rsio	337	15	not	not	RB
cord-016476-78r0rsio	337	16	recommended	recommend	VBN
cord-016476-78r0rsio	337	17	currently	currently	RB
cord-016476-78r0rsio	337	18	due	due	JJ
cord-016476-78r0rsio	337	19	to	to	IN
cord-016476-78r0rsio	337	20	its	-PRON-	PRP$
cord-016476-78r0rsio	337	21	poor	poor	JJ
cord-016476-78r0rsio	337	22	safety	safety	NN
cord-016476-78r0rsio	337	23	profile	profile	NN
cord-016476-78r0rsio	337	24	and	and	CC
cord-016476-78r0rsio	337	25	absence	absence	NN
cord-016476-78r0rsio	337	26	of	of	IN
cord-016476-78r0rsio	337	27	proven	prove	VBN
cord-016476-78r0rsio	337	28	benefit	benefit	NN
cord-016476-78r0rsio	337	29	on	on	IN
cord-016476-78r0rsio	337	30	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	337	31	or	or	CC
cord-016476-78r0rsio	337	32	joint	joint	JJ
cord-016476-78r0rsio	337	33	disease	disease	NN
cord-016476-78r0rsio	337	34	.	.	.
cord-016476-78r0rsio	338	1	Few	few	JJ
cord-016476-78r0rsio	338	2	publications	publication	NNS
cord-016476-78r0rsio	338	3	in	in	IN
cord-016476-78r0rsio	338	4	IPF	IPF	NNP
cord-016476-78r0rsio	338	5	have	have	VBP
cord-016476-78r0rsio	338	6	been	be	VBN
cord-016476-78r0rsio	338	7	less	less	JJR
cord-016476-78r0rsio	338	8	than	than	IN
cord-016476-78r0rsio	338	9	encouraging	encourage	VBG
cord-016476-78r0rsio	338	10	[	[	-LRB-
cord-016476-78r0rsio	338	11	170	170	CD
cord-016476-78r0rsio	338	12	,	,	,
cord-016476-78r0rsio	338	13	171	171	CD
cord-016476-78r0rsio	338	14	]	]	-RRB-
cord-016476-78r0rsio	338	15	;	;	:
cord-016476-78r0rsio	338	16	however	however	RB
cord-016476-78r0rsio	338	17	,	,	,
cord-016476-78r0rsio	338	18	it	-PRON-	PRP
cord-016476-78r0rsio	338	19	appears	appear	VBZ
cord-016476-78r0rsio	338	20	to	to	TO
cord-016476-78r0rsio	338	21	yield	yield	VB
cord-016476-78r0rsio	338	22	some	some	DT
cord-016476-78r0rsio	338	23	benefits	benefit	NNS
cord-016476-78r0rsio	338	24	according	accord	VBG
cord-016476-78r0rsio	338	25	to	to	IN
cord-016476-78r0rsio	338	26	anecdotal	anecdotal	JJ
cord-016476-78r0rsio	338	27	reports	report	NNS
cord-016476-78r0rsio	338	28	in	in	IN
cord-016476-78r0rsio	338	29	myositis	myositis	NN
cord-016476-78r0rsio	338	30	-	-	HYPH
cord-016476-78r0rsio	338	31	related	relate	VBN
cord-016476-78r0rsio	338	32	ILD	ILD	NNP
cord-016476-78r0rsio	338	33	particularly	particularly	RB
cord-016476-78r0rsio	338	34	anti	anti	JJ
cord-016476-78r0rsio	338	35	-	-	JJ
cord-016476-78r0rsio	338	36	synthetase	synthetase	JJ
cord-016476-78r0rsio	338	37	syndrome	syndrome	NN
cord-016476-78r0rsio	338	38	[	[	-LRB-
cord-016476-78r0rsio	338	39	172	172	CD
cord-016476-78r0rsio	338	40	]	]	-RRB-
cord-016476-78r0rsio	338	41	[	[	-LRB-
cord-016476-78r0rsio	338	42	173	173	CD
cord-016476-78r0rsio	338	43	]	]	-RRB-
cord-016476-78r0rsio	338	44	[	[	-LRB-
cord-016476-78r0rsio	338	45	174	174	CD
cord-016476-78r0rsio	338	46	]	]	-RRB-
cord-016476-78r0rsio	338	47	.	.	.
cord-016476-78r0rsio	339	1	Mycophenolate	Mycophenolate	NNP
cord-016476-78r0rsio	339	2	mofetil	mofetil	NNP
cord-016476-78r0rsio	339	3	often	often	RB
cord-016476-78r0rsio	339	4	used	use	VBN
cord-016476-78r0rsio	339	5	in	in	IN
cord-016476-78r0rsio	339	6	the	the	DT
cord-016476-78r0rsio	339	7	treatment	treatment	NN
cord-016476-78r0rsio	339	8	of	of	IN
cord-016476-78r0rsio	339	9	scleroderma	scleroderma	NN
cord-016476-78r0rsio	340	1	-ILD	-ild	PRP
cord-016476-78r0rsio	340	2	is	be	VBZ
cord-016476-78r0rsio	340	3	an	an	DT
cord-016476-78r0rsio	340	4	inhibitor	inhibitor	NN
cord-016476-78r0rsio	340	5	of	of	IN
cord-016476-78r0rsio	340	6	lymphocyte	lymphocyte	NN
cord-016476-78r0rsio	340	7	proliferation	proliferation	NN
cord-016476-78r0rsio	340	8	and	and	CC
cord-016476-78r0rsio	340	9	additionally	additionally	RB
cord-016476-78r0rsio	340	10	targets	target	VBZ
cord-016476-78r0rsio	340	11	nonimmune	nonimmune	JJ
cord-016476-78r0rsio	340	12	cells	cell	NNS
cord-016476-78r0rsio	340	13	such	such	JJ
cord-016476-78r0rsio	340	14	as	as	IN
cord-016476-78r0rsio	340	15	fibroblasts	fibroblast	NNS
cord-016476-78r0rsio	340	16	and	and	CC
cord-016476-78r0rsio	340	17	smooth	smooth	JJ
cord-016476-78r0rsio	340	18	muscle	muscle	NN
cord-016476-78r0rsio	340	19	cells	cell	NNS
cord-016476-78r0rsio	340	20	.	.	.
cord-016476-78r0rsio	341	1	The	the	DT
cord-016476-78r0rsio	341	2	majority	majority	NN
cord-016476-78r0rsio	341	3	of	of	IN
cord-016476-78r0rsio	341	4	the	the	DT
cord-016476-78r0rsio	341	5	evidence	evidence	NN
cord-016476-78r0rsio	341	6	for	for	IN
cord-016476-78r0rsio	341	7	use	use	NN
cord-016476-78r0rsio	341	8	has	have	VBZ
cord-016476-78r0rsio	341	9	been	be	VBN
cord-016476-78r0rsio	341	10	derived	derive	VBN
cord-016476-78r0rsio	341	11	from	from	IN
cord-016476-78r0rsio	341	12	small	small	JJ
cord-016476-78r0rsio	341	13	prospective	prospective	JJ
cord-016476-78r0rsio	341	14	case	case	NN
cord-016476-78r0rsio	341	15	series	series	NN
cord-016476-78r0rsio	341	16	and	and	CC
cord-016476-78r0rsio	341	17	retrospective	retrospective	JJ
cord-016476-78r0rsio	341	18	reviews	review	NNS
cord-016476-78r0rsio	341	19	and	and	CC
cord-016476-78r0rsio	341	20	has	have	VBZ
cord-016476-78r0rsio	341	21	been	be	VBN
cord-016476-78r0rsio	341	22	shown	show	VBN
cord-016476-78r0rsio	341	23	to	to	TO
cord-016476-78r0rsio	341	24	stabilise	stabilise	VB
cord-016476-78r0rsio	341	25	scleroderma	scleroderma	NN
cord-016476-78r0rsio	341	26	-	-	:
cord-016476-78r0rsio	341	27	ILD	ILD	NNP
cord-016476-78r0rsio	341	28	[	[	-LRB-
cord-016476-78r0rsio	341	29	175	175	CD
cord-016476-78r0rsio	341	30	]	]	-RRB-
cord-016476-78r0rsio	341	31	[	[	-LRB-
cord-016476-78r0rsio	341	32	176	176	CD
cord-016476-78r0rsio	341	33	]	]	-RRB-
cord-016476-78r0rsio	341	34	[	[	-LRB-
cord-016476-78r0rsio	341	35	177	177	CD
cord-016476-78r0rsio	341	36	]	]	-RRB-
cord-016476-78r0rsio	341	37	and	and	CC
cord-016476-78r0rsio	341	38	CTD	CTD	NNP
cord-016476-78r0rsio	341	39	-	-	HYPH
cord-016476-78r0rsio	341	40	ILD	ILD	NNP
cord-016476-78r0rsio	341	41	[	[	-LRB-
cord-016476-78r0rsio	341	42	178	178	CD
cord-016476-78r0rsio	341	43	]	]	-RRB-
cord-016476-78r0rsio	341	44	.	.	.
cord-016476-78r0rsio	342	1	In	in	IN
cord-016476-78r0rsio	342	2	the	the	DT
cord-016476-78r0rsio	342	3	latter	latter	JJ
cord-016476-78r0rsio	342	4	series	series	NN
cord-016476-78r0rsio	342	5	,	,	,
cord-016476-78r0rsio	342	6	18	18	CD
cord-016476-78r0rsio	342	7	patients	patient	NNS
cord-016476-78r0rsio	342	8	with	with	IN
cord-016476-78r0rsio	342	9	RA	RA	NNP
cord-016476-78r0rsio	342	10	-	-	HYPH
cord-016476-78r0rsio	342	11	ILD	ILD	NNP
cord-016476-78r0rsio	342	12	were	be	VBD
cord-016476-78r0rsio	342	13	included	include	VBN
cord-016476-78r0rsio	342	14	;	;	:
cord-016476-78r0rsio	342	15	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	342	16	was	be	VBD
cord-016476-78r0rsio	342	17	associated	associate	VBN
cord-016476-78r0rsio	342	18	with	with	IN
cord-016476-78r0rsio	342	19	modest	modest	JJ
cord-016476-78r0rsio	342	20	improvements	improvement	NNS
cord-016476-78r0rsio	342	21	in	in	IN
cord-016476-78r0rsio	342	22	forced	force	VBN
cord-016476-78r0rsio	342	23	vital	vital	JJ
cord-016476-78r0rsio	342	24	capacity	capacity	NN
cord-016476-78r0rsio	342	25	(	(	-LRB-
cord-016476-78r0rsio	342	26	FVC	FVC	NNP
cord-016476-78r0rsio	342	27	)	)	-RRB-
cord-016476-78r0rsio	342	28	,	,	,
cord-016476-78r0rsio	342	29	diffusing	diffuse	VBG
cord-016476-78r0rsio	342	30	capacity	capacity	NN
cord-016476-78r0rsio	342	31	and	and	CC
cord-016476-78r0rsio	342	32	reductions	reduction	NNS
cord-016476-78r0rsio	342	33	in	in	IN
cord-016476-78r0rsio	342	34	the	the	DT
cord-016476-78r0rsio	342	35	prednisone	prednisone	NNP
cord-016476-78r0rsio	342	36	dose	dose	NN
cord-016476-78r0rsio	342	37	[	[	-LRB-
cord-016476-78r0rsio	342	38	178	178	CD
cord-016476-78r0rsio	342	39	]	]	-RRB-
cord-016476-78r0rsio	342	40	.	.	.
cord-016476-78r0rsio	343	1	A	a	DT
cord-016476-78r0rsio	343	2	head	head	NN
cord-016476-78r0rsio	343	3	-	-	HYPH
cord-016476-78r0rsio	343	4	to	to	IN
cord-016476-78r0rsio	343	5	-	-	HYPH
cord-016476-78r0rsio	343	6	head	head	NN
cord-016476-78r0rsio	343	7	RCT	RCT	NNP
cord-016476-78r0rsio	343	8	assessing	assess	VBG
cord-016476-78r0rsio	343	9	the	the	DT
cord-016476-78r0rsio	343	10	use	use	NN
cord-016476-78r0rsio	343	11	of	of	IN
cord-016476-78r0rsio	343	12	a	a	DT
cord-016476-78r0rsio	343	13	twoyear	twoyear	JJ
cord-016476-78r0rsio	343	14	course	course	NN
cord-016476-78r0rsio	343	15	of	of	IN
cord-016476-78r0rsio	343	16	mycophenolate	mycophenolate	NN
cord-016476-78r0rsio	343	17	compared	compare	VBN
cord-016476-78r0rsio	343	18	to	to	IN
cord-016476-78r0rsio	343	19	oral	oral	JJ
cord-016476-78r0rsio	343	20	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	343	21	for	for	IN
cord-016476-78r0rsio	343	22	12	12	CD
cord-016476-78r0rsio	343	23	months	month	NNS
cord-016476-78r0rsio	343	24	in	in	IN
cord-016476-78r0rsio	343	25	SSc	SSc	NNS
cord-016476-78r0rsio	343	26	-	-	HYPH
cord-016476-78r0rsio	343	27	ILD	ILD	NNP
cord-016476-78r0rsio	343	28	has	have	VBZ
cord-016476-78r0rsio	343	29	recently	recently	RB
cord-016476-78r0rsio	343	30	been	be	VBN
cord-016476-78r0rsio	343	31	published	publish	VBN
cord-016476-78r0rsio	343	32	,	,	,
cord-016476-78r0rsio	343	33	demonstrating	demonstrate	VBG
cord-016476-78r0rsio	343	34	a	a	DT
cord-016476-78r0rsio	343	35	more	more	RBR
cord-016476-78r0rsio	343	36	favourable	favourable	JJ
cord-016476-78r0rsio	343	37	safety	safety	NN
cord-016476-78r0rsio	343	38	profile	profile	NN
cord-016476-78r0rsio	343	39	with	with	IN
cord-016476-78r0rsio	343	40	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	343	41	;	;	:
cord-016476-78r0rsio	343	42	however	however	RB
cord-016476-78r0rsio	343	43	,	,	,
cord-016476-78r0rsio	343	44	both	both	DT
cord-016476-78r0rsio	343	45	treatment	treatment	NN
cord-016476-78r0rsio	343	46	arms	arm	NNS
cord-016476-78r0rsio	343	47	demonstrate	demonstrate	VBP
cord-016476-78r0rsio	343	48	similar	similar	JJ
cord-016476-78r0rsio	343	49	efficacy	efficacy	NN
cord-016476-78r0rsio	343	50	on	on	IN
cord-016476-78r0rsio	343	51	lung	lung	NN
cord-016476-78r0rsio	343	52	function	function	NN
cord-016476-78r0rsio	343	53	[	[	-LRB-
cord-016476-78r0rsio	343	54	179	179	CD
cord-016476-78r0rsio	343	55	]	]	-RRB-
cord-016476-78r0rsio	343	56	.	.	.
cord-016476-78r0rsio	344	1	In	in	IN
cord-016476-78r0rsio	344	2	the	the	DT
cord-016476-78r0rsio	344	3	treatment	treatment	NN
cord-016476-78r0rsio	344	4	of	of	IN
cord-016476-78r0rsio	344	5	RA	RA	NNP
cord-016476-78r0rsio	344	6	-	-	HYPH
cord-016476-78r0rsio	344	7	ILD	ILD	NNP
cord-016476-78r0rsio	344	8	,	,	,
cord-016476-78r0rsio	344	9	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	344	10	has	have	VBZ
cord-016476-78r0rsio	344	11	been	be	VBN
cord-016476-78r0rsio	344	12	prescribed	prescribe	VBN
cord-016476-78r0rsio	344	13	at	at	IN
cord-016476-78r0rsio	344	14	doses	dose	NNS
cord-016476-78r0rsio	344	15	of	of	IN
cord-016476-78r0rsio	344	16	1	1	CD
cord-016476-78r0rsio	344	17	-	-	SYM
cord-016476-78r0rsio	344	18	2	2	CD
cord-016476-78r0rsio	344	19	g	g	NN
cord-016476-78r0rsio	344	20	per	per	IN
cord-016476-78r0rsio	344	21	day	day	NN
cord-016476-78r0rsio	344	22	in	in	IN
cord-016476-78r0rsio	344	23	patients	patient	NNS
cord-016476-78r0rsio	344	24	with	with	IN
cord-016476-78r0rsio	344	25	RA	RA	NNP
cord-016476-78r0rsio	344	26	who	who	WP
cord-016476-78r0rsio	344	27	have	have	VBP
cord-016476-78r0rsio	344	28	limited	limit	VBN
cord-016476-78r0rsio	344	29	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	344	30	disease	disease	NN
cord-016476-78r0rsio	344	31	with	with	IN
cord-016476-78r0rsio	344	32	some	some	DT
cord-016476-78r0rsio	344	33	benefit	benefit	NN
cord-016476-78r0rsio	344	34	[	[	-LRB-
cord-016476-78r0rsio	344	35	175	175	CD
cord-016476-78r0rsio	344	36	,	,	,
cord-016476-78r0rsio	344	37	180	180	CD
cord-016476-78r0rsio	344	38	]	]	-RRB-
cord-016476-78r0rsio	344	39	.	.	.
cord-016476-78r0rsio	345	1	However	however	RB
cord-016476-78r0rsio	345	2	it	-PRON-	PRP
cord-016476-78r0rsio	345	3	is	be	VBZ
cord-016476-78r0rsio	345	4	not	not	RB
cord-016476-78r0rsio	345	5	effective	effective	JJ
cord-016476-78r0rsio	345	6	in	in	IN
cord-016476-78r0rsio	345	7	the	the	DT
cord-016476-78r0rsio	345	8	treatment	treatment	NN
cord-016476-78r0rsio	345	9	of	of	IN
cord-016476-78r0rsio	345	10	active	active	JJ
cord-016476-78r0rsio	345	11	articular	articular	JJ
cord-016476-78r0rsio	345	12	disease	disease	NN
cord-016476-78r0rsio	345	13	on	on	IN
cord-016476-78r0rsio	345	14	RA	RA	NNP
cord-016476-78r0rsio	345	15	,	,	,
cord-016476-78r0rsio	345	16	requiring	require	VBG
cord-016476-78r0rsio	345	17	the	the	DT
cord-016476-78r0rsio	345	18	use	use	NN
cord-016476-78r0rsio	345	19	of	of	IN
cord-016476-78r0rsio	345	20	concomitant	concomitant	JJ
cord-016476-78r0rsio	345	21	nbDMARDs	nbdmards	NN
cord-016476-78r0rsio	345	22	,	,	,
cord-016476-78r0rsio	345	23	which	which	WDT
cord-016476-78r0rsio	345	24	may	may	MD
cord-016476-78r0rsio	345	25	have	have	VB
cord-016476-78r0rsio	345	26	additional	additional	JJ
cord-016476-78r0rsio	345	27	consequences	consequence	NNS
cord-016476-78r0rsio	345	28	on	on	IN
cord-016476-78r0rsio	345	29	tolerability	tolerability	NN
cord-016476-78r0rsio	345	30	.	.	.
cord-016476-78r0rsio	346	1	Whilst	whilst	IN
cord-016476-78r0rsio	346	2	studies	study	NNS
cord-016476-78r0rsio	346	3	supporting	support	VBG
cord-016476-78r0rsio	346	4	the	the	DT
cord-016476-78r0rsio	346	5	use	use	NN
cord-016476-78r0rsio	346	6	of	of	IN
cord-016476-78r0rsio	346	7	mycophenolate	mycophenolate	NN
cord-016476-78r0rsio	346	8	in	in	IN
cord-016476-78r0rsio	346	9	RA	RA	NNP
cord-016476-78r0rsio	346	10	-	-	HYPH
cord-016476-78r0rsio	346	11	ILD	ILD	NNP
cord-016476-78r0rsio	346	12	represent	represent	VBP
cord-016476-78r0rsio	346	13	a	a	DT
cord-016476-78r0rsio	346	14	relatively	relatively	RB
cord-016476-78r0rsio	346	15	small	small	JJ
cord-016476-78r0rsio	346	16	number	number	NN
cord-016476-78r0rsio	346	17	of	of	IN
cord-016476-78r0rsio	346	18	patients	patient	NNS
cord-016476-78r0rsio	346	19	,	,	,
cord-016476-78r0rsio	346	20	further	further	JJ
cord-016476-78r0rsio	346	21	work	work	NN
cord-016476-78r0rsio	346	22	on	on	IN
cord-016476-78r0rsio	346	23	tolerability	tolerability	NN
cord-016476-78r0rsio	346	24	and	and	CC
cord-016476-78r0rsio	346	25	safety	safety	NN
cord-016476-78r0rsio	346	26	in	in	IN
cord-016476-78r0rsio	346	27	the	the	DT
cord-016476-78r0rsio	346	28	context	context	NN
cord-016476-78r0rsio	346	29	of	of	IN
cord-016476-78r0rsio	346	30	active	active	JJ
cord-016476-78r0rsio	346	31	RA	RA	NNP
cord-016476-78r0rsio	346	32	is	be	VBZ
cord-016476-78r0rsio	346	33	required	require	VBN
cord-016476-78r0rsio	346	34	,	,	,
cord-016476-78r0rsio	346	35	and	and	CC
cord-016476-78r0rsio	346	36	if	if	IN
cord-016476-78r0rsio	346	37	promising	promise	VBG
cord-016476-78r0rsio	346	38	well	well	RB
cord-016476-78r0rsio	346	39	-	-	HYPH
cord-016476-78r0rsio	346	40	designed	design	VBN
cord-016476-78r0rsio	346	41	trials	trial	NNS
cord-016476-78r0rsio	346	42	may	may	MD
cord-016476-78r0rsio	346	43	be	be	VB
cord-016476-78r0rsio	346	44	helpful	helpful	JJ
cord-016476-78r0rsio	346	45	before	before	IN
cord-016476-78r0rsio	346	46	advocating	advocate	VBG
cord-016476-78r0rsio	346	47	its	-PRON-	PRP$
cord-016476-78r0rsio	346	48	use	use	NN
cord-016476-78r0rsio	346	49	in	in	IN
cord-016476-78r0rsio	346	50	this	this	DT
cord-016476-78r0rsio	346	51	area	area	NN
cord-016476-78r0rsio	346	52	.	.	.
cord-016476-78r0rsio	347	1	Of	of	IN
cord-016476-78r0rsio	347	2	the	the	DT
cord-016476-78r0rsio	347	3	biologics	biologic	NNS
cord-016476-78r0rsio	347	4	having	have	VBG
cord-016476-78r0rsio	347	5	potential	potential	JJ
cord-016476-78r0rsio	347	6	utility	utility	NN
cord-016476-78r0rsio	347	7	for	for	IN
cord-016476-78r0rsio	347	8	treatment	treatment	NN
cord-016476-78r0rsio	347	9	of	of	IN
cord-016476-78r0rsio	347	10	RA	RA	NNP
cord-016476-78r0rsio	347	11	and	and	CC
cord-016476-78r0rsio	347	12	other	other	JJ
cord-016476-78r0rsio	347	13	connective	connective	JJ
cord-016476-78r0rsio	347	14	tissue	tissue	NN
cord-016476-78r0rsio	347	15	disease	disease	NN
cord-016476-78r0rsio	347	16	-	-	HYPH
cord-016476-78r0rsio	347	17	related	relate	VBN
cord-016476-78r0rsio	347	18	ILD	ILD	NNP
cord-016476-78r0rsio	347	19	,	,	,
cord-016476-78r0rsio	347	20	perhaps	perhaps	RB
cord-016476-78r0rsio	347	21	rituximab	rituximab	NN
cord-016476-78r0rsio	347	22	has	have	VBZ
cord-016476-78r0rsio	347	23	had	have	VBN
cord-016476-78r0rsio	347	24	the	the	DT
cord-016476-78r0rsio	347	25	most	most	JJS
cord-016476-78r0rsio	347	26	interest	interest	NN
cord-016476-78r0rsio	347	27	and	and	CC
cord-016476-78r0rsio	347	28	shown	show	VBN
cord-016476-78r0rsio	347	29	some	some	DT
cord-016476-78r0rsio	347	30	promising	promising	JJ
cord-016476-78r0rsio	347	31	results	result	NNS
cord-016476-78r0rsio	347	32	in	in	IN
cord-016476-78r0rsio	347	33	published	publish	VBN
cord-016476-78r0rsio	347	34	case	case	NN
cord-016476-78r0rsio	347	35	reports	report	NNS
cord-016476-78r0rsio	347	36	and	and	CC
cord-016476-78r0rsio	347	37	case	case	NN
cord-016476-78r0rsio	347	38	series	series	NN
cord-016476-78r0rsio	347	39	,	,	,
cord-016476-78r0rsio	347	40	not	not	RB
cord-016476-78r0rsio	347	41	inclusive	inclusive	JJ
cord-016476-78r0rsio	347	42	of	of	IN
cord-016476-78r0rsio	347	43	RA	RA	NNP
cord-016476-78r0rsio	347	44	[	[	-LRB-
cord-016476-78r0rsio	347	45	181	181	CD
cord-016476-78r0rsio	347	46	]	]	-RRB-
cord-016476-78r0rsio	347	47	[	[	-LRB-
cord-016476-78r0rsio	347	48	182	182	CD
cord-016476-78r0rsio	347	49	]	]	-RRB-
cord-016476-78r0rsio	347	50	[	[	-LRB-
cord-016476-78r0rsio	347	51	183	183	CD
cord-016476-78r0rsio	347	52	]	]	-RRB-
cord-016476-78r0rsio	347	53	[	[	-LRB-
cord-016476-78r0rsio	347	54	184	184	CD
cord-016476-78r0rsio	347	55	]	]	-RRB-
cord-016476-78r0rsio	347	56	.	.	.
cord-016476-78r0rsio	348	1	A	a	DT
cord-016476-78r0rsio	348	2	recent	recent	JJ
cord-016476-78r0rsio	348	3	retrospective	retrospective	JJ
cord-016476-78r0rsio	348	4	review	review	NN
cord-016476-78r0rsio	348	5	of	of	IN
cord-016476-78r0rsio	348	6	CTD	CTD	NNP
cord-016476-78r0rsio	348	7	-	-	HYPH
cord-016476-78r0rsio	348	8	ILD	ILD	NNP
cord-016476-78r0rsio	348	9	cases	case	NNS
cord-016476-78r0rsio	348	10	treated	treat	VBN
cord-016476-78r0rsio	348	11	with	with	IN
cord-016476-78r0rsio	348	12	rituximab	rituximab	NN
cord-016476-78r0rsio	348	13	,	,	,
cord-016476-78r0rsio	348	14	which	which	WDT
cord-016476-78r0rsio	348	15	included	include	VBD
cord-016476-78r0rsio	348	16	anti	anti	JJ
cord-016476-78r0rsio	348	17	-	-	JJ
cord-016476-78r0rsio	348	18	synthetase	synthetase	JJ
cord-016476-78r0rsio	348	19	syndrome	syndrome	NN
cord-016476-78r0rsio	348	20	(	(	-LRB-
cord-016476-78r0rsio	348	21	n	n	NN
cord-016476-78r0rsio	348	22	=	=	SYM
cord-016476-78r0rsio	348	23	10	10	CD
cord-016476-78r0rsio	348	24	)	)	-RRB-
cord-016476-78r0rsio	348	25	,	,	,
cord-016476-78r0rsio	348	26	dermatomyositis	dermatomyositis	NNP
cord-016476-78r0rsio	348	27	(	(	-LRB-
cord-016476-78r0rsio	348	28	n	n	NN
cord-016476-78r0rsio	348	29	=	=	SYM
cord-016476-78r0rsio	348	30	3	3	CD
cord-016476-78r0rsio	348	31	)	)	-RRB-
cord-016476-78r0rsio	348	32	,	,	,
cord-016476-78r0rsio	348	33	systemic	systemic	JJ
cord-016476-78r0rsio	348	34	sclerosis	sclerosis	NN
cord-016476-78r0rsio	348	35	(	(	-LRB-
cord-016476-78r0rsio	348	36	n	n	NN
cord-016476-78r0rsio	348	37	=	=	SYM
cord-016476-78r0rsio	348	38	3	3	CD
cord-016476-78r0rsio	348	39	)	)	-RRB-
cord-016476-78r0rsio	348	40	,	,	,
cord-016476-78r0rsio	348	41	systemic	systemic	JJ
cord-016476-78r0rsio	348	42	lupus	lupus	NN
cord-016476-78r0rsio	348	43	erythematosus	erythematosus	NN
cord-016476-78r0rsio	348	44	(	(	-LRB-
cord-016476-78r0rsio	348	45	n	n	NN
cord-016476-78r0rsio	348	46	=	=	SYM
cord-016476-78r0rsio	348	47	2	2	CD
cord-016476-78r0rsio	348	48	)	)	-RRB-
cord-016476-78r0rsio	348	49	and	and	CC
cord-016476-78r0rsio	348	50	unclassifiable	unclassifiable	JJ
cord-016476-78r0rsio	348	51	CTD	CTD	NNP
cord-016476-78r0rsio	348	52	-	-	HYPH
cord-016476-78r0rsio	348	53	ILD	ILD	NNP
cord-016476-78r0rsio	348	54	(	(	-LRB-
cord-016476-78r0rsio	348	55	n	n	NN
cord-016476-78r0rsio	348	56	=	=	SYM
cord-016476-78r0rsio	348	57	4	4	CD
cord-016476-78r0rsio	348	58	)	)	-RRB-
cord-016476-78r0rsio	348	59	,	,	,
cord-016476-78r0rsio	348	60	suggested	suggest	VBD
cord-016476-78r0rsio	348	61	stabilisation	stabilisation	NN
cord-016476-78r0rsio	348	62	of	of	IN
cord-016476-78r0rsio	348	63	lung	lung	NN
cord-016476-78r0rsio	348	64	disease	disease	NN
cord-016476-78r0rsio	348	65	in	in	IN
cord-016476-78r0rsio	348	66	11	11	CD
cord-016476-78r0rsio	348	67	patients	patient	NNS
cord-016476-78r0rsio	348	68	and	and	CC
cord-016476-78r0rsio	348	69	worsening	worsen	VBG
cord-016476-78r0rsio	348	70	in	in	IN
cord-016476-78r0rsio	348	71	nine	nine	CD
cord-016476-78r0rsio	348	72	patients	patient	NNS
cord-016476-78r0rsio	348	73	.	.	.
cord-016476-78r0rsio	349	1	Four	four	CD
cord-016476-78r0rsio	349	2	patients	patient	NNS
cord-016476-78r0rsio	349	3	with	with	IN
cord-016476-78r0rsio	349	4	myositis	myositis	NN
cord-016476-78r0rsio	349	5	had	have	VBD
cord-016476-78r0rsio	349	6	a	a	DT
cord-016476-78r0rsio	349	7	reported	report	VBN
cord-016476-78r0rsio	349	8	clinically	clinically	RB
cord-016476-78r0rsio	349	9	significant	significant	JJ
cord-016476-78r0rsio	349	10	improvement	improvement	NN
cord-016476-78r0rsio	349	11	with	with	IN
cord-016476-78r0rsio	349	12	an	an	DT
cord-016476-78r0rsio	349	13	FVC	fvc	NN
cord-016476-78r0rsio	349	14	of	of	IN
cord-016476-78r0rsio	349	15	>	>	XX
cord-016476-78r0rsio	349	16	10	10	CD
cord-016476-78r0rsio	349	17	%	%	NN
cord-016476-78r0rsio	349	18	post	post	NN
cord-016476-78r0rsio	349	19	treatment	treatment	NN
cord-016476-78r0rsio	349	20	.	.	.
cord-016476-78r0rsio	350	1	Whilst	whilst	IN
cord-016476-78r0rsio	350	2	encouraging	encourage	VBG
cord-016476-78r0rsio	350	3	in	in	IN
cord-016476-78r0rsio	350	4	a	a	DT
cord-016476-78r0rsio	350	5	CTD	CTD	NNP
cord-016476-78r0rsio	350	6	-	-	HYPH
cord-016476-78r0rsio	350	7	ILD	ILD	NNP
cord-016476-78r0rsio	350	8	setting	setting	NN
cord-016476-78r0rsio	350	9	,	,	,
cord-016476-78r0rsio	350	10	most	most	RBS
cord-016476-78r0rsio	350	11	published	publish	VBN
cord-016476-78r0rsio	350	12	work	work	NN
cord-016476-78r0rsio	350	13	is	be	VBZ
cord-016476-78r0rsio	350	14	in	in	IN
cord-016476-78r0rsio	350	15	the	the	DT
cord-016476-78r0rsio	350	16	form	form	NN
cord-016476-78r0rsio	350	17	of	of	IN
cord-016476-78r0rsio	350	18	case	case	NN
cord-016476-78r0rsio	350	19	reports	report	NNS
cord-016476-78r0rsio	350	20	,	,	,
cord-016476-78r0rsio	350	21	subject	subject	JJ
cord-016476-78r0rsio	350	22	to	to	IN
cord-016476-78r0rsio	350	23	reporting	report	VBG
cord-016476-78r0rsio	350	24	bias	bias	NN
cord-016476-78r0rsio	350	25	,	,	,
cord-016476-78r0rsio	350	26	or	or	CC
cord-016476-78r0rsio	350	27	retrospective	retrospective	JJ
cord-016476-78r0rsio	350	28	case	case	NN
cord-016476-78r0rsio	350	29	series	series	NN
cord-016476-78r0rsio	350	30	.	.	.
cord-016476-78r0rsio	351	1	Evidence	evidence	NN
cord-016476-78r0rsio	351	2	of	of	IN
cord-016476-78r0rsio	351	3	rituximab	rituximab	JJ
cord-016476-78r0rsio	351	4	use	use	NN
cord-016476-78r0rsio	351	5	for	for	IN
cord-016476-78r0rsio	351	6	the	the	DT
cord-016476-78r0rsio	351	7	treatment	treatment	NN
cord-016476-78r0rsio	351	8	of	of	IN
cord-016476-78r0rsio	351	9	RA	RA	NNP
cord-016476-78r0rsio	351	10	-	-	HYPH
cord-016476-78r0rsio	351	11	ILD	ILD	NNP
cord-016476-78r0rsio	351	12	has	have	VBZ
cord-016476-78r0rsio	351	13	not	not	RB
cord-016476-78r0rsio	351	14	been	be	VBN
cord-016476-78r0rsio	351	15	encouraging	encouraging	JJ
cord-016476-78r0rsio	351	16	and	and	CC
cord-016476-78r0rsio	351	17	studies	study	NNS
cord-016476-78r0rsio	351	18	to	to	IN
cord-016476-78r0rsio	351	19	date	date	NN
cord-016476-78r0rsio	351	20	have	have	VBP
cord-016476-78r0rsio	351	21	been	be	VBN
cord-016476-78r0rsio	351	22	small	small	JJ
cord-016476-78r0rsio	351	23	or	or	CC
cord-016476-78r0rsio	351	24	inconclusive	inconclusive	JJ
cord-016476-78r0rsio	351	25	.	.	.
cord-016476-78r0rsio	352	1	In	in	IN
cord-016476-78r0rsio	352	2	an	an	DT
cord-016476-78r0rsio	352	3	open	open	JJ
cord-016476-78r0rsio	352	4	-	-	HYPH
cord-016476-78r0rsio	352	5	label	label	NN
cord-016476-78r0rsio	352	6	pilot	pilot	NN
cord-016476-78r0rsio	352	7	study	study	NN
cord-016476-78r0rsio	352	8	of	of	IN
cord-016476-78r0rsio	352	9	rituximab	rituximab	NN
cord-016476-78r0rsio	352	10	in	in	IN
cord-016476-78r0rsio	352	11	RA	RA	NNP
cord-016476-78r0rsio	352	12	-	-	HYPH
cord-016476-78r0rsio	352	13	ILD	ILD	NNP
cord-016476-78r0rsio	352	14	[	[	-LRB-
cord-016476-78r0rsio	352	15	185	185	CD
cord-016476-78r0rsio	352	16	]	]	-RRB-
cord-016476-78r0rsio	352	17	of	of	IN
cord-016476-78r0rsio	352	18	seven	seven	CD
cord-016476-78r0rsio	352	19	patients	patient	NNS
cord-016476-78r0rsio	352	20	who	who	WP
cord-016476-78r0rsio	352	21	completed	complete	VBD
cord-016476-78r0rsio	352	22	a	a	DT
cord-016476-78r0rsio	352	23	48-week	48-week	CD
cord-016476-78r0rsio	352	24	follow	follow	NN
cord-016476-78r0rsio	352	25	-	-	HYPH
cord-016476-78r0rsio	352	26	up	up	NN
cord-016476-78r0rsio	352	27	,	,	,
cord-016476-78r0rsio	352	28	one	one	CD
cord-016476-78r0rsio	352	29	showed	show	VBD
cord-016476-78r0rsio	352	30	improvement	improvement	NN
cord-016476-78r0rsio	352	31	in	in	IN
cord-016476-78r0rsio	352	32	respiratory	respiratory	JJ
cord-016476-78r0rsio	352	33	function	function	NN
cord-016476-78r0rsio	352	34	,	,	,
cord-016476-78r0rsio	352	35	five	five	CD
cord-016476-78r0rsio	352	36	were	be	VBD
cord-016476-78r0rsio	352	37	stable	stable	JJ
cord-016476-78r0rsio	352	38	and	and	CC
cord-016476-78r0rsio	352	39	one	one	CD
cord-016476-78r0rsio	352	40	deteriorated	deteriorate	VBD
cord-016476-78r0rsio	352	41	.	.	.
cord-016476-78r0rsio	353	1	The	the	DT
cord-016476-78r0rsio	353	2	study	study	NN
cord-016476-78r0rsio	353	3	initially	initially	RB
cord-016476-78r0rsio	353	4	recruited	recruit	VBD
cord-016476-78r0rsio	353	5	ten	ten	CD
cord-016476-78r0rsio	353	6	patients	patient	NNS
cord-016476-78r0rsio	353	7	,	,	,
cord-016476-78r0rsio	353	8	and	and	CC
cord-016476-78r0rsio	353	9	of	of	IN
cord-016476-78r0rsio	353	10	the	the	DT
cord-016476-78r0rsio	353	11	three	three	CD
cord-016476-78r0rsio	353	12	who	who	WP
cord-016476-78r0rsio	353	13	did	do	VBD
cord-016476-78r0rsio	353	14	not	not	RB
cord-016476-78r0rsio	353	15	complete	complete	VB
cord-016476-78r0rsio	353	16	the	the	DT
cord-016476-78r0rsio	353	17	study	study	NN
cord-016476-78r0rsio	353	18	,	,	,
cord-016476-78r0rsio	353	19	one	one	CD
cord-016476-78r0rsio	353	20	patient	patient	NN
cord-016476-78r0rsio	353	21	died	die	VBD
cord-016476-78r0rsio	353	22	of	of	IN
cord-016476-78r0rsio	353	23	ARDS	ARDS	NNP
cord-016476-78r0rsio	353	24	/	/	SYM
cord-016476-78r0rsio	353	25	possible	possible	JJ
cord-016476-78r0rsio	353	26	pneumonia	pneumonia	NN
cord-016476-78r0rsio	353	27	,	,	,
cord-016476-78r0rsio	353	28	6	6	CD
cord-016476-78r0rsio	353	29	weeks	week	NNS
cord-016476-78r0rsio	353	30	post	post	NN
cord-016476-78r0rsio	353	31	treatment	treatment	NN
cord-016476-78r0rsio	353	32	(	(	-LRB-
cord-016476-78r0rsio	353	33	no	no	DT
cord-016476-78r0rsio	353	34	infective	infective	JJ
cord-016476-78r0rsio	353	35	source	source	NN
cord-016476-78r0rsio	353	36	identified	identify	VBN
cord-016476-78r0rsio	353	37	)	)	-RRB-
cord-016476-78r0rsio	353	38	.	.	.
cord-016476-78r0rsio	354	1	Four	four	CD
cord-016476-78r0rsio	354	2	small	small	JJ
cord-016476-78r0rsio	354	3	retrospective	retrospective	JJ
cord-016476-78r0rsio	354	4	observational	observational	JJ
cord-016476-78r0rsio	354	5	studies	study	NNS
cord-016476-78r0rsio	354	6	assessing	assess	VBG
cord-016476-78r0rsio	354	7	the	the	DT
cord-016476-78r0rsio	354	8	use	use	NN
cord-016476-78r0rsio	354	9	of	of	IN
cord-016476-78r0rsio	354	10	rituximab	rituximab	NN
cord-016476-78r0rsio	354	11	in	in	IN
cord-016476-78r0rsio	354	12	RA	RA	NNP
cord-016476-78r0rsio	354	13	-	-	HYPH
cord-016476-78r0rsio	354	14	ILD	ILD	NNP
cord-016476-78r0rsio	354	15	have	have	VBP
cord-016476-78r0rsio	354	16	been	be	VBN
cord-016476-78r0rsio	354	17	inconclusive	inconclusive	JJ
cord-016476-78r0rsio	354	18	(	(	-LRB-
cord-016476-78r0rsio	354	19	all	all	DT
cord-016476-78r0rsio	354	20	still	still	RB
cord-016476-78r0rsio	354	21	in	in	IN
cord-016476-78r0rsio	354	22	abstract	abstract	JJ
cord-016476-78r0rsio	354	23	form	form	NN
cord-016476-78r0rsio	354	24	,	,	,
cord-016476-78r0rsio	354	25	full	full	JJ
cord-016476-78r0rsio	354	26	papers	paper	NNS
cord-016476-78r0rsio	354	27	not	not	RB
cord-016476-78r0rsio	354	28	published	publish	VBN
cord-016476-78r0rsio	354	29	)	)	-RRB-
cord-016476-78r0rsio	354	30	.	.	.
cord-016476-78r0rsio	355	1	Dass	Dass	NNP
cord-016476-78r0rsio	355	2	and	and	CC
cord-016476-78r0rsio	355	3	colleagues	colleague	NNS
cord-016476-78r0rsio	355	4	in	in	IN
cord-016476-78r0rsio	355	5	2011	2011	CD
cord-016476-78r0rsio	355	6	[	[	-LRB-
cord-016476-78r0rsio	355	7	186	186	CD
cord-016476-78r0rsio	355	8	]	]	-RRB-
cord-016476-78r0rsio	355	9	presented	present	VBN
cord-016476-78r0rsio	355	10	data	datum	NNS
cord-016476-78r0rsio	355	11	from	from	IN
cord-016476-78r0rsio	355	12	48	48	CD
cord-016476-78r0rsio	355	13	patients	patient	NNS
cord-016476-78r0rsio	355	14	with	with	IN
cord-016476-78r0rsio	355	15	baseline	baseline	JJ
cord-016476-78r0rsio	355	16	RA	RA	NNP
cord-016476-78r0rsio	355	17	-	-	HYPH
cord-016476-78r0rsio	355	18	ILD	ILD	NNP
cord-016476-78r0rsio	355	19	;	;	:
cord-016476-78r0rsio	355	20	three	three	CD
cord-016476-78r0rsio	355	21	deaths	death	NNS
cord-016476-78r0rsio	355	22	were	be	VBD
cord-016476-78r0rsio	355	23	reported	report	VBN
cord-016476-78r0rsio	355	24	in	in	IN
cord-016476-78r0rsio	355	25	patients	patient	NNS
cord-016476-78r0rsio	355	26	with	with	IN
cord-016476-78r0rsio	355	27	RA	RA	NNP
cord-016476-78r0rsio	355	28	-	-	HYPH
cord-016476-78r0rsio	355	29	ILD	ILD	NNP
cord-016476-78r0rsio	355	30	following	follow	VBG
cord-016476-78r0rsio	355	31	rituximab	rituximab	JJ
cord-016476-78r0rsio	355	32	treatment	treatment	NN
cord-016476-78r0rsio	355	33	,	,	,
cord-016476-78r0rsio	355	34	one	one	CD
cord-016476-78r0rsio	355	35	due	due	IN
cord-016476-78r0rsio	355	36	to	to	IN
cord-016476-78r0rsio	355	37	pneumonia	pneumonia	NN
cord-016476-78r0rsio	355	38	and	and	CC
cord-016476-78r0rsio	355	39	possible	possible	JJ
cord-016476-78r0rsio	355	40	acute	acute	JJ
cord-016476-78r0rsio	355	41	progression	progression	NN
cord-016476-78r0rsio	355	42	of	of	IN
cord-016476-78r0rsio	355	43	ILD	ILD	NNP
cord-016476-78r0rsio	355	44	,	,	,
cord-016476-78r0rsio	355	45	4	4	CD
cord-016476-78r0rsio	355	46	weeks	week	NNS
cord-016476-78r0rsio	355	47	after	after	IN
cord-016476-78r0rsio	355	48	the	the	DT
cord-016476-78r0rsio	355	49	first	first	JJ
cord-016476-78r0rsio	355	50	cycle	cycle	NN
cord-016476-78r0rsio	355	51	of	of	IN
cord-016476-78r0rsio	355	52	rituximab	rituximab	NN
cord-016476-78r0rsio	355	53	therapy	therapy	NN
cord-016476-78r0rsio	355	54	.	.	.
cord-016476-78r0rsio	356	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	356	2	,	,	,
cord-016476-78r0rsio	356	3	five	five	CD
cord-016476-78r0rsio	356	4	patients	patient	NNS
cord-016476-78r0rsio	356	5	had	have	VBD
cord-016476-78r0rsio	356	6	a	a	DT
cord-016476-78r0rsio	356	7	decline	decline	NN
cord-016476-78r0rsio	356	8	in	in	IN
cord-016476-78r0rsio	356	9	transfer	transfer	NN
cord-016476-78r0rsio	356	10	factor	factor	NN
cord-016476-78r0rsio	356	11	of	of	IN
cord-016476-78r0rsio	356	12	>	>	XX
cord-016476-78r0rsio	356	13	10	10	CD
cord-016476-78r0rsio	356	14	%	%	NN
cord-016476-78r0rsio	356	15	over	over	IN
cord-016476-78r0rsio	356	16	an	an	DT
cord-016476-78r0rsio	356	17	unspecified	unspecified	JJ
cord-016476-78r0rsio	356	18	time	time	NN
cord-016476-78r0rsio	356	19	in	in	IN
cord-016476-78r0rsio	356	20	the	the	DT
cord-016476-78r0rsio	356	21	presented	present	VBN
cord-016476-78r0rsio	356	22	results	result	NNS
cord-016476-78r0rsio	356	23	of	of	IN
cord-016476-78r0rsio	356	24	this	this	DT
cord-016476-78r0rsio	356	25	study	study	NN
cord-016476-78r0rsio	356	26	.	.	.
cord-016476-78r0rsio	357	1	The	the	DT
cord-016476-78r0rsio	357	2	same	same	JJ
cord-016476-78r0rsio	357	3	group	group	NN
cord-016476-78r0rsio	357	4	reported	report	VBD
cord-016476-78r0rsio	357	5	their	-PRON-	PRP$
cord-016476-78r0rsio	357	6	rituximab	rituximab	JJ
cord-016476-78r0rsio	357	7	experience	experience	NN
cord-016476-78r0rsio	357	8	in	in	IN
cord-016476-78r0rsio	357	9	RA	RA	NNP
cord-016476-78r0rsio	357	10	-	-	HYPH
cord-016476-78r0rsio	357	11	ILD	ILD	NNP
cord-016476-78r0rsio	357	12	over	over	IN
cord-016476-78r0rsio	357	13	10	10	CD
cord-016476-78r0rsio	357	14	years	year	NNS
cord-016476-78r0rsio	357	15	(	(	-LRB-
cord-016476-78r0rsio	357	16	January	January	NNP
cord-016476-78r0rsio	357	17	2004-July	2004-july	CD
cord-016476-78r0rsio	357	18	2014	2014	CD
cord-016476-78r0rsio	357	19	)	)	-RRB-
cord-016476-78r0rsio	357	20	in	in	IN
cord-016476-78r0rsio	357	21	2015	2015	CD
cord-016476-78r0rsio	357	22	[	[	-LRB-
cord-016476-78r0rsio	357	23	187	187	CD
cord-016476-78r0rsio	357	24	]	]	-RRB-
cord-016476-78r0rsio	357	25	.	.	.
cord-016476-78r0rsio	358	1	Of	of	IN
cord-016476-78r0rsio	358	2	the	the	DT
cord-016476-78r0rsio	358	3	53	53	CD
cord-016476-78r0rsio	358	4	patients	patient	NNS
cord-016476-78r0rsio	358	5	with	with	IN
cord-016476-78r0rsio	358	6	RA	RA	NNP
cord-016476-78r0rsio	358	7	-	-	HYPH
cord-016476-78r0rsio	358	8	ILD	ILD	NNP
cord-016476-78r0rsio	358	9	on	on	IN
cord-016476-78r0rsio	358	10	rituximab	rituximab	NN
cord-016476-78r0rsio	358	11	with	with	IN
cord-016476-78r0rsio	358	12	a	a	DT
cord-016476-78r0rsio	358	13	total	total	NN
cord-016476-78r0rsio	358	14	of	of	IN
cord-016476-78r0rsio	358	15	171	171	CD
cord-016476-78r0rsio	358	16	patient	patient	NN
cord-016476-78r0rsio	358	17	-	-	HYPH
cord-016476-78r0rsio	358	18	years	year	NNS
cord-016476-78r0rsio	358	19	,	,	,
cord-016476-78r0rsio	358	20	the	the	DT
cord-016476-78r0rsio	358	21	authors	author	NNS
cord-016476-78r0rsio	358	22	concluded	conclude	VBD
cord-016476-78r0rsio	358	23	there	there	EX
cord-016476-78r0rsio	358	24	was	be	VBD
cord-016476-78r0rsio	358	25	no	no	DT
cord-016476-78r0rsio	358	26	significant	significant	JJ
cord-016476-78r0rsio	358	27	improvement	improvement	NN
cord-016476-78r0rsio	358	28	or	or	CC
cord-016476-78r0rsio	358	29	deterioration	deterioration	NN
cord-016476-78r0rsio	358	30	in	in	IN
cord-016476-78r0rsio	358	31	the	the	DT
cord-016476-78r0rsio	358	32	majority	majority	NN
cord-016476-78r0rsio	358	33	(	(	-LRB-
cord-016476-78r0rsio	358	34	as	as	IN
cord-016476-78r0rsio	358	35	measured	measure	VBN
cord-016476-78r0rsio	358	36	using	use	VBG
cord-016476-78r0rsio	358	37	FVC/	FVC/	NNP
cord-016476-78r0rsio	358	38	DLCO	DLCO	NNP
cord-016476-78r0rsio	358	39	;	;	:
cord-016476-78r0rsio	358	40	actual	actual	JJ
cord-016476-78r0rsio	358	41	data	datum	NNS
cord-016476-78r0rsio	358	42	not	not	RB
cord-016476-78r0rsio	358	43	available	available	JJ
cord-016476-78r0rsio	358	44	in	in	IN
cord-016476-78r0rsio	358	45	abstract	abstract	JJ
cord-016476-78r0rsio	358	46	)	)	-RRB-
cord-016476-78r0rsio	358	47	.	.	.
cord-016476-78r0rsio	359	1	However	however	RB
cord-016476-78r0rsio	359	2	there	there	EX
cord-016476-78r0rsio	359	3	were	be	VBD
cord-016476-78r0rsio	359	4	12	12	CD
cord-016476-78r0rsio	359	5	deaths	death	NNS
cord-016476-78r0rsio	359	6	reported	report	VBN
cord-016476-78r0rsio	359	7	,	,	,
cord-016476-78r0rsio	359	8	nine	nine	CD
cord-016476-78r0rsio	359	9	of	of	IN
cord-016476-78r0rsio	359	10	which	which	WDT
cord-016476-78r0rsio	359	11	were	be	VBD
cord-016476-78r0rsio	359	12	attributed	attribute	VBN
cord-016476-78r0rsio	359	13	to	to	IN
cord-016476-78r0rsio	359	14	progressive	progressive	JJ
cord-016476-78r0rsio	359	15	ILD	ILD	NNP
cord-016476-78r0rsio	359	16	(	(	-LRB-
cord-016476-78r0rsio	359	17	median	median	NN
cord-016476-78r0rsio	359	18	DLCO	dlco	DT
cord-016476-78r0rsio	359	19	of	of	IN
cord-016476-78r0rsio	359	20	41	41	CD
cord-016476-78r0rsio	359	21	%	%	NN
cord-016476-78r0rsio	359	22	[	[	-LRB-
cord-016476-78r0rsio	359	23	range	range	NN
cord-016476-78r0rsio	359	24	35	35	CD
cord-016476-78r0rsio	359	25	-64	-64	NN
cord-016476-78r0rsio	359	26	%	%	NN
cord-016476-78r0rsio	359	27	]	]	-RRB-
cord-016476-78r0rsio	359	28	pre	pre	JJ
cord-016476-78r0rsio	359	29	-	-	JJ
cord-016476-78r0rsio	359	30	rituximab	rituximab	JJ
cord-016476-78r0rsio	359	31	)	)	-RRB-
cord-016476-78r0rsio	359	32	.	.	.
cord-016476-78r0rsio	360	1	Other	other	JJ
cord-016476-78r0rsio	360	2	reasons	reason	NNS
cord-016476-78r0rsio	360	3	for	for	IN
cord-016476-78r0rsio	360	4	death	death	NN
cord-016476-78r0rsio	360	5	were	be	VBD
cord-016476-78r0rsio	360	6	lung	lung	NN
cord-016476-78r0rsio	360	7	cancer	cancer	NN
cord-016476-78r0rsio	360	8	,	,	,
cord-016476-78r0rsio	360	9	colon	colon	NN
cord-016476-78r0rsio	360	10	cancer	cancer	NN
cord-016476-78r0rsio	360	11	and	and	CC
cord-016476-78r0rsio	360	12	infection	infection	NN
cord-016476-78r0rsio	360	13	post	post	NN
cord-016476-78r0rsio	360	14	surgery	surgery	NN
cord-016476-78r0rsio	361	1	(	(	-LRB-
cord-016476-78r0rsio	361	2	n	n	NN
cord-016476-78r0rsio	361	3	=	=	SYM
cord-016476-78r0rsio	361	4	1	1	CD
cord-016476-78r0rsio	361	5	each	each	DT
cord-016476-78r0rsio	361	6	)	)	-RRB-
cord-016476-78r0rsio	361	7	.	.	.
cord-016476-78r0rsio	362	1	Becerra	Becerra	NNP
cord-016476-78r0rsio	362	2	et	et	NNP
cord-016476-78r0rsio	362	3	al	al	NNP
cord-016476-78r0rsio	362	4	.	.	.
cord-016476-78r0rsio	363	1	[	[	-LRB-
cord-016476-78r0rsio	363	2	188	188	CD
cord-016476-78r0rsio	363	3	]	]	-RRB-
cord-016476-78r0rsio	363	4	reported	report	VBN
cord-016476-78r0rsio	363	5	on	on	IN
cord-016476-78r0rsio	363	6	a	a	DT
cord-016476-78r0rsio	363	7	single	single	JJ
cord-016476-78r0rsio	363	8	-	-	HYPH
cord-016476-78r0rsio	363	9	centre	centre	NN
cord-016476-78r0rsio	363	10	retrospective	retrospective	JJ
cord-016476-78r0rsio	363	11	review	review	NN
cord-016476-78r0rsio	363	12	of	of	IN
cord-016476-78r0rsio	363	13	38	38	CD
cord-016476-78r0rsio	363	14	patients	patient	NNS
cord-016476-78r0rsio	363	15	with	with	IN
cord-016476-78r0rsio	363	16	RA	RA	NNP
cord-016476-78r0rsio	363	17	and	and	CC
cord-016476-78r0rsio	363	18	known	know	VBN
cord-016476-78r0rsio	363	19	lung	lung	NN
cord-016476-78r0rsio	363	20	involvement	involvement	NN
cord-016476-78r0rsio	363	21	who	who	WP
cord-016476-78r0rsio	363	22	were	be	VBD
cord-016476-78r0rsio	363	23	undergoing	undergo	VBG
cord-016476-78r0rsio	363	24	therapy	therapy	NN
cord-016476-78r0rsio	363	25	with	with	IN
cord-016476-78r0rsio	363	26	rituximab	rituximab	NN
cord-016476-78r0rsio	363	27	,	,	,
cord-016476-78r0rsio	363	28	of	of	IN
cord-016476-78r0rsio	363	29	whom	whom	WP
cord-016476-78r0rsio	363	30	19	19	CD
cord-016476-78r0rsio	363	31	had	have	VBD
cord-016476-78r0rsio	363	32	established	establish	VBN
cord-016476-78r0rsio	363	33	RA	RA	NNP
cord-016476-78r0rsio	363	34	-	-	HYPH
cord-016476-78r0rsio	363	35	ILD	ILD	NNP
cord-016476-78r0rsio	363	36	.	.	.
cord-016476-78r0rsio	364	1	Progression	progression	NN
cord-016476-78r0rsio	364	2	of	of	IN
cord-016476-78r0rsio	364	3	ILD	ILD	NNP
cord-016476-78r0rsio	364	4	over	over	IN
cord-016476-78r0rsio	364	5	4	4	CD
cord-016476-78r0rsio	364	6	years	year	NNS
cord-016476-78r0rsio	364	7	was	be	VBD
cord-016476-78r0rsio	364	8	described	describe	VBN
cord-016476-78r0rsio	364	9	in	in	IN
cord-016476-78r0rsio	364	10	one	one	CD
cord-016476-78r0rsio	364	11	patient	patient	NN
cord-016476-78r0rsio	364	12	with	with	IN
cord-016476-78r0rsio	364	13	severe	severe	JJ
cord-016476-78r0rsio	364	14	UIP	UIP	NNP
cord-016476-78r0rsio	364	15	at	at	IN
cord-016476-78r0rsio	364	16	baseline	baseline	NN
cord-016476-78r0rsio	364	17	.	.	.
cord-016476-78r0rsio	365	1	Improvement	improvement	NN
cord-016476-78r0rsio	365	2	in	in	IN
cord-016476-78r0rsio	365	3	lung	lung	NN
cord-016476-78r0rsio	365	4	function	function	NN
cord-016476-78r0rsio	365	5	was	be	VBD
cord-016476-78r0rsio	365	6	observed	observe	VBN
cord-016476-78r0rsio	365	7	in	in	IN
cord-016476-78r0rsio	365	8	none	none	NN
cord-016476-78r0rsio	365	9	of	of	IN
cord-016476-78r0rsio	365	10	the	the	DT
cord-016476-78r0rsio	365	11	patients	patient	NNS
cord-016476-78r0rsio	365	12	,	,	,
cord-016476-78r0rsio	365	13	66	66	CD
cord-016476-78r0rsio	365	14	%	%	NN
cord-016476-78r0rsio	365	15	(	(	-LRB-
cord-016476-78r0rsio	365	16	n	n	NN
cord-016476-78r0rsio	365	17	=	=	SYM
cord-016476-78r0rsio	365	18	25	25	CD
cord-016476-78r0rsio	365	19	)	)	-RRB-
cord-016476-78r0rsio	365	20	reporting	report	VBG
cord-016476-78r0rsio	365	21	respiratory	respiratory	JJ
cord-016476-78r0rsio	365	22	infections	infection	NNS
cord-016476-78r0rsio	365	23	,	,	,
cord-016476-78r0rsio	365	24	two	two	CD
cord-016476-78r0rsio	365	25	of	of	IN
cord-016476-78r0rsio	365	26	which	which	WDT
cord-016476-78r0rsio	365	27	required	require	VBD
cord-016476-78r0rsio	365	28	hospitalisation	hospitalisation	NN
cord-016476-78r0rsio	365	29	.	.	.
cord-016476-78r0rsio	366	1	Recent	recent	JJ
cord-016476-78r0rsio	366	2	work	work	NN
cord-016476-78r0rsio	366	3	from	from	IN
cord-016476-78r0rsio	366	4	the	the	DT
cord-016476-78r0rsio	366	5	BSRBR	BSRBR	NNP
cord-016476-78r0rsio	366	6	-	-	HYPH
cord-016476-78r0rsio	366	7	RA	RA	NNP
cord-016476-78r0rsio	366	8	compared	compare	VBN
cord-016476-78r0rsio	366	9	mortality	mortality	NN
cord-016476-78r0rsio	366	10	of	of	IN
cord-016476-78r0rsio	366	11	353	353	CD
cord-016476-78r0rsio	366	12	patients	patient	NNS
cord-016476-78r0rsio	366	13	with	with	IN
cord-016476-78r0rsio	366	14	physician	physician	NN
cord-016476-78r0rsio	366	15	-	-	HYPH
cord-016476-78r0rsio	366	16	reported	report	VBN
cord-016476-78r0rsio	366	17	RA	RA	NNP
cord-016476-78r0rsio	366	18	-	-	HYPH
cord-016476-78r0rsio	366	19	ILD	ILD	NNP
cord-016476-78r0rsio	366	20	,	,	,
cord-016476-78r0rsio	366	21	of	of	IN
cord-016476-78r0rsio	366	22	whom	whom	WP
cord-016476-78r0rsio	366	23	310	310	CD
cord-016476-78r0rsio	366	24	were	be	VBD
cord-016476-78r0rsio	366	25	treated	treat	VBN
cord-016476-78r0rsio	366	26	with	with	IN
cord-016476-78r0rsio	366	27	TNFi	TNFi	NNS
cord-016476-78r0rsio	366	28	and	and	CC
cord-016476-78r0rsio	366	29	43	43	CD
cord-016476-78r0rsio	366	30	on	on	IN
cord-016476-78r0rsio	366	31	rituximab	rituximab	NN
cord-016476-78r0rsio	366	32	[	[	-LRB-
cord-016476-78r0rsio	366	33	189	189	CD
cord-016476-78r0rsio	366	34	]	]	-RRB-
cord-016476-78r0rsio	366	35	.	.	.
cord-016476-78r0rsio	367	1	The	the	DT
cord-016476-78r0rsio	367	2	differences	difference	NNS
cord-016476-78r0rsio	367	3	in	in	IN
cord-016476-78r0rsio	367	4	mortality	mortality	NN
cord-016476-78r0rsio	367	5	between	between	IN
cord-016476-78r0rsio	367	6	the	the	DT
cord-016476-78r0rsio	367	7	two	two	CD
cord-016476-78r0rsio	367	8	groups	group	NNS
cord-016476-78r0rsio	367	9	were	be	VBD
cord-016476-78r0rsio	367	10	not	not	RB
cord-016476-78r0rsio	367	11	statistically	statistically	RB
cord-016476-78r0rsio	367	12	significant	significant	JJ
cord-016476-78r0rsio	367	13	,	,	,
cord-016476-78r0rsio	367	14	and	and	CC
cord-016476-78r0rsio	367	15	adjustment	adjustment	NN
cord-016476-78r0rsio	367	16	for	for	IN
cord-016476-78r0rsio	367	17	baseline	baseline	JJ
cord-016476-78r0rsio	367	18	confounders	confounder	NNS
cord-016476-78r0rsio	367	19	made	make	VBD
cord-016476-78r0rsio	367	20	little	little	JJ
cord-016476-78r0rsio	367	21	difference	difference	NN
cord-016476-78r0rsio	367	22	to	to	IN
cord-016476-78r0rsio	367	23	the	the	DT
cord-016476-78r0rsio	367	24	estimates	estimate	NNS
cord-016476-78r0rsio	367	25	(	(	-LRB-
cord-016476-78r0rsio	367	26	HR	HR	NNP
cord-016476-78r0rsio	367	27	adj	adj	JJ
cord-016476-78r0rsio	367	28	0.51	0.51	CD
cord-016476-78r0rsio	367	29	,	,	,
cord-016476-78r0rsio	367	30	95	95	CD
cord-016476-78r0rsio	367	31	%	%	NN
cord-016476-78r0rsio	367	32	CI	CI	NNP
cord-016476-78r0rsio	367	33	0.25	0.25	CD
cord-016476-78r0rsio	367	34	-	-	SYM
cord-016476-78r0rsio	367	35	1.06	1.06	CD
cord-016476-78r0rsio	367	36	)	)	-RRB-
cord-016476-78r0rsio	367	37	.	.	.
cord-016476-78r0rsio	368	1	However	however	RB
cord-016476-78r0rsio	368	2	,	,	,
cord-016476-78r0rsio	368	3	methodological	methodological	JJ
cord-016476-78r0rsio	368	4	issues	issue	NNS
cord-016476-78r0rsio	368	5	included	include	VBD
cord-016476-78r0rsio	368	6	inherent	inherent	JJ
cord-016476-78r0rsio	368	7	differences	difference	NNS
cord-016476-78r0rsio	368	8	in	in	IN
cord-016476-78r0rsio	368	9	the	the	DT
cord-016476-78r0rsio	368	10	two	two	CD
cord-016476-78r0rsio	368	11	treated	treat	VBN
cord-016476-78r0rsio	368	12	groups	group	NNS
cord-016476-78r0rsio	368	13	(	(	-LRB-
cord-016476-78r0rsio	368	14	the	the	DT
cord-016476-78r0rsio	368	15	TNFi	TNFi	NNP
cord-016476-78r0rsio	368	16	group	group	NN
cord-016476-78r0rsio	368	17	being	be	VBG
cord-016476-78r0rsio	368	18	a	a	DT
cord-016476-78r0rsio	368	19	more	more	RBR
cord-016476-78r0rsio	368	20	historic	historic	JJ
cord-016476-78r0rsio	368	21	cohort	cohort	NN
cord-016476-78r0rsio	368	22	,	,	,
cord-016476-78r0rsio	368	23	therefore	therefore	RB
cord-016476-78r0rsio	368	24	likely	likely	RB
cord-016476-78r0rsio	368	25	to	to	TO
cord-016476-78r0rsio	368	26	have	have	VB
cord-016476-78r0rsio	368	27	more	more	JJR
cord-016476-78r0rsio	368	28	severe	severe	JJ
cord-016476-78r0rsio	368	29	disease	disease	NN
cord-016476-78r0rsio	368	30	)	)	-RRB-
cord-016476-78r0rsio	368	31	,	,	,
cord-016476-78r0rsio	368	32	low	low	JJ
cord-016476-78r0rsio	368	33	numbers	number	NNS
cord-016476-78r0rsio	368	34	of	of	IN
cord-016476-78r0rsio	368	35	deaths	death	NNS
cord-016476-78r0rsio	368	36	and	and	CC
cord-016476-78r0rsio	368	37	no	no	DT
cord-016476-78r0rsio	368	38	information	information	NN
cord-016476-78r0rsio	368	39	on	on	IN
cord-016476-78r0rsio	368	40	baseline	baseline	JJ
cord-016476-78r0rsio	368	41	RA	RA	NNP
cord-016476-78r0rsio	368	42	-	-	HYPH
cord-016476-78r0rsio	368	43	ILD	ILD	NNP
cord-016476-78r0rsio	368	44	severity	severity	NN
cord-016476-78r0rsio	368	45	.	.	.
cord-016476-78r0rsio	369	1	The	the	DT
cord-016476-78r0rsio	369	2	results	result	NNS
cord-016476-78r0rsio	369	3	of	of	IN
cord-016476-78r0rsio	369	4	all	all	DT
cord-016476-78r0rsio	369	5	four	four	CD
cord-016476-78r0rsio	369	6	of	of	IN
cord-016476-78r0rsio	369	7	these	these	DT
cord-016476-78r0rsio	369	8	studies	study	NNS
cord-016476-78r0rsio	369	9	are	be	VBP
cord-016476-78r0rsio	369	10	difficult	difficult	JJ
cord-016476-78r0rsio	369	11	to	to	TO
cord-016476-78r0rsio	369	12	interpret	interpret	VB
cord-016476-78r0rsio	369	13	often	often	RB
cord-016476-78r0rsio	369	14	due	due	IN
cord-016476-78r0rsio	369	15	to	to	IN
cord-016476-78r0rsio	369	16	a	a	DT
cord-016476-78r0rsio	369	17	lack	lack	NN
cord-016476-78r0rsio	369	18	of	of	IN
cord-016476-78r0rsio	369	19	well	well	RB
cord-016476-78r0rsio	369	20	-	-	HYPH
cord-016476-78r0rsio	369	21	matched	match	VBN
cord-016476-78r0rsio	369	22	comparator	comparator	NN
cord-016476-78r0rsio	369	23	groups	group	NNS
cord-016476-78r0rsio	369	24	and	and	CC
cord-016476-78r0rsio	369	25	uncertainty	uncertainty	NN
cord-016476-78r0rsio	369	26	about	about	IN
cord-016476-78r0rsio	369	27	the	the	DT
cord-016476-78r0rsio	369	28	natural	natural	JJ
cord-016476-78r0rsio	369	29	history	history	NN
cord-016476-78r0rsio	369	30	of	of	IN
cord-016476-78r0rsio	369	31	RA	RA	NNP
cord-016476-78r0rsio	369	32	-	-	HYPH
cord-016476-78r0rsio	369	33	ILD	ILD	NNP
cord-016476-78r0rsio	369	34	.	.	.
cord-016476-78r0rsio	370	1	Therefore	therefore	RB
cord-016476-78r0rsio	370	2	,	,	,
cord-016476-78r0rsio	370	3	currently	currently	RB
cord-016476-78r0rsio	370	4	,	,	,
cord-016476-78r0rsio	370	5	few	few	JJ
cord-016476-78r0rsio	370	6	data	datum	NNS
cord-016476-78r0rsio	370	7	exists	exist	VBZ
cord-016476-78r0rsio	370	8	that	that	WDT
cord-016476-78r0rsio	370	9	suggest	suggest	VBP
cord-016476-78r0rsio	370	10	that	that	IN
cord-016476-78r0rsio	370	11	rituximab	rituximab	NN
cord-016476-78r0rsio	370	12	can	can	MD
cord-016476-78r0rsio	370	13	markedly	markedly	RB
cord-016476-78r0rsio	370	14	improve	improve	VB
cord-016476-78r0rsio	370	15	RA	RA	NNP
cord-016476-78r0rsio	370	16	-	-	HYPH
cord-016476-78r0rsio	370	17	ILD	ILD	NNP
cord-016476-78r0rsio	370	18	.	.	.
cord-016476-78r0rsio	371	1	In	in	IN
cord-016476-78r0rsio	371	2	comparison	comparison	NN
cord-016476-78r0rsio	371	3	to	to	IN
cord-016476-78r0rsio	371	4	other	other	JJ
cord-016476-78r0rsio	371	5	biologics	biologic	NNS
cord-016476-78r0rsio	371	6	,	,	,
cord-016476-78r0rsio	371	7	there	there	EX
cord-016476-78r0rsio	371	8	did	do	VBD
cord-016476-78r0rsio	371	9	not	not	RB
cord-016476-78r0rsio	371	10	seem	seem	VB
cord-016476-78r0rsio	371	11	to	to	TO
cord-016476-78r0rsio	371	12	be	be	VB
cord-016476-78r0rsio	371	13	a	a	DT
cord-016476-78r0rsio	371	14	significantly	significantly	RB
cord-016476-78r0rsio	371	15	lower	low	JJR
cord-016476-78r0rsio	371	16	risk	risk	NN
cord-016476-78r0rsio	371	17	of	of	IN
cord-016476-78r0rsio	371	18	complications	complication	NNS
cord-016476-78r0rsio	371	19	related	relate	VBN
cord-016476-78r0rsio	371	20	to	to	IN
cord-016476-78r0rsio	371	21	ILD	ILD	NNP
cord-016476-78r0rsio	371	22	in	in	IN
cord-016476-78r0rsio	371	23	the	the	DT
cord-016476-78r0rsio	371	24	Curtis	Curtis	NNP
cord-016476-78r0rsio	371	25	et	et	NNP
cord-016476-78r0rsio	371	26	al	al	NNP
cord-016476-78r0rsio	371	27	.	.	.
cord-016476-78r0rsio	372	1	study	study	VB
cord-016476-78r0rsio	372	2	[	[	-LRB-
cord-016476-78r0rsio	372	3	81	81	CD
cord-016476-78r0rsio	372	4	]	]	-RRB-
cord-016476-78r0rsio	372	5	,	,	,
cord-016476-78r0rsio	372	6	although	although	IN
cord-016476-78r0rsio	372	7	channelling	channel	VBG
cord-016476-78r0rsio	372	8	bias	bias	NN
cord-016476-78r0rsio	372	9	may	may	MD
cord-016476-78r0rsio	372	10	exist	exist	VB
cord-016476-78r0rsio	372	11	.	.	.
cord-016476-78r0rsio	373	1	Furthermore	furthermore	RB
cord-016476-78r0rsio	373	2	rituximab	rituximab	RB
cord-016476-78r0rsio	373	3	is	be	VBZ
cord-016476-78r0rsio	373	4	known	know	VBN
cord-016476-78r0rsio	373	5	to	to	TO
cord-016476-78r0rsio	373	6	reduce	reduce	VB
cord-016476-78r0rsio	373	7	IgG	igg	NN
cord-016476-78r0rsio	373	8	levels	level	NNS
cord-016476-78r0rsio	373	9	,	,	,
cord-016476-78r0rsio	373	10	which	which	WDT
cord-016476-78r0rsio	373	11	in	in	IN
cord-016476-78r0rsio	373	12	turn	turn	NN
cord-016476-78r0rsio	373	13	may	may	MD
cord-016476-78r0rsio	373	14	be	be	VB
cord-016476-78r0rsio	373	15	associated	associate	VBN
cord-016476-78r0rsio	373	16	with	with	IN
cord-016476-78r0rsio	373	17	an	an	DT
cord-016476-78r0rsio	373	18	increased	increase	VBN
cord-016476-78r0rsio	373	19	infection	infection	NN
cord-016476-78r0rsio	373	20	risk	risk	NN
cord-016476-78r0rsio	373	21	,	,	,
cord-016476-78r0rsio	373	22	which	which	WDT
cord-016476-78r0rsio	373	23	bears	bear	VBZ
cord-016476-78r0rsio	373	24	consideration	consideration	NN
cord-016476-78r0rsio	373	25	whilst	whilst	IN
cord-016476-78r0rsio	373	26	making	make	VBG
cord-016476-78r0rsio	373	27	such	such	JJ
cord-016476-78r0rsio	373	28	treatment	treatment	NN
cord-016476-78r0rsio	373	29	decisions	decision	NNS
cord-016476-78r0rsio	373	30	[	[	-LRB-
cord-016476-78r0rsio	373	31	190	190	CD
cord-016476-78r0rsio	373	32	]	]	-RRB-
cord-016476-78r0rsio	373	33	.	.	.
cord-016476-78r0rsio	374	1	In	in	IN
cord-016476-78r0rsio	374	2	the	the	DT
cord-016476-78r0rsio	374	3	context	context	NN
cord-016476-78r0rsio	374	4	of	of	IN
cord-016476-78r0rsio	374	5	RA	RA	NNP
cord-016476-78r0rsio	374	6	overlap	overlap	VB
cord-016476-78r0rsio	374	7	with	with	IN
cord-016476-78r0rsio	374	8	another	another	DT
cord-016476-78r0rsio	374	9	CTD	CTD	NNP
cord-016476-78r0rsio	374	10	,	,	,
cord-016476-78r0rsio	374	11	however	however	RB
cord-016476-78r0rsio	374	12	,	,	,
cord-016476-78r0rsio	374	13	RTX	RTX	NNP
cord-016476-78r0rsio	374	14	may	may	MD
cord-016476-78r0rsio	374	15	have	have	VB
cord-016476-78r0rsio	374	16	a	a	DT
cord-016476-78r0rsio	374	17	role	role	NN
cord-016476-78r0rsio	374	18	in	in	IN
cord-016476-78r0rsio	374	19	stabilising	stabilise	VBG
cord-016476-78r0rsio	374	20	ILD	ILD	NNP
cord-016476-78r0rsio	374	21	,	,	,
cord-016476-78r0rsio	374	22	especially	especially	RB
cord-016476-78r0rsio	374	23	with	with	IN
cord-016476-78r0rsio	374	24	other	other	JJ
cord-016476-78r0rsio	374	25	extra	extra	JJ
cord-016476-78r0rsio	374	26	-	-	JJ
cord-016476-78r0rsio	374	27	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	374	28	manifestations	manifestation	NNS
cord-016476-78r0rsio	374	29	of	of	IN
cord-016476-78r0rsio	374	30	CTD	CTD	NNP
cord-016476-78r0rsio	374	31	which	which	WDT
cord-016476-78r0rsio	374	32	exist	exist	VBP
cord-016476-78r0rsio	374	33	that	that	WDT
cord-016476-78r0rsio	374	34	may	may	MD
cord-016476-78r0rsio	374	35	benefit	benefit	VB
cord-016476-78r0rsio	374	36	from	from	IN
cord-016476-78r0rsio	374	37	B	b	NN
cord-016476-78r0rsio	374	38	-	-	HYPH
cord-016476-78r0rsio	374	39	cell	cell	NN
cord-016476-78r0rsio	374	40	depletion	depletion	NN
cord-016476-78r0rsio	374	41	.	.	.
cord-016476-78r0rsio	375	1	A	a	DT
cord-016476-78r0rsio	375	2	clinical	clinical	JJ
cord-016476-78r0rsio	375	3	trial	trial	NN
cord-016476-78r0rsio	375	4	is	be	VBZ
cord-016476-78r0rsio	375	5	currently	currently	RB
cord-016476-78r0rsio	375	6	underway	underway	JJ
cord-016476-78r0rsio	375	7	comparing	compare	VBG
cord-016476-78r0rsio	375	8	rituximab	rituximab	NN
cord-016476-78r0rsio	375	9	versus	versus	IN
cord-016476-78r0rsio	375	10	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	375	11	in	in	IN
cord-016476-78r0rsio	375	12	patients	patient	NNS
cord-016476-78r0rsio	375	13	with	with	IN
cord-016476-78r0rsio	375	14	systemic	systemic	JJ
cord-016476-78r0rsio	375	15	sclerosis	sclerosis	NN
cord-016476-78r0rsio	375	16	,	,	,
cord-016476-78r0rsio	375	17	myositis	myositis	NN
cord-016476-78r0rsio	375	18	and	and	CC
cord-016476-78r0rsio	375	19	mixed	mixed	JJ
cord-016476-78r0rsio	375	20	connective	connective	JJ
cord-016476-78r0rsio	375	21	tissue	tissue	NN
cord-016476-78r0rsio	375	22	disease	disease	NN
cord-016476-78r0rsio	375	23	(	(	-LRB-
cord-016476-78r0rsio	375	24	RECITAL	recital	NN
cord-016476-78r0rsio	375	25	,	,	,
cord-016476-78r0rsio	375	26	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-016476-78r0rsio	375	27	Identifier	identifier	NN
cord-016476-78r0rsio	375	28	:	:	:
cord-016476-78r0rsio	375	29	NCT01862926	NCT01862926	NNP
cord-016476-78r0rsio	375	30	)	)	-RRB-
cord-016476-78r0rsio	375	31	.	.	.
cord-016476-78r0rsio	376	1	Currently	currently	RB
cord-016476-78r0rsio	376	2	,	,	,
cord-016476-78r0rsio	376	3	therefore	therefore	RB
cord-016476-78r0rsio	376	4	,	,	,
cord-016476-78r0rsio	376	5	the	the	DT
cord-016476-78r0rsio	376	6	evidence	evidence	NN
cord-016476-78r0rsio	376	7	does	do	VBZ
cord-016476-78r0rsio	376	8	not	not	RB
cord-016476-78r0rsio	376	9	support	support	VB
cord-016476-78r0rsio	376	10	preferentially	preferentially	RB
cord-016476-78r0rsio	376	11	switching	switch	VBG
cord-016476-78r0rsio	376	12	to	to	IN
cord-016476-78r0rsio	376	13	rituximab	rituximab	NN
cord-016476-78r0rsio	376	14	in	in	IN
cord-016476-78r0rsio	376	15	all	all	DT
cord-016476-78r0rsio	376	16	patients	patient	NNS
cord-016476-78r0rsio	376	17	with	with	IN
cord-016476-78r0rsio	376	18	RA	RA	NNP
cord-016476-78r0rsio	376	19	-	-	HYPH
cord-016476-78r0rsio	376	20	ILD	ILD	NNP
cord-016476-78r0rsio	376	21	who	who	WP
cord-016476-78r0rsio	376	22	have	have	VBP
cord-016476-78r0rsio	376	23	active	active	JJ
cord-016476-78r0rsio	376	24	joint	joint	JJ
cord-016476-78r0rsio	376	25	disease	disease	NN
cord-016476-78r0rsio	376	26	,	,	,
cord-016476-78r0rsio	376	27	regardless	regardless	RB
cord-016476-78r0rsio	376	28	of	of	IN
cord-016476-78r0rsio	376	29	the	the	DT
cord-016476-78r0rsio	376	30	severity	severity	NN
cord-016476-78r0rsio	376	31	of	of	IN
cord-016476-78r0rsio	376	32	lung	lung	NN
cord-016476-78r0rsio	376	33	disease	disease	NN
cord-016476-78r0rsio	376	34	.	.	.
cord-016476-78r0rsio	377	1	In	in	IN
cord-016476-78r0rsio	377	2	end	end	NN
cord-016476-78r0rsio	377	3	-	-	HYPH
cord-016476-78r0rsio	377	4	stage	stage	NN
cord-016476-78r0rsio	377	5	refractory	refractory	JJ
cord-016476-78r0rsio	377	6	RA	RA	NNP
cord-016476-78r0rsio	377	7	-	-	HYPH
cord-016476-78r0rsio	377	8	ILD	ILD	NNP
cord-016476-78r0rsio	377	9	,	,	,
cord-016476-78r0rsio	377	10	single	single	JJ
cord-016476-78r0rsio	377	11	lung	lung	NN
cord-016476-78r0rsio	377	12	transplantation	transplantation	NN
cord-016476-78r0rsio	377	13	may	may	MD
cord-016476-78r0rsio	377	14	be	be	VB
cord-016476-78r0rsio	377	15	considered	consider	VBN
cord-016476-78r0rsio	377	16	.	.	.
cord-016476-78r0rsio	378	1	However	however	RB
cord-016476-78r0rsio	378	2	there	there	EX
cord-016476-78r0rsio	378	3	are	be	VBP
cord-016476-78r0rsio	378	4	limited	limited	JJ
cord-016476-78r0rsio	378	5	data	datum	NNS
cord-016476-78r0rsio	378	6	on	on	IN
cord-016476-78r0rsio	378	7	long	long	JJ
cord-016476-78r0rsio	378	8	-	-	HYPH
cord-016476-78r0rsio	378	9	term	term	NN
cord-016476-78r0rsio	378	10	outcomes	outcome	NNS
cord-016476-78r0rsio	378	11	for	for	IN
cord-016476-78r0rsio	378	12	lung	lung	NN
cord-016476-78r0rsio	378	13	transplant	transplant	NN
cord-016476-78r0rsio	378	14	in	in	IN
cord-016476-78r0rsio	378	15	RA	RA	NNP
cord-016476-78r0rsio	378	16	-	-	HYPH
cord-016476-78r0rsio	378	17	ILD	ILD	NNP
cord-016476-78r0rsio	378	18	.	.	.
cord-016476-78r0rsio	379	1	Amongst	amongst	IN
cord-016476-78r0rsio	379	2	ten	ten	CD
cord-016476-78r0rsio	379	3	patients	patient	NNS
cord-016476-78r0rsio	379	4	with	with	IN
cord-016476-78r0rsio	379	5	RA	RA	NNP
cord-016476-78r0rsio	379	6	-	-	HYPH
cord-016476-78r0rsio	379	7	ILD	ILD	NNP
cord-016476-78r0rsio	379	8	who	who	WP
cord-016476-78r0rsio	379	9	underwent	undergo	VBD
cord-016476-78r0rsio	379	10	transplantation	transplantation	NN
cord-016476-78r0rsio	379	11	,	,	,
cord-016476-78r0rsio	379	12	survival	survival	NN
cord-016476-78r0rsio	379	13	at	at	IN
cord-016476-78r0rsio	379	14	1	1	CD
cord-016476-78r0rsio	379	15	year	year	NN
cord-016476-78r0rsio	379	16	was	be	VBD
cord-016476-78r0rsio	379	17	similar	similar	JJ
cord-016476-78r0rsio	379	18	to	to	IN
cord-016476-78r0rsio	379	19	IPF	IPF	NNP
cord-016476-78r0rsio	379	20	lung	lung	NN
cord-016476-78r0rsio	379	21	transplant	transplant	NN
cord-016476-78r0rsio	379	22	recipients	recipient	NNS
cord-016476-78r0rsio	379	23	(	(	-LRB-
cord-016476-78r0rsio	379	24	67	67	CD
cord-016476-78r0rsio	379	25	and	and	CC
cord-016476-78r0rsio	379	26	69	69	CD
cord-016476-78r0rsio	379	27	%	%	NN
cord-016476-78r0rsio	379	28	,	,	,
cord-016476-78r0rsio	379	29	respectively	respectively	RB
cord-016476-78r0rsio	379	30	)	)	-RRB-
cord-016476-78r0rsio	379	31	,	,	,
cord-016476-78r0rsio	379	32	although	although	IN
cord-016476-78r0rsio	379	33	higher	high	JJR
cord-016476-78r0rsio	379	34	for	for	IN
cord-016476-78r0rsio	379	35	scleroderma	scleroderma	NN
cord-016476-78r0rsio	379	36	-	-	:
cord-016476-78r0rsio	379	37	ILD	ILD	NNP
cord-016476-78r0rsio	379	38	at	at	IN
cord-016476-78r0rsio	379	39	82	82	CD
cord-016476-78r0rsio	379	40	%	%	NN
cord-016476-78r0rsio	379	41	[	[	-LRB-
cord-016476-78r0rsio	379	42	191	191	CD
cord-016476-78r0rsio	379	43	]	]	-RRB-
cord-016476-78r0rsio	379	44	.	.	.
cord-016476-78r0rsio	380	1	Eligibility	eligibility	NN
cord-016476-78r0rsio	380	2	for	for	IN
cord-016476-78r0rsio	380	3	lung	lung	NN
cord-016476-78r0rsio	380	4	transplantation	transplantation	NN
cord-016476-78r0rsio	380	5	may	may	MD
cord-016476-78r0rsio	380	6	be	be	VB
cord-016476-78r0rsio	380	7	restricted	restrict	VBN
cord-016476-78r0rsio	380	8	due	due	IN
cord-016476-78r0rsio	380	9	to	to	IN
cord-016476-78r0rsio	380	10	age	age	NN
cord-016476-78r0rsio	380	11	(	(	-LRB-
cord-016476-78r0rsio	380	12	typically	typically	RB
cord-016476-78r0rsio	380	13	<	<	XX
cord-016476-78r0rsio	380	14	65	65	CD
cord-016476-78r0rsio	380	15	years	year	NNS
cord-016476-78r0rsio	380	16	)	)	-RRB-
cord-016476-78r0rsio	380	17	,	,	,
cord-016476-78r0rsio	380	18	contraindicated	contraindicate	VBN
cord-016476-78r0rsio	380	19	with	with	IN
cord-016476-78r0rsio	380	20	certain	certain	JJ
cord-016476-78r0rsio	380	21	comorbidities	comorbiditie	NNS
cord-016476-78r0rsio	380	22	common	common	JJ
cord-016476-78r0rsio	380	23	in	in	IN
cord-016476-78r0rsio	380	24	RA	RA	NNP
cord-016476-78r0rsio	380	25	including	include	VBG
cord-016476-78r0rsio	380	26	osteoporosis	osteoporosis	NN
cord-016476-78r0rsio	380	27	,	,	,
cord-016476-78r0rsio	380	28	whilst	whilst	IN
cord-016476-78r0rsio	380	29	other	other	JJ
cord-016476-78r0rsio	380	30	extra	extra	JJ
cord-016476-78r0rsio	380	31	-	-	JJ
cord-016476-78r0rsio	380	32	articular	articular	JJ
cord-016476-78r0rsio	380	33	manifestations	manifestation	NNS
cord-016476-78r0rsio	380	34	of	of	IN
cord-016476-78r0rsio	380	35	RA	RA	NNP
cord-016476-78r0rsio	380	36	may	may	MD
cord-016476-78r0rsio	380	37	in	in	IN
cord-016476-78r0rsio	380	38	turn	turn	NN
cord-016476-78r0rsio	380	39	complicate	complicate	VB
cord-016476-78r0rsio	380	40	transplantation	transplantation	NN
cord-016476-78r0rsio	380	41	.	.	.
cord-016476-78r0rsio	381	1	Nonetheless	nonetheless	RB
cord-016476-78r0rsio	381	2	,	,	,
cord-016476-78r0rsio	381	3	comparable	comparable	JJ
cord-016476-78r0rsio	381	4	survival	survival	NN
cord-016476-78r0rsio	381	5	outcomes	outcome	NNS
cord-016476-78r0rsio	381	6	of	of	IN
cord-016476-78r0rsio	381	7	RA	RA	NNP
cord-016476-78r0rsio	381	8	-	-	HYPH
cord-016476-78r0rsio	381	9	ILD	ILD	NNP
cord-016476-78r0rsio	381	10	with	with	IN
cord-016476-78r0rsio	381	11	IPF	IPF	NNP
cord-016476-78r0rsio	381	12	are	be	VBP
cord-016476-78r0rsio	381	13	somewhat	somewhat	RB
cord-016476-78r0rsio	381	14	reassuring	reassuring	JJ
cord-016476-78r0rsio	381	15	.	.	.
cord-016476-78r0rsio	382	1	In	in	IN
cord-016476-78r0rsio	382	2	summary	summary	NN
cord-016476-78r0rsio	382	3	at	at	IN
cord-016476-78r0rsio	382	4	present	present	JJ
cord-016476-78r0rsio	382	5	,	,	,
cord-016476-78r0rsio	382	6	there	there	EX
cord-016476-78r0rsio	382	7	are	be	VBP
cord-016476-78r0rsio	382	8	no	no	DT
cord-016476-78r0rsio	382	9	current	current	JJ
cord-016476-78r0rsio	382	10	treatments	treatment	NNS
cord-016476-78r0rsio	382	11	available	available	JJ
cord-016476-78r0rsio	382	12	that	that	WDT
cord-016476-78r0rsio	382	13	have	have	VBP
cord-016476-78r0rsio	382	14	appeared	appear	VBN
cord-016476-78r0rsio	382	15	to	to	TO
cord-016476-78r0rsio	382	16	consistently	consistently	RB
cord-016476-78r0rsio	382	17	stabilise	stabilise	VB
cord-016476-78r0rsio	382	18	RA	RA	NNP
cord-016476-78r0rsio	382	19	-	-	HYPH
cord-016476-78r0rsio	382	20	ILD	ILD	NNP
cord-016476-78r0rsio	382	21	as	as	RB
cord-016476-78r0rsio	382	22	well	well	RB
cord-016476-78r0rsio	382	23	as	as	IN
cord-016476-78r0rsio	382	24	adequately	adequately	RB
cord-016476-78r0rsio	382	25	treat	treat	VB
cord-016476-78r0rsio	382	26	joint	joint	JJ
cord-016476-78r0rsio	382	27	symptoms	symptom	NNS
cord-016476-78r0rsio	382	28	.	.	.
cord-016476-78r0rsio	383	1	The	the	DT
cord-016476-78r0rsio	383	2	risks	risk	NNS
cord-016476-78r0rsio	383	3	and	and	CC
cord-016476-78r0rsio	383	4	limited	limited	JJ
cord-016476-78r0rsio	383	5	benefits	benefit	NNS
cord-016476-78r0rsio	383	6	of	of	IN
cord-016476-78r0rsio	383	7	such	such	JJ
cord-016476-78r0rsio	383	8	medications	medication	NNS
cord-016476-78r0rsio	383	9	bear	bear	NN
cord-016476-78r0rsio	383	10	consideration	consideration	NN
cord-016476-78r0rsio	383	11	,	,	,
cord-016476-78r0rsio	383	12	especially	especially	RB
cord-016476-78r0rsio	383	13	since	since	IN
cord-016476-78r0rsio	383	14	most	most	JJS
cord-016476-78r0rsio	383	15	evidence	evidence	NN
cord-016476-78r0rsio	383	16	for	for	IN
cord-016476-78r0rsio	383	17	efficacy	efficacy	NN
cord-016476-78r0rsio	383	18	has	have	VBZ
cord-016476-78r0rsio	383	19	been	be	VBN
cord-016476-78r0rsio	383	20	demonstrated	demonstrate	VBN
cord-016476-78r0rsio	383	21	in	in	IN
cord-016476-78r0rsio	383	22	IPF	IPF	NNP
cord-016476-78r0rsio	383	23	and	and	CC
cord-016476-78r0rsio	383	24	CTD	CTD	NNP
cord-016476-78r0rsio	383	25	-	-	HYPH
cord-016476-78r0rsio	383	26	ILD	ILD	NNP
cord-016476-78r0rsio	383	27	.	.	.
cord-016476-78r0rsio	384	1	Glucocorticoids	Glucocorticoids	NNP
cord-016476-78r0rsio	384	2	may	may	MD
cord-016476-78r0rsio	384	3	be	be	VB
cord-016476-78r0rsio	384	4	used	use	VBN
cord-016476-78r0rsio	384	5	in	in	IN
cord-016476-78r0rsio	384	6	RA	RA	NNP
cord-016476-78r0rsio	384	7	-	-	HYPH
cord-016476-78r0rsio	384	8	ILD	ILD	NNP
cord-016476-78r0rsio	384	9	,	,	,
cord-016476-78r0rsio	384	10	however	however	RB
cord-016476-78r0rsio	384	11	,	,	,
cord-016476-78r0rsio	384	12	with	with	IN
cord-016476-78r0rsio	384	13	the	the	DT
cord-016476-78r0rsio	384	14	lowest	low	JJS
cord-016476-78r0rsio	384	15	effective	effective	JJ
cord-016476-78r0rsio	384	16	dose	dose	NN
cord-016476-78r0rsio	384	17	for	for	IN
cord-016476-78r0rsio	384	18	the	the	DT
cord-016476-78r0rsio	384	19	shortest	short	JJS
cord-016476-78r0rsio	384	20	possible	possible	JJ
cord-016476-78r0rsio	384	21	duration	duration	NN
cord-016476-78r0rsio	384	22	to	to	TO
cord-016476-78r0rsio	384	23	minimise	minimise	VB
cord-016476-78r0rsio	384	24	risk	risk	NN
cord-016476-78r0rsio	384	25	of	of	IN
cord-016476-78r0rsio	384	26	infection	infection	NN
cord-016476-78r0rsio	384	27	amongst	amongst	IN
cord-016476-78r0rsio	384	28	others	other	NNS
cord-016476-78r0rsio	384	29	.	.	.
cord-016476-78r0rsio	385	1	Robust	robust	JJ
cord-016476-78r0rsio	385	2	RCTs	rct	NNS
cord-016476-78r0rsio	385	3	are	be	VBP
cord-016476-78r0rsio	385	4	required	require	VBN
cord-016476-78r0rsio	385	5	to	to	TO
cord-016476-78r0rsio	385	6	support	support	VB
cord-016476-78r0rsio	385	7	the	the	DT
cord-016476-78r0rsio	385	8	use	use	NN
cord-016476-78r0rsio	385	9	of	of	IN
cord-016476-78r0rsio	385	10	novel	novel	JJ
cord-016476-78r0rsio	385	11	antfibrotic	antfibrotic	JJ
cord-016476-78r0rsio	385	12	agents	agent	NNS
cord-016476-78r0rsio	385	13	or	or	CC
cord-016476-78r0rsio	385	14	immunosuppressive	immunosuppressive	JJ
cord-016476-78r0rsio	385	15	therapies	therapy	NNS
cord-016476-78r0rsio	385	16	directed	direct	VBN
cord-016476-78r0rsio	385	17	towards	towards	IN
cord-016476-78r0rsio	385	18	treatment	treatment	NN
cord-016476-78r0rsio	385	19	of	of	IN
cord-016476-78r0rsio	385	20	RA	RA	NNP
cord-016476-78r0rsio	385	21	-	-	HYPH
cord-016476-78r0rsio	385	22	ILD	ILD	NNP
cord-016476-78r0rsio	385	23	.	.	.
cord-016476-78r0rsio	386	1	However	however	RB
cord-016476-78r0rsio	386	2	,	,	,
cord-016476-78r0rsio	386	3	at	at	IN
cord-016476-78r0rsio	386	4	present	present	NN
cord-016476-78r0rsio	386	5	there	there	EX
cord-016476-78r0rsio	386	6	is	be	VBZ
cord-016476-78r0rsio	386	7	a	a	DT
cord-016476-78r0rsio	386	8	paucity	paucity	NN
cord-016476-78r0rsio	386	9	of	of	IN
cord-016476-78r0rsio	386	10	evidence	evidence	NN
cord-016476-78r0rsio	386	11	to	to	TO
cord-016476-78r0rsio	386	12	support	support	VB
cord-016476-78r0rsio	386	13	the	the	DT
cord-016476-78r0rsio	386	14	routine	routine	JJ
cord-016476-78r0rsio	386	15	use	use	NN
cord-016476-78r0rsio	386	16	of	of	IN
cord-016476-78r0rsio	386	17	these	these	DT
cord-016476-78r0rsio	386	18	strategiest	strategi	JJS
cord-016476-78r0rsio	386	19	.	.	.
cord-016476-78r0rsio	387	1	Evidence	evidence	NN
cord-016476-78r0rsio	387	2	to	to	TO
cord-016476-78r0rsio	387	3	guide	guide	VB
cord-016476-78r0rsio	387	4	management	management	NN
cord-016476-78r0rsio	387	5	and	and	CC
cord-016476-78r0rsio	387	6	treatment	treatment	NN
cord-016476-78r0rsio	387	7	of	of	IN
cord-016476-78r0rsio	387	8	RA	RA	NNP
cord-016476-78r0rsio	387	9	-	-	HYPH
cord-016476-78r0rsio	387	10	ILD	ILD	NNP
cord-016476-78r0rsio	387	11	is	be	VBZ
cord-016476-78r0rsio	387	12	of	of	IN
cord-016476-78r0rsio	387	13	low	low	JJ
cord-016476-78r0rsio	387	14	quality	quality	NN
cord-016476-78r0rsio	387	15	or	or	CC
cord-016476-78r0rsio	387	16	absent	absent	JJ
cord-016476-78r0rsio	387	17	,	,	,
cord-016476-78r0rsio	387	18	hence	hence	RB
cord-016476-78r0rsio	387	19	extrapolated	extrapolate	VBN
cord-016476-78r0rsio	387	20	from	from	IN
cord-016476-78r0rsio	387	21	systemic	systemic	JJ
cord-016476-78r0rsio	387	22	sclerosis	sclerosis	NN
cord-016476-78r0rsio	387	23	-	-	:
cord-016476-78r0rsio	387	24	ILD	ILD	NNP
cord-016476-78r0rsio	387	25	or	or	CC
cord-016476-78r0rsio	387	26	IPF	IPF	NNP
cord-016476-78r0rsio	387	27	.	.	.
cord-016476-78r0rsio	388	1	However	however	RB
cord-016476-78r0rsio	388	2	,	,	,
cord-016476-78r0rsio	388	3	despite	despite	IN
cord-016476-78r0rsio	388	4	the	the	DT
cord-016476-78r0rsio	388	5	lack	lack	NN
cord-016476-78r0rsio	388	6	of	of	IN
cord-016476-78r0rsio	388	7	robust	robust	JJ
cord-016476-78r0rsio	388	8	data	datum	NNS
cord-016476-78r0rsio	388	9	,	,	,
cord-016476-78r0rsio	388	10	clinicians	clinician	NNS
cord-016476-78r0rsio	388	11	are	be	VBP
cord-016476-78r0rsio	388	12	required	require	VBN
cord-016476-78r0rsio	388	13	to	to	TO
cord-016476-78r0rsio	388	14	advise	advise	VB
cord-016476-78r0rsio	388	15	patients	patient	NNS
cord-016476-78r0rsio	388	16	on	on	IN
cord-016476-78r0rsio	388	17	the	the	DT
cord-016476-78r0rsio	388	18	comparative	comparative	JJ
cord-016476-78r0rsio	388	19	safety	safety	NN
cord-016476-78r0rsio	388	20	of	of	IN
cord-016476-78r0rsio	388	21	treatment	treatment	NN
cord-016476-78r0rsio	388	22	and	and	CC
cord-016476-78r0rsio	388	23	strategies	strategy	NNS
cord-016476-78r0rsio	388	24	to	to	TO
cord-016476-78r0rsio	388	25	minimise	minimise	VB
cord-016476-78r0rsio	388	26	complications	complication	NNS
cord-016476-78r0rsio	388	27	of	of	IN
cord-016476-78r0rsio	388	28	RA	RA	NNP
cord-016476-78r0rsio	388	29	-	-	HYPH
cord-016476-78r0rsio	388	30	ILD	ILD	NNP
cord-016476-78r0rsio	388	31	such	such	JJ
cord-016476-78r0rsio	388	32	as	as	IN
cord-016476-78r0rsio	388	33	infection	infection	NN
cord-016476-78r0rsio	388	34	and	and	CC
cord-016476-78r0rsio	388	35	reduce	reduce	VB
cord-016476-78r0rsio	388	36	the	the	DT
cord-016476-78r0rsio	388	37	overall	overall	JJ
cord-016476-78r0rsio	388	38	burden	burden	NN
cord-016476-78r0rsio	388	39	of	of	IN
cord-016476-78r0rsio	388	40	morbidity	morbidity	NN
cord-016476-78r0rsio	388	41	to	to	TO
cord-016476-78r0rsio	388	42	prolong	prolong	VB
cord-016476-78r0rsio	388	43	survival	survival	NN
cord-016476-78r0rsio	388	44	.	.	.
cord-016476-78r0rsio	389	1	In	in	IN
cord-016476-78r0rsio	389	2	addition	addition	NN
cord-016476-78r0rsio	389	3	RA	RA	NNP
cord-016476-78r0rsio	389	4	management	management	NN
cord-016476-78r0rsio	389	5	has	have	VBZ
cord-016476-78r0rsio	389	6	become	become	VBN
cord-016476-78r0rsio	389	7	increasingly	increasingly	RB
cord-016476-78r0rsio	389	8	complex	complex	JJ
cord-016476-78r0rsio	389	9	over	over	IN
cord-016476-78r0rsio	389	10	the	the	DT
cord-016476-78r0rsio	389	11	last	last	JJ
cord-016476-78r0rsio	389	12	decade	decade	NN
cord-016476-78r0rsio	389	13	.	.	.
cord-016476-78r0rsio	390	1	Several	several	JJ
cord-016476-78r0rsio	390	2	effective	effective	JJ
cord-016476-78r0rsio	390	3	DMARDs	dmard	NNS
cord-016476-78r0rsio	390	4	are	be	VBP
cord-016476-78r0rsio	390	5	available	available	JJ
cord-016476-78r0rsio	390	6	,	,	,
cord-016476-78r0rsio	390	7	and	and	CC
cord-016476-78r0rsio	390	8	treat	treat	VB
cord-016476-78r0rsio	390	9	-	-	HYPH
cord-016476-78r0rsio	390	10	to	to	IN
cord-016476-78r0rsio	390	11	-	-	HYPH
cord-016476-78r0rsio	390	12	target	target	NN
cord-016476-78r0rsio	390	13	strategies	strategy	NNS
cord-016476-78r0rsio	390	14	support	support	VBP
cord-016476-78r0rsio	390	15	the	the	DT
cord-016476-78r0rsio	390	16	use	use	NN
cord-016476-78r0rsio	390	17	of	of	IN
cord-016476-78r0rsio	390	18	early	early	JJ
cord-016476-78r0rsio	390	19	,	,	,
cord-016476-78r0rsio	390	20	rapidly	rapidly	RB
cord-016476-78r0rsio	390	21	escalating	escalate	VBG
cord-016476-78r0rsio	390	22	treatment	treatment	NN
cord-016476-78r0rsio	390	23	often	often	RB
cord-016476-78r0rsio	390	24	in	in	IN
cord-016476-78r0rsio	390	25	combination	combination	NN
cord-016476-78r0rsio	390	26	with	with	IN
cord-016476-78r0rsio	390	27	each	each	DT
cord-016476-78r0rsio	390	28	other	other	JJ
cord-016476-78r0rsio	390	29	.	.	.
cord-016476-78r0rsio	391	1	As	as	IN
cord-016476-78r0rsio	391	2	discussed	discuss	VBN
cord-016476-78r0rsio	391	3	earlier	early	RBR
cord-016476-78r0rsio	391	4	,	,	,
cord-016476-78r0rsio	391	5	there	there	EX
cord-016476-78r0rsio	391	6	are	be	VBP
cord-016476-78r0rsio	391	7	no	no	DT
cord-016476-78r0rsio	391	8	treatments	treatment	NNS
cord-016476-78r0rsio	391	9	that	that	WDT
cord-016476-78r0rsio	391	10	conclusively	conclusively	RB
cord-016476-78r0rsio	391	11	improve	improve	VBP
cord-016476-78r0rsio	391	12	both	both	CC
cord-016476-78r0rsio	391	13	joint	joint	JJ
cord-016476-78r0rsio	391	14	and	and	CC
cord-016476-78r0rsio	391	15	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	391	16	disease	disease	NN
cord-016476-78r0rsio	391	17	in	in	IN
cord-016476-78r0rsio	391	18	all	all	DT
cord-016476-78r0rsio	391	19	patients	patient	NNS
cord-016476-78r0rsio	391	20	;	;	:
cord-016476-78r0rsio	391	21	therefore	therefore	RB
cord-016476-78r0rsio	391	22	,	,	,
cord-016476-78r0rsio	391	23	careful	careful	JJ
cord-016476-78r0rsio	391	24	baseline	baseline	JJ
cord-016476-78r0rsio	391	25	assessment	assessment	NN
cord-016476-78r0rsio	391	26	,	,	,
cord-016476-78r0rsio	391	27	adequate	adequate	JJ
cord-016476-78r0rsio	391	28	risk	risk	NN
cord-016476-78r0rsio	391	29	assessment	assessment	NN
cord-016476-78r0rsio	391	30	for	for	IN
cord-016476-78r0rsio	391	31	adverse	adverse	JJ
cord-016476-78r0rsio	391	32	outcomes	outcome	NNS
cord-016476-78r0rsio	391	33	and	and	CC
cord-016476-78r0rsio	391	34	regular	regular	JJ
cord-016476-78r0rsio	391	35	monitoring	monitoring	NN
cord-016476-78r0rsio	391	36	and	and	CC
cord-016476-78r0rsio	391	37	vigilance	vigilance	NN
cord-016476-78r0rsio	391	38	whilst	whilst	IN
cord-016476-78r0rsio	391	39	using	use	VBG
cord-016476-78r0rsio	391	40	the	the	DT
cord-016476-78r0rsio	391	41	majority	majority	NN
cord-016476-78r0rsio	391	42	of	of	IN
cord-016476-78r0rsio	391	43	DMARD	DMARD	NNP
cord-016476-78r0rsio	391	44	strategies	strategy	NNS
cord-016476-78r0rsio	391	45	are	be	VBP
cord-016476-78r0rsio	391	46	essential	essential	JJ
cord-016476-78r0rsio	391	47	.	.	.
cord-016476-78r0rsio	392	1	To	to	TO
cord-016476-78r0rsio	392	2	enable	enable	VB
cord-016476-78r0rsio	392	3	guidance	guidance	NN
cord-016476-78r0rsio	392	4	of	of	IN
cord-016476-78r0rsio	392	5	management	management	NN
cord-016476-78r0rsio	392	6	strategies	strategy	NNS
cord-016476-78r0rsio	392	7	,	,	,
cord-016476-78r0rsio	392	8	a	a	DT
cord-016476-78r0rsio	392	9	recent	recent	JJ
cord-016476-78r0rsio	392	10	approach	approach	NN
cord-016476-78r0rsio	392	11	in	in	IN
cord-016476-78r0rsio	392	12	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	392	13	interstitial	interstitial	JJ
cord-016476-78r0rsio	392	14	pneumonias	pneumonia	NNS
cord-016476-78r0rsio	392	15	(	(	-LRB-
cord-016476-78r0rsio	392	16	IIP	IIP	NNP
cord-016476-78r0rsio	392	17	)	)	-RRB-
cord-016476-78r0rsio	392	18	has	have	VBZ
cord-016476-78r0rsio	392	19	been	be	VBN
cord-016476-78r0rsio	392	20	to	to	TO
cord-016476-78r0rsio	392	21	classify	classify	VB
cord-016476-78r0rsio	392	22	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	392	23	disease	disease	NN
cord-016476-78r0rsio	392	24	as	as	IN
cord-016476-78r0rsio	392	25	self	self	NN
cord-016476-78r0rsio	392	26	-	-	HYPH
cord-016476-78r0rsio	392	27	limiting	limit	VBG
cord-016476-78r0rsio	392	28	,	,	,
cord-016476-78r0rsio	392	29	reversible	reversible	JJ
cord-016476-78r0rsio	392	30	,	,	,
cord-016476-78r0rsio	392	31	stable	stable	JJ
cord-016476-78r0rsio	392	32	,	,	,
cord-016476-78r0rsio	392	33	progressive	progressive	JJ
cord-016476-78r0rsio	392	34	or	or	CC
cord-016476-78r0rsio	392	35	irreversible	irreversible	JJ
cord-016476-78r0rsio	392	36	[	[	-LRB-
cord-016476-78r0rsio	392	37	143	143	CD
cord-016476-78r0rsio	392	38	,	,	,
cord-016476-78r0rsio	392	39	192	192	CD
cord-016476-78r0rsio	392	40	,	,	,
cord-016476-78r0rsio	392	41	193	193	CD
cord-016476-78r0rsio	392	42	]	]	-RRB-
cord-016476-78r0rsio	392	43	.	.	.
cord-016476-78r0rsio	393	1	A	a	DT
cord-016476-78r0rsio	393	2	thorough	thorough	JJ
cord-016476-78r0rsio	393	3	assessment	assessment	NN
cord-016476-78r0rsio	393	4	of	of	IN
cord-016476-78r0rsio	393	5	baseline	baseline	JJ
cord-016476-78r0rsio	393	6	RA	RA	NNP
cord-016476-78r0rsio	393	7	-	-	HYPH
cord-016476-78r0rsio	393	8	ILD	ILD	NNP
cord-016476-78r0rsio	393	9	severity	severity	NN
cord-016476-78r0rsio	393	10	should	should	MD
cord-016476-78r0rsio	393	11	consider	consider	VB
cord-016476-78r0rsio	393	12	clinical	clinical	JJ
cord-016476-78r0rsio	393	13	features	feature	NNS
cord-016476-78r0rsio	393	14	,	,	,
cord-016476-78r0rsio	393	15	PFTs	pft	NNS
cord-016476-78r0rsio	393	16	and	and	CC
cord-016476-78r0rsio	393	17	imaging	imaging	NN
cord-016476-78r0rsio	393	18	pattern	pattern	NN
cord-016476-78r0rsio	393	19	/	/	SYM
cord-016476-78r0rsio	393	20	extent	extent	NN
cord-016476-78r0rsio	393	21	on	on	IN
cord-016476-78r0rsio	393	22	HRCT	HRCT	NNP
cord-016476-78r0rsio	393	23	,	,	,
cord-016476-78r0rsio	393	24	low	low	JJ
cord-016476-78r0rsio	393	25	DLCO	DLCO	NNP
cord-016476-78r0rsio	393	26	and	and	CC
cord-016476-78r0rsio	393	27	a	a	DT
cord-016476-78r0rsio	393	28	high	high	JJ
cord-016476-78r0rsio	393	29	radiological	radiological	JJ
cord-016476-78r0rsio	393	30	fibrosis	fibrosis	NN
cord-016476-78r0rsio	393	31	score	score	NN
cord-016476-78r0rsio	393	32	on	on	IN
cord-016476-78r0rsio	393	33	HRCT	HRCT	NNP
cord-016476-78r0rsio	393	34	being	be	VBG
cord-016476-78r0rsio	393	35	predictors	predictor	NNS
cord-016476-78r0rsio	393	36	of	of	IN
cord-016476-78r0rsio	393	37	poor	poor	JJ
cord-016476-78r0rsio	393	38	survival	survival	NN
cord-016476-78r0rsio	393	39	[	[	-LRB-
cord-016476-78r0rsio	393	40	194	194	CD
cord-016476-78r0rsio	393	41	]	]	-RRB-
cord-016476-78r0rsio	393	42	[	[	-LRB-
cord-016476-78r0rsio	393	43	195	195	CD
cord-016476-78r0rsio	393	44	]	]	-RRB-
cord-016476-78r0rsio	393	45	[	[	-LRB-
cord-016476-78r0rsio	393	46	196	196	CD
cord-016476-78r0rsio	393	47	]	]	-RRB-
cord-016476-78r0rsio	393	48	.	.	.
cord-016476-78r0rsio	394	1	Such	such	JJ
cord-016476-78r0rsio	394	2	information	information	NN
cord-016476-78r0rsio	394	3	in	in	IN
cord-016476-78r0rsio	394	4	combination	combination	NN
cord-016476-78r0rsio	394	5	with	with	IN
cord-016476-78r0rsio	394	6	monitoring	monitor	VBG
cord-016476-78r0rsio	394	7	disease	disease	NN
cord-016476-78r0rsio	394	8	progression	progression	NN
cord-016476-78r0rsio	394	9	over	over	IN
cord-016476-78r0rsio	394	10	time	time	NN
cord-016476-78r0rsio	394	11	allows	allow	VBZ
cord-016476-78r0rsio	394	12	mapping	mapping	NN
cord-016476-78r0rsio	394	13	of	of	IN
cord-016476-78r0rsio	394	14	the	the	DT
cord-016476-78r0rsio	394	15	disease	disease	NN
cord-016476-78r0rsio	394	16	trajectory	trajectory	NN
cord-016476-78r0rsio	394	17	and	and	CC
cord-016476-78r0rsio	394	18	may	may	MD
cord-016476-78r0rsio	394	19	better	better	RB
cord-016476-78r0rsio	394	20	inform	inform	VB
cord-016476-78r0rsio	394	21	management	management	NN
cord-016476-78r0rsio	394	22	decisions	decision	NNS
cord-016476-78r0rsio	394	23	in	in	IN
cord-016476-78r0rsio	394	24	the	the	DT
cord-016476-78r0rsio	394	25	face	face	NN
cord-016476-78r0rsio	394	26	of	of	IN
cord-016476-78r0rsio	394	27	poor	poor	JJ
cord-016476-78r0rsio	394	28	evidence	evidence	NN
cord-016476-78r0rsio	394	29	.	.	.
cord-016476-78r0rsio	395	1	Clinical	clinical	JJ
cord-016476-78r0rsio	395	2	assessment	assessment	NN
cord-016476-78r0rsio	395	3	including	include	VBG
cord-016476-78r0rsio	395	4	quantification	quantification	NN
cord-016476-78r0rsio	395	5	of	of	IN
cord-016476-78r0rsio	395	6	exercise	exercise	NN
cord-016476-78r0rsio	395	7	tolerance	tolerance	NN
cord-016476-78r0rsio	395	8	using	use	VBG
cord-016476-78r0rsio	395	9	instruments	instrument	NNS
cord-016476-78r0rsio	395	10	such	such	JJ
cord-016476-78r0rsio	395	11	as	as	IN
cord-016476-78r0rsio	395	12	the	the	DT
cord-016476-78r0rsio	395	13	five	five	CD
cord-016476-78r0rsio	395	14	-	-	HYPH
cord-016476-78r0rsio	395	15	point	point	NN
cord-016476-78r0rsio	395	16	Medical	Medical	NNP
cord-016476-78r0rsio	395	17	Research	Research	NNP
cord-016476-78r0rsio	395	18	Council	Council	NNP
cord-016476-78r0rsio	395	19	(	(	-LRB-
cord-016476-78r0rsio	395	20	MRC	MRC	NNP
cord-016476-78r0rsio	395	21	)	)	-RRB-
cord-016476-78r0rsio	395	22	breathlessness	breathlessness	NN
cord-016476-78r0rsio	395	23	scale	scale	NN
cord-016476-78r0rsio	395	24	[	[	-LRB-
cord-016476-78r0rsio	395	25	197	197	CD
cord-016476-78r0rsio	395	26	]	]	-RRB-
cord-016476-78r0rsio	395	27	can	can	MD
cord-016476-78r0rsio	395	28	help	help	VB
cord-016476-78r0rsio	395	29	aid	aid	VB
cord-016476-78r0rsio	395	30	serial	serial	JJ
cord-016476-78r0rsio	395	31	assessment	assessment	NN
cord-016476-78r0rsio	395	32	of	of	IN
cord-016476-78r0rsio	395	33	the	the	DT
cord-016476-78r0rsio	395	34	symptoms	symptom	NNS
cord-016476-78r0rsio	395	35	of	of	IN
cord-016476-78r0rsio	395	36	RA	RA	NNP
cord-016476-78r0rsio	395	37	-	-	HYPH
cord-016476-78r0rsio	395	38	ILD	ILD	NNP
cord-016476-78r0rsio	395	39	(	(	-LRB-
cord-016476-78r0rsio	395	40	Table	table	NN
cord-016476-78r0rsio	395	41	9	9	CD
cord-016476-78r0rsio	395	42	.3	.3	CD
cord-016476-78r0rsio	395	43	)	)	-RRB-
cord-016476-78r0rsio	395	44	.	.	.
cord-016476-78r0rsio	396	1	Bibasilar	Bibasilar	NNP
cord-016476-78r0rsio	396	2	crepitations	crepitation	NNS
cord-016476-78r0rsio	396	3	are	be	VBP
cord-016476-78r0rsio	396	4	an	an	DT
cord-016476-78r0rsio	396	5	associated	associate	VBN
cord-016476-78r0rsio	396	6	feature	feature	NN
cord-016476-78r0rsio	396	7	that	that	WDT
cord-016476-78r0rsio	396	8	may	may	MD
cord-016476-78r0rsio	396	9	help	help	VB
cord-016476-78r0rsio	396	10	trigger	trigger	VB
cord-016476-78r0rsio	396	11	detection	detection	NN
cord-016476-78r0rsio	396	12	of	of	IN
cord-016476-78r0rsio	396	13	asymptomatic	asymptomatic	JJ
cord-016476-78r0rsio	396	14	ILD	ILD	NNP
cord-016476-78r0rsio	396	15	,	,	,
cord-016476-78r0rsio	396	16	but	but	CC
cord-016476-78r0rsio	396	17	have	have	VBP
cord-016476-78r0rsio	396	18	limited	limit	VBN
cord-016476-78r0rsio	396	19	value	value	NN
cord-016476-78r0rsio	396	20	in	in	IN
cord-016476-78r0rsio	396	21	assessing	assess	VBG
cord-016476-78r0rsio	396	22	severity	severity	NN
cord-016476-78r0rsio	396	23	or	or	CC
cord-016476-78r0rsio	396	24	monitoring	monitoring	NN
cord-016476-78r0rsio	396	25	progression	progression	NN
cord-016476-78r0rsio	396	26	.	.	.
cord-016476-78r0rsio	397	1	The	the	DT
cord-016476-78r0rsio	397	2	6-min	6-min	CD
cord-016476-78r0rsio	397	3	walk	walk	NN
cord-016476-78r0rsio	397	4	test	test	NN
cord-016476-78r0rsio	397	5	is	be	VBZ
cord-016476-78r0rsio	397	6	a	a	DT
cord-016476-78r0rsio	397	7	commonly	commonly	RB
cord-016476-78r0rsio	397	8	used	use	VBN
cord-016476-78r0rsio	397	9	instrument	instrument	NN
cord-016476-78r0rsio	397	10	for	for	IN
cord-016476-78r0rsio	397	11	assessing	assess	VBG
cord-016476-78r0rsio	397	12	IPF	IPF	NNP
cord-016476-78r0rsio	397	13	and	and	CC
cord-016476-78r0rsio	397	14	can	can	MD
cord-016476-78r0rsio	397	15	be	be	VB
cord-016476-78r0rsio	397	16	performed	perform	VBN
cord-016476-78r0rsio	397	17	easily	easily	RB
cord-016476-78r0rsio	397	18	.	.	.
cord-016476-78r0rsio	398	1	Reduced	reduce	VBN
cord-016476-78r0rsio	398	2	walk	walk	NN
cord-016476-78r0rsio	398	3	distance	distance	NN
cord-016476-78r0rsio	398	4	and	and	CC
cord-016476-78r0rsio	398	5	oxygen	oxygen	NN
cord-016476-78r0rsio	398	6	desaturation	desaturation	NN
cord-016476-78r0rsio	398	7	below	below	IN
cord-016476-78r0rsio	398	8	88	88	CD
cord-016476-78r0rsio	398	9	%	%	NN
cord-016476-78r0rsio	398	10	are	be	VBP
cord-016476-78r0rsio	398	11	poor	poor	JJ
cord-016476-78r0rsio	398	12	prognostic	prognostic	JJ
cord-016476-78r0rsio	398	13	factors	factor	NNS
cord-016476-78r0rsio	398	14	in	in	IN
cord-016476-78r0rsio	398	15	IPF	IPF	NNP
cord-016476-78r0rsio	398	16	[	[	-LRB-
cord-016476-78r0rsio	398	17	144	144	CD
cord-016476-78r0rsio	398	18	,	,	,
cord-016476-78r0rsio	398	19	198	198	CD
cord-016476-78r0rsio	398	20	]	]	-RRB-
cord-016476-78r0rsio	398	21	;	;	:
cord-016476-78r0rsio	398	22	however	however	RB
cord-016476-78r0rsio	398	23	,	,	,
cord-016476-78r0rsio	398	24	practically	practically	RB
cord-016476-78r0rsio	398	25	this	this	DT
cord-016476-78r0rsio	398	26	may	may	MD
cord-016476-78r0rsio	398	27	be	be	VB
cord-016476-78r0rsio	398	28	challenging	challenge	VBG
cord-016476-78r0rsio	398	29	to	to	TO
cord-016476-78r0rsio	398	30	perform	perform	VB
cord-016476-78r0rsio	398	31	in	in	IN
cord-016476-78r0rsio	398	32	RA	RA	NNP
cord-016476-78r0rsio	398	33	patients	patient	NNS
cord-016476-78r0rsio	398	34	with	with	IN
cord-016476-78r0rsio	398	35	poor	poor	JJ
cord-016476-78r0rsio	398	36	mobility	mobility	NN
cord-016476-78r0rsio	398	37	.	.	.
cord-016476-78r0rsio	399	1	PFTs	pft	NNS
cord-016476-78r0rsio	399	2	provide	provide	VBP
cord-016476-78r0rsio	399	3	objective	objective	JJ
cord-016476-78r0rsio	399	4	measures	measure	NNS
cord-016476-78r0rsio	399	5	of	of	IN
cord-016476-78r0rsio	399	6	lung	lung	NN
cord-016476-78r0rsio	399	7	function	function	NN
cord-016476-78r0rsio	399	8	and	and	CC
cord-016476-78r0rsio	399	9	should	should	MD
cord-016476-78r0rsio	399	10	be	be	VB
cord-016476-78r0rsio	399	11	performed	perform	VBN
cord-016476-78r0rsio	399	12	in	in	IN
cord-016476-78r0rsio	399	13	all	all	DT
cord-016476-78r0rsio	399	14	patients	patient	NNS
cord-016476-78r0rsio	399	15	with	with	IN
cord-016476-78r0rsio	399	16	respiratory	respiratory	JJ
cord-016476-78r0rsio	399	17	clinical	clinical	JJ
cord-016476-78r0rsio	399	18	features	feature	NNS
cord-016476-78r0rsio	399	19	,	,	,
cord-016476-78r0rsio	399	20	or	or	CC
cord-016476-78r0rsio	399	21	confirmed	confirm	VBD
cord-016476-78r0rsio	399	22	RA	RA	NNP
cord-016476-78r0rsio	399	23	-	-	HYPH
cord-016476-78r0rsio	399	24	ILD	ILD	NNP
cord-016476-78r0rsio	399	25	,	,	,
cord-016476-78r0rsio	399	26	prior	prior	RB
cord-016476-78r0rsio	399	27	to	to	IN
cord-016476-78r0rsio	399	28	decisions	decision	NNS
cord-016476-78r0rsio	399	29	about	about	IN
cord-016476-78r0rsio	399	30	therapy	therapy	NN
cord-016476-78r0rsio	399	31	.	.	.
cord-016476-78r0rsio	400	1	ILDs	ILDs	NNPS
cord-016476-78r0rsio	400	2	share	share	VBP
cord-016476-78r0rsio	400	3	a	a	DT
cord-016476-78r0rsio	400	4	restrictive	restrictive	JJ
cord-016476-78r0rsio	400	5	pattern	pattern	NN
cord-016476-78r0rsio	400	6	,	,	,
cord-016476-78r0rsio	400	7	with	with	IN
cord-016476-78r0rsio	400	8	reductions	reduction	NNS
cord-016476-78r0rsio	400	9	in	in	IN
cord-016476-78r0rsio	400	10	lung	lung	NN
cord-016476-78r0rsio	400	11	volumes	volume	NNS
cord-016476-78r0rsio	400	12	and	and	CC
cord-016476-78r0rsio	400	13	a	a	DT
cord-016476-78r0rsio	400	14	reduced	reduce	VBN
cord-016476-78r0rsio	400	15	DLCO	DLCO	NNP
cord-016476-78r0rsio	400	16	[	[	-LRB-
cord-016476-78r0rsio	400	17	199	199	CD
cord-016476-78r0rsio	400	18	]	]	-RRB-
cord-016476-78r0rsio	400	19	.	.	.
cord-016476-78r0rsio	401	1	Low	low	JJ
cord-016476-78r0rsio	401	2	baseline	baseline	JJ
cord-016476-78r0rsio	401	3	FVC	fvc	NN
cord-016476-78r0rsio	401	4	and	and	CC
cord-016476-78r0rsio	401	5	DLCO	DLCO	NNP
cord-016476-78r0rsio	401	6	(	(	-LRB-
cord-016476-78r0rsio	401	7	FVC	FVC	NNP
cord-016476-78r0rsio	401	8	<	<	XX
cord-016476-78r0rsio	401	9	60	60	CD
cord-016476-78r0rsio	401	10	%	%	NN
cord-016476-78r0rsio	401	11	and	and	CC
cord-016476-78r0rsio	401	12	DLCO	dlco	RB
cord-016476-78r0rsio	401	13	<	<	XX
cord-016476-78r0rsio	401	14	40	40	CD
cord-016476-78r0rsio	401	15	%	%	NN
cord-016476-78r0rsio	401	16	of	of	IN
cord-016476-78r0rsio	401	17	predicted	predict	VBN
cord-016476-78r0rsio	401	18	values	value	NNS
cord-016476-78r0rsio	401	19	)	)	-RRB-
cord-016476-78r0rsio	401	20	are	be	VBP
cord-016476-78r0rsio	401	21	independent	independent	JJ
cord-016476-78r0rsio	401	22	predictors	predictor	NNS
cord-016476-78r0rsio	401	23	of	of	IN
cord-016476-78r0rsio	401	24	early	early	JJ
cord-016476-78r0rsio	401	25	death	death	NN
cord-016476-78r0rsio	401	26	in	in	IN
cord-016476-78r0rsio	401	27	patients	patient	NNS
cord-016476-78r0rsio	401	28	with	with	IN
cord-016476-78r0rsio	401	29	IPF	IPF	NNP
cord-016476-78r0rsio	401	30	[	[	-LRB-
cord-016476-78r0rsio	401	31	195	195	CD
cord-016476-78r0rsio	401	32	,	,	,
cord-016476-78r0rsio	401	33	196	196	CD
cord-016476-78r0rsio	401	34	]	]	-RRB-
cord-016476-78r0rsio	401	35	.	.	.
cord-016476-78r0rsio	402	1	Importantly	importantly	RB
cord-016476-78r0rsio	402	2	,	,	,
cord-016476-78r0rsio	402	3	a	a	DT
cord-016476-78r0rsio	402	4	6	6	CD
cord-016476-78r0rsio	402	5	-	-	HYPH
cord-016476-78r0rsio	402	6	12-month	12-month	JJ
cord-016476-78r0rsio	402	7	decline	decline	NN
cord-016476-78r0rsio	402	8	in	in	IN
cord-016476-78r0rsio	402	9	FVC	FVC	NNP
cord-016476-78r0rsio	402	10	of	of	IN
cord-016476-78r0rsio	402	11	≥10	≥10	NNP
cord-016476-78r0rsio	402	12	%	%	NN
cord-016476-78r0rsio	402	13	,	,	,
cord-016476-78r0rsio	402	14	or	or	CC
cord-016476-78r0rsio	402	15	a	a	DT
cord-016476-78r0rsio	402	16	decline	decline	NN
cord-016476-78r0rsio	402	17	in	in	IN
cord-016476-78r0rsio	402	18	DLCO	DLCO	NNP
cord-016476-78r0rsio	402	19	of	of	IN
cord-016476-78r0rsio	402	20	≥15	≥15	NNP
cord-016476-78r0rsio	402	21	%	%	NN
cord-016476-78r0rsio	402	22	,	,	,
cord-016476-78r0rsio	402	23	is	be	VBZ
cord-016476-78r0rsio	402	24	associated	associate	VBN
cord-016476-78r0rsio	402	25	with	with	IN
cord-016476-78r0rsio	402	26	increased	increase	VBN
cord-016476-78r0rsio	402	27	mortality	mortality	NN
cord-016476-78r0rsio	402	28	in	in	IN
cord-016476-78r0rsio	402	29	IPF	IPF	NNP
cord-016476-78r0rsio	402	30	[	[	-LRB-
cord-016476-78r0rsio	402	31	200	200	CD
cord-016476-78r0rsio	402	32	]	]	-RRB-
cord-016476-78r0rsio	402	33	;	;	:
cord-016476-78r0rsio	402	34	this	this	DT
cord-016476-78r0rsio	402	35	association	association	NN
cord-016476-78r0rsio	402	36	might	may	MD
cord-016476-78r0rsio	402	37	also	also	RB
cord-016476-78r0rsio	402	38	exist	exist	VB
cord-016476-78r0rsio	402	39	in	in	IN
cord-016476-78r0rsio	402	40	patients	patient	NNS
cord-016476-78r0rsio	402	41	with	with	IN
cord-016476-78r0rsio	402	42	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	402	43	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	402	44	NSIP	NSIP	NNP
cord-016476-78r0rsio	402	45	.	.	.
cord-016476-78r0rsio	403	1	bDMARDs	bDMARDs	NNP
cord-016476-78r0rsio	403	2	biologic	biologic	JJ
cord-016476-78r0rsio	403	3	disease	disease	NN
cord-016476-78r0rsio	403	4	-	-	HYPH
cord-016476-78r0rsio	403	5	modifying	modify	VBG
cord-016476-78r0rsio	403	6	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	403	7	drugs	drug	NNS
cord-016476-78r0rsio	403	8	,	,	,
cord-016476-78r0rsio	403	9	DLCO	dlco	RB
cord-016476-78r0rsio	403	10	diffusing	diffuse	VBG
cord-016476-78r0rsio	403	11	capacity	capacity	NN
cord-016476-78r0rsio	403	12	of	of	IN
cord-016476-78r0rsio	403	13	the	the	DT
cord-016476-78r0rsio	403	14	lungs	lung	NNS
cord-016476-78r0rsio	403	15	for	for	IN
cord-016476-78r0rsio	403	16	carbon	carbon	NN
cord-016476-78r0rsio	403	17	monoxide	monoxide	NN
cord-016476-78r0rsio	403	18	,	,	,
cord-016476-78r0rsio	403	19	FVC	FVC	NNP
cord-016476-78r0rsio	403	20	forced	force	VBD
cord-016476-78r0rsio	403	21	vital	vital	JJ
cord-016476-78r0rsio	403	22	capacity	capacity	NN
cord-016476-78r0rsio	403	23	,	,	,
cord-016476-78r0rsio	403	24	ILD	ILD	NNP
cord-016476-78r0rsio	403	25	interstitial	interstitial	JJ
cord-016476-78r0rsio	403	26	lung	lung	NN
cord-016476-78r0rsio	403	27	disease	disease	NN
cord-016476-78r0rsio	403	28	,	,	,
cord-016476-78r0rsio	403	29	HRCT	HRCT	NNP
cord-016476-78r0rsio	403	30	highresolution	highresolution	NN
cord-016476-78r0rsio	403	31	computed	compute	VBD
cord-016476-78r0rsio	403	32	tomography	tomography	NNP
cord-016476-78r0rsio	403	33	,	,	,
cord-016476-78r0rsio	403	34	nbDMARDs	nbdmards	FW
cord-016476-78r0rsio	403	35	non	non	JJ
cord-016476-78r0rsio	403	36	-	-	JJ
cord-016476-78r0rsio	403	37	biologic	biologic	JJ
cord-016476-78r0rsio	403	38	disease	disease	NN
cord-016476-78r0rsio	403	39	-	-	HYPH
cord-016476-78r0rsio	403	40	modifying	modify	VBG
cord-016476-78r0rsio	403	41	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	403	42	drugs	drug	NNS
cord-016476-78r0rsio	403	43	,	,	,
cord-016476-78r0rsio	403	44	PFTs	pft	NNS
cord-016476-78r0rsio	403	45	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	403	46	function	function	NN
cord-016476-78r0rsio	403	47	tests	test	NNS
cord-016476-78r0rsio	403	48	,	,	,
cord-016476-78r0rsio	403	49	TB	TB	NNP
cord-016476-78r0rsio	403	50	tuberculosis	tuberculosis	NN
cord-016476-78r0rsio	403	51	,	,	,
cord-016476-78r0rsio	403	52	UIP	UIP	NNP
cord-016476-78r0rsio	403	53	usual	usual	JJ
cord-016476-78r0rsio	403	54	interstitial	interstitial	JJ
cord-016476-78r0rsio	403	55	pneumonia	pneumonia	NN
cord-016476-78r0rsio	403	56	HRCT	HRCT	NNP
cord-016476-78r0rsio	403	57	imaging	imaging	NN
cord-016476-78r0rsio	403	58	is	be	VBZ
cord-016476-78r0rsio	403	59	indicated	indicate	VBN
cord-016476-78r0rsio	403	60	in	in	IN
cord-016476-78r0rsio	403	61	patients	patient	NNS
cord-016476-78r0rsio	403	62	with	with	IN
cord-016476-78r0rsio	403	63	RA	RA	NNP
cord-016476-78r0rsio	403	64	-	-	HYPH
cord-016476-78r0rsio	403	65	ILD	ILD	NNP
cord-016476-78r0rsio	403	66	clinical	clinical	JJ
cord-016476-78r0rsio	403	67	features	feature	NNS
cord-016476-78r0rsio	403	68	or	or	CC
cord-016476-78r0rsio	403	69	in	in	IN
cord-016476-78r0rsio	403	70	asymptomatic	asymptomatic	JJ
cord-016476-78r0rsio	403	71	patients	patient	NNS
cord-016476-78r0rsio	403	72	with	with	IN
cord-016476-78r0rsio	403	73	a	a	DT
cord-016476-78r0rsio	403	74	DLCO	dlco	NN
cord-016476-78r0rsio	403	75	of	of	IN
cord-016476-78r0rsio	403	76	<	<	$
cord-016476-78r0rsio	403	77	70	70	CD
cord-016476-78r0rsio	403	78	%	%	NN
cord-016476-78r0rsio	403	79	of	of	IN
cord-016476-78r0rsio	403	80	predicted	predict	VBN
cord-016476-78r0rsio	403	81	[	[	-LRB-
cord-016476-78r0rsio	403	82	201	201	CD
cord-016476-78r0rsio	403	83	]	]	-RRB-
cord-016476-78r0rsio	403	84	.	.	.
cord-016476-78r0rsio	404	1	Individuals	individual	NNS
cord-016476-78r0rsio	404	2	with	with	IN
cord-016476-78r0rsio	404	3	HRCT	HRCT	NNP
cord-016476-78r0rsio	404	4	findings	finding	NNS
cord-016476-78r0rsio	404	5	consistent	consistent	JJ
cord-016476-78r0rsio	404	6	with	with	IN
cord-016476-78r0rsio	404	7	UIP	UIP	NNP
cord-016476-78r0rsio	404	8	,	,	,
cord-016476-78r0rsio	404	9	such	such	JJ
cord-016476-78r0rsio	404	10	as	as	IN
cord-016476-78r0rsio	404	11	basally	basally	RB
cord-016476-78r0rsio	404	12	dominant	dominant	JJ
cord-016476-78r0rsio	404	13	honeycomb	honeycomb	NN
cord-016476-78r0rsio	404	14	cysts	cyst	NNS
cord-016476-78r0rsio	404	15	with	with	IN
cord-016476-78r0rsio	404	16	little	little	JJ
cord-016476-78r0rsio	404	17	or	or	CC
cord-016476-78r0rsio	404	18	no	no	DT
cord-016476-78r0rsio	404	19	ground	ground	NN
cord-016476-78r0rsio	404	20	-	-	HYPH
cord-016476-78r0rsio	404	21	glass	glass	NN
cord-016476-78r0rsio	404	22	change	change	NN
cord-016476-78r0rsio	404	23	,	,	,
cord-016476-78r0rsio	404	24	have	have	VBP
cord-016476-78r0rsio	404	25	poorer	poor	JJR
cord-016476-78r0rsio	404	26	prognosis	prognosis	NN
cord-016476-78r0rsio	404	27	than	than	IN
cord-016476-78r0rsio	404	28	those	those	DT
cord-016476-78r0rsio	404	29	with	with	IN
cord-016476-78r0rsio	404	30	HRCT	HRCT	NNP
cord-016476-78r0rsio	404	31	-	-	HYPH
cord-016476-78r0rsio	404	32	detected	detect	VBN
cord-016476-78r0rsio	404	33	features	feature	NNS
cord-016476-78r0rsio	404	34	indicative	indicative	JJ
cord-016476-78r0rsio	404	35	of	of	IN
cord-016476-78r0rsio	404	36	other	other	JJ
cord-016476-78r0rsio	404	37	types	type	NNS
cord-016476-78r0rsio	404	38	of	of	IN
cord-016476-78r0rsio	404	39	IIP	IIP	NNP
cord-016476-78r0rsio	404	40	[	[	-LRB-
cord-016476-78r0rsio	404	41	142	142	CD
cord-016476-78r0rsio	404	42	,	,	,
cord-016476-78r0rsio	404	43	202	202	CD
cord-016476-78r0rsio	404	44	]	]	-RRB-
cord-016476-78r0rsio	404	45	.	.	.
cord-016476-78r0rsio	405	1	In	in	IN
cord-016476-78r0rsio	405	2	SSc	SSc	NNP
cord-016476-78r0rsio	405	3	-	-	HYPH
cord-016476-78r0rsio	405	4	ILD	ILD	NNP
cord-016476-78r0rsio	405	5	,	,	,
cord-016476-78r0rsio	405	6	an	an	DT
cord-016476-78r0rsio	405	7	HRCT	HRCT	NNP
cord-016476-78r0rsio	405	8	-	-	HYPH
cord-016476-78r0rsio	405	9	based	base	VBN
cord-016476-78r0rsio	405	10	prognostic	prognostic	JJ
cord-016476-78r0rsio	405	11	staging	staging	NN
cord-016476-78r0rsio	405	12	system	system	NN
cord-016476-78r0rsio	405	13	has	have	VBZ
cord-016476-78r0rsio	405	14	been	be	VBN
cord-016476-78r0rsio	405	15	developed	develop	VBN
cord-016476-78r0rsio	405	16	,	,	,
cord-016476-78r0rsio	405	17	categorising	categorise	VBG
cord-016476-78r0rsio	405	18	patients	patient	NNS
cord-016476-78r0rsio	405	19	as	as	IN
cord-016476-78r0rsio	405	20	having	have	VBG
cord-016476-78r0rsio	405	21	limited	limit	VBN
cord-016476-78r0rsio	405	22	(	(	-LRB-
cord-016476-78r0rsio	405	23	<	<	XX
cord-016476-78r0rsio	405	24	20	20	CD
cord-016476-78r0rsio	405	25	%	%	NN
cord-016476-78r0rsio	405	26	lung	lung	NN
cord-016476-78r0rsio	405	27	involvement	involvement	NN
cord-016476-78r0rsio	405	28	)	)	-RRB-
cord-016476-78r0rsio	405	29	or	or	CC
cord-016476-78r0rsio	405	30	extensive	extensive	JJ
cord-016476-78r0rsio	405	31	(	(	-LRB-
cord-016476-78r0rsio	405	32	>	>	NFP
cord-016476-78r0rsio	405	33	20	20	CD
cord-016476-78r0rsio	405	34	%	%	NN
cord-016476-78r0rsio	405	35	lung	lung	NN
cord-016476-78r0rsio	405	36	involvement	involvement	NN
cord-016476-78r0rsio	405	37	)	)	-RRB-
cord-016476-78r0rsio	406	1	SSc	SSc	NNP
cord-016476-78r0rsio	406	2	-	-	HYPH
cord-016476-78r0rsio	406	3	ILD	ILD	NNP
cord-016476-78r0rsio	406	4	,	,	,
cord-016476-78r0rsio	406	5	with	with	IN
cord-016476-78r0rsio	406	6	extensive	extensive	JJ
cord-016476-78r0rsio	406	7	disease	disease	NN
cord-016476-78r0rsio	406	8	found	find	VBN
cord-016476-78r0rsio	406	9	to	to	TO
cord-016476-78r0rsio	406	10	be	be	VB
cord-016476-78r0rsio	406	11	a	a	DT
cord-016476-78r0rsio	406	12	strong	strong	JJ
cord-016476-78r0rsio	406	13	predictor	predictor	NN
cord-016476-78r0rsio	406	14	of	of	IN
cord-016476-78r0rsio	406	15	mortality	mortality	NN
cord-016476-78r0rsio	406	16	[	[	-LRB-
cord-016476-78r0rsio	406	17	203	203	CD
cord-016476-78r0rsio	406	18	]	]	-RRB-
cord-016476-78r0rsio	406	19	.	.	.
cord-016476-78r0rsio	407	1	Similarly	similarly	RB
cord-016476-78r0rsio	407	2	quantifying	quantify	VBG
cord-016476-78r0rsio	407	3	the	the	DT
cord-016476-78r0rsio	407	4	extent	extent	NN
cord-016476-78r0rsio	407	5	of	of	IN
cord-016476-78r0rsio	407	6	fibrosis	fibrosis	NN
cord-016476-78r0rsio	407	7	and	and	CC
cord-016476-78r0rsio	407	8	disease	disease	NN
cord-016476-78r0rsio	407	9	on	on	IN
cord-016476-78r0rsio	407	10	HRCT	HRCT	NNP
cord-016476-78r0rsio	407	11	has	have	VBZ
cord-016476-78r0rsio	407	12	been	be	VBN
cord-016476-78r0rsio	407	13	shown	show	VBN
cord-016476-78r0rsio	407	14	to	to	TO
cord-016476-78r0rsio	407	15	predict	predict	VB
cord-016476-78r0rsio	407	16	disease	disease	NN
cord-016476-78r0rsio	407	17	progression	progression	NN
cord-016476-78r0rsio	407	18	in	in	IN
cord-016476-78r0rsio	407	19	IPF	IPF	NNP
cord-016476-78r0rsio	407	20	[	[	-LRB-
cord-016476-78r0rsio	407	21	204	204	CD
cord-016476-78r0rsio	407	22	]	]	-RRB-
cord-016476-78r0rsio	407	23	.	.	.
cord-016476-78r0rsio	408	1	No	no	DT
cord-016476-78r0rsio	408	2	comparable	comparable	JJ
cord-016476-78r0rsio	408	3	studies	study	NNS
cord-016476-78r0rsio	408	4	have	have	VBP
cord-016476-78r0rsio	408	5	assessed	assess	VBN
cord-016476-78r0rsio	408	6	the	the	DT
cord-016476-78r0rsio	408	7	use	use	NN
cord-016476-78r0rsio	408	8	of	of	IN
cord-016476-78r0rsio	408	9	similar	similar	JJ
cord-016476-78r0rsio	408	10	HRCT	HRCT	NNP
cord-016476-78r0rsio	408	11	-	-	HYPH
cord-016476-78r0rsio	408	12	based	base	VBN
cord-016476-78r0rsio	408	13	scoring	scoring	NN
cord-016476-78r0rsio	408	14	in	in	IN
cord-016476-78r0rsio	408	15	RA	RA	NNP
cord-016476-78r0rsio	408	16	-	-	HYPH
cord-016476-78r0rsio	408	17	ILD	ILD	NNP
cord-016476-78r0rsio	408	18	,	,	,
cord-016476-78r0rsio	408	19	although	although	IN
cord-016476-78r0rsio	408	20	a	a	DT
cord-016476-78r0rsio	408	21	small	small	JJ
cord-016476-78r0rsio	408	22	study	study	NN
cord-016476-78r0rsio	408	23	suggested	suggest	VBD
cord-016476-78r0rsio	408	24	that	that	IN
cord-016476-78r0rsio	408	25	the	the	DT
cord-016476-78r0rsio	408	26	degree	degree	NN
cord-016476-78r0rsio	408	27	of	of	IN
cord-016476-78r0rsio	408	28	interstitial	interstitial	JJ
cord-016476-78r0rsio	408	29	changes	change	NNS
cord-016476-78r0rsio	408	30	detected	detect	VBD
cord-016476-78r0rsio	408	31	using	use	VBG
cord-016476-78r0rsio	408	32	HRCT	HRCT	NNP
cord-016476-78r0rsio	408	33	imaging	imaging	NN
cord-016476-78r0rsio	408	34	was	be	VBD
cord-016476-78r0rsio	408	35	predictive	predictive	JJ
cord-016476-78r0rsio	408	36	of	of	IN
cord-016476-78r0rsio	408	37	prognosis	prognosis	NN
cord-016476-78r0rsio	408	38	[	[	-LRB-
cord-016476-78r0rsio	408	39	205	205	CD
cord-016476-78r0rsio	408	40	]	]	-RRB-
cord-016476-78r0rsio	408	41	.	.	.
cord-016476-78r0rsio	409	1	On	on	IN
cord-016476-78r0rsio	409	2	the	the	DT
cord-016476-78r0rsio	409	3	basis	basis	NN
cord-016476-78r0rsio	409	4	of	of	IN
cord-016476-78r0rsio	409	5	these	these	DT
cord-016476-78r0rsio	409	6	factors	factor	NNS
cord-016476-78r0rsio	409	7	,	,	,
cord-016476-78r0rsio	409	8	the	the	DT
cord-016476-78r0rsio	409	9	authors	author	NNS
cord-016476-78r0rsio	409	10	have	have	VBP
cord-016476-78r0rsio	409	11	previously	previously	RB
cord-016476-78r0rsio	409	12	proposed	propose	VBN
cord-016476-78r0rsio	409	13	a	a	DT
cord-016476-78r0rsio	409	14	framework	framework	NN
cord-016476-78r0rsio	409	15	for	for	IN
cord-016476-78r0rsio	409	16	assessment	assessment	NN
cord-016476-78r0rsio	409	17	of	of	IN
cord-016476-78r0rsio	409	18	RA	RA	NNP
cord-016476-78r0rsio	409	19	-	-	HYPH
cord-016476-78r0rsio	409	20	ILD	ILD	NNP
cord-016476-78r0rsio	409	21	,	,	,
cord-016476-78r0rsio	409	22	risk	risk	NN
cord-016476-78r0rsio	409	23	assessment	assessment	NN
cord-016476-78r0rsio	409	24	before	before	IN
cord-016476-78r0rsio	409	25	initiation	initiation	NN
cord-016476-78r0rsio	409	26	of	of	IN
cord-016476-78r0rsio	409	27	biologic	biologic	JJ
cord-016476-78r0rsio	409	28	therapy	therapy	NN
cord-016476-78r0rsio	409	29	and	and	CC
cord-016476-78r0rsio	409	30	post	post	JJ
cord-016476-78r0rsio	409	31	-	-	JJ
cord-016476-78r0rsio	409	32	treatment	treatment	JJ
cord-016476-78r0rsio	409	33	monitoring	monitoring	NN
cord-016476-78r0rsio	409	34	[	[	-LRB-
cord-016476-78r0rsio	409	35	206	206	CD
cord-016476-78r0rsio	409	36	]	]	-RRB-
cord-016476-78r0rsio	410	1	(	(	-LRB-
cord-016476-78r0rsio	410	2	Fig	Fig	NNP
cord-016476-78r0rsio	410	3	.	.	.
cord-016476-78r0rsio	410	4	9.1	9.1	CD
cord-016476-78r0rsio	410	5	)	)	-RRB-
cord-016476-78r0rsio	410	6	.	.	.
cord-016476-78r0rsio	411	1	The	the	DT
cord-016476-78r0rsio	411	2	proposed	propose	VBN
cord-016476-78r0rsio	411	3	approach	approach	NN
cord-016476-78r0rsio	411	4	is	be	VBZ
cord-016476-78r0rsio	411	5	designed	design	VBN
cord-016476-78r0rsio	411	6	to	to	TO
cord-016476-78r0rsio	411	7	help	help	VB
cord-016476-78r0rsio	411	8	predict	predict	VB
cord-016476-78r0rsio	411	9	short	short	JJ
cord-016476-78r0rsio	411	10	-	-	HYPH
cord-016476-78r0rsio	411	11	term	term	NN
cord-016476-78r0rsio	411	12	progression	progression	NN
cord-016476-78r0rsio	411	13	of	of	IN
cord-016476-78r0rsio	411	14	ILD	ILD	NNP
cord-016476-78r0rsio	411	15	irrespective	irrespective	RB
cord-016476-78r0rsio	411	16	of	of	IN
cord-016476-78r0rsio	411	17	biologic	biologic	JJ
cord-016476-78r0rsio	411	18	therapy	therapy	NN
cord-016476-78r0rsio	411	19	.	.	.
cord-016476-78r0rsio	412	1	In	in	IN
cord-016476-78r0rsio	412	2	patients	patient	NNS
cord-016476-78r0rsio	412	3	at	at	IN
cord-016476-78r0rsio	412	4	higher	high	JJR
cord-016476-78r0rsio	412	5	risk	risk	NN
cord-016476-78r0rsio	412	6	of	of	IN
cord-016476-78r0rsio	412	7	progression	progression	NN
cord-016476-78r0rsio	412	8	,	,	,
cord-016476-78r0rsio	412	9	even	even	RB
cord-016476-78r0rsio	412	10	in	in	IN
cord-016476-78r0rsio	412	11	patients	patient	NNS
cord-016476-78r0rsio	412	12	who	who	WP
cord-016476-78r0rsio	412	13	appear	appear	VBP
cord-016476-78r0rsio	412	14	to	to	TO
cord-016476-78r0rsio	412	15	have	have	VB
cord-016476-78r0rsio	412	16	stable	stable	JJ
cord-016476-78r0rsio	412	17	lung	lung	NN
cord-016476-78r0rsio	412	18	disease	disease	NN
cord-016476-78r0rsio	412	19	over	over	IN
cord-016476-78r0rsio	412	20	a	a	DT
cord-016476-78r0rsio	412	21	one	one	CD
cord-016476-78r0rsio	412	22	-	-	HYPH
cord-016476-78r0rsio	412	23	or	or	CC
cord-016476-78r0rsio	412	24	two	two	CD
cord-016476-78r0rsio	412	25	-	-	HYPH
cord-016476-78r0rsio	412	26	year	year	NN
cord-016476-78r0rsio	412	27	period	period	NN
cord-016476-78r0rsio	412	28	,	,	,
cord-016476-78r0rsio	412	29	treatment	treatment	NN
cord-016476-78r0rsio	412	30	decisions	decision	NNS
cord-016476-78r0rsio	412	31	should	should	MD
cord-016476-78r0rsio	412	32	involve	involve	VB
cord-016476-78r0rsio	412	33	a	a	DT
cord-016476-78r0rsio	412	34	multidisciplinary	multidisciplinary	JJ
cord-016476-78r0rsio	412	35	approach	approach	NN
cord-016476-78r0rsio	412	36	including	include	VBG
cord-016476-78r0rsio	412	37	a	a	DT
cord-016476-78r0rsio	412	38	respiratory	respiratory	JJ
cord-016476-78r0rsio	412	39	physician	physician	NN
cord-016476-78r0rsio	412	40	as	as	RB
cord-016476-78r0rsio	412	41	well	well	RB
cord-016476-78r0rsio	412	42	as	as	IN
cord-016476-78r0rsio	412	43	a	a	DT
cord-016476-78r0rsio	412	44	careful	careful	JJ
cord-016476-78r0rsio	412	45	discussion	discussion	NN
cord-016476-78r0rsio	412	46	with	with	IN
cord-016476-78r0rsio	412	47	the	the	DT
cord-016476-78r0rsio	412	48	patient	patient	NN
cord-016476-78r0rsio	412	49	regarding	regard	VBG
cord-016476-78r0rsio	412	50	the	the	DT
cord-016476-78r0rsio	412	51	benefits	benefit	NNS
cord-016476-78r0rsio	412	52	and	and	CC
cord-016476-78r0rsio	412	53	risks	risk	NNS
cord-016476-78r0rsio	412	54	of	of	IN
cord-016476-78r0rsio	412	55	treatment	treatment	NN
cord-016476-78r0rsio	412	56	options	option	NNS
cord-016476-78r0rsio	412	57	available	available	JJ
cord-016476-78r0rsio	412	58	.	.	.
cord-016476-78r0rsio	413	1	In	in	IN
cord-016476-78r0rsio	413	2	all	all	DT
cord-016476-78r0rsio	413	3	patients	patient	NNS
cord-016476-78r0rsio	413	4	,	,	,
cord-016476-78r0rsio	413	5	including	include	VBG
cord-016476-78r0rsio	413	6	those	those	DT
cord-016476-78r0rsio	413	7	with	with	IN
cord-016476-78r0rsio	413	8	self	self	NN
cord-016476-78r0rsio	413	9	-	-	HYPH
cord-016476-78r0rsio	413	10	limiting	limit	VBG
cord-016476-78r0rsio	413	11	and	and	CC
cord-016476-78r0rsio	413	12	stable	stable	JJ
cord-016476-78r0rsio	413	13	RA	RA	NNP
cord-016476-78r0rsio	413	14	-	-	HYPH
cord-016476-78r0rsio	413	15	ILD	ILD	NNP
cord-016476-78r0rsio	413	16	on	on	IN
cord-016476-78r0rsio	413	17	treatment	treatment	NN
cord-016476-78r0rsio	413	18	for	for	IN
cord-016476-78r0rsio	413	19	their	-PRON-	PRP$
cord-016476-78r0rsio	413	20	joint	joint	JJ
cord-016476-78r0rsio	413	21	disease	disease	NN
cord-016476-78r0rsio	413	22	,	,	,
cord-016476-78r0rsio	413	23	rheumatologists	rheumatologist	NNS
cord-016476-78r0rsio	413	24	should	should	MD
cord-016476-78r0rsio	413	25	prompt	prompt	VB
cord-016476-78r0rsio	413	26	questioning	questioning	NN
cord-016476-78r0rsio	413	27	of	of	IN
cord-016476-78r0rsio	413	28	new	new	JJ
cord-016476-78r0rsio	413	29	or	or	CC
cord-016476-78r0rsio	413	30	evolving	evolve	VBG
cord-016476-78r0rsio	413	31	respiratory	respiratory	JJ
cord-016476-78r0rsio	413	32	symptoms	symptom	NNS
cord-016476-78r0rsio	413	33	at	at	IN
cord-016476-78r0rsio	413	34	follow	follow	NN
cord-016476-78r0rsio	413	35	-	-	HYPH
cord-016476-78r0rsio	413	36	up	up	NN
cord-016476-78r0rsio	413	37	,	,	,
cord-016476-78r0rsio	413	38	as	as	IN
cord-016476-78r0rsio	413	39	patients	patient	NNS
cord-016476-78r0rsio	413	40	may	may	MD
cord-016476-78r0rsio	413	41	not	not	RB
cord-016476-78r0rsio	413	42	spontaneously	spontaneously	RB
cord-016476-78r0rsio	413	43	disclose	disclose	VB
cord-016476-78r0rsio	413	44	such	such	JJ
cord-016476-78r0rsio	413	45	information	information	NN
cord-016476-78r0rsio	413	46	.	.	.
cord-016476-78r0rsio	414	1	All	all	DT
cord-016476-78r0rsio	414	2	patients	patient	NNS
cord-016476-78r0rsio	414	3	who	who	WP
cord-016476-78r0rsio	414	4	smoke	smoke	VBP
cord-016476-78r0rsio	414	5	should	should	MD
cord-016476-78r0rsio	414	6	be	be	VB
cord-016476-78r0rsio	414	7	educated	educate	VBN
cord-016476-78r0rsio	414	8	about	about	IN
cord-016476-78r0rsio	414	9	the	the	DT
cord-016476-78r0rsio	414	10	important	important	JJ
cord-016476-78r0rsio	414	11	associated	associate	VBN
cord-016476-78r0rsio	414	12	risks	risk	NNS
cord-016476-78r0rsio	414	13	.	.	.
cord-016476-78r0rsio	415	1	Whilst	whilst	IN
cord-016476-78r0rsio	415	2	being	be	VBG
cord-016476-78r0rsio	415	3	implicated	implicate	VBN
cord-016476-78r0rsio	415	4	in	in	IN
cord-016476-78r0rsio	415	5	the	the	DT
cord-016476-78r0rsio	415	6	pathogenesis	pathogenesis	NN
cord-016476-78r0rsio	415	7	of	of	IN
cord-016476-78r0rsio	415	8	RA	RA	NNP
cord-016476-78r0rsio	415	9	-	-	HYPH
cord-016476-78r0rsio	415	10	ILD	ILD	NNP
cord-016476-78r0rsio	415	11	,	,	,
cord-016476-78r0rsio	415	12	it	-PRON-	PRP
cord-016476-78r0rsio	415	13	may	may	MD
cord-016476-78r0rsio	415	14	also	also	RB
cord-016476-78r0rsio	415	15	lead	lead	VB
cord-016476-78r0rsio	415	16	to	to	IN
cord-016476-78r0rsio	415	17	deterioration	deterioration	NN
cord-016476-78r0rsio	415	18	of	of	IN
cord-016476-78r0rsio	415	19	lung	lung	NN
cord-016476-78r0rsio	415	20	disease	disease	NN
cord-016476-78r0rsio	415	21	and	and	CC
cord-016476-78r0rsio	415	22	is	be	VBZ
cord-016476-78r0rsio	415	23	associated	associate	VBN
cord-016476-78r0rsio	415	24	with	with	IN
cord-016476-78r0rsio	415	25	higher	high	JJR
cord-016476-78r0rsio	415	26	joint	joint	JJ
cord-016476-78r0rsio	415	27	disease	disease	NN
cord-016476-78r0rsio	415	28	activity	activity	NN
cord-016476-78r0rsio	415	29	and	and	CC
cord-016476-78r0rsio	415	30	reduction	reduction	NN
cord-016476-78r0rsio	415	31	in	in	IN
cord-016476-78r0rsio	415	32	the	the	DT
cord-016476-78r0rsio	415	33	effectiveness	effectiveness	NN
cord-016476-78r0rsio	415	34	of	of	IN
cord-016476-78r0rsio	415	35	medications	medication	NNS
cord-016476-78r0rsio	415	36	such	such	JJ
cord-016476-78r0rsio	415	37	as	as	IN
cord-016476-78r0rsio	415	38	MTX	MTX	NNP
cord-016476-78r0rsio	415	39	and	and	CC
cord-016476-78r0rsio	415	40	TNFi	tnfi	JJ
cord-016476-78r0rsio	415	41	drugs	drug	NNS
cord-016476-78r0rsio	415	42	[	[	-LRB-
cord-016476-78r0rsio	415	43	207	207	CD
cord-016476-78r0rsio	415	44	]	]	-RRB-
cord-016476-78r0rsio	415	45	.	.	.
cord-016476-78r0rsio	416	1	Smoking	smoke	VBG
cord-016476-78r0rsio	416	2	cessation	cessation	NN
cord-016476-78r0rsio	416	3	advice	advice	NN
cord-016476-78r0rsio	416	4	and	and	CC
cord-016476-78r0rsio	416	5	further	further	JJ
cord-016476-78r0rsio	416	6	support	support	NN
cord-016476-78r0rsio	416	7	such	such	JJ
cord-016476-78r0rsio	416	8	as	as	IN
cord-016476-78r0rsio	416	9	nicotine	nicotine	NN
cord-016476-78r0rsio	416	10	replacement	replacement	NN
cord-016476-78r0rsio	416	11	therapy	therapy	NN
cord-016476-78r0rsio	416	12	should	should	MD
cord-016476-78r0rsio	416	13	be	be	VB
cord-016476-78r0rsio	416	14	made	make	VBN
cord-016476-78r0rsio	416	15	available	available	JJ
cord-016476-78r0rsio	416	16	for	for	IN
cord-016476-78r0rsio	416	17	all	all	DT
cord-016476-78r0rsio	416	18	patients	patient	NNS
cord-016476-78r0rsio	416	19	with	with	IN
cord-016476-78r0rsio	416	20	RA	RA	NNP
cord-016476-78r0rsio	416	21	-	-	HYPH
cord-016476-78r0rsio	416	22	ILD	ILD	NNP
cord-016476-78r0rsio	416	23	[	[	-LRB-
cord-016476-78r0rsio	416	24	159	159	CD
cord-016476-78r0rsio	416	25	]	]	-RRB-
cord-016476-78r0rsio	416	26	.	.	.
cord-016476-78r0rsio	417	1	Following	follow	VBG
cord-016476-78r0rsio	417	2	an	an	DT
cord-016476-78r0rsio	417	3	adequate	adequate	JJ
cord-016476-78r0rsio	417	4	period	period	NN
cord-016476-78r0rsio	417	5	of	of	IN
cord-016476-78r0rsio	417	6	monitored	monitored	JJ
cord-016476-78r0rsio	417	7	observation	observation	NN
cord-016476-78r0rsio	417	8	,	,	,
cord-016476-78r0rsio	417	9	classification	classification	NN
cord-016476-78r0rsio	417	10	of	of	IN
cord-016476-78r0rsio	417	11	the	the	DT
cord-016476-78r0rsio	417	12	trajectory	trajectory	NN
cord-016476-78r0rsio	417	13	of	of	IN
cord-016476-78r0rsio	417	14	RA	RA	NNP
cord-016476-78r0rsio	417	15	-	-	HYPH
cord-016476-78r0rsio	417	16	ILD	ILD	NNP
cord-016476-78r0rsio	417	17	may	may	MD
cord-016476-78r0rsio	417	18	be	be	VB
cord-016476-78r0rsio	417	19	possible	possible	JJ
cord-016476-78r0rsio	417	20	in	in	IN
cord-016476-78r0rsio	417	21	the	the	DT
cord-016476-78r0rsio	417	22	individual	individual	JJ
cord-016476-78r0rsio	417	23	patient	patient	NN
cord-016476-78r0rsio	417	24	.	.	.
cord-016476-78r0rsio	418	1	In	in	IN
cord-016476-78r0rsio	418	2	patients	patient	NNS
cord-016476-78r0rsio	418	3	in	in	IN
cord-016476-78r0rsio	418	4	whom	whom	WP
cord-016476-78r0rsio	418	5	a	a	DT
cord-016476-78r0rsio	418	6	12	12	CD
cord-016476-78r0rsio	418	7	-	-	HYPH
cord-016476-78r0rsio	418	8	24-month	24-month	JJ
cord-016476-78r0rsio	418	9	period	period	NN
cord-016476-78r0rsio	418	10	of	of	IN
cord-016476-78r0rsio	418	11	stability	stability	NN
cord-016476-78r0rsio	418	12	is	be	VBZ
cord-016476-78r0rsio	418	13	observed	observe	VBN
cord-016476-78r0rsio	418	14	,	,	,
cord-016476-78r0rsio	418	15	PFT	PFT	NNP
cord-016476-78r0rsio	418	16	follow	follow	VB
cord-016476-78r0rsio	418	17	-	-	HYPH
cord-016476-78r0rsio	418	18	up	up	RP
cord-016476-78r0rsio	418	19	intervals	interval	NNS
cord-016476-78r0rsio	418	20	can	can	MD
cord-016476-78r0rsio	418	21	be	be	VB
cord-016476-78r0rsio	418	22	extended	extend	VBN
cord-016476-78r0rsio	418	23	to	to	IN
cord-016476-78r0rsio	418	24	12	12	CD
cord-016476-78r0rsio	418	25	monthly	monthly	NN
cord-016476-78r0rsio	418	26	.	.	.
cord-016476-78r0rsio	419	1	Routine	routine	JJ
cord-016476-78r0rsio	419	2	monitoring	monitoring	NN
cord-016476-78r0rsio	419	3	of	of	IN
cord-016476-78r0rsio	419	4	PFTs	pft	NNS
cord-016476-78r0rsio	419	5	is	be	VBZ
cord-016476-78r0rsio	419	6	suggested	suggest	VBN
cord-016476-78r0rsio	419	7	every	every	DT
cord-016476-78r0rsio	419	8	3	3	CD
cord-016476-78r0rsio	419	9	-	-	SYM
cord-016476-78r0rsio	419	10	6	6	CD
cord-016476-78r0rsio	419	11	months	month	NNS
cord-016476-78r0rsio	419	12	in	in	IN
cord-016476-78r0rsio	419	13	individuals	individual	NNS
cord-016476-78r0rsio	419	14	at	at	IN
cord-016476-78r0rsio	419	15	high	high	JJ
cord-016476-78r0rsio	419	16	risk	risk	NN
cord-016476-78r0rsio	419	17	of	of	IN
cord-016476-78r0rsio	419	18	progression	progression	NN
cord-016476-78r0rsio	419	19	of	of	IN
cord-016476-78r0rsio	419	20	RA	RA	NNP
cord-016476-78r0rsio	419	21	-	-	HYPH
cord-016476-78r0rsio	419	22	ILD	ILD	NNP
cord-016476-78r0rsio	419	23	or	or	CC
cord-016476-78r0rsio	419	24	on	on	IN
cord-016476-78r0rsio	419	25	any	any	DT
cord-016476-78r0rsio	419	26	biologic	biologic	JJ
cord-016476-78r0rsio	419	27	drug	drug	NN
cord-016476-78r0rsio	419	28	[	[	-LRB-
cord-016476-78r0rsio	419	29	206	206	CD
cord-016476-78r0rsio	419	30	]	]	-RRB-
cord-016476-78r0rsio	419	31	.	.	.
cord-016476-78r0rsio	420	1	An	an	DT
cord-016476-78r0rsio	420	2	observed	observed	JJ
cord-016476-78r0rsio	420	3	decline	decline	NN
cord-016476-78r0rsio	420	4	following	follow	VBG
cord-016476-78r0rsio	420	5	serial	serial	JJ
cord-016476-78r0rsio	420	6	PFTs	pft	NNS
cord-016476-78r0rsio	420	7	could	could	MD
cord-016476-78r0rsio	420	8	be	be	VB
cord-016476-78r0rsio	420	9	due	due	JJ
cord-016476-78r0rsio	420	10	to	to	IN
cord-016476-78r0rsio	420	11	progression	progression	NN
cord-016476-78r0rsio	420	12	of	of	IN
cord-016476-78r0rsio	420	13	RA	RA	NNP
cord-016476-78r0rsio	420	14	-	-	HYPH
cord-016476-78r0rsio	420	15	ILD	ILD	NNP
cord-016476-78r0rsio	420	16	,	,	,
cord-016476-78r0rsio	420	17	either	either	CC
cord-016476-78r0rsio	420	18	its	-PRON-	PRP$
cord-016476-78r0rsio	420	19	natural	natural	JJ
cord-016476-78r0rsio	420	20	[	[	-LRB-
cord-016476-78r0rsio	420	21	206	206	CD
cord-016476-78r0rsio	420	22	]	]	-RRB-
cord-016476-78r0rsio	420	23	history	history	NN
cord-016476-78r0rsio	420	24	or	or	CC
cord-016476-78r0rsio	420	25	accelerated	accelerate	VBN
cord-016476-78r0rsio	420	26	by	by	IN
cord-016476-78r0rsio	420	27	therapy	therapy	NN
cord-016476-78r0rsio	420	28	or	or	CC
cord-016476-78r0rsio	420	29	attributable	attributable	JJ
cord-016476-78r0rsio	420	30	to	to	IN
cord-016476-78r0rsio	420	31	other	other	JJ
cord-016476-78r0rsio	420	32	causes	cause	NNS
cord-016476-78r0rsio	420	33	that	that	WDT
cord-016476-78r0rsio	420	34	may	may	MD
cord-016476-78r0rsio	420	35	or	or	CC
cord-016476-78r0rsio	420	36	may	may	MD
cord-016476-78r0rsio	420	37	not	not	RB
cord-016476-78r0rsio	420	38	have	have	VB
cord-016476-78r0rsio	420	39	an	an	DT
cord-016476-78r0rsio	420	40	association	association	NN
cord-016476-78r0rsio	420	41	with	with	IN
cord-016476-78r0rsio	420	42	the	the	DT
cord-016476-78r0rsio	420	43	DMARD	DMARD	NNP
cord-016476-78r0rsio	420	44	prescribed	prescribe	VBN
cord-016476-78r0rsio	420	45	.	.	.
cord-016476-78r0rsio	420	46	'	'	''
cord-016476-78r0rsio	421	1	Reversible	reversible	JJ
cord-016476-78r0rsio	421	2	'	'	''
cord-016476-78r0rsio	421	3	decline	decline	NN
cord-016476-78r0rsio	421	4	has	have	VBZ
cord-016476-78r0rsio	421	5	been	be	VBN
cord-016476-78r0rsio	421	6	categorised	categorise	VBN
cord-016476-78r0rsio	421	7	into	into	IN
cord-016476-78r0rsio	421	8	potentially	potentially	RB
cord-016476-78r0rsio	421	9	reversible	reversible	JJ
cord-016476-78r0rsio	421	10	with	with	IN
cord-016476-78r0rsio	421	11	risk	risk	NN
cord-016476-78r0rsio	421	12	of	of	IN
cord-016476-78r0rsio	421	13	irreversible	irreversible	JJ
cord-016476-78r0rsio	421	14	disease	disease	NN
cord-016476-78r0rsio	421	15	(	(	-LRB-
cord-016476-78r0rsio	421	16	e.g.	e.g.	IN
cord-016476-78r0rsio	421	17	cases	case	NNS
cord-016476-78r0rsio	421	18	of	of	IN
cord-016476-78r0rsio	421	19	drug	drug	NN
cord-016476-78r0rsio	421	20	-	-	HYPH
cord-016476-78r0rsio	421	21	induced	induce	VBN
cord-016476-78r0rsio	421	22	lung	lung	NN
cord-016476-78r0rsio	421	23	disease	disease	NN
cord-016476-78r0rsio	421	24	)	)	-RRB-
cord-016476-78r0rsio	421	25	or	or	CC
cord-016476-78r0rsio	421	26	reversible	reversible	JJ
cord-016476-78r0rsio	421	27	disease	disease	NN
cord-016476-78r0rsio	421	28	with	with	IN
cord-016476-78r0rsio	421	29	risk	risk	NN
cord-016476-78r0rsio	421	30	of	of	IN
cord-016476-78r0rsio	421	31	progression	progression	NN
cord-016476-78r0rsio	421	32	(	(	-LRB-
cord-016476-78r0rsio	421	33	e.g.	e.g.	RB
cord-016476-78r0rsio	421	34	RA	ra	NN
cord-016476-78r0rsio	421	35	-	-	HYPH
cord-016476-78r0rsio	421	36	cellular	cellular	JJ
cord-016476-78r0rsio	421	37	NSIP	NSIP	NNP
cord-016476-78r0rsio	421	38	,	,	,
cord-016476-78r0rsio	421	39	some	some	DT
cord-016476-78r0rsio	421	40	RA	ra	NN
cord-016476-78r0rsio	421	41	-	-	HYPH
cord-016476-78r0rsio	421	42	fibrotic	fibrotic	JJ
cord-016476-78r0rsio	421	43	NSIP	NSIP	NNP
cord-016476-78r0rsio	421	44	,	,	,
cord-016476-78r0rsio	421	45	RA	RA	NNP
cord-016476-78r0rsio	421	46	-	-	HYPH
cord-016476-78r0rsio	421	47	organising	organise	VBG
cord-016476-78r0rsio	421	48	pneumonia	pneumonia	NN
cord-016476-78r0rsio	421	49	)	)	-RRB-
cord-016476-78r0rsio	421	50	[	[	-LRB-
cord-016476-78r0rsio	421	51	143	143	CD
cord-016476-78r0rsio	421	52	]	]	-RRB-
cord-016476-78r0rsio	421	53	.	.	.
cord-016476-78r0rsio	422	1	Management	management	NN
cord-016476-78r0rsio	422	2	strategy	strategy	NN
cord-016476-78r0rsio	422	3	for	for	IN
cord-016476-78r0rsio	422	4	the	the	DT
cord-016476-78r0rsio	422	5	former	former	JJ
cord-016476-78r0rsio	422	6	would	would	MD
cord-016476-78r0rsio	422	7	involve	involve	VB
cord-016476-78r0rsio	422	8	cessation	cessation	NN
cord-016476-78r0rsio	422	9	of	of	IN
cord-016476-78r0rsio	422	10	the	the	DT
cord-016476-78r0rsio	422	11	putative	putative	JJ
cord-016476-78r0rsio	422	12	drug	drug	NN
cord-016476-78r0rsio	422	13	with	with	IN
cord-016476-78r0rsio	422	14	or	or	CC
cord-016476-78r0rsio	422	15	without	without	IN
cord-016476-78r0rsio	422	16	further	further	JJ
cord-016476-78r0rsio	422	17	treatment	treatment	NN
cord-016476-78r0rsio	422	18	with	with	IN
cord-016476-78r0rsio	422	19	glucocorticoids	glucocorticoid	NNS
cord-016476-78r0rsio	422	20	if	if	IN
cord-016476-78r0rsio	422	21	required	require	VBN
cord-016476-78r0rsio	422	22	,	,	,
cord-016476-78r0rsio	422	23	whilst	whilst	IN
cord-016476-78r0rsio	422	24	the	the	DT
cord-016476-78r0rsio	422	25	latter	latter	JJ
cord-016476-78r0rsio	422	26	may	may	MD
cord-016476-78r0rsio	422	27	require	require	VB
cord-016476-78r0rsio	422	28	more	more	RBR
cord-016476-78r0rsio	422	29	prolonged	prolong	VBN
cord-016476-78r0rsio	422	30	therapy	therapy	NN
cord-016476-78r0rsio	422	31	and	and	CC
cord-016476-78r0rsio	422	32	monitoring	monitoring	NN
cord-016476-78r0rsio	422	33	.	.	.
cord-016476-78r0rsio	423	1	In	in	IN
cord-016476-78r0rsio	423	2	practice	practice	NN
cord-016476-78r0rsio	423	3	,	,	,
cord-016476-78r0rsio	423	4	the	the	DT
cord-016476-78r0rsio	423	5	two	two	CD
cord-016476-78r0rsio	423	6	are	be	VBP
cord-016476-78r0rsio	423	7	difficult	difficult	JJ
cord-016476-78r0rsio	423	8	to	to	TO
cord-016476-78r0rsio	423	9	delineate	delineate	VB
cord-016476-78r0rsio	423	10	given	give	VBN
cord-016476-78r0rsio	423	11	their	-PRON-	PRP$
cord-016476-78r0rsio	423	12	similar	similar	JJ
cord-016476-78r0rsio	423	13	presentations	presentation	NNS
cord-016476-78r0rsio	423	14	,	,	,
cord-016476-78r0rsio	423	15	and	and	CC
cord-016476-78r0rsio	423	16	therefore	therefore	RB
cord-016476-78r0rsio	423	17	rheumatologists	rheumatologist	NNS
cord-016476-78r0rsio	423	18	faced	face	VBN
cord-016476-78r0rsio	423	19	with	with	IN
cord-016476-78r0rsio	423	20	such	such	JJ
cord-016476-78r0rsio	423	21	patients	patient	NNS
cord-016476-78r0rsio	423	22	demonstrating	demonstrate	VBG
cord-016476-78r0rsio	423	23	worsening	worsen	VBG
cord-016476-78r0rsio	423	24	respiratory	respiratory	JJ
cord-016476-78r0rsio	423	25	symptoms	symptom	NNS
cord-016476-78r0rsio	423	26	or	or	CC
cord-016476-78r0rsio	423	27	lung	lung	NN
cord-016476-78r0rsio	423	28	function	function	NN
cord-016476-78r0rsio	423	29	should	should	MD
cord-016476-78r0rsio	423	30	consult	consult	VB
cord-016476-78r0rsio	423	31	with	with	IN
cord-016476-78r0rsio	423	32	respiratory	respiratory	JJ
cord-016476-78r0rsio	423	33	colleagues	colleague	NNS
cord-016476-78r0rsio	423	34	early	early	RB
cord-016476-78r0rsio	423	35	.	.	.
cord-016476-78r0rsio	424	1	If	if	IN
cord-016476-78r0rsio	424	2	the	the	DT
cord-016476-78r0rsio	424	3	deterioration	deterioration	NN
cord-016476-78r0rsio	424	4	in	in	IN
cord-016476-78r0rsio	424	5	clinical	clinical	JJ
cord-016476-78r0rsio	424	6	picture	picture	NN
cord-016476-78r0rsio	424	7	is	be	VBZ
cord-016476-78r0rsio	424	8	found	find	VBN
cord-016476-78r0rsio	424	9	to	to	TO
cord-016476-78r0rsio	424	10	be	be	VB
cord-016476-78r0rsio	424	11	due	due	JJ
cord-016476-78r0rsio	424	12	to	to	IN
cord-016476-78r0rsio	424	13	progression	progression	NN
cord-016476-78r0rsio	424	14	of	of	IN
cord-016476-78r0rsio	424	15	RA	RA	NNP
cord-016476-78r0rsio	424	16	-	-	HYPH
cord-016476-78r0rsio	424	17	ILD	ILD	NNP
cord-016476-78r0rsio	424	18	,	,	,
cord-016476-78r0rsio	424	19	the	the	DT
cord-016476-78r0rsio	424	20	decision	decision	NN
cord-016476-78r0rsio	424	21	to	to	TO
cord-016476-78r0rsio	424	22	continue	continue	VB
cord-016476-78r0rsio	424	23	any	any	DT
cord-016476-78r0rsio	424	24	DMARD	DMARD	NNP
cord-016476-78r0rsio	424	25	,	,	,
cord-016476-78r0rsio	424	26	but	but	CC
cord-016476-78r0rsio	424	27	especially	especially	RB
cord-016476-78r0rsio	424	28	bDMARDs	bdmards	VBP
cord-016476-78r0rsio	424	29	or	or	CC
cord-016476-78r0rsio	424	30	tsDMARDs	tsdmards	NN
cord-016476-78r0rsio	424	31	,	,	,
cord-016476-78r0rsio	424	32	necessitates	necessitate	VBZ
cord-016476-78r0rsio	424	33	clinical	clinical	JJ
cord-016476-78r0rsio	424	34	decisions	decision	NNS
cord-016476-78r0rsio	424	35	on	on	IN
cord-016476-78r0rsio	424	36	a	a	DT
cord-016476-78r0rsio	424	37	case	case	NN
cord-016476-78r0rsio	424	38	-	-	HYPH
cord-016476-78r0rsio	424	39	to	to	IN
cord-016476-78r0rsio	424	40	-	-	HYPH
cord-016476-78r0rsio	424	41	case	case	NN
cord-016476-78r0rsio	424	42	basis	basis	NN
cord-016476-78r0rsio	424	43	.	.	.
cord-016476-78r0rsio	425	1	The	the	DT
cord-016476-78r0rsio	425	2	choice	choice	NN
cord-016476-78r0rsio	425	3	of	of	IN
cord-016476-78r0rsio	425	4	whether	whether	IN
cord-016476-78r0rsio	425	5	to	to	TO
cord-016476-78r0rsio	425	6	continue	continue	VB
cord-016476-78r0rsio	425	7	with	with	IN
cord-016476-78r0rsio	425	8	effective	effective	JJ
cord-016476-78r0rsio	425	9	DMARD	DMARD	NNP
cord-016476-78r0rsio	425	10	therapy	therapy	NN
cord-016476-78r0rsio	425	11	for	for	IN
cord-016476-78r0rsio	425	12	joint	joint	JJ
cord-016476-78r0rsio	425	13	disease	disease	NN
cord-016476-78r0rsio	425	14	or	or	CC
cord-016476-78r0rsio	425	15	the	the	DT
cord-016476-78r0rsio	425	16	risk	risk	NN
cord-016476-78r0rsio	425	17	of	of	IN
cord-016476-78r0rsio	425	18	potential	potential	JJ
cord-016476-78r0rsio	425	19	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	425	20	toxicity	toxicity	NN
cord-016476-78r0rsio	425	21	may	may	MD
cord-016476-78r0rsio	425	22	be	be	VB
cord-016476-78r0rsio	425	23	based	base	VBN
cord-016476-78r0rsio	425	24	on	on	IN
cord-016476-78r0rsio	425	25	the	the	DT
cord-016476-78r0rsio	425	26	perceived	perceive	VBN
cord-016476-78r0rsio	425	27	likelihood	likelihood	NN
cord-016476-78r0rsio	425	28	that	that	IN
cord-016476-78r0rsio	425	29	the	the	DT
cord-016476-78r0rsio	425	30	DMARD	DMARD	NNP
cord-016476-78r0rsio	425	31	in	in	IN
cord-016476-78r0rsio	425	32	question	question	NN
cord-016476-78r0rsio	425	33	is	be	VBZ
cord-016476-78r0rsio	425	34	driving	drive	VBG
cord-016476-78r0rsio	425	35	deterioration	deterioration	NN
cord-016476-78r0rsio	425	36	(	(	-LRB-
cord-016476-78r0rsio	425	37	e.g.	e.g.	DT
cord-016476-78r0rsio	425	38	temporal	temporal	JJ
cord-016476-78r0rsio	425	39	relationship	relationship	NN
cord-016476-78r0rsio	425	40	of	of	IN
cord-016476-78r0rsio	425	41	starting	start	VBG
cord-016476-78r0rsio	425	42	the	the	DT
cord-016476-78r0rsio	425	43	drug	drug	NN
cord-016476-78r0rsio	425	44	with	with	IN
cord-016476-78r0rsio	425	45	the	the	DT
cord-016476-78r0rsio	425	46	clinical	clinical	JJ
cord-016476-78r0rsio	425	47	scenario	scenario	NN
cord-016476-78r0rsio	425	48	)	)	-RRB-
cord-016476-78r0rsio	425	49	.	.	.
cord-016476-78r0rsio	426	1	Currently	currently	RB
cord-016476-78r0rsio	426	2	there	there	EX
cord-016476-78r0rsio	426	3	is	be	VBZ
cord-016476-78r0rsio	426	4	no	no	DT
cord-016476-78r0rsio	426	5	observational	observational	JJ
cord-016476-78r0rsio	426	6	evidence	evidence	NN
cord-016476-78r0rsio	426	7	that	that	WDT
cord-016476-78r0rsio	426	8	preferentially	preferentially	RB
cord-016476-78r0rsio	426	9	switching	switch	VBG
cord-016476-78r0rsio	426	10	between	between	IN
cord-016476-78r0rsio	426	11	biologics	biologic	NNS
cord-016476-78r0rsio	426	12	,	,	,
cord-016476-78r0rsio	426	13	for	for	IN
cord-016476-78r0rsio	426	14	instance	instance	NN
cord-016476-78r0rsio	426	15	,	,	,
cord-016476-78r0rsio	426	16	helps	help	VBZ
cord-016476-78r0rsio	426	17	prolong	prolong	VB
cord-016476-78r0rsio	426	18	survival	survival	NN
cord-016476-78r0rsio	426	19	or	or	CC
cord-016476-78r0rsio	426	20	stabilises	stabilise	VBZ
cord-016476-78r0rsio	426	21	the	the	DT
cord-016476-78r0rsio	426	22	disease	disease	NN
cord-016476-78r0rsio	426	23	;	;	:
cord-016476-78r0rsio	426	24	however	however	RB
cord-016476-78r0rsio	426	25	,	,	,
cord-016476-78r0rsio	426	26	this	this	DT
cord-016476-78r0rsio	426	27	may	may	MD
cord-016476-78r0rsio	426	28	be	be	VB
cord-016476-78r0rsio	426	29	tried	try	VBN
cord-016476-78r0rsio	426	30	in	in	IN
cord-016476-78r0rsio	426	31	individuals	individual	NNS
cord-016476-78r0rsio	426	32	that	that	WDT
cord-016476-78r0rsio	426	33	require	require	VBP
cord-016476-78r0rsio	426	34	management	management	NN
cord-016476-78r0rsio	426	35	of	of	IN
cord-016476-78r0rsio	426	36	their	-PRON-	PRP$
cord-016476-78r0rsio	426	37	articular	articular	JJ
cord-016476-78r0rsio	426	38	disease	disease	NN
cord-016476-78r0rsio	426	39	following	follow	VBG
cord-016476-78r0rsio	426	40	careful	careful	JJ
cord-016476-78r0rsio	426	41	discussion	discussion	NN
cord-016476-78r0rsio	426	42	.	.	.
cord-016476-78r0rsio	427	1	In	in	IN
cord-016476-78r0rsio	427	2	patients	patient	NNS
cord-016476-78r0rsio	427	3	deemed	deem	VBN
cord-016476-78r0rsio	427	4	to	to	TO
cord-016476-78r0rsio	427	5	have	have	VB
cord-016476-78r0rsio	427	6	progressive	progressive	JJ
cord-016476-78r0rsio	427	7	,	,	,
cord-016476-78r0rsio	427	8	irreversible	irreversible	JJ
cord-016476-78r0rsio	427	9	disease	disease	NN
cord-016476-78r0rsio	427	10	,	,	,
cord-016476-78r0rsio	427	11	management	management	NN
cord-016476-78r0rsio	427	12	of	of	IN
cord-016476-78r0rsio	427	13	patients	patient	NNS
cord-016476-78r0rsio	427	14	with	with	IN
cord-016476-78r0rsio	427	15	RA	RA	NNP
cord-016476-78r0rsio	427	16	-	-	HYPH
cord-016476-78r0rsio	427	17	ILD	ILD	NNP
cord-016476-78r0rsio	427	18	in	in	IN
cord-016476-78r0rsio	427	19	a	a	DT
cord-016476-78r0rsio	427	20	joint	joint	JJ
cord-016476-78r0rsio	427	21	pulmonary	pulmonary	NN
cord-016476-78r0rsio	427	22	and	and	CC
cord-016476-78r0rsio	427	23	rheumatology	rheumatology	NN
cord-016476-78r0rsio	427	24	clinic	clinic	NN
cord-016476-78r0rsio	427	25	should	should	MD
cord-016476-78r0rsio	427	26	be	be	VB
cord-016476-78r0rsio	427	27	especially	especially	RB
cord-016476-78r0rsio	427	28	considered	consider	VBN
cord-016476-78r0rsio	427	29	where	where	WRB
cord-016476-78r0rsio	427	30	possible	possible	JJ
cord-016476-78r0rsio	427	31	,	,	,
cord-016476-78r0rsio	427	32	with	with	IN
cord-016476-78r0rsio	427	33	attempts	attempt	NNS
cord-016476-78r0rsio	427	34	made	make	VBN
cord-016476-78r0rsio	427	35	at	at	IN
cord-016476-78r0rsio	427	36	stabilisation	stabilisation	NN
cord-016476-78r0rsio	427	37	.	.	.
cord-016476-78r0rsio	428	1	In	in	IN
cord-016476-78r0rsio	428	2	all	all	DT
cord-016476-78r0rsio	428	3	patients	patient	NNS
cord-016476-78r0rsio	428	4	,	,	,
cord-016476-78r0rsio	428	5	and	and	CC
cord-016476-78r0rsio	428	6	especially	especially	RB
cord-016476-78r0rsio	428	7	in	in	IN
cord-016476-78r0rsio	428	8	those	those	DT
cord-016476-78r0rsio	428	9	with	with	IN
cord-016476-78r0rsio	428	10	multimorbidity	multimorbidity	NN
cord-016476-78r0rsio	428	11	,	,	,
cord-016476-78r0rsio	428	12	conservative	conservative	JJ
cord-016476-78r0rsio	428	13	and	and	CC
cord-016476-78r0rsio	428	14	nonpharmacological	nonpharmacological	JJ
cord-016476-78r0rsio	428	15	options	option	NNS
cord-016476-78r0rsio	428	16	that	that	WDT
cord-016476-78r0rsio	428	17	may	may	MD
cord-016476-78r0rsio	428	18	be	be	VB
cord-016476-78r0rsio	428	19	worth	worth	JJ
cord-016476-78r0rsio	428	20	exploring	explore	VBG
cord-016476-78r0rsio	428	21	include	include	VBP
cord-016476-78r0rsio	428	22	education	education	NN
cord-016476-78r0rsio	428	23	,	,	,
cord-016476-78r0rsio	428	24	psychological	psychological	JJ
cord-016476-78r0rsio	428	25	support	support	NN
cord-016476-78r0rsio	428	26	,	,	,
cord-016476-78r0rsio	428	27	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	428	28	rehabilitation	rehabilitation	NN
cord-016476-78r0rsio	428	29	and	and	CC
cord-016476-78r0rsio	428	30	supplemental	supplemental	JJ
cord-016476-78r0rsio	428	31	oxygen	oxygen	NN
cord-016476-78r0rsio	428	32	if	if	IN
cord-016476-78r0rsio	428	33	appropriate	appropriate	JJ
cord-016476-78r0rsio	428	34	[	[	-LRB-
cord-016476-78r0rsio	428	35	143	143	CD
cord-016476-78r0rsio	428	36	,	,	,
cord-016476-78r0rsio	428	37	159	159	CD
cord-016476-78r0rsio	428	38	,	,	,
cord-016476-78r0rsio	428	39	208	208	CD
cord-016476-78r0rsio	428	40	]	]	-RRB-
cord-016476-78r0rsio	428	41	.	.	.
cord-016476-78r0rsio	429	1	SRAEs	srae	NNS
cord-016476-78r0rsio	429	2	following	follow	VBG
cord-016476-78r0rsio	429	3	treatments	treatment	NNS
cord-016476-78r0rsio	429	4	for	for	IN
cord-016476-78r0rsio	429	5	RA	RA	NNP
cord-016476-78r0rsio	429	6	may	may	MD
cord-016476-78r0rsio	429	7	be	be	VB
cord-016476-78r0rsio	429	8	due	due	JJ
cord-016476-78r0rsio	429	9	to	to	IN
cord-016476-78r0rsio	429	10	incidence	incidence	NN
cord-016476-78r0rsio	429	11	/	/	SYM
cord-016476-78r0rsio	429	12	exacerbation	exacerbation	NN
cord-016476-78r0rsio	429	13	of	of	IN
cord-016476-78r0rsio	429	14	RA	RA	NNP
cord-016476-78r0rsio	429	15	-	-	HYPH
cord-016476-78r0rsio	429	16	ILD	ILD	NNP
cord-016476-78r0rsio	429	17	or	or	CC
cord-016476-78r0rsio	429	18	due	due	IN
cord-016476-78r0rsio	429	19	to	to	IN
cord-016476-78r0rsio	429	20	other	other	JJ
cord-016476-78r0rsio	429	21	reported	report	VBN
cord-016476-78r0rsio	429	22	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	429	23	complications	complication	NNS
cord-016476-78r0rsio	429	24	summarised	summarise	VBN
cord-016476-78r0rsio	429	25	in	in	IN
cord-016476-78r0rsio	429	26	Table	Table	NNP
cord-016476-78r0rsio	429	27	9	9	CD
cord-016476-78r0rsio	429	28	.4	.4	CD
cord-016476-78r0rsio	429	29	.	.	.
cord-016476-78r0rsio	430	1	Careful	careful	JJ
cord-016476-78r0rsio	430	2	consideration	consideration	NN
cord-016476-78r0rsio	430	3	of	of	IN
cord-016476-78r0rsio	430	4	the	the	DT
cord-016476-78r0rsio	430	5	underlying	underlying	JJ
cord-016476-78r0rsio	430	6	aetiology	aetiology	NN
cord-016476-78r0rsio	430	7	of	of	IN
cord-016476-78r0rsio	430	8	SRAEs	srae	NNS
cord-016476-78r0rsio	430	9	is	be	VBZ
cord-016476-78r0rsio	430	10	essential	essential	JJ
cord-016476-78r0rsio	430	11	,	,	,
cord-016476-78r0rsio	430	12	as	as	IN
cord-016476-78r0rsio	430	13	deterioration	deterioration	NN
cord-016476-78r0rsio	430	14	in	in	IN
cord-016476-78r0rsio	430	15	chest	chest	NN
cord-016476-78r0rsio	430	16	symptoms	symptom	NNS
cord-016476-78r0rsio	430	17	may	may	MD
cord-016476-78r0rsio	430	18	not	not	RB
cord-016476-78r0rsio	430	19	be	be	VB
cord-016476-78r0rsio	430	20	due	due	JJ
cord-016476-78r0rsio	430	21	to	to	IN
cord-016476-78r0rsio	430	22	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	430	23	or	or	CC
cord-016476-78r0rsio	430	24	progression	progression	NN
cord-016476-78r0rsio	430	25	of	of	IN
cord-016476-78r0rsio	430	26	ILD	ILD	NNP
cord-016476-78r0rsio	430	27	,	,	,
cord-016476-78r0rsio	430	28	which	which	WDT
cord-016476-78r0rsio	430	29	has	have	VBZ
cord-016476-78r0rsio	430	30	been	be	VBN
cord-016476-78r0rsio	430	31	the	the	DT
cord-016476-78r0rsio	430	32	focus	focus	NN
cord-016476-78r0rsio	430	33	of	of	IN
cord-016476-78r0rsio	430	34	review	review	NN
cord-016476-78r0rsio	430	35	in	in	IN
cord-016476-78r0rsio	430	36	this	this	DT
cord-016476-78r0rsio	430	37	chapter	chapter	NN
cord-016476-78r0rsio	430	38	.	.	.
cord-016476-78r0rsio	431	1	A	a	DT
cord-016476-78r0rsio	431	2	thorough	thorough	JJ
cord-016476-78r0rsio	431	3	investigation	investigation	NN
cord-016476-78r0rsio	431	4	of	of	IN
cord-016476-78r0rsio	431	5	common	common	JJ
cord-016476-78r0rsio	431	6	and	and	CC
cord-016476-78r0rsio	431	7	opportunistic	opportunistic	JJ
cord-016476-78r0rsio	431	8	infections	infection	NNS
cord-016476-78r0rsio	431	9	is	be	VBZ
cord-016476-78r0rsio	431	10	imperative	imperative	JJ
cord-016476-78r0rsio	431	11	in	in	IN
cord-016476-78r0rsio	431	12	patients	patient	NNS
cord-016476-78r0rsio	431	13	with	with	IN
cord-016476-78r0rsio	431	14	RA	RA	NNP
cord-016476-78r0rsio	431	15	,	,	,
cord-016476-78r0rsio	431	16	especially	especially	RB
cord-016476-78r0rsio	431	17	on	on	IN
cord-016476-78r0rsio	431	18	high	high	JJ
cord-016476-78r0rsio	431	19	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	431	20	doses	dose	NNS
cord-016476-78r0rsio	431	21	,	,	,
cord-016476-78r0rsio	431	22	certain	certain	JJ
cord-016476-78r0rsio	431	23	nbDMARDs	nbDMARDs	NNP
cord-016476-78r0rsio	431	24	,	,	,
cord-016476-78r0rsio	431	25	bDMARDs	bDMARDs	NNP
cord-016476-78r0rsio	431	26	and	and	CC
cord-016476-78r0rsio	431	27	tsDMARDs	tsdmards	NN
cord-016476-78r0rsio	431	28	.	.	.
cord-016476-78r0rsio	432	1	A	a	DT
cord-016476-78r0rsio	432	2	full	full	JJ
cord-016476-78r0rsio	432	3	review	review	NN
cord-016476-78r0rsio	432	4	of	of	IN
cord-016476-78r0rsio	432	5	infection	infection	NN
cord-016476-78r0rsio	432	6	risk	risk	NN
cord-016476-78r0rsio	432	7	and	and	CC
cord-016476-78r0rsio	432	8	biologics	biologic	NNS
cord-016476-78r0rsio	432	9	is	be	VBZ
cord-016476-78r0rsio	432	10	beyond	beyond	IN
cord-016476-78r0rsio	432	11	the	the	DT
cord-016476-78r0rsio	432	12	scope	scope	NN
cord-016476-78r0rsio	432	13	of	of	IN
cord-016476-78r0rsio	432	14	this	this	DT
cord-016476-78r0rsio	432	15	chapter	chapter	NN
cord-016476-78r0rsio	432	16	,	,	,
cord-016476-78r0rsio	432	17	as	as	IN
cord-016476-78r0rsio	432	18	has	have	VBZ
cord-016476-78r0rsio	432	19	been	be	VBN
cord-016476-78r0rsio	432	20	extensively	extensively	RB
cord-016476-78r0rsio	432	21	reviewed	review	VBN
cord-016476-78r0rsio	432	22	recently	recently	RB
cord-016476-78r0rsio	432	23	[	[	-LRB-
cord-016476-78r0rsio	432	24	209	209	CD
cord-016476-78r0rsio	432	25	,	,	,
cord-016476-78r0rsio	432	26	210	210	CD
cord-016476-78r0rsio	432	27	]	]	-RRB-
cord-016476-78r0rsio	432	28	.	.	.
cord-016476-78r0rsio	433	1	Rare	rare	JJ
cord-016476-78r0rsio	433	2	reports	report	NNS
cord-016476-78r0rsio	433	3	of	of	IN
cord-016476-78r0rsio	433	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	433	5	manifestations	manifestation	NNS
cord-016476-78r0rsio	433	6	of	of	IN
cord-016476-78r0rsio	433	7	certain	certain	JJ
cord-016476-78r0rsio	433	8	drugs	drug	NNS
cord-016476-78r0rsio	433	9	have	have	VBP
cord-016476-78r0rsio	433	10	also	also	RB
cord-016476-78r0rsio	433	11	been	be	VBN
cord-016476-78r0rsio	433	12	reported	report	VBN
cord-016476-78r0rsio	433	13	in	in	IN
cord-016476-78r0rsio	433	14	the	the	DT
cord-016476-78r0rsio	433	15	literature	literature	NN
cord-016476-78r0rsio	433	16	and	and	CC
cord-016476-78r0rsio	433	17	are	be	VBP
cord-016476-78r0rsio	433	18	summarised	summarise	VBN
cord-016476-78r0rsio	433	19	in	in	IN
cord-016476-78r0rsio	433	20	Table	Table	NNP
cord-016476-78r0rsio	433	21	9	9	CD
cord-016476-78r0rsio	433	22	.4	.4	CD
cord-016476-78r0rsio	433	23	.	.	.
cord-016476-78r0rsio	434	1	For	for	IN
cord-016476-78r0rsio	434	2	instance	instance	NN
cord-016476-78r0rsio	434	3	,	,	,
cord-016476-78r0rsio	434	4	lymphoproliferative	lymphoproliferative	JJ
cord-016476-78r0rsio	434	5	disease	disease	NN
cord-016476-78r0rsio	434	6	(	(	-LRB-
cord-016476-78r0rsio	434	7	including	include	VBG
cord-016476-78r0rsio	434	8	non	non	JJ
cord-016476-78r0rsio	434	9	-	-	JJ
cord-016476-78r0rsio	434	10	Hodgkin	Hodgkin	NNP
cord-016476-78r0rsio	434	11	lymphoma	lymphoma	NN
cord-016476-78r0rsio	434	12	)	)	-RRB-
cord-016476-78r0rsio	434	13	have	have	VBP
cord-016476-78r0rsio	434	14	been	be	VBN
cord-016476-78r0rsio	434	15	described	describe	VBN
cord-016476-78r0rsio	434	16	during	during	IN
cord-016476-78r0rsio	434	17	treatment	treatment	NN
cord-016476-78r0rsio	434	18	with	with	IN
cord-016476-78r0rsio	434	19	MTX	MTX	NNP
cord-016476-78r0rsio	434	20	and	and	CC
cord-016476-78r0rsio	434	21	may	may	MD
cord-016476-78r0rsio	434	22	regress	regress	VB
cord-016476-78r0rsio	434	23	following	follow	VBG
cord-016476-78r0rsio	434	24	cessation	cessation	NN
cord-016476-78r0rsio	434	25	[	[	-LRB-
cord-016476-78r0rsio	434	26	211	211	CD
cord-016476-78r0rsio	434	27	,	,	,
cord-016476-78r0rsio	434	28	212	212	CD
cord-016476-78r0rsio	434	29	]	]	-RRB-
cord-016476-78r0rsio	434	30	.	.	.
cord-016476-78r0rsio	435	1	TNFis	tnfis	NN
cord-016476-78r0rsio	435	2	have	have	VBP
cord-016476-78r0rsio	435	3	been	be	VBN
cord-016476-78r0rsio	435	4	associated	associate	VBN
cord-016476-78r0rsio	435	5	with	with	IN
cord-016476-78r0rsio	435	6	paradoxical	paradoxical	JJ
cord-016476-78r0rsio	435	7	AEs	ae	NNS
cord-016476-78r0rsio	435	8	(	(	-LRB-
cord-016476-78r0rsio	435	9	associated	associate	VBN
cord-016476-78r0rsio	435	10	with	with	IN
cord-016476-78r0rsio	435	11	the	the	DT
cord-016476-78r0rsio	435	12	9	9	CD
cord-016476-78r0rsio	435	13	Management	Management	NNP
cord-016476-78r0rsio	435	14	of	of	IN
cord-016476-78r0rsio	435	15	the	the	DT
cord-016476-78r0rsio	435	16	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	435	17	Arthritis	arthritis	NN
cord-016476-78r0rsio	435	18	Patient	Patient	NNP
cord-016476-78r0rsio	435	19	with	with	IN
cord-016476-78r0rsio	435	20	Interstitial	Interstitial	NNP
cord-016476-78r0rsio	435	21	Lung	Lung	NNP
cord-016476-78r0rsio	435	22	Disease	Disease	NNP
cord-016476-78r0rsio	435	23	treatment	treatment	NN
cord-016476-78r0rsio	435	24	and	and	CC
cord-016476-78r0rsio	435	25	possible	possible	JJ
cord-016476-78r0rsio	435	26	induction	induction	NN
cord-016476-78r0rsio	435	27	of	of	IN
cord-016476-78r0rsio	435	28	the	the	DT
cord-016476-78r0rsio	435	29	same	same	JJ
cord-016476-78r0rsio	435	30	event	event	NN
cord-016476-78r0rsio	435	31	)	)	-RRB-
cord-016476-78r0rsio	435	32	such	such	JJ
cord-016476-78r0rsio	435	33	as	as	IN
cord-016476-78r0rsio	435	34	sarcoidosis	sarcoidosis	NN
cord-016476-78r0rsio	435	35	and	and	CC
cord-016476-78r0rsio	435	36	vasculitis	vasculitis	NN
cord-016476-78r0rsio	435	37	[	[	-LRB-
cord-016476-78r0rsio	435	38	48	48	CD
cord-016476-78r0rsio	435	39	]	]	-RRB-
cord-016476-78r0rsio	435	40	.	.	.
cord-016476-78r0rsio	436	1	The	the	DT
cord-016476-78r0rsio	436	2	authors	author	NNS
cord-016476-78r0rsio	436	3	recommend	recommend	VBP
cord-016476-78r0rsio	436	4	a	a	DT
cord-016476-78r0rsio	436	5	low	low	JJ
cord-016476-78r0rsio	436	6	threshold	threshold	NN
cord-016476-78r0rsio	436	7	for	for	IN
cord-016476-78r0rsio	436	8	withholding	withhold	VBG
cord-016476-78r0rsio	436	9	treatment	treatment	NN
cord-016476-78r0rsio	436	10	with	with	IN
cord-016476-78r0rsio	436	11	such	such	JJ
cord-016476-78r0rsio	436	12	cases	case	NNS
cord-016476-78r0rsio	436	13	,	,	,
cord-016476-78r0rsio	436	14	close	close	JJ
cord-016476-78r0rsio	436	15	liaison	liaison	NN
cord-016476-78r0rsio	436	16	with	with	IN
cord-016476-78r0rsio	436	17	respiratory	respiratory	JJ
cord-016476-78r0rsio	436	18	and	and	CC
cord-016476-78r0rsio	436	19	infectious	infectious	JJ
cord-016476-78r0rsio	436	20	disease	disease	NN
cord-016476-78r0rsio	436	21	physicians	physician	NNS
cord-016476-78r0rsio	436	22	and	and	CC
cord-016476-78r0rsio	436	23	imaging	image	VBG
cord-016476-78r0rsio	436	24	using	use	VBG
cord-016476-78r0rsio	436	25	HRCT	HRCT	NNP
cord-016476-78r0rsio	436	26	,	,	,
cord-016476-78r0rsio	436	27	which	which	WDT
cord-016476-78r0rsio	436	28	in	in	IN
cord-016476-78r0rsio	436	29	turn	turn	NN
cord-016476-78r0rsio	436	30	may	may	MD
cord-016476-78r0rsio	436	31	help	help	VB
cord-016476-78r0rsio	436	32	determine	determine	VB
cord-016476-78r0rsio	436	33	the	the	DT
cord-016476-78r0rsio	436	34	cause	cause	NN
cord-016476-78r0rsio	436	35	of	of	IN
cord-016476-78r0rsio	436	36	the	the	DT
cord-016476-78r0rsio	436	37	deterioration	deterioration	NN
cord-016476-78r0rsio	436	38	.	.	.
cord-016476-78r0rsio	437	1	The	the	DT
cord-016476-78r0rsio	437	2	respiratory	respiratory	JJ
cord-016476-78r0rsio	437	3	safety	safety	NN
cord-016476-78r0rsio	437	4	of	of	IN
cord-016476-78r0rsio	437	5	RA	RA	NNP
cord-016476-78r0rsio	437	6	therapy	therapy	NN
cord-016476-78r0rsio	437	7	is	be	VBZ
cord-016476-78r0rsio	437	8	an	an	DT
cord-016476-78r0rsio	437	9	important	important	JJ
cord-016476-78r0rsio	437	10	consideration	consideration	NN
cord-016476-78r0rsio	437	11	whilst	whilst	IN
cord-016476-78r0rsio	437	12	deciding	decide	VBG
cord-016476-78r0rsio	437	13	on	on	IN
cord-016476-78r0rsio	437	14	the	the	DT
cord-016476-78r0rsio	437	15	best	good	JJS
cord-016476-78r0rsio	437	16	treatment	treatment	NN
cord-016476-78r0rsio	437	17	for	for	IN
cord-016476-78r0rsio	437	18	patients	patient	NNS
cord-016476-78r0rsio	437	19	with	with	IN
cord-016476-78r0rsio	437	20	RA	RA	NNP
cord-016476-78r0rsio	437	21	with	with	IN
cord-016476-78r0rsio	437	22	active	active	JJ
cord-016476-78r0rsio	437	23	joint	joint	JJ
cord-016476-78r0rsio	437	24	disease	disease	NN
cord-016476-78r0rsio	437	25	and	and	CC
cord-016476-78r0rsio	437	26	coexisting	coexist	VBG
cord-016476-78r0rsio	437	27	ILD	ILD	NNP
cord-016476-78r0rsio	437	28	.	.	.
cord-016476-78r0rsio	438	1	This	this	DT
cord-016476-78r0rsio	438	2	chapter	chapter	NN
cord-016476-78r0rsio	438	3	summarises	summarise	VBZ
cord-016476-78r0rsio	438	4	the	the	DT
cord-016476-78r0rsio	438	5	current	current	JJ
cord-016476-78r0rsio	438	6	evidence	evidence	NN
cord-016476-78r0rsio	438	7	available	available	JJ
cord-016476-78r0rsio	438	8	of	of	IN
cord-016476-78r0rsio	438	9	the	the	DT
cord-016476-78r0rsio	438	10	use	use	NN
cord-016476-78r0rsio	438	11	of	of	IN
cord-016476-78r0rsio	438	12	DMARDs	dmard	NNS
cord-016476-78r0rsio	438	13	in	in	IN
cord-016476-78r0rsio	438	14	the	the	DT
cord-016476-78r0rsio	438	15	context	context	NN
cord-016476-78r0rsio	438	16	of	of	IN
cord-016476-78r0rsio	438	17	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	438	18	toxicity	toxicity	NN
cord-016476-78r0rsio	438	19	.	.	.
cord-016476-78r0rsio	439	1	However	however	RB
cord-016476-78r0rsio	439	2	several	several	JJ
cord-016476-78r0rsio	439	3	limitations	limitation	NNS
cord-016476-78r0rsio	439	4	of	of	IN
cord-016476-78r0rsio	439	5	the	the	DT
cord-016476-78r0rsio	439	6	existing	exist	VBG
cord-016476-78r0rsio	439	7	literature	literature	NN
cord-016476-78r0rsio	439	8	exist	exist	VBP
cord-016476-78r0rsio	439	9	.	.	.
cord-016476-78r0rsio	440	1	Whilst	whilst	IN
cord-016476-78r0rsio	440	2	RA	RA	NNP
cord-016476-78r0rsio	440	3	-	-	HYPH
cord-016476-78r0rsio	440	4	ILD	ILD	NNP
cord-016476-78r0rsio	440	5	is	be	VBZ
cord-016476-78r0rsio	440	6	increasingly	increasingly	RB
cord-016476-78r0rsio	440	7	recognised	recognise	VBN
cord-016476-78r0rsio	440	8	,	,	,
cord-016476-78r0rsio	440	9	its	-PRON-	PRP$
cord-016476-78r0rsio	440	10	natural	natural	JJ
cord-016476-78r0rsio	440	11	history	history	NN
cord-016476-78r0rsio	440	12	is	be	VBZ
cord-016476-78r0rsio	440	13	still	still	RB
cord-016476-78r0rsio	440	14	poorly	poorly	RB
cord-016476-78r0rsio	440	15	understood	understand	VBN
cord-016476-78r0rsio	440	16	.	.	.
cord-016476-78r0rsio	441	1	With	with	IN
cord-016476-78r0rsio	441	2	newer	new	JJR
cord-016476-78r0rsio	441	3	treatments	treatment	NNS
cord-016476-78r0rsio	441	4	,	,	,
cord-016476-78r0rsio	441	5	case	case	NN
cord-016476-78r0rsio	441	6	reports	report	NNS
cord-016476-78r0rsio	441	7	are	be	VBP
cord-016476-78r0rsio	441	8	helpful	helpful	JJ
cord-016476-78r0rsio	441	9	to	to	TO
cord-016476-78r0rsio	441	10	identify	identify	VB
cord-016476-78r0rsio	441	11	a	a	DT
cord-016476-78r0rsio	441	12	signal	signal	NN
cord-016476-78r0rsio	441	13	for	for	IN
cord-016476-78r0rsio	441	14	concern	concern	NN
cord-016476-78r0rsio	441	15	,	,	,
cord-016476-78r0rsio	441	16	although	although	IN
cord-016476-78r0rsio	441	17	such	such	JJ
cord-016476-78r0rsio	441	18	case	case	NN
cord-016476-78r0rsio	441	19	reports	report	NNS
cord-016476-78r0rsio	441	20	are	be	VBP
cord-016476-78r0rsio	441	21	insufficient	insufficient	JJ
cord-016476-78r0rsio	441	22	alone	alone	RB
cord-016476-78r0rsio	441	23	to	to	TO
cord-016476-78r0rsio	441	24	provide	provide	VB
cord-016476-78r0rsio	441	25	a	a	DT
cord-016476-78r0rsio	441	26	clear	clear	JJ
cord-016476-78r0rsio	441	27	picture	picture	NN
cord-016476-78r0rsio	441	28	of	of	IN
cord-016476-78r0rsio	441	29	drug	drug	NN
cord-016476-78r0rsio	441	30	toxicity	toxicity	NN
cord-016476-78r0rsio	441	31	.	.	.
cord-016476-78r0rsio	442	1	Where	where	WRB
cord-016476-78r0rsio	442	2	observational	observational	JJ
cord-016476-78r0rsio	442	3	evidence	evidence	NN
cord-016476-78r0rsio	442	4	is	be	VBZ
cord-016476-78r0rsio	442	5	available	available	JJ
cord-016476-78r0rsio	442	6	,	,	,
cord-016476-78r0rsio	442	7	confounding	confound	VBG
cord-016476-78r0rsio	442	8	by	by	IN
cord-016476-78r0rsio	442	9	indication	indication	NN
cord-016476-78r0rsio	442	10	and	and	CC
cord-016476-78r0rsio	442	11	channelling	channel	VBG
cord-016476-78r0rsio	442	12	to	to	IN
cord-016476-78r0rsio	442	13	certain	certain	JJ
cord-016476-78r0rsio	442	14	treatments	treatment	NNS
cord-016476-78r0rsio	442	15	may	may	MD
cord-016476-78r0rsio	442	16	limit	limit	VB
cord-016476-78r0rsio	442	17	robust	robust	JJ
cord-016476-78r0rsio	442	18	conclusions	conclusion	NNS
cord-016476-78r0rsio	442	19	.	.	.
cord-016476-78r0rsio	443	1	The	the	DT
cord-016476-78r0rsio	443	2	lack	lack	NN
cord-016476-78r0rsio	443	3	of	of	IN
cord-016476-78r0rsio	443	4	adequate	adequate	JJ
cord-016476-78r0rsio	443	5	comparator	comparator	NN
cord-016476-78r0rsio	443	6	groups	group	NNS
cord-016476-78r0rsio	443	7	in	in	IN
cord-016476-78r0rsio	443	8	several	several	JJ
cord-016476-78r0rsio	443	9	retrospective	retrospective	JJ
cord-016476-78r0rsio	443	10	studies	study	NNS
cord-016476-78r0rsio	443	11	may	may	MD
cord-016476-78r0rsio	443	12	No	no	DT
cord-016476-78r0rsio	443	13	conclusive	conclusive	JJ
cord-016476-78r0rsio	443	14	data	datum	NNS
cord-016476-78r0rsio	443	15	on	on	IN
cord-016476-78r0rsio	443	16	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	443	17	risk	risk	NN
cord-016476-78r0rsio	443	18	bDMARDs	bDMARDs	NNP
cord-016476-78r0rsio	443	19	biologic	biologic	JJ
cord-016476-78r0rsio	443	20	disease	disease	NN
cord-016476-78r0rsio	443	21	-	-	HYPH
cord-016476-78r0rsio	443	22	modifying	modify	VBG
cord-016476-78r0rsio	443	23	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	443	24	drugs	drug	NNS
cord-016476-78r0rsio	443	25	,	,	,
cord-016476-78r0rsio	443	26	DRESS	dress	VB
cord-016476-78r0rsio	443	27	drug	drug	NN
cord-016476-78r0rsio	443	28	reaction	reaction	NN
cord-016476-78r0rsio	443	29	with	with	IN
cord-016476-78r0rsio	443	30	eosinophilia	eosinophilia	JJ
cord-016476-78r0rsio	443	31	and	and	CC
cord-016476-78r0rsio	443	32	systemic	systemic	JJ
cord-016476-78r0rsio	443	33	symptoms	symptom	NNS
cord-016476-78r0rsio	443	34	,	,	,
cord-016476-78r0rsio	443	35	ILD	ILD	NNP
cord-016476-78r0rsio	443	36	interstitial	interstitial	JJ
cord-016476-78r0rsio	443	37	lung	lung	NN
cord-016476-78r0rsio	443	38	disease	disease	NN
cord-016476-78r0rsio	443	39	,	,	,
cord-016476-78r0rsio	443	40	nbDMARDs	nbdmards	FW
cord-016476-78r0rsio	443	41	non	non	JJ
cord-016476-78r0rsio	443	42	-	-	JJ
cord-016476-78r0rsio	443	43	biologic	biologic	JJ
cord-016476-78r0rsio	443	44	biologic	biologic	JJ
cord-016476-78r0rsio	443	45	disease	disease	NN
cord-016476-78r0rsio	443	46	-	-	HYPH
cord-016476-78r0rsio	443	47	modifying	modify	VBG
cord-016476-78r0rsio	443	48	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	443	49	drugs	drug	NNS
cord-016476-78r0rsio	443	50	,	,	,
cord-016476-78r0rsio	443	51	tsDMARDs	tsdmard	VBZ
cord-016476-78r0rsio	443	52	targeted	target	VBN
cord-016476-78r0rsio	443	53	synthetic	synthetic	JJ
cord-016476-78r0rsio	443	54	disease	disease	NN
cord-016476-78r0rsio	443	55	-	-	HYPH
cord-016476-78r0rsio	443	56	modifying	modify	VBG
cord-016476-78r0rsio	443	57	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	443	58	drugs	drug	NNS
cord-016476-78r0rsio	443	59	further	far	RBR
cord-016476-78r0rsio	443	60	limit	limit	VB
cord-016476-78r0rsio	443	61	inferences	inference	NNS
cord-016476-78r0rsio	443	62	drawn	draw	VBN
cord-016476-78r0rsio	443	63	from	from	IN
cord-016476-78r0rsio	443	64	the	the	DT
cord-016476-78r0rsio	443	65	evidence	evidence	NN
cord-016476-78r0rsio	443	66	.	.	.
cord-016476-78r0rsio	444	1	It	-PRON-	PRP
cord-016476-78r0rsio	444	2	appears	appear	VBZ
cord-016476-78r0rsio	444	3	that	that	IN
cord-016476-78r0rsio	444	4	legitimate	legitimate	JJ
cord-016476-78r0rsio	444	5	concerns	concern	NNS
cord-016476-78r0rsio	444	6	are	be	VBP
cord-016476-78r0rsio	444	7	associated	associate	VBN
cord-016476-78r0rsio	444	8	with	with	IN
cord-016476-78r0rsio	444	9	several	several	JJ
cord-016476-78r0rsio	444	10	therapies	therapy	NNS
cord-016476-78r0rsio	444	11	;	;	:
cord-016476-78r0rsio	444	12	therefore	therefore	RB
cord-016476-78r0rsio	444	13	,	,	,
cord-016476-78r0rsio	444	14	involving	involve	VBG
cord-016476-78r0rsio	444	15	patients	patient	NNS
cord-016476-78r0rsio	444	16	and	and	CC
cord-016476-78r0rsio	444	17	multidisciplinary	multidisciplinary	JJ
cord-016476-78r0rsio	444	18	teams	team	NNS
cord-016476-78r0rsio	444	19	in	in	IN
cord-016476-78r0rsio	444	20	such	such	JJ
cord-016476-78r0rsio	444	21	decisions	decision	NNS
cord-016476-78r0rsio	444	22	is	be	VBZ
cord-016476-78r0rsio	444	23	important	important	JJ
cord-016476-78r0rsio	444	24	.	.	.
cord-016476-78r0rsio	445	1	Careful	careful	JJ
cord-016476-78r0rsio	445	2	discussion	discussion	NN
cord-016476-78r0rsio	445	3	of	of	IN
cord-016476-78r0rsio	445	4	the	the	DT
cord-016476-78r0rsio	445	5	benefits	benefit	NNS
cord-016476-78r0rsio	445	6	and	and	CC
cord-016476-78r0rsio	445	7	harms	harm	NNS
cord-016476-78r0rsio	445	8	of	of	IN
cord-016476-78r0rsio	445	9	treatments	treatment	NNS
cord-016476-78r0rsio	445	10	is	be	VBZ
cord-016476-78r0rsio	445	11	encouraged	encourage	VBN
cord-016476-78r0rsio	445	12	,	,	,
cord-016476-78r0rsio	445	13	although	although	IN
cord-016476-78r0rsio	445	14	this	this	DT
cord-016476-78r0rsio	445	15	is	be	VBZ
cord-016476-78r0rsio	445	16	made	make	VBN
cord-016476-78r0rsio	445	17	more	more	RBR
cord-016476-78r0rsio	445	18	challenging	challenging	JJ
cord-016476-78r0rsio	445	19	by	by	IN
cord-016476-78r0rsio	445	20	the	the	DT
cord-016476-78r0rsio	445	21	uncertainty	uncertainty	NN
cord-016476-78r0rsio	445	22	of	of	IN
cord-016476-78r0rsio	445	23	the	the	DT
cord-016476-78r0rsio	445	24	current	current	JJ
cord-016476-78r0rsio	445	25	safety	safety	NN
cord-016476-78r0rsio	445	26	profile	profile	NN
cord-016476-78r0rsio	445	27	.	.	.
cord-016476-78r0rsio	446	1	Systematic	systematic	JJ
cord-016476-78r0rsio	446	2	pre	pre	JJ
cord-016476-78r0rsio	446	3	-	-	JJ
cord-016476-78r0rsio	446	4	and	and	CC
cord-016476-78r0rsio	446	5	post	post	JJ
cord-016476-78r0rsio	446	6	-	-	JJ
cord-016476-78r0rsio	446	7	treatment	treatment	JJ
cord-016476-78r0rsio	446	8	assessment	assessment	NN
cord-016476-78r0rsio	446	9	can	can	MD
cord-016476-78r0rsio	446	10	help	help	VB
cord-016476-78r0rsio	446	11	identify	identify	VB
cord-016476-78r0rsio	446	12	the	the	DT
cord-016476-78r0rsio	446	13	trajectory	trajectory	NN
cord-016476-78r0rsio	446	14	of	of	IN
cord-016476-78r0rsio	446	15	patients	patient	NNS
cord-016476-78r0rsio	446	16	with	with	IN
cord-016476-78r0rsio	446	17	RA	RA	NNP
cord-016476-78r0rsio	446	18	-	-	HYPH
cord-016476-78r0rsio	446	19	ILD	ILD	NNP
cord-016476-78r0rsio	446	20	and	and	CC
cord-016476-78r0rsio	446	21	enable	enable	VB
cord-016476-78r0rsio	446	22	more	more	JJR
cord-016476-78r0rsio	446	23	effective	effective	JJ
cord-016476-78r0rsio	446	24	risk	risk	NN
cord-016476-78r0rsio	446	25	stratification	stratification	NN
cord-016476-78r0rsio	446	26	,	,	,
cord-016476-78r0rsio	446	27	enabling	enable	VBG
cord-016476-78r0rsio	446	28	clinicians	clinician	NNS
cord-016476-78r0rsio	446	29	and	and	CC
cord-016476-78r0rsio	446	30	patients	patient	NNS
cord-016476-78r0rsio	446	31	to	to	TO
cord-016476-78r0rsio	446	32	make	make	VB
cord-016476-78r0rsio	446	33	better	well	RBR
cord-016476-78r0rsio	446	34	-	-	HYPH
cord-016476-78r0rsio	446	35	informed	inform	VBN
cord-016476-78r0rsio	446	36	decisions	decision	NNS
cord-016476-78r0rsio	446	37	.	.	.
cord-016476-78r0rsio	447	1	Unfortunately	unfortunately	RB
cord-016476-78r0rsio	447	2	at	at	IN
cord-016476-78r0rsio	447	3	present	present	JJ
cord-016476-78r0rsio	447	4	,	,	,
cord-016476-78r0rsio	447	5	there	there	EX
cord-016476-78r0rsio	447	6	are	be	VBP
cord-016476-78r0rsio	447	7	limited	limit	VBN
cord-016476-78r0rsio	447	8	therapeutic	therapeutic	JJ
cord-016476-78r0rsio	447	9	options	option	NNS
cord-016476-78r0rsio	447	10	for	for	IN
cord-016476-78r0rsio	447	11	additional	additional	JJ
cord-016476-78r0rsio	447	12	treatment	treatment	NN
cord-016476-78r0rsio	447	13	for	for	IN
cord-016476-78r0rsio	447	14	specifically	specifically	RB
cord-016476-78r0rsio	447	15	stabilising	stabilise	VBG
cord-016476-78r0rsio	447	16	or	or	CC
cord-016476-78r0rsio	447	17	reversing	reverse	VBG
cord-016476-78r0rsio	447	18	established	establish	VBN
cord-016476-78r0rsio	447	19	fibrosis	fibrosis	NN
cord-016476-78r0rsio	447	20	;	;	:
cord-016476-78r0rsio	447	21	however	however	RB
cord-016476-78r0rsio	447	22	,	,	,
cord-016476-78r0rsio	447	23	emerging	emerge	VBG
cord-016476-78r0rsio	447	24	treatments	treatment	NNS
cord-016476-78r0rsio	447	25	such	such	JJ
cord-016476-78r0rsio	447	26	as	as	IN
cord-016476-78r0rsio	447	27	novel	novel	JJ
cord-016476-78r0rsio	447	28	anti	anti	NNS
cord-016476-78r0rsio	447	29	-	-	NNS
cord-016476-78r0rsio	447	30	fibrotics	fibrotic	NNS
cord-016476-78r0rsio	447	31	may	may	MD
cord-016476-78r0rsio	447	32	hold	hold	VB
cord-016476-78r0rsio	447	33	promise	promise	NN
cord-016476-78r0rsio	447	34	.	.	.
cord-016476-78r0rsio	448	1	Given	give	VBN
cord-016476-78r0rsio	448	2	the	the	DT
cord-016476-78r0rsio	448	3	current	current	JJ
cord-016476-78r0rsio	448	4	evidence	evidence	NN
cord-016476-78r0rsio	448	5	base	base	NN
cord-016476-78r0rsio	448	6	,	,	,
cord-016476-78r0rsio	448	7	the	the	DT
cord-016476-78r0rsio	448	8	decision	decision	NN
cord-016476-78r0rsio	448	9	to	to	TO
cord-016476-78r0rsio	448	10	start	start	VB
cord-016476-78r0rsio	448	11	an	an	DT
cord-016476-78r0rsio	448	12	DMARD	DMARD	NNP
cord-016476-78r0rsio	448	13	in	in	IN
cord-016476-78r0rsio	448	14	patients	patient	NNS
cord-016476-78r0rsio	448	15	with	with	IN
cord-016476-78r0rsio	448	16	RA	RA	NNP
cord-016476-78r0rsio	448	17	who	who	WP
cord-016476-78r0rsio	448	18	have	have	VBP
cord-016476-78r0rsio	448	19	ILD	ILD	NNP
cord-016476-78r0rsio	448	20	should	should	MD
cord-016476-78r0rsio	448	21	be	be	VB
cord-016476-78r0rsio	448	22	based	base	VBN
cord-016476-78r0rsio	448	23	on	on	IN
cord-016476-78r0rsio	448	24	its	-PRON-	PRP$
cord-016476-78r0rsio	448	25	potential	potential	NN
cord-016476-78r0rsio	448	26	for	for	IN
cord-016476-78r0rsio	448	27	improving	improve	VBG
cord-016476-78r0rsio	448	28	joint	joint	JJ
cord-016476-78r0rsio	448	29	disease	disease	NN
cord-016476-78r0rsio	448	30	,	,	,
cord-016476-78r0rsio	448	31	individual	individual	JJ
cord-016476-78r0rsio	448	32	patient	patient	NN
cord-016476-78r0rsio	448	33	characteristics	characteristic	NNS
cord-016476-78r0rsio	448	34	,	,	,
cord-016476-78r0rsio	448	35	patient	patient	JJ
cord-016476-78r0rsio	448	36	education	education	NN
cord-016476-78r0rsio	448	37	about	about	IN
cord-016476-78r0rsio	448	38	the	the	DT
cord-016476-78r0rsio	448	39	known	know	VBN
cord-016476-78r0rsio	448	40	risks	risk	NNS
cord-016476-78r0rsio	448	41	and	and	CC
cord-016476-78r0rsio	448	42	benefits	benefit	NNS
cord-016476-78r0rsio	448	43	of	of	IN
cord-016476-78r0rsio	448	44	treatment	treatment	NN
cord-016476-78r0rsio	448	45	and	and	CC
cord-016476-78r0rsio	448	46	multidisciplinary	multidisciplinary	JJ
cord-016476-78r0rsio	448	47	team	team	NN
cord-016476-78r0rsio	448	48	input	input	NN
cord-016476-78r0rsio	448	49	.	.	.
cord-016476-78r0rsio	449	1	Rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	449	2	arthritis	arthritis	NN
cord-016476-78r0rsio	449	3	classification	classification	NN
cord-016476-78r0rsio	449	4	criteria	criterion	NNS
cord-016476-78r0rsio	449	5	:	:	:
cord-016476-78r0rsio	449	6	an	an	DT
cord-016476-78r0rsio	449	7	American	American	NNP
cord-016476-78r0rsio	449	8	College	College	NNP
cord-016476-78r0rsio	449	9	of	of	IN
cord-016476-78r0rsio	449	10	Rheumatology	Rheumatology	NNP
cord-016476-78r0rsio	449	11	/	/	SYM
cord-016476-78r0rsio	449	12	European	European	NNP
cord-016476-78r0rsio	449	13	league	league	NNP
cord-016476-78r0rsio	449	14	against	against	IN
cord-016476-78r0rsio	449	15	rheumatism	rheumatism	NN
cord-016476-78r0rsio	449	16	collaborative	collaborative	NNP
cord-016476-78r0rsio	449	17	initiative	initiative	NN
cord-016476-78r0rsio	449	18	Treating	treat	VBG
cord-016476-78r0rsio	449	19	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	449	20	arthritis	arthritis	NN
cord-016476-78r0rsio	449	21	to	to	TO
cord-016476-78r0rsio	449	22	target	target	VB
cord-016476-78r0rsio	449	23	:	:	:
cord-016476-78r0rsio	449	24	2014	2014	CD
cord-016476-78r0rsio	449	25	update	update	NN
cord-016476-78r0rsio	449	26	of	of	IN
cord-016476-78r0rsio	449	27	the	the	DT
cord-016476-78r0rsio	449	28	recommendations	recommendation	NNS
cord-016476-78r0rsio	449	29	of	of	IN
cord-016476-78r0rsio	449	30	an	an	DT
cord-016476-78r0rsio	449	31	international	international	JJ
cord-016476-78r0rsio	449	32	task	task	NN
cord-016476-78r0rsio	449	33	force	force	NN
cord-016476-78r0rsio	449	34	EULAR	EULAR	NNP
cord-016476-78r0rsio	449	35	recommendations	recommendation	NNS
cord-016476-78r0rsio	449	36	for	for	IN
cord-016476-78r0rsio	449	37	the	the	DT
cord-016476-78r0rsio	449	38	management	management	NN
cord-016476-78r0rsio	449	39	of	of	IN
cord-016476-78r0rsio	449	40	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	449	41	arthritis	arthritis	NN
cord-016476-78r0rsio	449	42	with	with	IN
cord-016476-78r0rsio	449	43	synthetic	synthetic	JJ
cord-016476-78r0rsio	449	44	and	and	CC
cord-016476-78r0rsio	449	45	biological	biological	JJ
cord-016476-78r0rsio	449	46	disease	disease	NN
cord-016476-78r0rsio	449	47	-	-	HYPH
cord-016476-78r0rsio	449	48	modifying	modify	VBG
cord-016476-78r0rsio	449	49	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	449	50	drugs	drug	NNS
cord-016476-78r0rsio	449	51	:	:	:
cord-016476-78r0rsio	449	52	2013	2013	CD
cord-016476-78r0rsio	449	53	update	update	NN
cord-016476-78r0rsio	449	54	Acute	acute	JJ
cord-016476-78r0rsio	449	55	lymphocytic	lymphocytic	JJ
cord-016476-78r0rsio	449	56	leukemia	leukemia	NN
cord-016476-78r0rsio	449	57	in	in	IN
cord-016476-78r0rsio	449	58	children	child	NNS
cord-016476-78r0rsio	449	59	:	:	:
cord-016476-78r0rsio	450	1	maintenance	maintenance	NN
cord-016476-78r0rsio	450	2	therapy	therapy	NN
cord-016476-78r0rsio	450	3	with	with	IN
cord-016476-78r0rsio	450	4	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	450	5	administered	administer	VBD
cord-016476-78r0rsio	450	6	intermittently	intermittently	RB
cord-016476-78r0rsio	450	7	Acute	acute	JJ
cord-016476-78r0rsio	450	8	lung	lung	NN
cord-016476-78r0rsio	450	9	disease	disease	NN
cord-016476-78r0rsio	450	10	associated	associate	VBN
cord-016476-78r0rsio	450	11	with	with	IN
cord-016476-78r0rsio	450	12	low	low	JJ
cord-016476-78r0rsio	450	13	-	-	HYPH
cord-016476-78r0rsio	450	14	dose	dose	NN
cord-016476-78r0rsio	450	15	pulse	pulse	NN
cord-016476-78r0rsio	450	16	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	450	17	therapy	therapy	NN
cord-016476-78r0rsio	450	18	in	in	IN
cord-016476-78r0rsio	450	19	patients	patient	NNS
cord-016476-78r0rsio	450	20	with	with	IN
cord-016476-78r0rsio	450	21	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	450	22	arthritis	arthritis	NN
cord-016476-78r0rsio	450	23	Methotrexate	Methotrexate	NNP
cord-016476-78r0rsio	450	24	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	450	25	:	:	:
cord-016476-78r0rsio	450	26	review	review	NN
cord-016476-78r0rsio	450	27	of	of	IN
cord-016476-78r0rsio	450	28	the	the	DT
cord-016476-78r0rsio	450	29	literature	literature	NN
cord-016476-78r0rsio	450	30	and	and	CC
cord-016476-78r0rsio	450	31	histopathological	histopathological	NNP
cord-016476-78r0rsio	450	32	findings	finding	NNS
cord-016476-78r0rsio	450	33	in	in	IN
cord-016476-78r0rsio	450	34	nine	nine	CD
cord-016476-78r0rsio	450	35	patients	patient	NNS
cord-016476-78r0rsio	450	36	Investigation	Investigation	NNP
cord-016476-78r0rsio	450	37	of	of	IN
cord-016476-78r0rsio	450	38	the	the	DT
cord-016476-78r0rsio	450	39	chronic	chronic	JJ
cord-016476-78r0rsio	450	40	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	450	41	effects	effect	NNS
cord-016476-78r0rsio	450	42	of	of	IN
cord-016476-78r0rsio	450	43	low	low	JJ
cord-016476-78r0rsio	450	44	-	-	HYPH
cord-016476-78r0rsio	450	45	dose	dose	NN
cord-016476-78r0rsio	450	46	oral	oral	JJ
cord-016476-78r0rsio	450	47	methotrexate	methotrexate	NN
cord-016476-78r0rsio	450	48	in	in	IN
cord-016476-78r0rsio	450	49	patients	patient	NNS
cord-016476-78r0rsio	450	50	with	with	IN
cord-016476-78r0rsio	450	51	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	450	52	arthritis	arthritis	NN
cord-016476-78r0rsio	450	53	:	:	:
cord-016476-78r0rsio	451	1	a	a	DT
cord-016476-78r0rsio	451	2	prospective	prospective	JJ
cord-016476-78r0rsio	451	3	study	study	NN
cord-016476-78r0rsio	451	4	incorporating	incorporate	VBG
cord-016476-78r0rsio	451	5	HRCT	HRCT	NNP
cord-016476-78r0rsio	451	6	scanning	scanning	NN
cord-016476-78r0rsio	451	7	and	and	CC
cord-016476-78r0rsio	451	8	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	451	9	function	function	NN
cord-016476-78r0rsio	451	10	tests	test	VBZ
cord-016476-78r0rsio	451	11	Long	long	JJ
cord-016476-78r0rsio	451	12	-	-	HYPH
cord-016476-78r0rsio	451	13	term	term	NN
cord-016476-78r0rsio	451	14	safety	safety	NN
cord-016476-78r0rsio	451	15	of	of	IN
cord-016476-78r0rsio	451	16	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	451	17	monotherapy	monotherapy	NNP
cord-016476-78r0rsio	451	18	in	in	IN
cord-016476-78r0rsio	451	19	patients	patient	NNS
cord-016476-78r0rsio	451	20	with	with	IN
cord-016476-78r0rsio	451	21	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	451	22	arthritis	arthritis	NN
cord-016476-78r0rsio	451	23	:	:	:
cord-016476-78r0rsio	451	24	a	a	DT
cord-016476-78r0rsio	451	25	systematic	systematic	JJ
cord-016476-78r0rsio	451	26	literature	literature	NN
cord-016476-78r0rsio	451	27	research	research	NN
cord-016476-78r0rsio	451	28	How	how	WRB
cord-016476-78r0rsio	451	29	common	common	JJ
cord-016476-78r0rsio	451	30	is	be	VBZ
cord-016476-78r0rsio	451	31	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	451	32	pneumonitis	pneumonitis	NNP
cord-016476-78r0rsio	451	33	?	?	.
cord-016476-78r0rsio	452	1	A	a	DT
cord-016476-78r0rsio	452	2	large	large	JJ
cord-016476-78r0rsio	452	3	prospective	prospective	JJ
cord-016476-78r0rsio	452	4	study	study	NN
cord-016476-78r0rsio	452	5	investigates	investigate	VBZ
cord-016476-78r0rsio	452	6	Methotrexate	Methotrexate	NNP
cord-016476-78r0rsio	452	7	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	452	8	in	in	IN
cord-016476-78r0rsio	452	9	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	452	10	arthritis	arthritis	NN
cord-016476-78r0rsio	452	11	:	:	:
cord-016476-78r0rsio	452	12	potential	potential	JJ
cord-016476-78r0rsio	452	13	risk	risk	NN
cord-016476-78r0rsio	452	14	factors	factor	NNS
cord-016476-78r0rsio	452	15	.	.	.
cord-016476-78r0rsio	453	1	Four	four	CD
cord-016476-78r0rsio	453	2	case	case	NN
cord-016476-78r0rsio	453	3	reports	report	NNS
cord-016476-78r0rsio	453	4	and	and	CC
cord-016476-78r0rsio	453	5	a	a	DT
cord-016476-78r0rsio	453	6	review	review	NN
cord-016476-78r0rsio	453	7	of	of	IN
cord-016476-78r0rsio	453	8	the	the	DT
cord-016476-78r0rsio	453	9	literature	literature	NN
cord-016476-78r0rsio	453	10	Pulmonary	pulmonary	JJ
cord-016476-78r0rsio	453	11	disease	disease	NN
cord-016476-78r0rsio	453	12	during	during	IN
cord-016476-78r0rsio	453	13	the	the	DT
cord-016476-78r0rsio	453	14	treatment	treatment	NN
cord-016476-78r0rsio	453	15	of	of	IN
cord-016476-78r0rsio	453	16	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	453	17	arthritis	arthritis	NN
cord-016476-78r0rsio	453	18	with	with	IN
cord-016476-78r0rsio	453	19	low	low	JJ
cord-016476-78r0rsio	453	20	dose	dose	NN
cord-016476-78r0rsio	453	21	pulse	pulse	NN
cord-016476-78r0rsio	453	22	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	453	23	Clinical	Clinical	NNP
cord-016476-78r0rsio	453	24	,	,	,
cord-016476-78r0rsio	453	25	laboratory	laboratory	NN
cord-016476-78r0rsio	453	26	,	,	,
cord-016476-78r0rsio	453	27	radiographic	radiographic	JJ
cord-016476-78r0rsio	453	28	,	,	,
cord-016476-78r0rsio	453	29	and	and	CC
cord-016476-78r0rsio	453	30	histopathologic	histopathologic	NNP
cord-016476-78r0rsio	453	31	features	feature	NNS
cord-016476-78r0rsio	453	32	of	of	IN
cord-016476-78r0rsio	453	33	methotrexate	methotrexate	NN
cord-016476-78r0rsio	453	34	-	-	HYPH
cord-016476-78r0rsio	453	35	associated	associate	VBN
cord-016476-78r0rsio	453	36	lung	lung	NN
cord-016476-78r0rsio	453	37	injury	injury	NN
cord-016476-78r0rsio	453	38	in	in	IN
cord-016476-78r0rsio	453	39	patients	patient	NNS
cord-016476-78r0rsio	453	40	with	with	IN
cord-016476-78r0rsio	453	41	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	453	42	arthritis	arthritis	NN
cord-016476-78r0rsio	453	43	:	:	:
cord-016476-78r0rsio	453	44	a	a	DT
cord-016476-78r0rsio	453	45	multicenter	multicenter	JJ
cord-016476-78r0rsio	453	46	study	study	NN
cord-016476-78r0rsio	453	47	with	with	IN
cord-016476-78r0rsio	453	48	literature	literature	NN
cord-016476-78r0rsio	453	49	review	review	NN
cord-016476-78r0rsio	453	50	Methotrexate	Methotrexate	NNP
cord-016476-78r0rsio	453	51	-	-	HYPH
cord-016476-78r0rsio	453	52	induced	induce	VBN
cord-016476-78r0rsio	453	53	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	453	54	injury	injury	NN
cord-016476-78r0rsio	453	55	:	:	:
cord-016476-78r0rsio	454	1	serial	serial	JJ
cord-016476-78r0rsio	454	2	CT	CT	NNP
cord-016476-78r0rsio	454	3	findings	finding	NNS
cord-016476-78r0rsio	454	4	Spectrum	Spectrum	NNP
cord-016476-78r0rsio	454	5	of	of	IN
cord-016476-78r0rsio	454	6	CD4	CD4	NNP
cord-016476-78r0rsio	454	7	to	to	IN
cord-016476-78r0rsio	454	8	CD8	CD8	NNP
cord-016476-78r0rsio	454	9	T	T	NNP
cord-016476-78r0rsio	454	10	-	-	HYPH
cord-016476-78r0rsio	454	11	cell	cell	NN
cord-016476-78r0rsio	454	12	ratios	ratio	NNS
cord-016476-78r0rsio	454	13	in	in	IN
cord-016476-78r0rsio	454	14	lymphocytic	lymphocytic	JJ
cord-016476-78r0rsio	454	15	alveolitis	alveolitis	NN
cord-016476-78r0rsio	454	16	associated	associate	VBN
cord-016476-78r0rsio	454	17	with	with	IN
cord-016476-78r0rsio	454	18	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	454	19	-	-	HYPH
cord-016476-78r0rsio	454	20	induced	induce	VBN
cord-016476-78r0rsio	454	21	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	454	22	Bronchoalveolar	Bronchoalveolar	NNP
cord-016476-78r0rsio	454	23	lavage	lavage	NN
cord-016476-78r0rsio	454	24	cell	cell	NN
cord-016476-78r0rsio	454	25	profile	profile	NN
cord-016476-78r0rsio	454	26	in	in	IN
cord-016476-78r0rsio	454	27	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	454	28	induced	induce	VBN
cord-016476-78r0rsio	454	29	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	454	30	Incidence	incidence	NN
cord-016476-78r0rsio	454	31	,	,	,
cord-016476-78r0rsio	454	32	prevalence	prevalence	NN
cord-016476-78r0rsio	454	33	and	and	CC
cord-016476-78r0rsio	454	34	possible	possible	JJ
cord-016476-78r0rsio	454	35	risk	risk	NN
cord-016476-78r0rsio	454	36	factors	factor	NNS
cord-016476-78r0rsio	454	37	for	for	IN
cord-016476-78r0rsio	454	38	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	454	39	in	in	IN
cord-016476-78r0rsio	454	40	patients	patient	NNS
cord-016476-78r0rsio	454	41	with	with	IN
cord-016476-78r0rsio	454	42	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	454	43	arthritis	arthritis	NN
cord-016476-78r0rsio	454	44	receiving	receive	VBG
cord-016476-78r0rsio	454	45	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	454	46	Pneumonitis	Pneumonitis	NNP
cord-016476-78r0rsio	454	47	complicating	complicate	VBG
cord-016476-78r0rsio	454	48	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	454	49	therapy	therapy	NN
cord-016476-78r0rsio	454	50	for	for	IN
cord-016476-78r0rsio	454	51	pustular	pustular	JJ
cord-016476-78r0rsio	454	52	psoriasis	psoriasis	NN
cord-016476-78r0rsio	455	1	Methotrexate	Methotrexate	NNP
cord-016476-78r0rsio	455	2	use	use	NN
cord-016476-78r0rsio	455	3	and	and	CC
cord-016476-78r0rsio	455	4	risk	risk	NN
cord-016476-78r0rsio	455	5	of	of	IN
cord-016476-78r0rsio	455	6	lung	lung	NN
cord-016476-78r0rsio	455	7	disease	disease	NN
cord-016476-78r0rsio	455	8	in	in	IN
cord-016476-78r0rsio	455	9	psoriasis	psoriasis	NN
cord-016476-78r0rsio	455	10	,	,	,
cord-016476-78r0rsio	455	11	psoriatic	psoriatic	JJ
cord-016476-78r0rsio	455	12	arthritis	arthritis	NN
cord-016476-78r0rsio	455	13	,	,	,
cord-016476-78r0rsio	455	14	and	and	CC
cord-016476-78r0rsio	455	15	inflammatory	inflammatory	JJ
cord-016476-78r0rsio	455	16	bowel	bowel	NN
cord-016476-78r0rsio	455	17	disease	disease	NN
cord-016476-78r0rsio	455	18	:	:	:
cord-016476-78r0rsio	455	19	systematic	systematic	JJ
cord-016476-78r0rsio	455	20	literature	literature	NN
cord-016476-78r0rsio	455	21	review	review	NN
cord-016476-78r0rsio	455	22	and	and	CC
cord-016476-78r0rsio	455	23	metaanalysis	metaanalysis	NN
cord-016476-78r0rsio	455	24	of	of	IN
cord-016476-78r0rsio	455	25	randomised	randomised	JJ
cord-016476-78r0rsio	455	26	controlled	control	VBN
cord-016476-78r0rsio	455	27	trials	trial	NNS
cord-016476-78r0rsio	455	28	Risk	Risk	NNP
cord-016476-78r0rsio	455	29	factors	factor	NNS
cord-016476-78r0rsio	455	30	for	for	IN
cord-016476-78r0rsio	455	31	methotrexate	methotrexate	NN
cord-016476-78r0rsio	455	32	-	-	HYPH
cord-016476-78r0rsio	455	33	induced	induce	VBN
cord-016476-78r0rsio	455	34	lung	lung	NN
cord-016476-78r0rsio	455	35	injury	injury	NN
cord-016476-78r0rsio	455	36	in	in	IN
cord-016476-78r0rsio	455	37	patients	patient	NNS
cord-016476-78r0rsio	455	38	with	with	IN
cord-016476-78r0rsio	455	39	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	455	40	arthritis	arthritis	NN
cord-016476-78r0rsio	455	41	:	:	:
cord-016476-78r0rsio	455	42	a	a	DT
cord-016476-78r0rsio	455	43	multicenter	multicenter	NN
cord-016476-78r0rsio	455	44	,	,	,
cord-016476-78r0rsio	455	45	case	case	NN
cord-016476-78r0rsio	455	46	-	-	HYPH
cord-016476-78r0rsio	455	47	control	control	NN
cord-016476-78r0rsio	455	48	study	study	NN
cord-016476-78r0rsio	455	49	Reducing	reduce	VBG
cord-016476-78r0rsio	455	50	the	the	DT
cord-016476-78r0rsio	455	51	risk	risk	NN
cord-016476-78r0rsio	455	52	of	of	IN
cord-016476-78r0rsio	455	53	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	455	54	pneumonitis	pneumonitis	NNP
cord-016476-78r0rsio	455	55	in	in	IN
cord-016476-78r0rsio	455	56	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	455	57	arthritis	arthritis	NN
cord-016476-78r0rsio	455	58	Pulmonary	pulmonary	JJ
cord-016476-78r0rsio	455	59	function	function	NN
cord-016476-78r0rsio	455	60	in	in	IN
cord-016476-78r0rsio	455	61	patients	patient	NNS
cord-016476-78r0rsio	455	62	receiving	receive	VBG
cord-016476-78r0rsio	455	63	long	long	JJ
cord-016476-78r0rsio	455	64	-	-	HYPH
cord-016476-78r0rsio	455	65	term	term	NN
cord-016476-78r0rsio	455	66	low	low	JJ
cord-016476-78r0rsio	455	67	-	-	HYPH
cord-016476-78r0rsio	455	68	dose	dose	NN
cord-016476-78r0rsio	455	69	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	455	70	Can	Can	MD
cord-016476-78r0rsio	455	71	baseline	baseline	VB
cord-016476-78r0rsio	455	72	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	455	73	function	function	NN
cord-016476-78r0rsio	455	74	tests	test	NNS
cord-016476-78r0rsio	455	75	predict	predict	VBP
cord-016476-78r0rsio	455	76	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	455	77	toxicity	toxicity	NN
cord-016476-78r0rsio	455	78	in	in	IN
cord-016476-78r0rsio	455	79	patients	patient	NNS
cord-016476-78r0rsio	455	80	receiving	receive	VBG
cord-016476-78r0rsio	455	81	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	455	82	for	for	IN
cord-016476-78r0rsio	455	83	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	455	84	arthritis	arthritis	NN
cord-016476-78r0rsio	455	85	?	?	.
cord-016476-78r0rsio	456	1	Interstitial	interstitial	JJ
cord-016476-78r0rsio	456	2	lung	lung	NN
cord-016476-78r0rsio	456	3	disease	disease	NN
cord-016476-78r0rsio	456	4	related	relate	VBN
cord-016476-78r0rsio	456	5	to	to	IN
cord-016476-78r0rsio	456	6	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	456	7	arthritis	arthritis	NN
cord-016476-78r0rsio	456	8	:	:	:
cord-016476-78r0rsio	457	1	evolution	evolution	NN
cord-016476-78r0rsio	457	2	after	after	IN
cord-016476-78r0rsio	457	3	treatment	treatment	NN
cord-016476-78r0rsio	457	4	Interstitial	interstitial	JJ
cord-016476-78r0rsio	457	5	lung	lung	NN
cord-016476-78r0rsio	457	6	disease	disease	NN
cord-016476-78r0rsio	457	7	associated	associate	VBN
cord-016476-78r0rsio	457	8	with	with	IN
cord-016476-78r0rsio	457	9	leflunomide	leflunomide	NN
cord-016476-78r0rsio	457	10	Japan	Japan	NNP
cord-016476-78r0rsio	457	11	deaths	death	NNS
cord-016476-78r0rsio	457	12	spark	spark	VBP
cord-016476-78r0rsio	457	13	concerns	concern	NNS
cord-016476-78r0rsio	457	14	over	over	IN
cord-016476-78r0rsio	457	15	arthritis	arthritis	NN
cord-016476-78r0rsio	457	16	drug	drug	NN
cord-016476-78r0rsio	457	17	Risk	Risk	NNP
cord-016476-78r0rsio	457	18	of	of	IN
cord-016476-78r0rsio	457	19	interstitial	interstitial	JJ
cord-016476-78r0rsio	457	20	lung	lung	NN
cord-016476-78r0rsio	457	21	disease	disease	NN
cord-016476-78r0rsio	457	22	associated	associate	VBN
cord-016476-78r0rsio	457	23	with	with	IN
cord-016476-78r0rsio	457	24	leflunomide	leflunomide	JJ
cord-016476-78r0rsio	457	25	treatment	treatment	NN
cord-016476-78r0rsio	457	26	in	in	IN
cord-016476-78r0rsio	457	27	Korean	korean	JJ
cord-016476-78r0rsio	457	28	patients	patient	NNS
cord-016476-78r0rsio	457	29	with	with	IN
cord-016476-78r0rsio	457	30	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	457	31	arthritis	arthritis	NN
cord-016476-78r0rsio	457	32	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	457	33	arthritis	arthritis	NN
cord-016476-78r0rsio	457	34	complicated	complicate	VBN
cord-016476-78r0rsio	457	35	with	with	IN
cord-016476-78r0rsio	457	36	acute	acute	JJ
cord-016476-78r0rsio	457	37	interstitial	interstitial	JJ
cord-016476-78r0rsio	457	38	pneumonia	pneumonia	NN
cord-016476-78r0rsio	457	39	induced	induce	VBN
cord-016476-78r0rsio	457	40	by	by	IN
cord-016476-78r0rsio	457	41	leflunomide	leflunomide	NN
cord-016476-78r0rsio	457	42	as	as	IN
cord-016476-78r0rsio	457	43	an	an	DT
cord-016476-78r0rsio	457	44	adverse	adverse	JJ
cord-016476-78r0rsio	457	45	reaction	reaction	NN
cord-016476-78r0rsio	457	46	Leflunomide	Leflunomide	NNP
cord-016476-78r0rsio	457	47	-	-	HYPH
cord-016476-78r0rsio	457	48	related	relate	VBN
cord-016476-78r0rsio	457	49	acute	acute	JJ
cord-016476-78r0rsio	457	50	interstitial	interstitial	JJ
cord-016476-78r0rsio	457	51	pneumonia	pneumonia	NN
cord-016476-78r0rsio	457	52	in	in	IN
cord-016476-78r0rsio	457	53	two	two	CD
cord-016476-78r0rsio	457	54	patients	patient	NNS
cord-016476-78r0rsio	457	55	with	with	IN
cord-016476-78r0rsio	457	56	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	457	57	arthritis	arthritis	NN
cord-016476-78r0rsio	457	58	:	:	:
cord-016476-78r0rsio	457	59	autopsy	autopsy	JJ
cord-016476-78r0rsio	457	60	findings	finding	NNS
cord-016476-78r0rsio	457	61	with	with	IN
cord-016476-78r0rsio	457	62	a	a	DT
cord-016476-78r0rsio	457	63	mosaic	mosaic	JJ
cord-016476-78r0rsio	457	64	pattern	pattern	NN
cord-016476-78r0rsio	457	65	of	of	IN
cord-016476-78r0rsio	457	66	acute	acute	JJ
cord-016476-78r0rsio	457	67	and	and	CC
cord-016476-78r0rsio	457	68	organizing	organizing	NN
cord-016476-78r0rsio	458	1	diffuse	diffuse	VB
cord-016476-78r0rsio	458	2	alveolar	alveolar	NN
cord-016476-78r0rsio	458	3	damage	damage	NN
cord-016476-78r0rsio	458	4	Pneumonitis	Pneumonitis	NNP
cord-016476-78r0rsio	458	5	associated	associate	VBN
cord-016476-78r0rsio	458	6	with	with	IN
cord-016476-78r0rsio	458	7	leflunomide	leflunomide	NN
cord-016476-78r0rsio	458	8	:	:	:
cord-016476-78r0rsio	458	9	a	a	DT
cord-016476-78r0rsio	458	10	profile	profile	NN
cord-016476-78r0rsio	458	11	of	of	IN
cord-016476-78r0rsio	458	12	New	New	NNP
cord-016476-78r0rsio	458	13	Zealand	Zealand	NNP
cord-016476-78r0rsio	458	14	and	and	CC
cord-016476-78r0rsio	459	1	Australian	australian	JJ
cord-016476-78r0rsio	459	2	reports	report	VBZ
cord-016476-78r0rsio	459	3	Clinical	clinical	JJ
cord-016476-78r0rsio	459	4	expression	expression	NN
cord-016476-78r0rsio	459	5	of	of	IN
cord-016476-78r0rsio	459	6	leflunomide	leflunomide	NN
cord-016476-78r0rsio	459	7	-	-	HYPH
cord-016476-78r0rsio	459	8	induced	induce	VBN
cord-016476-78r0rsio	459	9	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	459	10	Leflunomide	Leflunomide	NNP
cord-016476-78r0rsio	459	11	use	use	NN
cord-016476-78r0rsio	459	12	and	and	CC
cord-016476-78r0rsio	459	13	the	the	DT
cord-016476-78r0rsio	459	14	risk	risk	NN
cord-016476-78r0rsio	459	15	of	of	IN
cord-016476-78r0rsio	459	16	interstitial	interstitial	JJ
cord-016476-78r0rsio	459	17	lung	lung	NN
cord-016476-78r0rsio	459	18	disease	disease	NN
cord-016476-78r0rsio	459	19	in	in	IN
cord-016476-78r0rsio	459	20	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	459	21	arthritis	arthritis	NN
cord-016476-78r0rsio	459	22	Leflunomide	Leflunomide	NNP
cord-016476-78r0rsio	459	23	-	-	HYPH
cord-016476-78r0rsio	459	24	induced	induce	VBN
cord-016476-78r0rsio	459	25	interstitial	interstitial	JJ
cord-016476-78r0rsio	459	26	lung	lung	NN
cord-016476-78r0rsio	459	27	disease	disease	NN
cord-016476-78r0rsio	459	28	:	:	:
cord-016476-78r0rsio	459	29	prevalence	prevalence	NN
cord-016476-78r0rsio	459	30	and	and	CC
cord-016476-78r0rsio	459	31	risk	risk	NN
cord-016476-78r0rsio	459	32	factors	factor	NNS
cord-016476-78r0rsio	459	33	in	in	IN
cord-016476-78r0rsio	459	34	Japanese	japanese	JJ
cord-016476-78r0rsio	459	35	patients	patient	NNS
cord-016476-78r0rsio	459	36	with	with	IN
cord-016476-78r0rsio	459	37	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	459	38	arthritis	arthritis	NN
cord-016476-78r0rsio	459	39	Interstitial	interstitial	JJ
cord-016476-78r0rsio	459	40	lung	lung	NN
cord-016476-78r0rsio	459	41	diseases	disease	NNS
cord-016476-78r0rsio	459	42	induced	induce	VBN
cord-016476-78r0rsio	459	43	or	or	CC
cord-016476-78r0rsio	459	44	exacerbated	exacerbate	VBN
cord-016476-78r0rsio	459	45	by	by	IN
cord-016476-78r0rsio	459	46	DMARDS	DMARDS	NNP
cord-016476-78r0rsio	459	47	and	and	CC
cord-016476-78r0rsio	459	48	biologic	biologic	JJ
cord-016476-78r0rsio	459	49	agents	agent	NNS
cord-016476-78r0rsio	459	50	in	in	IN
cord-016476-78r0rsio	459	51	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	459	52	arthritis	arthritis	NN
cord-016476-78r0rsio	459	53	:	:	:
cord-016476-78r0rsio	460	1	a	a	DT
cord-016476-78r0rsio	460	2	systematic	systematic	JJ
cord-016476-78r0rsio	460	3	literature	literature	NN
cord-016476-78r0rsio	460	4	review	review	NN
cord-016476-78r0rsio	460	5	HLA	HLA	NNP
cord-016476-78r0rsio	460	6	-	-	HYPH
cord-016476-78r0rsio	460	7	A*31:01	A*31:01	NNP
cord-016476-78r0rsio	460	8	and	and	CC
cord-016476-78r0rsio	460	9	methotrexate	methotrexate	NN
cord-016476-78r0rsio	460	10	-	-	HYPH
cord-016476-78r0rsio	460	11	induced	induce	VBN
cord-016476-78r0rsio	460	12	interstitial	interstitial	JJ
cord-016476-78r0rsio	460	13	lung	lung	NN
cord-016476-78r0rsio	460	14	disease	disease	NN
cord-016476-78r0rsio	460	15	in	in	IN
cord-016476-78r0rsio	460	16	Japanese	japanese	JJ
cord-016476-78r0rsio	460	17	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	460	18	arthritis	arthritis	NN
cord-016476-78r0rsio	460	19	patients	patient	NNS
cord-016476-78r0rsio	460	20	:	:	:
cord-016476-78r0rsio	460	21	a	a	DT
cord-016476-78r0rsio	460	22	multidrug	multidrug	NN
cord-016476-78r0rsio	460	23	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	460	24	marker	marker	NN
cord-016476-78r0rsio	460	25	?	?	.
cord-016476-78r0rsio	461	1	Risk	risk	NN
cord-016476-78r0rsio	461	2	of	of	IN
cord-016476-78r0rsio	461	3	interstitial	interstitial	JJ
cord-016476-78r0rsio	461	4	lung	lung	NN
cord-016476-78r0rsio	461	5	disease	disease	NN
cord-016476-78r0rsio	461	6	associated	associate	VBN
cord-016476-78r0rsio	461	7	with	with	IN
cord-016476-78r0rsio	461	8	leflunomide	leflunomide	JJ
cord-016476-78r0rsio	461	9	treatment	treatment	NN
cord-016476-78r0rsio	461	10	in	in	IN
cord-016476-78r0rsio	461	11	Korean	korean	JJ
cord-016476-78r0rsio	461	12	patients	patient	NNS
cord-016476-78r0rsio	461	13	with	with	IN
cord-016476-78r0rsio	461	14	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	461	15	arthritis	arthritis	NN
cord-016476-78r0rsio	461	16	Factors	factor	NNS
cord-016476-78r0rsio	461	17	associated	associate	VBN
cord-016476-78r0rsio	461	18	with	with	IN
cord-016476-78r0rsio	461	19	fatal	fatal	JJ
cord-016476-78r0rsio	461	20	outcome	outcome	NN
cord-016476-78r0rsio	461	21	of	of	IN
cord-016476-78r0rsio	461	22	leflunomideinduced	leflunomideinduced	JJ
cord-016476-78r0rsio	461	23	lung	lung	NN
cord-016476-78r0rsio	461	24	injury	injury	NN
cord-016476-78r0rsio	461	25	in	in	IN
cord-016476-78r0rsio	461	26	Japanese	japanese	JJ
cord-016476-78r0rsio	461	27	patients	patient	NNS
cord-016476-78r0rsio	461	28	with	with	IN
cord-016476-78r0rsio	461	29	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	461	30	arthritis	arthritis	NN
cord-016476-78r0rsio	461	31	Sulfasalazine	Sulfasalazine	NNP
cord-016476-78r0rsio	461	32	:	:	:
cord-016476-78r0rsio	461	33	a	a	DT
cord-016476-78r0rsio	461	34	rare	rare	JJ
cord-016476-78r0rsio	461	35	cause	cause	NN
cord-016476-78r0rsio	461	36	of	of	IN
cord-016476-78r0rsio	461	37	acute	acute	JJ
cord-016476-78r0rsio	461	38	eosinophilic	eosinophilic	JJ
cord-016476-78r0rsio	461	39	pneumonia	pneumonia	NN
cord-016476-78r0rsio	461	40	A	a	DT
cord-016476-78r0rsio	461	41	case	case	NN
cord-016476-78r0rsio	461	42	of	of	IN
cord-016476-78r0rsio	461	43	severe	severe	JJ
cord-016476-78r0rsio	461	44	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	461	45	infiltration	infiltration	NN
cord-016476-78r0rsio	461	46	with	with	IN
cord-016476-78r0rsio	461	47	eosinophilia	eosinophilia	NN
cord-016476-78r0rsio	461	48	(	(	-LRB-
cord-016476-78r0rsio	461	49	PIE	pie	NN
cord-016476-78r0rsio	461	50	)	)	-RRB-
cord-016476-78r0rsio	461	51	syndrome	syndrome	NN
cord-016476-78r0rsio	461	52	induced	induce	VBN
cord-016476-78r0rsio	461	53	by	by	IN
cord-016476-78r0rsio	461	54	sulphasalazine	sulphasalazine	NN
cord-016476-78r0rsio	461	55	Pulmonary	pulmonary	JJ
cord-016476-78r0rsio	461	56	infiltration	infiltration	NN
cord-016476-78r0rsio	461	57	and	and	CC
cord-016476-78r0rsio	461	58	eosinophilia	eosinophilia	NN
cord-016476-78r0rsio	461	59	associated	associate	VBN
cord-016476-78r0rsio	461	60	with	with	IN
cord-016476-78r0rsio	461	61	sulfasalazine	sulfasalazine	NN
cord-016476-78r0rsio	461	62	therapy	therapy	NN
cord-016476-78r0rsio	461	63	for	for	IN
cord-016476-78r0rsio	461	64	ulcerative	ulcerative	JJ
cord-016476-78r0rsio	461	65	colitis	colitis	NNP
cord-016476-78r0rsio	461	66	:	:	:
cord-016476-78r0rsio	461	67	a	a	DT
cord-016476-78r0rsio	461	68	case	case	NN
cord-016476-78r0rsio	461	69	report	report	NN
cord-016476-78r0rsio	461	70	and	and	CC
cord-016476-78r0rsio	461	71	review	review	NN
cord-016476-78r0rsio	461	72	of	of	IN
cord-016476-78r0rsio	461	73	literature	literature	NN
cord-016476-78r0rsio	461	74	Sulphasalazine	Sulphasalazine	NNP
cord-016476-78r0rsio	461	75	and	and	CC
cord-016476-78r0rsio	461	76	lung	lung	NN
cord-016476-78r0rsio	461	77	toxicity	toxicity	NN
cord-016476-78r0rsio	461	78	DRESS	dress	NN
cord-016476-78r0rsio	461	79	syndrome	syndrome	NN
cord-016476-78r0rsio	461	80	in	in	IN
cord-016476-78r0rsio	461	81	a	a	DT
cord-016476-78r0rsio	461	82	patient	patient	NN
cord-016476-78r0rsio	461	83	on	on	IN
cord-016476-78r0rsio	461	84	sulfasalazine	sulfasalazine	NN
cord-016476-78r0rsio	461	85	for	for	IN
cord-016476-78r0rsio	461	86	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	461	87	arthritis	arthritis	NN
cord-016476-78r0rsio	461	88	Severe	severe	JJ
cord-016476-78r0rsio	461	89	drug	drug	NN
cord-016476-78r0rsio	461	90	hypersensitivity	hypersensitivity	NN
cord-016476-78r0rsio	461	91	syndrome	syndrome	NN
cord-016476-78r0rsio	461	92	due	due	JJ
cord-016476-78r0rsio	461	93	to	to	IN
cord-016476-78r0rsio	461	94	sulphasalazine	sulphasalazine	NN
cord-016476-78r0rsio	461	95	in	in	IN
cord-016476-78r0rsio	461	96	patient	patient	NN
cord-016476-78r0rsio	461	97	with	with	IN
cord-016476-78r0rsio	461	98	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	461	99	arthritis	arthritis	NN
cord-016476-78r0rsio	461	100	Review	Review	NNP
cord-016476-78r0rsio	461	101	series	series	NN
cord-016476-78r0rsio	461	102	:	:	:
cord-016476-78r0rsio	461	103	aspects	aspect	NNS
cord-016476-78r0rsio	461	104	of	of	IN
cord-016476-78r0rsio	461	105	interstitial	interstitial	JJ
cord-016476-78r0rsio	461	106	lung	lung	NN
cord-016476-78r0rsio	461	107	disease	disease	NN
cord-016476-78r0rsio	461	108	:	:	:
cord-016476-78r0rsio	461	109	connective	connective	JJ
cord-016476-78r0rsio	461	110	tissue	tissue	NN
cord-016476-78r0rsio	461	111	disease	disease	NN
cord-016476-78r0rsio	461	112	-	-	HYPH
cord-016476-78r0rsio	461	113	associated	associate	VBN
cord-016476-78r0rsio	461	114	interstitial	interstitial	JJ
cord-016476-78r0rsio	461	115	lung	lung	NN
cord-016476-78r0rsio	461	116	disease	disease	NN
cord-016476-78r0rsio	462	1	:	:	:
cord-016476-78r0rsio	462	2	how	how	WRB
cord-016476-78r0rsio	462	3	does	do	VBZ
cord-016476-78r0rsio	462	4	it	-PRON-	PRP
cord-016476-78r0rsio	462	5	differ	differ	VB
cord-016476-78r0rsio	462	6	from	from	IN
cord-016476-78r0rsio	462	7	IPF	IPF	NNP
cord-016476-78r0rsio	462	8	?	?	.
cord-016476-78r0rsio	463	1	How	how	WRB
cord-016476-78r0rsio	463	2	should	should	MD
cord-016476-78r0rsio	463	3	the	the	DT
cord-016476-78r0rsio	463	4	clinical	clinical	JJ
cord-016476-78r0rsio	463	5	approach	approach	NN
cord-016476-78r0rsio	463	6	differ	differ	VB
cord-016476-78r0rsio	463	7	?	?	.
cord-016476-78r0rsio	464	1	Interstitial	interstitial	JJ
cord-016476-78r0rsio	464	2	lung	lung	NN
cord-016476-78r0rsio	464	3	disease	disease	NN
cord-016476-78r0rsio	464	4	induced	induce	VBN
cord-016476-78r0rsio	464	5	by	by	IN
cord-016476-78r0rsio	464	6	hydroxychloroquine	hydroxychloroquine	NNP
cord-016476-78r0rsio	464	7	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-016476-78r0rsio	464	8	-	-	HYPH
cord-016476-78r0rsio	464	9	induced	induce	VBN
cord-016476-78r0rsio	464	10	DRESS	dress	NN
cord-016476-78r0rsio	464	11	syndrome	syndrome	NN
cord-016476-78r0rsio	464	12	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-016476-78r0rsio	464	13	in	in	IN
cord-016476-78r0rsio	464	14	children	child	NNS
cord-016476-78r0rsio	464	15	with	with	IN
cord-016476-78r0rsio	464	16	interstitial	interstitial	JJ
cord-016476-78r0rsio	464	17	(	(	-LRB-
cord-016476-78r0rsio	464	18	diffuse	diffuse	JJ
cord-016476-78r0rsio	464	19	parenchymal	parenchymal	NN
cord-016476-78r0rsio	464	20	)	)	-RRB-
cord-016476-78r0rsio	464	21	lung	lung	NN
cord-016476-78r0rsio	464	22	diseases	disease	NNS
cord-016476-78r0rsio	465	1	Biologics	biologic	NNS
cord-016476-78r0rsio	465	2	-	-	HYPH
cord-016476-78r0rsio	465	3	induced	induce	VBN
cord-016476-78r0rsio	465	4	autoimmune	autoimmune	JJ
cord-016476-78r0rsio	465	5	diseases	disease	NNS
cord-016476-78r0rsio	466	1	Autoimmune	autoimmune	JJ
cord-016476-78r0rsio	466	2	diseases	disease	NNS
cord-016476-78r0rsio	466	3	induced	induce	VBN
cord-016476-78r0rsio	466	4	by	by	IN
cord-016476-78r0rsio	466	5	TNFtargeted	tnftargeted	JJ
cord-016476-78r0rsio	466	6	therapies	therapy	NNS
cord-016476-78r0rsio	466	7	:	:	:
cord-016476-78r0rsio	466	8	analysis	analysis	NN
cord-016476-78r0rsio	466	9	of	of	IN
cord-016476-78r0rsio	466	10	233	233	CD
cord-016476-78r0rsio	466	11	cases	case	NNS
cord-016476-78r0rsio	466	12	Role	role	NN
cord-016476-78r0rsio	466	13	of	of	IN
cord-016476-78r0rsio	466	14	tumor	tumor	NN
cord-016476-78r0rsio	466	15	necrosis	necrosis	NN
cord-016476-78r0rsio	466	16	factor	factor	NN
cord-016476-78r0rsio	466	17	-	-	HYPH
cord-016476-78r0rsio	466	18	alpha	alpha	NN
cord-016476-78r0rsio	466	19	in	in	IN
cord-016476-78r0rsio	466	20	the	the	DT
cord-016476-78r0rsio	466	21	spontaneous	spontaneous	JJ
cord-016476-78r0rsio	466	22	development	development	NN
cord-016476-78r0rsio	466	23	of	of	IN
cord-016476-78r0rsio	466	24	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	466	25	fibrosis	fibrosis	NN
cord-016476-78r0rsio	466	26	in	in	IN
cord-016476-78r0rsio	466	27	viable	viable	JJ
cord-016476-78r0rsio	466	28	motheaten	motheaten	JJ
cord-016476-78r0rsio	466	29	mutant	mutant	JJ
cord-016476-78r0rsio	466	30	mice	mice	NN
cord-016476-78r0rsio	466	31	Expression	expression	NN
cord-016476-78r0rsio	466	32	and	and	CC
cord-016476-78r0rsio	466	33	localization	localization	NN
cord-016476-78r0rsio	466	34	of	of	IN
cord-016476-78r0rsio	466	35	tumor	tumor	NN
cord-016476-78r0rsio	466	36	necrosis	necrosis	NN
cord-016476-78r0rsio	466	37	factoralpha	factoralpha	NNP
cord-016476-78r0rsio	466	38	and	and	CC
cord-016476-78r0rsio	466	39	its	-PRON-	PRP$
cord-016476-78r0rsio	466	40	mRNA	mrna	NN
cord-016476-78r0rsio	466	41	in	in	IN
cord-016476-78r0rsio	466	42	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	466	43	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	466	44	fibrosis	fibrosis	NN
cord-016476-78r0rsio	466	45	A	a	DT
cord-016476-78r0rsio	466	46	case	case	NN
cord-016476-78r0rsio	466	47	of	of	IN
cord-016476-78r0rsio	466	48	interstitial	interstitial	JJ
cord-016476-78r0rsio	466	49	pneumonia	pneumonia	NN
cord-016476-78r0rsio	466	50	induced	induce	VBN
cord-016476-78r0rsio	466	51	by	by	IN
cord-016476-78r0rsio	466	52	rituximab	rituximab	NN
cord-016476-78r0rsio	466	53	therapy	therapy	NN
cord-016476-78r0rsio	467	1	Infliximab	Infliximab	NNP
cord-016476-78r0rsio	467	2	(	(	-LRB-
cord-016476-78r0rsio	467	3	chimeric	chimeric	JJ
cord-016476-78r0rsio	467	4	anti	anti	JJ
cord-016476-78r0rsio	467	5	-	-	JJ
cord-016476-78r0rsio	467	6	tumour	tumour	JJ
cord-016476-78r0rsio	467	7	necrosis	necrosis	NN
cord-016476-78r0rsio	467	8	factor	factor	NN
cord-016476-78r0rsio	467	9	alpha	alpha	NN
cord-016476-78r0rsio	467	10	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	467	11	antibody	antibody	NN
cord-016476-78r0rsio	467	12	)	)	-RRB-
cord-016476-78r0rsio	467	13	versus	versus	IN
cord-016476-78r0rsio	467	14	placebo	placebo	NN
cord-016476-78r0rsio	467	15	in	in	IN
cord-016476-78r0rsio	467	16	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	467	17	arthritis	arthritis	NN
cord-016476-78r0rsio	467	18	patients	patient	NNS
cord-016476-78r0rsio	467	19	receiving	receive	VBG
cord-016476-78r0rsio	467	20	concomitant	concomitant	JJ
cord-016476-78r0rsio	467	21	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	467	22	:	:	:
cord-016476-78r0rsio	467	23	a	a	DT
cord-016476-78r0rsio	467	24	randomised	randomised	JJ
cord-016476-78r0rsio	467	25	phase	phase	NN
cord-016476-78r0rsio	467	26	III	iii	CD
cord-016476-78r0rsio	467	27	trial	trial	NN
cord-016476-78r0rsio	467	28	.	.	.
cord-016476-78r0rsio	468	1	ATTRACT	attract	VB
cord-016476-78r0rsio	468	2	study	study	NN
cord-016476-78r0rsio	468	3	group	group	NN
cord-016476-78r0rsio	469	1	A	a	DT
cord-016476-78r0rsio	469	2	comparison	comparison	NN
cord-016476-78r0rsio	469	3	of	of	IN
cord-016476-78r0rsio	469	4	etanercept	etanercept	NNP
cord-016476-78r0rsio	469	5	and	and	CC
cord-016476-78r0rsio	469	6	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	469	7	in	in	IN
cord-016476-78r0rsio	469	8	patients	patient	NNS
cord-016476-78r0rsio	469	9	with	with	IN
cord-016476-78r0rsio	469	10	early	early	JJ
cord-016476-78r0rsio	469	11	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	469	12	arthritis	arthritis	NN
cord-016476-78r0rsio	469	13	Etanercept	Etanercept	NNP
cord-016476-78r0rsio	469	14	versus	versus	IN
cord-016476-78r0rsio	469	15	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	469	16	in	in	IN
cord-016476-78r0rsio	469	17	patients	patient	NNS
cord-016476-78r0rsio	469	18	with	with	IN
cord-016476-78r0rsio	469	19	early	early	JJ
cord-016476-78r0rsio	469	20	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	469	21	arthritis	arthritis	NN
cord-016476-78r0rsio	469	22	:	:	:
cord-016476-78r0rsio	469	23	two	two	CD
cord-016476-78r0rsio	469	24	-	-	HYPH
cord-016476-78r0rsio	469	25	year	year	NN
cord-016476-78r0rsio	469	26	radiographic	radiographic	JJ
cord-016476-78r0rsio	469	27	and	and	CC
cord-016476-78r0rsio	469	28	clinical	clinical	JJ
cord-016476-78r0rsio	469	29	outcomes	outcome	NNS
cord-016476-78r0rsio	470	1	Longterm	longterm	JJ
cord-016476-78r0rsio	470	2	safety	safety	NN
cord-016476-78r0rsio	470	3	,	,	,
cord-016476-78r0rsio	470	4	efficacy	efficacy	NN
cord-016476-78r0rsio	470	5	,	,	,
cord-016476-78r0rsio	470	6	and	and	CC
cord-016476-78r0rsio	470	7	radiographic	radiographic	JJ
cord-016476-78r0rsio	470	8	outcome	outcome	NN
cord-016476-78r0rsio	470	9	with	with	IN
cord-016476-78r0rsio	470	10	etanercept	etanercept	NNP
cord-016476-78r0rsio	470	11	treatment	treatment	NN
cord-016476-78r0rsio	470	12	in	in	IN
cord-016476-78r0rsio	470	13	patients	patient	NNS
cord-016476-78r0rsio	470	14	with	with	IN
cord-016476-78r0rsio	470	15	early	early	JJ
cord-016476-78r0rsio	470	16	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	470	17	arthritis	arthritis	NN
cord-016476-78r0rsio	470	18	Etanercept	Etanercept	NNP
cord-016476-78r0rsio	470	19	treatment	treatment	NN
cord-016476-78r0rsio	470	20	in	in	IN
cord-016476-78r0rsio	470	21	adults	adult	NNS
cord-016476-78r0rsio	470	22	with	with	IN
cord-016476-78r0rsio	470	23	established	establish	VBN
cord-016476-78r0rsio	470	24	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	470	25	arthritis	arthritis	NN
cord-016476-78r0rsio	470	26	:	:	:
cord-016476-78r0rsio	470	27	7	7	CD
cord-016476-78r0rsio	470	28	years	year	NNS
cord-016476-78r0rsio	470	29	of	of	IN
cord-016476-78r0rsio	470	30	clinical	clinical	JJ
cord-016476-78r0rsio	470	31	experience	experience	NN
cord-016476-78r0rsio	471	1	The	the	DT
cord-016476-78r0rsio	471	2	PREMIER	PREMIER	NNP
cord-016476-78r0rsio	471	3	study	study	NN
cord-016476-78r0rsio	471	4	:	:	:
cord-016476-78r0rsio	471	5	a	a	DT
cord-016476-78r0rsio	471	6	multicenter	multicenter	NN
cord-016476-78r0rsio	471	7	,	,	,
cord-016476-78r0rsio	471	8	randomized	randomized	JJ
cord-016476-78r0rsio	471	9	,	,	,
cord-016476-78r0rsio	471	10	double	double	JJ
cord-016476-78r0rsio	471	11	-	-	HYPH
cord-016476-78r0rsio	471	12	blind	blind	JJ
cord-016476-78r0rsio	471	13	clinical	clinical	JJ
cord-016476-78r0rsio	471	14	trial	trial	NN
cord-016476-78r0rsio	471	15	of	of	IN
cord-016476-78r0rsio	471	16	combination	combination	NN
cord-016476-78r0rsio	471	17	therapy	therapy	NN
cord-016476-78r0rsio	471	18	with	with	IN
cord-016476-78r0rsio	471	19	adalimumab	adalimumab	NNP
cord-016476-78r0rsio	471	20	plus	plus	CC
cord-016476-78r0rsio	471	21	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	471	22	versus	versus	IN
cord-016476-78r0rsio	471	23	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	471	24	alone	alone	RB
cord-016476-78r0rsio	471	25	or	or	CC
cord-016476-78r0rsio	471	26	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	471	27	alone	alone	JJ
cord-016476-78r0rsio	471	28	in	in	IN
cord-016476-78r0rsio	471	29	patients	patient	NNS
cord-016476-78r0rsio	471	30	with	with	IN
cord-016476-78r0rsio	471	31	early	early	JJ
cord-016476-78r0rsio	471	32	,	,	,
cord-016476-78r0rsio	471	33	aggressive	aggressive	JJ
cord-016476-78r0rsio	471	34	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	35	arthritis	arthritis	NN
cord-016476-78r0rsio	471	36	who	who	WP
cord-016476-78r0rsio	471	37	had	have	VBD
cord-016476-78r0rsio	471	38	not	not	RB
cord-016476-78r0rsio	471	39	had	have	VBN
cord-016476-78r0rsio	471	40	previo	previo	NNP
cord-016476-78r0rsio	471	41	Adalimumab	Adalimumab	NNP
cord-016476-78r0rsio	471	42	alone	alone	RB
cord-016476-78r0rsio	471	43	and	and	CC
cord-016476-78r0rsio	471	44	in	in	IN
cord-016476-78r0rsio	471	45	combination	combination	NN
cord-016476-78r0rsio	471	46	with	with	IN
cord-016476-78r0rsio	471	47	disease	disease	NN
cord-016476-78r0rsio	471	48	-	-	HYPH
cord-016476-78r0rsio	471	49	modifying	modify	VBG
cord-016476-78r0rsio	471	50	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	471	51	drugs	drug	NNS
cord-016476-78r0rsio	471	52	for	for	IN
cord-016476-78r0rsio	471	53	the	the	DT
cord-016476-78r0rsio	471	54	treatment	treatment	NN
cord-016476-78r0rsio	471	55	of	of	IN
cord-016476-78r0rsio	471	56	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	471	57	arthritis	arthritis	NN
cord-016476-78r0rsio	471	58	in	in	IN
cord-016476-78r0rsio	471	59	clinical	clinical	JJ
cord-016476-78r0rsio	471	60	practice	practice	NN
cord-016476-78r0rsio	471	61	:	:	:
cord-016476-78r0rsio	471	62	the	the	DT
cord-016476-78r0rsio	471	63	research	research	NN
cord-016476-78r0rsio	471	64	in	in	IN
cord-016476-78r0rsio	471	65	active	active	JJ
cord-016476-78r0rsio	471	66	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	67	arthritis	arthritis	NN
cord-016476-78r0rsio	471	68	(	(	-LRB-
cord-016476-78r0rsio	471	69	ReAct	ReAct	NNP
cord-016476-78r0rsio	471	70	)	)	-RRB-
cord-016476-78r0rsio	471	71	trial	trial	NN
cord-016476-78r0rsio	471	72	Golimumab	Golimumab	NNP
cord-016476-78r0rsio	471	73	,	,	,
cord-016476-78r0rsio	471	74	a	a	DT
cord-016476-78r0rsio	471	75	human	human	JJ
cord-016476-78r0rsio	471	76	anti	anti	JJ
cord-016476-78r0rsio	471	77	-	-	JJ
cord-016476-78r0rsio	471	78	tumor	tumor	JJ
cord-016476-78r0rsio	471	79	necrosis	necrosis	NN
cord-016476-78r0rsio	471	80	factor	factor	NN
cord-016476-78r0rsio	471	81	alpha	alpha	NN
cord-016476-78r0rsio	471	82	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	471	83	antibody	antibody	NN
cord-016476-78r0rsio	471	84	,	,	,
cord-016476-78r0rsio	471	85	injected	inject	VBN
cord-016476-78r0rsio	471	86	subcutaneously	subcutaneously	RB
cord-016476-78r0rsio	471	87	every	every	DT
cord-016476-78r0rsio	471	88	four	four	CD
cord-016476-78r0rsio	471	89	weeks	week	NNS
cord-016476-78r0rsio	471	90	in	in	IN
cord-016476-78r0rsio	471	91	methotrexatenaive	methotrexatenaive	JJ
cord-016476-78r0rsio	471	92	patients	patient	NNS
cord-016476-78r0rsio	471	93	with	with	IN
cord-016476-78r0rsio	471	94	active	active	JJ
cord-016476-78r0rsio	471	95	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	96	arthritis	arthritis	NN
cord-016476-78r0rsio	471	97	:	:	:
cord-016476-78r0rsio	471	98	twenty	twenty	CD
cord-016476-78r0rsio	471	99	-	-	HYPH
cord-016476-78r0rsio	471	100	four	four	CD
cord-016476-78r0rsio	471	101	-	-	HYPH
cord-016476-78r0rsio	471	102	week	week	NN
cord-016476-78r0rsio	471	103	results	result	NNS
cord-016476-78r0rsio	471	104	of	of	IN
cord-016476-78r0rsio	471	105	a	a	DT
cord-016476-78r0rsio	471	106	phase	phase	NN
cord-016476-78r0rsio	471	107	III	iii	CD
cord-016476-78r0rsio	471	108	,	,	,
cord-016476-78r0rsio	471	109	multicenter	multicenter	JJ
cord-016476-78r0rsio	471	110	,	,	,
cord-016476-78r0rsio	471	111	randomized	randomized	JJ
cord-016476-78r0rsio	471	112	,	,	,
cord-016476-78r0rsio	471	113	double	double	JJ
cord-016476-78r0rsio	471	114	-	-	HYPH
cord-016476-78r0rsio	471	115	bli	bli	NNP
cord-016476-78r0rsio	471	116	Golimumab	Golimumab	NNP
cord-016476-78r0rsio	471	117	,	,	,
cord-016476-78r0rsio	471	118	a	a	DT
cord-016476-78r0rsio	471	119	human	human	JJ
cord-016476-78r0rsio	471	120	antibody	antibody	NN
cord-016476-78r0rsio	471	121	to	to	TO
cord-016476-78r0rsio	471	122	tumour	tumour	VB
cord-016476-78r0rsio	471	123	necrosis	necrosis	NN
cord-016476-78r0rsio	471	124	factor	factor	NN
cord-016476-78r0rsio	471	125	{	{	-LRB-
cord-016476-78r0rsio	471	126	alpha	alpha	NN
cord-016476-78r0rsio	471	127	}	}	-RRB-
cord-016476-78r0rsio	471	128	given	give	VBN
cord-016476-78r0rsio	471	129	by	by	IN
cord-016476-78r0rsio	471	130	monthly	monthly	JJ
cord-016476-78r0rsio	471	131	subcutaneous	subcutaneous	JJ
cord-016476-78r0rsio	471	132	injections	injection	NNS
cord-016476-78r0rsio	471	133	,	,	,
cord-016476-78r0rsio	471	134	in	in	IN
cord-016476-78r0rsio	471	135	active	active	JJ
cord-016476-78r0rsio	471	136	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	137	arthritis	arthritis	NN
cord-016476-78r0rsio	471	138	despite	despite	IN
cord-016476-78r0rsio	471	139	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	471	140	therapy	therapy	NNP
cord-016476-78r0rsio	471	141	:	:	:
cord-016476-78r0rsio	471	142	the	the	DT
cord-016476-78r0rsio	471	143	GO	GO	NNP
cord-016476-78r0rsio	471	144	-	-	HYPH
cord-016476-78r0rsio	471	145	FORWARD	FORWARD	NNP
cord-016476-78r0rsio	471	146	study	study	NN
cord-016476-78r0rsio	471	147	Golimumab	Golimumab	NNP
cord-016476-78r0rsio	471	148	in	in	IN
cord-016476-78r0rsio	471	149	patients	patient	NNS
cord-016476-78r0rsio	471	150	with	with	IN
cord-016476-78r0rsio	471	151	active	active	JJ
cord-016476-78r0rsio	471	152	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	153	arthritis	arthritis	NN
cord-016476-78r0rsio	471	154	who	who	WP
cord-016476-78r0rsio	471	155	have	have	VBP
cord-016476-78r0rsio	471	156	previous	previous	JJ
cord-016476-78r0rsio	471	157	experience	experience	NN
cord-016476-78r0rsio	471	158	with	with	IN
cord-016476-78r0rsio	471	159	tumour	tumour	NN
cord-016476-78r0rsio	471	160	necrosis	necrosis	NN
cord-016476-78r0rsio	471	161	factor	factor	NN
cord-016476-78r0rsio	471	162	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	471	163	:	:	:
cord-016476-78r0rsio	471	164	results	result	NNS
cord-016476-78r0rsio	471	165	of	of	IN
cord-016476-78r0rsio	471	166	a	a	DT
cord-016476-78r0rsio	471	167	long	long	JJ
cord-016476-78r0rsio	471	168	-	-	HYPH
cord-016476-78r0rsio	471	169	term	term	NN
cord-016476-78r0rsio	471	170	extension	extension	NN
cord-016476-78r0rsio	471	171	of	of	IN
cord-016476-78r0rsio	471	172	the	the	DT
cord-016476-78r0rsio	471	173	randomised	randomised	JJ
cord-016476-78r0rsio	471	174	,	,	,
cord-016476-78r0rsio	471	175	double	double	JJ
cord-016476-78r0rsio	471	176	-	-	HYPH
cord-016476-78r0rsio	471	177	blind	blind	JJ
cord-016476-78r0rsio	471	178	,	,	,
cord-016476-78r0rsio	471	179	placebo	placebo	NN
cord-016476-78r0rsio	471	180	-	-	HYPH
cord-016476-78r0rsio	471	181	controlled	control	VBN
cord-016476-78r0rsio	471	182	GO	GO	NNP
cord-016476-78r0rsio	471	183	-	-	HYPH
cord-016476-78r0rsio	471	184	AFTER	after	IN
cord-016476-78r0rsio	471	185	study	study	NN
cord-016476-78r0rsio	471	186	through	through	IN
cord-016476-78r0rsio	471	187	week	week	NN
cord-016476-78r0rsio	471	188	160	160	CD
cord-016476-78r0rsio	471	189	Golimumab	Golimumab	NNPS
cord-016476-78r0rsio	471	190	in	in	IN
cord-016476-78r0rsio	471	191	patients	patient	NNS
cord-016476-78r0rsio	471	192	with	with	IN
cord-016476-78r0rsio	471	193	active	active	JJ
cord-016476-78r0rsio	471	194	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	471	195	arthritis	arthritis	NN
cord-016476-78r0rsio	471	196	after	after	IN
cord-016476-78r0rsio	471	197	treatment	treatment	NN
cord-016476-78r0rsio	471	198	with	with	IN
cord-016476-78r0rsio	471	199	tumor	tumor	NN
cord-016476-78r0rsio	471	200	necrosis	necrosis	NN
cord-016476-78r0rsio	471	201	factor	factor	NN
cord-016476-78r0rsio	472	1	α	α	NNP
cord-016476-78r0rsio	472	2	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	472	3	:	:	:
cord-016476-78r0rsio	472	4	findings	finding	NNS
cord-016476-78r0rsio	472	5	with	with	IN
cord-016476-78r0rsio	472	6	up	up	IN
cord-016476-78r0rsio	472	7	to	to	TO
cord-016476-78r0rsio	472	8	five	five	CD
cord-016476-78r0rsio	472	9	years	year	NNS
cord-016476-78r0rsio	472	10	of	of	IN
cord-016476-78r0rsio	472	11	treatment	treatment	NN
cord-016476-78r0rsio	472	12	in	in	IN
cord-016476-78r0rsio	472	13	the	the	DT
cord-016476-78r0rsio	472	14	multicenter	multicenter	NN
cord-016476-78r0rsio	472	15	,	,	,
cord-016476-78r0rsio	472	16	randomized	randomized	JJ
cord-016476-78r0rsio	472	17	,	,	,
cord-016476-78r0rsio	472	18	double	double	JJ
cord-016476-78r0rsio	472	19	-	-	HYPH
cord-016476-78r0rsio	472	20	blind	blind	JJ
cord-016476-78r0rsio	472	21	,	,	,
cord-016476-78r0rsio	472	22	placebo	placebo	NN
cord-016476-78r0rsio	472	23	-	-	HYPH
cord-016476-78r0rsio	472	24	controlled	control	VBN
cord-016476-78r0rsio	472	25	,	,	,
cord-016476-78r0rsio	472	26	phase	phase	NN
cord-016476-78r0rsio	472	27	3	3	CD
cord-016476-78r0rsio	472	28	GO	go	VB
cord-016476-78r0rsio	472	29	-	-	HYPH
cord-016476-78r0rsio	472	30	AFTER	after	IN
cord-016476-78r0rsio	472	31	study	study	NN
cord-016476-78r0rsio	473	1	Certolizumab	Certolizumab	NNP
cord-016476-78r0rsio	473	2	pegol	pegol	NNP
cord-016476-78r0rsio	473	3	plus	plus	CC
cord-016476-78r0rsio	473	4	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	473	5	is	be	VBZ
cord-016476-78r0rsio	473	6	significantly	significantly	RB
cord-016476-78r0rsio	473	7	more	more	RBR
cord-016476-78r0rsio	473	8	effective	effective	JJ
cord-016476-78r0rsio	473	9	than	than	IN
cord-016476-78r0rsio	473	10	placebo	placebo	NN
cord-016476-78r0rsio	473	11	plus	plus	CC
cord-016476-78r0rsio	473	12	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	473	13	in	in	IN
cord-016476-78r0rsio	473	14	active	active	JJ
cord-016476-78r0rsio	473	15	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	473	16	arthritis	arthritis	NN
cord-016476-78r0rsio	473	17	:	:	:
cord-016476-78r0rsio	473	18	findings	finding	NNS
cord-016476-78r0rsio	473	19	of	of	IN
cord-016476-78r0rsio	473	20	a	a	DT
cord-016476-78r0rsio	473	21	fifty	fifty	CD
cord-016476-78r0rsio	473	22	-	-	HYPH
cord-016476-78r0rsio	473	23	two	two	CD
cord-016476-78r0rsio	473	24	-	-	HYPH
cord-016476-78r0rsio	473	25	week	week	NN
cord-016476-78r0rsio	473	26	,	,	,
cord-016476-78r0rsio	473	27	phase	phase	NN
cord-016476-78r0rsio	473	28	III	III	NNP
cord-016476-78r0rsio	473	29	,	,	,
cord-016476-78r0rsio	473	30	multicenter	multicenter	JJ
cord-016476-78r0rsio	473	31	,	,	,
cord-016476-78r0rsio	473	32	randomized	randomized	JJ
cord-016476-78r0rsio	473	33	,	,	,
cord-016476-78r0rsio	473	34	double	double	JJ
cord-016476-78r0rsio	473	35	-	-	HYPH
cord-016476-78r0rsio	473	36	blind	blind	JJ
cord-016476-78r0rsio	473	37	,	,	,
cord-016476-78r0rsio	473	38	placebo	placebo	NN
cord-016476-78r0rsio	473	39	-	-	HYPH
cord-016476-78r0rsio	473	40	controlled	control	VBN
cord-016476-78r0rsio	473	41	,	,	,
cord-016476-78r0rsio	473	42	parallel	parallel	JJ
cord-016476-78r0rsio	473	43	-	-	HYPH
cord-016476-78r0rsio	473	44	group	group	NN
cord-016476-78r0rsio	473	45	study	study	NN
cord-016476-78r0rsio	473	46	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	473	47	and	and	CC
cord-016476-78r0rsio	473	48	safety	safety	NN
cord-016476-78r0rsio	473	49	of	of	IN
cord-016476-78r0rsio	473	50	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	473	51	pegol	pegol	NNP
cord-016476-78r0rsio	473	52	plus	plus	CC
cord-016476-78r0rsio	473	53	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	473	54	in	in	IN
cord-016476-78r0rsio	473	55	active	active	JJ
cord-016476-78r0rsio	473	56	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	473	57	arthritis	arthritis	NN
cord-016476-78r0rsio	473	58	:	:	:
cord-016476-78r0rsio	473	59	the	the	DT
cord-016476-78r0rsio	473	60	RAPID	rapid	JJ
cord-016476-78r0rsio	473	61	2	2	CD
cord-016476-78r0rsio	473	62	study	study	NN
cord-016476-78r0rsio	473	63	.	.	.
cord-016476-78r0rsio	474	1	A	a	DT
cord-016476-78r0rsio	474	2	randomised	randomised	JJ
cord-016476-78r0rsio	474	3	controlled	control	VBN
cord-016476-78r0rsio	474	4	trial	trial	NN
cord-016476-78r0rsio	474	5	Long	long	JJ
cord-016476-78r0rsio	474	6	-	-	HYPH
cord-016476-78r0rsio	474	7	term	term	NN
cord-016476-78r0rsio	474	8	safety	safety	NN
cord-016476-78r0rsio	474	9	and	and	CC
cord-016476-78r0rsio	474	10	efficacy	efficacy	NN
cord-016476-78r0rsio	474	11	of	of	IN
cord-016476-78r0rsio	474	12	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	474	13	pegol	pegol	NNP
cord-016476-78r0rsio	474	14	in	in	IN
cord-016476-78r0rsio	474	15	combination	combination	NN
cord-016476-78r0rsio	474	16	with	with	IN
cord-016476-78r0rsio	474	17	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	474	18	in	in	IN
cord-016476-78r0rsio	474	19	the	the	DT
cord-016476-78r0rsio	474	20	treatment	treatment	NN
cord-016476-78r0rsio	474	21	of	of	IN
cord-016476-78r0rsio	474	22	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	474	23	arthritis	arthritis	NN
cord-016476-78r0rsio	474	24	:	:	:
cord-016476-78r0rsio	475	1	5-year	5-year	CD
cord-016476-78r0rsio	475	2	results	result	NNS
cord-016476-78r0rsio	475	3	from	from	IN
cord-016476-78r0rsio	475	4	the	the	DT
cord-016476-78r0rsio	475	5	RAPID	rapid	JJ
cord-016476-78r0rsio	475	6	1	1	CD
cord-016476-78r0rsio	475	7	trial	trial	NN
cord-016476-78r0rsio	475	8	and	and	CC
cord-016476-78r0rsio	475	9	open	open	JJ
cord-016476-78r0rsio	475	10	-	-	HYPH
cord-016476-78r0rsio	475	11	label	label	NN
cord-016476-78r0rsio	475	12	extension	extension	NN
cord-016476-78r0rsio	475	13	Fatal	fatal	JJ
cord-016476-78r0rsio	475	14	exacerbation	exacerbation	NN
cord-016476-78r0rsio	475	15	of	of	IN
cord-016476-78r0rsio	475	16	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	475	17	arthritis	arthritis	NN
cord-016476-78r0rsio	475	18	associated	associate	VBD
cord-016476-78r0rsio	475	19	fibrosing	fibrose	VBG
cord-016476-78r0rsio	475	20	alveolitis	alveolitis	NNP
cord-016476-78r0rsio	475	21	in	in	IN
cord-016476-78r0rsio	475	22	patients	patient	NNS
cord-016476-78r0rsio	475	23	given	give	VBN
cord-016476-78r0rsio	475	24	infliximab	infliximab	JJ
cord-016476-78r0rsio	475	25	Pulmonary	pulmonary	JJ
cord-016476-78r0rsio	475	26	complications	complication	NNS
cord-016476-78r0rsio	475	27	of	of	IN
cord-016476-78r0rsio	475	28	infliximab	infliximab	JJ
cord-016476-78r0rsio	475	29	therapy	therapy	NN
cord-016476-78r0rsio	475	30	in	in	IN
cord-016476-78r0rsio	475	31	patients	patient	NNS
cord-016476-78r0rsio	475	32	with	with	IN
cord-016476-78r0rsio	475	33	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	475	34	arthritis	arthritis	NN
cord-016476-78r0rsio	475	35	Interstitial	Interstitial	NNP
cord-016476-78r0rsio	475	36	lung	lung	NN
cord-016476-78r0rsio	475	37	disease	disease	NN
cord-016476-78r0rsio	475	38	induced	induce	VBN
cord-016476-78r0rsio	475	39	or	or	CC
cord-016476-78r0rsio	475	40	exacerbated	exacerbate	VBN
cord-016476-78r0rsio	475	41	by	by	IN
cord-016476-78r0rsio	475	42	TNF	TNF	NNP
cord-016476-78r0rsio	475	43	-	-	HYPH
cord-016476-78r0rsio	475	44	targeted	target	VBN
cord-016476-78r0rsio	475	45	therapies	therapy	NNS
cord-016476-78r0rsio	475	46	:	:	:
cord-016476-78r0rsio	475	47	analysis	analysis	NN
cord-016476-78r0rsio	475	48	of	of	IN
cord-016476-78r0rsio	475	49	122	122	CD
cord-016476-78r0rsio	475	50	cases	case	NNS
cord-016476-78r0rsio	475	51	Interstitial	interstitial	JJ
cord-016476-78r0rsio	475	52	lung	lung	NN
cord-016476-78r0rsio	475	53	disease	disease	NN
cord-016476-78r0rsio	475	54	following	follow	VBG
cord-016476-78r0rsio	475	55	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	475	56	pegol	pegol	NNP
cord-016476-78r0rsio	475	57	A	a	DT
cord-016476-78r0rsio	475	58	case	case	NN
cord-016476-78r0rsio	475	59	of	of	IN
cord-016476-78r0rsio	475	60	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	475	61	-	-	HYPH
cord-016476-78r0rsio	475	62	induced	induce	VBN
cord-016476-78r0rsio	475	63	interstitial	interstitial	JJ
cord-016476-78r0rsio	475	64	lung	lung	NN
cord-016476-78r0rsio	475	65	disease	disease	NN
cord-016476-78r0rsio	475	66	in	in	IN
cord-016476-78r0rsio	475	67	a	a	DT
cord-016476-78r0rsio	475	68	patient	patient	NN
cord-016476-78r0rsio	475	69	with	with	IN
cord-016476-78r0rsio	475	70	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	475	71	arthritis	arthritis	NN
cord-016476-78r0rsio	475	72	Severe	severe	JJ
cord-016476-78r0rsio	475	73	interstitial	interstitial	JJ
cord-016476-78r0rsio	475	74	lung	lung	NN
cord-016476-78r0rsio	475	75	disease	disease	NN
cord-016476-78r0rsio	475	76	following	follow	VBG
cord-016476-78r0rsio	475	77	treatment	treatment	NN
cord-016476-78r0rsio	475	78	with	with	IN
cord-016476-78r0rsio	475	79	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	475	80	pegol	pegol	NNP
cord-016476-78r0rsio	475	81	:	:	:
cord-016476-78r0rsio	475	82	a	a	DT
cord-016476-78r0rsio	475	83	case	case	NN
cord-016476-78r0rsio	475	84	report	report	NN
cord-016476-78r0rsio	475	85	Acute	acute	JJ
cord-016476-78r0rsio	475	86	exacerbation	exacerbation	NN
cord-016476-78r0rsio	475	87	of	of	IN
cord-016476-78r0rsio	475	88	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	475	89	interstitial	interstitial	JJ
cord-016476-78r0rsio	475	90	lung	lung	NN
cord-016476-78r0rsio	475	91	disease	disease	NN
cord-016476-78r0rsio	475	92	during	during	IN
cord-016476-78r0rsio	475	93	the	the	DT
cord-016476-78r0rsio	475	94	maintenance	maintenance	NN
cord-016476-78r0rsio	475	95	therapy	therapy	NN
cord-016476-78r0rsio	475	96	with	with	IN
cord-016476-78r0rsio	475	97	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	475	98	pegol	pegol	NNP
cord-016476-78r0rsio	475	99	Non	non	JJ
cord-016476-78r0rsio	475	100	-	-	JJ
cord-016476-78r0rsio	475	101	infectious	infectious	JJ
cord-016476-78r0rsio	475	102	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	475	103	complications	complication	NNS
cord-016476-78r0rsio	475	104	of	of	IN
cord-016476-78r0rsio	475	105	newer	new	JJR
cord-016476-78r0rsio	475	106	biological	biological	JJ
cord-016476-78r0rsio	475	107	agents	agent	NNS
cord-016476-78r0rsio	475	108	for	for	IN
cord-016476-78r0rsio	475	109	rheumatic	rheumatic	JJ
cord-016476-78r0rsio	475	110	diseases	disease	NNS
cord-016476-78r0rsio	475	111	-	-	:
cord-016476-78r0rsio	475	112	a	a	DT
cord-016476-78r0rsio	475	113	systematic	systematic	JJ
cord-016476-78r0rsio	475	114	literature	literature	NN
cord-016476-78r0rsio	475	115	review	review	NN
cord-016476-78r0rsio	475	116	Fatal	fatal	JJ
cord-016476-78r0rsio	475	117	fibrosing	fibrose	VBG
cord-016476-78r0rsio	475	118	alveolitis	alveolitis	NNP
cord-016476-78r0rsio	475	119	with	with	IN
cord-016476-78r0rsio	475	120	certolizumab	certolizumab	NNP
cord-016476-78r0rsio	475	121	Infliximab	Infliximab	NNP
cord-016476-78r0rsio	475	122	treatment	treatment	NN
cord-016476-78r0rsio	475	123	in	in	IN
cord-016476-78r0rsio	475	124	a	a	DT
cord-016476-78r0rsio	475	125	patient	patient	NN
cord-016476-78r0rsio	475	126	with	with	IN
cord-016476-78r0rsio	475	127	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	475	128	arthritis	arthritis	NN
cord-016476-78r0rsio	475	129	and	and	CC
cord-016476-78r0rsio	475	130	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	475	131	fibrosis	fibrosis	NN
cord-016476-78r0rsio	476	1	Clinical	clinical	JJ
cord-016476-78r0rsio	476	2	response	response	NN
cord-016476-78r0rsio	476	3	of	of	IN
cord-016476-78r0rsio	476	4	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	476	5	arthritis	arthritis	NN
cord-016476-78r0rsio	476	6	-	-	HYPH
cord-016476-78r0rsio	476	7	associated	associate	VBN
cord-016476-78r0rsio	476	8	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	476	9	fibrosis	fibrosis	NN
cord-016476-78r0rsio	476	10	to	to	TO
cord-016476-78r0rsio	476	11	tumor	tumor	NN
cord-016476-78r0rsio	476	12	necrosis	necrosis	NN
cord-016476-78r0rsio	476	13	factor	factor	NN
cord-016476-78r0rsio	476	14	-	-	HYPH
cord-016476-78r0rsio	476	15	alpha	alpha	NN
cord-016476-78r0rsio	476	16	inhibition	inhibition	NN
cord-016476-78r0rsio	477	1	Infliximab	Infliximab	NNP
cord-016476-78r0rsio	477	2	therapy	therapy	NN
cord-016476-78r0rsio	477	3	in	in	IN
cord-016476-78r0rsio	477	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	477	5	fibrosis	fibrosis	NN
cord-016476-78r0rsio	477	6	associated	associate	VBN
cord-016476-78r0rsio	477	7	with	with	IN
cord-016476-78r0rsio	477	8	collagen	collagen	NN
cord-016476-78r0rsio	477	9	vascular	vascular	JJ
cord-016476-78r0rsio	477	10	disease	disease	NN
cord-016476-78r0rsio	477	11	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	477	12	arthritis	arthritis	NN
cord-016476-78r0rsio	477	13	treatment	treatment	NN
cord-016476-78r0rsio	477	14	and	and	CC
cord-016476-78r0rsio	477	15	the	the	DT
cord-016476-78r0rsio	477	16	risk	risk	NN
cord-016476-78r0rsio	477	17	of	of	IN
cord-016476-78r0rsio	477	18	severe	severe	JJ
cord-016476-78r0rsio	477	19	interstitial	interstitial	JJ
cord-016476-78r0rsio	477	20	lung	lung	NN
cord-016476-78r0rsio	477	21	disease	disease	NNP
cord-016476-78r0rsio	477	22	Association	Association	NNP
cord-016476-78r0rsio	477	23	between	between	IN
cord-016476-78r0rsio	477	24	anti	anti	JJ
cord-016476-78r0rsio	477	25	-	-	JJ
cord-016476-78r0rsio	477	26	TNF	tnf	JJ
cord-016476-78r0rsio	477	27	-	-	HYPH
cord-016476-78r0rsio	477	28	alpha	alpha	NN
cord-016476-78r0rsio	477	29	therapy	therapy	NN
cord-016476-78r0rsio	477	30	and	and	CC
cord-016476-78r0rsio	477	31	interstitial	interstitial	JJ
cord-016476-78r0rsio	477	32	lung	lung	NN
cord-016476-78r0rsio	477	33	disease	disease	NN
cord-016476-78r0rsio	477	34	Incidence	Incidence	NNP
cord-016476-78r0rsio	477	35	and	and	CC
cord-016476-78r0rsio	477	36	complications	complication	NNS
cord-016476-78r0rsio	477	37	of	of	IN
cord-016476-78r0rsio	477	38	interstitial	interstitial	JJ
cord-016476-78r0rsio	477	39	lung	lung	NN
cord-016476-78r0rsio	477	40	disease	disease	NN
cord-016476-78r0rsio	477	41	in	in	IN
cord-016476-78r0rsio	477	42	users	user	NNS
cord-016476-78r0rsio	477	43	of	of	IN
cord-016476-78r0rsio	477	44	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	477	45	,	,	,
cord-016476-78r0rsio	477	46	rituximab	rituximab	NN
cord-016476-78r0rsio	477	47	,	,	,
cord-016476-78r0rsio	477	48	abatacept	abatacept	NNP
cord-016476-78r0rsio	477	49	and	and	CC
cord-016476-78r0rsio	477	50	anti	anti	JJ
cord-016476-78r0rsio	477	51	-	-	JJ
cord-016476-78r0rsio	477	52	tumor	tumor	JJ
cord-016476-78r0rsio	477	53	necrosis	necrosis	NN
cord-016476-78r0rsio	477	54	factor	factor	NN
cord-016476-78r0rsio	478	1	α	α	NNP
cord-016476-78r0rsio	478	2	agents	agent	NNS
cord-016476-78r0rsio	478	3	,	,	,
cord-016476-78r0rsio	478	4	a	a	DT
cord-016476-78r0rsio	478	5	retrospective	retrospective	JJ
cord-016476-78r0rsio	478	6	cohort	cohort	NN
cord-016476-78r0rsio	478	7	study	study	NN
cord-016476-78r0rsio	478	8	Potential	potential	JJ
cord-016476-78r0rsio	478	9	risk	risk	NN
cord-016476-78r0rsio	478	10	of	of	IN
cord-016476-78r0rsio	478	11	TNF	TNF	NNP
cord-016476-78r0rsio	478	12	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	478	13	on	on	IN
cord-016476-78r0rsio	478	14	the	the	DT
cord-016476-78r0rsio	478	15	progression	progression	NN
cord-016476-78r0rsio	478	16	of	of	IN
cord-016476-78r0rsio	478	17	interstitial	interstitial	JJ
cord-016476-78r0rsio	478	18	lung	lung	NN
cord-016476-78r0rsio	478	19	disease	disease	NN
cord-016476-78r0rsio	478	20	in	in	IN
cord-016476-78r0rsio	478	21	patients	patient	NNS
cord-016476-78r0rsio	478	22	with	with	IN
cord-016476-78r0rsio	478	23	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	478	24	arthritis	arthritis	NN
cord-016476-78r0rsio	478	25	Influence	influence	NN
cord-016476-78r0rsio	478	26	of	of	IN
cord-016476-78r0rsio	478	27	anti	anti	JJ
cord-016476-78r0rsio	478	28	-	-	JJ
cord-016476-78r0rsio	478	29	TNF	tnf	JJ
cord-016476-78r0rsio	478	30	therapy	therapy	NN
cord-016476-78r0rsio	478	31	on	on	IN
cord-016476-78r0rsio	478	32	mortality	mortality	NN
cord-016476-78r0rsio	478	33	in	in	IN
cord-016476-78r0rsio	478	34	patients	patient	NNS
cord-016476-78r0rsio	478	35	with	with	IN
cord-016476-78r0rsio	478	36	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	478	37	arthritis	arthritis	NN
cord-016476-78r0rsio	478	38	-	-	HYPH
cord-016476-78r0rsio	478	39	associated	associate	VBN
cord-016476-78r0rsio	478	40	interstitial	interstitial	JJ
cord-016476-78r0rsio	478	41	lung	lung	NN
cord-016476-78r0rsio	478	42	disease	disease	NN
cord-016476-78r0rsio	478	43	:	:	:
cord-016476-78r0rsio	479	1	results	result	NNS
cord-016476-78r0rsio	479	2	from	from	IN
cord-016476-78r0rsio	479	3	the	the	DT
cord-016476-78r0rsio	479	4	British	British	NNP
cord-016476-78r0rsio	479	5	Society	Society	NNP
cord-016476-78r0rsio	479	6	for	for	IN
cord-016476-78r0rsio	479	7	Rheumatology	Rheumatology	NNP
cord-016476-78r0rsio	479	8	biologics	biologic	NNS
cord-016476-78r0rsio	479	9	register	register	VBP
cord-016476-78r0rsio	479	10	The	the	DT
cord-016476-78r0rsio	479	11	role	role	NN
cord-016476-78r0rsio	479	12	of	of	IN
cord-016476-78r0rsio	479	13	biosimilars	biosimilar	NNS
cord-016476-78r0rsio	479	14	in	in	IN
cord-016476-78r0rsio	479	15	the	the	DT
cord-016476-78r0rsio	479	16	treatment	treatment	NN
cord-016476-78r0rsio	479	17	of	of	IN
cord-016476-78r0rsio	479	18	rheumatic	rheumatic	JJ
cord-016476-78r0rsio	479	19	diseases	disease	NNS
cord-016476-78r0rsio	480	1	A	a	DT
cord-016476-78r0rsio	480	2	randomised	randomised	JJ
cord-016476-78r0rsio	480	3	,	,	,
cord-016476-78r0rsio	480	4	double	double	JJ
cord-016476-78r0rsio	480	5	-	-	HYPH
cord-016476-78r0rsio	480	6	blind	blind	JJ
cord-016476-78r0rsio	480	7	,	,	,
cord-016476-78r0rsio	480	8	parallel	parallel	JJ
cord-016476-78r0rsio	480	9	-	-	HYPH
cord-016476-78r0rsio	480	10	group	group	NN
cord-016476-78r0rsio	480	11	study	study	NN
cord-016476-78r0rsio	480	12	to	to	TO
cord-016476-78r0rsio	480	13	demonstrate	demonstrate	VB
cord-016476-78r0rsio	480	14	equivalence	equivalence	NN
cord-016476-78r0rsio	480	15	in	in	IN
cord-016476-78r0rsio	480	16	efficacy	efficacy	NN
cord-016476-78r0rsio	480	17	and	and	CC
cord-016476-78r0rsio	480	18	safety	safety	NN
cord-016476-78r0rsio	480	19	of	of	IN
cord-016476-78r0rsio	480	20	CT	CT	NNP
cord-016476-78r0rsio	480	21	-	-	HYPH
cord-016476-78r0rsio	480	22	P13	P13	NNP
cord-016476-78r0rsio	480	23	compared	compare	VBN
cord-016476-78r0rsio	480	24	with	with	IN
cord-016476-78r0rsio	480	25	innovator	innovator	NN
cord-016476-78r0rsio	480	26	infliximab	infliximab	VBD
cord-016476-78r0rsio	480	27	when	when	WRB
cord-016476-78r0rsio	480	28	coadministered	coadministere	VBN
cord-016476-78r0rsio	480	29	with	with	IN
cord-016476-78r0rsio	480	30	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	480	31	in	in	IN
cord-016476-78r0rsio	480	32	patients	patient	NNS
cord-016476-78r0rsio	480	33	with	with	IN
cord-016476-78r0rsio	480	34	active	active	JJ
cord-016476-78r0rsio	480	35	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	480	36	arthritis	arthritis	NN
cord-016476-78r0rsio	480	37	:	:	:
cord-016476-78r0rsio	481	1	the	the	DT
cord-016476-78r0rsio	481	2	PLANETRA	PLANETRA	NNP
cord-016476-78r0rsio	481	3	study	study	VBP
cord-016476-78r0rsio	481	4	A	a	DT
cord-016476-78r0rsio	481	5	phase	phase	NN
cord-016476-78r0rsio	481	6	III	iii	CD
cord-016476-78r0rsio	481	7	randomized	randomized	JJ
cord-016476-78r0rsio	481	8	study	study	NN
cord-016476-78r0rsio	481	9	to	to	TO
cord-016476-78r0rsio	481	10	evaluate	evaluate	VB
cord-016476-78r0rsio	481	11	the	the	DT
cord-016476-78r0rsio	481	12	efficacy	efficacy	NN
cord-016476-78r0rsio	481	13	and	and	CC
cord-016476-78r0rsio	481	14	safety	safety	NN
cord-016476-78r0rsio	481	15	of	of	IN
cord-016476-78r0rsio	481	16	CT	CT	NNP
cord-016476-78r0rsio	481	17	-	-	HYPH
cord-016476-78r0rsio	481	18	P13	P13	NNP
cord-016476-78r0rsio	481	19	compared	compare	VBN
cord-016476-78r0rsio	481	20	with	with	IN
cord-016476-78r0rsio	481	21	reference	reference	NN
cord-016476-78r0rsio	481	22	infliximab	infliximab	VBN
cord-016476-78r0rsio	481	23	in	in	IN
cord-016476-78r0rsio	481	24	patients	patient	NNS
cord-016476-78r0rsio	481	25	with	with	IN
cord-016476-78r0rsio	481	26	active	active	JJ
cord-016476-78r0rsio	481	27	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	481	28	arthritis	arthritis	NN
cord-016476-78r0rsio	481	29	:	:	:
cord-016476-78r0rsio	482	1	54-week	54-week	CD
cord-016476-78r0rsio	482	2	results	result	NNS
cord-016476-78r0rsio	482	3	from	from	IN
cord-016476-78r0rsio	482	4	the	the	DT
cord-016476-78r0rsio	482	5	PLANETRA	PLANETRA	NNP
cord-016476-78r0rsio	482	6	study	study	NN
cord-016476-78r0rsio	483	1	A	a	DT
cord-016476-78r0rsio	483	2	randomised	randomised	JJ
cord-016476-78r0rsio	483	3	,	,	,
cord-016476-78r0rsio	483	4	double	double	JJ
cord-016476-78r0rsio	483	5	-	-	HYPH
cord-016476-78r0rsio	483	6	blind	blind	JJ
cord-016476-78r0rsio	483	7	,	,	,
cord-016476-78r0rsio	483	8	multicentre	multicentre	NNP
cord-016476-78r0rsio	483	9	,	,	,
cord-016476-78r0rsio	483	10	parallel	parallel	JJ
cord-016476-78r0rsio	483	11	-	-	HYPH
cord-016476-78r0rsio	483	12	group	group	NN
cord-016476-78r0rsio	483	13	,	,	,
cord-016476-78r0rsio	483	14	prospective	prospective	JJ
cord-016476-78r0rsio	483	15	study	study	NN
cord-016476-78r0rsio	483	16	comparing	compare	VBG
cord-016476-78r0rsio	483	17	the	the	DT
cord-016476-78r0rsio	483	18	pharmacokinetics	pharmacokinetic	NNS
cord-016476-78r0rsio	483	19	,	,	,
cord-016476-78r0rsio	483	20	safety	safety	NN
cord-016476-78r0rsio	483	21	,	,	,
cord-016476-78r0rsio	483	22	and	and	CC
cord-016476-78r0rsio	483	23	efficacy	efficacy	NN
cord-016476-78r0rsio	483	24	of	of	IN
cord-016476-78r0rsio	483	25	CT	CT	NNP
cord-016476-78r0rsio	483	26	-	-	HYPH
cord-016476-78r0rsio	483	27	P13	P13	NNP
cord-016476-78r0rsio	483	28	and	and	CC
cord-016476-78r0rsio	483	29	innovator	innovator	NN
cord-016476-78r0rsio	483	30	infliximab	infliximab	VBD
cord-016476-78r0rsio	483	31	in	in	IN
cord-016476-78r0rsio	483	32	patients	patient	NNS
cord-016476-78r0rsio	483	33	with	with	IN
cord-016476-78r0rsio	483	34	ankylosing	ankylosing	NNP
cord-016476-78r0rsio	483	35	spondylitis	spondylitis	NN
cord-016476-78r0rsio	483	36	:	:	:
cord-016476-78r0rsio	483	37	the	the	DT
cord-016476-78r0rsio	483	38	PLANETAS	PLANETAS	NNP
cord-016476-78r0rsio	483	39	study	study	NN
cord-016476-78r0rsio	483	40	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	483	41	and	and	CC
cord-016476-78r0rsio	483	42	safety	safety	NN
cord-016476-78r0rsio	483	43	of	of	IN
cord-016476-78r0rsio	483	44	CT	CT	NNP
cord-016476-78r0rsio	483	45	-	-	HYPH
cord-016476-78r0rsio	483	46	P13	P13	NNP
cord-016476-78r0rsio	483	47	(	(	-LRB-
cord-016476-78r0rsio	483	48	biosimilar	biosimilar	NNP
cord-016476-78r0rsio	483	49	infliximab	infliximab	NNP
cord-016476-78r0rsio	483	50	)	)	-RRB-
cord-016476-78r0rsio	484	1	in	in	IN
cord-016476-78r0rsio	484	2	patients	patient	NNS
cord-016476-78r0rsio	484	3	with	with	IN
cord-016476-78r0rsio	484	4	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	5	arthritis	arthritis	NN
cord-016476-78r0rsio	484	6	:	:	:
cord-016476-78r0rsio	484	7	comparison	comparison	NN
cord-016476-78r0rsio	484	8	between	between	IN
cord-016476-78r0rsio	484	9	switching	switch	VBG
cord-016476-78r0rsio	484	10	from	from	IN
cord-016476-78r0rsio	484	11	reference	reference	NN
cord-016476-78r0rsio	484	12	infliximab	infliximab	VBN
cord-016476-78r0rsio	484	13	to	to	IN
cord-016476-78r0rsio	484	14	CT	CT	NNP
cord-016476-78r0rsio	484	15	-	-	HYPH
cord-016476-78r0rsio	484	16	P13	P13	NNP
cord-016476-78r0rsio	484	17	and	and	CC
cord-016476-78r0rsio	484	18	continuing	continue	VBG
cord-016476-78r0rsio	484	19	CT	CT	NNP
cord-016476-78r0rsio	484	20	-	-	HYPH
cord-016476-78r0rsio	484	21	P13	P13	NNP
cord-016476-78r0rsio	484	22	in	in	IN
cord-016476-78r0rsio	484	23	the	the	DT
cord-016476-78r0rsio	484	24	PLANETRA	PLANETRA	NNP
cord-016476-78r0rsio	484	25	extension	extension	NN
cord-016476-78r0rsio	484	26	study	study	NN
cord-016476-78r0rsio	484	27	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	484	28	and	and	CC
cord-016476-78r0rsio	484	29	safety	safety	NN
cord-016476-78r0rsio	484	30	of	of	IN
cord-016476-78r0rsio	484	31	switching	switch	VBG
cord-016476-78r0rsio	484	32	from	from	IN
cord-016476-78r0rsio	484	33	reference	reference	NN
cord-016476-78r0rsio	484	34	infliximab	infliximab	VBN
cord-016476-78r0rsio	484	35	to	to	IN
cord-016476-78r0rsio	484	36	CT	CT	NNP
cord-016476-78r0rsio	484	37	-	-	HYPH
cord-016476-78r0rsio	484	38	P13	P13	NNP
cord-016476-78r0rsio	484	39	compared	compare	VBN
cord-016476-78r0rsio	484	40	with	with	IN
cord-016476-78r0rsio	484	41	maintenance	maintenance	NN
cord-016476-78r0rsio	484	42	of	of	IN
cord-016476-78r0rsio	484	43	CT	CT	NNP
cord-016476-78r0rsio	484	44	-	-	HYPH
cord-016476-78r0rsio	484	45	P13	P13	NNP
cord-016476-78r0rsio	484	46	in	in	IN
cord-016476-78r0rsio	484	47	ankylosing	ankylosing	NNP
cord-016476-78r0rsio	484	48	spondylitis	spondylitis	NN
cord-016476-78r0rsio	484	49	:	:	:
cord-016476-78r0rsio	484	50	102-week	102-week	CD
cord-016476-78r0rsio	484	51	data	datum	NNS
cord-016476-78r0rsio	484	52	from	from	IN
cord-016476-78r0rsio	484	53	the	the	DT
cord-016476-78r0rsio	484	54	PLANETAS	PLANETAS	NNP
cord-016476-78r0rsio	484	55	extension	extension	NN
cord-016476-78r0rsio	484	56	study	study	NN
cord-016476-78r0rsio	484	57	A	a	DT
cord-016476-78r0rsio	484	58	phase	phase	NN
cord-016476-78r0rsio	484	59	III	iii	CD
cord-016476-78r0rsio	484	60	randomised	randomised	JJ
cord-016476-78r0rsio	484	61	,	,	,
cord-016476-78r0rsio	484	62	double	double	JJ
cord-016476-78r0rsio	484	63	-	-	HYPH
cord-016476-78r0rsio	484	64	blind	blind	JJ
cord-016476-78r0rsio	484	65	,	,	,
cord-016476-78r0rsio	484	66	parallelgroup	parallelgroup	NNP
cord-016476-78r0rsio	484	67	study	study	NN
cord-016476-78r0rsio	484	68	comparing	compare	VBG
cord-016476-78r0rsio	484	69	SB4	SB4	NNP
cord-016476-78r0rsio	484	70	with	with	IN
cord-016476-78r0rsio	484	71	etanercept	etanercept	NNP
cord-016476-78r0rsio	484	72	reference	reference	NN
cord-016476-78r0rsio	484	73	product	product	NN
cord-016476-78r0rsio	484	74	in	in	IN
cord-016476-78r0rsio	484	75	patients	patient	NNS
cord-016476-78r0rsio	484	76	with	with	IN
cord-016476-78r0rsio	484	77	active	active	JJ
cord-016476-78r0rsio	484	78	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	79	arthritis	arthritis	NN
cord-016476-78r0rsio	484	80	despite	despite	IN
cord-016476-78r0rsio	484	81	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	484	82	therapy	therapy	NN
cord-016476-78r0rsio	484	83	Rituximab	Rituximab	NNP
cord-016476-78r0rsio	484	84	-	-	HYPH
cord-016476-78r0rsio	484	85	induced	induce	VBN
cord-016476-78r0rsio	484	86	lung	lung	NN
cord-016476-78r0rsio	484	87	disease	disease	NN
cord-016476-78r0rsio	484	88	:	:	:
cord-016476-78r0rsio	484	89	a	a	DT
cord-016476-78r0rsio	484	90	systematic	systematic	JJ
cord-016476-78r0rsio	484	91	literature	literature	NN
cord-016476-78r0rsio	484	92	review	review	NN
cord-016476-78r0rsio	484	93	Rituximab	Rituximab	NNP
cord-016476-78r0rsio	484	94	-	-	HYPH
cord-016476-78r0rsio	484	95	induced	induce	VBN
cord-016476-78r0rsio	484	96	interstitial	interstitial	JJ
cord-016476-78r0rsio	484	97	lung	lung	NN
cord-016476-78r0rsio	484	98	disease	disease	NN
cord-016476-78r0rsio	484	99	Rituximab	Rituximab	NNP
cord-016476-78r0rsio	484	100	-	-	HYPH
cord-016476-78r0rsio	484	101	induced	induce	VBN
cord-016476-78r0rsio	484	102	interstitial	interstitial	JJ
cord-016476-78r0rsio	484	103	lung	lung	NN
cord-016476-78r0rsio	484	104	disease	disease	NN
cord-016476-78r0rsio	484	105	:	:	:
cord-016476-78r0rsio	484	106	five	five	CD
cord-016476-78r0rsio	484	107	case	case	NN
cord-016476-78r0rsio	484	108	reports	report	VBZ
cord-016476-78r0rsio	484	109	Lung	Lung	NNP
cord-016476-78r0rsio	484	110	involvement	involvement	NN
cord-016476-78r0rsio	484	111	and	and	CC
cord-016476-78r0rsio	484	112	drug	drug	NN
cord-016476-78r0rsio	484	113	-	-	HYPH
cord-016476-78r0rsio	484	114	induced	induce	VBN
cord-016476-78r0rsio	484	115	lung	lung	NN
cord-016476-78r0rsio	484	116	disease	disease	NN
cord-016476-78r0rsio	484	117	in	in	IN
cord-016476-78r0rsio	484	118	patients	patient	NNS
cord-016476-78r0rsio	484	119	with	with	IN
cord-016476-78r0rsio	484	120	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	121	arthritis	arthritis	NN
cord-016476-78r0rsio	484	122	Safety	Safety	NNP
cord-016476-78r0rsio	484	123	and	and	CC
cord-016476-78r0rsio	484	124	effectiveness	effectiveness	NN
cord-016476-78r0rsio	484	125	of	of	IN
cord-016476-78r0rsio	484	126	rituximab	rituximab	NN
cord-016476-78r0rsio	484	127	in	in	IN
cord-016476-78r0rsio	484	128	patients	patient	NNS
cord-016476-78r0rsio	484	129	with	with	IN
cord-016476-78r0rsio	484	130	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	131	arthritis	arthritis	NN
cord-016476-78r0rsio	484	132	following	follow	VBG
cord-016476-78r0rsio	484	133	an	an	DT
cord-016476-78r0rsio	484	134	inadequate	inadequate	JJ
cord-016476-78r0rsio	484	135	response	response	NN
cord-016476-78r0rsio	484	136	to	to	IN
cord-016476-78r0rsio	484	137	1	1	CD
cord-016476-78r0rsio	484	138	prior	prior	JJ
cord-016476-78r0rsio	484	139	tumor	tumor	NN
cord-016476-78r0rsio	484	140	necrosis	necrosis	NN
cord-016476-78r0rsio	484	141	factor	factor	NN
cord-016476-78r0rsio	484	142	inhibitor	inhibitor	NN
cord-016476-78r0rsio	484	143	:	:	:
cord-016476-78r0rsio	484	144	the	the	DT
cord-016476-78r0rsio	484	145	RESET	reset	NN
cord-016476-78r0rsio	484	146	trial	trial	NN
cord-016476-78r0rsio	484	147	The	the	DT
cord-016476-78r0rsio	484	148	efficacy	efficacy	NN
cord-016476-78r0rsio	484	149	and	and	CC
cord-016476-78r0rsio	484	150	safety	safety	NN
cord-016476-78r0rsio	484	151	of	of	IN
cord-016476-78r0rsio	484	152	rituximab	rituximab	NN
cord-016476-78r0rsio	484	153	in	in	IN
cord-016476-78r0rsio	484	154	patients	patient	NNS
cord-016476-78r0rsio	484	155	with	with	IN
cord-016476-78r0rsio	484	156	active	active	JJ
cord-016476-78r0rsio	484	157	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	158	arthritis	arthritis	NN
cord-016476-78r0rsio	484	159	despite	despite	IN
cord-016476-78r0rsio	484	160	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	484	161	treatment	treatment	NN
cord-016476-78r0rsio	484	162	:	:	:
cord-016476-78r0rsio	484	163	results	result	NNS
cord-016476-78r0rsio	484	164	of	of	IN
cord-016476-78r0rsio	484	165	a	a	DT
cord-016476-78r0rsio	484	166	phase	phase	NN
cord-016476-78r0rsio	484	167	IIB	IIB	NNP
cord-016476-78r0rsio	484	168	randomized	randomize	VBN
cord-016476-78r0rsio	484	169	,	,	,
cord-016476-78r0rsio	484	170	double	double	JJ
cord-016476-78r0rsio	484	171	-	-	HYPH
cord-016476-78r0rsio	484	172	blind	blind	JJ
cord-016476-78r0rsio	484	173	,	,	,
cord-016476-78r0rsio	484	174	placebo	placebo	NN
cord-016476-78r0rsio	484	175	-	-	HYPH
cord-016476-78r0rsio	484	176	controlled	control	VBN
cord-016476-78r0rsio	484	177	,	,	,
cord-016476-78r0rsio	484	178	dose	dose	RB
cord-016476-78r0rsio	484	179	-	-	HYPH
cord-016476-78r0rsio	484	180	ranging	range	VBG
cord-016476-78r0rsio	484	181	trial	trial	NN
cord-016476-78r0rsio	484	182	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	484	183	and	and	CC
cord-016476-78r0rsio	484	184	safety	safety	NN
cord-016476-78r0rsio	484	185	of	of	IN
cord-016476-78r0rsio	484	186	different	different	JJ
cord-016476-78r0rsio	484	187	doses	dose	NNS
cord-016476-78r0rsio	484	188	and	and	CC
cord-016476-78r0rsio	484	189	retreatment	retreatment	NN
cord-016476-78r0rsio	484	190	of	of	IN
cord-016476-78r0rsio	484	191	rituximab	rituximab	NN
cord-016476-78r0rsio	484	192	:	:	:
cord-016476-78r0rsio	484	193	a	a	DT
cord-016476-78r0rsio	484	194	randomised	randomised	JJ
cord-016476-78r0rsio	484	195	,	,	,
cord-016476-78r0rsio	484	196	placebo	placebo	NN
cord-016476-78r0rsio	484	197	-	-	HYPH
cord-016476-78r0rsio	484	198	controlled	control	VBN
cord-016476-78r0rsio	484	199	trial	trial	NN
cord-016476-78r0rsio	484	200	in	in	IN
cord-016476-78r0rsio	484	201	patients	patient	NNS
cord-016476-78r0rsio	484	202	who	who	WP
cord-016476-78r0rsio	484	203	are	be	VBP
cord-016476-78r0rsio	484	204	biological	biological	JJ
cord-016476-78r0rsio	484	205	naive	naive	JJ
cord-016476-78r0rsio	484	206	with	with	IN
cord-016476-78r0rsio	484	207	active	active	JJ
cord-016476-78r0rsio	484	208	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	209	arthritis	arthritis	NN
cord-016476-78r0rsio	484	210	and	and	CC
cord-016476-78r0rsio	484	211	an	an	DT
cord-016476-78r0rsio	484	212	inadequate	inadequate	JJ
cord-016476-78r0rsio	484	213	response	response	NN
cord-016476-78r0rsio	484	214	to	to	IN
cord-016476-78r0rsio	484	215	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	484	216	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	484	217	and	and	CC
cord-016476-78r0rsio	484	218	safety	safety	NN
cord-016476-78r0rsio	484	219	of	of	IN
cord-016476-78r0rsio	484	220	retreatment	retreatment	NN
cord-016476-78r0rsio	484	221	in	in	IN
cord-016476-78r0rsio	484	222	patients	patient	NNS
cord-016476-78r0rsio	484	223	with	with	IN
cord-016476-78r0rsio	484	224	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	225	arthritis	arthritis	NN
cord-016476-78r0rsio	484	226	with	with	IN
cord-016476-78r0rsio	484	227	previous	previous	JJ
cord-016476-78r0rsio	484	228	inadequate	inadequate	JJ
cord-016476-78r0rsio	484	229	response	response	NN
cord-016476-78r0rsio	484	230	to	to	IN
cord-016476-78r0rsio	484	231	tumor	tumor	NN
cord-016476-78r0rsio	484	232	necrosis	necrosis	NN
cord-016476-78r0rsio	484	233	factor	factor	NN
cord-016476-78r0rsio	484	234	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	484	235	:	:	:
cord-016476-78r0rsio	484	236	results	result	NNS
cord-016476-78r0rsio	484	237	from	from	IN
cord-016476-78r0rsio	484	238	the	the	DT
cord-016476-78r0rsio	484	239	SUNRISE	SUNRISE	NNP
cord-016476-78r0rsio	484	240	trial	trial	NN
cord-016476-78r0rsio	484	241	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	484	242	of	of	IN
cord-016476-78r0rsio	484	243	B	b	NN
cord-016476-78r0rsio	484	244	-	-	HYPH
cord-016476-78r0rsio	484	245	cell	cell	NN
cord-016476-78r0rsio	484	246	-	-	HYPH
cord-016476-78r0rsio	484	247	targeted	target	VBN
cord-016476-78r0rsio	484	248	therapy	therapy	NN
cord-016476-78r0rsio	484	249	with	with	IN
cord-016476-78r0rsio	484	250	rituximab	rituximab	NN
cord-016476-78r0rsio	484	251	in	in	IN
cord-016476-78r0rsio	484	252	patients	patient	NNS
cord-016476-78r0rsio	484	253	with	with	IN
cord-016476-78r0rsio	484	254	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	255	arthritis	arthritis	NN
cord-016476-78r0rsio	484	256	Non	non	JJ
cord-016476-78r0rsio	484	257	-	-	JJ
cord-016476-78r0rsio	484	258	infectious	infectious	JJ
cord-016476-78r0rsio	484	259	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	484	260	toxicity	toxicity	NN
cord-016476-78r0rsio	484	261	of	of	IN
cord-016476-78r0rsio	484	262	rituximab	rituximab	NN
cord-016476-78r0rsio	484	263	:	:	:
cord-016476-78r0rsio	484	264	a	a	DT
cord-016476-78r0rsio	484	265	systematic	systematic	JJ
cord-016476-78r0rsio	484	266	review	review	NN
cord-016476-78r0rsio	484	267	Safety	Safety	NNP
cord-016476-78r0rsio	484	268	of	of	IN
cord-016476-78r0rsio	484	269	abatacept	abatacept	NNP
cord-016476-78r0rsio	484	270	administered	administer	VBD
cord-016476-78r0rsio	484	271	intravenously	intravenously	RB
cord-016476-78r0rsio	484	272	in	in	IN
cord-016476-78r0rsio	484	273	treatment	treatment	NN
cord-016476-78r0rsio	484	274	of	of	IN
cord-016476-78r0rsio	484	275	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	484	276	arthritis	arthritis	NN
cord-016476-78r0rsio	484	277	:	:	:
cord-016476-78r0rsio	484	278	integrated	integrate	VBN
cord-016476-78r0rsio	484	279	analyses	analysis	NNS
cord-016476-78r0rsio	484	280	of	of	IN
cord-016476-78r0rsio	484	281	up	up	IN
cord-016476-78r0rsio	484	282	to	to	TO
cord-016476-78r0rsio	484	283	8	8	CD
cord-016476-78r0rsio	484	284	years	year	NNS
cord-016476-78r0rsio	484	285	of	of	IN
cord-016476-78r0rsio	484	286	treatment	treatment	NN
cord-016476-78r0rsio	484	287	from	from	IN
cord-016476-78r0rsio	484	288	the	the	DT
cord-016476-78r0rsio	484	289	abatacept	abatacept	NNP
cord-016476-78r0rsio	484	290	clinical	clinical	JJ
cord-016476-78r0rsio	484	291	trial	trial	NN
cord-016476-78r0rsio	484	292	program	program	NN
cord-016476-78r0rsio	484	293	A	a	DT
cord-016476-78r0rsio	484	294	case	case	NN
cord-016476-78r0rsio	484	295	of	of	IN
cord-016476-78r0rsio	484	296	acute	acute	JJ
cord-016476-78r0rsio	484	297	respiratory	respiratory	JJ
cord-016476-78r0rsio	484	298	failure	failure	NN
cord-016476-78r0rsio	484	299	in	in	IN
cord-016476-78r0rsio	484	300	a	a	DT
cord-016476-78r0rsio	484	301	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	484	302	arthritis	arthritis	NN
cord-016476-78r0rsio	484	303	patient	patient	NN
cord-016476-78r0rsio	484	304	after	after	IN
cord-016476-78r0rsio	484	305	the	the	DT
cord-016476-78r0rsio	484	306	administration	administration	NN
cord-016476-78r0rsio	484	307	of	of	IN
cord-016476-78r0rsio	484	308	abatacept	abatacept	NNP
cord-016476-78r0rsio	484	309	A	a	DT
cord-016476-78r0rsio	484	310	case	case	NN
cord-016476-78r0rsio	484	311	of	of	IN
cord-016476-78r0rsio	484	312	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	484	313	arthritis	arthritis	NN
cord-016476-78r0rsio	484	314	complicated	complicate	VBN
cord-016476-78r0rsio	484	315	with	with	IN
cord-016476-78r0rsio	484	316	deteriorated	deteriorate	VBN
cord-016476-78r0rsio	484	317	interstitial	interstitial	JJ
cord-016476-78r0rsio	484	318	pneumonia	pneumonia	NN
cord-016476-78r0rsio	484	319	after	after	IN
cord-016476-78r0rsio	484	320	the	the	DT
cord-016476-78r0rsio	484	321	administration	administration	NN
cord-016476-78r0rsio	484	322	of	of	IN
cord-016476-78r0rsio	484	323	abatacept	abatacept	NNP
cord-016476-78r0rsio	484	324	Refractory	refractory	JJ
cord-016476-78r0rsio	484	325	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	484	326	arthritis	arthritis	NN
cord-016476-78r0rsio	484	327	with	with	IN
cord-016476-78r0rsio	484	328	interstitial	interstitial	JJ
cord-016476-78r0rsio	484	329	lung	lung	NN
cord-016476-78r0rsio	484	330	disease	disease	NN
cord-016476-78r0rsio	484	331	:	:	:
cord-016476-78r0rsio	484	332	could	could	MD
cord-016476-78r0rsio	484	333	abatacept	abatacept	TO
cord-016476-78r0rsio	484	334	be	be	VB
cord-016476-78r0rsio	484	335	the	the	DT
cord-016476-78r0rsio	484	336	answer	answer	NN
cord-016476-78r0rsio	484	337	?	?	.
cord-016476-78r0rsio	485	1	Abatacept	Abatacept	NNP
cord-016476-78r0rsio	485	2	can	can	MD
cord-016476-78r0rsio	485	3	be	be	VB
cord-016476-78r0rsio	485	4	used	use	VBN
cord-016476-78r0rsio	485	5	safely	safely	RB
cord-016476-78r0rsio	485	6	for	for	IN
cord-016476-78r0rsio	485	7	RA	RA	NNP
cord-016476-78r0rsio	485	8	patients	patient	NNS
cord-016476-78r0rsio	485	9	with	with	IN
cord-016476-78r0rsio	485	10	interstitial	interstitial	JJ
cord-016476-78r0rsio	485	11	lung	lung	NN
cord-016476-78r0rsio	485	12	disease	disease	NN
cord-016476-78r0rsio	485	13	Risk	Risk	NNP
cord-016476-78r0rsio	485	14	of	of	IN
cord-016476-78r0rsio	485	15	hospitalised	hospitalise	VBN
cord-016476-78r0rsio	485	16	infection	infection	NN
cord-016476-78r0rsio	485	17	in	in	IN
cord-016476-78r0rsio	485	18	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	485	19	arthritis	arthritis	NN
cord-016476-78r0rsio	485	20	patients	patient	NNS
cord-016476-78r0rsio	485	21	receiving	receive	VBG
cord-016476-78r0rsio	485	22	biologics	biologic	NNS
cord-016476-78r0rsio	485	23	following	follow	VBG
cord-016476-78r0rsio	485	24	a	a	DT
cord-016476-78r0rsio	485	25	previous	previous	JJ
cord-016476-78r0rsio	485	26	infection	infection	NN
cord-016476-78r0rsio	485	27	while	while	IN
cord-016476-78r0rsio	485	28	on	on	IN
cord-016476-78r0rsio	485	29	treatment	treatment	NN
cord-016476-78r0rsio	485	30	with	with	IN
cord-016476-78r0rsio	485	31	anti	anti	JJ
cord-016476-78r0rsio	485	32	-	-	JJ
cord-016476-78r0rsio	485	33	TNF	tnf	NN
cord-016476-78r0rsio	485	34	therapy	therapy	NN
cord-016476-78r0rsio	485	35	American	American	NNP
cord-016476-78r0rsio	485	36	College	College	NNP
cord-016476-78r0rsio	485	37	of	of	IN
cord-016476-78r0rsio	485	38	Rheumatology	Rheumatology	NNP
cord-016476-78r0rsio	485	39	guideline	guideline	NN
cord-016476-78r0rsio	485	40	for	for	IN
cord-016476-78r0rsio	485	41	the	the	DT
cord-016476-78r0rsio	485	42	treatment	treatment	NN
cord-016476-78r0rsio	485	43	of	of	IN
cord-016476-78r0rsio	485	44	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	485	45	arthritis	arthritis	NN
cord-016476-78r0rsio	486	1	Adding	add	VBG
cord-016476-78r0rsio	486	2	tocilizumab	tocilizumab	NNS
cord-016476-78r0rsio	486	3	or	or	CC
cord-016476-78r0rsio	486	4	switching	switch	VBG
cord-016476-78r0rsio	486	5	to	to	IN
cord-016476-78r0rsio	486	6	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	486	7	monotherapy	monotherapy	IN
cord-016476-78r0rsio	486	8	in	in	IN
cord-016476-78r0rsio	486	9	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	486	10	inadequate	inadequate	JJ
cord-016476-78r0rsio	486	11	responders	responder	NNS
cord-016476-78r0rsio	486	12	:	:	:
cord-016476-78r0rsio	486	13	24-week	24-week	JJ
cord-016476-78r0rsio	486	14	symptomatic	symptomatic	JJ
cord-016476-78r0rsio	486	15	and	and	CC
cord-016476-78r0rsio	486	16	structural	structural	JJ
cord-016476-78r0rsio	486	17	results	result	NNS
cord-016476-78r0rsio	486	18	of	of	IN
cord-016476-78r0rsio	486	19	a	a	DT
cord-016476-78r0rsio	486	20	2-year	2-year	CD
cord-016476-78r0rsio	486	21	randomised	randomised	JJ
cord-016476-78r0rsio	486	22	controlled	control	VBN
cord-016476-78r0rsio	486	23	strategy	strategy	NN
cord-016476-78r0rsio	486	24	trial	trial	NN
cord-016476-78r0rsio	486	25	Comparison	comparison	NN
cord-016476-78r0rsio	486	26	of	of	IN
cord-016476-78r0rsio	486	27	adding	add	VBG
cord-016476-78r0rsio	486	28	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	486	29	to	to	IN
cord-016476-78r0rsio	486	30	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	486	31	with	with	IN
cord-016476-78r0rsio	486	32	switching	switch	VBG
cord-016476-78r0rsio	486	33	to	to	IN
cord-016476-78r0rsio	486	34	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	486	35	in	in	IN
cord-016476-78r0rsio	486	36	patients	patient	NNS
cord-016476-78r0rsio	486	37	with	with	IN
cord-016476-78r0rsio	486	38	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	486	39	arthritis	arthritis	NN
cord-016476-78r0rsio	486	40	with	with	IN
cord-016476-78r0rsio	486	41	inadequate	inadequate	JJ
cord-016476-78r0rsio	486	42	response	response	NN
cord-016476-78r0rsio	486	43	to	to	IN
cord-016476-78r0rsio	486	44	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	486	45	:	:	:
cord-016476-78r0rsio	486	46	52-week	52-week	CD
cord-016476-78r0rsio	486	47	results	result	NNS
cord-016476-78r0rsio	486	48	from	from	IN
cord-016476-78r0rsio	486	49	a	a	DT
cord-016476-78r0rsio	486	50	prospective	prospective	JJ
cord-016476-78r0rsio	486	51	,	,	,
cord-016476-78r0rsio	486	52	randomised	randomised	JJ
cord-016476-78r0rsio	486	53	,	,	,
cord-016476-78r0rsio	486	54	controlled	controlled	JJ
cord-016476-78r0rsio	486	55	study	study	NN
cord-016476-78r0rsio	486	56	(	(	-LRB-
cord-016476-78r0rsio	486	57	SURPRISE	SURPRISE	NNP
cord-016476-78r0rsio	486	58	study	study	NN
cord-016476-78r0rsio	486	59	)	)	-RRB-
cord-016476-78r0rsio	487	1	Inverse	inverse	JJ
cord-016476-78r0rsio	487	2	effects	effect	NNS
cord-016476-78r0rsio	487	3	of	of	IN
cord-016476-78r0rsio	487	4	interleukin-6	interleukin-6	NNP
cord-016476-78r0rsio	487	5	on	on	IN
cord-016476-78r0rsio	487	6	apoptosis	apoptosis	NN
cord-016476-78r0rsio	487	7	of	of	IN
cord-016476-78r0rsio	487	8	fibroblasts	fibroblast	NNS
cord-016476-78r0rsio	487	9	from	from	IN
cord-016476-78r0rsio	487	10	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	487	11	fibrosis	fibrosis	NN
cord-016476-78r0rsio	487	12	and	and	CC
cord-016476-78r0rsio	488	1	normal	normal	JJ
cord-016476-78r0rsio	488	2	lungs	lung	NNS
cord-016476-78r0rsio	488	3	Treatment	treatment	NN
cord-016476-78r0rsio	488	4	of	of	IN
cord-016476-78r0rsio	488	5	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	488	6	arthritis	arthritis	NN
cord-016476-78r0rsio	488	7	with	with	IN
cord-016476-78r0rsio	488	8	humanized	humanized	JJ
cord-016476-78r0rsio	488	9	anti	anti	NNP
cord-016476-78r0rsio	488	10	-	-	JJ
cord-016476-78r0rsio	488	11	interleukin-6	interleukin-6	JJ
cord-016476-78r0rsio	488	12	receptor	receptor	NN
cord-016476-78r0rsio	488	13	antibody	antibody	NN
cord-016476-78r0rsio	488	14	:	:	:
cord-016476-78r0rsio	488	15	a	a	DT
cord-016476-78r0rsio	488	16	multicenter	multicenter	JJ
cord-016476-78r0rsio	488	17	,	,	,
cord-016476-78r0rsio	488	18	double	double	JJ
cord-016476-78r0rsio	488	19	-	-	HYPH
cord-016476-78r0rsio	488	20	blind	blind	JJ
cord-016476-78r0rsio	488	21	,	,	,
cord-016476-78r0rsio	488	22	placebo	placebo	NN
cord-016476-78r0rsio	488	23	-	-	HYPH
cord-016476-78r0rsio	488	24	controlled	control	VBN
cord-016476-78r0rsio	488	25	trial	trial	NN
cord-016476-78r0rsio	488	26	Effect	effect	NN
cord-016476-78r0rsio	488	27	of	of	IN
cord-016476-78r0rsio	488	28	interleukin-6	interleukin-6	NNP
cord-016476-78r0rsio	488	29	receptor	receptor	NN
cord-016476-78r0rsio	488	30	inhibition	inhibition	NN
cord-016476-78r0rsio	488	31	with	with	IN
cord-016476-78r0rsio	488	32	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	488	33	in	in	IN
cord-016476-78r0rsio	488	34	patients	patient	NNS
cord-016476-78r0rsio	488	35	with	with	IN
cord-016476-78r0rsio	488	36	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	488	37	arthritis	arthritis	NN
cord-016476-78r0rsio	488	38	(	(	-LRB-
cord-016476-78r0rsio	488	39	OPTION	option	NN
cord-016476-78r0rsio	488	40	study	study	NN
cord-016476-78r0rsio	488	41	)	)	-RRB-
cord-016476-78r0rsio	488	42	:	:	:
cord-016476-78r0rsio	488	43	a	a	DT
cord-016476-78r0rsio	488	44	double	double	JJ
cord-016476-78r0rsio	488	45	-	-	HYPH
cord-016476-78r0rsio	488	46	blind	blind	JJ
cord-016476-78r0rsio	488	47	,	,	,
cord-016476-78r0rsio	488	48	placebocontrolled	placebocontrolled	JJ
cord-016476-78r0rsio	488	49	,	,	,
cord-016476-78r0rsio	488	50	randomised	randomised	JJ
cord-016476-78r0rsio	488	51	trial	trial	NN
cord-016476-78r0rsio	488	52	Study	Study	NNP
cord-016476-78r0rsio	488	53	of	of	IN
cord-016476-78r0rsio	488	54	active	active	JJ
cord-016476-78r0rsio	488	55	controlled	control	VBN
cord-016476-78r0rsio	488	56	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	488	57	monotherapy	monotherapy	IN
cord-016476-78r0rsio	488	58	for	for	IN
cord-016476-78r0rsio	488	59	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	488	60	arthritis	arthritis	NN
cord-016476-78r0rsio	488	61	patients	patient	NNS
cord-016476-78r0rsio	488	62	with	with	IN
cord-016476-78r0rsio	488	63	an	an	DT
cord-016476-78r0rsio	488	64	inadequate	inadequate	JJ
cord-016476-78r0rsio	488	65	response	response	NN
cord-016476-78r0rsio	488	66	to	to	IN
cord-016476-78r0rsio	488	67	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	488	68	(	(	-LRB-
cord-016476-78r0rsio	488	69	SATORI	SATORI	NNP
cord-016476-78r0rsio	488	70	)	)	-RRB-
cord-016476-78r0rsio	488	71	:	:	:
cord-016476-78r0rsio	488	72	significant	significant	JJ
cord-016476-78r0rsio	488	73	reduction	reduction	NN
cord-016476-78r0rsio	488	74	in	in	IN
cord-016476-78r0rsio	488	75	disease	disease	NN
cord-016476-78r0rsio	488	76	activity	activity	NN
cord-016476-78r0rsio	488	77	and	and	CC
cord-016476-78r0rsio	488	78	serum	serum	NN
cord-016476-78r0rsio	488	79	vascular	vascular	JJ
cord-016476-78r0rsio	488	80	endothelial	endothelial	JJ
cord-016476-78r0rsio	488	81	growth	growth	NN
cord-016476-78r0rsio	488	82	factor	factor	NN
cord-016476-78r0rsio	488	83	by	by	IN
cord-016476-78r0rsio	489	1	IL-6	IL-6	NNP
cord-016476-78r0rsio	489	2	receptor	receptor	NN
cord-016476-78r0rsio	489	3	inhibition	inhibition	NN
cord-016476-78r0rsio	489	4	Tocilizumab	Tocilizumab	NNP
cord-016476-78r0rsio	489	5	monotherapy	monotherapy	VBD
cord-016476-78r0rsio	489	6	versus	versus	IN
cord-016476-78r0rsio	489	7	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	490	1	monotherapy	monotherapy	NN
cord-016476-78r0rsio	490	2	for	for	IN
cord-016476-78r0rsio	490	3	treatment	treatment	NN
cord-016476-78r0rsio	490	4	of	of	IN
cord-016476-78r0rsio	490	5	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	490	6	arthritis	arthritis	NN
cord-016476-78r0rsio	490	7	(	(	-LRB-
cord-016476-78r0rsio	490	8	ADACTA	ADACTA	NNP
cord-016476-78r0rsio	490	9	)	)	-RRB-
cord-016476-78r0rsio	490	10	:	:	:
cord-016476-78r0rsio	490	11	a	a	DT
cord-016476-78r0rsio	490	12	randomised	randomised	JJ
cord-016476-78r0rsio	490	13	,	,	,
cord-016476-78r0rsio	490	14	double	double	JJ
cord-016476-78r0rsio	490	15	-	-	HYPH
cord-016476-78r0rsio	490	16	blind	blind	JJ
cord-016476-78r0rsio	490	17	,	,	,
cord-016476-78r0rsio	490	18	controlled	control	VBN
cord-016476-78r0rsio	490	19	phase	phase	NN
cord-016476-78r0rsio	490	20	4	4	CD
cord-016476-78r0rsio	490	21	trial	trial	NN
cord-016476-78r0rsio	490	22	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	490	23	and	and	CC
cord-016476-78r0rsio	490	24	safety	safety	NN
cord-016476-78r0rsio	490	25	of	of	IN
cord-016476-78r0rsio	490	26	subcutaneous	subcutaneous	JJ
cord-016476-78r0rsio	490	27	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	490	28	versus	versus	IN
cord-016476-78r0rsio	490	29	intravenous	intravenous	JJ
cord-016476-78r0rsio	490	30	tocilizumab	tocilizumab	NN
cord-016476-78r0rsio	490	31	in	in	IN
cord-016476-78r0rsio	490	32	combination	combination	NN
cord-016476-78r0rsio	490	33	with	with	IN
cord-016476-78r0rsio	490	34	traditional	traditional	JJ
cord-016476-78r0rsio	490	35	DMARDs	dmard	NNS
cord-016476-78r0rsio	490	36	in	in	IN
cord-016476-78r0rsio	490	37	patients	patient	NNS
cord-016476-78r0rsio	490	38	with	with	IN
cord-016476-78r0rsio	490	39	RA	RA	NNP
cord-016476-78r0rsio	490	40	at	at	IN
cord-016476-78r0rsio	490	41	week	week	NN
cord-016476-78r0rsio	490	42	97	97	CD
cord-016476-78r0rsio	490	43	(	(	-LRB-
cord-016476-78r0rsio	490	44	SUMMACTA	SUMMACTA	NNP
cord-016476-78r0rsio	490	45	)	)	-RRB-
cord-016476-78r0rsio	491	1	Sarilumab	Sarilumab	NNP
cord-016476-78r0rsio	491	2	,	,	,
cord-016476-78r0rsio	491	3	a	a	DT
cord-016476-78r0rsio	491	4	fully	fully	RB
cord-016476-78r0rsio	491	5	human	human	JJ
cord-016476-78r0rsio	491	6	monoclonal	monoclonal	JJ
cord-016476-78r0rsio	491	7	antibody	antibody	NN
cord-016476-78r0rsio	491	8	against	against	IN
cord-016476-78r0rsio	491	9	IL-6Rα	il-6rα	CD
cord-016476-78r0rsio	491	10	in	in	IN
cord-016476-78r0rsio	491	11	patients	patient	NNS
cord-016476-78r0rsio	491	12	with	with	IN
cord-016476-78r0rsio	491	13	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	14	arthritis	arthritis	NN
cord-016476-78r0rsio	491	15	and	and	CC
cord-016476-78r0rsio	491	16	an	an	DT
cord-016476-78r0rsio	491	17	inadequate	inadequate	JJ
cord-016476-78r0rsio	491	18	response	response	NN
cord-016476-78r0rsio	491	19	to	to	IN
cord-016476-78r0rsio	491	20	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	491	21	:	:	:
cord-016476-78r0rsio	491	22	efficacy	efficacy	NN
cord-016476-78r0rsio	491	23	and	and	CC
cord-016476-78r0rsio	491	24	safety	safety	NN
cord-016476-78r0rsio	491	25	results	result	NNS
cord-016476-78r0rsio	491	26	from	from	IN
cord-016476-78r0rsio	491	27	the	the	DT
cord-016476-78r0rsio	491	28	randomised	randomised	JJ
cord-016476-78r0rsio	491	29	SARIL	SARIL	NNP
cord-016476-78r0rsio	491	30	-	-	HYPH
cord-016476-78r0rsio	491	31	RA	RA	NNP
cord-016476-78r0rsio	491	32	-	-	HYPH
cord-016476-78r0rsio	491	33	MOBILITY	MOBILITY	NNP
cord-016476-78r0rsio	491	34	part	part	NN
cord-016476-78r0rsio	491	35	a	a	DT
cord-016476-78r0rsio	491	36	trial	trial	NN
cord-016476-78r0rsio	491	37	Sarilumab	Sarilumab	NNP
cord-016476-78r0rsio	491	38	plus	plus	CC
cord-016476-78r0rsio	491	39	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	491	40	in	in	IN
cord-016476-78r0rsio	491	41	patients	patient	NNS
cord-016476-78r0rsio	491	42	with	with	IN
cord-016476-78r0rsio	491	43	active	active	JJ
cord-016476-78r0rsio	491	44	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	45	arthritis	arthritis	NN
cord-016476-78r0rsio	491	46	and	and	CC
cord-016476-78r0rsio	491	47	inadequate	inadequate	JJ
cord-016476-78r0rsio	491	48	response	response	NN
cord-016476-78r0rsio	491	49	to	to	IN
cord-016476-78r0rsio	491	50	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	491	51	:	:	:
cord-016476-78r0rsio	491	52	results	result	NNS
cord-016476-78r0rsio	491	53	of	of	IN
cord-016476-78r0rsio	491	54	a	a	DT
cord-016476-78r0rsio	491	55	phase	phase	NN
cord-016476-78r0rsio	491	56	III	iii	CD
cord-016476-78r0rsio	491	57	study	study	NN
cord-016476-78r0rsio	491	58	A	a	DT
cord-016476-78r0rsio	491	59	case	case	NN
cord-016476-78r0rsio	491	60	of	of	IN
cord-016476-78r0rsio	491	61	organizing	organize	VBG
cord-016476-78r0rsio	491	62	pneumonia	pneumonia	NN
cord-016476-78r0rsio	491	63	induced	induce	VBN
cord-016476-78r0rsio	491	64	by	by	IN
cord-016476-78r0rsio	491	65	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	491	66	A	a	DT
cord-016476-78r0rsio	491	67	fatal	fatal	JJ
cord-016476-78r0rsio	491	68	case	case	NN
cord-016476-78r0rsio	491	69	of	of	IN
cord-016476-78r0rsio	491	70	acute	acute	JJ
cord-016476-78r0rsio	491	71	exacerbation	exacerbation	NN
cord-016476-78r0rsio	491	72	of	of	IN
cord-016476-78r0rsio	491	73	interstitial	interstitial	JJ
cord-016476-78r0rsio	491	74	lung	lung	NN
cord-016476-78r0rsio	491	75	disease	disease	NN
cord-016476-78r0rsio	491	76	in	in	IN
cord-016476-78r0rsio	491	77	a	a	DT
cord-016476-78r0rsio	491	78	patient	patient	NN
cord-016476-78r0rsio	491	79	with	with	IN
cord-016476-78r0rsio	491	80	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	491	81	arthritis	arthritis	NN
cord-016476-78r0rsio	491	82	during	during	IN
cord-016476-78r0rsio	491	83	treatment	treatment	NN
cord-016476-78r0rsio	491	84	with	with	IN
cord-016476-78r0rsio	491	85	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	491	86	Exacerbation	Exacerbation	NNP
cord-016476-78r0rsio	491	87	of	of	IN
cord-016476-78r0rsio	491	88	combined	combine	VBN
cord-016476-78r0rsio	491	89	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	491	90	fibrosis	fibrosis	NN
cord-016476-78r0rsio	491	91	and	and	CC
cord-016476-78r0rsio	491	92	emphysema	emphysema	NNP
cord-016476-78r0rsio	491	93	syndrome	syndrome	NN
cord-016476-78r0rsio	491	94	during	during	IN
cord-016476-78r0rsio	491	95	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	491	96	therapy	therapy	NN
cord-016476-78r0rsio	491	97	for	for	IN
cord-016476-78r0rsio	491	98	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	491	99	arthritis	arthritis	NN
cord-016476-78r0rsio	491	100	Acute	Acute	NNP
cord-016476-78r0rsio	491	101	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	491	102	in	in	IN
cord-016476-78r0rsio	491	103	a	a	DT
cord-016476-78r0rsio	491	104	patient	patient	NN
cord-016476-78r0rsio	491	105	with	with	IN
cord-016476-78r0rsio	491	106	adult	adult	NN
cord-016476-78r0rsio	491	107	-	-	HYPH
cord-016476-78r0rsio	491	108	onset	onset	NN
cord-016476-78r0rsio	491	109	disease	disease	NN
cord-016476-78r0rsio	491	110	after	after	IN
cord-016476-78r0rsio	491	111	toclizumab	toclizumab	VBD
cord-016476-78r0rsio	491	112	treatment	treatment	NN
cord-016476-78r0rsio	491	113	with	with	IN
cord-016476-78r0rsio	491	114	good	good	JJ
cord-016476-78r0rsio	491	115	response	response	NN
cord-016476-78r0rsio	491	116	to	to	IN
cord-016476-78r0rsio	491	117	anakinra	anakinra	NNP
cord-016476-78r0rsio	491	118	Interstitial	interstitial	JJ
cord-016476-78r0rsio	491	119	lung	lung	NN
cord-016476-78r0rsio	491	120	disease	disease	NN
cord-016476-78r0rsio	491	121	in	in	IN
cord-016476-78r0rsio	491	122	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	491	123	arthritis	arthritis	NN
cord-016476-78r0rsio	491	124	:	:	:
cord-016476-78r0rsio	491	125	response	response	NN
cord-016476-78r0rsio	491	126	to	to	IN
cord-016476-78r0rsio	491	127	IL-6R	IL-6R	NNP
cord-016476-78r0rsio	491	128	blockade	blockade	NN
cord-016476-78r0rsio	491	129	Postmarketing	Postmarketing	NNP
cord-016476-78r0rsio	491	130	surveillance	surveillance	NN
cord-016476-78r0rsio	491	131	of	of	IN
cord-016476-78r0rsio	491	132	tocilizumab	tocilizumab	NNP
cord-016476-78r0rsio	491	133	for	for	IN
cord-016476-78r0rsio	491	134	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	135	arthritis	arthritis	NN
cord-016476-78r0rsio	491	136	in	in	IN
cord-016476-78r0rsio	491	137	Japan	Japan	NNP
cord-016476-78r0rsio	491	138	:	:	:
cord-016476-78r0rsio	491	139	interim	interim	JJ
cord-016476-78r0rsio	491	140	analysis	analysis	NN
cord-016476-78r0rsio	491	141	of	of	IN
cord-016476-78r0rsio	491	142	3881	3881	CD
cord-016476-78r0rsio	491	143	patients	patient	NNS
cord-016476-78r0rsio	491	144	Association	Association	NNP
cord-016476-78r0rsio	491	145	of	of	IN
cord-016476-78r0rsio	491	146	disease	disease	NN
cord-016476-78r0rsio	491	147	activity	activity	NN
cord-016476-78r0rsio	491	148	with	with	IN
cord-016476-78r0rsio	491	149	acute	acute	JJ
cord-016476-78r0rsio	491	150	exacerbation	exacerbation	NN
cord-016476-78r0rsio	491	151	of	of	IN
cord-016476-78r0rsio	491	152	interstitial	interstitial	JJ
cord-016476-78r0rsio	491	153	lung	lung	NN
cord-016476-78r0rsio	491	154	disease	disease	NN
cord-016476-78r0rsio	491	155	during	during	IN
cord-016476-78r0rsio	491	156	tocilizumab	tocilizumab	JJ
cord-016476-78r0rsio	491	157	treatment	treatment	NN
cord-016476-78r0rsio	491	158	in	in	IN
cord-016476-78r0rsio	491	159	patients	patient	NNS
cord-016476-78r0rsio	491	160	with	with	IN
cord-016476-78r0rsio	491	161	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	162	arthritis	arthritis	NN
cord-016476-78r0rsio	491	163	:	:	:
cord-016476-78r0rsio	491	164	a	a	DT
cord-016476-78r0rsio	491	165	retrospective	retrospective	JJ
cord-016476-78r0rsio	491	166	,	,	,
cord-016476-78r0rsio	491	167	case	case	NN
cord-016476-78r0rsio	491	168	-	-	HYPH
cord-016476-78r0rsio	491	169	control	control	NN
cord-016476-78r0rsio	491	170	study	study	NN
cord-016476-78r0rsio	491	171	Recombinant	recombinant	JJ
cord-016476-78r0rsio	491	172	human	human	JJ
cord-016476-78r0rsio	491	173	interleukin-1	interleukin-1	NNP
cord-016476-78r0rsio	491	174	receptor	receptor	NN
cord-016476-78r0rsio	491	175	type	type	NN
cord-016476-78r0rsio	491	176	I	-PRON-	PRP
cord-016476-78r0rsio	491	177	in	in	IN
cord-016476-78r0rsio	491	178	the	the	DT
cord-016476-78r0rsio	491	179	treatment	treatment	NN
cord-016476-78r0rsio	491	180	of	of	IN
cord-016476-78r0rsio	491	181	patients	patient	NNS
cord-016476-78r0rsio	491	182	with	with	IN
cord-016476-78r0rsio	491	183	active	active	JJ
cord-016476-78r0rsio	491	184	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	185	arthritis	arthritis	NN
cord-016476-78r0rsio	491	186	Dose	dose	NN
cord-016476-78r0rsio	491	187	-	-	HYPH
cord-016476-78r0rsio	491	188	range	range	NN
cord-016476-78r0rsio	491	189	and	and	CC
cord-016476-78r0rsio	491	190	dose	dose	NN
cord-016476-78r0rsio	491	191	-	-	HYPH
cord-016476-78r0rsio	491	192	frequency	frequency	NN
cord-016476-78r0rsio	491	193	study	study	NN
cord-016476-78r0rsio	491	194	of	of	IN
cord-016476-78r0rsio	491	195	recombinant	recombinant	JJ
cord-016476-78r0rsio	491	196	human	human	JJ
cord-016476-78r0rsio	491	197	interleukin-1	interleukin-1	NNP
cord-016476-78r0rsio	491	198	receptor	receptor	NN
cord-016476-78r0rsio	491	199	antagonist	antagonist	NN
cord-016476-78r0rsio	491	200	in	in	IN
cord-016476-78r0rsio	491	201	patients	patient	NNS
cord-016476-78r0rsio	491	202	with	with	IN
cord-016476-78r0rsio	491	203	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	491	204	arthritis	arthritis	NN
cord-016476-78r0rsio	491	205	.	.	.
cord-016476-78r0rsio	492	1	The	the	DT
cord-016476-78r0rsio	492	2	IL-1Ra	IL-1Ra	NNP
cord-016476-78r0rsio	492	3	arthritis	arthritis	NN
cord-016476-78r0rsio	492	4	study	study	NN
cord-016476-78r0rsio	492	5	group	group	NN
cord-016476-78r0rsio	492	6	Treatment	Treatment	NNP
cord-016476-78r0rsio	492	7	of	of	IN
cord-016476-78r0rsio	492	8	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	492	9	arthritis	arthritis	NN
cord-016476-78r0rsio	492	10	with	with	IN
cord-016476-78r0rsio	492	11	recombinant	recombinant	JJ
cord-016476-78r0rsio	492	12	human	human	JJ
cord-016476-78r0rsio	492	13	interleukin-1	interleukin-1	NNP
cord-016476-78r0rsio	492	14	receptor	receptor	NN
cord-016476-78r0rsio	492	15	antagonist	antagonist	NN
cord-016476-78r0rsio	492	16	Treatment	Treatment	NNP
cord-016476-78r0rsio	492	17	of	of	IN
cord-016476-78r0rsio	492	18	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	492	19	arthritis	arthritis	NN
cord-016476-78r0rsio	492	20	with	with	IN
cord-016476-78r0rsio	492	21	anakinra	anakinra	NNP
cord-016476-78r0rsio	492	22	,	,	,
cord-016476-78r0rsio	492	23	a	a	DT
cord-016476-78r0rsio	492	24	recombinant	recombinant	JJ
cord-016476-78r0rsio	492	25	human	human	NN
cord-016476-78r0rsio	492	26	interleukin-1	interleukin-1	NNP
cord-016476-78r0rsio	492	27	receptor	receptor	NN
cord-016476-78r0rsio	492	28	antagonist	antagonist	NN
cord-016476-78r0rsio	492	29	,	,	,
cord-016476-78r0rsio	492	30	in	in	IN
cord-016476-78r0rsio	492	31	combination	combination	NN
cord-016476-78r0rsio	492	32	with	with	IN
cord-016476-78r0rsio	492	33	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	492	34	:	:	:
cord-016476-78r0rsio	492	35	results	result	NNS
cord-016476-78r0rsio	492	36	of	of	IN
cord-016476-78r0rsio	492	37	a	a	DT
cord-016476-78r0rsio	492	38	twenty	twenty	CD
cord-016476-78r0rsio	492	39	-	-	HYPH
cord-016476-78r0rsio	492	40	four	four	CD
cord-016476-78r0rsio	492	41	-	-	HYPH
cord-016476-78r0rsio	492	42	week	week	NN
cord-016476-78r0rsio	492	43	,	,	,
cord-016476-78r0rsio	492	44	multicenter	multicenter	JJ
cord-016476-78r0rsio	492	45	,	,	,
cord-016476-78r0rsio	492	46	randomized	randomized	JJ
cord-016476-78r0rsio	492	47	,	,	,
cord-016476-78r0rsio	492	48	double	double	JJ
cord-016476-78r0rsio	492	49	-	-	HYPH
cord-016476-78r0rsio	492	50	blind	blind	JJ
cord-016476-78r0rsio	492	51	,	,	,
cord-016476-78r0rsio	492	52	placebo	placebo	NN
cord-016476-78r0rsio	492	53	-	-	HYPH
cord-016476-78r0rsio	492	54	controlled	control	VBN
cord-016476-78r0rsio	492	55	trial	trial	NN
cord-016476-78r0rsio	493	1	A	a	DT
cord-016476-78r0rsio	493	2	randomised	randomised	JJ
cord-016476-78r0rsio	493	3	trial	trial	NN
cord-016476-78r0rsio	493	4	evaluating	evaluate	VBG
cord-016476-78r0rsio	493	5	anakinra	anakinra	NNP
cord-016476-78r0rsio	493	6	in	in	IN
cord-016476-78r0rsio	493	7	early	early	JJ
cord-016476-78r0rsio	493	8	active	active	JJ
cord-016476-78r0rsio	493	9	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	10	arthritis	arthritis	NN
cord-016476-78r0rsio	493	11	Combination	combination	NN
cord-016476-78r0rsio	493	12	therapy	therapy	NN
cord-016476-78r0rsio	493	13	with	with	IN
cord-016476-78r0rsio	493	14	Etanercept	Etanercept	NNP
cord-016476-78r0rsio	493	15	and	and	CC
cord-016476-78r0rsio	493	16	Anakinra	Anakinra	NNP
cord-016476-78r0rsio	493	17	in	in	IN
cord-016476-78r0rsio	493	18	the	the	DT
cord-016476-78r0rsio	493	19	treatment	treatment	NN
cord-016476-78r0rsio	493	20	of	of	IN
cord-016476-78r0rsio	493	21	patients	patient	NNS
cord-016476-78r0rsio	493	22	with	with	IN
cord-016476-78r0rsio	493	23	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	24	arthritis	arthritis	NN
cord-016476-78r0rsio	493	25	who	who	WP
cord-016476-78r0rsio	493	26	have	have	VBP
cord-016476-78r0rsio	493	27	been	be	VBN
cord-016476-78r0rsio	493	28	treated	treat	VBN
cord-016476-78r0rsio	493	29	unsuccessfully	unsuccessfully	RB
cord-016476-78r0rsio	493	30	with	with	IN
cord-016476-78r0rsio	493	31	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	493	32	Proposal	Proposal	NNP
cord-016476-78r0rsio	493	33	for	for	IN
cord-016476-78r0rsio	493	34	a	a	DT
cord-016476-78r0rsio	493	35	new	new	JJ
cord-016476-78r0rsio	493	36	nomenclature	nomenclature	NN
cord-016476-78r0rsio	493	37	of	of	IN
cord-016476-78r0rsio	493	38	diseasemodifying	diseasemodifye	VBG
cord-016476-78r0rsio	493	39	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	493	40	drugs	drug	NNS
cord-016476-78r0rsio	493	41	Baricitinib	Baricitinib	NNP
cord-016476-78r0rsio	493	42	versus	versus	IN
cord-016476-78r0rsio	493	43	placebo	placebo	NN
cord-016476-78r0rsio	493	44	or	or	CC
cord-016476-78r0rsio	493	45	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	493	46	in	in	IN
cord-016476-78r0rsio	493	47	patients	patient	NNS
cord-016476-78r0rsio	493	48	with	with	IN
cord-016476-78r0rsio	493	49	active	active	JJ
cord-016476-78r0rsio	493	50	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	51	arthritis	arthritis	NN
cord-016476-78r0rsio	493	52	(	(	-LRB-
cord-016476-78r0rsio	493	53	RA	RA	NNP
cord-016476-78r0rsio	493	54	)	)	-RRB-
cord-016476-78r0rsio	493	55	and	and	CC
cord-016476-78r0rsio	493	56	an	an	DT
cord-016476-78r0rsio	493	57	inadequate	inadequate	JJ
cord-016476-78r0rsio	493	58	response	response	NN
cord-016476-78r0rsio	493	59	to	to	TO
cord-016476-78r0rsio	493	60	background	background	VB
cord-016476-78r0rsio	493	61	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	493	62	therapy	therapy	NN
cord-016476-78r0rsio	493	63	:	:	:
cord-016476-78r0rsio	493	64	results	result	NNS
cord-016476-78r0rsio	493	65	of	of	IN
cord-016476-78r0rsio	493	66	a	a	DT
cord-016476-78r0rsio	493	67	phase	phase	NN
cord-016476-78r0rsio	493	68	3	3	CD
cord-016476-78r0rsio	493	69	study	study	NN
cord-016476-78r0rsio	493	70	Tofacitinib	Tofacitinib	NNP
cord-016476-78r0rsio	493	71	or	or	CC
cord-016476-78r0rsio	493	72	adalimumab	adalimumab	NNS
cord-016476-78r0rsio	493	73	versus	versus	IN
cord-016476-78r0rsio	493	74	placebo	placebo	NN
cord-016476-78r0rsio	493	75	in	in	IN
cord-016476-78r0rsio	493	76	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	493	77	arthritis	arthritis	NN
cord-016476-78r0rsio	493	78	CP-690,550	CP-690,550	NNP
cord-016476-78r0rsio	493	79	)	)	-RRB-
cord-016476-78r0rsio	493	80	in	in	IN
cord-016476-78r0rsio	493	81	combination	combination	NN
cord-016476-78r0rsio	493	82	with	with	IN
cord-016476-78r0rsio	493	83	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	493	84	in	in	IN
cord-016476-78r0rsio	493	85	patients	patient	NNS
cord-016476-78r0rsio	493	86	with	with	IN
cord-016476-78r0rsio	493	87	active	active	JJ
cord-016476-78r0rsio	493	88	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	89	arthritis	arthritis	NN
cord-016476-78r0rsio	493	90	with	with	IN
cord-016476-78r0rsio	493	91	an	an	DT
cord-016476-78r0rsio	493	92	inadequate	inadequate	JJ
cord-016476-78r0rsio	493	93	response	response	NN
cord-016476-78r0rsio	493	94	to	to	IN
cord-016476-78r0rsio	493	95	tumour	tumour	NN
cord-016476-78r0rsio	493	96	necrosis	necrosis	NN
cord-016476-78r0rsio	493	97	factor	factor	NN
cord-016476-78r0rsio	493	98	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	493	99	:	:	:
cord-016476-78r0rsio	493	100	a	a	DT
cord-016476-78r0rsio	493	101	randomised	randomised	JJ
cord-016476-78r0rsio	493	102	phase	phase	NN
cord-016476-78r0rsio	493	103	3	3	CD
cord-016476-78r0rsio	493	104	trial	trial	NN
cord-016476-78r0rsio	493	105	CP-690,550	cp-690,550	NN
cord-016476-78r0rsio	493	106	)	)	-RRB-
cord-016476-78r0rsio	493	107	in	in	IN
cord-016476-78r0rsio	493	108	patients	patient	NNS
cord-016476-78r0rsio	493	109	with	with	IN
cord-016476-78r0rsio	493	110	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	111	arthritis	arthritis	NN
cord-016476-78r0rsio	493	112	receiving	receive	VBG
cord-016476-78r0rsio	493	113	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	493	114	:	:	:
cord-016476-78r0rsio	493	115	twelve	twelve	CD
cord-016476-78r0rsio	493	116	-	-	HYPH
cord-016476-78r0rsio	493	117	month	month	NN
cord-016476-78r0rsio	493	118	data	datum	NNS
cord-016476-78r0rsio	493	119	from	from	IN
cord-016476-78r0rsio	493	120	a	a	DT
cord-016476-78r0rsio	493	121	twenty	twenty	CD
cord-016476-78r0rsio	493	122	-	-	HYPH
cord-016476-78r0rsio	493	123	four	four	CD
cord-016476-78r0rsio	493	124	-	-	HYPH
cord-016476-78r0rsio	493	125	month	month	NN
cord-016476-78r0rsio	493	126	phase	phase	NN
cord-016476-78r0rsio	493	127	III	iii	CD
cord-016476-78r0rsio	493	128	randomized	randomized	JJ
cord-016476-78r0rsio	493	129	radiographic	radiographic	JJ
cord-016476-78r0rsio	493	130	study	study	NN
cord-016476-78r0rsio	493	131	Placebo	Placebo	NNP
cord-016476-78r0rsio	493	132	-	-	HYPH
cord-016476-78r0rsio	493	133	controlled	control	VBN
cord-016476-78r0rsio	493	134	trial	trial	NN
cord-016476-78r0rsio	493	135	of	of	IN
cord-016476-78r0rsio	493	136	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	493	137	monotherapy	monotherapy	IN
cord-016476-78r0rsio	493	138	in	in	IN
cord-016476-78r0rsio	493	139	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	140	arthritis	arthritis	NN
cord-016476-78r0rsio	493	141	Safety	Safety	NNP
cord-016476-78r0rsio	493	142	and	and	CC
cord-016476-78r0rsio	493	143	efficacy	efficacy	NN
cord-016476-78r0rsio	493	144	of	of	IN
cord-016476-78r0rsio	493	145	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	493	146	,	,	,
cord-016476-78r0rsio	493	147	an	an	DT
cord-016476-78r0rsio	493	148	oral	oral	JJ
cord-016476-78r0rsio	493	149	janus	janus	NNP
cord-016476-78r0rsio	493	150	kinase	kinase	NNP
cord-016476-78r0rsio	493	151	inhibitor	inhibitor	NN
cord-016476-78r0rsio	493	152	,	,	,
cord-016476-78r0rsio	493	153	for	for	IN
cord-016476-78r0rsio	493	154	the	the	DT
cord-016476-78r0rsio	493	155	treatment	treatment	NN
cord-016476-78r0rsio	493	156	of	of	IN
cord-016476-78r0rsio	493	157	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	493	158	arthritis	arthritis	NN
cord-016476-78r0rsio	493	159	in	in	IN
cord-016476-78r0rsio	493	160	open	open	JJ
cord-016476-78r0rsio	493	161	-	-	HYPH
cord-016476-78r0rsio	493	162	label	label	NN
cord-016476-78r0rsio	493	163	,	,	,
cord-016476-78r0rsio	493	164	longterm	longterm	JJ
cord-016476-78r0rsio	493	165	extension	extension	NN
cord-016476-78r0rsio	493	166	studies	study	NNS
cord-016476-78r0rsio	493	167	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	493	168	and	and	CC
cord-016476-78r0rsio	493	169	safety	safety	NN
cord-016476-78r0rsio	493	170	of	of	IN
cord-016476-78r0rsio	493	171	tofacitinib	tofacitinib	NNP
cord-016476-78r0rsio	493	172	in	in	IN
cord-016476-78r0rsio	493	173	the	the	DT
cord-016476-78r0rsio	493	174	treatment	treatment	NN
cord-016476-78r0rsio	493	175	of	of	IN
cord-016476-78r0rsio	493	176	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	493	177	arthritis	arthritis	NN
cord-016476-78r0rsio	493	178	:	:	:
cord-016476-78r0rsio	493	179	a	a	DT
cord-016476-78r0rsio	493	180	systematic	systematic	JJ
cord-016476-78r0rsio	493	181	review	review	NN
cord-016476-78r0rsio	493	182	and	and	CC
cord-016476-78r0rsio	493	183	meta	meta	NNP
cord-016476-78r0rsio	493	184	-	-	HYPH
cord-016476-78r0rsio	493	185	analysis	analysis	NN
cord-016476-78r0rsio	493	186	Safety	safety	NN
cord-016476-78r0rsio	493	187	and	and	CC
cord-016476-78r0rsio	493	188	efficacy	efficacy	NN
cord-016476-78r0rsio	493	189	of	of	IN
cord-016476-78r0rsio	493	190	baricitinib	baricitinib	NN
cord-016476-78r0rsio	493	191	at	at	IN
cord-016476-78r0rsio	493	192	24	24	CD
cord-016476-78r0rsio	493	193	weeks	week	NNS
cord-016476-78r0rsio	493	194	in	in	IN
cord-016476-78r0rsio	493	195	patients	patient	NNS
cord-016476-78r0rsio	493	196	with	with	IN
cord-016476-78r0rsio	493	197	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	198	arthritis	arthritis	NN
cord-016476-78r0rsio	493	199	who	who	WP
cord-016476-78r0rsio	493	200	have	have	VBP
cord-016476-78r0rsio	493	201	had	have	VBN
cord-016476-78r0rsio	493	202	an	an	DT
cord-016476-78r0rsio	493	203	inadequate	inadequate	JJ
cord-016476-78r0rsio	493	204	response	response	NN
cord-016476-78r0rsio	493	205	to	to	IN
cord-016476-78r0rsio	493	206	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	493	207	Baricitinib	Baricitinib	NNP
cord-016476-78r0rsio	493	208	in	in	IN
cord-016476-78r0rsio	493	209	patients	patient	NNS
cord-016476-78r0rsio	493	210	with	with	IN
cord-016476-78r0rsio	493	211	refractory	refractory	JJ
cord-016476-78r0rsio	493	212	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	493	213	arthritis	arthritis	NN
cord-016476-78r0rsio	493	214	Risk	Risk	NNP
cord-016476-78r0rsio	493	215	evaluation	evaluation	NN
cord-016476-78r0rsio	493	216	and	and	CC
cord-016476-78r0rsio	493	217	mitigation	mitigation	NN
cord-016476-78r0rsio	493	218	strategy	strategy	NN
cord-016476-78r0rsio	493	219	(	(	-LRB-
cord-016476-78r0rsio	493	220	REMS	REMS	NNP
cord-016476-78r0rsio	493	221	)	)	-RRB-
cord-016476-78r0rsio	493	222	NDA	NDA	NNP
cord-016476-78r0rsio	493	223	203	203	CD
cord-016476-78r0rsio	493	224	Usual	usual	JJ
cord-016476-78r0rsio	493	225	interstitial	interstitial	JJ
cord-016476-78r0rsio	493	226	pneumonia	pneumonia	NN
cord-016476-78r0rsio	493	227	in	in	IN
cord-016476-78r0rsio	493	228	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	493	229	arthritisassociated	arthritisassociate	VBN
cord-016476-78r0rsio	493	230	interstitial	interstitial	JJ
cord-016476-78r0rsio	493	231	lung	lung	NN
cord-016476-78r0rsio	493	232	disease	disease	NN
cord-016476-78r0rsio	493	233	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	493	234	arthritis	arthritis	NN
cord-016476-78r0rsio	493	235	and	and	CC
cord-016476-78r0rsio	493	236	lung	lung	NN
cord-016476-78r0rsio	493	237	disease	disease	NN
cord-016476-78r0rsio	493	238	:	:	:
cord-016476-78r0rsio	493	239	from	from	IN
cord-016476-78r0rsio	493	240	mechanisms	mechanism	NNS
cord-016476-78r0rsio	493	241	to	to	IN
cord-016476-78r0rsio	493	242	a	a	DT
cord-016476-78r0rsio	493	243	practical	practical	JJ
cord-016476-78r0rsio	493	244	approach	approach	NN
cord-016476-78r0rsio	494	1	An	an	DT
cord-016476-78r0rsio	494	2	official	official	JJ
cord-016476-78r0rsio	494	3	ATS	ATS	NNP
cord-016476-78r0rsio	494	4	/	/	SYM
cord-016476-78r0rsio	494	5	ERS	ERS	NNP
cord-016476-78r0rsio	494	6	/	/	SYM
cord-016476-78r0rsio	494	7	JRS	JRS	NNP
cord-016476-78r0rsio	494	8	/	/	SYM
cord-016476-78r0rsio	494	9	ALAT	ALAT	NNP
cord-016476-78r0rsio	494	10	clinical	clinical	JJ
cord-016476-78r0rsio	494	11	practice	practice	NN
cord-016476-78r0rsio	494	12	guideline	guideline	NN
cord-016476-78r0rsio	494	13	:	:	:
cord-016476-78r0rsio	494	14	treatment	treatment	NN
cord-016476-78r0rsio	494	15	of	of	IN
cord-016476-78r0rsio	494	16	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	494	17	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	494	18	fibrosis	fibrosis	NN
cord-016476-78r0rsio	494	19	:	:	:
cord-016476-78r0rsio	494	20	an	an	DT
cord-016476-78r0rsio	494	21	update	update	NN
cord-016476-78r0rsio	494	22	of	of	IN
cord-016476-78r0rsio	494	23	the	the	DT
cord-016476-78r0rsio	494	24	2011	2011	CD
cord-016476-78r0rsio	494	25	clinical	clinical	JJ
cord-016476-78r0rsio	494	26	practice	practice	NN
cord-016476-78r0rsio	494	27	guideline	guideline	NN
cord-016476-78r0rsio	494	28	The	the	DT
cord-016476-78r0rsio	494	29	lung	lung	NN
cord-016476-78r0rsio	494	30	disease	disease	NN
cord-016476-78r0rsio	494	31	of	of	IN
cord-016476-78r0rsio	494	32	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	494	33	arthritis	arthritis	NN
cord-016476-78r0rsio	494	34	Azathioprine	Azathioprine	NNP
cord-016476-78r0rsio	494	35	combined	combine	VBN
cord-016476-78r0rsio	494	36	with	with	IN
cord-016476-78r0rsio	494	37	prednisone	prednisone	NN
cord-016476-78r0rsio	494	38	in	in	IN
cord-016476-78r0rsio	494	39	the	the	DT
cord-016476-78r0rsio	494	40	treatment	treatment	NN
cord-016476-78r0rsio	494	41	of	of	IN
cord-016476-78r0rsio	494	42	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	494	43	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	494	44	fibrosis	fibrosis	NN
cord-016476-78r0rsio	494	45	:	:	:
cord-016476-78r0rsio	494	46	a	a	DT
cord-016476-78r0rsio	494	47	prospective	prospective	JJ
cord-016476-78r0rsio	494	48	double	double	JJ
cord-016476-78r0rsio	494	49	-	-	HYPH
cord-016476-78r0rsio	494	50	blind	blind	JJ
cord-016476-78r0rsio	494	51	,	,	,
cord-016476-78r0rsio	494	52	randomized	randomized	JJ
cord-016476-78r0rsio	494	53	,	,	,
cord-016476-78r0rsio	494	54	placebo	placebo	NN
cord-016476-78r0rsio	494	55	-	-	HYPH
cord-016476-78r0rsio	494	56	controlled	control	VBN
cord-016476-78r0rsio	494	57	clinical	clinical	JJ
cord-016476-78r0rsio	494	58	trial	trial	NN
cord-016476-78r0rsio	494	59	Prednisone	Prednisone	NNP
cord-016476-78r0rsio	494	60	,	,	,
cord-016476-78r0rsio	494	61	azathioprine	azathioprine	NN
cord-016476-78r0rsio	494	62	,	,	,
cord-016476-78r0rsio	494	63	and	and	CC
cord-016476-78r0rsio	494	64	N	n	NN
cord-016476-78r0rsio	494	65	-	-	HYPH
cord-016476-78r0rsio	494	66	acetylcysteine	acetylcysteine	NN
cord-016476-78r0rsio	494	67	for	for	IN
cord-016476-78r0rsio	494	68	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	494	69	fibrosis	fibrosis	NN
cord-016476-78r0rsio	494	70	Risk	Risk	NNP
cord-016476-78r0rsio	494	71	of	of	IN
cord-016476-78r0rsio	494	72	serious	serious	JJ
cord-016476-78r0rsio	494	73	infection	infection	NN
cord-016476-78r0rsio	494	74	in	in	IN
cord-016476-78r0rsio	494	75	patients	patient	NNS
cord-016476-78r0rsio	494	76	with	with	IN
cord-016476-78r0rsio	494	77	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	494	78	arthritis	arthritis	NN
cord-016476-78r0rsio	494	79	-	-	HYPH
cord-016476-78r0rsio	494	80	associated	associate	VBN
cord-016476-78r0rsio	494	81	interstitial	interstitial	JJ
cord-016476-78r0rsio	494	82	lung	lung	NN
cord-016476-78r0rsio	494	83	disease	disease	NN
cord-016476-78r0rsio	494	84	Immediate	Immediate	NNP
cord-016476-78r0rsio	494	85	and	and	CC
cord-016476-78r0rsio	494	86	delayed	delayed	JJ
cord-016476-78r0rsio	494	87	impact	impact	NN
cord-016476-78r0rsio	494	88	of	of	IN
cord-016476-78r0rsio	494	89	oral	oral	JJ
cord-016476-78r0rsio	494	90	glucocorticoid	glucocorticoid	NN
cord-016476-78r0rsio	494	91	therapy	therapy	NN
cord-016476-78r0rsio	494	92	on	on	IN
cord-016476-78r0rsio	494	93	risk	risk	NN
cord-016476-78r0rsio	494	94	of	of	IN
cord-016476-78r0rsio	494	95	serious	serious	JJ
cord-016476-78r0rsio	494	96	infection	infection	NN
cord-016476-78r0rsio	494	97	in	in	IN
cord-016476-78r0rsio	494	98	older	old	JJR
cord-016476-78r0rsio	494	99	patients	patient	NNS
cord-016476-78r0rsio	494	100	with	with	IN
cord-016476-78r0rsio	494	101	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	494	102	arthritis	arthritis	NN
cord-016476-78r0rsio	494	103	:	:	:
cord-016476-78r0rsio	494	104	a	a	DT
cord-016476-78r0rsio	494	105	nested	nest	VBN
cord-016476-78r0rsio	494	106	case	case	NN
cord-016476-78r0rsio	494	107	-	-	HYPH
cord-016476-78r0rsio	494	108	control	control	NN
cord-016476-78r0rsio	494	109	analysis	analysis	NN
cord-016476-78r0rsio	495	1	Pirfenidone	Pirfenidone	NNP
cord-016476-78r0rsio	495	2	in	in	IN
cord-016476-78r0rsio	495	3	patients	patient	NNS
cord-016476-78r0rsio	495	4	with	with	IN
cord-016476-78r0rsio	495	5	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	495	6	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	495	7	fibrosis	fibrosis	NN
cord-016476-78r0rsio	495	8	(	(	-LRB-
cord-016476-78r0rsio	495	9	CAPACITY	capacity	NN
cord-016476-78r0rsio	495	10	)	)	-RRB-
cord-016476-78r0rsio	496	1	:	:	:
cord-016476-78r0rsio	496	2	two	two	CD
cord-016476-78r0rsio	496	3	randomised	randomised	JJ
cord-016476-78r0rsio	496	4	trials	trial	NNS
cord-016476-78r0rsio	497	1	Pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	497	2	in	in	IN
cord-016476-78r0rsio	497	3	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	497	4	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	497	5	fibrosis	fibrosis	NN
cord-016476-78r0rsio	497	6	Pirfenidone	Pirfenidone	NNP
cord-016476-78r0rsio	497	7	for	for	IN
cord-016476-78r0rsio	497	8	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	497	9	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	497	10	fibrosis	fibrosis	NN
cord-016476-78r0rsio	497	11	:	:	:
cord-016476-78r0rsio	498	1	analysis	analysis	NN
cord-016476-78r0rsio	498	2	of	of	IN
cord-016476-78r0rsio	498	3	pooled	pool	VBN
cord-016476-78r0rsio	498	4	data	datum	NNS
cord-016476-78r0rsio	498	5	from	from	IN
cord-016476-78r0rsio	498	6	three	three	CD
cord-016476-78r0rsio	498	7	multinational	multinational	JJ
cord-016476-78r0rsio	498	8	phase	phase	NN
cord-016476-78r0rsio	498	9	3	3	CD
cord-016476-78r0rsio	498	10	trials	trial	NNS
cord-016476-78r0rsio	498	11	Open	open	VB
cord-016476-78r0rsio	498	12	-	-	HYPH
cord-016476-78r0rsio	498	13	label	label	NN
cord-016476-78r0rsio	498	14	compassionate	compassionate	JJ
cord-016476-78r0rsio	498	15	use	use	NN
cord-016476-78r0rsio	498	16	one	one	CD
cord-016476-78r0rsio	498	17	year	year	NN
cord-016476-78r0rsio	498	18	-	-	HYPH
cord-016476-78r0rsio	498	19	treatment	treatment	NN
cord-016476-78r0rsio	498	20	with	with	IN
cord-016476-78r0rsio	498	21	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	498	22	to	to	IN
cord-016476-78r0rsio	498	23	patients	patient	NNS
cord-016476-78r0rsio	498	24	with	with	IN
cord-016476-78r0rsio	498	25	chronic	chronic	JJ
cord-016476-78r0rsio	498	26	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	498	27	fibrosis	fibrosis	NN
cord-016476-78r0rsio	498	28	Clinical	clinical	JJ
cord-016476-78r0rsio	498	29	experience	experience	NN
cord-016476-78r0rsio	498	30	with	with	IN
cord-016476-78r0rsio	498	31	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	498	32	in	in	IN
cord-016476-78r0rsio	498	33	five	five	CD
cord-016476-78r0rsio	498	34	patients	patient	NNS
cord-016476-78r0rsio	498	35	with	with	IN
cord-016476-78r0rsio	498	36	scleroderma	scleroderma	NN
cord-016476-78r0rsio	498	37	-	-	HYPH
cord-016476-78r0rsio	498	38	related	relate	VBN
cord-016476-78r0rsio	498	39	interstitial	interstitial	JJ
cord-016476-78r0rsio	498	40	lung	lung	NN
cord-016476-78r0rsio	498	41	disease	disease	NN
cord-016476-78r0rsio	499	1	Improved	improve	VBN
cord-016476-78r0rsio	499	2	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	499	3	function	function	NN
cord-016476-78r0rsio	499	4	following	follow	VBG
cord-016476-78r0rsio	499	5	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	499	6	treatment	treatment	NN
cord-016476-78r0rsio	499	7	in	in	IN
cord-016476-78r0rsio	499	8	a	a	DT
cord-016476-78r0rsio	499	9	patient	patient	NN
cord-016476-78r0rsio	499	10	with	with	IN
cord-016476-78r0rsio	499	11	progressive	progressive	JJ
cord-016476-78r0rsio	499	12	interstitial	interstitial	JJ
cord-016476-78r0rsio	499	13	lung	lung	NN
cord-016476-78r0rsio	499	14	disease	disease	NN
cord-016476-78r0rsio	499	15	associated	associate	VBN
cord-016476-78r0rsio	499	16	with	with	IN
cord-016476-78r0rsio	499	17	systemic	systemic	JJ
cord-016476-78r0rsio	499	18	sclerosis	sclerosis	NN
cord-016476-78r0rsio	499	19	A	a	DT
cord-016476-78r0rsio	499	20	case	case	NN
cord-016476-78r0rsio	499	21	report	report	NN
cord-016476-78r0rsio	499	22	:	:	:
cord-016476-78r0rsio	499	23	the	the	DT
cord-016476-78r0rsio	499	24	efficacy	efficacy	NN
cord-016476-78r0rsio	499	25	of	of	IN
cord-016476-78r0rsio	499	26	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	499	27	in	in	IN
cord-016476-78r0rsio	499	28	a	a	DT
cord-016476-78r0rsio	499	29	Chinese	chinese	JJ
cord-016476-78r0rsio	499	30	patient	patient	NN
cord-016476-78r0rsio	499	31	with	with	IN
cord-016476-78r0rsio	499	32	progressive	progressive	JJ
cord-016476-78r0rsio	499	33	systemic	systemic	JJ
cord-016476-78r0rsio	499	34	sclerosis	sclerosis	NN
cord-016476-78r0rsio	499	35	-	-	HYPH
cord-016476-78r0rsio	499	36	associated	associate	VBN
cord-016476-78r0rsio	499	37	interstitial	interstitial	JJ
cord-016476-78r0rsio	499	38	lung	lung	NN
cord-016476-78r0rsio	499	39	disease	disease	NN
cord-016476-78r0rsio	499	40	:	:	:
cord-016476-78r0rsio	499	41	a	a	DT
cord-016476-78r0rsio	499	42	CARE	care	NN
cord-016476-78r0rsio	499	43	-	-	HYPH
cord-016476-78r0rsio	499	44	compliant	compliant	JJ
cord-016476-78r0rsio	499	45	article	article	NN
cord-016476-78r0rsio	500	1	An	an	DT
cord-016476-78r0rsio	500	2	open	open	JJ
cord-016476-78r0rsio	500	3	-	-	HYPH
cord-016476-78r0rsio	500	4	label	label	NN
cord-016476-78r0rsio	500	5	,	,	,
cord-016476-78r0rsio	500	6	phase	phase	NN
cord-016476-78r0rsio	500	7	II	ii	CD
cord-016476-78r0rsio	500	8	study	study	NN
cord-016476-78r0rsio	500	9	of	of	IN
cord-016476-78r0rsio	500	10	the	the	DT
cord-016476-78r0rsio	500	11	safety	safety	NN
cord-016476-78r0rsio	500	12	and	and	CC
cord-016476-78r0rsio	500	13	tolerability	tolerability	NN
cord-016476-78r0rsio	500	14	of	of	IN
cord-016476-78r0rsio	500	15	pirfenidone	pirfenidone	NN
cord-016476-78r0rsio	500	16	in	in	IN
cord-016476-78r0rsio	500	17	patients	patient	NNS
cord-016476-78r0rsio	500	18	with	with	IN
cord-016476-78r0rsio	500	19	scleroderma	scleroderma	NN
cord-016476-78r0rsio	500	20	-	-	HYPH
cord-016476-78r0rsio	500	21	associated	associate	VBN
cord-016476-78r0rsio	500	22	interstitial	interstitial	JJ
cord-016476-78r0rsio	500	23	lung	lung	NN
cord-016476-78r0rsio	500	24	disease	disease	NN
cord-016476-78r0rsio	500	25	:	:	:
cord-016476-78r0rsio	501	1	the	the	DT
cord-016476-78r0rsio	501	2	LOTUSS	LOTUSS	NNP
cord-016476-78r0rsio	501	3	trial	trial	NN
cord-016476-78r0rsio	501	4	Is	be	VBZ
cord-016476-78r0rsio	501	5	pirfenidone	pirfenidone	JJ
cord-016476-78r0rsio	501	6	ready	ready	JJ
cord-016476-78r0rsio	501	7	for	for	IN
cord-016476-78r0rsio	501	8	use	use	NN
cord-016476-78r0rsio	501	9	in	in	IN
cord-016476-78r0rsio	501	10	non	non	JJ
cord-016476-78r0rsio	501	11	-	-	JJ
cord-016476-78r0rsio	501	12	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	501	13	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	501	14	fibrosis	fibrosis	NN
cord-016476-78r0rsio	501	15	interstitial	interstitial	JJ
cord-016476-78r0rsio	501	16	lung	lung	NN
cord-016476-78r0rsio	501	17	diseases	disease	NNS
cord-016476-78r0rsio	501	18	?	?	.
cord-016476-78r0rsio	502	1	Treatment	treatment	NN
cord-016476-78r0rsio	502	2	of	of	IN
cord-016476-78r0rsio	502	3	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	502	4	arthritis	arthritis	NN
cord-016476-78r0rsio	502	5	-	-	HYPH
cord-016476-78r0rsio	502	6	associated	associate	VBN
cord-016476-78r0rsio	502	7	interstitial	interstitial	JJ
cord-016476-78r0rsio	502	8	lung	lung	NN
cord-016476-78r0rsio	502	9	disease	disease	NN
cord-016476-78r0rsio	502	10	:	:	:
cord-016476-78r0rsio	503	1	a	a	DT
cord-016476-78r0rsio	503	2	perspective	perspective	NN
cord-016476-78r0rsio	503	3	review	review	NN
cord-016476-78r0rsio	503	4	Phase	phase	NN
cord-016476-78r0rsio	503	5	ll	will	MD
cord-016476-78r0rsio	503	6	Study	Study	NNP
cord-016476-78r0rsio	503	7	of	of	IN
cord-016476-78r0rsio	503	8	Pirfenidone	Pirfenidone	NNP
cord-016476-78r0rsio	503	9	in	in	IN
cord-016476-78r0rsio	503	10	patients	patient	NNS
cord-016476-78r0rsio	503	11	with	with	IN
cord-016476-78r0rsio	503	12	RA	RA	NNP
cord-016476-78r0rsio	503	13	-	-	HYPH
cord-016476-78r0rsio	503	14	ILD	ILD	NNP
cord-016476-78r0rsio	503	15	.	.	.
cord-016476-78r0rsio	504	1	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-016476-78r0rsio	504	2	Identifier	Identifier	NNP
cord-016476-78r0rsio	504	3	:	:	:
cord-016476-78r0rsio	504	4	NCT02808871	NCT02808871	NNP
cord-016476-78r0rsio	505	1	Nintedanib	Nintedanib	NNP
cord-016476-78r0rsio	505	2	inhibits	inhibit	VBZ
cord-016476-78r0rsio	505	3	fibroblast	fibroblast	NN
cord-016476-78r0rsio	505	4	activation	activation	NN
cord-016476-78r0rsio	505	5	and	and	CC
cord-016476-78r0rsio	505	6	ameliorates	ameliorate	VBZ
cord-016476-78r0rsio	505	7	fibrosis	fibrosis	NN
cord-016476-78r0rsio	505	8	in	in	IN
cord-016476-78r0rsio	505	9	preclinical	preclinical	JJ
cord-016476-78r0rsio	505	10	models	model	NNS
cord-016476-78r0rsio	505	11	of	of	IN
cord-016476-78r0rsio	505	12	systemic	systemic	JJ
cord-016476-78r0rsio	505	13	sclerosis	sclerosis	NN
cord-016476-78r0rsio	505	14	Combined	combine	VBN
cord-016476-78r0rsio	505	15	corticosteroid	corticosteroid	NN
cord-016476-78r0rsio	505	16	and	and	CC
cord-016476-78r0rsio	505	17	cyclophosphamide	cyclophosphamide	JJ
cord-016476-78r0rsio	505	18	therapy	therapy	NN
cord-016476-78r0rsio	505	19	does	do	VBZ
cord-016476-78r0rsio	505	20	not	not	RB
cord-016476-78r0rsio	505	21	alter	alter	VB
cord-016476-78r0rsio	505	22	survival	survival	NN
cord-016476-78r0rsio	505	23	in	in	IN
cord-016476-78r0rsio	505	24	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	505	25	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	505	26	fibrosis	fibrosis	NN
cord-016476-78r0rsio	505	27	Cyclophosphamide	Cyclophosphamide	NNP
cord-016476-78r0rsio	505	28	for	for	IN
cord-016476-78r0rsio	505	29	scleroderma	scleroderma	NN
cord-016476-78r0rsio	505	30	lung	lung	NN
cord-016476-78r0rsio	505	31	disease	disease	NN
cord-016476-78r0rsio	505	32	Cyclophosphamide	Cyclophosphamide	NNP
cord-016476-78r0rsio	505	33	versus	versus	IN
cord-016476-78r0rsio	505	34	placebo	placebo	NN
cord-016476-78r0rsio	505	35	in	in	IN
cord-016476-78r0rsio	505	36	scleroderma	scleroderma	NN
cord-016476-78r0rsio	505	37	lung	lung	NN
cord-016476-78r0rsio	505	38	disease	disease	NN
cord-016476-78r0rsio	506	1	A	a	DT
cord-016476-78r0rsio	506	2	multicenter	multicenter	JJ
cord-016476-78r0rsio	506	3	,	,	,
cord-016476-78r0rsio	506	4	prospective	prospective	JJ
cord-016476-78r0rsio	506	5	,	,	,
cord-016476-78r0rsio	506	6	randomized	randomized	JJ
cord-016476-78r0rsio	506	7	,	,	,
cord-016476-78r0rsio	506	8	doubleblind	doubleblind	NN
cord-016476-78r0rsio	506	9	,	,	,
cord-016476-78r0rsio	506	10	placebo	placebo	NN
cord-016476-78r0rsio	506	11	-	-	HYPH
cord-016476-78r0rsio	506	12	controlled	control	VBN
cord-016476-78r0rsio	506	13	trial	trial	NN
cord-016476-78r0rsio	506	14	of	of	IN
cord-016476-78r0rsio	506	15	corticosteroids	corticosteroid	NNS
cord-016476-78r0rsio	506	16	and	and	CC
cord-016476-78r0rsio	506	17	intravenous	intravenous	JJ
cord-016476-78r0rsio	506	18	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	506	19	followed	follow	VBN
cord-016476-78r0rsio	506	20	by	by	IN
cord-016476-78r0rsio	506	21	oral	oral	JJ
cord-016476-78r0rsio	506	22	azathioprine	azathioprine	NN
cord-016476-78r0rsio	506	23	for	for	IN
cord-016476-78r0rsio	506	24	the	the	DT
cord-016476-78r0rsio	506	25	treatment	treatment	NN
cord-016476-78r0rsio	506	26	of	of	IN
cord-016476-78r0rsio	506	27	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	506	28	fibrosis	fibrosis	NN
cord-016476-78r0rsio	506	29	in	in	IN
cord-016476-78r0rsio	506	30	scleroderma	scleroderma	NN
cord-016476-78r0rsio	506	31	Predicting	predict	VBG
cord-016476-78r0rsio	506	32	treatment	treatment	NN
cord-016476-78r0rsio	506	33	outcomes	outcome	NNS
cord-016476-78r0rsio	506	34	and	and	CC
cord-016476-78r0rsio	506	35	responder	responder	NN
cord-016476-78r0rsio	506	36	subsets	subset	NNS
cord-016476-78r0rsio	506	37	in	in	IN
cord-016476-78r0rsio	506	38	scleroderma	scleroderma	NN
cord-016476-78r0rsio	506	39	-	-	HYPH
cord-016476-78r0rsio	506	40	related	relate	VBN
cord-016476-78r0rsio	506	41	interstitial	interstitial	JJ
cord-016476-78r0rsio	506	42	lung	lung	NN
cord-016476-78r0rsio	506	43	disease	disease	NN
cord-016476-78r0rsio	506	44	Effects	effect	NNS
cord-016476-78r0rsio	506	45	of	of	IN
cord-016476-78r0rsio	506	46	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	506	47	on	on	IN
cord-016476-78r0rsio	506	48	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	506	49	function	function	NN
cord-016476-78r0rsio	506	50	in	in	IN
cord-016476-78r0rsio	506	51	patients	patient	NNS
cord-016476-78r0rsio	506	52	with	with	IN
cord-016476-78r0rsio	506	53	scleroderma	scleroderma	NNS
cord-016476-78r0rsio	506	54	and	and	CC
cord-016476-78r0rsio	506	55	interstitial	interstitial	JJ
cord-016476-78r0rsio	506	56	lung	lung	NN
cord-016476-78r0rsio	506	57	disease	disease	NN
cord-016476-78r0rsio	506	58	:	:	:
cord-016476-78r0rsio	507	1	a	a	DT
cord-016476-78r0rsio	507	2	systematic	systematic	JJ
cord-016476-78r0rsio	507	3	review	review	NN
cord-016476-78r0rsio	507	4	and	and	CC
cord-016476-78r0rsio	507	5	meta	meta	NNP
cord-016476-78r0rsio	507	6	-	-	HYPH
cord-016476-78r0rsio	507	7	analysis	analysis	NN
cord-016476-78r0rsio	507	8	of	of	IN
cord-016476-78r0rsio	507	9	randomized	randomized	JJ
cord-016476-78r0rsio	507	10	controlled	control	VBN
cord-016476-78r0rsio	507	11	trials	trial	NNS
cord-016476-78r0rsio	507	12	and	and	CC
cord-016476-78r0rsio	507	13	observational	observational	JJ
cord-016476-78r0rsio	507	14	prospective	prospective	JJ
cord-016476-78r0rsio	507	15	cohort	cohort	NN
cord-016476-78r0rsio	507	16	studies	study	NNS
cord-016476-78r0rsio	507	17	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	507	18	of	of	IN
cord-016476-78r0rsio	507	19	intensive	intensive	JJ
cord-016476-78r0rsio	507	20	immunosuppression	immunosuppression	NN
cord-016476-78r0rsio	507	21	in	in	IN
cord-016476-78r0rsio	507	22	exacerbated	exacerbate	VBN
cord-016476-78r0rsio	507	23	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	507	24	arthritis	arthritis	NN
cord-016476-78r0rsio	507	25	-	-	HYPH
cord-016476-78r0rsio	507	26	associated	associate	VBN
cord-016476-78r0rsio	507	27	interstitial	interstitial	JJ
cord-016476-78r0rsio	507	28	lung	lung	NN
cord-016476-78r0rsio	507	29	disease	disease	NN
cord-016476-78r0rsio	507	30	Rheumatoid	Rheumatoid	NNP
cord-016476-78r0rsio	507	31	arthritis	arthritis	NN
cord-016476-78r0rsio	507	32	associated	associate	VBN
cord-016476-78r0rsio	507	33	with	with	IN
cord-016476-78r0rsio	507	34	methotrexateinduced	methotrexateinduced	JJ
cord-016476-78r0rsio	507	35	pneumonitis	pneumonitis	NN
cord-016476-78r0rsio	507	36	:	:	:
cord-016476-78r0rsio	507	37	improvement	improvement	NN
cord-016476-78r0rsio	507	38	with	with	IN
cord-016476-78r0rsio	507	39	i.v	i.v	NNP
cord-016476-78r0rsio	507	40	.	.	.
cord-016476-78r0rsio	508	1	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	508	2	therapy	therapy	NN
cord-016476-78r0rsio	508	3	Cyclosporin	Cyclosporin	NNP
cord-016476-78r0rsio	508	4	as	as	IN
cord-016476-78r0rsio	508	5	a	a	DT
cord-016476-78r0rsio	508	6	treatment	treatment	NN
cord-016476-78r0rsio	508	7	for	for	IN
cord-016476-78r0rsio	508	8	interstitial	interstitial	JJ
cord-016476-78r0rsio	508	9	lung	lung	NN
cord-016476-78r0rsio	508	10	disease	disease	NN
cord-016476-78r0rsio	508	11	of	of	IN
cord-016476-78r0rsio	508	12	unknown	unknown	JJ
cord-016476-78r0rsio	508	13	aetiology	aetiology	NN
cord-016476-78r0rsio	508	14	Progression	progression	NN
cord-016476-78r0rsio	508	15	of	of	IN
cord-016476-78r0rsio	508	16	fibrosis	fibrosis	NN
cord-016476-78r0rsio	508	17	in	in	IN
cord-016476-78r0rsio	508	18	usual	usual	JJ
cord-016476-78r0rsio	508	19	interstitial	interstitial	JJ
cord-016476-78r0rsio	508	20	pneumonia	pneumonia	NN
cord-016476-78r0rsio	508	21	:	:	:
cord-016476-78r0rsio	508	22	serial	serial	JJ
cord-016476-78r0rsio	508	23	evaluation	evaluation	NN
cord-016476-78r0rsio	508	24	of	of	IN
cord-016476-78r0rsio	508	25	the	the	DT
cord-016476-78r0rsio	508	26	native	native	JJ
cord-016476-78r0rsio	508	27	lung	lung	NN
cord-016476-78r0rsio	508	28	after	after	IN
cord-016476-78r0rsio	508	29	single	single	JJ
cord-016476-78r0rsio	508	30	lung	lung	NN
cord-016476-78r0rsio	508	31	transplantation	transplantation	NN
cord-016476-78r0rsio	508	32	Cyclosporine	Cyclosporine	NNP
cord-016476-78r0rsio	508	33	in	in	IN
cord-016476-78r0rsio	508	34	anti	anti	JJ
cord-016476-78r0rsio	508	35	-	-	JJ
cord-016476-78r0rsio	508	36	Jo1-positive	jo1-positive	JJ
cord-016476-78r0rsio	508	37	patients	patient	NNS
cord-016476-78r0rsio	508	38	with	with	IN
cord-016476-78r0rsio	508	39	corticosteroid	corticosteroid	JJ
cord-016476-78r0rsio	508	40	-	-	HYPH
cord-016476-78r0rsio	508	41	refractory	refractory	JJ
cord-016476-78r0rsio	508	42	interstitial	interstitial	JJ
cord-016476-78r0rsio	508	43	lung	lung	NN
cord-016476-78r0rsio	508	44	disease	disease	NN
cord-016476-78r0rsio	509	1	The	the	DT
cord-016476-78r0rsio	509	2	efficacy	efficacy	NN
cord-016476-78r0rsio	509	3	of	of	IN
cord-016476-78r0rsio	509	4	calcineurin	calcineurin	NNP
cord-016476-78r0rsio	509	5	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	509	6	for	for	IN
cord-016476-78r0rsio	509	7	the	the	DT
cord-016476-78r0rsio	509	8	treatment	treatment	NN
cord-016476-78r0rsio	509	9	of	of	IN
cord-016476-78r0rsio	509	10	interstitial	interstitial	JJ
cord-016476-78r0rsio	509	11	lung	lung	NN
cord-016476-78r0rsio	509	12	disease	disease	NN
cord-016476-78r0rsio	509	13	associated	associate	VBN
cord-016476-78r0rsio	509	14	with	with	IN
cord-016476-78r0rsio	509	15	polymyositis	polymyositis	NN
cord-016476-78r0rsio	509	16	/	/	SYM
cord-016476-78r0rsio	509	17	dermatomyositis	dermatomyositis	NNP
cord-016476-78r0rsio	509	18	Survival	Survival	NNP
cord-016476-78r0rsio	509	19	benefit	benefit	NN
cord-016476-78r0rsio	509	20	associated	associate	VBN
cord-016476-78r0rsio	509	21	with	with	IN
cord-016476-78r0rsio	509	22	early	early	JJ
cord-016476-78r0rsio	509	23	cyclosporine	cyclosporine	JJ
cord-016476-78r0rsio	509	24	treatment	treatment	NN
cord-016476-78r0rsio	509	25	for	for	IN
cord-016476-78r0rsio	509	26	dermatomyositis	dermatomyositis	NN
cord-016476-78r0rsio	509	27	-	-	HYPH
cord-016476-78r0rsio	509	28	associated	associate	VBN
cord-016476-78r0rsio	509	29	interstitial	interstitial	JJ
cord-016476-78r0rsio	509	30	lung	lung	NN
cord-016476-78r0rsio	509	31	disease	disease	NN
cord-016476-78r0rsio	509	32	Experience	Experience	NNP
cord-016476-78r0rsio	509	33	of	of	IN
cord-016476-78r0rsio	509	34	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	509	35	mofetil	mofetil	NNP
cord-016476-78r0rsio	509	36	in	in	IN
cord-016476-78r0rsio	509	37	10	10	CD
cord-016476-78r0rsio	509	38	patients	patient	NNS
cord-016476-78r0rsio	509	39	with	with	IN
cord-016476-78r0rsio	509	40	autoimmune	autoimmune	NN
cord-016476-78r0rsio	509	41	-	-	HYPH
cord-016476-78r0rsio	509	42	related	relate	VBN
cord-016476-78r0rsio	509	43	interstitial	interstitial	JJ
cord-016476-78r0rsio	509	44	lung	lung	NN
cord-016476-78r0rsio	509	45	disease	disease	NN
cord-016476-78r0rsio	509	46	demonstrates	demonstrate	VBZ
cord-016476-78r0rsio	509	47	promising	promising	JJ
cord-016476-78r0rsio	509	48	effects	effect	NNS
cord-016476-78r0rsio	509	49	A	a	DT
cord-016476-78r0rsio	509	50	prospective	prospective	JJ
cord-016476-78r0rsio	509	51	observational	observational	JJ
cord-016476-78r0rsio	509	52	study	study	NN
cord-016476-78r0rsio	509	53	of	of	IN
cord-016476-78r0rsio	509	54	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	509	55	mofetil	mofetil	NNP
cord-016476-78r0rsio	509	56	treatment	treatment	NN
cord-016476-78r0rsio	509	57	in	in	IN
cord-016476-78r0rsio	509	58	progressive	progressive	JJ
cord-016476-78r0rsio	509	59	diffuse	diffuse	JJ
cord-016476-78r0rsio	509	60	cutaneous	cutaneous	JJ
cord-016476-78r0rsio	509	61	systemic	systemic	JJ
cord-016476-78r0rsio	509	62	sclerosis	sclerosis	NN
cord-016476-78r0rsio	509	63	of	of	IN
cord-016476-78r0rsio	509	64	recent	recent	JJ
cord-016476-78r0rsio	509	65	onset	onset	NN
cord-016476-78r0rsio	509	66	Cyclophosphamide	Cyclophosphamide	NNP
cord-016476-78r0rsio	509	67	versus	versus	IN
cord-016476-78r0rsio	509	68	mycophenolate	mycophenolate	NNP
cord-016476-78r0rsio	509	69	mofetil	mofetil	NNP
cord-016476-78r0rsio	509	70	in	in	IN
cord-016476-78r0rsio	509	71	scleroderma	scleroderma	NNP
cord-016476-78r0rsio	510	1	interstitial	interstitial	JJ
cord-016476-78r0rsio	510	2	lung	lung	NN
cord-016476-78r0rsio	510	3	disease	disease	NN
cord-016476-78r0rsio	510	4	(	(	-LRB-
cord-016476-78r0rsio	510	5	SSc	SSc	NNP
cord-016476-78r0rsio	510	6	-	-	HYPH
cord-016476-78r0rsio	510	7	ILD	ILD	NNP
cord-016476-78r0rsio	510	8	)	)	-RRB-
cord-016476-78r0rsio	510	9	as	as	IN
cord-016476-78r0rsio	510	10	induction	induction	NN
cord-016476-78r0rsio	510	11	therapy	therapy	NN
cord-016476-78r0rsio	510	12	:	:	:
cord-016476-78r0rsio	510	13	a	a	DT
cord-016476-78r0rsio	510	14	singlecentre	singlecentre	NN
cord-016476-78r0rsio	510	15	,	,	,
cord-016476-78r0rsio	511	1	retrospective	retrospective	JJ
cord-016476-78r0rsio	511	2	analysis	analysis	NNP
cord-016476-78r0rsio	512	1	Mycophenolate	Mycophenolate	NNP
cord-016476-78r0rsio	512	2	mofetil	mofetil	NNP
cord-016476-78r0rsio	512	3	improves	improve	VBZ
cord-016476-78r0rsio	512	4	lung	lung	NN
cord-016476-78r0rsio	512	5	function	function	NN
cord-016476-78r0rsio	512	6	in	in	IN
cord-016476-78r0rsio	512	7	connective	connective	JJ
cord-016476-78r0rsio	512	8	tissue	tissue	NN
cord-016476-78r0rsio	512	9	disease	disease	NN
cord-016476-78r0rsio	512	10	-	-	HYPH
cord-016476-78r0rsio	512	11	associated	associate	VBN
cord-016476-78r0rsio	512	12	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	13	lung	lung	NN
cord-016476-78r0rsio	512	14	disease	disease	NN
cord-016476-78r0rsio	512	15	Mycophenolate	Mycophenolate	NNP
cord-016476-78r0rsio	512	16	mofetil	mofetil	NNP
cord-016476-78r0rsio	512	17	versus	versus	IN
cord-016476-78r0rsio	512	18	oral	oral	JJ
cord-016476-78r0rsio	512	19	cyclophosphamide	cyclophosphamide	NN
cord-016476-78r0rsio	512	20	in	in	IN
cord-016476-78r0rsio	512	21	scleroderma	scleroderma	NN
cord-016476-78r0rsio	512	22	-	-	HYPH
cord-016476-78r0rsio	512	23	related	relate	VBN
cord-016476-78r0rsio	512	24	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	25	lung	lung	NN
cord-016476-78r0rsio	512	26	disease	disease	NN
cord-016476-78r0rsio	512	27	(	(	-LRB-
cord-016476-78r0rsio	512	28	SLS	SLS	NNP
cord-016476-78r0rsio	512	29	II	II	NNP
cord-016476-78r0rsio	512	30	)	)	-RRB-
cord-016476-78r0rsio	512	31	:	:	:
cord-016476-78r0rsio	512	32	a	a	DT
cord-016476-78r0rsio	512	33	randomised	randomised	JJ
cord-016476-78r0rsio	512	34	controlled	control	VBN
cord-016476-78r0rsio	512	35	,	,	,
cord-016476-78r0rsio	512	36	double	double	JJ
cord-016476-78r0rsio	512	37	-	-	HYPH
cord-016476-78r0rsio	512	38	blind	blind	JJ
cord-016476-78r0rsio	512	39	,	,	,
cord-016476-78r0rsio	512	40	parallel	parallel	JJ
cord-016476-78r0rsio	512	41	group	group	NN
cord-016476-78r0rsio	512	42	trial	trial	NN
cord-016476-78r0rsio	512	43	Mycophenolate	Mycophenolate	NNP
cord-016476-78r0rsio	512	44	mofetil	mofetil	NNP
cord-016476-78r0rsio	512	45	is	be	VBZ
cord-016476-78r0rsio	512	46	safe	safe	JJ
cord-016476-78r0rsio	512	47	,	,	,
cord-016476-78r0rsio	512	48	well	well	RB
cord-016476-78r0rsio	512	49	tolerated	tolerate	VBN
cord-016476-78r0rsio	512	50	,	,	,
cord-016476-78r0rsio	512	51	and	and	CC
cord-016476-78r0rsio	512	52	preserves	preserve	VBZ
cord-016476-78r0rsio	512	53	lung	lung	NN
cord-016476-78r0rsio	512	54	function	function	NN
cord-016476-78r0rsio	512	55	in	in	IN
cord-016476-78r0rsio	512	56	patients	patient	NNS
cord-016476-78r0rsio	512	57	with	with	IN
cord-016476-78r0rsio	512	58	connective	connective	JJ
cord-016476-78r0rsio	512	59	tissue	tissue	NN
cord-016476-78r0rsio	512	60	disease	disease	NN
cord-016476-78r0rsio	512	61	-	-	HYPH
cord-016476-78r0rsio	512	62	related	relate	VBN
cord-016476-78r0rsio	512	63	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	64	lung	lung	NN
cord-016476-78r0rsio	512	65	disease	disease	NN
cord-016476-78r0rsio	512	66	B	b	NN
cord-016476-78r0rsio	512	67	-	-	HYPH
cord-016476-78r0rsio	512	68	cell	cell	NN
cord-016476-78r0rsio	512	69	depletion	depletion	NN
cord-016476-78r0rsio	512	70	salvage	salvage	NN
cord-016476-78r0rsio	512	71	therapy	therapy	NN
cord-016476-78r0rsio	512	72	in	in	IN
cord-016476-78r0rsio	512	73	rapidly	rapidly	RB
cord-016476-78r0rsio	512	74	progressive	progressive	JJ
cord-016476-78r0rsio	512	75	dermatomyositis	dermatomyositis	NN
cord-016476-78r0rsio	512	76	related	relate	VBN
cord-016476-78r0rsio	512	77	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	78	lung	lung	NN
cord-016476-78r0rsio	512	79	disease	disease	NN
cord-016476-78r0rsio	512	80	Successful	successful	JJ
cord-016476-78r0rsio	512	81	experience	experience	NN
cord-016476-78r0rsio	512	82	of	of	IN
cord-016476-78r0rsio	512	83	rituximab	rituximab	NN
cord-016476-78r0rsio	512	84	therapy	therapy	NN
cord-016476-78r0rsio	512	85	for	for	IN
cord-016476-78r0rsio	512	86	systemic	systemic	JJ
cord-016476-78r0rsio	512	87	sclerosis	sclerosis	NN
cord-016476-78r0rsio	512	88	-	-	HYPH
cord-016476-78r0rsio	512	89	associated	associate	VBN
cord-016476-78r0rsio	512	90	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	91	lung	lung	NN
cord-016476-78r0rsio	512	92	disease	disease	NN
cord-016476-78r0rsio	512	93	with	with	IN
cord-016476-78r0rsio	512	94	concomitant	concomitant	JJ
cord-016476-78r0rsio	512	95	systemic	systemic	JJ
cord-016476-78r0rsio	512	96	lupus	lupus	NN
cord-016476-78r0rsio	512	97	erythematosus	erythematosus	NN
cord-016476-78r0rsio	512	98	Severe	severe	JJ
cord-016476-78r0rsio	512	99	interstitial	interstitial	JJ
cord-016476-78r0rsio	512	100	lung	lung	NN
cord-016476-78r0rsio	512	101	disease	disease	NN
cord-016476-78r0rsio	512	102	in	in	IN
cord-016476-78r0rsio	512	103	connective	connective	JJ
cord-016476-78r0rsio	512	104	tissue	tissue	NN
cord-016476-78r0rsio	512	105	disease	disease	NN
cord-016476-78r0rsio	512	106	:	:	:
cord-016476-78r0rsio	512	107	rituximab	rituximab	VBN
cord-016476-78r0rsio	512	108	as	as	IN
cord-016476-78r0rsio	512	109	rescue	rescue	NN
cord-016476-78r0rsio	512	110	therapy	therapy	NN
cord-016476-78r0rsio	512	111	Long	long	JJ
cord-016476-78r0rsio	512	112	-	-	HYPH
cord-016476-78r0rsio	512	113	term	term	NN
cord-016476-78r0rsio	512	114	efficacy	efficacy	NN
cord-016476-78r0rsio	512	115	of	of	IN
cord-016476-78r0rsio	512	116	B	b	NN
cord-016476-78r0rsio	512	117	cell	cell	NN
cord-016476-78r0rsio	512	118	depletion	depletion	NN
cord-016476-78r0rsio	512	119	therapy	therapy	NN
cord-016476-78r0rsio	512	120	on	on	IN
cord-016476-78r0rsio	512	121	lung	lung	NN
cord-016476-78r0rsio	512	122	and	and	CC
cord-016476-78r0rsio	512	123	skin	skin	NN
cord-016476-78r0rsio	512	124	involvement	involvement	NN
cord-016476-78r0rsio	512	125	in	in	IN
cord-016476-78r0rsio	512	126	diffuse	diffuse	JJ
cord-016476-78r0rsio	512	127	systemic	systemic	JJ
cord-016476-78r0rsio	512	128	sclerosis	sclerosis	NN
cord-016476-78r0rsio	512	129	Open	open	JJ
cord-016476-78r0rsio	512	130	-	-	HYPH
cord-016476-78r0rsio	512	131	label	label	NN
cord-016476-78r0rsio	513	1	,	,	,
cord-016476-78r0rsio	513	2	pilot	pilot	NN
cord-016476-78r0rsio	513	3	study	study	NN
cord-016476-78r0rsio	513	4	of	of	IN
cord-016476-78r0rsio	513	5	the	the	DT
cord-016476-78r0rsio	513	6	safety	safety	NN
cord-016476-78r0rsio	513	7	and	and	CC
cord-016476-78r0rsio	513	8	clinical	clinical	JJ
cord-016476-78r0rsio	513	9	effects	effect	NNS
cord-016476-78r0rsio	513	10	of	of	IN
cord-016476-78r0rsio	513	11	rituximab	rituximab	NN
cord-016476-78r0rsio	513	12	in	in	IN
cord-016476-78r0rsio	513	13	patients	patient	NNS
cord-016476-78r0rsio	513	14	with	with	IN
cord-016476-78r0rsio	513	15	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	513	16	arthritis	arthritis	NN
cord-016476-78r0rsio	513	17	associated	associate	VBN
cord-016476-78r0rsio	513	18	interstitial	interstitial	JJ
cord-016476-78r0rsio	513	19	pneumonia	pneumonia	NN
cord-016476-78r0rsio	513	20	Safety	Safety	NNP
cord-016476-78r0rsio	513	21	of	of	IN
cord-016476-78r0rsio	513	22	rituximab	rituximab	NN
cord-016476-78r0rsio	513	23	in	in	IN
cord-016476-78r0rsio	513	24	patients	patient	NNS
cord-016476-78r0rsio	513	25	with	with	IN
cord-016476-78r0rsio	513	26	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	513	27	arthritis	arthritis	NN
cord-016476-78r0rsio	513	28	and	and	CC
cord-016476-78r0rsio	513	29	concomitant	concomitant	JJ
cord-016476-78r0rsio	513	30	lung	lung	NN
cord-016476-78r0rsio	513	31	disease	disease	NN
cord-016476-78r0rsio	513	32	Efficacy	Efficacy	NNP
cord-016476-78r0rsio	513	33	and	and	CC
cord-016476-78r0rsio	513	34	safety	safety	NN
cord-016476-78r0rsio	513	35	of	of	IN
cord-016476-78r0rsio	513	36	rituximab	rituximab	NN
cord-016476-78r0rsio	513	37	in	in	IN
cord-016476-78r0rsio	513	38	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	513	39	arthritis	arthritis	NN
cord-016476-78r0rsio	513	40	patients	patient	NNS
cord-016476-78r0rsio	513	41	with	with	IN
cord-016476-78r0rsio	513	42	concomitant	concomitant	JJ
cord-016476-78r0rsio	513	43	interstitial	interstitial	JJ
cord-016476-78r0rsio	513	44	lung	lung	NN
cord-016476-78r0rsio	513	45	disease	disease	NN
cord-016476-78r0rsio	513	46	:	:	:
cord-016476-78r0rsio	514	1	10-year	10-year	CD
cord-016476-78r0rsio	514	2	experience	experience	NN
cord-016476-78r0rsio	514	3	at	at	IN
cord-016476-78r0rsio	514	4	single	single	JJ
cord-016476-78r0rsio	514	5	centre	centre	NN
cord-016476-78r0rsio	514	6	Safety	safety	NN
cord-016476-78r0rsio	514	7	and	and	CC
cord-016476-78r0rsio	514	8	efficacy	efficacy	NN
cord-016476-78r0rsio	514	9	of	of	IN
cord-016476-78r0rsio	514	10	rituximab	rituximab	NN
cord-016476-78r0rsio	514	11	in	in	IN
cord-016476-78r0rsio	514	12	patients	patient	NNS
cord-016476-78r0rsio	514	13	with	with	IN
cord-016476-78r0rsio	514	14	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	514	15	arthritis	arthritis	NN
cord-016476-78r0rsio	514	16	and	and	CC
cord-016476-78r0rsio	514	17	lung	lung	NN
cord-016476-78r0rsio	514	18	involvement	involvement	NN
cord-016476-78r0rsio	514	19	Mortality	mortality	NN
cord-016476-78r0rsio	514	20	in	in	IN
cord-016476-78r0rsio	514	21	patients	patient	NNS
cord-016476-78r0rsio	514	22	with	with	IN
cord-016476-78r0rsio	514	23	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	514	24	arthritis	arthritis	NN
cord-016476-78r0rsio	514	25	and	and	CC
cord-016476-78r0rsio	514	26	interstitial	interstitial	JJ
cord-016476-78r0rsio	514	27	lung	lung	NN
cord-016476-78r0rsio	514	28	disease	disease	NN
cord-016476-78r0rsio	514	29	treated	treat	VBN
cord-016476-78r0rsio	514	30	with	with	IN
cord-016476-78r0rsio	514	31	first	first	JJ
cord-016476-78r0rsio	514	32	line	line	NN
cord-016476-78r0rsio	514	33	TNFi	TNFi	NNS
cord-016476-78r0rsio	514	34	or	or	CC
cord-016476-78r0rsio	514	35	rituximab	rituximab	JJ
cord-016476-78r0rsio	514	36	therapies	therapy	NNS
cord-016476-78r0rsio	514	37	:	:	:
cord-016476-78r0rsio	514	38	results	result	NNS
cord-016476-78r0rsio	514	39	from	from	IN
cord-016476-78r0rsio	514	40	the	the	DT
cord-016476-78r0rsio	514	41	BSRBR	BSRBR	NNP
cord-016476-78r0rsio	514	42	-	-	HYPH
cord-016476-78r0rsio	514	43	RA	RA	NNP
cord-016476-78r0rsio	514	44	Updated	update	VBN
cord-016476-78r0rsio	514	45	consensus	consensus	NN
cord-016476-78r0rsio	514	46	statement	statement	NN
cord-016476-78r0rsio	514	47	on	on	IN
cord-016476-78r0rsio	514	48	the	the	DT
cord-016476-78r0rsio	514	49	use	use	NN
cord-016476-78r0rsio	514	50	of	of	IN
cord-016476-78r0rsio	514	51	rituximab	rituximab	NN
cord-016476-78r0rsio	514	52	in	in	IN
cord-016476-78r0rsio	514	53	patients	patient	NNS
cord-016476-78r0rsio	514	54	with	with	IN
cord-016476-78r0rsio	514	55	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	514	56	arthritis	arthritis	NN
cord-016476-78r0rsio	514	57	Survival	Survival	NNP
cord-016476-78r0rsio	514	58	and	and	CC
cord-016476-78r0rsio	514	59	quality	quality	NN
cord-016476-78r0rsio	514	60	of	of	IN
cord-016476-78r0rsio	514	61	life	life	NN
cord-016476-78r0rsio	514	62	in	in	IN
cord-016476-78r0rsio	514	63	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	514	64	arthritisassociated	arthritisassociate	VBN
cord-016476-78r0rsio	514	65	interstitial	interstitial	JJ
cord-016476-78r0rsio	514	66	lung	lung	NN
cord-016476-78r0rsio	514	67	disease	disease	NN
cord-016476-78r0rsio	514	68	after	after	IN
cord-016476-78r0rsio	514	69	lung	lung	NN
cord-016476-78r0rsio	514	70	transplantation	transplantation	NN
cord-016476-78r0rsio	514	71	Pragmatic	pragmatic	JJ
cord-016476-78r0rsio	514	72	prognostic	prognostic	JJ
cord-016476-78r0rsio	514	73	approach	approach	NN
cord-016476-78r0rsio	514	74	of	of	IN
cord-016476-78r0rsio	514	75	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	514	76	arthritis	arthritis	NN
cord-016476-78r0rsio	514	77	-	-	HYPH
cord-016476-78r0rsio	514	78	associated	associate	VBN
cord-016476-78r0rsio	514	79	interstitial	interstitial	JJ
cord-016476-78r0rsio	514	80	lung	lung	NN
cord-016476-78r0rsio	514	81	disease	disease	NN
cord-016476-78r0rsio	515	1	An	an	DT
cord-016476-78r0rsio	515	2	official	official	JJ
cord-016476-78r0rsio	515	3	American	American	NNP
cord-016476-78r0rsio	515	4	Thoracic	Thoracic	NNP
cord-016476-78r0rsio	515	5	Society	Society	NNP
cord-016476-78r0rsio	515	6	/	/	SYM
cord-016476-78r0rsio	515	7	European	European	NNP
cord-016476-78r0rsio	515	8	Respiratory	Respiratory	NNP
cord-016476-78r0rsio	515	9	Society	Society	NNP
cord-016476-78r0rsio	515	10	statement	statement	NN
cord-016476-78r0rsio	515	11	:	:	:
cord-016476-78r0rsio	515	12	update	update	NN
cord-016476-78r0rsio	515	13	of	of	IN
cord-016476-78r0rsio	515	14	the	the	DT
cord-016476-78r0rsio	515	15	international	international	JJ
cord-016476-78r0rsio	515	16	multidisciplinary	multidisciplinary	JJ
cord-016476-78r0rsio	515	17	classification	classification	NN
cord-016476-78r0rsio	515	18	of	of	IN
cord-016476-78r0rsio	515	19	the	the	DT
cord-016476-78r0rsio	515	20	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	515	21	interstitial	interstitial	JJ
cord-016476-78r0rsio	515	22	pneumonias	pneumonia	NNS
cord-016476-78r0rsio	515	23	Prevalence	prevalence	NN
cord-016476-78r0rsio	515	24	and	and	CC
cord-016476-78r0rsio	515	25	prognosis	prognosis	NN
cord-016476-78r0rsio	515	26	of	of	IN
cord-016476-78r0rsio	515	27	unclassifiable	unclassifiable	JJ
cord-016476-78r0rsio	515	28	interstitial	interstitial	JJ
cord-016476-78r0rsio	515	29	lung	lung	NN
cord-016476-78r0rsio	515	30	disease	disease	NN
cord-016476-78r0rsio	515	31	Lung	Lung	NNP
cord-016476-78r0rsio	515	32	function	function	NN
cord-016476-78r0rsio	515	33	estimates	estimate	NNS
cord-016476-78r0rsio	515	34	in	in	IN
cord-016476-78r0rsio	515	35	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	515	36	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	515	37	fibrosis	fibrosis	NN
cord-016476-78r0rsio	515	38	:	:	:
cord-016476-78r0rsio	515	39	the	the	DT
cord-016476-78r0rsio	515	40	potential	potential	NN
cord-016476-78r0rsio	515	41	for	for	IN
cord-016476-78r0rsio	515	42	a	a	DT
cord-016476-78r0rsio	515	43	simple	simple	JJ
cord-016476-78r0rsio	515	44	classification	classification	NN
cord-016476-78r0rsio	515	45	A	a	DT
cord-016476-78r0rsio	515	46	multidimensional	multidimensional	JJ
cord-016476-78r0rsio	515	47	index	index	NN
cord-016476-78r0rsio	515	48	and	and	CC
cord-016476-78r0rsio	515	49	staging	stage	VBG
cord-016476-78r0rsio	515	50	system	system	NN
cord-016476-78r0rsio	515	51	for	for	IN
cord-016476-78r0rsio	515	52	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	515	53	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	515	54	fibrosis	fibrosis	NN
cord-016476-78r0rsio	516	1	The	the	DT
cord-016476-78r0rsio	516	2	MRC	MRC	NNP
cord-016476-78r0rsio	516	3	breathlessness	breathlessness	NN
cord-016476-78r0rsio	516	4	scale	scale	NN
cord-016476-78r0rsio	517	1	An	an	DT
cord-016476-78r0rsio	517	2	official	official	JJ
cord-016476-78r0rsio	517	3	ATS	ATS	NNP
cord-016476-78r0rsio	517	4	/	/	SYM
cord-016476-78r0rsio	517	5	ERS	ERS	NNP
cord-016476-78r0rsio	517	6	/	/	SYM
cord-016476-78r0rsio	517	7	JRS	JRS	NNP
cord-016476-78r0rsio	517	8	/	/	SYM
cord-016476-78r0rsio	517	9	ALAT	ALAT	NNP
cord-016476-78r0rsio	517	10	statement	statement	NN
cord-016476-78r0rsio	517	11	:	:	:
cord-016476-78r0rsio	517	12	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	517	13	pulmonary	pulmonary	JJ
cord-016476-78r0rsio	517	14	fibrosis	fibrosis	NN
cord-016476-78r0rsio	517	15	:	:	:
cord-016476-78r0rsio	517	16	evidence	evidence	NN
cord-016476-78r0rsio	517	17	-	-	HYPH
cord-016476-78r0rsio	517	18	based	base	VBN
cord-016476-78r0rsio	517	19	guidelines	guideline	NNS
cord-016476-78r0rsio	517	20	for	for	IN
cord-016476-78r0rsio	517	21	diagnosis	diagnosis	NN
cord-016476-78r0rsio	517	22	and	and	CC
cord-016476-78r0rsio	517	23	management	management	NN
cord-016476-78r0rsio	517	24	A	a	DT
cord-016476-78r0rsio	517	25	clinician	clinician	NN
cord-016476-78r0rsio	517	26	's	's	POS
cord-016476-78r0rsio	517	27	guide	guide	NN
cord-016476-78r0rsio	517	28	to	to	IN
cord-016476-78r0rsio	517	29	the	the	DT
cord-016476-78r0rsio	517	30	diagnosis	diagnosis	NN
cord-016476-78r0rsio	517	31	and	and	CC
cord-016476-78r0rsio	517	32	treatment	treatment	NN
cord-016476-78r0rsio	517	33	of	of	IN
cord-016476-78r0rsio	517	34	interstitial	interstitial	JJ
cord-016476-78r0rsio	517	35	lung	lung	NN
cord-016476-78r0rsio	517	36	diseases	disease	NNS
cord-016476-78r0rsio	518	1	Fibrotic	fibrotic	JJ
cord-016476-78r0rsio	518	2	idiopathic	idiopathic	JJ
cord-016476-78r0rsio	518	3	interstitial	interstitial	JJ
cord-016476-78r0rsio	518	4	pneumonia	pneumonia	NN
cord-016476-78r0rsio	518	5	:	:	:
cord-016476-78r0rsio	518	6	the	the	DT
cord-016476-78r0rsio	518	7	prognostic	prognostic	JJ
cord-016476-78r0rsio	518	8	value	value	NN
cord-016476-78r0rsio	518	9	of	of	IN
cord-016476-78r0rsio	518	10	longitudinal	longitudinal	JJ
cord-016476-78r0rsio	518	11	functional	functional	JJ
cord-016476-78r0rsio	518	12	trends	trend	NNS
cord-016476-78r0rsio	518	13	Rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	518	14	arthritis	arthritis	NN
cord-016476-78r0rsio	518	15	-	-	HYPH
cord-016476-78r0rsio	518	16	associated	associate	VBN
cord-016476-78r0rsio	518	17	interstitial	interstitial	JJ
cord-016476-78r0rsio	518	18	lung	lung	NN
cord-016476-78r0rsio	518	19	disease	disease	NN
cord-016476-78r0rsio	518	20	:	:	:
cord-016476-78r0rsio	518	21	diagnostic	diagnostic	JJ
cord-016476-78r0rsio	518	22	dilemma	dilemma	NN
cord-016476-78r0rsio	518	23	Radiological	radiological	JJ
cord-016476-78r0rsio	518	24	versus	versus	IN
cord-016476-78r0rsio	518	25	histological	histological	JJ
cord-016476-78r0rsio	518	26	diagnosis	diagnosis	NN
cord-016476-78r0rsio	518	27	in	in	IN
cord-016476-78r0rsio	518	28	UIP	UIP	NNP
cord-016476-78r0rsio	518	29	and	and	CC
cord-016476-78r0rsio	518	30	NSIP	NSIP	NNP
cord-016476-78r0rsio	518	31	:	:	:
cord-016476-78r0rsio	519	1	survival	survival	NN
cord-016476-78r0rsio	519	2	implications	implication	NNS
cord-016476-78r0rsio	520	1	Interstitial	interstitial	JJ
cord-016476-78r0rsio	520	2	lung	lung	NN
cord-016476-78r0rsio	520	3	disease	disease	NN
cord-016476-78r0rsio	520	4	in	in	IN
cord-016476-78r0rsio	520	5	systemic	systemic	JJ
cord-016476-78r0rsio	520	6	sclerosis	sclerosis	NN
cord-016476-78r0rsio	520	7	:	:	:
cord-016476-78r0rsio	520	8	a	a	DT
cord-016476-78r0rsio	520	9	simple	simple	JJ
cord-016476-78r0rsio	520	10	staging	staging	NN
cord-016476-78r0rsio	520	11	system	system	NN
cord-016476-78r0rsio	520	12	Update	update	NN
cord-016476-78r0rsio	520	13	in	in	IN
cord-016476-78r0rsio	520	14	diffuse	diffuse	JJ
cord-016476-78r0rsio	520	15	parenchymal	parenchymal	NN
cord-016476-78r0rsio	520	16	lung	lung	NN
cord-016476-78r0rsio	520	17	disease	disease	NN
cord-016476-78r0rsio	520	18	Patients	patient	NNS
cord-016476-78r0rsio	520	19	with	with	IN
cord-016476-78r0rsio	520	20	limited	limited	JJ
cord-016476-78r0rsio	520	21	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	520	22	arthritis	arthritis	NN
cord-016476-78r0rsio	520	23	-	-	HYPH
cord-016476-78r0rsio	520	24	related	relate	VBN
cord-016476-78r0rsio	520	25	interstitial	interstitial	JJ
cord-016476-78r0rsio	520	26	lung	lung	NN
cord-016476-78r0rsio	520	27	disease	disease	NN
cord-016476-78r0rsio	520	28	have	have	VBP
cord-016476-78r0rsio	520	29	a	a	DT
cord-016476-78r0rsio	520	30	better	well	JJR
cord-016476-78r0rsio	520	31	prognosis	prognosis	NN
cord-016476-78r0rsio	520	32	than	than	IN
cord-016476-78r0rsio	520	33	those	those	DT
cord-016476-78r0rsio	520	34	with	with	IN
cord-016476-78r0rsio	520	35	extensive	extensive	JJ
cord-016476-78r0rsio	520	36	disease	disease	NN
cord-016476-78r0rsio	521	1	The	the	DT
cord-016476-78r0rsio	521	2	safety	safety	NN
cord-016476-78r0rsio	521	3	of	of	IN
cord-016476-78r0rsio	521	4	biologic	biologic	JJ
cord-016476-78r0rsio	521	5	therapies	therapy	NNS
cord-016476-78r0rsio	521	6	in	in	IN
cord-016476-78r0rsio	521	7	RA	RA	NNP
cord-016476-78r0rsio	521	8	-	-	HYPH
cord-016476-78r0rsio	521	9	associated	associate	VBN
cord-016476-78r0rsio	521	10	interstitial	interstitial	JJ
cord-016476-78r0rsio	521	11	lung	lung	NN
cord-016476-78r0rsio	521	12	disease	disease	NN
cord-016476-78r0rsio	521	13	Patients	patient	NNS
cord-016476-78r0rsio	521	14	with	with	IN
cord-016476-78r0rsio	521	15	early	early	JJ
cord-016476-78r0rsio	521	16	rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	521	17	arthritis	arthritis	NN
cord-016476-78r0rsio	521	18	who	who	WP
cord-016476-78r0rsio	521	19	smoke	smoke	VBP
cord-016476-78r0rsio	521	20	are	be	VBP
cord-016476-78r0rsio	521	21	less	less	RBR
cord-016476-78r0rsio	521	22	likely	likely	JJ
cord-016476-78r0rsio	521	23	to	to	TO
cord-016476-78r0rsio	521	24	respond	respond	VB
cord-016476-78r0rsio	521	25	to	to	IN
cord-016476-78r0rsio	521	26	treatment	treatment	NN
cord-016476-78r0rsio	521	27	with	with	IN
cord-016476-78r0rsio	521	28	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	521	29	and	and	CC
cord-016476-78r0rsio	521	30	tumor	tumor	NN
cord-016476-78r0rsio	521	31	necrosis	necrosis	NN
cord-016476-78r0rsio	521	32	factor	factor	NN
cord-016476-78r0rsio	521	33	inhibitors	inhibitor	NNS
cord-016476-78r0rsio	521	34	:	:	:
cord-016476-78r0rsio	521	35	observations	observation	NNS
cord-016476-78r0rsio	521	36	from	from	IN
cord-016476-78r0rsio	521	37	the	the	DT
cord-016476-78r0rsio	521	38	epidemiological	epidemiological	JJ
cord-016476-78r0rsio	521	39	investigation	investigation	NN
cord-016476-78r0rsio	521	40	of	of	IN
cord-016476-78r0rsio	521	41	rheumatoid	rheumatoid	NNP
cord-016476-78r0rsio	521	42	arthritis	arthritis	NN
cord-016476-78r0rsio	521	43	and	and	CC
cord-016476-78r0rsio	521	44	the	the	DT
cord-016476-78r0rsio	521	45	Swedish	swedish	JJ
cord-016476-78r0rsio	521	46	rheumatology	rheumatology	NN
cord-016476-78r0rsio	521	47	register	register	VBP
cord-016476-78r0rsio	521	48	cohorts	cohort	NNS
cord-016476-78r0rsio	521	49	Rheumatoid	rheumatoid	JJ
cord-016476-78r0rsio	521	50	arthritis	arthritis	NN
cord-016476-78r0rsio	521	51	(	(	-LRB-
cord-016476-78r0rsio	521	52	RA	RA	NNP
cord-016476-78r0rsio	521	53	)	)	-RRB-
cord-016476-78r0rsio	522	1	associated	associate	VBN
cord-016476-78r0rsio	522	2	interstitial	interstitial	JJ
cord-016476-78r0rsio	522	3	lung	lung	NN
cord-016476-78r0rsio	522	4	disease	disease	NN
cord-016476-78r0rsio	522	5	(	(	-LRB-
cord-016476-78r0rsio	522	6	ILD	ILD	NNP
cord-016476-78r0rsio	522	7	)	)	-RRB-
cord-016476-78r0rsio	523	1	Opportunistic	opportunistic	JJ
cord-016476-78r0rsio	523	2	infections	infection	NNS
cord-016476-78r0rsio	523	3	and	and	CC
cord-016476-78r0rsio	523	4	biologic	biologic	JJ
cord-016476-78r0rsio	523	5	therapies	therapy	NNS
cord-016476-78r0rsio	523	6	in	in	IN
cord-016476-78r0rsio	523	7	immune	immune	NN
cord-016476-78r0rsio	523	8	-	-	HYPH
cord-016476-78r0rsio	523	9	mediated	mediate	VBN
cord-016476-78r0rsio	523	10	inflammatory	inflammatory	JJ
cord-016476-78r0rsio	523	11	diseases	disease	NNS
cord-016476-78r0rsio	523	12	:	:	:
cord-016476-78r0rsio	524	1	consensus	consensus	NN
cord-016476-78r0rsio	524	2	recommendations	recommendation	NNS
cord-016476-78r0rsio	524	3	for	for	IN
cord-016476-78r0rsio	524	4	infection	infection	NN
cord-016476-78r0rsio	524	5	reporting	report	VBG
cord-016476-78r0rsio	524	6	during	during	IN
cord-016476-78r0rsio	524	7	clinical	clinical	JJ
cord-016476-78r0rsio	524	8	trials	trial	NNS
cord-016476-78r0rsio	524	9	and	and	CC
cord-016476-78r0rsio	524	10	postmarketing	postmarkete	VBG
cord-016476-78r0rsio	524	11	surveillance	surveillance	NN
cord-016476-78r0rsio	524	12	Risk	risk	NN
cord-016476-78r0rsio	524	13	of	of	IN
cord-016476-78r0rsio	524	14	infection	infection	NN
cord-016476-78r0rsio	524	15	with	with	IN
cord-016476-78r0rsio	524	16	biologic	biologic	JJ
cord-016476-78r0rsio	524	17	antirheumatic	antirheumatic	JJ
cord-016476-78r0rsio	524	18	therapies	therapy	NNS
cord-016476-78r0rsio	524	19	in	in	IN
cord-016476-78r0rsio	524	20	patients	patient	NNS
cord-016476-78r0rsio	524	21	with	with	IN
cord-016476-78r0rsio	524	22	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	524	23	arthritis	arthritis	NN
cord-016476-78r0rsio	524	24	Lymphoproliferative	lymphoproliferative	JJ
cord-016476-78r0rsio	524	25	disorders	disorder	NNS
cord-016476-78r0rsio	524	26	in	in	IN
cord-016476-78r0rsio	524	27	rheumatoid	rheumatoid	NN
cord-016476-78r0rsio	524	28	arthritis	arthritis	NN
cord-016476-78r0rsio	524	29	:	:	:
cord-016476-78r0rsio	524	30	clinicopathological	clinicopathological	NNP
cord-016476-78r0rsio	524	31	analysis	analysis	NN
cord-016476-78r0rsio	524	32	of	of	IN
cord-016476-78r0rsio	524	33	76	76	CD
cord-016476-78r0rsio	524	34	cases	case	NNS
cord-016476-78r0rsio	524	35	in	in	IN
cord-016476-78r0rsio	524	36	relation	relation	NN
cord-016476-78r0rsio	524	37	to	to	IN
cord-016476-78r0rsio	524	38	methotrexate	methotrexate	NNP
cord-016476-78r0rsio	524	39	medication	medication	NN
cord-016476-78r0rsio	524	40	Spontaneous	spontaneous	JJ
cord-016476-78r0rsio	524	41	remission	remission	NN
cord-016476-78r0rsio	524	42	of	of	IN
cord-016476-78r0rsio	524	43	'	'	``
cord-016476-78r0rsio	524	44	methotrexate	methotrexate	NN
cord-016476-78r0rsio	524	45	-	-	HYPH
cord-016476-78r0rsio	524	46	associated	associate	VBN
cord-016476-78r0rsio	524	47	lymphoproliferative	lymphoproliferative	JJ
cord-016476-78r0rsio	524	48	disorders	disorder	NNS
cord-016476-78r0rsio	524	49	'	'	''
cord-016476-78r0rsio	525	1	after	after	IN
cord-016476-78r0rsio	525	2	discontinuation	discontinuation	NN
cord-016476-78r0rsio	525	3	of	of	IN
cord-016476-78r0rsio	525	4	immunosuppressive	immunosuppressive	JJ
cord-016476-78r0rsio	525	5	treatment	treatment	NN
cord-016476-78r0rsio	525	6	for	for	IN
cord-016476-78r0rsio	525	7	autoimmune	autoimmune	JJ
cord-016476-78r0rsio	525	8	disease	disease	NN
cord-016476-78r0rsio	525	9	.	.	.
cord-016476-78r0rsio	526	1	Review	Review	NNP
cord-016476-78r0rsio	526	2	of	of	IN
cord-016476-78r0rsio	526	3	the	the	DT
cord-016476-78r0rsio	526	4	literature	literature	NN